nct_id,start_date,primary_completion__date,study_type,brief_title,overall_status,phase,sponsor,why_stopped,ctg_links,Abstract,Registry,Total_pubs,vaccine_trial_flag,Number_of_updates,US_site_flag,country,Has_Results,mapped_intervention,ArticleType
NCT04326790,2020-04-03,2020-04-27,Interventional,The GReek Study in the Effects of Colchicine in Covid-19 cOmplications Prevention,Terminated,Phase 2,National and Kapodistrian University of Athens,Slow enrollment as a result of the rapid flattening of the curve of COVID-19 cases in Greece,https://clinicaltrials.gov/ct2/show/NCT04326790,2,0,2,0,5,0,Greece,0,colchicine|standard care,Clinical Trial Protocol|Journal Article/Journal Article|Randomized Controlled Trial
NCT04292964,2020-03-01,2020-03-13,Observational,Prognostic Factors of Patients With COVID-19,Completed,NA,Chongqing Medical University,NA,https://clinicaltrials.gov/ct2/show/NCT04292964,2,0,2,0,3,0,China,0,"NA",Journal Article|Observational Study/Journal Article|Multicenter Study|Observational Study
NCT04315948,2020-03-22,2023-03-31,Interventional,Trial of Treatments for COVID-19 in Hospitalized Adults,"Active, not recruiting",Phase 3,"Institut National de la SantÃ© Et de la Recherche MÃ©dicale, France",NA,https://clinicaltrials.gov/ct2/show/NCT04315948,3,1,4,0,9,0,Austria|Belgium|France|Luxembourg|Portugal,0,remdesivir|lopinavir/ritonavir|interferon|hydroxychloroquine|standard care|azd7442|placebo|lopinavir|ritonavir,"Journal Article/Adaptive Clinical Trial|Clinical Trial Protocol|Clinical Trial, Phase III|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't/Comparative Study|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't/Comparative Study|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04323527,2020-03-23,2020-05-07,Interventional,Chloroquine Diphosphate for the Treatment of Severe Acute Respiratory Syndrome Secondary to SARS-CoV2,Completed,Phase 2,FundaÃ§Ã£o de Medicina Tropical Dr. Heitor Vieira Dourado,NA,https://clinicaltrials.gov/ct2/show/NCT04323527,1,0,1,0,3,0,Brazil,0,chloroquine,"Clinical Trial, Phase II|Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04279782,2020-01-20,2021-01-31,Observational,Clinical Features of Suspected and Confirmed Patients of 2019 Novel Coronavirus Infection,Recruiting,NA,"Third Affiliated Hospital, Sun Yat-Sen University",NA,https://clinicaltrials.gov/ct2/show/NCT04279782,1,0,1,0,1,0,China,0,comprehensive treatment,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04318366,2020-03-19,2022-03-19,Observational,"COVID-19 Patients Characterization, Biobank, Treatment Response and Outcome Predictor",Recruiting,NA,UniversitÃ  Vita-Salute San Raffaele,NA,https://clinicaltrials.gov/ct2/show/NCT04318366,8,0,8,0,3,0,Italy,0,observational,Journal Article/Journal Article/Journal Article|Observational Study/Journal Article/Journal Article/Clinical Trial|Journal Article|Multicenter Study/Journal Article/Journal Article|Multicenter Study
NCT04355936,2020-05-19,2020-11-02,Interventional,Telmisartan for Treatment of COVID-19 Patients,Completed,Phase 4,Laboratorio Elea Phoenix S.A.,NA,https://clinicaltrials.gov/ct2/show/NCT04355936,1,0,1,0,8,0,Argentina,0,telmisartan|standard care,Journal Article
NCT04308668,2020-03-17,2020-05-20,Interventional,Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2,Completed,Phase 3,University of Minnesota,NA,https://clinicaltrials.gov/ct2/show/NCT04308668,4,1,5,0,12,1,United States|Canada,0,hydroxychloroquine|placebo,"Clinical Trial Protocol|Journal Article|Multicenter Study|Randomized Controlled Trial/Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't/Journal Article|Multicenter Study|Randomized Controlled Trial/Journal Article|Systematic Review/Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't"
NCT04321278,2020-03-28,2020-06-14,Interventional,Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),Completed,Phase 3,Hospital Israelita Albert Einstein,NA,https://clinicaltrials.gov/ct2/show/NCT04321278,2,0,2,0,6,0,Brazil,0,hydroxychloroquine / azithromycin|hydroxychloroquine|azithromycin,"Editorial/Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04261517,2020-02-06,2020-02-25,Interventional,Efficacy and Safety of Hydroxychloroquine for Treatment of COVID-19,Completed,Phase 3,Shanghai Public Health Clinical Center,NA,https://clinicaltrials.gov/ct2/show/NCT04261517,1,0,1,0,3,0,China,0,hydroxychloroquine,Journal Article|Randomized Controlled Trial
NCT04276688,2020-02-10,2020-03-30,Interventional,"Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment",Completed,Phase 2,The University of Hong Kong,NA,https://clinicaltrials.gov/ct2/show/NCT04276688,2,0,2,0,2,0,Hong Kong,0,lopinavir/ritonavir|ribavirin|interferon|lopinavir|ritonavir,"Clinical Trial, Phase II|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't/Journal Article|Review"
NCT04366960,2020-05-14,2021-08-31,Interventional,Comparison of Two Doses of Enoxaparin for Thromboprophylaxis in Hospitalized COVID-19 Patients,Recruiting,Phase 3,Niguarda Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04366960,2,0,2,0,3,0,Italy,0,enoxaparin,"Journal Article/Journal Article|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04372589,2020-05-20,2021-05-31,Interventional,Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC),"Active, not recruiting",Phase 2/Phase 3,University of Manitoba,NA,https://clinicaltrials.gov/ct2/show/NCT04372589,3,0,3,1,5,1,United States|Brazil|Canada|Mexico,0,heparin,"Journal Article/Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't/Journal Article|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04367831,2020-05-02,2020-11-30,Interventional,Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19,Recruiting,Phase 4,Columbia University,NA,https://clinicaltrials.gov/ct2/show/NCT04367831,2,0,2,0,2,1,United States,0,enoxaparin|heparin|enoxaparin/lovenox|lovenox,"Journal Article/Journal Article|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04345848,2020-04-28,2021-03-31,Interventional,Preventing COVID-19 Complications With Low- and High-dose Anticoagulation,Recruiting,Phase 3,"University Hospital, Geneva",NA,https://clinicaltrials.gov/ct2/show/NCT04345848,2,0,2,0,3,0,Switzerland,0,enoxaparin,"Journal Article/Journal Article|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04257656,2020-02-06,2020-03-30,Interventional,A Trial of Remdesivir in Adults With Severe COVID-19,Terminated,Phase 3,Capital Medical University,"The epidemic of COVID-19 has been controlled well in China, no eligible patients can be
    enrolled at present.",https://clinicaltrials.gov/ct2/show/NCT04257656,2,0,2,0,3,0,China,0,remdesivir|placebo,Journal Article|Multicenter Study|Randomized Controlled Trial/Clinical Trial Protocol|Journal Article
NCT04329832,2020-03-30,2020-12-18,Interventional,Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19,"Active, not recruiting",Phase 2,"Intermountain Health Care, Inc.",NA,https://clinicaltrials.gov/ct2/show/NCT04329832,2,0,2,0,3,1,United States,0,hydroxychloroquine|azithromycin,"Clinical Trial Protocol|Journal Article|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't/Journal Article"
NCT04374071,2020-03-12,2020-03-27,Observational,Early Short Course Corticosteroids in COVID-19,Completed,NA,Henry Ford Health System,NA,https://clinicaltrials.gov/ct2/show/NCT04374071,1,0,1,0,0,1,United States,0,methylprednisolone,Journal Article
NCT04280705,2020-02-21,2020-05-21,Interventional,Adaptive COVID-19 Treatment Trial (ACTT),Completed,Phase 3,National Institute of Allergy and Infectious Diseases (NIAID),NA,https://clinicaltrials.gov/ct2/show/NCT04280705,3,0,3,0,24,1,"United States|Denmark|Germany|Greece|Japan|Korea, Republic of|Mexico|Singapore|Spain|United Kingdom",1,placebo|remdesivir,"Clinical Trial, Phase III|Journal Article|Randomized Controlled Trial|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't/Introductory Journal Article|Research Support, Non-U.S. Gov't/Journal Article|Review"
NCT04313127,2020-03-16,2020-12-30,Interventional,Phase I Clinical Trial of a COVID-19 Vaccine in 18-60 Healthy Adults,"Active, not recruiting",Phase 1,CanSino Biologics Inc.,NA,https://clinicaltrials.gov/ct2/show/NCT04313127,1,0,1,1,4,0,China,0,adenovirus type 5 vector,"Clinical Trial, Phase I|Journal Article"
NCT04292899,2020-03-06,2020-04-09,Interventional,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â„¢) in Participants With Severe Coronavirus Disease (COVID-19),Completed,Phase 3,Gilead Sciences,NA,https://clinicaltrials.gov/ct2/show/NCT04292899,1,0,1,0,20,1,"United States|China|France|Germany|Hong Kong|Italy|Japan|Korea, Republic of|Netherlands|Singapore|Spain|Sweden|Switzerland|Taiwan|United Kingdom",1,remdesivir|standard care,"Clinical Trial, Phase III|Comparative Study|Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04321421,2020-03-17,2020-04-28,Interventional,Hyperimmune Plasma for Critical Patients With COVID-19,Completed,N/A,Foundation IRCCS San Matteo Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04321421,3,0,3,0,2,0,Italy,0,convalescent plasma,"Clinical Trial Protocol|Journal Article|Multicenter Study/Journal Article|Meta-Analysis|Research Support, Non-U.S. Gov't|Systematic Review/Journal Article|Meta-Analysis|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04324736,2020-03-10,2020-04-10,Observational,"""COVID-19 and Diabetes Outcomes""",Completed,NA,Nantes University Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04324736,3,0,3,0,7,0,France,0,no interventional study,"Journal Article|Multicenter Study|Research Support, Non-U.S. Gov't/Letter|Comment/Journal Article|Multicenter Study|Observational Study|Research Support, Non-U.S. Gov't"
NCT04354701,2020-03-17,2021-12-31,Observational [Patient Registry],COVID-19 and Cancer Consortium Registry,Recruiting,NA,Vanderbilt-Ingram Cancer Center,NA,https://clinicaltrials.gov/ct2/show/NCT04354701,2,0,2,0,4,1,United States,0,web-based redcap survey,"Journal Article|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't/Journal Article"
NCT04332991,2020-04-02,2020-06-19,Interventional,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Completed,Phase 3,Massachusetts General Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04332991,2,0,2,0,9,1,United States,1,hydroxychloroquine|placebo,"Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, N.I.H., Extramural/Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, N.I.H., Extramural"
NCT04330638,2020-04-03,2020-12-18,Interventional,Treatment of COVID-19 Patients With Anti-interleukin Drugs,"Active, not recruiting",Phase 3,"University Hospital, Ghent",NA,https://clinicaltrials.gov/ct2/show/NCT04330638,1,0,1,0,7,0,Belgium,0,standard care|anakinra|siltuximab|tocilizumab,Clinical Trial Protocol|Letter
NCT04343768,2020-04-09,2020-04-27,Interventional,"An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial",Completed,Phase 2,Shahid Beheshti University of Medical Sciences,NA,https://clinicaltrials.gov/ct2/show/NCT04343768,2,0,2,0,3,0,"Iran, Islamic Republic of",0,hydroxychloroquine|lopinavir/ritonavir|interferon|lopinavir|ritonavir,Clinical Trial Protocol|Letter/Journal Article|Randomized Controlled Trial
NCT04328961,2020-03-31,2020-09-24,Interventional,Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP),Completed,Phase 2/Phase 3,University of Washington,NA,https://clinicaltrials.gov/ct2/show/NCT04328961,2,0,2,0,5,1,United States,0,hydroxychloroquine|vitamin c,"Clinical Trial Protocol|Letter/Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04331171,2020-03-17,2020-11-15,Observational [Patient Registry],Epidemiological Observation From a Smartphone Self-monitoring Application for Suspected COVID-19 Patients' Triage,Completed,NA,Weprom,NA,https://clinicaltrials.gov/ct2/show/NCT04331171,3,0,3,0,4,0,France,0,web application users,Journal Article/Journal Article|Observational Study/Journal Article|Observational Study
NCT04328441,2020-03-25,2021-03-31,Interventional,Reducing Health Care Workers Absenteeism in Covid-19 Pandemic Through BCG Vaccine,"Active, not recruiting",Phase 3,UMC Utrecht,NA,https://clinicaltrials.gov/ct2/show/NCT04328441,1,0,1,1,3,0,Netherlands,0,bcg|placebo,Clinical Trial Protocol|Letter
NCT04360980,2020-03-20,2021-09-01,Interventional,The Effects of Standard Protocol With or Without Colchicine in Covid-19 Infection,Recruiting,Phase 2,Shahid Beheshti University of Medical Sciences,NA,https://clinicaltrials.gov/ct2/show/NCT04360980,1,0,1,0,3,0,"Iran, Islamic Republic of",0,colchicine,Clinical Trial Protocol|Letter
NCT04333589,2020-04-01,2020-06-01,Interventional,Corona Virus Disease 2019 Patients Whose Nucleic Acids Changed From Negative to Positive,Recruiting,N/A,Peking University First Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04333589,1,0,1,0,2,0,China,0,favipiravir,Clinical Trial Protocol|Letter
NCT04316377,2020-03-25,2020-05-25,Interventional,Norwegian Coronavirus Disease 2019 Study,"Active, not recruiting",Phase 4,"University Hospital, Akershus",NA,https://clinicaltrials.gov/ct2/show/NCT04316377,2,0,2,0,3,0,Norway,0,hydroxychloroquine,"Clinical Trial Protocol|Letter/Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04326920,2020-03-24,2020-09-28,Interventional,Sargramostim in Patients With Acute Hypoxic Respiratory Failure Due to COVID-19 (SARPAC),Completed,Phase 4,"University Hospital, Ghent",NA,https://clinicaltrials.gov/ct2/show/NCT04326920,2,0,2,0,5,0,Belgium,0,sargramostim|control,"Clinical Trial Protocol|Letter/Journal Article|Research Support, Non-U.S. Gov't|Review"
NCT04306393,2020-03-21,2021-03-21,Interventional,Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19,Recruiting,Phase 2,Massachusetts General Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04306393,2,0,2,0,7,1,United States,0,nitric oxide,Preprint/Journal Article
NCT04335786,2020-04-17,2020-12-31,Interventional,Valsartan for Prevention of Acute Respiratory Distress Syndrome in Hospitalized Patients With SARS-COV-2 (COVID-19) Infection Disease,Recruiting,Phase 4,Radboud University,NA,https://clinicaltrials.gov/ct2/show/NCT04335786,1,0,1,0,6,0,Netherlands,0,diovan|placebo,"Clinical Trial Protocol|Journal Article|Research Support, Non-U.S. Gov't"
NCT04341493,2020-04-06,2020-08-30,Interventional,Hydroxychloroquine vs Nitazoxanide in Patients With COVID-19,Terminated,Phase 4,Materno-Perinatal Hospital of the State of Mexico,Concerns about safety of Hydroxychloroquine,https://clinicaltrials.gov/ct2/show/NCT04341493,1,0,1,0,3,0,Mexico,0,nitazoxanide|hydroxychloroquine,Clinical Trial Protocol|Letter
NCT04334265,2020-04-01,2020-06-01,Interventional,Efficacy and Safety of Anluohuaxian in the Treatment of Rehabilitation Patients With Corona Virus Disease 2019,Recruiting,N/A,Peking University First Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04334265,1,0,1,0,1,0,China,0,anluohuaxian,Clinical Trial Protocol|Letter
NCT04359810,2020-04-21,2020-12-31,Interventional,Plasma Therapy of COVID-19 in Severely Ill Patients,Recruiting,Phase 2,Columbia University,NA,https://clinicaltrials.gov/ct2/show/NCT04359810,1,0,1,0,3,1,United States|Brazil,0,convalescent plasma|plasma,Clinical Trial Protocol|Letter
NCT04338958,2020-04-22,2021-07-31,Interventional,Ruxolitinib in Covid-19 Patients With Defined Hyperinflammation,Recruiting,Phase 2,University of Jena,NA,https://clinicaltrials.gov/ct2/show/NCT04338958,1,0,1,0,4,0,Germany,0,ruxolitinib,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04368338,2020-04-28,2021-01-28,Observational,Lung Ultrasound to Diagnose COVID-19,Recruiting,NA,"Centre Hospitalier Universitaire, Amiens",NA,https://clinicaltrials.gov/ct2/show/NCT04368338,1,0,1,0,1,0,France,0,pcr|lung ultrasound,Journal Article|Observational Study
NCT04322396,2020-04-06,2021-02-02,Interventional,Proactive Protection With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19,Completed,Phase 2,"Chronic Obstructive Pulmonary Disease Trial Network, Denmark",NA,https://clinicaltrials.gov/ct2/show/NCT04322396,2,0,2,0,4,0,Denmark,0,azithromycin|hydroxychloroquine|placebo,Clinical Trial Protocol|Letter/Journal Article|Multicenter Study|Randomized Controlled Trial
NCT04352517,2020-03-16,2020-08-31,Observational,Influence Physical Activity Psychological Responses COVID-19 Pandemic,Completed,NA,University of Extremadura,NA,https://clinicaltrials.gov/ct2/show/NCT04352517,1,0,1,0,2,0,Brazil|Chile|Uruguay,0,online survey,Journal Article|Multicenter Study|Observational Study
NCT04336254,2020-05-06,2021-11-30,Interventional,Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe COVID-19 Patients,Recruiting,Phase 1/Phase 2,Renmin Hospital of Wuhan University,NA,https://clinicaltrials.gov/ct2/show/NCT04336254,1,0,1,0,1,0,China,0,mesenchymal stem cells|placebo|utooth btc),"Clinical Trial Protocol|Clinical Trial, Phase I|Clinical Trial, Phase II|Letter"
NCT04369469,2020-05-11,2021-05-31,Interventional,Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia,"Active, not recruiting",Phase 3,Alexion Pharmaceuticals,NA,https://clinicaltrials.gov/ct2/show/NCT04369469,3,0,3,0,9,1,United States|France|Japan|Spain|United Kingdom,0,ravulizumab|best supportive care,"Journal Article|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't|Review/Clinical Trial Protocol|Letter/Journal Article"
NCT04354259,2020-05-13,2020-08-01,Interventional,Interferon Lambda for Immediate Antiviral Therapy at Diagnosis in COVID-19,Recruiting,Phase 2,"University Health Network, Toronto",NA,https://clinicaltrials.gov/ct2/show/NCT04354259,3,0,3,0,1,0,Canada,0,peginterferon|placebo,"Journal Article|Review/Journal Article|Research Support, Non-U.S. Gov't/Journal Article|Research Support, Non-U.S. Gov't"
NCT04343781,2020-03-22,2020-04-05,Observational,National Survey of Symptoms of People Aged 70 and Overs Diagnosed With COVID-19,Completed,NA,"University Hospital, Angers",NA,https://clinicaltrials.gov/ct2/show/NCT04343781,1,0,1,0,2,0,France,0,observation,Journal Article
NCT04355364,2020-04-21,2021-12-21,Interventional,Efficacy and Safety of aerosolizedDornase Alfa Administration in Patients With COVID19 Induced ARDS (COVIDORNASE),Recruiting,Phase 3,Fondation Ophtalmologique Adolphe de Rothschild,NA,https://clinicaltrials.gov/ct2/show/NCT04355364,1,0,1,0,8,0,France,0,pulmozyme|standard care,Clinical Trial Protocol|Letter|Multicenter Study
NCT04331574,2020-03-10,2020-04-10,Observational [Patient Registry],Renin-Angiotensin System Inhibitors and COVID-19,Recruiting,NA,Societa Italiana dell'Ipertensione Arteriosa,NA,https://clinicaltrials.gov/ct2/show/NCT04331574,2,0,2,0,0,0,Italy,0,"NA","Journal Article|Multicenter Study|Observational Study|Research Support, Non-U.S. Gov't/Clinical Trial|Journal Article|Multicenter Study|Observational Study|Research Support, Non-U.S. Gov't"
NCT04365959,2020-03-20,2020-04-09,Observational,The Prone Position in Covid-19 Affected Patients,"Active, not recruiting",NA,University of Milano Bicocca,NA,https://clinicaltrials.gov/ct2/show/NCT04365959,1,0,1,0,2,0,Italy,0,prone positioning,"Clinical Trial|Journal Article|Research Support, Non-U.S. Gov't"
NCT04368156,2020-04-20,2021-02-23,Interventional,Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms,"Active, not recruiting",N/A,Hospital ClÃ­nico Universitario de Valencia,NA,https://clinicaltrials.gov/ct2/show/NCT04368156,1,0,1,0,1,0,Spain,0,gammacoreâ® (vagus nerve stimulation)|gammacoreâ® (vagus nerve stimulation),Clinical Trial Protocol|Letter
NCT04348513,2020-05-29,2021-05-02,Interventional,Triiodothyronine for the Treatment of Critically Ill Patients With COVID-19 Infection,Recruiting,Phase 2,Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.,NA,https://clinicaltrials.gov/ct2/show/NCT04348513,1,0,1,0,1,0,Greece,0,t3 solution|placebo,"Clinical Trial Protocol|Clinical Trial, Phase II|Letter|Multicenter Study"
NCT04338672,2020-04-05,2021-04-01,Observational,The Impact of the Covid-19 Outbreak on Emergency Room Attendances of Surgical Patients,Recruiting,NA,Sheba Medical Center,NA,https://clinicaltrials.gov/ct2/show/NCT04338672,1,0,1,0,1,0,Israel,0,covid-19 pandemic,Journal Article|Observational Study
NCT04334291,2020-03-23,2020-05-01,Observational [Patient Registry],"International COVID19 Clinical Evaluation Registry,",Completed,NA,"St Carlos Hospital, Madrid, Spain",NA,https://clinicaltrials.gov/ct2/show/NCT04334291,6,6,12,0,3,0,Spain,0,observational,"Journal Article|Research Support, Non-U.S. Gov't/Journal Article/Journal Article/Journal Article/Comparative Study|Journal Article|Multicenter Study|Observational Study/Journal Article/Journal Article|Research Support, Non-U.S. Gov't/Journal Article|Multicenter Study/Journal Article/Journal Article/Journal Article|Multicenter Study/Journal Article|Multicenter Study"
NCT04327531,2020-03-26,2020-05-22,Observational,"Evaluation of Covid 19 Knowledge Anxiety and Expectation Levels of Turkish Physicians, Survey Study",Completed,NA,Kanuni Sultan Suleyman Training and Research Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04327531,1,0,1,0,4,0,Turkey,0,turkish physicians,Journal Article
NCT04339608,2020-04-02,2020-05-30,Observational,Max COVID19- Study,Recruiting,NA,Max Healthcare Insititute Limited,NA,https://clinicaltrials.gov/ct2/show/NCT04339608,1,0,1,0,0,0,India,0,"NA",Journal Article
NCT04380818,2020-06-05,2021-05-04,Interventional,Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19,Recruiting,N/A,Grupo de InvestigaciÃ³n ClÃ­nica en OncologÃ­a Radioterapia,NA,https://clinicaltrials.gov/ct2/show/NCT04380818,1,0,1,0,2,0,Spain,0,radiotherapy|hydroxychloroquine|lopinavir/ritonavir|tocilizumab|azithromycin|corticosteroid|heparin|oxygen|ritonavir|lopinavir,Journal Article
NCT04410562,2020-05-13,2021-05-13,Interventional,Hydroxychloroquine Efficacy and Safety in Preventing SARS-CoV-2 Infection and COVID-19 Disease Severity During Pregnancy and Postpartum,Recruiting,Phase 3,Barcelona Institute for Global Health,NA,https://clinicaltrials.gov/ct2/show/NCT04410562,1,0,1,0,1,0,Spain,0,hydroxychloroquine|placebo,Clinical Trial Protocol|Letter
NCT04307693,2020-03-11,2020-04-30,Interventional,Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19),Terminated,Phase 2,Asan Medical Center,Terminated early because no patients were further enrolled since mid-Apr 2020.,https://clinicaltrials.gov/ct2/show/NCT04307693,1,0,1,0,2,0,"Korea, Republic of",0,lopinavir/ritonavir|hydroxychloroquine|lopinavir|ritonavir,Journal Article|Comment
NCT04368676,2020-06-25,2022-06-30,Interventional,Breath Regulation and Yogic Exercise An Online Therapy for Calm and Happiness During the COVID-19 Pandemic,"Active, not recruiting",Early Phase 1,Lawson Health Research Institute,NA,https://clinicaltrials.gov/ct2/show/NCT04368676,2,0,2,0,3,0,Canada,0,sudarshan kriya yoga (sky)|health enhancement program,"Journal Article|Meta-Analysis|Research Support, Non-U.S. Gov't|Systematic Review/Clinical Trial Protocol|Clinical Trial, Phase I|Clinical Trial, Phase II|Letter"
NCT04331106,2020-03-27,2022-04-30,Observational,Survey of the Anxiety Associated With the COVID-19 Pandemic,Recruiting,NA,"Charite University, Berlin, Germany",NA,https://clinicaltrials.gov/ct2/show/NCT04331106,1,0,1,0,4,0,Germany,0,online survey,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04390464,2020-05-08,2021-05-07,Interventional,mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Repurposed Drugs (TACTIC-R),Recruiting,Phase 4,Cambridge University Hospitals NHS Foundation Trust,NA,https://clinicaltrials.gov/ct2/show/NCT04390464,1,0,1,0,1,0,United Kingdom,0,ravulizumab|baricitinib|standard care,"Clinical Trial Protocol|Clinical Trial, Phase IV|Letter"
NCT04339816,2020-05-13,2020-11-04,Interventional,Azithromycin Added to Hydrochloroquine in Patients Admitted to Intensive Care With COVID-19: Randomised Controlled Trial,Terminated,Phase 3,"Charles University, Czech Republic",Steering Committee decision in accordance with stopping rule 1: Emergence of new data,https://clinicaltrials.gov/ct2/show/NCT04339816,1,0,1,0,3,0,Czechia,0,azithromycin|hydroxychloroquine|placebo,Clinical Trial Protocol|Journal Article|Multicenter Study
NCT04264533,2020-02-14,2020-03-02,Interventional,Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia,Terminated,Phase 2,Zhongnan Hospital,"the study was started in the second half of the outbreak, and the number of qualifying COVID-19
    patients decreased with the control of the epidemic so that we had to stop our trial before
    reaching the predefined sample size.",https://clinicaltrials.gov/ct2/show/NCT04264533,1,0,1,0,2,0,China,0,vitamin c|water,"Clinical Trial Protocol|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04321265,2020-03-19,2021-09-30,Observational,Outcomes and Prognostic Factors in COVID-19,Recruiting,NA,"Heinrich-Heine University, Duesseldorf",NA,https://clinicaltrials.gov/ct2/show/NCT04321265,2,0,2,0,4,0,Denmark|France|Germany|Norway,0,"NA","Journal Article|Multicenter Study/Journal Article|Multicenter Study|Research Support, Non-U.S. Gov't"
NCT04471701,2020-04-13,2020-07-31,Observational,Italian Web-based Cross-sectional Survey on COVID-19,Recruiting,NA,"Institute of Biomedical Technologies-National Research Council, Italy",NA,https://clinicaltrials.gov/ct2/show/NCT04471701,3,0,3,0,1,0,Italy,0,environmental exposure/clinical features|environmental exposure|clinical features,Journal Article/Journal Article/Journal Article|Observational Study
NCT04312009,2020-04-13,2021-02-01,Interventional,Losartan for Patients With COVID-19 Requiring Hospitalization,Completed,Phase 2,University of Minnesota,NA,https://clinicaltrials.gov/ct2/show/NCT04312009,1,0,1,0,14,1,United States,0,losartan|placebo,Journal Article
NCT04335123,2020-04-04,2020-06-21,Interventional,Study of Open Label Losartan in COVID-19,Completed,Phase 1,University of Kansas Medical Center,NA,https://clinicaltrials.gov/ct2/show/NCT04335123,1,0,1,0,3,1,United States,0,losartan,Journal Article
NCT04311177,2020-04-09,2021-02-01,Interventional,Losartan for Patients With COVID-19 Not Requiring Hospitalization,Completed,Phase 2,University of Minnesota,NA,https://clinicaltrials.gov/ct2/show/NCT04311177,1,0,1,0,10,1,United States,0,losartan|placebo,Journal Article
NCT04283461,2020-03-16,2022-11-22,Interventional,Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19),"Active, not recruiting",Phase 1,National Institute of Allergy and Infectious Diseases (NIAID),NA,https://clinicaltrials.gov/ct2/show/NCT04283461,2,0,2,1,24,1,United States,0,mrna-1273,"Clinical Trial, Phase I|Journal Article|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't/Clinical Trial, Phase I|Journal Article|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't"
NCT04252274,2020-01-30,2020-08-31,Interventional,Efficacy and Safety of Darunavir and Cobicistat for Treatment of COVID-19,Recruiting,Phase 3,Shanghai Public Health Clinical Center,NA,https://clinicaltrials.gov/ct2/show/NCT04252274,1,0,1,0,2,0,China,0,darunavir/cobicistat|darunavir|cobicistat,Journal Article
NCT04251871,2020-01-22,2021-01-22,Interventional,Treatment and Prevention of Traditional Chinese Medicines (TCMs) on COVID-19 Infection,Recruiting,N/A,Beijing 302 Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04251871,2,0,2,0,1,0,China,0,"conventional medicines (oxygen therapy, alfa interferon via aerosol inhalation,/lopinavir/ritonavir)/traditional chinese medicines (tcms) granules|conventional medicines (oxygen therapy, alfa interferon via aerosol inhalation,/lopinavir/ritonavir)|conventional medicines (oxygen therapy, alfa interferon via aerosol inhalation,|lopinavir|ritonavir|traditional chinese medicine",Journal Article|Randomized Controlled Trial/Journal Article|Systematic Review
NCT04370067,2020-05-01,2021-05-01,Observational [Patient Registry],HUNgarian COronaVirus Disease-19 Epidemiological Research,Recruiting,NA,Semmelweis University Heart and Vascular Center,NA,https://clinicaltrials.gov/ct2/show/NCT04370067,1,0,1,0,2,0,Hungary,0,"NA","Journal Article|Research Support, Non-U.S. Gov't"
NCT04381936,2020-03-19,2021-12-31,Interventional,Randomised Evaluation of COVID-19 Therapy,Recruiting,Phase 2/Phase 3,University of Oxford,NA,https://clinicaltrials.gov/ct2/show/NCT04381936,3,2,5,0,9,0,Indonesia|Nepal|United Kingdom,0,lopinavir/ritonavir|corticosteroid|hydroxychloroquine|azithromycin|convalescent plasma|tocilizumab|immunoglobulin|synthetic neutralising antibodies|aspirin|colchicine|baricitinib|anakinra|dimethyl fumarate|infliximab|high dose corticosteroid,Comparative Study|Journal Article|Multicenter Study|Randomized Controlled Trial/Comparative Study|Journal Article|Multicenter Study|Randomized Controlled Trial/Journal Article/Comparative Study|Journal Article|Multicenter Study|Randomized Controlled Trial/Comparative Study|Journal Article|Multicenter Study|Randomized Controlled Trial
NCT04368390,2020-04-03,2021-04-30,Observational,Neuroradiolological Analysis of COVID-19 Patients,Recruiting,NA,"University Hospital, Strasbourg, France",NA,https://clinicaltrials.gov/ct2/show/NCT04368390,1,0,1,0,2,0,France,0,"NA",Journal Article|Multicenter Study
NCT04361474,2020-05-18,2020-11-24,Interventional,Trial Evaluating the Efficacy of Local Budesonide Therapy in the Management of Hyposmia in COVID-19 Patients Without Signs of Severity,"Active, not recruiting",Phase 3,Fondation Ophtalmologique Adolphe de Rothschild,NA,https://clinicaltrials.gov/ct2/show/NCT04361474,1,0,1,0,4,0,France,0,budesonide|serum,Clinical Trial Protocol|Letter|Multicenter Study
NCT04279899,2020-02-01,2023-11-30,Observational,The Investigation of the Neonates With or With Risk of COVID-19,Recruiting,NA,Children's Hospital of Fudan University,NA,https://clinicaltrials.gov/ct2/show/NCT04279899,1,0,1,0,1,0,China,0,"NA",Journal Article|Multicenter Study|Observational Study
NCT04403607,2020-05-22,2020-09-30,Observational,Cardiac Imaging in SARS-CoV-2 (COVID-19),Recruiting,NA,NHS Greater Glasgow and Clyde,NA,https://clinicaltrials.gov/ct2/show/NCT04403607,1,0,1,0,2,0,United Kingdom,0,"NA",Journal Article|Multicenter Study|Observational Study
NCT04324606,2020-04-23,2021-10-31,Interventional,A Study of a Candidate COVID-19 Vaccine (COV001),"Active, not recruiting",Phase 1/Phase 2,University of Oxford,NA,https://clinicaltrials.gov/ct2/show/NCT04324606,4,0,4,1,14,0,United Kingdom,0,chadox1|menacwy|paracetamol|chadox1 ncov-19 0.5ml (3.5-6.5x10^10vp) late vaccine (lv)|chadox1 ncov-19 0.5ml (3.5-6.5x10^10vp) late vaccine two (lvt),"Clinical Trial, Phase I|Clinical Trial, Phase II|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't/Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't/Clinical Trial, Phase I|Clinical Trial, Phase II|Journal Article|Research Support, Non-U.S. Gov't/Journal Article|Meta-Analysis|Research Support, Non-U.S. Gov't"
NCT04341389,2020-04-12,2021-01-31,Interventional,A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for COVID-19 (Adenovirus Vector),"Active, not recruiting",Phase 2,"Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China",NA,https://clinicaltrials.gov/ct2/show/NCT04341389,1,0,1,1,3,0,China,0,adenovirus type 5 vector|placebo,"Clinical Trial, Phase II|Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04322123,2020-04-01,2020-08-30,Interventional,Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),"Active, not recruiting",Phase 3,Hospital do Coracao,NA,https://clinicaltrials.gov/ct2/show/NCT04322123,1,0,1,0,7,0,Brazil,0,hydroxychloroquine|hydroxychloroquine / azithromycin|azithromycin,"Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04441489,2020-03-27,2020-05-03,Observational,Assessment of Lung Inflammation With FDG PET/CT in COVID-19,Completed,NA,Centre Hospitalier Princesse Grace,NA,https://clinicaltrials.gov/ct2/show/NCT04441489,1,0,1,0,0,0,Monaco,0,"NA",Clinical Trial|Journal Article
NCT04323644,2020-01-01,2020-09-30,Observational,Outcomes of Surgery in COVID-19 Infection: International Cohort Study (CovidSurg),Recruiting,NA,University of Birmingham,NA,https://clinicaltrials.gov/ct2/show/NCT04323644,1,0,1,0,1,0,Spain,0,surgery,Journal Article
NCT04331834,2020-04-03,2020-06-25,Interventional,Pre-Exposure Prophylaxis With Hydroxychloroquine for High-Risk Healthcare Workers During the COVID-19 Pandemic,Completed,Phase 3,Barcelona Institute for Global Health,NA,https://clinicaltrials.gov/ct2/show/NCT04331834,1,0,1,0,3,0,Spain,0,hydroxychloroquine|placebo,Clinical Trial Protocol|Letter|Multicenter Study
NCT04368975,2020-03-12,2020-04-21,Observational [Patient Registry],ARDS Caused by COVID-19,Recruiting,NA,Hospital Clinic of Barcelona,NA,https://clinicaltrials.gov/ct2/show/NCT04368975,1,0,1,0,0,0,Spain,0,"NA","Journal Article|Multicenter Study|Observational Study|Research Support, Non-U.S. Gov't"
NCT04393246,2020-07-03,2022-02-15,Interventional,mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Experimental Drugs and Mechanisms,Recruiting,Phase 2/Phase 3,Cambridge University Hospitals NHS Foundation Trust,NA,https://clinicaltrials.gov/ct2/show/NCT04393246,1,0,1,0,3,0,United Kingdom,0,edp1815|dapagliflozin|ambrisentan|standard care,"Clinical Trial Protocol|Clinical Trial, Phase II|Clinical Trial, Phase III|Letter"
NCT04363827,2020-05-14,2021-06-30,Interventional,Protect: Study With Hydroxychloroquine for Prevention and Early Phase Treatment of Coronavirus Disease (COVID-19),"Active, not recruiting",Phase 2,Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori,NA,https://clinicaltrials.gov/ct2/show/NCT04363827,1,0,1,0,3,0,Italy,0,hydroxychloroquine,Clinical Trial Protocol|Comparative Study|Journal Article|Observational Study
NCT04433910,2020-08-30,2021-01-21,Interventional,A Clinical Trial of Convalescent Plasma Compared to Best Supportive Care for Treatment of Patients With Severe COVID-19,Completed,Phase 2,Deutsches Rotes Kreuz DRK-Blutspendedienst Baden-Wurttemberg-Hessen,NA,https://clinicaltrials.gov/ct2/show/NCT04433910,1,0,1,0,4,0,Germany,0,convalescent plasma,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04416399,2020-07-16,2021-01-12,Interventional,STerOids in COVID-19 Study,Terminated,Phase 2,University of Oxford,Independent statistical review advice,https://clinicaltrials.gov/ct2/show/NCT04416399,2,0,2,0,4,0,United Kingdom,0,budesonide,"Journal Article|Research Support, Non-U.S. Gov't/Journal Article"
NCT04331470,2020-04-04,2020-04-20,Interventional,Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in Treatment of COVID-19,Recruiting,Phase 2/Phase 3,Fasa University of Medical Sciences,NA,https://clinicaltrials.gov/ct2/show/NCT04331470,1,0,1,0,2,0,"Iran, Islamic Republic of",0,levamisole / budesonide/formoterol|lopinavir/ritonavir / hydoxychloroquine|levamisole|budesonide|formoterol|lopinavir|ritonavir|hydroxychloroquine,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04330586,2020-04-01,2021-03-31,Interventional,A Trial of Ciclesonide in Adults With Mild-to-moderate COVID-19,Recruiting,Phase 2,Korea University Guro Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04330586,1,0,1,0,2,0,"Korea, Republic of",0,ciclesonide,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04355637,2020-04-21,2021-08-31,Interventional,Inhaled Corticosteroid Treatment of COVID19 Patients With Pneumonia,Recruiting,Phase 4,Fundacion Clinic per a la Recerca BiomÃ©dica,NA,https://clinicaltrials.gov/ct2/show/NCT04355637,1,0,1,0,4,0,Argentina|Spain,0,budesonide,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04377711,2020-06-08,2021-01-05,Interventional,A Study of the Safety and Efficacy of Ciclesonide in the Treatment of Non-hospitalized COVID-19 Patients,Completed,Phase 3,Covis Pharma S.Ã .r.l.,NA,https://clinicaltrials.gov/ct2/show/NCT04377711,1,0,1,0,4,1,United States,0,ciclesonide|placebo,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04331509,2020-03-23,2022-03-23,Observational,COVID-19 Symptom Tracker,Recruiting,NA,King's College London,NA,https://clinicaltrials.gov/ct2/show/NCT04331509,1,0,1,0,2,1,United States|United Kingdom,0,no intervention,"Journal Article|Observational Study|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't"
NCT04346186,2020-04-15,2020-10-01,Observational,COVID-19: Investigation of Transmission and Immunisation Among Hospital Staff,Enrolling by invitation,NA,Herlev Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04346186,1,0,1,0,1,0,Denmark,0,igm/igg rapid test|igm|igg antibody test|igg,"Journal Article|Observational Study|Research Support, Non-U.S. Gov't"
NCT04296643,2020-04-01,2021-02-01,Interventional,Medical Masks vs N95 Respirators for COVID-19,Recruiting,N/A,McMaster University,NA,https://clinicaltrials.gov/ct2/show/NCT04296643,1,0,1,0,2,0,Canada|Israel,0,medical mask|n95 respirator,Journal Article
NCT04392245,2020-04-15,2020-04-26,Observational,Proctologic Practice and Covid-19,Completed,NA,Societa Italiana di Chirurgia ColoRettale,NA,https://clinicaltrials.gov/ct2/show/NCT04392245,1,0,1,0,0,0,Italy,0,"NA",Journal Article
NCT04338698,2020-04-22,2020-09-01,Interventional,"Hydroxychloroquine, Oseltamivir and Azithromycin for the Treatment of COVID-19 Infection: An RCT",Recruiting,Phase 3,University of Health Sciences Lahore,NA,https://clinicaltrials.gov/ct2/show/NCT04338698,1,0,1,0,2,0,Pakistan,0,hydroxychloroquine|oseltamivir|azithromycin,Clinical Trial Protocol|Letter|Multicenter Study|Observational Study|Randomized Controlled Trial
NCT04401202,2020-05-21,2020-12-31,Interventional,Nigella Sativa in COVID-19,Completed,Phase 2,King Abdulaziz University,NA,https://clinicaltrials.gov/ct2/show/NCT04401202,1,0,1,0,1,0,Saudi Arabia,0,nigella sativa oil,"Clinical Trial Protocol|Clinical Trial, Phase II|Letter"
NCT04401540,2020-05-01,2020-10-30,Observational [Patient Registry],Characteristics of Neonatal Covid-19 in Turkey,Recruiting,NA,Recep Tayyip Erdogan University Training and Research Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04401540,1,3,4,0,2,0,Turkey,0,"NA",Clinical Trial|Journal Article|Multicenter Study/Journal Article|Review/Journal Article
NCT04434131,2020-04-28,2021-04-28,Interventional,Treatment With Investigational Convalescent Plasma and Measure Antibody Levels in Patients Hospitalized With COVID-19,Recruiting,Phase 2,University of New Mexico,NA,https://clinicaltrials.gov/ct2/show/NCT04434131,2,0,2,0,2,1,United States,0,convalescent plasma,"Clinical Trial|Journal Article/Journal Article|Meta-Analysis|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04316949,2020-03-20,2020-04-30,Observational,Predictors of Respiratory Failure in SARS-Cov-2 Infection,Recruiting,NA,University of Bologna,NA,https://clinicaltrials.gov/ct2/show/NCT04316949,1,0,1,0,4,0,Italy,0,"NA",Journal Article|Multicenter Study
NCT04368728,2020-04-29,2021-10-29,Interventional,"Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals",Recruiting,Phase 2/Phase 3,BioNTech SE,NA,https://clinicaltrials.gov/ct2/show/NCT04368728,4,0,4,1,28,1,United States|Argentina|Brazil|Germany|South Africa|Turkey,0,bnt162b1|bnt162b2|placebo|bnt162b2sa,"Clinical Trial, Phase I|Clinical Trial, Phase II|Journal Article|Randomized Controlled Trial/Clinical Trial, Phase I|Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't/Clinical Trial, Phase II|Clinical Trial, Phase III|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't/Journal Article"
NCT04343729,2020-04-18,2020-06-16,Interventional,Methylprednisolone in the Treatment of Patients With Signs of Severe Acute Respiratory Syndrome in Covid-19,Completed,Phase 2,FundaÃ§Ã£o de Medicina Tropical Dr. Heitor Vieira Dourado,NA,https://clinicaltrials.gov/ct2/show/NCT04343729,1,0,1,0,7,0,Brazil,0,methylprednisolone|placebo,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04394000,2020-05-04,2020-05-15,Observational [Patient Registry],Impact of an Intensified Thromboprofylaxis Protocol in COVID-19,Completed,NA,Jessa Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04394000,1,0,1,0,0,0,Belgium,0,thromboprofylaxis protocol|standard care,Journal Article
NCT04344600,2020-05-29,2021-06-30,Interventional,Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 (COVID-19) Infection,Recruiting,Phase 2,Johns Hopkins University,NA,https://clinicaltrials.gov/ct2/show/NCT04344600,1,0,1,0,3,1,United States,0,peginterferon|saline,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04385095,2020-03-16,2021-02-17,Interventional,Trial of Inhaled Anti-viral (SNG001) for SARS-CoV-2 (COVID-19) Infection,"Active, not recruiting",Phase 2,Synairgen Research Ltd.,NA,https://clinicaltrials.gov/ct2/show/NCT04385095,2,0,2,0,3,0,United Kingdom,0,sng001|placebo,"Journal Article|Research Support, Non-U.S. Gov't/Clinical Trial, Phase II|Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04343976,2020-06-22,2021-09-01,Interventional,Pegylated Interferon Lambda Treatment for COVID-19,Enrolling by invitation,Phase 2,Massachusetts General Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04343976,1,0,1,0,4,1,United States,0,peginterferon,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04347993,2020-03-27,2022-03-31,Observational [Patient Registry],"A Prospective ""Universal"" Observational Database for COVID-19",Recruiting,NA,Hackensack Meridian Health,NA,https://clinicaltrials.gov/ct2/show/NCT04347993,2,0,2,0,2,1,United States,0,"NA",Journal Article|Multicenter Study|Observational Study/Journal Article
NCT04345614,2020-04-08,2021-07-31,Interventional,A Study of Auxora in Patients With Severe COVID-19 Pneumonia,Recruiting,Phase 2,"CalciMedica, Inc.",NA,https://clinicaltrials.gov/ct2/show/NCT04345614,1,0,1,0,18,1,United States|Puerto Rico,0,auxora|placebo,"Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04352556,2020-04-07,2021-04-30,Observational,COVID19-hematological Malignancies: the Italian Hematology Alliance,Recruiting,NA,Ospedale di Circolo - Fondazione Macchi,NA,https://clinicaltrials.gov/ct2/show/NCT04352556,1,0,1,0,2,0,Italy,0,"NA",Journal Article|Multicenter Study|Observational Study
NCT04325061,2020-04-03,2020-06-19,Interventional,Efficacy of Dexamethasone Treatment for Patients With ARDS Caused by COVID-19,Terminated,Phase 4,Dr. Negrin University Hospital,Lack of enrollment,https://clinicaltrials.gov/ct2/show/NCT04325061,1,2,3,0,8,0,Spain,0,dexamethasone,"Clinical Trial Protocol|Journal Article|Multicenter Study/Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04375410,2020-04-22,2020-04-30,Observational,Consequences of Intensified Handwash and Hand Disinfection Among Children During the COVID19 Pandemic,Completed,NA,Vendsyssel Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04375410,1,0,1,0,1,0,Denmark,0,"NA",Journal Article|Multicenter Study|Observational Study
NCT04381962,2020-06-03,2021-01-29,Interventional,A Multicentre Open-label Two-arm Randomised Superiority Clinical Trial of Azithromycin Versus Usual Care In Ambulatory COVID19 (ATOMIC2),Completed,Phase 3,University of Oxford,NA,https://clinicaltrials.gov/ct2/show/NCT04381962,1,0,1,0,2,0,United Kingdom,0,azithromycin,"Clinical Trial Protocol|Clinical Trial, Phase II|Clinical Trial, Phase III|Comparative Study|Journal Article|Multicenter Study"
NCT04438629,2020-03-26,2020-06-10,Observational,Evaluation of Immune Response in COVID-19 Patients,Recruiting,NA,Azienda Ospedaliera Universitaria Integrata Verona,NA,https://clinicaltrials.gov/ct2/show/NCT04438629,1,0,1,0,1,0,Italy,0,covid-19 treatment,Clinical Trial|Journal Article|Multicenter Study|Observational Study
NCT04412057,2020-06-09,2020-12-02,Interventional,Clinical Trial to Evaluate CERC-002 in Adults With COVID-19 Pneumonia and Acute Lung Injury,Completed,Phase 2,Cerecor Inc,NA,https://clinicaltrials.gov/ct2/show/NCT04412057,1,0,1,0,6,1,United States,0,cerc-002|placebo,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04292730,2020-03-15,2020-04-29,Interventional,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â„¢) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Completed,Phase 3,Gilead Sciences,NA,https://clinicaltrials.gov/ct2/show/NCT04292730,1,1,2,0,20,1,"Japan|United States|China|France|Germany|Hong Kong|Italy|Korea, Republic of|Netherlands|Singapore|Spain|Sweden|Switzerland|Taiwan|United Kingdom",1,remdesivir|standard care,"Clinical Trial, Phase III|Comparative Study|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't/Clinical Trial, Phase III|Comparative Study|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04370288,2020-04-19,2020-09-20,Interventional,Clinical Application of Methylene Blue for Treatment of Covid-19 Patients,Recruiting,Phase 1,Mashhad University of Medical Sciences,NA,https://clinicaltrials.gov/ct2/show/NCT04370288,1,0,1,0,1,0,"Iran, Islamic Republic of",0,methylene blue/ vitamin c/n-acetyl cysteine,Case Reports|Journal Article
NCT04262921,2020-02-08,2020-08-07,Observational,French COVID Cohort,Recruiting,NA,"Institut National de la SantÃ© Et de la Recherche MÃ©dicale, France",NA,https://clinicaltrials.gov/ct2/show/NCT04262921,3,0,3,0,2,0,France,0,"NA","Case Reports|Journal Article|Research Support, Non-U.S. Gov't/Journal Article|Research Support, Non-U.S. Gov't/Journal Article"
NCT04337541,2020-04-02,2020-06-02,Interventional,Reduction in COVID-19 Infection Using Surgical Facial Masks Outside the Healthcare System,Completed,N/A,"Rigshospitalet, Denmark",NA,https://clinicaltrials.gov/ct2/show/NCT04337541,2,0,2,0,1,0,Denmark,0,surgical facial mask,"Journal Article|Randomized Controlled Trial/Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04357730,2020-05-14,2021-03-22,Interventional,Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection,"Active, not recruiting",Phase 2,Denver Health and Hospital Authority,NA,https://clinicaltrials.gov/ct2/show/NCT04357730,1,0,1,0,9,1,United States,0,activase,Journal Article
NCT04252885,2020-01-28,2020-04-30,Interventional,The Efficacy of Lopinavir Plus Ritonavir and Arbidol Against Novel Coronavirus Infection,Completed,Phase 4,Guangzhou 8th People's Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04252885,1,0,1,0,1,0,China,0,lopinavir/ritonavir|arbidol|lopinavir|ritonavir,Journal Article
NCT04395105,2020-05-21,2020-12-31,Interventional,"Dexamethasone for COVID-19 Related ARDS: a Multicenter, Randomized Clinical Trial",Recruiting,Phase 3,Centro de EducaciÃ³n Medica e Investigaciones ClÃ­nicas Norberto Quirno,NA,https://clinicaltrials.gov/ct2/show/NCT04395105,1,0,1,0,3,0,Argentina,0,dexamethasone,Clinical Trial Protocol|Letter|Multicenter Study|Randomized Controlled Trial
NCT04420741,2020-06-15,2021-02-23,Interventional,Infusion of Prostacyclin (Iloprost) vs Placebo for 72-hours in COVID-19 Patients With Respiratory Failure,"Active, not recruiting",Phase 2,"Rigshospitalet, Denmark",NA,https://clinicaltrials.gov/ct2/show/NCT04420741,1,0,1,0,6,0,Denmark,0,iloprost|saline,Clinical Trial Protocol|Letter|Multicenter Study|Randomized Controlled Trial
NCT04378595,2020-04-10,2020-12-30,Observational,Assessing Pediatric Food Insecurity During the COVID-19 Pandemic in Austin,Recruiting,NA,University of Texas at Austin,NA,https://clinicaltrials.gov/ct2/show/NCT04378595,1,0,1,0,1,1,United States,0,during covid-19 pandemic|after covid-19 pandemic,Journal Article
NCT04378582,2020-05-07,2020-07-28,Observational,Characteristics and Outcomes of Patients With COVID-19 Admitted to the ICU,Completed,NA,University of Sao Paulo General Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04378582,1,0,1,0,3,0,Brazil,0,risk factors,Journal Article
NCT04327401,2020-04-13,2020-07-22,Interventional,COVID-19-associated ARDS Treated With Dexamethasone: Alliance Covid-19 Brasil III,Terminated,Phase 3,Hospital Sirio-Libanes,"The Data Monitoring Committee recommended to stop the trial based on the Recovery Trial
    results, which was accepted by the CoDEX Steering Committee.",https://clinicaltrials.gov/ct2/show/NCT04327401,1,0,1,0,5,0,Brazil,0,dexamethasone,"Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04305574,2020-03-07,2020-04-21,Observational,Social Media Use During COVID-19,Completed,NA,Yale-NUS College,NA,https://clinicaltrials.gov/ct2/show/NCT04305574,1,0,1,0,2,0,Singapore,0,use of social media during covid-19,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04368988,2020-05-25,2020-12-01,Interventional,Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle Vaccine With/Without Matrix-M Adjuvant,"Active, not recruiting",Phase 1/Phase 2,Novavax,NA,https://clinicaltrials.gov/ct2/show/NCT04368988,3,0,3,1,5,1,United States|Australia,0,sars-cov-2 rs|sars-cov-2 rs/matrix-m1 adjuvant|placebo|adjuvant|21 - phase 2,"Clinical Trial, Phase I|Clinical Trial, Phase II|Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't/Journal Article|Research Support, Non-U.S. Gov't/Journal Article|Research Support, Non-U.S. Gov't"
NCT04338841,2020-04-09,2020-06-17,Interventional,HOME-CoV: Hospitalization or Outpatient ManagEment of Patients With a SARS-CoV-2 Infection,Completed,N/A,"University Hospital, Angers",NA,https://clinicaltrials.gov/ct2/show/NCT04338841,1,0,1,0,2,0,Belgium|France|Monaco,0,home-cov rule implementation,Journal Article
NCT04445935,2020-06-28,2020-09-28,Interventional,Anticoagulation in Patients Suffering From COVID-19 Disease The ANTI-CO Trial,Recruiting,Phase 4,Hamad Medical Corporation,NA,https://clinicaltrials.gov/ct2/show/NCT04445935,1,0,1,0,0,0,Qatar,0,bivalirudin|standard care,Clinical Trial Protocol|Equivalence Trial|Letter
NCT04436471,2020-06-17,2020-08-03,Interventional,"An Open Study of the Safety, Tolerability and Immunogenicity of the Drug ""Gam-COVID-Vac"" Vaccine Against COVID-19",Completed,Phase 1/Phase 2,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",NA,https://clinicaltrials.gov/ct2/show/NCT04436471,1,0,1,1,3,0,Russian Federation,0,gam-covid-vac,"Clinical Trial, Phase I|Clinical Trial, Phase II|Journal Article|Multicenter Study|Research Support, Non-U.S. Gov't"
NCT04437875,2020-06-17,2020-08-03,Interventional,"An Open Study of the Safety, Tolerability and Immunogenicity of ""Gam-COVID-Vac Lyo"" Vaccine Against COVID-19",Completed,Phase 1/Phase 2,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",NA,https://clinicaltrials.gov/ct2/show/NCT04437875,1,0,1,1,3,0,Russian Federation,0,gam-covid-vac lyo,"Clinical Trial, Phase I|Clinical Trial, Phase II|Journal Article|Multicenter Study|Research Support, Non-U.S. Gov't"
NCT04333849,2020-03-25,2020-05-11,Observational,Telephony Or Videophony for Isolated elDerly in Maine-Et-Loire 49 During COVID-19,Completed,NA,"University Hospital, Angers",NA,https://clinicaltrials.gov/ct2/show/NCT04333849,1,0,1,0,2,0,France,0,"NA",Clinical Trial|Journal Article
NCT04347681,2020-04-18,2020-12-31,Interventional,Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19,Recruiting,Phase 2,King Fahad Specialist Hospital Dammam,NA,https://clinicaltrials.gov/ct2/show/NCT04347681,2,0,2,0,3,0,Saudi Arabia,0,convalescent plasma,Journal Article/Journal Article
NCT04400799,2020-06-15,2022-03-14,Interventional,Enoxaparin for Primary Thromboprophylaxis in Ambulatory Patients With COVID-19,Recruiting,Phase 3,University of Zurich,NA,https://clinicaltrials.gov/ct2/show/NCT04400799,1,0,1,0,2,0,Switzerland,0,enoxaparin|0.4ml inj syringe 0.4ml,Clinical Trial Protocol|Letter
NCT04357808,2020-04-13,2020-11-30,Interventional,Efficacy of Subcutaneous Sarilumab in Hospitalised Patients With Moderate-severe COVID-19 Infection (SARCOVID),Completed,Phase 2,FundaciÃ³n de InvestigaciÃ³n BiomÃ©dica - Hospital Universitario de La Princesa,NA,https://clinicaltrials.gov/ct2/show/NCT04357808,1,0,1,0,3,0,Spain,0,sarilumab|standard care,Clinical Trial Protocol|Letter
NCT04396197,2020-03-01,2020-05-08,Observational,Physical Activity Levels in COVID-19 Patients Admitted to Intensive Care,Completed,NA,University Hospital Birmingham NHS Foundation Trust,NA,https://clinicaltrials.gov/ct2/show/NCT04396197,1,0,1,0,0,0,United Kingdom,0,physiotherapy,Journal Article|Observational Study
NCT04399317,2020-05-28,2020-07-31,Interventional,Flow Controlled Ventilation in ARDS Associated With COVID-19,Recruiting,N/A,Hamad Medical Corporation,NA,https://clinicaltrials.gov/ct2/show/NCT04399317,1,0,1,0,1,0,Qatar,0,flow controlled ventilation (evone-ventilator),Clinical Trial Protocol|Letter
NCT04327206,2020-03-30,2021-06-30,Interventional,BCG Vaccination to Protect Healthcare Workers Against COVID-19,"Active, not recruiting",Phase 3,Murdoch Childrens Research Institute,NA,https://clinicaltrials.gov/ct2/show/NCT04327206,1,0,1,1,11,0,Australia|Brazil|Netherlands|Spain|United Kingdom,0,bcg|saline,"Journal Article|Research Support, Non-U.S. Gov't|Review"
NCT04352959,2020-04-27,2020-12-11,Interventional,COVID-19: Nasal and Salivary Detection of the SARS-CoV-2 Virus After Antiviral Mouthrinses,Completed,N/A,Claude Bernard University,NA,https://clinicaltrials.gov/ct2/show/NCT04352959,2,0,2,0,4,0,France,0,mouthrinse with bãªta-cyclodextrin/citrox|mouthrinse without bãªta-cyclodextrin/citrox|mouthrinse with bãªta-cyclodextrin|citrox|mouthrinse without bãªta-cyclodextrin,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review/Clinical Trial Protocol|Letter"
NCT04364802,2020-04-29,2021-05-31,Interventional,COVID-19: Povidone-Iodine Intranasal Prophylaxis in Front-line Healthcare Personnel and Inpatients,Recruiting,Phase 2,University of Kentucky,NA,https://clinicaltrials.gov/ct2/show/NCT04364802,1,0,1,0,2,1,United States,0,povidone/iodine|gargle,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04373291,2020-05-18,2021-07-31,Interventional,Using BCG Vaccine to Protect Health Care Workers in the COVID-19 Pandemic,"Active, not recruiting",Phase 3,Bandim Health Project,NA,https://clinicaltrials.gov/ct2/show/NCT04373291,1,0,1,1,4,0,Denmark,0,bcg-denmark|saline,Clinical Trial Protocol|Letter
NCT04367129,2020-04-14,2021-04-01,Observational,Electrocardiogram Analysis in COVID-19 Patients,Recruiting,NA,University Hospital of Ferrara,NA,https://clinicaltrials.gov/ct2/show/NCT04367129,1,0,1,0,1,0,Italy,0,ecg,Journal Article|Multicenter Study
NCT04439084,2020-03-06,2021-06-30,Observational,COVID-19 in Patients With Chronic Liver Diseases,Enrolling by invitation,NA,Stanford University,NA,https://clinicaltrials.gov/ct2/show/NCT04439084,1,0,1,0,1,1,United States,0,prospective chart review,Journal Article
NCT04343261,2020-04-10,2020-07-23,Interventional,Convalescent Plasma in the Treatment of COVID 19,Completed,Phase 2,Saint Francis Care,NA,https://clinicaltrials.gov/ct2/show/NCT04343261,3,2,5,0,9,1,United States,1,convalescent plasma,"Journal Article/Journal Article/Journal Article|Meta-Analysis|Research Support, Non-U.S. Gov't|Systematic Review/Clinical Trial, Phase II|Journal Article/Journal Article"
NCT04335162,2020-02-28,2021-08-31,Observational,Cardiovascular Complications and COVID-19 (CovCardioVasc-Study),Recruiting,NA,Centre Hospitalier Universitaire de Nice,NA,https://clinicaltrials.gov/ct2/show/NCT04335162,1,0,1,0,4,0,France,0,"NA",Journal Article
NCT04321928,2020-04-01,2021-04-21,Interventional,Personalized Health Education Against the Health Damage of Novel Coronavirus (COVID-19) Outbreak in Hungary,Recruiting,N/A,University of Pecs,NA,https://clinicaltrials.gov/ct2/show/NCT04321928,1,0,1,0,2,0,Hungary,0,personalized health education|general health education,Clinical Trial Protocol|Journal Article
NCT04394416,2020-06-02,2022-06-01,Interventional,Trial of Imatinib for Hospitalized Adults With COVID-19,Recruiting,Phase 3,"University of Maryland, Baltimore",NA,https://clinicaltrials.gov/ct2/show/NCT04394416,2,0,2,0,1,1,United States,0,imatinib|placebo,"Letter|Research Support, N.I.H., Extramural/Clinical Trial Protocol|Letter"
NCT04329923,2020-04-09,2020-11-11,Interventional,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Terminated,Phase 2,University of Pennsylvania,"Cohort 1: slow accrual Cohort 2: Other studies showed no benefit Cohort 3: Study met
    pre-specificied futility analysis at planned second interim analysis",https://clinicaltrials.gov/ct2/show/NCT04329923,1,1,2,0,7,1,United States,1,hydroxychloroquine|placebo,Journal Article|Multicenter Study|Randomized Controlled Trial/Journal Article|Multicenter Study|Randomized Controlled Trial
NCT04377815,2020-04-23,2020-05-14,Observational,Finding Out if COVID-19 Infection Can be pREdicted by ChAnges in Smell and/or Taste,Completed,NA,"University College, London",NA,https://clinicaltrials.gov/ct2/show/NCT04377815,2,0,2,0,1,0,United Kingdom,0,general public cohort,"Journal Article|Observational Study|Research Support, Non-U.S. Gov't/Journal Article"
NCT04352764,2020-03-27,2020-12-31,Observational [Patient Registry],ANTIBODY BASED TESTS FOR SARSCoV-2 COVID-19) - Evaluation of Patients and Healthcare Providers in the Confines of Healthcare Settings,Recruiting,NA,Texas Cardiac Arrhythmia Research Foundation,NA,https://clinicaltrials.gov/ct2/show/NCT04352764,1,0,1,0,2,1,United States,0,igm/igg rapid test|igg antibody test|igm,Journal Article
NCT04333420,2020-03-31,2021-05-31,Interventional,"Randomized, Controlled Study of IFX-1 in Patients With Severe COVID-19 Pneumonia",Recruiting,Phase 2/Phase 3,InflaRx GmbH,NA,https://clinicaltrials.gov/ct2/show/NCT04333420,1,0,1,0,8,0,Belgium|Brazil|France|Germany|Mexico|Netherlands|Peru|Russian Federation,0,soc / ifx-1|soc / placebo|standard care|ifx-1|placebo,Journal Article
NCT04384926,2020-03-30,2020-12-31,Observational,Outcomes of Elective Cancer Surgery During the COVID-19 Pandemic Crisis,Recruiting,NA,University of Birmingham,NA,https://clinicaltrials.gov/ct2/show/NCT04384926,1,0,1,0,0,0,Spain,0,elective cancer surgery,"Comparative Study|Journal Article|Multicenter Study|Research Support, Non-U.S. Gov't"
NCT04358029,2020-04-09,2022-05-31,Observational,Cardiac Arrhythmias In Patients With Coronavirus Disease (COVID-19),Recruiting,NA,Icahn School of Medicine at Mount Sinai,NA,https://clinicaltrials.gov/ct2/show/NCT04358029,1,0,1,0,2,1,United States,0,"NA",Comparative Study|Journal Article
NCT04323839,2020-03-20,2024-03-31,Observational [Patient Registry],COVID-19 PRIORITY (Pregnancy CoRonavIrus Outcomes RegIsTrY),Enrolling by invitation,NA,"University of California, San Francisco",NA,https://clinicaltrials.gov/ct2/show/NCT04323839,1,0,1,0,4,1,United States,0,pregnant women under investigation for coronavirus/diagnosed with covid-19|postpartum women under investigation for coronavirus/diagnosed with covid-19|pregnant women under investigation for coronavirus|diagnosed with covid-19|postpartum,"Journal Article|Observational Study|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't"
NCT04317092,2020-03-19,2021-12-19,Interventional,Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),"Active, not recruiting",Phase 2,"National Cancer Institute, Naples",NA,https://clinicaltrials.gov/ct2/show/NCT04317092,3,0,3,0,4,0,Italy,0,tocilizumab,"Clinical Trial Protocol|Journal Article/Journal Article/Clinical Trial, Phase II|Journal Article|Multicenter Study"
NCT04307459,2020-03-19,2020-09-01,Observational,Acute Respiratory Failure and COVID-19 in Real Life,Recruiting,NA,University of Milan,NA,https://clinicaltrials.gov/ct2/show/NCT04307459,1,0,1,0,3,0,Italy,0,SOP,Journal Article|Multicenter Study|Observational Study
NCT04342182,2020-04-08,2021-07-01,Interventional,Convalescent Plasma as Therapy for Covid-19 Severe SARS-CoV-2 Disease (CONCOVID Study),"Active, not recruiting",Phase 2/Phase 3,Erasmus Medical Center,NA,https://clinicaltrials.gov/ct2/show/NCT04342182,1,0,1,0,11,0,Netherlands,0,convalescent plasma,"Journal Article|Meta-Analysis|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04340050,2020-04-10,2020-12-23,Interventional,COVID-19 Convalescent Plasma,Completed,Early Phase 1,University of Chicago,NA,https://clinicaltrials.gov/ct2/show/NCT04340050,1,0,1,0,4,1,United States,0,convalescent plasma,"Journal Article|Meta-Analysis|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04357106,2020-04-13,2020-07-31,Interventional,COPLA Study: Treatment of Severe Forms of COronavirus Infection With Convalescent PLAsma,Recruiting,Phase 2,Centro de HematologÃ­a y Medicina Interna,NA,https://clinicaltrials.gov/ct2/show/NCT04357106,1,0,1,0,0,0,Mexico,0,convalescent plasma,"Journal Article|Meta-Analysis|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04441424,2020-04-03,2020-06-01,Interventional,Convalescent Plasma Therapy on Critically-ill Novel Coronavirus (COVID-19) Patients,Completed,N/A,Alkarkh Health Directorate-Baghdad,NA,https://clinicaltrials.gov/ct2/show/NCT04441424,1,0,1,0,1,0,Iraq,0,convalescent plasma|hydroxychloroquine / azithromycin,"Journal Article|Meta-Analysis|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04507282,2020-05-15,2020-07-01,Observational,Eosinophil and Anticoagulation in COVID-19 Patients,Completed,NA,Bursa Postgraduate Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04507282,1,0,1,0,1,0,Turkey,0,lmwh,Journal Article
NCT04555096,2020-09-09,2021-11-30,Interventional,A Trial of GC4419 in Patients With Critical Illness Due to COVID-19,Recruiting,Phase 2,"Galera Therapeutics, Inc.",NA,https://clinicaltrials.gov/ct2/show/NCT04555096,1,0,1,0,4,1,United States,0,gc4419|placebo,Journal Article
NCT04356495,2020-07-29,2021-08-15,Interventional,Trial of COVID-19 Outpatient Treatment in Individuals With Risk Factors for Aggravation,Recruiting,Phase 2/Phase 3,"University Hospital, Bordeaux",NA,https://clinicaltrials.gov/ct2/show/NCT04356495,1,0,1,0,6,0,France,0,vitamins|telmisartan|ciclesonide|interferon î²-1b|interferon î²-1b,"Clinical Trial, Phase III|Letter|Randomized Controlled Trial"
NCT04445467,2020-08-01,2020-11-30,Interventional,An Adaptive Clinical Trial of Antivirals for COVID-19 Infection,Recruiting,Phase 2,Bayside Health,NA,https://clinicaltrials.gov/ct2/show/NCT04445467,1,0,1,0,1,0,Australia,0,favipiravir,"Clinical Trial, Phase II|Letter|Multicenter Study|Randomized Controlled Trial"
NCT04314232,2020-03-18,2021-12-31,Observational,Mechanisms for Covid-19 Disease Complications,Recruiting,NA,"University Hospital, Akershus",NA,https://clinicaltrials.gov/ct2/show/NCT04314232,2,0,2,0,1,0,Norway,0,"NA","Journal Article/Journal Article|Research Support, Non-U.S. Gov't"
NCT04448717,2020-06-16,2021-03-31,Observational,Longitudinal Study of Seroprevalence of SARS-CoV-2 Antibodies and Development of Immunity in School Children,Recruiting,NA,University of Zurich,NA,https://clinicaltrials.gov/ct2/show/NCT04448717,3,0,3,0,1,0,Switzerland,0,covid-19 antibody testing,"Journal Article/Journal Article|Research Support, Non-U.S. Gov't/Journal Article"
NCT04343963,2020-04-04,2020-09-30,Interventional,Pyridostigmine in Severe SARS-CoV-2 Infection,Recruiting,Phase 2/Phase 3,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,NA,https://clinicaltrials.gov/ct2/show/NCT04343963,1,0,1,0,2,0,Mexico,0,pyridostigmine bromide|placebo,Clinical Trial Protocol|Journal Article
NCT04423770,2020-06-08,2021-06-08,Observational,COVID-19 Related Health and Infection Control Practices Among Dentists,"Active, not recruiting",NA,American Dental Association,NA,https://clinicaltrials.gov/ct2/show/NCT04423770,1,0,1,0,3,1,United States,0,no intervention,Journal Article
NCT04323592,2020-03-23,2020-05-10,Observational [Patient Registry],Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Completed,NA,University of Trieste,NA,https://clinicaltrials.gov/ct2/show/NCT04323592,1,0,1,0,6,0,Italy,1,methylprednisolone|standard care,Journal Article
NCT04411459,2020-02-01,2020-06-30,Observational,Risk Factors for Prolonged Invasive Mechanical Ventilation in COVID-19 Acute Respiratory Distress Syndrome,Completed,NA,Azienda Usl di Bologna,NA,https://clinicaltrials.gov/ct2/show/NCT04411459,1,3,4,0,2,0,Italy,0,invasive mechanical ventilation,"Journal Article/Journal Article|Multicenter Study|Research Support, N.I.H., Extramural/Journal Article|Research Support, Non-U.S. Gov't/Journal Article|Research Support, N.I.H., Extramural"
NCT04346355,2020-03-31,2020-06-06,Interventional,Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,Terminated,Phase 2,Azienda UnitÃ  Sanitaria Locale Reggio Emilia,Based on interim analysis for futility and given an enrolment rate almost nil,https://clinicaltrials.gov/ct2/show/NCT04346355,1,0,1,0,2,0,Italy,0,tocilizumab,"Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04331808,2020-03-30,2021-03-31,Interventional,CORIMUNO-19 - Tocilizumab Trial - TOCI (CORIMUNO-TOCI),"Active, not recruiting",Phase 2,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicaltrials.gov/ct2/show/NCT04331808,1,0,1,0,2,0,France,0,tocilizumab,"Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04436276,2020-07-15,2021-12-03,Interventional,A Study of Ad26.COV2.S in Adults (COVID-19),"Active, not recruiting",Phase 1/Phase 2,Janssen Vaccines & Prevention B.V.,NA,https://clinicaltrials.gov/ct2/show/NCT04436276,3,0,3,0,10,1,United States|Belgium,0,ad26.cov2.s|placebo,"Journal Article/Journal Article/Clinical Trial, Phase I|Comparative Study|Journal Article|Randomized Controlled Trial|Research Support, N.I.H., Extramural"
NCT04356937,2020-04-20,2020-07-13,Interventional,Efficacy of Tocilizumab on Patients With COVID-19,Completed,Phase 3,Massachusetts General Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04356937,1,0,1,0,4,1,United States,0,tocilizumab|placebo,"Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04416100,2020-04-29,2022-04-28,Observational,Development of Interstitial Lung Disease (ILD) in Patients With Severe SARS-CoV-2 Infection (COVID-19),Recruiting,NA,Medical University Innsbruck,NA,https://clinicaltrials.gov/ct2/show/NCT04416100,2,0,2,0,1,0,Austria,0,pulmonary function tests|imaging|blood sample,"Journal Article|Multicenter Study|Observational Study/Journal Article|Research Support, Non-U.S. Gov't"
NCT04282135,2020-02-15,2020-05-08,Observational,Detection of Influenza or SARS-CoV-2 Infection by IMS of Nasal Air Sampling,Completed,NA,Klinikum Bayreuth GmbH,NA,https://clinicaltrials.gov/ct2/show/NCT04282135,1,0,1,0,1,0,Germany,0,mcc ims,Evaluation Study|Journal Article
NCT04374526,2020-05-27,2021-04-30,Interventional,Early transfusIon of Convalescent Plasma in Elderly COVID-19 Patients. to Prevent Disease Progression.,Recruiting,Phase 2/Phase 3,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,NA,https://clinicaltrials.gov/ct2/show/NCT04374526,1,0,1,0,2,0,Italy,0,convalescent plasma,"Clinical Trial, Phase II|Clinical Trial, Phase III|Comparative Study|Letter|Randomized Controlled Trial"
NCT04290780,2020-03-09,2021-12-31,Observational,COVID-19 - Multicenter Study on Nosocomial Transmission of SARS-CoV-2 Virus,Recruiting,NA,Hospices Civils de Lyon,NA,https://clinicaltrials.gov/ct2/show/NCT04290780,1,0,1,0,6,0,France,0,nosocomial|hospital acquired infection,Journal Article|Multicenter Study|Observational Study
NCT04403477,2020-05-20,2020-07-20,Interventional,Convalescent Plasma Therapy in Severe COVID-19 Infection,Recruiting,Phase 2,"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh",NA,https://clinicaltrials.gov/ct2/show/NCT04403477,1,0,1,0,0,0,Bangladesh,0,convalescent plasma,"Clinical Trial, Phase II|Letter|Multicenter Study|Randomized Controlled Trial"
NCT04389840,2020-06-03,2021-02-28,Interventional,Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure,Recruiting,Phase 2/Phase 3,Chimerix,NA,https://clinicaltrials.gov/ct2/show/NCT04389840,1,0,1,0,11,1,United States,0,dociparstat sodium|placebo,"Clinical Trial, Phase II|Clinical Trial, Phase III|Journal Article|Randomized Controlled Trial"
NCT04344197,2020-04-02,2020-04-08,Observational,"Surgery During Covid-19: The Role of Asymptomatic Patients, a Survey",Completed,NA,University of Rome Tor Vergata,NA,https://clinicaltrials.gov/ct2/show/NCT04344197,1,0,1,0,1,0,Italy,0,global survey,Journal Article
NCT04328493,2020-04-07,2021-04-01,Interventional,The Vietnam Chloroquine Treatment on COVID-19,Recruiting,Phase 2,"Oxford University Clinical Research Unit, Vietnam",NA,https://clinicaltrials.gov/ct2/show/NCT04328493,1,0,1,0,3,0,Vietnam,0,chloroquine,Journal Article
NCT04440098,2020-04-22,2020-05-11,Observational,Isolated During COVID-19: Effects of COVID-19's Social Restrictions on Loneliness and Psychosocial Symptomatology,Completed,NA,University of Miami,NA,https://clinicaltrials.gov/ct2/show/NCT04440098,1,0,1,0,0,1,United States,0,"NA","Journal Article|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't"
NCT04427501,2020-06-17,2020-09-20,Interventional,A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness,Recruiting,Phase 2/Phase 3,Eli Lilly and Company,NA,https://clinicaltrials.gov/ct2/show/NCT04427501,2,0,2,0,36,1,United States|Puerto Rico,0,ly3819253|ly3832479|placebo,"Clinical Trial, Phase II|Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't/Clinical Trial, Phase II|Clinical Trial, Phase III|Comparative Study|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04407156,2020-06-01,2020-06-07,Observational,Epidemiology of Acute Kidney Injury in COVID19 Disease in United Kingdom,Completed,NA,University Hospitals of Derby and Burton NHS Foundation Trust,NA,https://clinicaltrials.gov/ct2/show/NCT04407156,1,0,1,0,2,0,United Kingdom,0,acute kidney injury,Journal Article
NCT04392973,2020-05-21,2021-11-30,Interventional,FAvipiravir and HydroxyChloroquine Combination Therapy,Recruiting,N/A,King Abdullah International Medical Research Center,NA,https://clinicaltrials.gov/ct2/show/NCT04392973,1,0,1,0,2,0,Saudi Arabia,0,favipiravir/hydroxychloroquine|favipiravir|hydroxychloroquine,Clinical Trial Protocol|Letter
NCT04521309,2020-06-19,2021-01-26,Interventional,SARS-CoV-2 Antibodies Based IVIG Therapy for COVID-19 Patients,Completed,Phase 1/Phase 2,Dow University of Health Sciences,NA,https://clinicaltrials.gov/ct2/show/NCT04521309,2,0,2,0,4,0,Pakistan,0,sars-cov-2 antibody based ivig therapy,"Clinical Trial Protocol|Letter/Journal Article|Research Support, Non-U.S. Gov't"
NCT04336345,2020-04-01,2020-04-30,Observational [Patient Registry],Outcomes of Patients With COVID-19 in the Intensive Care Unit,Completed,NA,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,NA,https://clinicaltrials.gov/ct2/show/NCT04336345,1,0,1,0,6,0,Mexico,0,"NA",Journal Article|Multicenter Study|Observational Study
NCT04401579,2020-05-08,2020-07-31,Interventional,Adaptive COVID-19 Treatment Trial 2 (ACTT-2),Completed,Phase 3,National Institute of Allergy and Infectious Diseases (NIAID),NA,https://clinicaltrials.gov/ct2/show/NCT04401579,2,0,2,0,16,1,"United States|Denmark|Japan|Korea, Republic of|Mexico|Singapore|Spain|United Kingdom",1,placebo|remdesivir|baricitinib,"Journal Article|Review/Comparative Study|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't"
NCT04492475,2020-08-05,2020-12-21,Interventional,Adaptive COVID-19 Treatment Trial 3 (ACTT-3),Completed,Phase 3,National Institute of Allergy and Infectious Diseases (NIAID),NA,https://clinicaltrials.gov/ct2/show/NCT04492475,1,0,1,0,29,1,"United States|Japan|Korea, Republic of|Mexico|Singapore",0,interferon|placebo|remdesivir,Journal Article|Review
NCT04349202,2020-04-10,2021-06-30,Observational,Beaumont Health Large-scale Automated Serologic Testing for COVID-19,Recruiting,NA,William Beaumont Hospitals,NA,https://clinicaltrials.gov/ct2/show/NCT04349202,1,0,1,0,2,1,United States,0,euroimmun assay,Journal Article
NCT04557605,2020-09-14,2020-10-15,Interventional,Effects of a Face Mask on Oxygenation During Exercise,Completed,N/A,University of Saskatchewan,NA,https://clinicaltrials.gov/ct2/show/NCT04557605,1,0,1,0,1,0,Canada,0,progressive cycling exercise test to exhaustion,Journal Article|Randomized Controlled Trial
NCT04351152,2020-05-05,2021-03-31,Interventional,Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19,"Active, not recruiting",Phase 3,"Humanigen, Inc.",NA,https://clinicaltrials.gov/ct2/show/NCT04351152,2,0,2,0,11,1,United States|Brazil,0,lenzilumab|standard care,"Journal Article|Multicenter Study|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't/Letter|Comment"
NCT04428099,2020-01-13,2022-01-12,Interventional,Healthy Lifestyle Promotion as Adjunctive Teletherapy for Treatment-resistant Major Depression,Recruiting,N/A,University of the Balearic Islands,NA,https://clinicaltrials.gov/ct2/show/NCT04428099,1,0,1,0,0,0,Spain,0,lifestyle change promotion program|mindfulness|information,Clinical Trial Protocol|Journal Article
NCT04412538,2020-05-15,2020-09-30,Interventional,Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19,Recruiting,Phase 1/Phase 2,Chinese Academy of Medical Sciences,NA,https://clinicaltrials.gov/ct2/show/NCT04412538,2,0,2,1,1,0,China,0,inactivated sars-cov-2 vaccine|medium dosage inactivated sars-cov-2 vaccine on a 0-/28-day schedule|medium dosage inactivated sars-cov-2 vaccine on a 0-/14-day schedule|placebo|28-day schedule|14-day schedule|medium dosage inactivated sars-cov-2 vaccine on a 0-,"Journal Article/Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04346342,2020-03-06,2020-09-01,Observational,PRactice of VENTilation in COVID-19 Patients (PRoVENT-COVID),Completed,NA,Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA),NA,https://clinicaltrials.gov/ct2/show/NCT04346342,2,0,2,0,3,0,Netherlands,0,"NA","Journal Article|Multicenter Study|Observational Study|Research Support, Non-U.S. Gov't/Journal Article"
NCT04557241,2020-01-14,2021-01-14,Interventional,Brief Informational Intervention for COVID-19 Misinformation Prophylaxis,Completed,N/A,Indiana University,NA,https://clinicaltrials.gov/ct2/show/NCT04557241,1,0,1,0,1,1,United States,0,brief informational infographic|placebo control (non-behavioral infographic),Journal Article
NCT04486404,2020-04-01,2020-06-30,Observational,"Needs, Perceptions and Acute Stress of Healtcare Workers Caring for COVID-19 Patients in South America",Enrolling by invitation,NA,Universidad Miguel Hernandez de Elche,NA,https://clinicaltrials.gov/ct2/show/NCT04486404,1,0,1,0,3,0,Argentina|Chile|Colombia|Ecuador|Spain,0,online survey,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04366882,2020-04-14,2020-12-31,Interventional,Minimal Invasive Autopsies to Investigate Changes in Deceased COVID-19 Patients,Recruiting,N/A,Jessa Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04366882,1,0,1,0,0,0,Belgium,0,ct-scan,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04487990,2020-06-29,2020-12-31,Interventional,CoV-Hep Study: Regional Anticoagulation Modalities in Continuous Venous Venous Hemodialysis in Patients With COVID-19,Recruiting,N/A,University of Sao Paulo General Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04487990,1,0,1,0,0,0,Brazil,0,heparin,Clinical Trial Protocol|Letter
NCT04347941,2020-07-11,2021-06-11,Interventional,Awake Prone Positioning to Reduce Invasive VEntilation in COVID-19 Induced Acute Respiratory failurE,Recruiting,N/A,University College Hospital Galway,NA,https://clinicaltrials.gov/ct2/show/NCT04347941,1,0,1,0,1,0,Ireland,0,prone positioning|standard care,"Clinical Trial Protocol|Journal Article|Research Support, Non-U.S. Gov't"
NCT04391140,2020-05-13,2020-12-31,Interventional,Prone Positioning and High-flow Nasal Cannula in COVID-19 Induced ARDS,Recruiting,N/A,Hospital Universitari Vall d'Hebron Research Institute,NA,https://clinicaltrials.gov/ct2/show/NCT04391140,1,0,1,0,2,0,Spain,0,prone positioning,"Clinical Trial Protocol|Journal Article|Research Support, Non-U.S. Gov't"
NCT04358939,2020-04-27,2021-02-21,Interventional,Prone Position in Patients on High-flow Nasal Oxygen Therapy for COVID-19 (HIGH-PRONE-COVID-19),Completed,N/A,"University Hospital, Tours",NA,https://clinicaltrials.gov/ct2/show/NCT04358939,1,0,1,0,8,0,France,0,prone positioning,"Clinical Trial Protocol|Journal Article|Research Support, Non-U.S. Gov't"
NCT04395144,2020-05-15,2021-03-15,Interventional,COVid-19: Awake Proning and High-flow Nasal Cannula in respiratorY DistrEss,Completed,N/A,HÃ´pital de Verdun,NA,https://clinicaltrials.gov/ct2/show/NCT04395144,1,0,1,0,3,0,Canada,0,prone positioning|standard care,"Clinical Trial Protocol|Journal Article|Research Support, Non-U.S. Gov't"
NCT04386395,2020-03-30,2020-05-01,Observational,Immune Changes in Severe COVID-19 Pulmonary Infections,"Active, not recruiting",NA,"Central Hospital, Nancy, France",NA,https://clinicaltrials.gov/ct2/show/NCT04386395,1,0,1,0,0,0,France,0,"NA",Clinical Trial|Journal Article
NCT04342663,2020-04-10,2020-08-20,Interventional,"A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection",Completed,Phase 2,Washington University School of Medicine,NA,https://clinicaltrials.gov/ct2/show/NCT04342663,2,0,2,0,5,1,United States,0,fluvoxamine|placebo,"Journal Article|Randomized Controlled Trial|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't/Journal Article|Review"
NCT04412655,2020-05-05,2020-05-30,Observational,Primary Angioplasty for STEMI During COVID-19 Pandemic (ISACS-STEMI COVID-19) Registry,"Active, not recruiting",NA,"UniversitÃ  degli Studi del Piemonte Orientale ""Amedeo Avogadro""",NA,https://clinicaltrials.gov/ct2/show/NCT04412655,2,0,2,0,1,0,Italy,0,percutaneous coronary revascularization for stemi,"Journal Article|Multicenter Study/Comparative Study|Journal Article|Multicenter Study|Research Support, Non-U.S. Gov't"
NCT04364022,2020-04-23,2021-03-24,Interventional,Efficacy of Pragmatic Same-day COVID-19 Ring Prophylaxis for Adult Individuals Exposed to SARS-CoV-2 in Switzerland,Completed,Phase 3,"University Hospital, Geneva",NA,https://clinicaltrials.gov/ct2/show/NCT04364022,1,0,1,0,2,0,Brazil|Switzerland,0,lopinavir/ritonavir|lopinavir|ritonavir,"Clinical Trial Protocol|Journal Article|Research Support, Non-U.S. Gov't"
NCT04435041,2020-06-01,2021-05-31,Observational [Patient Registry],Remote-by-Default Care in the COVID-19 Pandemic,"Active, not recruiting",NA,University of Oxford,NA,https://clinicaltrials.gov/ct2/show/NCT04435041,2,0,2,0,0,0,United Kingdom,0,"NA","Journal Article|Research Support, Non-U.S. Gov't/Journal Article"
NCT04459247,2020-06-15,2021-08-30,Interventional,"Short Term, High Dose Vitamin D Supplementation for COVID-19","Active, not recruiting",N/A,Postgraduate Institute of Medical Education and Research,NA,https://clinicaltrials.gov/ct2/show/NCT04459247,1,0,1,0,2,0,India,0,vitamin d,Journal Article
NCT04435184,2020-07-09,2020-11-28,Interventional,Crizanlizumab for Treating COVID-19 Vasculopathy,Completed,Phase 2,Johns Hopkins University,NA,https://clinicaltrials.gov/ct2/show/NCT04435184,1,0,1,0,5,1,United States,0,crizanlizumab|saline,"Comparative Study|Journal Article|Research Support, N.I.H., Extramural"
NCT04374149,2020-04-30,2020-09-30,Interventional,Therapeutic Plasma Exchange Alone or in Combination With Ruxolitinib in COVID-19 Associated CRS,Completed,Phase 2,Prisma Health-Upstate,NA,https://clinicaltrials.gov/ct2/show/NCT04374149,1,0,1,0,2,1,United States,0,therapeutic plasma exchange (tpe)|ruxolitinib,"Clinical Trial|Journal Article|Research Support, Non-U.S. Gov't"
NCT04487964,2020-01-01,2020-12-01,Interventional,Complementary Intervention for COVID-19,Recruiting,N/A,Egyptian Biomedical Research Network,NA,https://clinicaltrials.gov/ct2/show/NCT04487964,1,0,1,0,1,0,Egypt,0,licorice extract,Journal Article
NCT04468893,2020-05-20,2021-07-31,Interventional,Online Positive Psychology Intervention for Depression and Anxiety Due to COVID-19,Recruiting,N/A,Universidad Internacional de Valencia,NA,https://clinicaltrials.gov/ct2/show/NCT04468893,1,5,6,0,2,0,Mexico,0,online intervention mental health covid-19,Journal Article/Journal Article
NCT04455360,2020-10-01,2021-03-31,Interventional,Early EMDR Following Covid-19 Critical Illness: A Feasibility Trial,Recruiting,N/A,University Hospital Southampton NHS Foundation Trust,NA,https://clinicaltrials.gov/ct2/show/NCT04455360,1,0,1,0,1,0,United Kingdom,0,eye movement desensitisation/reprocessing recent traumatic event protocol|eye movement desensitisation|reprocessing recent traumatic event protocol,Clinical Trial Protocol|Letter
NCT04328467,2020-04-06,2020-08-31,Interventional,Pre-exposure Prophylaxis for SARS-Coronavirus-2,"Active, not recruiting",Phase 3,University of Minnesota,NA,https://clinicaltrials.gov/ct2/show/NCT04328467,1,0,1,0,5,1,United States,0,hydroxychloroquine|placebo,Journal Article
NCT04341922,2020-05-09,2020-08-20,Interventional,A Online-delivered Cognitive-behavioral Intervention for Dysfunctional Worry Related to the Covid-19 Pandemic,"Active, not recruiting",N/A,Karolinska Institutet,NA,https://clinicaltrials.gov/ct2/show/NCT04341922,1,0,1,0,5,0,Sweden,0,internet-delivered cognitive behavior therapy (icbt) for dysfunctional worry related to the covid-19 pandemic,Journal Article|Randomized Controlled Trial
NCT04382755,2020-05-22,2020-12-29,Interventional,ZilucoplanÂ® in Improving Oxygenation and Short- and Long-term Outcome of COVID-19 Patients With Acute Hypoxic Respiratory Failure,"Active, not recruiting",Phase 2,"University Hospital, Ghent",NA,https://clinicaltrials.gov/ct2/show/NCT04382755,1,0,1,0,3,0,Belgium,0,zilucoplanâ®|placebo|zilucoplanâ®,"Clinical Trial, Phase II|Letter|Multicenter Study|Randomized Controlled Trial"
NCT04352608,2020-04-16,2020-07-10,Interventional,Safety and Immunogenicity Study of Inactivated Vaccine for Prophylaxis of SARS CoV-2 Infection (COVID-19),"Active, not recruiting",Phase 1/Phase 2,"Sinovac Biotech Co., Ltd",NA,https://clinicaltrials.gov/ct2/show/NCT04352608,1,0,1,1,3,0,China,0,placebo|inactivated sars-cov-2 vaccine,"Clinical Trial, Phase I|Clinical Trial, Phase II|Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04400838,2020-05-28,2021-09-30,Interventional,Investigating a Vaccine Against COVID-19,Recruiting,Phase 2/Phase 3,University of Oxford,NA,https://clinicaltrials.gov/ct2/show/NCT04400838,5,0,5,1,10,0,United Kingdom,0,chadox1|menacwy|menacwy vaccine|two dose menacwy vaccine min. 4 weeks apart|two dose chadox1 ncov-19/covishield 0.5ml|two dose chadox1 ncov-19/covishield 0.25ml/0.5ml|2.2x10^10vp (qpcr) boost|boost|two dose chadox1 ncov-19|covishield 0.5ml|covishield 0.25ml|0.5ml,"Clinical Trial, Phase II|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't/Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't/Clinical Trial, Phase I|Clinical Trial, Phase II|Journal Article|Randomized Controlled Trial|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't/Journal Article|Meta-Analysis|Research Support, Non-U.S. Gov't/Clinical Trial, Phase II|Clinical Trial, Phase III|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04406090,2020-04-01,2020-06-30,Observational,Endovascular Thrombectomy in COVID-19 Infected Patients,Completed,NA,"University Hospital, Montpellier",NA,https://clinicaltrials.gov/ct2/show/NCT04406090,1,0,1,0,1,0,France,0,mechanical trombectomy,Journal Article|Multicenter Study
NCT04412304,2020-03-06,2020-04-30,Observational,Anticoagulant Therapy and 28-days Mortality in Critically Ill COVID-19 Patients,Completed,NA,Karolinska Institutet,NA,https://clinicaltrials.gov/ct2/show/NCT04412304,1,0,1,0,2,0,Sweden,0,tinzaparin/dalteparin|tinzaparin|dalteparin,Journal Article
NCT04449380,2020-11-02,2021-03-30,Interventional,Clinical Study for the Treatment With Interferon-ÃŸ-1a (IFNÃŸ-1a) of COVID-19 Patients,Terminated,Phase 2,IRCCS San Raffaele,Futility,https://clinicaltrials.gov/ct2/show/NCT04449380,1,0,1,0,5,0,Italy,0,interferon-ãÿ-1a|standard care|interferon-ãÿ-1a,"Clinical Trial, Phase II|Journal Article|Randomized Controlled Trial"
NCT04495816,2020-07-15,2021-08-31,Interventional,COVID-19 Anosmia Study,Recruiting,Phase 2,Icahn School of Medicine at Mount Sinai,NA,https://clinicaltrials.gov/ct2/show/NCT04495816,1,0,1,0,3,1,United States,0,omega-3|placebo/control|placebo|control,Letter|Randomized Controlled Trial
NCT04477655,2020-05-03,2021-01-26,Interventional,Prone Positioning in Non-intubated Patients With COVID-19 Associated Acute Respiratory Failure,Completed,N/A,Hospital Civil de Guadalajara,NA,https://clinicaltrials.gov/ct2/show/NCT04477655,1,0,1,0,3,0,Mexico,0,prone positioning|oxygen,Letter|Randomized Controlled Trial
NCT04438070,2020-04-10,2020-06-30,Interventional,COVID Screening Strategies in Homeless Shelters,Recruiting,N/A,St. Joseph's Healthcare Hamilton,NA,https://clinicaltrials.gov/ct2/show/NCT04438070,1,0,1,0,0,0,Canada,0,covid-19 swab,Comparative Study|Letter|Randomized Controlled Trial
NCT04357535,2020-05-10,2020-07-01,Observational,Prognosis of Coronavirus Disease 2019 (COVID-19) Patients Receiving Receiving Antihypertensives,Completed,NA,King Faisal Specialist Hospital & Research Center,NA,https://clinicaltrials.gov/ct2/show/NCT04357535,1,0,1,0,8,0,Saudi Arabia,0,angiotensin-converting enzyme inhibitors (ace-i)/angiotensin ii receptor blockers (arb)|ace inhibitor|arb blocker,Journal Article|Multicenter Study
NCT04383535,2020-05-15,2020-09-27,Interventional,Convalescent Plasma and Placebo for the Treatment of COVID-19 Severe Pneumonia,Completed,N/A,Hospital Italiano de Buenos Aires,NA,https://clinicaltrials.gov/ct2/show/NCT04383535,1,1,2,0,4,0,Argentina,0,convalescent plasma|placebo,"Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04529525,2020-08-19,2021-02-28,Interventional,Ivermectin to Prevent Hospitalizations in COVID-19,Recruiting,Phase 2/Phase 3,Instituto de CardiologÃ­a de Corrientes,NA,https://clinicaltrials.gov/ct2/show/NCT04529525,1,11,12,0,5,0,Argentina,0,ivermectin|placebo,Letter|Randomized Controlled Trial
NCT04341142,2020-04-09,2023-04-09,Interventional,Assessment of Serological Techniques for Screening Patients Regarding COVID-19-COVID-SER,Recruiting,N/A,Hospices Civils de Lyon,NA,https://clinicaltrials.gov/ct2/show/NCT04341142,1,0,1,0,5,0,France,0,serology test,Clinical Study|Journal Article|Multicenter Study
NCT04380987,2020-05-04,2021-07-31,Observational,Luxembourg Cohort of Positive Patients for COVID-19: a Stratification Study to Predict Patient Prognosis,Recruiting,NA,Luxembourg Institute of Health,NA,https://clinicaltrials.gov/ct2/show/NCT04380987,1,0,1,0,0,0,Luxembourg,0,biological samples,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04344119,2020-04-09,2021-04-30,Observational,Assessment of Chilbains Occuring During Covid-19 Infection,Recruiting,NA,Centre Hospitalier Universitaire de Nice,NA,https://clinicaltrials.gov/ct2/show/NCT04344119,1,0,1,0,2,0,France,0,"NA","Journal Article|Research Support, Non-U.S. Gov't"
NCT04430608,2020-05-25,2021-04-25,Interventional,Remote Continues Glucose Monitoring During the COVID-19 Pandemic in Quarantined Hospitalized Patients,Recruiting,N/A,Nordsjaellands Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04430608,1,0,1,0,0,0,Denmark,0,dexcom,Letter|Randomized Controlled Trial
NCT04244591,2020-01-26,2020-04-13,Interventional,Glucocorticoid Therapy for COVID-19 Critically Ill Patients With Severe Acute Respiratory Failure,Completed,Phase 2/Phase 3,Peking Union Medical College Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04244591,1,0,1,0,6,0,China,0,methylprednisolone|standard care,Journal Article|Review
NCT04321174,2020-04-17,2021-03-31,Interventional,COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir,Recruiting,Phase 3,"St. Michael's Hospital, Toronto",NA,https://clinicaltrials.gov/ct2/show/NCT04321174,3,0,3,0,1,0,Canada,0,lopinavir/ritonavir|lopinavir|ritonavir,Journal Article|Review/Journal Article|Systematic Review/Clinical Trial Protocol|Journal Article
NCT04304313,2020-02-09,2020-03-01,Interventional,A Pilot Study of Sildenafil in COVID-19,Recruiting,Phase 3,Tongji Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04304313,1,0,1,0,1,0,China,0,sildenafil citrate,Journal Article|Review
NCT04348695,2020-04-12,2020-05-13,Interventional,Study of Ruxolitinib Plus Simvastatin in the Prevention and Treatment of Respiratory Failure of COVID-19.,Recruiting,Phase 2,FundaciÃ³n de investigaciÃ³n HM,NA,https://clinicaltrials.gov/ct2/show/NCT04348695,1,0,1,0,1,0,Spain,0,ruxolitinib|standard care|simvastatin,Journal Article|Review
NCT04359329,2020-04-20,2020-11-15,Interventional,Estrogen Patch for COVID-19 Symptoms,Recruiting,Phase 2,Stony Brook University,NA,https://clinicaltrials.gov/ct2/show/NCT04359329,1,0,1,0,0,1,United States,0,estradiol,Journal Article|Review
NCT04429854,2020-05-02,2021-04-30,Interventional,Donated Antibodies Working Against nCoV,"Active, not recruiting",Phase 2,Universitaire Ziekenhuizen Leuven,NA,https://clinicaltrials.gov/ct2/show/NCT04429854,1,0,1,0,3,0,Belgium,0,convalescent plasma|standard care,"Clinical Trial, Phase II|Journal Article|Multicenter Study|Randomized Controlled Trial"
NCT04447534,2020-06-23,2030-10-01,Interventional,Zinc With Chloroquine/Hydroxychloroquine in Treatment of COVID-19,Recruiting,Phase 3,Tanta University,NA,https://clinicaltrials.gov/ct2/show/NCT04447534,1,0,1,0,3,0,Egypt,0,chloroquine|zinc,Journal Article
NCT04444661,2020-06-10,2020-11-11,Observational,Effects of COVID-19 Induced Deconditioning After Long-term High Intensity Resistance Exercise,Completed,NA,University of Erlangen-NÃ¼rnberg Medical School,NA,https://clinicaltrials.gov/ct2/show/NCT04444661,1,0,1,0,4,0,Germany,0,"NA",Journal Article
NCT04349592,2020-04-14,2020-08-14,Interventional,Hydroxychloroquine With or Without Azithromycin for Virologic Cure of COVID-19,Completed,N/A,Hamad Medical Corporation,NA,https://clinicaltrials.gov/ct2/show/NCT04349592,1,0,1,0,2,0,Qatar,0,hydroxychloroquine|azithromycin|placebo,Journal Article
NCT04386083,2020-06-10,2020-12-31,Observational,Neurologic Manifestations of COVID-19,Recruiting,NA,University of the Philippines,NA,https://clinicaltrials.gov/ct2/show/NCT04386083,1,0,1,0,1,0,Philippines,0,"NA","Journal Article|Research Support, Non-U.S. Gov't"
NCT04361877,2020-03-30,2020-04-20,Observational,Cardiovascular Prevention During COVID-19 Pandemic Lockdown in Young Adults (COLA Trial),Completed,NA,Klinikum der Universitaet Muenchen,NA,https://clinicaltrials.gov/ct2/show/NCT04361877,1,0,1,0,2,0,Germany,0,"NA",Journal Article
NCT04445324,2020-08-25,2020-08-25,Interventional,Effects of Online and Recovery-oriented Peer Support Groups Facilitated by Peer Support Workers in Times of COVID-19,"Active, not recruiting",N/A,Centre de Recherche de l'Institut Universitaire en santÃ© Mentale de MontrÃ©al,NA,https://clinicaltrials.gov/ct2/show/NCT04445324,1,0,1,0,4,0,Canada,0,"online support group|control|or psychotherapy, n=10)",Journal Article
NCT04405726,2020-03-27,2022-03-31,Observational,Prognostic Factors of COVID19,Recruiting,NA,"University Hospital, Strasbourg, France",NA,https://clinicaltrials.gov/ct2/show/NCT04405726,1,0,1,0,2,0,France,0,"NA",Journal Article
NCT04343053,2020-04-08,2020-06-09,Interventional,Pro-thrombotic Status in Patients With SARS-Cov-2 Infection,"Active, not recruiting",N/A,University Hospital of Ferrara,NA,https://clinicaltrials.gov/ct2/show/NCT04343053,3,0,3,0,2,0,Italy,0,sars-cov-2 infection,"Journal Article/Journal Article|Research Support, Non-U.S. Gov't/Journal Article"
NCT04395807,2020-06-03,2021-04-12,Interventional,Helmet CPAP Versus HFNC in COVID-19,Terminated,N/A,Lund University,"1. Few eligible patients at study start

      2. Patients received HFNC prior to intermediate care ward admission

      3. NIV was locally considered a step-up therapy to HFNC

      4. Full-face masks replaced the Helmet interface as local NIV standard",https://clinicaltrials.gov/ct2/show/NCT04395807,1,0,1,0,2,0,Sweden,0,cpap|oxygen,Comparative Study|Journal Article|Randomized Controlled Trial
NCT04405739,2020-06-16,2021-05-28,Interventional,The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID),Recruiting,Phase 2,"Ridgeback Biotherapeutics, LP",NA,https://clinicaltrials.gov/ct2/show/NCT04405739,1,0,1,0,15,1,United States,0,eidd-2801|placebo,"Journal Article|Research Support, N.I.H., Extramural"
NCT04405570,2020-06-16,2021-02-21,Interventional,"A Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19",Completed,Phase 2,"Ridgeback Biotherapeutics, LP",NA,https://clinicaltrials.gov/ct2/show/NCT04405570,1,0,1,0,18,1,United States,0,eidd-2801|placebo,"Journal Article|Research Support, N.I.H., Extramural"
NCT04645563,2020-03-11,2020-05-30,Observational,Using Whatsapp for the Consultation,Completed,NA,Kafkas University,NA,https://clinicaltrials.gov/ct2/show/NCT04645563,1,0,1,0,0,0,Turkey,0,sending thorax ct video images via smartphone applications,Journal Article
NCT04558476,2020-09-01,2022-09-01,Interventional,Efficacy of CONvalescent Plasma in Patients With COVID-19 Treated With Mechanical Ventilation,Recruiting,Phase 2,University of Liege,NA,https://clinicaltrials.gov/ct2/show/NCT04558476,1,0,1,0,0,0,Belgium,0,convalescent plasma|standard care,Clinical Trial Protocol|Journal Article
NCT04304053,2020-03-18,2020-06-15,Interventional,Treatment of COVID-19 Cases and Chemoprophylaxis of Contacts as Prevention,Completed,Phase 3,"FundaciÃ³n FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la PromociÃ³n de la Salud y la Ciencia",NA,https://clinicaltrials.gov/ct2/show/NCT04304053,2,0,2,0,9,0,Spain,0,treatment/prophylaxis|standard care|treatment|prophylaxis,"Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't/Journal Article|Systematic Review"
NCT04476667,2020-06-15,2021-05-31,Interventional,"Online Delivery of Psychotherapy, Tailored to Patients' Suffering From Mental Health Problems Due to COVID-19",Recruiting,N/A,Queen's University,NA,https://clinicaltrials.gov/ct2/show/NCT04476667,1,0,1,0,1,0,Canada,0,psychotherapy,Journal Article
NCT04510623,2020-03-17,2021-06-30,Observational,Host Response Mediators in Coronavirus (COVID-19) Infection,Recruiting,NA,University of British Columbia,NA,https://clinicaltrials.gov/ct2/show/NCT04510623,1,0,1,0,0,0,Canada,0,ace/arb|standard care|arb|ace inhibitor,"Clinical Trial Protocol|Journal Article|Research Support, Non-U.S. Gov't"
NCT04502108,2020-04-01,2022-12-31,Observational,Behavior During and After COVID-19 Crisis,Recruiting,NA,Bern University of Applied Sciences,NA,https://clinicaltrials.gov/ct2/show/NCT04502108,2,0,2,0,1,0,Switzerland,0,covid-19,Journal Article/Journal Article
NCT04369378,2020-08-19,2021-02-28,Interventional,Effectiveness of Using a Meditation App in Reducing Anxiety and Improving Well-being During the Covid-19 Pandemic,Recruiting,N/A,Lake Erie College of Osteopathic Medicine,NA,https://clinicaltrials.gov/ct2/show/NCT04369378,1,0,1,0,2,1,United States,0,meditation app usage,Letter|Randomized Controlled Trial
NCT04362059,2020-06-18,2021-07-27,Interventional,A Clinical Trial of Nebulized Surfactant for the Treatment of Moderate to Severe COVID-19,Recruiting,N/A,University Hospital Southampton NHS Foundation Trust,NA,https://clinicaltrials.gov/ct2/show/NCT04362059,1,14,15,0,3,0,United Kingdom,0,covsurf drug delivery system|standard care,Letter|Randomized Controlled Trial
NCT04348929,2020-04-16,2021-08-16,Interventional,Birth Experience During COVID-19 Confinement,Recruiting,N/A,"Central Hospital, Nancy, France",NA,https://clinicaltrials.gov/ct2/show/NCT04348929,1,0,1,0,3,0,France,0,questionnaire,Comparative Study|Journal Article|Multicenter Study
NCT04351906,2020-05-03,2021-06-01,Interventional,Low-flow Extracorporeal Carbon Dioxide Removal in COVID-19-associated Acute Respiratory Distress Syndrome,Recruiting,N/A,University of Giessen,NA,https://clinicaltrials.gov/ct2/show/NCT04351906,1,1,2,0,5,0,Germany,0,ecco2r,Journal Article
NCT04444674,2020-06-24,2020-12-31,Interventional,COVID-19 Vaccine (ChAdOx1 nCoV-19) Trial in South African Adults With and Without HIV-infection,"Active, not recruiting",Phase 1/Phase 2,University of Oxford,NA,https://clinicaltrials.gov/ct2/show/NCT04444674,3,0,3,1,4,0,South Africa,0,chadox1|saline,"Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't/Journal Article|Meta-Analysis|Research Support, Non-U.S. Gov't/Journal Article"
NCT04315480,2020-03-12,2020-04-09,Interventional,Tocilizumab for SARS-CoV2 (COVID-19) Severe Pneumonitis,"Active, not recruiting",Phase 2,UniversitÃ  Politecnica delle Marche,NA,https://clinicaltrials.gov/ct2/show/NCT04315480,1,0,1,0,2,0,Italy,0,tocilizumab,"Clinical Trial, Phase II|Journal Article|Multicenter Study"
NCT04444531,2020-03-20,2020-05-19,Observational,Ozone Therapy and Coronavirus Disease of 2019 (COVID-19) Pneumonia,Completed,NA,Institut d'InvestigaciÃ³ BiomÃ¨dica de Girona Dr. Josep Trueta,NA,https://clinicaltrials.gov/ct2/show/NCT04444531,1,0,1,0,3,0,Spain,0,"NA",Controlled Clinical Trial|Journal Article
NCT04369690,2020-04-03,2021-04-03,Observational,"The Psychological, Social, and Economic Impacts of COVID-19",Recruiting,NA,University of Ottawa,NA,https://clinicaltrials.gov/ct2/show/NCT04369690,1,0,1,0,0,0,Canada,0,"NA",Journal Article|Multicenter Study|Observational Study
NCT04555005,2020-03-10,2020-04-26,Interventional,Mindfulness-based Crisis Intervention for COVID-19 Frontline Healthcare Workers During COVID-19,Completed,N/A,Instituto de InvestigaciÃ³n Hospital Universitario La Paz,NA,https://clinicaltrials.gov/ct2/show/NCT04555005,1,0,1,0,0,0,Spain,0,mindfulness,Journal Article
NCT04425629,2020-06-16,2021-04-10,Interventional,"Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult and Pediatric Patients With COVID-19",Recruiting,Phase 2/Phase 3,Regeneron Pharmaceuticals,NA,https://clinicaltrials.gov/ct2/show/NCT04425629,1,0,1,0,18,1,United States|Chile|Mexico|Romania,0,regn10933/regn10987 combination therapy|placebo|regn10933|regn10987,"Clinical Trial, Phase I|Clinical Trial, Phase II|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04372186,2020-05-14,2020-08-18,Interventional,A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,Recruiting,Phase 3,"Genentech, Inc.",NA,https://clinicaltrials.gov/ct2/show/NCT04372186,1,0,1,0,8,1,United States|Brazil|Kenya|Mexico|Peru|South Africa,0,placebo|tocilizumab,"Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04371419,2020-05-13,2020-05-24,Interventional,COVID-19 Health Messaging to Underserved Communities,Completed,N/A,"National Bureau of Economic Research, Inc.",NA,https://clinicaltrials.gov/ct2/show/NCT04371419,1,0,1,0,2,1,United States,0,messaging,"Comparative Study|Journal Article|Randomized Controlled Trial|Research Support, N.I.H., Extramural|Video-Audio Media"
NCT04492904,2020-07-23,2021-03-31,Observational,Singapore COVID-19 Chemosensory Tracking (SCCT) Study,Recruiting,NA,"Clinical Nutrition Research Centre, Singapore",NA,https://clinicaltrials.gov/ct2/show/NCT04492904,1,0,1,0,0,0,Singapore,0,questionnaire|home-use test,Journal Article
NCT04501978,2020-08-04,2022-07-31,Interventional,ACTIV-3: Therapeutics for Inpatients With COVID-19,Recruiting,Phase 3,National Institute of Allergy and Infectious Diseases (NIAID),NA,https://clinicaltrials.gov/ct2/show/NCT04501978,1,0,1,0,33,1,United States|Denmark|India|Poland|Singapore|Spain|Switzerland|United Kingdom,0,vir-7831|ly3819253|placebo|remdesivir|brii-196/brii-198|azd7442|brii-196|brii-198,"Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't"
NCT04358380,2020-04-15,2020-12-31,Observational,Liver Injury in Patients With COVID-19,Enrolling by invitation,NA,"Austral University, Argentina",NA,https://clinicaltrials.gov/ct2/show/NCT04358380,2,0,2,0,2,0,Argentina,0,liver,Journal Article|Multicenter Study/Journal Article
NCT04579393,2020-10-08,2021-03-30,Interventional,Fostamatinib for Hospitalized Adults With COVID-19,"Active, not recruiting",Phase 2,National Institutes of Health Clinical Center (CC),NA,https://clinicaltrials.gov/ct2/show/NCT04579393,1,0,1,0,19,1,United States,0,placebo|fostamatinib,Journal Article
NCT04344041,2020-04-15,2021-01-14,Interventional,COvid-19 and Vitamin D Supplementation: a Multicenter Randomized Controlled Trial of High Dose Versus Standard Dose Vitamin D3 in High-risk COVID-19 Patients (CoVitTrial),Completed,Phase 3,"University Hospital, Angers",NA,https://clinicaltrials.gov/ct2/show/NCT04344041,1,0,1,0,5,0,France,0,cholecalciferol,Journal Article|Multicenter Study|Randomized Controlled Trial
NCT04635241,2020-06-01,2021-04-01,Interventional,Inhaled Heparin for Hospitalised COVID-19 Patients,Recruiting,Phase 2/Phase 3,Australian National University,NA,https://clinicaltrials.gov/ct2/show/NCT04635241,1,0,1,0,1,0,Argentina|Egypt,0,heparin,Journal Article
NCT04470427,2020-07-27,2022-10-27,Interventional,"A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19","Active, not recruiting",Phase 3,"ModernaTX, Inc.",NA,https://clinicaltrials.gov/ct2/show/NCT04470427,1,0,1,1,15,1,United States,0,mrna-1273|placebo,"Clinical Trial, Phase III|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't"
NCT04540029,2020-05-06,2022-10-31,Observational,Measuring Outcomes of Maternal COVID-19-related Prenatal Exposure,Recruiting,NA,"IRCCS National Neurological Institute ""C. Mondino"" Foundation",NA,https://clinicaltrials.gov/ct2/show/NCT04540029,1,0,1,0,0,0,Italy,0,maternal stress,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04344327,2020-04-10,2020-04-21,Observational,Early Risk Stratification of Patient Hospitalized for SARS-CoV2 Infection: Critical COVID-19 France CCF,Completed,NA,French Cardiology Society,NA,https://clinicaltrials.gov/ct2/show/NCT04344327,1,0,1,0,1,0,France,0,"NA",Journal Article
NCT04336410,2020-04-03,2022-01-31,Interventional,"Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers","Active, not recruiting",Phase 1,Inovio Pharmaceuticals,NA,https://clinicaltrials.gov/ct2/show/NCT04336410,1,0,1,1,9,1,United States,0,ino-4800|cellectraâ® 2000|cellectraâ® 2000,Journal Article
NCT04382235,2020-03-26,2021-04-30,Observational,Non-invasive Ventilatory Support of Patients Affected by COVID-19,"Active, not recruiting",NA,University of Milano Bicocca,NA,https://clinicaltrials.gov/ct2/show/NCT04382235,1,0,1,0,2,0,Italy,0,non-invasive ventilatory support,Journal Article
NCT04549376,2020-07-01,2020-10-20,Interventional,Virucidal Effect of Povidone Iodine on COVID-19 In-Vivo,Recruiting,Phase 2,"Pi Research Consultancy Center, Bangladesh",NA,https://clinicaltrials.gov/ct2/show/NCT04549376,1,0,1,0,0,0,Bangladesh,0,povidone-iodine|placebo,Clinical Trial Protocol|Letter
NCT04414631,2020-08-06,2021-06-30,Interventional,Conestat Alfa in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19,Recruiting,Phase 2,"University Hospital, Basel, Switzerland",NA,https://clinicaltrials.gov/ct2/show/NCT04414631,1,0,1,0,5,0,Brazil|Mexico|Switzerland,0,conestat alfa,Clinical Trial Protocol|Letter
NCT04459286,2020-10-09,2021-03-31,Interventional,The Nitazoxanide Plus Atazanavir for COVID-19 Study,Recruiting,Phase 2,Obafemi Awolowo University,NA,https://clinicaltrials.gov/ct2/show/NCT04459286,1,0,1,0,3,0,Nigeria,0,nitazoxanide/atazanavir/ritonavir|standard care|nitazoxanide|atazanavir|ritonavir,Clinical Trial Protocol|Comparative Study|Letter
NCT04463706,2020-06-01,2021-06-30,Observational,COVID19 Severity Prediction and Health Services Research Evaluation,Recruiting,NA,Hospital Galdakao-Usansolo,NA,https://clinicaltrials.gov/ct2/show/NCT04463706,1,0,1,0,1,0,Spain,0,predictors adverse evolution|predictors of health care provide,Journal Article
NCT04345536,2020-03-15,2022-01-01,Observational [Patient Registry],Prospective Quality Register of Patients With Confirmed Covid-19 at Oslo University Hospital,Recruiting,NA,Oslo University Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04345536,1,0,1,0,1,0,Norway,0,"NA",Journal Article
NCT04479163,2020-06-04,2020-10-25,Interventional,Prevention of Severe Covid-19 in Infected Elderly by Early Administration of Convalescent Plasma With High-titers of Antibody Against SARS-CoV2,Completed,N/A,Fundacion Infant,NA,https://clinicaltrials.gov/ct2/show/NCT04479163,1,0,1,0,3,0,Argentina,0,convalescent plasma|placebo,"Comparative Study|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04615429,2020-09-15,2021-01-04,Interventional,Clinical Trial to Assess the Efficacy of MSC in Patients With ARDS Due to COVID-19,"Active, not recruiting",Phase 2,Puerta de Hierro University Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04615429,1,0,1,0,2,0,Spain,0,mesenchymal stem cells|placebo,Clinical Trial Protocol|Letter
NCT04422418,2020-07-01,2020-12-14,Observational,Impact of Burnout on Cardiovascular and Immune Biomarkers in Healthcare Professionals - Covid-19 Pandemic in Abu Dhabi,Recruiting,NA,Khalifa University for Science and Technology,NA,https://clinicaltrials.gov/ct2/show/NCT04422418,1,0,1,0,1,0,United Arab Emirates,0,"NA",Journal Article
NCT04385121,2020-04-16,2020-04-16,Observational,Psychological Impact of the Hospitalization of a Family Member in Intensive Care for Covid-19 Infection,Recruiting,NA,"University Hospital, Strasbourg, France",NA,https://clinicaltrials.gov/ct2/show/NCT04385121,1,0,1,0,1,0,France,0,questionnaire,Journal Article
NCT04338009,2020-03-31,2020-08-20,Interventional,Elimination or Prolongation of ACE Inhibitors and ARB in Coronavirus Disease 2019,Completed,N/A,University of Pennsylvania,NA,https://clinicaltrials.gov/ct2/show/NCT04338009,1,0,1,0,3,1,United States,1,discontinuation of arb|continuation of arb|ace inhibitor,"Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't"
NCT04484493,2020-08-08,2020-10-25,Interventional,Corticosteroid Nasal Spray in COVID-19 Anosmia,Completed,Phase 3,Benha University,NA,https://clinicaltrials.gov/ct2/show/NCT04484493,1,0,1,0,5,0,Egypt,0,mometasone furoate nasal spray,Journal Article|Randomized Controlled Trial
NCT04438980,2020-05-15,2020-12-31,Interventional,Glucocorticoids in COVID-19 (CORTIVID),Recruiting,Phase 3,Fundacion Miguel Servet,NA,https://clinicaltrials.gov/ct2/show/NCT04438980,1,0,1,0,1,0,Spain,0,methylprednisolone|placebo,Clinical Trial Protocol|Letter
NCT04472728,2020-06-16,2021-07-31,Interventional,Testing the Efficacy and Safety of BIO101 for the Prevention of Respiratory Deterioration in COVID-19 Patients,Recruiting,Phase 2/Phase 3,Biophytis,NA,https://clinicaltrials.gov/ct2/show/NCT04472728,1,0,1,0,6,1,United States|Belgium|Brazil|France|Puerto Rico,0,bio101|placebo,Clinical Trial Protocol|Letter
NCT04389645,2020-04-07,2020-05-12,Observational,Interferon Gamma Induced Protein 10 (IP-10) in a Clinical Decision Support Protocol in COVID-19 Patients,Completed,NA,MeMed Diagnostics Ltd.,NA,https://clinicaltrials.gov/ct2/show/NCT04389645,1,0,1,0,0,0,Israel,0,ip-10,Clinical Trial|Journal Article|Observational Study
NCT04458337,2020-03-13,2022-03-13,Observational,SURgical Outcomes in COvid Patients - the SUROCO Multicenter Cohort Study (COVID-19),Recruiting,NA,Centre hospitalier de l'UniversitÃ© de MontrÃ©al (CHUM),NA,https://clinicaltrials.gov/ct2/show/NCT04458337,1,0,1,0,4,0,Canada,0,"NA","Journal Article|Multicenter Study|Observational Study|Research Support, Non-U.S. Gov't"
NCT04357938,2020-04-15,2021-04-20,Observational,Risk Stratification With Chest CT to Rule-out Suspected SARS-CoV-2 Infections,"Active, not recruiting",NA,Jena University Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04357938,1,0,1,0,1,0,Germany,0,ct-scan,Journal Article|Observational Study
NCT04330261,2020-03-18,2021-03-17,Observational,Clinical Characteristics and Outcomes of Pediatric COVID-19,Recruiting,NA,University of Calgary,NA,https://clinicaltrials.gov/ct2/show/NCT04330261,1,0,1,0,0,0,Canada,0,exposure,"Journal Article|Multicenter Study|Observational Study|Research Support, Non-U.S. Gov't"
NCT04364893,2020-04-09,2020-10-01,Interventional,Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors and Adverse Outcomes in Patients With COVID19,Recruiting,N/A,D'Or Institute for Research and Education,NA,https://clinicaltrials.gov/ct2/show/NCT04364893,1,0,1,0,2,0,Brazil,0,suspension/maintenance of angiotensin receptor blockers/angiotensin-converting enzyme inhibitors|suspension|maintenance|ace inhibitor,Journal Article|Multicenter Study|Pragmatic Clinical Trial|Randomized Controlled Trial
NCT04405869,2020-04-29,2021-04-30,Observational,Thromboembolic Events in Severe COVID-19 Patients,Recruiting,NA,"University Hospital, Strasbourg, France",NA,https://clinicaltrials.gov/ct2/show/NCT04405869,1,0,1,0,1,0,France,0,"NA",Journal Article
NCT04344145,2020-04-16,2020-05-25,Observational,Exhaustion and Needs in Frontline COVID-19 Healthcare Workers: Cross-sectional Study in a Belgian Population,Completed,NA,UniversitÃ© Libre de Bruxelles,NA,https://clinicaltrials.gov/ct2/show/NCT04344145,1,16,17,0,4,0,Belgium,0,"NA",Journal Article/Journal Article|Practice Guideline
NCT04346602,2020-02-01,2020-06-01,Observational,A Study on the Clinical and Psychological Characteristics of Patients With COVID-2019,Recruiting,NA,Jilin University,NA,https://clinicaltrials.gov/ct2/show/NCT04346602,1,0,1,0,0,0,China,0,all treatment about covid-2019,Journal Article
NCT04345523,2020-04-03,2021-02-28,Interventional,Convalescent Plasma Therapy vs. SOC for the Treatment of COVID-19 in Hospitalized Patients,Recruiting,Phase 2,Puerta de Hierro University Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04345523,1,0,1,0,2,0,Spain,0,blood/derivatives|standard care|blood|derivatives.,Clinical Trial Protocol|Journal Article
NCT04403685,2020-05-08,2020-07-08,Interventional,Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers,Terminated,Phase 3,BeneficÃªncia Portuguesa de SÃ£o Paulo,Safety,https://clinicaltrials.gov/ct2/show/NCT04403685,1,0,1,0,3,0,Brazil,0,tocilizumab,"Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04454333,2020-06-03,2020-06-18,Observational,COVID-19 in Pain Perspective,Completed,NA,Sisli Hamidiye Etfal Training and Research Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04454333,1,0,1,0,0,0,Turkey,0,"NA",Journal Article
NCT04319731,2020-03-20,2021-03-20,Interventional,A Pilot Study of Human Amniotic Fluid for COVID19 Associated Respiratory Failure,Recruiting,Early Phase 1,University of Utah,NA,https://clinicaltrials.gov/ct2/show/NCT04319731,1,0,1,0,1,1,United States,0,human amniotic fluid,Clinical Trial|Journal Article
NCT04471519,2020-07-15,2020-07-31,Interventional,Whole-Virion Inactivated SARS-CoV-2 Vaccine (BBV152) for COVID-19 in Healthy Volunteers,"Active, not recruiting",Phase 1/Phase 2,Bharat Biotech International Limited,NA,https://clinicaltrials.gov/ct2/show/NCT04471519,3,0,3,1,3,0,India,0,bbv152a - phase i|bbv152b - phase i|bbv152c - phase i|placebo - phase i|bbv152a - phase ii|bbv152b - phase ii,"Clinical Trial, Phase I|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't/Journal Article|Research Support, Non-U.S. Gov't/Journal Article"
NCT04273321,2020-02-14,2020-04-15,Interventional,Efficacy and Safety of Corticosteroids in COVID-19,Completed,N/A,Beijing Chao Yang Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04273321,1,0,1,0,4,0,China,0,methylprednisolone,Journal Article|Multicenter Study|Randomized Controlled Trial
NCT04351295,2020-04-20,2020-12-01,Interventional,Efficacy of Faviprevir in COVID-19 Treatment,Recruiting,Phase 2/Phase 3,Tanta University,NA,https://clinicaltrials.gov/ct2/show/NCT04351295,1,0,1,0,2,0,Egypt,0,favipiravir|placebo,"Clinical Trial, Phase II|Clinical Trial, Phase III|Journal Article|Multicenter Study|Randomized Controlled Trial"
NCT04341038,2020-04-01,2020-06-01,Interventional,Clinical Trial to Evaluate Methylprednisolone Pulses and Tacrolimus in Patients With COVID-19 Lung Injury,Recruiting,Phase 3,Hospital Universitari de Bellvitge,NA,https://clinicaltrials.gov/ct2/show/NCT04341038,1,0,1,0,0,0,Spain,0,tacrolimus|methylprednisolone,Journal Article|Review
NCT04390022,2020-07-31,2020-09-17,Interventional,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Completed,Phase 2,"Clinica Universidad de Navarra, Universidad de Navarra",NA,https://clinicaltrials.gov/ct2/show/NCT04390022,1,0,1,0,6,0,Spain,1,ivermectin|placebo,Journal Article
NCT04451174,2020-06-23,2020-11-30,Interventional,Early Use of Corticosteroids in Non-critical Patients With COVID-19 Pneumonia,Recruiting,Phase 3,University of Chile,NA,https://clinicaltrials.gov/ct2/show/NCT04451174,1,0,1,0,3,0,Chile,0,prednisone,Letter
NCT04394182,2020-04-21,2020-12-31,Interventional,Ultra Low Doses of Therapy With Radiation Applicated to COVID-19,Recruiting,N/A,Fundacion GenesisCare,NA,https://clinicaltrials.gov/ct2/show/NCT04394182,1,10,11,0,0,0,Spain,0,radiotherapy|oxygen|lopinavir/ritonavir|hydroxychloroquine|azithromycin|piperacillin/tazobactam|heparin|corticosteroid|tocilizumab|lopinavir|ritonavir|piperacillin|tazobactam,Case Reports|Clinical Trial|Journal Article/Journal Article/Journal Article|Review/Editorial|Comment/Journal Article
NCT04393805,2020-06-01,2021-02-26,Observational,Heparins for Thromboprophylaxis in COVID-19 Patients: HETHICO Study in Veneto,Completed,NA,Quovadis Associazione,NA,https://clinicaltrials.gov/ct2/show/NCT04393805,1,0,1,0,3,0,Italy,0,heparin,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04373707,2020-05-13,2021-11-30,Interventional,Weight-Adjusted vs Fixed Low Doses of Low Molecular Weight Heparin For Venous Thromboembolism Prevention in COVID-19,Recruiting,Phase 4,"Central Hospital, Nancy, France",NA,https://clinicaltrials.gov/ct2/show/NCT04373707,1,0,1,0,5,0,France,0,enoxaparin,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04368377,2020-04-06,2020-04-23,Interventional,Enhanced Platelet Inhibition in Critically Ill Patients With COVID-19,Completed,Phase 2,University of Milan,NA,https://clinicaltrials.gov/ct2/show/NCT04368377,1,0,1,0,0,0,Italy,0,tirofiban|clopidogrel|acetylsalicylic acid|fondaparinux,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04416048,2020-11-30,2021-04-30,Interventional,Effect of Anticoagulation Therapy on Clinical Outcomes in COVID-19,Recruiting,Phase 3,"Charite University, Berlin, Germany",NA,https://clinicaltrials.gov/ct2/show/NCT04416048,1,0,1,0,3,0,Germany,0,rivaroxaban|standard care,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04362085,2020-05-11,2022-03-31,Interventional,Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care,Recruiting,Phase 3,"St. Michael's Hospital, Toronto",NA,https://clinicaltrials.gov/ct2/show/NCT04362085,2,0,2,0,3,0,Canada,0,anticoagulation,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review/Clinical Trial Protocol|Letter"
NCT04360824,2020-05-06,2021-04-16,Interventional,Covid-19 Associated Coagulopathy,Recruiting,Phase 4,University of Iowa,NA,https://clinicaltrials.gov/ct2/show/NCT04360824,1,0,1,0,4,1,United States,0,thromboprophylaxis|standard of care thromboprophylaxis,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04359277,2020-04-21,2020-09-20,Interventional,A Randomized Trial of Anticoagulation Strategies in COVID-19,Terminated,Phase 3,NYU Langone Health,the PROTECT study is being transitioned to ACTIV4 ACUTE anticoagulation inpatient study,https://clinicaltrials.gov/ct2/show/NCT04359277,1,0,1,0,3,1,United States,0,enoxaparin|anticoagulation,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04354155,2020-06-02,2022-09-30,Interventional,COVID-19 Anticoagulation in Children - Thromboprophlaxis (COVAC-TP) Trial,Recruiting,Phase 2,Johns Hopkins All Children's Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04354155,1,0,1,0,2,1,United States,0,enoxaparin,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04397510,2020-06-01,2021-12-31,Interventional,Nebulized Heparin for the Treatment of COVID-19 Induced Lung Injury,Enrolling by invitation,Phase 4,Frederick Health,NA,https://clinicaltrials.gov/ct2/show/NCT04397510,1,0,1,0,7,1,United States,0,heparin|saline,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04394377,2020-06-21,2021-03-31,Interventional,Full Anticoagulation Versus Prophylaxis in COVID-19: COALIZAO ACTION Trial,"Active, not recruiting",Phase 4,Brazilian Clinical Research Institute,NA,https://clinicaltrials.gov/ct2/show/NCT04394377,2,0,2,0,8,0,Brazil,0,group 1: rivaroxaban 20mg/d followed by enoxaparin/unfractionated heparin when needed|enoxaparin|rivaroxaban|d followed by enoxaparin|heparin|d,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review/Journal Article"
NCT04401293,2020-04-26,2021-04-26,Interventional,Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients,Recruiting,Phase 3,Northwell Health,NA,https://clinicaltrials.gov/ct2/show/NCT04401293,2,0,2,0,2,1,United States,0,enoxaparin|prophylactic,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review/Journal Article|Multicenter Study"
NCT04359212,2020-05-01,2020-06-30,Observational,Increased Risk of VTE and Higher Hypercoagulability in Patients Recovered in ICU and in Medical Ward for COVID-19,Completed,NA,Quovadis Associazione,NA,https://clinicaltrials.gov/ct2/show/NCT04359212,1,0,1,0,3,0,Italy,0,thromboprophylaxis|fondaparinux,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04647604,2020-06-23,2021-04-30,Interventional,Resolving Inflammatory Storm in COVID-19 Patients by Omega-3 Polyunsaturated Fatty Acids -,Recruiting,Phase 2,Karolinska University Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04647604,1,0,1,0,0,0,Sweden,0,omegavenâ®|sodium chloride|omegavenâ®,Journal Article|Review
NCT04359836,2020-04-16,2021-04-30,Observational,A Study to Explore the Role of Gut Flora in COVID-19 Infection,Recruiting,NA,ProgenaBiome,NA,https://clinicaltrials.gov/ct2/show/NCT04359836,1,0,1,0,2,1,United States,0,there is no intervention in this study,Journal Article
NCT04411446,2020-08-11,2021-05-15,Interventional,Cholecalciferol to Improve the Outcomes of COVID-19 Patients,Recruiting,Phase 4,Vitamin D Study Group,NA,https://clinicaltrials.gov/ct2/show/NCT04411446,1,1,2,0,4,0,Argentina,0,vitamin d|placebo,Clinical Trial Protocol|Letter
NCT04405908,2020-06-19,2020-10-16,Interventional,SCB-2019 as COVID-19 Vaccine,"Active, not recruiting",Phase 1,Clover Biopharmaceuticals AUS Pty Ltd,NA,https://clinicaltrials.gov/ct2/show/NCT04405908,1,0,1,1,4,0,Australia,0,scb-2019|scb-2019 with as03 adjuvant|scb-2019 with cpg 1018 adjuvant/alum adjuvant|scb-2019 with cpg 1018 adjuvant|alum adjuvant,"Clinical Trial, Phase I|Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04505722,2020-09-07,2021-01-22,Interventional,A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants,"Active, not recruiting",Phase 3,Janssen Vaccines & Prevention B.V.,NA,https://clinicaltrials.gov/ct2/show/NCT04505722,2,0,2,0,13,1,South Africa|United States|Argentina|Brazil|Chile|Colombia|Mexico|Peru,0,ad26.cov2.s|placebo,"Journal Article|Research Support, Non-U.S. Gov't/Journal Article"
NCT04371744,2020-04-17,2020-06-04,Observational [Patient Registry],QT-Logs : Artificial Intelligence for QT Interval Analysis of ECG From Smartwatches in Patient Receiving Treatment for Covid-19,Completed,NA,Assistance Publique Hopitaux De Marseille,NA,https://clinicaltrials.gov/ct2/show/NCT04371744,1,0,1,0,1,0,France,0,"NA",Journal Article|Observational Study
NCT04380701,2020-04-23,2023-04-30,Interventional,A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-2019 in Healthy and Immunocompromised Adults,Recruiting,Phase 1/Phase 2,BioNTech SE,NA,https://clinicaltrials.gov/ct2/show/NCT04380701,1,0,1,1,5,0,Germany,0,bnt162a1|bnt162b1|bnt162b2|bnt162c2,Journal Article
NCT04334954,2020-08-26,2022-03-31,Observational,SARS-COV2 Pandemic Serosurvey and Blood Sampling,"Active, not recruiting",NA,National Institutes of Health Clinical Center (CC),NA,https://clinicaltrials.gov/ct2/show/NCT04334954,1,0,1,0,100,1,United States,0,"NA",Preprint
NCT04462393,2020-03-06,2020-05-06,Observational,Characteristics and Outcomes of Patients Admitted to Swedish Intensive Care Units for COVID-19,Completed,NA,Linkoeping University,NA,https://clinicaltrials.gov/ct2/show/NCT04462393,1,0,1,0,1,0,Sweden,0,admission to icu for covid-19,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04371965,2020-09-01,2020-10-23,Interventional,"Povidone Iodine Mouthwash, Gargle, and Nasal Spray to Reduce Naso- Pharyngeal Viral Load in Patients With COVID-19",Completed,Phase 2,Poitiers University Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04371965,1,0,1,0,3,0,France,0,povidone/iodine,"Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04411784,2020-05-20,2020-07-31,Observational,"PROTECT-ASUC: Covid-19 Pandemic Response Of assessmenT, EndosCopy and Treatment in Acute Severe Ulcerative Colitis","Active, not recruiting",NA,Hull University Teaching Hospitals NHS Trust,NA,https://clinicaltrials.gov/ct2/show/NCT04411784,1,0,1,0,0,0,United Kingdom,0,"NA",Journal Article|Multicenter Study|Observational Study
NCT04530396,2020-09-07,2021-05-01,Interventional,"Clinical Trial of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Vaccine Against COVID-19","Active, not recruiting",Phase 3,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",NA,https://clinicaltrials.gov/ct2/show/NCT04530396,1,0,1,1,8,0,Russian Federation,0,gam-covid-vac|placebo,"Clinical Trial, Phase III|Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04275414,2020-02-15,2020-04-05,Interventional,Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia,Completed,Phase 2,Qilu Hospital of Shandong University,NA,https://clinicaltrials.gov/ct2/show/NCT04275414,1,0,1,0,2,0,China|Italy,0,bevacizumab,"Clinical Trial|Journal Article|Multicenter Study|Research Support, Non-U.S. Gov't"
NCT04383574,2020-05-22,2020-08-28,Interventional,Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of SARS-CoV-2 Infection(COVID-19),"Active, not recruiting",Phase 1/Phase 2,"Sinovac Biotech Co., Ltd",NA,https://clinicaltrials.gov/ct2/show/NCT04383574,1,0,1,1,2,0,China,0,"two doses of low dosage inactivated sars-cov-2 vaccine at the schedule of day 0,28|two doses of medium dosage inactivated sars-cov-2 vaccine at the schedule of day 0,28|two doses of high dosage inactivated sars-cov-2 vaccine at the schedule of day 0,28|placebo",Journal Article
NCT04323787,2020-03-30,2021-04-30,Observational,Viral Infection and Respiratory Illness Universal Study[VIRUS]: COVID-19 Registry,Recruiting,NA,Mayo Clinic,NA,https://clinicaltrials.gov/ct2/show/NCT04323787,2,0,2,0,4,1,United States,0,observational,Journal Article|Multicenter Study|Observational Study/Journal Article
NCT04350723,2020-06-10,2021-07-30,Interventional,Awake Prone Position in Hypoxemic Patients With Coronavirus Disease 19 (COVI-PRONE): A Randomized Clinical Trial,Recruiting,N/A,St. Joseph's Healthcare Hamilton,NA,https://clinicaltrials.gov/ct2/show/NCT04350723,1,0,1,0,1,0,Canada|Saudi Arabia,0,prone positioning,"Journal Article|Research Support, U.S. Gov't, Non-P.H.S."
NCT04568525,2020-07-01,2020-07-25,Interventional,Passive Microwave Radiometry (MWR) and AI for COVID-19 Complications Early Diagnostics of Lungs,Completed,N/A,Kyrgyz State Medical Academy,NA,https://clinicaltrials.gov/ct2/show/NCT04568525,1,0,1,0,0,0,Kyrgyzstan,0,passive microwave radiometry,Journal Article
NCT04533360,2020-09-28,2020-10-09,Observational [Patient Registry],Prevalence of COVID-19 Antibodies Kingman AZ,Enrolling by invitation,NA,Kingman Regional Medical Center,NA,https://clinicaltrials.gov/ct2/show/NCT04533360,1,0,1,0,3,1,United States,0,vitros anti-sars-cov-2 igg test,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04473261,2020-07-14,2021-07-15,Interventional,Efficacy of Iodine Complex Against COVID-19 Patients,Recruiting,Phase 1/Phase 2,Sheikh Zayed Federal Postgraduate Medical Institute,NA,https://clinicaltrials.gov/ct2/show/NCT04473261,1,0,1,0,1,0,Pakistan,0,iodine|placebo|idoine complex,Clinical Trial Protocol|Letter
NCT04288102,2020-03-05,2020-05-12,Interventional,Treatment With Human Umbilical Cord-derived Mesenchymal Stem Cells for Severe Corona Virus Disease 2019 (COVID-19),Completed,Phase 2,Beijing 302 Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04288102,1,0,1,0,5,0,China,0,mesenchymal stem cells|saline containing 1% human serum albuminï¼ˆsolution without uc-mscsï¼‰|saline containing 1% human serum albuminï¼ˆsolution without uc-mscsï¼‰,"Clinical Trial, Phase II|Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04303507,2020-04-29,2021-04-30,Interventional,Chloroquine/ Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting,Recruiting,N/A,University of Oxford,NA,https://clinicaltrials.gov/ct2/show/NCT04303507,1,0,1,0,7,0,Indonesia|Italy|Lao People's Democratic Republic|Pakistan|Thailand|United Kingdom,0,chloroquine/hydroxychloroquine|placebo|chloroquine|hydroxychloroquine,Journal Article|Systematic Review
NCT04312243,2020-04-07,2021-04-07,Interventional,NO Prevention of COVID-19 for Healthcare Providers,"Active, not recruiting",Phase 2,Massachusetts General Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04312243,1,0,1,0,3,1,United States,0,nitric oxide,Journal Article|Systematic Review
NCT04318444,2020-03-29,2021-03-31,Interventional,Hydroxychloroquine Post Exposure Prophylaxis for Coronavirus Disease (COVID-19),Recruiting,Phase 2/Phase 3,Columbia University,NA,https://clinicaltrials.gov/ct2/show/NCT04318444,1,0,1,0,2,1,United States,0,hydroxychloroquine|placebo,Journal Article|Systematic Review
NCT04413968,2020-06-02,2020-07-02,Interventional,"COVID-19 Infection and Transmission in Exposed, Confined and Community-based Infants",Completed,N/A,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicaltrials.gov/ct2/show/NCT04413968,1,0,1,0,3,0,France,0,rapid test|nasopharyngeal swab|stool collection,"Clinical Trial|Journal Article|Multicenter Study|Research Support, Non-U.S. Gov't"
NCT04609865,2020-11-04,2021-12-31,Interventional,Impact of Intravenous Lidocaine on Clinical Outcomes of Patients With ARDS During COVID-19 Pandemia,Recruiting,Phase 3,"University Hospital, Strasbourg, France",NA,https://clinicaltrials.gov/ct2/show/NCT04609865,1,0,1,0,2,0,France,0,lidocaine 2%|control,Clinical Trial Protocol|Letter
NCT04379440,2020-04-25,2020-09-30,Observational [Patient Registry],Geriatric Population COVID-19 Observational Study (GEROCOVIDobs),Recruiting,NA,Campus Bio-Medico University,NA,https://clinicaltrials.gov/ct2/show/NCT04379440,1,0,1,0,0,0,Italy,0,"NA",Journal Article
NCT04383678,2020-03-01,2021-04-01,Observational,Outcome of COVID-19 Patients After Extracorporeal Membrane Oxygenation for Acute Respiratory Distress Syndrome,Completed,NA,Helsinki University Central Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04383678,1,0,1,0,4,0,Finland|France|Germany|Italy|Sweden|United Kingdom,0,extracorporeal membrane oxygenation,Journal Article
NCT04497389,2020-10-28,2021-09-15,Interventional,Safety and Feasibility of Amniotic Fluid as a Treatment for COVID-19 Patients,Recruiting,Phase 1/Phase 2,University of Utah,NA,https://clinicaltrials.gov/ct2/show/NCT04497389,1,0,1,0,2,1,United States,0,human amniotic fluid,"Clinical Trial Protocol|Journal Article|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't"
NCT04342728,2020-04-08,2020-12-30,Interventional,Coronavirus 2019 (COVID-19)- Using Ascorbic Acid and Zinc Supplementation,Completed,N/A,The Cleveland Clinic,NA,https://clinicaltrials.gov/ct2/show/NCT04342728,1,0,1,0,6,1,United States,0,vitamin c|zinc|ascorbic acid/zinc gluconate|standard care,Comparative Study|Journal Article|Multicenter Study|Randomized Controlled Trial
NCT04411576,2020-04-23,2020-07-01,Observational,Current and Past SARS-CoV-2 Infection and COVID-19 in Healthcare,Recruiting,NA,Karolinska University Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04411576,2,0,2,0,0,0,Sweden,0,throat swab sample for measuring current infection with sars-cov-2|blood sample,"Journal Article/Journal Article|Research Support, Non-U.S. Gov't"
NCT04509973,2020-08-27,2021-09-17,Interventional,Higher vs. Lower Doses of Dexamethasone for COVID-19 and Severe Hypoxia,Recruiting,Phase 3,Scandinavian Critical Care Trials Group,NA,https://clinicaltrials.gov/ct2/show/NCT04509973,1,0,1,0,1,0,Denmark|India|Sweden|Switzerland,0,dexamethasone,Clinical Trial Protocol|Comparative Study|Journal Article
NCT04730323,2020-05-12,2020-06-12,Interventional,TOCILIZUMAB - An Option for Patients With COVID-19 Associated Cytokine Release Syndrome; A Single Center Experience,Completed,Phase 4,FMH College of Medicine and Dentistry,NA,https://clinicaltrials.gov/ct2/show/NCT04730323,1,0,1,0,0,0,Pakistan,0,tocilizumab,Journal Article
NCT04569188,2020-05-15,2020-08-15,Interventional,Convalescent Plasma in COVID-19 Elderly Patients,Completed,Phase 2,Azienda Socio Sanitaria Territoriale di Mantova,NA,https://clinicaltrials.gov/ct2/show/NCT04569188,1,0,1,0,1,0,Italy,0,convalescent plasma,Journal Article
NCT04479150,2020-03-01,2020-08-31,Observational [Patient Registry],Complications and Mortality Following Emergency Digestive Surgery During the COVID-19 Pandemic,Completed,NA,Hospital Universitari de Bellvitge,NA,https://clinicaltrials.gov/ct2/show/NCT04479150,1,0,1,0,2,0,Spain,0,"NA",Journal Article
NCT04449718,2020-06-01,2020-10-07,Interventional,Vitamin D Supplementation in Patients With COVID-19,Completed,N/A,University of Sao Paulo,NA,https://clinicaltrials.gov/ct2/show/NCT04449718,1,0,1,0,1,0,Brazil,0,vitamin d|placebo,"Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04363333,2020-04-27,2021-05-31,Observational,Obstructive Sleep Apnea & Covid-19 Outcomes,"Active, not recruiting",NA,KoÃ§ University,NA,https://clinicaltrials.gov/ct2/show/NCT04363333,1,0,1,0,5,0,Turkey,0,home sleep apnea testing/in-hospital polysomnography|home sleep apnea testing|polysomnography,Journal Article
NCT04595123,2020-06-15,2020-11-01,Observational,Impact of COVID-19 Pandemic in Perinatal Mental Health (RISEUP-PPD-COVID-19),Recruiting,NA,University of Minho,NA,https://clinicaltrials.gov/ct2/show/NCT04595123,1,0,1,0,2,0,Albania|Brazil|Bulgaria|Chile|Cyprus|France|Greece|Israel|Malta|Portugal|Spain|Turkey|United Kingdom,0,"NA",Journal Article|Observational Study
NCT04426084,2020-03-01,2020-05-11,Observational [Patient Registry],Cardiovascular Risk Factors and Severe COVID-19. A Nationwide Registry-based Case-Control Study,"Active, not recruiting",NA,Karolinska Institutet,NA,https://clinicaltrials.gov/ct2/show/NCT04426084,1,0,1,0,0,0,Sweden,0,hypertension|diabetes type 2|obesity|antihypertensives|statins,"Journal Article|Observational Study|Research Support, Non-U.S. Gov't"
NCT04433260,2020-07-25,2021-05-31,Observational,COVID19 and Physical and Emotional Wellbeing of HCP,Recruiting,NA,Queen Mary University of London,NA,https://clinicaltrials.gov/ct2/show/NCT04433260,1,0,1,0,2,0,United Kingdom,0,questionnaire|informed consent,Journal Article
NCT04340921,2020-05-14,2021-11-10,Observational,The Role of Adaptive Immunity in COVID-19 Associated Myocardial Injury,Recruiting,NA,Barts & The London NHS Trust,NA,https://clinicaltrials.gov/ct2/show/NCT04340921,1,7,8,0,1,0,United Kingdom,0,exposure,"Letter|Research Support, Non-U.S. Gov't/Journal Article|Research Support, Non-U.S. Gov't/Letter"
NCT04365127,2020-04-27,2020-08-20,Interventional,Progesterone for the Treatment of COVID-19 in Hospitalized Men,Completed,Phase 1,Cedars-Sinai Medical Center,NA,https://clinicaltrials.gov/ct2/show/NCT04365127,1,0,1,0,2,1,United States,0,progesterone,Journal Article
NCT04610554,2020-05-14,2020-10-12,Observational,Lung Diffusing Capacity for Nitric Oxide and Carbon Monoxide Early After Mild-to-severe COVID-19,Completed,NA,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",NA,https://clinicaltrials.gov/ct2/show/NCT04610554,1,1,2,0,0,0,Italy,0,"NA",Journal Article/Evaluation Study|Journal Article
NCT04424992,2020-02-28,2021-12-31,Observational,The Natural History of Hospitalized COVID-19 Patients,Recruiting,NA,University of Milano Bicocca,NA,https://clinicaltrials.gov/ct2/show/NCT04424992,1,0,1,0,1,0,Italy,0,observational cohort study on the natural history of hospitalized sars-cov-2 patients.,"Journal Article|Observational Study|Research Support, Non-U.S. Gov't"
NCT04542915,2020-09-29,2021-10-31,Observational,COVID-19-Related Health and Practices Among Dental Hygienists,"Active, not recruiting",NA,American Dental Association,NA,https://clinicaltrials.gov/ct2/show/NCT04542915,1,0,1,0,1,1,United States,0,no intervention,Journal Article
NCT04557046,2020-06-26,2021-11-30,Interventional,Performance Evaluation of LumiraDx COVID-19 (SARS-CoV-2) Ag Test,Recruiting,N/A,LumiraDx UK Limited,NA,https://clinicaltrials.gov/ct2/show/NCT04557046,1,0,1,0,3,1,United States,0,nasal|nasopharyngeal swab|throat swab|fingerstick|saliva,Journal Article
NCT04320615,2020-04-03,2020-06-24,Interventional,A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,Completed,Phase 3,Hoffmann-La Roche,NA,https://clinicaltrials.gov/ct2/show/NCT04320615,1,0,1,0,10,1,United States|Canada|Denmark|France|Germany|Italy|Netherlands|Spain|United Kingdom,0,tocilizumab|placebo,"Clinical Trial, Phase III|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04366050,2020-05-11,2021-05-31,Interventional,Ramipril for the Treatment of COVID-19,Recruiting,Phase 2,"University of California, San Diego",NA,https://clinicaltrials.gov/ct2/show/NCT04366050,1,0,1,0,2,1,United States,0,ramipril|placebo,"Journal Article|Research Support, N.I.H., Extramural"
NCT04407260,2020-03-06,2020-05-01,Observational,"Use of Oxygen Hoods in Patients Failing on Conventional High-flow Oxygen Delivery Systems, Effects on Oxygenation, Mechanical Ventilation and Mortality Rates in Hypoxic COVID-19 Patients. Prospective Cohort Study.",Completed,NA,Northwell Health,NA,https://clinicaltrials.gov/ct2/show/NCT04407260,1,0,1,0,3,1,United States,0,oxygen hood,Journal Article|Randomized Controlled Trial
NCT04719234,2020-06-15,2020-12-01,Interventional,Lung Ultrasonography in COVID-19 Pneumonia,Completed,N/A,Bursa YÃ¼ksek Ä°htisas Education and Research Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04719234,1,0,1,0,0,0,Turkey,0,lung ultrasonography,Journal Article
NCT04344587,2020-04-23,2021-05-31,Interventional,Awake Prone Position for Early Hypoxemia in COVID-19,"Active, not recruiting",N/A,Boston University,NA,https://clinicaltrials.gov/ct2/show/NCT04344587,1,0,1,0,12,1,United States|Spain,0,prone positioning|standard care,Journal Article
NCT04380909,2020-05-06,2021-07-31,Interventional,ROCO - Self-help for People With Psychological Distress Due to the Covid-19 Situation,"Active, not recruiting",N/A,University of Bern,NA,https://clinicaltrials.gov/ct2/show/NCT04380909,1,0,1,0,2,0,Switzerland,0,internet-based self-help|internet-based self-help after 3 weeks,Clinical Trial Protocol|Journal Article
NCT04350580,2020-04-11,2021-04-30,Interventional,Polyvalent Immunoglobulin in COVID-19 Related ARds,Recruiting,Phase 3,Centre Hospitalier St Anne,NA,https://clinicaltrials.gov/ct2/show/NCT04350580,1,0,1,0,2,0,France,0,immunoglobulin|placebo,Clinical Trial Protocol|Journal Article
NCT04663555,2021-02-02,2022-03-31,Interventional,Effect of Two Different Doses of Dexamethasone in Patients With ARDS and COVID-19,Recruiting,Phase 4,Brno University Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04663555,1,0,1,0,3,0,Czechia,0,dexamethasone,Clinical Trial Protocol|Letter
NCT04549831,2020-04-08,2021-04-08,Observational,Genetic Bases of COVID-19 Clinical Variability,Recruiting,NA,University of Siena,NA,https://clinicaltrials.gov/ct2/show/NCT04549831,1,0,1,0,1,0,Italy,0,massive parallel sequencing of host genome,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04375098,2020-05-04,2020-08-17,Interventional,Efficacy and Safety of Early COVID-19 Convalescent Plasma in Patients Admitted for COVID-19 Infection,Completed,Phase 2,Pontificia Universidad Catolica de Chile,NA,https://clinicaltrials.gov/ct2/show/NCT04375098,1,0,1,0,3,0,Chile,0,convalescent plasma,"Clinical Trial, Phase II|Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04405843,2020-07-14,2020-12-21,Interventional,Efficacy of Ivermectin in Adult Patients With Early Stages of COVID-19 (EPIC Trial),Completed,Phase 2/Phase 3,Centro de Estudios en InfectogÃ­a Pediatrica,NA,https://clinicaltrials.gov/ct2/show/NCT04405843,1,0,1,0,8,0,Colombia,0,ivermectin|placebo,"Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04318431,2020-04-14,2020-05-12,Interventional,Prevalence of SARS -Cov2 Carriage in Asymptomatic and Mildly-symptomatic Children,Completed,N/A,Centre Hospitalier Intercommunal Creteil,NA,https://clinicaltrials.gov/ct2/show/NCT04318431,1,0,1,0,7,0,France,0,data collection/rhinopharyngeal swab|data collection|rhinopharyngeal,Journal Article
NCT04393818,2020-05-05,2020-08-24,Interventional,Mobile Phone Based Intervention to Protect Mental Health in Healthcare Workers at Frontline Against COVID19,Completed,Phase 3,FundaciÃ³ d'investigaciÃ³ SanitÃ ria de les Illes Balears,NA,https://clinicaltrials.gov/ct2/show/NCT04393818,2,0,2,0,4,0,Spain,0,intervention app,Journal Article/Journal Article
NCT04327388,2020-03-28,2020-07-30,Interventional,Sarilumab COVID-19,Completed,Phase 3,Sanofi,NA,https://clinicaltrials.gov/ct2/show/NCT04327388,1,0,1,0,18,0,Argentina|Brazil|Canada|Chile|France|Germany|Israel|Italy|Japan|Russian Federation|Spain,0,sarilumab|placebo,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04354428,2020-04-16,2020-12-31,Interventional,Treatment for COVID-19 in High-Risk Adult Outpatients,"Active, not recruiting",Phase 2/Phase 3,University of Washington,NA,https://clinicaltrials.gov/ct2/show/NCT04354428,1,0,1,0,6,1,United States,0,vitamin c|hydroxychloroquine|azithromycin|folic acid|lopinavir 200 mg / ritonavir 50 mg [kaletra]|lopinavir 200 mg|ritonavir 50 mg [kaletra],Journal Article
NCT04357366,2020-04-15,2022-04-15,Interventional,suPAR-guided Anakinra Treatment for Validation of the Risk and Management of Respiratory Failure by COVID-19 (SAVE),Recruiting,Phase 2,Hellenic Institute for the Study of Sepsis,NA,https://clinicaltrials.gov/ct2/show/NCT04357366,1,0,1,0,6,0,Greece,0,anakinra,"Clinical Trial|Journal Article|Research Support, Non-U.S. Gov't"
NCT04385017,2020-05-11,2021-06-12,Interventional,Role of Inflammasomes in COVID-19 Disease,Recruiting,N/A,Centre Hospitalier Universitaire de Nice,NA,https://clinicaltrials.gov/ct2/show/NCT04385017,1,0,1,0,0,0,France,0,covid-19 patients,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04499677,2020-09-24,2021-11-30,Interventional,FLARE: Favipiravir +/- Lopinavir: A RCT of Early Antivirals,Recruiting,Phase 2,"University College, London",NA,https://clinicaltrials.gov/ct2/show/NCT04499677,1,0,1,0,3,0,United Kingdom,0,favipiravir|lopinavir/ ritonavir|placebo|lopinavir|ritonavir,Clinical Trial Protocol|Letter
NCT04362176,2020-04-24,2021-05-31,Interventional,Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults,Recruiting,Phase 3,Vanderbilt University Medical Center,NA,https://clinicaltrials.gov/ct2/show/NCT04362176,2,0,2,0,6,1,United States,0,convalescent plasma|placebo,Preprint/Clinical Trial Protocol|Journal Article
NCT04636294,2020-08-01,2021-02-15,Observational,Borderline COVID-19 PCR Test Result,Completed,NA,Jessa Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04636294,1,0,1,0,1,0,Belgium,0,pcr,Journal Article
NCT04342806,2020-04-10,2099-12-31,Observational [Patient Registry],"Healthcare Worker Exposure Response and Outcomes (HERO) Registry Study, COVID-19",Recruiting,NA,Duke University,NA,https://clinicaltrials.gov/ct2/show/NCT04342806,1,0,1,0,3,1,United States,0,"NA",Journal Article
NCT04405076,2020-05-29,2021-11-01,Interventional,"Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older","Active, not recruiting",Phase 2,"ModernaTX, Inc.",NA,https://clinicaltrials.gov/ct2/show/NCT04405076,1,0,1,1,6,1,United States,0,biological: mrna-1273|placebo|mrna-1273.351,"Clinical Trial, Phase II|Journal Article|Randomized Controlled Trial|Research Support, N.I.H., Extramural"
NCT04420806,2020-03-14,2020-07-30,Interventional,Effects of COVID-19 Lockdown in Exercising Early Postmenopausal Women,Completed,N/A,University of Erlangen-NÃ¼rnberg Medical School,NA,https://clinicaltrials.gov/ct2/show/NCT04420806,1,0,1,0,3,0,Germany,0,exercise|placebo,Journal Article
NCT04546581,2020-10-08,2021-07-31,Interventional,Inpatient Treatment With Anti-Coronavirus Immunoglobulin (ITAC),"Active, not recruiting",Phase 3,University of Minnesota,NA,https://clinicaltrials.gov/ct2/show/NCT04546581,1,0,1,0,4,1,United States|Denmark|Greece|Japan|Nigeria|Spain|United Kingdom,0,hyperimmune immunoglobulin to sars-cov-2 (hivig)|placebo|remdesivir,Journal Article
NCT04537858,2020-06-18,2020-08-20,Interventional,Virtual Reality Therapy Influence on Heart Rate Variability of Inpatients With COVID-19,"Active, not recruiting",N/A,University of Sao Paulo,NA,https://clinicaltrials.gov/ct2/show/NCT04537858,1,0,1,0,0,0,Brazil,0,virtual reality therapy first|conventional therapy first,Journal Article
NCT04431466,2020-07-01,2020-12-01,Interventional,A Study to Compare the Efficacy and Safety of Different Doses of Ivermectin for COVID-19,Recruiting,Phase 2,Universidade Federal de Sao Carlos,NA,https://clinicaltrials.gov/ct2/show/NCT04431466,1,0,1,0,1,0,Brazil,0,ivermectin|standard care,Journal Article
NCT04475601,2020-07-15,2021-07-08,Interventional,Enzalutamide Treatment in COVID-19,Recruiting,Phase 2,VÃ¤sterbotten County Council,NA,https://clinicaltrials.gov/ct2/show/NCT04475601,1,0,1,0,0,0,Sweden,0,enzalutamide,Clinical Trial Protocol|Letter
NCT04534569,2020-09-04,2020-10-03,Observational,Expert Panel Statement for the Respiratory Management of COVID-19 Related Acute Respiratory Failure (C-ARF),Completed,NA,NMC Specialty Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04534569,1,0,1,0,6,0,United Arab Emirates,0,experts consensus,Journal Article
NCT04702945,2020-03-01,2022-12-31,Observational [Patient Registry],Canadian COVID-19 Emergency Department Registry,Recruiting,NA,University of British Columbia,NA,https://clinicaltrials.gov/ct2/show/NCT04702945,1,0,1,0,0,0,Canada,0,"NA","Journal Article|Research Support, Non-U.S. Gov't"
NCT04486508,2020-07-30,2021-04-04,Interventional,Intermediate-dose vs Standard Prophylactic Anticoagulation and Statin vs Placebo in ICU Patients With COVID-19,"Active, not recruiting",Phase 3,Rajaie Cardiovascular Medical and Research Center,NA,https://clinicaltrials.gov/ct2/show/NCT04486508,1,1,2,0,8,0,"Iran, Islamic Republic of",0,intermediate dose enoxaparin/ unfractionated heparin|standard prophylactic dose enoxaparin/ unfractionated heparin|atorvastatin|placebo|enoxaparin|heparin|standard prophylactic dose enoxaparin,"Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't/Clinical Trial Protocol|Journal Article"
NCT04382508,2020-03-22,2021-03-21,Observational,Coronavirus Infection in Primary or Secondary Immunosuppressed Children and Adults.,Enrolling by invitation,NA,University Hospital Southampton NHS Foundation Trust,NA,https://clinicaltrials.gov/ct2/show/NCT04382508,1,0,1,0,1,0,United Kingdom,0,questionnaire,"Journal Article|Observational Study|Research Support, Non-U.S. Gov't"
NCT04351503,2020-04-09,2022-04-30,Observational,A Systems Approach to Predict the Outcome of SARS-CoV-2 in the Population of a City; COVID-19,Recruiting,NA,"University Hospital, Basel, Switzerland",NA,https://clinicaltrials.gov/ct2/show/NCT04351503,1,0,1,0,2,0,Switzerland,0,study a|study b|study c|study d,Journal Article
NCT04453384,2020-09-01,2020-12-31,Interventional,Study to Evaluate the Safety and Efficacy of XAV-19 in Patients With COVID-19 Induced Moderate Pneumonia,Recruiting,Phase 2,Nantes University Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04453384,1,0,1,0,2,0,France,0,xav-19|placebo,Clinical Trial Protocol|Journal Article
NCT04492514,2020-05-20,2021-05-31,Interventional,Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflation,Recruiting,Phase 2,University of Cincinnati,NA,https://clinicaltrials.gov/ct2/show/NCT04492514,1,0,1,0,0,1,United States,0,mavrilimumab|placebo,Journal Article
NCT04399980,2020-05-20,2021-05-31,Interventional,Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation,"Active, not recruiting",Phase 2,The Cleveland Clinic,NA,https://clinicaltrials.gov/ct2/show/NCT04399980,1,0,1,0,3,1,United States,0,mavrilimumab|placebo,Journal Article
NCT04463004,2020-09-02,2021-08-31,Interventional,Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation,"Active, not recruiting",Phase 2,Virginia Commonwealth University,NA,https://clinicaltrials.gov/ct2/show/NCT04463004,1,0,1,0,4,1,United States,0,mavrilimumab|placebo,Journal Article
NCT04353934,2020-03-31,2021-05-01,Observational,The Ariel University Survey on Dietary Changes and Anxiety During the Coronavirus Pandemic,Recruiting,NA,Ariel University,NA,https://clinicaltrials.gov/ct2/show/NCT04353934,1,0,1,0,1,0,Israel,0,"NA",Journal Article
NCT04466085,2020-07-12,2020-10-22,Interventional,Clinical Study of Recombinant Novel Coronavirus Vaccine,"Active, not recruiting",Phase 2,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",NA,https://clinicaltrials.gov/ct2/show/NCT04466085,1,0,1,1,2,0,China,0,recombinant new coronavirus vaccine (cho cell) low-dose group|recombinant new coronavirus vaccine (cho cells) high-dose group|placebo,Journal Article
NCT04445194,2020-06-22,2020-10-22,Interventional,Phase I Clinical Study of Recombinant Novel Coronavirus Vaccine,"Active, not recruiting",Phase 1,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",NA,https://clinicaltrials.gov/ct2/show/NCT04445194,1,0,1,1,3,0,China,0,recombinant new coronavirus vaccine (cho cell) low-dose group|recombinant new coronavirus vaccine (cho cells) high-dose group|placebo,Journal Article
NCT04365634,2020-02-02,2020-03-15,Observational,A Single-center Retrospective Study to Find Prediction Factors Related to Mortality of COVID-19 Patients.,Completed,NA,Tongji Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04365634,1,0,1,0,0,0,China,0,"NA","Journal Article|Observational Study|Research Support, Non-U.S. Gov't"
NCT04369807,2020-04-21,2023-05-31,Observational,Mapping Organ Health Following COVID-19 Disease Due to SARS-CoV-2 Infection,Recruiting,NA,Perspectum,NA,https://clinicaltrials.gov/ct2/show/NCT04369807,1,19,20,0,0,0,United Kingdom,0,mri,"Journal Article|Observational Study|Research Support, Non-U.S. Gov't/Clinical Trial|Journal Article|Multicenter Study|Research Support, Non-U.S. Gov't/Journal Article|Research Support, Non-U.S. Gov't/Journal Article/Journal Article/Journal Article|Research Support, Non-U.S. Gov't|Review/Journal Article|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't|Review/Journal Article|Research Support, Non-U.S. Gov't/Journal Article|Research Support, Non-U.S. Gov't"
NCT04331899,2020-04-25,2020-08-14,Interventional,Single-Blind Study of a Single Dose of Peginterferon Lambda-1a Compared With Placebo in Outpatients With Mild COVID-19,"Active, not recruiting",Phase 2,Stanford University,NA,https://clinicaltrials.gov/ct2/show/NCT04331899,1,1,2,0,6,1,United States,1,peginterferon|placebo,"Journal Article|Randomized Controlled Trial|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't/Journal Article|Randomized Controlled Trial|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't"
NCT04316884,2020-03-12,2021-12-31,Observational,Mechanisms for Organ Dysfunction in Covid-19,Recruiting,NA,Uppsala University,NA,https://clinicaltrials.gov/ct2/show/NCT04316884,1,0,1,0,1,0,Sweden,0,"NA","Journal Article|Observational Study|Research Support, Non-U.S. Gov't"
NCT04353609,2020-04-18,2020-12-31,Observational,"Covid-19 in Patients With Chronic Inflammatory Rheumatism, Auto-immune or Auto-inflammatory Rare and Non-rare Diseases",Recruiting,NA,"University Hospital, Lille",NA,https://clinicaltrials.gov/ct2/show/NCT04353609,1,0,1,0,1,0,France,0,"NA",Journal Article
NCT04427332,2020-06-11,2020-10-16,Observational,Smell and Taste Disorders in COVID-19 Patients,Completed,NA,University of Milano Bicocca,NA,https://clinicaltrials.gov/ct2/show/NCT04427332,1,0,1,0,2,0,Italy,0,investigation of smell/taste disorders|investigation of smell|taste,Journal Article|Observational Study
NCT04486482,2021-01-12,2021-03-31,Interventional,A Clinical Study to Assess the Physiologic Effects of KB109 in Patients With COVID-19 on Gut Microbiota Structure and Function,Recruiting,N/A,Kaleido Biosciences,NA,https://clinicaltrials.gov/ct2/show/NCT04486482,1,0,1,0,1,1,United States,0,kb109 / self supportive care (ssc)|self supportive care (ssc) alone|kb109|self supportive care (ssc),Clinical Trial Protocol|Letter
NCT04578210,2020-09-04,2021-01-31,Interventional,Safety Infusion of NatuRal KillEr celLs or MEmory T Cells as Adoptive Therapy in COVID-19 pnEumonia or Lymphopenia,Recruiting,Phase 1/Phase 2,Instituto de InvestigaciÃ³n Hospital Universitario La Paz,NA,https://clinicaltrials.gov/ct2/show/NCT04578210,1,0,1,0,1,0,Spain,0,t memory cells/nk cells|t memory cells|nk cells,Congress
NCT04368923,2020-03-15,2020-06-21,Interventional,Management of Covid-19 Patients During Home Isolation,"Active, not recruiting",N/A,Cairo University,NA,https://clinicaltrials.gov/ct2/show/NCT04368923,1,0,1,0,1,0,Egypt,0,oxygen|physical therapy,Journal Article
NCT04388670,2020-02-22,2020-08-22,Observational,Epidemiological and Clinical Characteristics of Critically Ill Patients With COVID-19,Recruiting,NA,Policlinico Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04388670,1,0,1,0,0,0,Italy,0,"NA","Comparative Study|Journal Article|Multicenter Study|Research Support, Non-U.S. Gov't"
NCT04678843,2021-02-09,2021-10-31,Interventional,Adapting and Adopting Highly Specialized Pediatric Eating Disorder Treatment to Virtual Care: Implementation Research for the COVID-19 Context and Beyond,Enrolling by invitation,Early Phase 1,McMaster University,NA,https://clinicaltrials.gov/ct2/show/NCT04678843,1,0,1,0,1,0,Canada,0,virtual family-based treatment,Journal Article
NCT04715607,2021-01-22,2021-05-05,Interventional,"COVID-19: SARS-CoV-2 Detection in Saliva, Oropharyngeal and Nasopharyngeal Specimens",Recruiting,N/A,"Rigshospitalet, Denmark",NA,https://clinicaltrials.gov/ct2/show/NCT04715607,1,0,1,0,3,0,Denmark,0,sequence of testing.,Clinical Trial Protocol|Comparative Study|Journal Article
NCT04379453,2020-04-27,2020-04-27,Interventional,Robot Assisted Percutaneous Cardiovascular Intervention as a Strategy to Reduce or Risk of Intra-Procedure Contamination by COVID-19 and Other Respiratory Viruses,Recruiting,N/A,Hospital Israelita Albert Einstein,NA,https://clinicaltrials.gov/ct2/show/NCT04379453,1,0,1,0,1,0,Brazil,0,robot assisted percutaneous cardiovascular intervention,Journal Article
NCT04347694,2020-04-11,2021-04-11,Observational,Study to Determine the Immunization Status Among Nephrological Health Care Personnel Against SARS-CoV-2 in a Single Center Over the Course of 12 Months During the Worldwide COVID-19 Pandemic.,Recruiting,NA,Medical University of Vienna,NA,https://clinicaltrials.gov/ct2/show/NCT04347694,1,0,1,0,2,0,Austria,0,"NA",Journal Article
NCT04482647,2020-06-17,2021-07-01,Interventional,Breathing Techniques and Meditation for Health Care Workers During COVID-19 Pandemic,Recruiting,Phase 1,M.D. Anderson Cancer Center,NA,https://clinicaltrials.gov/ct2/show/NCT04482647,1,0,1,0,4,1,United States,0,media intervention|meditation therapy|quality-of-life assessment|questionnaire|yoga,Journal Article
NCT04635943,2020-08-29,2021-04-30,Interventional,Randomized Phase IIA Clinical Trial to Evaluate the Efficacy of Ivermectin to Obtain Negative PCR Results in Patients With Early Phase COVID-19,Recruiting,Phase 2,Universidad Peruana Cayetano Heredia,NA,https://clinicaltrials.gov/ct2/show/NCT04635943,1,0,1,0,1,0,Peru,0,ivermectin|placebo,Letter
NCT04569825,2020-08-01,2020-09-30,Interventional,Effect of Nasal Steroid in the Treatment of Anosmia Due to COVID-19 Disease,Recruiting,Early Phase 1,University Of Anbar,NA,https://clinicaltrials.gov/ct2/show/NCT04569825,1,0,1,0,0,0,Iraq,0,ophtamesone,Journal Article
NCT04649996,2020-09-01,2020-10-31,Observational,Variation in Acute Appendicitis During COVID-19 Pandemic in Italy,Completed,NA,University of Milano Bicocca,NA,https://clinicaltrials.gov/ct2/show/NCT04649996,1,0,1,0,1,0,Italy,0,appendectomy,Journal Article
NCT04581954,2020-10-02,2021-06-30,Interventional,Inflammatory Signal Inhibitors for COVID-19 (MATIS),Recruiting,Phase 1/Phase 2,Imperial College London,NA,https://clinicaltrials.gov/ct2/show/NCT04581954,1,0,1,0,1,0,United Kingdom,0,ruxolitinib|fostamatinib|standard care,Letter
NCT04582344,2020-09-14,2021-02-15,Interventional,Clinical Trial For SARS-CoV-2 Vaccine (COVID-19),Recruiting,Phase 3,Health Institutes of Turkey,NA,https://clinicaltrials.gov/ct2/show/NCT04582344,1,0,1,1,2,0,Turkey,0,coronavac|placebo,Letter
NCT04464408,2020-07-23,2021-12-31,Interventional,Favipiravir Therapy in Adults With Mild COVID-19,Recruiting,Phase 2/Phase 3,King Abdullah International Medical Research Center,NA,https://clinicaltrials.gov/ct2/show/NCT04464408,1,0,1,0,4,0,Saudi Arabia,0,favipiravir|placebo,"Clinical Trial Protocol|Journal Article|Research Support, Non-U.S. Gov't"
NCT04494984,2020-07-27,2020-11-23,Interventional,"A Study to Investigate the Pharmacokinetics, Efficacy and Safety of INM005 in Patients With COVID-19.",Completed,Phase 2/Phase 3,Inmunova S.A.,NA,https://clinicaltrials.gov/ct2/show/NCT04494984,1,0,1,0,4,0,Argentina,0,inm005|placebo,Journal Article
NCT04742738,2021-01-20,2021-08-31,Interventional,Safety and Immunogenicity Study of SARS-CoV-2 Nanoparticle Vaccine (GBP510) Adjuvanted With Aluminum Hydroxide (COVID-19),Recruiting,Phase 1/Phase 2,"SK Chemicals Co., Ltd.",NA,https://clinicaltrials.gov/ct2/show/NCT04742738,1,0,1,1,0,0,"Korea, Republic of",0,gbp510 adjuvanted with alum (rbd 10î¼g/dose) - stage 1|normal saline (0.9% sodium chloride solution) - stage 1|gbp510 adjuvanted with alum (rbd 25î¼g/dose) - stage 1|gbp510 adjuvanted with alum (rbd 10î¼g/dose) - stage 2|gbp510 adjuvanted with alum (rbd 25î¼g/dose)- stage 2|normal saline (0.9% sodium chloride solution)- stage 2|gbp510 adjuvanted with alum (rbd 10î¼g|dose) - stage 1|gbp510 adjuvanted with alum (rbd 25î¼g|dose) - stage 2|dose)- stage 2,Journal Article
NCT04750343,2021-02-03,2021-07-31,Interventional,Safety and Immunogenicity Study of SARS-CoV-2 Nanoparticle Vaccine (GBP510) Adjuvanted With or Without AS03 (COVID-19),Recruiting,Phase 1/Phase 2,"SK Chemicals Co., Ltd.",NA,https://clinicaltrials.gov/ct2/show/NCT04750343,1,0,1,1,0,0,"Korea, Republic of",0,gbp510 adjuvanted with as03 (rbd 10î¼g/dose) - stage 1|gbp510 (rbd 10î¼g/dose) - stage 1|normal saline (0.9% sodium chloride solution) - stage 1|gbp510 adjuvanted with as03 (rbd 25î¼g/dose) - stage 1|gbp510 (rbd 25î¼g/dose) - stage 1|gbp510 adjuvanted with as03 (rbd 10î¼g/dose) - stage 2|gbp510 adjuvanted with as03 (rbd 25î¼g/dose)- stage 2|gbp510 (rbd 25î¼g/dose)- stage 2|normal saline (0.9% sodium chloride solution)- stage 2|gbp510 adjuvanted with as03 (rbd 10î¼g|dose) - stage 1|gbp510 (rbd 10î¼g|gbp510 adjuvanted with as03 (rbd 25î¼g|gbp510 (rbd 25î¼g|dose) - stage 2|dose)- stage 2,Journal Article
NCT04670003,2021-01-02,2021-03-30,Observational [Patient Registry],Spread Analysis of COVID-19 Outbreak in France by Self-assessment Web-application,Completed,NA,Weprom,NA,https://clinicaltrials.gov/ct2/show/NCT04670003,1,0,1,0,1,0,France,0,users,Journal Article
NCT04642196,2020-05-02,2020-10-10,Observational,COVID-19 in Home Healthcare,Completed,NA,"University Hospital, Linkoeping",NA,https://clinicaltrials.gov/ct2/show/NCT04642196,1,0,1,0,0,0,Sweden,0,"NA",Journal Article
NCT04318314,2020-03-18,2020-12-31,Observational [Patient Registry],COVID-19: Healthcare Worker Bioresource: Immune Protection and Pathogenesis in SARS-CoV-2,Recruiting,NA,"University College, London",NA,https://clinicaltrials.gov/ct2/show/NCT04318314,1,0,1,0,2,0,United Kingdom,0,copan swabbing/blood sample collection|copan swabbing|blood sample,Journal Article
NCT04403100,2020-06-03,2021-02-01,Interventional,"Hydroxychloroquine and Lopinavir/ Ritonavir to Improve the Health of People With COVID-19: ""The Hope Coalition - 1""",Recruiting,Phase 3,Cardresearch,NA,https://clinicaltrials.gov/ct2/show/NCT04403100,1,0,1,0,2,0,Brazil,0,hydroxychloroquine|lopinavir/ritonavir|hydroxychloroquine/lopinavir/ritonavir|placebo|lopinavir|ritonavir,"Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04495933,2020-07-13,2020-10-09,Interventional,"A Study on the Safety, Tolerability and Immune Response of SARS-CoV-2 Sclamp (COVID-19) Vaccine in Healthy Adults",Recruiting,Phase 1,The University of Queensland,NA,https://clinicaltrials.gov/ct2/show/NCT04495933,1,0,1,1,2,0,Australia,0,mf59 adjuvanted sars-cov-2 sclamp vaccine|placebo,Journal Article
NCT04537208,2020-09-03,2021-11-30,Interventional,Study of Recombinant Protein Vaccine Formulations Against COVID-19 in Healthy Adults 18 Years of Age and Older,"Active, not recruiting",Phase 1/Phase 2,Sanofi,NA,https://clinicaltrials.gov/ct2/show/NCT04537208,1,0,1,1,5,1,United States,0,placebo|sars-cov-2 vaccine formulation 2 without adjuvant|sars-cov-2 vaccine formulation 1 with adjuvant 1|sars-cov-2 vaccine formulation 1 with adjuvant 2|sars-cov-2 vaccine formulation 2 with adjuvant 1|sars-cov-2 vaccine formulation 2 with adjuvant 2,Journal Article
NCT04528641,2020-08-10,2021-07-31,Interventional,GRAd-COV2 Vaccine Against COVID-19,"Active, not recruiting",Phase 1,ReiThera Srl,NA,https://clinicaltrials.gov/ct2/show/NCT04528641,1,0,1,1,2,0,Italy,0,grad-cov2,Journal Article
NCT04335279,2020-04-09,2020-06-03,Interventional,Evaluation of the Scleroderma Patient-centered Intervention Network COVID-19 Home-isolation Activities Together Program,Completed,N/A,Lady Davis Institute,NA,https://clinicaltrials.gov/ct2/show/NCT04335279,1,0,1,0,7,0,Canada,0,spin-chat program,Journal Article
NCT04747782,2020-03-23,2021-10-01,Observational,COVID-19 Longitudinal Biomarkers in Lung Injury,Recruiting,NA,Unity Health Toronto,NA,https://clinicaltrials.gov/ct2/show/NCT04747782,2,0,2,0,0,0,Canada,0,"no interventions performed. just collecting data, blood samples/post-mortem biopsies.|no interventions performed. just collecting data, blood samples|post-mortem biopsies.",Journal Article/Letter
NCT04321096,2020-04-04,2022-01-31,Interventional,The Impact of Camostat Mesilate on COVID-19 Infection,Recruiting,Phase 1/Phase 2,University of Aarhus,NA,https://clinicaltrials.gov/ct2/show/NCT04321096,1,0,1,0,5,0,Denmark|Sweden,0,camostat mesilate|placebo,Journal Article
NCT04420247,2020-04-16,2020-08-20,Interventional,Efficacy of Chloroquine or Hydroxychloroquine in Treating Pneumonia Caused by SARS-Cov-2 - COVID-19,Completed,Phase 3,Centro de Estudos e Pesquisa em Emergencias Medicas e Terapia Intensiva,NA,https://clinicaltrials.gov/ct2/show/NCT04420247,1,0,1,0,2,0,Brazil,0,chloroquine|hydroxychloroquine|standard care,Journal Article
NCT04385797,2020-05-04,2020-12-31,Observational [Patient Registry],Cognitive Outcomes During COVID-19 confiNemeNt in Elderly and Their Caregivers Using Technologies for DEMentia,"Active, not recruiting",NA,FundaciÃ³n PÃºblica Andaluza para la InvestigaciÃ³n de MÃ¡laga en Biomedicina y Salud,NA,https://clinicaltrials.gov/ct2/show/NCT04385797,1,0,1,0,3,0,Spain,0,telephone interview,Journal Article
NCT04403646,2020-06-12,2020-10-20,Interventional,Tannin Specific Natural Extract for COVID-19 Infection,Terminated,N/A,Hospital de Clinicas JosÃ© de San MartÃ­n,low rate of covid patients,https://clinicaltrials.gov/ct2/show/NCT04403646,1,0,1,0,1,0,Argentina,0,arbox|placebo,Letter
NCT04408209,2020-04-23,2021-08-30,Interventional,Convalescent Plasma for the Treatment of Patients With Severe COVID-19 Infection,Recruiting,N/A,National and Kapodistrian University of Athens,NA,https://clinicaltrials.gov/ct2/show/NCT04408209,1,0,1,0,4,0,Greece,0,convalescent plasma,Journal Article
NCT04368312,2020-05-06,2020-09-30,Observational,Psychological Impairment Due to Covid-19,Completed,NA,"University Hospital, Essen",NA,https://clinicaltrials.gov/ct2/show/NCT04368312,1,0,1,0,1,0,Germany,0,no intervention,Journal Article
NCT04397237,2020-06-10,2020-12-08,Observational,Prevalence and Seroconversion of COVID-19 in Autoimmune Diseases in Europe,"Active, not recruiting",NA,PitiÃ©-SalpÃªtriÃ¨re Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04397237,1,0,1,0,1,0,France,0,"NA",Journal Article
NCT04756869,2020-04-28,2021-01-16,Observational,Monitoring Health Care Workers at Risk for COVID-19 Using Wearable Sensors and Smartphone Technology,"Active, not recruiting",NA,University of Michigan,NA,https://clinicaltrials.gov/ct2/show/NCT04756869,1,0,1,0,0,1,United States,0,covid-19 monitoring using wearable sensors/smartphone technology|covid-19 monitoring using wearable sensors|smartphone technology,Journal Article
NCT04348656,2020-05-14,2021-03-31,Interventional,CONvalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness (CONCOR-1),"Active, not recruiting",Phase 3,McMaster University,NA,https://clinicaltrials.gov/ct2/show/NCT04348656,1,0,1,0,11,1,United States|Brazil|Canada,0,convalescent plasma,Journal Article
NCT04605692,2020-03-09,2020-05-20,Observational,Evaluation of Occupational Burnout and Stress Among Dentists in Covid-19 Pandemic,Completed,NA,Akdeniz University,NA,https://clinicaltrials.gov/ct2/show/NCT04605692,1,0,1,0,0,0,Turkey,0,"NA",Journal Article
NCT04339790,2020-04-07,2022-04-01,Observational,Mental Health Impact of COVID-19 Pandemic on NIMH Research Participants and Volunteers,"Active, not recruiting",NA,National Institutes of Health Clinical Center (CC),NA,https://clinicaltrials.gov/ct2/show/NCT04339790,1,0,1,0,141,1,United States,0,"NA",Preprint
NCT04575532,2020-10-05,2021-01-15,Observational,Detection of COVID-19 Decompensation,Enrolling by invitation,NA,"physIQ, Inc.",NA,https://clinicaltrials.gov/ct2/show/NCT04575532,1,0,1,0,0,1,United States,0,"use of the pinpointiq solution (physiq, inc.)",Journal Article
NCT04533399,2020-08-17,2021-11-30,Interventional,A Study Looking at the Effectiveness and Safety of a COVID-19 Vaccine in South African Adults,Recruiting,Phase 2,Novavax,NA,https://clinicaltrials.gov/ct2/show/NCT04533399,1,0,1,1,3,0,South Africa,0,sars-cov-2 rs/matrix-m1 adjuvant|placebo|sars-cov-2 rs|adjuvant,Journal Article
NCT04399252,2020-06-24,2022-05-25,Interventional,Effect of Lactobacillus on the Microbiome of Household Contacts Exposed to COVID-19,Recruiting,N/A,Duke University,NA,https://clinicaltrials.gov/ct2/show/NCT04399252,1,0,1,0,2,1,United States,0,lactobaciltus rhamnosus gg|placebo,Journal Article
NCT04387929,2020-05-04,2021-05-30,Observational [Patient Registry],Detection of Anti-COVID-19 Antibody Levels in an Hospital Population,Recruiting,NA,Istituto Clinico Humanitas,NA,https://clinicaltrials.gov/ct2/show/NCT04387929,1,0,1,0,1,0,Italy,0,antibody test,Journal Article
NCT04329533,2020-04-13,2020-11-01,Interventional,Effects of Using Mobile App on Perceived Stress During COVID-19 Pandemic,Completed,N/A,University of Arizona,NA,https://clinicaltrials.gov/ct2/show/NCT04329533,1,0,1,0,8,1,United States,0,"""calm"" is a mindfulness meditation mobile app",Journal Article
NCT04780126,2021-02-26,2021-04-30,Observational [Patient Registry],Sarco-COVID Study: Measuring the Loss of Skeletal Muscle Mass in the Hospitalized Patient With the Diagnosis of COVID-19,Recruiting,NA,Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz,NA,https://clinicaltrials.gov/ct2/show/NCT04780126,0,6,6,0,0,0,Spain,0,sarcopenia diagnosis,Journal Article
NCT04466670,2020-07-08,2020-12-30,Interventional,Hemostasis in COVID-19: an Adaptive Clinical Trial,Recruiting,Phase 3,University of Sao Paulo General Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04466670,0,36,36,0,0,0,Brazil,0,heparin|acetylsalicylic acid|enoxaparin,"Journal Article|Review/Journal Article/Letter|Comment/Journal Article|Multicenter Study/Journal Article|Review/Comparative Study|Journal Article/Letter/Comparative Study|Journal Article|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't/Journal Article/Clinical Trial, Phase II|Controlled Clinical Trial|Journal Article/Journal Article|Observational Study/Letter"
NCT04779944,2020-04-07,2020-07-30,Observational,Impact of SARS-CoV-2 Pandemic on Psychological State of Health Care Workers,Completed,NA,Assiut University,NA,https://clinicaltrials.gov/ct2/show/NCT04779944,0,3,3,0,0,0,Egypt,0,other,"Journal Article|Review/Journal Article|Research Support, N.I.H., Extramural"
NCT04333550,2020-04-30,2020-09-30,Interventional,Application of Desferal to Treat COVID-19,Recruiting,Phase 1/Phase 2,Kermanshah University of Medical Sciences,NA,https://clinicaltrials.gov/ct2/show/NCT04333550,0,17,17,0,2,0,"Iran, Islamic Republic of",0,deferoxamine,Journal Article
NCT04382768,2020-05-01,2021-01-31,Interventional,Inhaled Ibuprofen to Treat COVID-19,Recruiting,N/A,QuÃ­mica Luar SRL,NA,https://clinicaltrials.gov/ct2/show/NCT04382768,0,3,3,0,3,0,Argentina,0,ibuprofen,Journal Article/Journal Article
NCT04503434,2020-05-15,2020-05-31,Observational [Patient Registry],Patients' Experiences in a Medicalized Hotel for COVID-19 Acute Care Support,Completed,NA,Hospital Clinic of Barcelona,NA,https://clinicaltrials.gov/ct2/show/NCT04503434,0,3,3,0,0,0,Spain,0,"NA",Journal Article
NCT04424953,2020-06-01,2020-09-25,Interventional,To Compare Videolaryngoscope Against Direct Laryngoscope for Intubation When Powered Air Purifying Respirator is Worn,Completed,N/A,Singapore General Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04424953,0,17,17,0,3,0,Singapore,0,mcgrath videolaryngoscope|laryngoscope,"Journal Article/Journal Article/Comparative Study|Letter/Journal Article|Research Support, Non-U.S. Gov't"
NCT04445961,2020-05-01,2020-08-14,Observational,Respiratory Mechanics and Gas Exchange in Patients With COVID-19 and Hypoxemic Acute Respiratory Failure,Completed,NA,I.M. Sechenov First Moscow State Medical University,NA,https://clinicaltrials.gov/ct2/show/NCT04445961,0,3,3,0,1,0,Russian Federation,0,respiratory mechanics measurement|gas exchange measurement,"Journal Article/Journal Article|Research Support, Non-U.S. Gov't/Editorial"
NCT04632615,2020-05-22,2021-03-31,Observational,Sleep Behaviour in Athletes During Home Confinement Due to the Covid-19 Outbreak,"Active, not recruiting",NA,Istituto Ortopedico Galeazzi,NA,https://clinicaltrials.gov/ct2/show/NCT04632615,0,8,8,0,1,0,Italy,0,"NA","Journal Article|Observational Study/Journal Article/Journal Article/Journal Article|Research Support, Non-U.S. Gov't"
NCT04542512,2020-10-01,2021-09-30,Observational [Patient Registry],Risk Factors for Necrotic Cholecystitis During COVID-19 Pandemic.,Recruiting,NA,Poissy-Saint Germain Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04542512,0,6,6,0,4,0,France,0,"NA",Journal Article
NCT04482634,2020-09-01,2022-08-31,Interventional,Tele-rehabilitation Versus Home Exercise Program in COVID-19,Recruiting,N/A,KoÃ§ University,NA,https://clinicaltrials.gov/ct2/show/NCT04482634,0,10,10,0,1,0,Turkey,0,remote controlled exercise|home exercise,Journal Article|Review
NCT04359095,2020-08-18,2021-03-20,Interventional,Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,Recruiting,Phase 2/Phase 3,Universidad Nacional de Colombia,NA,https://clinicaltrials.gov/ct2/show/NCT04359095,0,21,21,0,3,0,Colombia,0,emtricitabine/tenofovir|colchicine pill|rosuvastatin|standard care|emtricitabine|tenofovir,Journal Article
NCT04668404,2020-08-24,2021-01-01,Observational [Patient Registry],Study of Coagulation Profile and Role of Heparin Like Effect in Patients With COVID-19,Recruiting,NA,Postgraduate Institute of Medical Education and Research,NA,https://clinicaltrials.gov/ct2/show/NCT04668404,0,12,12,0,0,0,India,0,sonoclot,Journal Article/Journal Article/Journal Article
NCT04441814,2019-07-23,2021-07-31,Observational,FOUND - Ancillary Study to Smile Protocol NCT03654105,Enrolling by invitation,NA,"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano",NA,https://clinicaltrials.gov/ct2/show/NCT04441814,0,8,8,0,1,0,Italy,0,"NA","Journal Article|Published Erratum/Journal Article/Journal Article/Journal Article|Meta-Analysis|Research Support, Non-U.S. Gov't|Review/Journal Article|Research Support, Non-U.S. Gov't/Journal Article|Review"
NCT04511429,2020-06-30,2020-10-31,Observational [Patient Registry],COVID-19 in Immunosuppressed Children,Recruiting,NA,D'Or Institute for Research and Education,NA,https://clinicaltrials.gov/ct2/show/NCT04511429,0,9,9,0,0,0,Brazil,0,"NA",Journal Article/Editorial/Letter
NCT04410328,2020-10-21,2021-03-15,Interventional,Aggrenox To Treat Acute Covid-19,Recruiting,Phase 3,"Rutgers, The State University of New Jersey",NA,https://clinicaltrials.gov/ct2/show/NCT04410328,0,5,5,0,4,1,United States,0,dipyridamole er 200mg/ aspirin 25mg orally/enterally/standard of care|standard care|dipyridamole er 200mg|aspirin 25mg orally|enterally,"Journal Article|Randomized Controlled Trial|Research Support, N.I.H., Extramural"
NCT04338568,2020-04-16,2020-11-30,Interventional,Screening COVID-19 by Point-of-care Lung Ultrasound: a Validation Study,Recruiting,N/A,Hasselt University,NA,https://clinicaltrials.gov/ct2/show/NCT04338568,0,2,2,0,3,0,Belgium,0,lung ultrasound,Journal Article/Evaluation Study|Journal Article
NCT04841785,2021-04-22,2023-05-01,Observational,Long Term Efficacy and Safety of COVID-19 (SARS-CoV-2) Vaccination in Kidney Disease Patients,Recruiting,NA,University Medical Center Groningen,NA,https://clinicaltrials.gov/ct2/show/NCT04841785,0,17,17,0,1,0,Netherlands,0,mailer-based finger-prick,Journal Article
NCT04642326,2020-06-26,2020-07-01,Interventional,Study Investigating the Effects of UVC Beam and Laser Beam Therapy According to Standard Therapy in Patients With Covid-19 Diagnosis,"Active, not recruiting",N/A,RD Global AraÅŸtirma GeliÅŸtirme SaÄŸlik IlaÃ§ InÅŸaat Yatirimlari A.Åž.,NA,https://clinicaltrials.gov/ct2/show/NCT04642326,0,7,7,0,0,0,Turkey,0,test group: experimental - uvc therapy applied,"Clinical Trial|Journal Article|Research Support, Non-U.S. Gov't/Journal Article"
NCT04374786,2020-05-15,2020-09-01,Interventional,Effects of Mobile App in House Staff Health and Well-being During COVID-19 Pandemic,Enrolling by invitation,N/A,University of Arizona,NA,https://clinicaltrials.gov/ct2/show/NCT04374786,0,4,4,0,2,1,United States,0,meditation,Journal Article/Journal Article
NCT04282902,2020-02-04,2020-04-30,Interventional,A Study to Evaluate the Efficacy and Safety of Pirfenidone With Novel Coronavirus Infection,Recruiting,Phase 3,Tongji Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04282902,0,4,4,0,0,0,China,0,pirfenidone,Journal Article
NCT04673214,2020-12-16,2021-02-02,Interventional,Evaluation of Prognostic Modification in COVID-19 Patients in Early Intervention Treatment,Recruiting,Phase 3,"CoordinaciÃ³n de InvestigaciÃ³n en Salud, Mexico",NA,https://clinicaltrials.gov/ct2/show/NCT04673214,0,6,6,0,3,0,Mexico,0,azithromycin / ivermectin / ribaroxaban / paracetamol|azithromycin / ribaroxaban / paracetamol|azithromycin|ivermectin|ribaroxaban|paracetamol,"Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't/Journal Article|Review"
NCT04594356,2020-11-19,2021-01-31,Observational,"Assessment of Netosis During COVID-19, Under Treatment With Anakinra, an Interleukin-1 Receptor Antagonist","Active, not recruiting",NA,Groupe Hospitalier Paris Saint Joseph,NA,https://clinicaltrials.gov/ct2/show/NCT04594356,0,10,10,0,2,0,France,0,"NA",Journal Article|Review
NCT04480034,2020-07-15,2021-01-31,Observational,Obesity Surgery During 2020 Italian Pandemic,Recruiting,NA,University of Roma La Sapienza,NA,https://clinicaltrials.gov/ct2/show/NCT04480034,0,25,25,0,1,0,Italy,0,bariatric procedures,"Journal Article/Journal Article|Video-Audio Media/Journal Article|Research Support, Non-U.S. Gov't/Journal Article|Observational Study"
NCT04501965,2020-06-01,2020-08-30,Interventional,Phytomedicines Versus Hydroxychloroquine as an Add on Therapy to Azythromycin in Asymptomatic Covid-19 Patients,Enrolling by invitation,Phase 2,Institute for Research and Development of Medicinal and Food Plants of Guinea,NA,https://clinicaltrials.gov/ct2/show/NCT04501965,0,19,19,0,1,0,Guinea,0,hydroxychloroquine / azithromycin|quinquina-stevia/azythromycin|4plants/azythromycin|hydroxychloroquine|azithromycin|quinquina-stevia|4plants,Journal Article|Review/Journal Article|Published Erratum
NCT04459819,2020-03-01,2020-09-30,Observational,Respiratory Physiotherapy in Severe COVID-19 Patients,Completed,NA,"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico",NA,https://clinicaltrials.gov/ct2/show/NCT04459819,0,5,5,0,2,0,Italy,0,respiratory physiotherapy,"Journal Article|Research Support, Non-U.S. Gov't/Journal Article/Journal Article|Practice Guideline"
NCT04567927,2020-03-03,2020-05-28,Observational,Prevalence and Risk Factors for Venous Thromboembolic Events in Critically Ill Patients With COVID-19,Completed,NA,"Ente Ospedaliero Cantonale, Bellinzona",NA,https://clinicaltrials.gov/ct2/show/NCT04567927,0,6,6,0,0,0,Switzerland,0,ultrasonography,"Journal Article|Research Support, Non-U.S. Gov't/Journal Article|Research Support, Non-U.S. Gov't/Journal Article|Research Support, Non-U.S. Gov't/Journal Article|Observational Study/Journal Article|Research Support, Non-U.S. Gov't/Journal Article"
NCT04631861,2014-01-01,2020-07-31,Observational,Physical Activity and the Risk of COVID-19 Infection and Mortality,Completed,NA,Wonju Severance Christian Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04631861,0,4,4,0,0,0,NA,0,"NA","Journal Article/Journal Article/Journal Article|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't/Journal Article|Observational Study"
NCT04407468,2020-05-01,2020-07-13,Observational,Awake Prone Positioning and Oxygen Therapy in Patients With COVID-19,Completed,NA,Hospital General San Juan del Rio,NA,https://clinicaltrials.gov/ct2/show/NCT04407468,0,9,9,0,1,0,Mexico,0,prone positioning,Journal Article|Multicenter Study|Observational Study/Comparative Study|Journal Article/Letter/Journal Article/Case Reports|Letter/Journal Article
NCT04374422,2020-04-10,2020-04-12,Observational,COVID-19 Pandemic and Female Sexual Behavior,Completed,NA,Acibadem University,NA,https://clinicaltrials.gov/ct2/show/NCT04374422,0,2,2,0,0,0,Turkey,0,fsfi survey,Journal Article
NCT04407689,2020-06-08,2021-07-30,Interventional,InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection FR BL Cohort,Recruiting,Phase 2,Revimmune,NA,https://clinicaltrials.gov/ct2/show/NCT04407689,0,2,2,0,2,0,France,0,interleukin|placebo,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04422535,2020-05-29,2020-09-01,Observational,Effects on the Qt Interval of COVID-19 Coronavirus Infection,Recruiting,NA,Hospital General Universitario Gregorio MaraÃ±on,NA,https://clinicaltrials.gov/ct2/show/NCT04422535,0,5,5,0,0,0,Spain,0,"NA","Journal Article|Research Support, Non-U.S. Gov't/Journal Article|Research Support, Non-U.S. Gov't"
NCT04499378,2020-08-15,2021-04-30,Observational,Tomographic Findings in COVID-19 and Influenza H1N1,Recruiting,NA,Universidad de Guanajuato,NA,https://clinicaltrials.gov/ct2/show/NCT04499378,0,13,13,0,1,0,Mexico,0,lung ct,"Journal Article|Research Support, Non-U.S. Gov't/Journal Article"
NCT04753762,2020-03-01,2022-01-01,Observational,Multimodal IMAgery Characterization of Cardiac Damage and Severity After COVID-19 Infection,Recruiting,NA,"Central Hospital, Nancy, France",NA,https://clinicaltrials.gov/ct2/show/NCT04753762,0,10,10,0,0,0,France,0,"NA","Journal Article|Research Support, Non-U.S. Gov't/Case Reports/Journal Article|Research Support, Non-U.S. Gov't/Journal Article|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't|Review/Case Reports|Journal Article/Case Reports|Journal Article/Journal Article|Review/Journal Article|Review/Journal Article|Review"
NCT04497311,2020-06-15,2021-04-30,Observational,Tomographic Findings in COVID-19 and Influenza,Recruiting,NA,Universidad de Guanajuato,NA,https://clinicaltrials.gov/ct2/show/NCT04497311,0,13,13,0,1,0,Mexico,0,thoraxic computed tomography,"Journal Article|Research Support, Non-U.S. Gov't/Journal Article|Research Support, Non-U.S. Gov't|Review/Journal Article|Multicenter Study|Research Support, Non-U.S. Gov't/Journal Article"
NCT04442178,2020-09-15,2021-10-30,Interventional,InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection ( ILIAD-7-US-I ),Recruiting,Phase 2,Revimmune,NA,https://clinicaltrials.gov/ct2/show/NCT04442178,0,4,4,0,2,1,United States,0,cyt107|placebo,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04367883,2020-03-01,2022-09-30,Observational,"Influenza Vaccination, ACEI and ARB in the Evolution of SARS-Covid19 Infection",Recruiting,NA,Consorci Sanitari de Terrassa,NA,https://clinicaltrials.gov/ct2/show/NCT04367883,0,1,1,0,3,0,Spain,0,ace inhibitor|arb,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04407169,2020-06-01,2020-11-17,Observational,Prevalence of Critical Forms of CoVid-19 in Patients With Chronic Respiratory Disease,Completed,NA,"Central Hospital, Nancy, France",NA,https://clinicaltrials.gov/ct2/show/NCT04407169,0,4,4,0,1,0,France,0,no intervention,Journal Article
NCT04661631,2020-05-08,2021-07-31,Observational [Patient Registry],Surgery and Lung Ultrasound in COVID-19 Infection,Recruiting,NA,Fundacion Clinica Valle del Lili,NA,https://clinicaltrials.gov/ct2/show/NCT04661631,0,30,30,0,1,0,Colombia,0,lung ultrasound,"Journal Article/Journal Article|Research Support, Non-U.S. Gov't/Comparative Study|Journal Article/Journal Article|Research Support, Non-U.S. Gov't|Review/Journal Article/Journal Article|Multicenter Study|Research Support, Non-U.S. Gov't/Letter/Journal Article|Research Support, Non-U.S. Gov't/Journal Article/Journal Article|Multicenter Study/Letter|Comment/Journal Article/Journal Article|Meta-Analysis|Research Support, Non-U.S. Gov't|Systematic Review/Journal Article/Journal Article"
NCT04517162,2020-08-19,2021-02-19,Interventional,Intramuscular Effect of Polymerized Type I Collagen on the Cytokine Storm in COVID-19 Patients,Recruiting,Phase 1/Phase 2,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,NA,https://clinicaltrials.gov/ct2/show/NCT04517162,0,31,31,0,3,0,Mexico,0,collagen-polyvinylpyrrolidone,"Journal Article|Meta-Analysis|Systematic Review/Journal Article|Multicenter Study|Research Support, Non-U.S. Gov't/Journal Article/Journal Article|Research Support, Non-U.S. Gov't|Validation Study"
NCT04366232,2020-08-19,2020-10-02,Interventional,Efficacy of Intravenous Anakinra and Ruxolitinib During COVID-19 Inflammation,Terminated,Phase 2,Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer,investigator decision,https://clinicaltrials.gov/ct2/show/NCT04366232,0,3,3,0,5,0,France,0,anakinra|anakinra/ruxolitinib|standard care|3)|ruxolitinib,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04475471,2020-06-11,2021-06-30,Observational,WORLD HEART FEDERATION (WHF) COVID-19 and Cardiovascular Disease Survey,Recruiting,NA,Public Health Foundation of India,NA,https://clinicaltrials.gov/ct2/show/NCT04475471,0,8,8,0,1,0,"Argentina|Bosnia and Herzegovina|Ghana|India|Iran, Islamic Republic of|Sudan",0,"NA","Journal Article|Research Support, Non-U.S. Gov't/Journal Article"
NCT04353674,2020-04-28,2021-12-31,Interventional,Modulation of Hyperinflammation in COVID-19,Recruiting,N/A,Lawson Health Research Institute,NA,https://clinicaltrials.gov/ct2/show/NCT04353674,0,17,17,0,6,0,Canada,0,control|sledd with a l-mod,"Journal Article|Research Support, Non-U.S. Gov't/Letter/Journal Article|Research Support, Non-U.S. Gov't/Journal Article/Journal Article/Journal Article"
NCT04368351,2020-03-01,2020-06-30,Observational,Bacteriotherapy in the Treatment of COVID-19,"Active, not recruiting",NA,University of Roma La Sapienza,NA,https://clinicaltrials.gov/ct2/show/NCT04368351,0,4,4,0,1,0,Italy,0,sivomixx|azithromycin|hydroxychloroquine,Journal Article/Journal Article|Systematic Review
NCT04611269,2020-03-20,2020-10-31,Observational [Patient Registry],Clinical Characteristics and Outcomes of Patients With COVID-19 on Mechanical Ventilation in Argentina,Completed,NA,Argentinian Intensive Care Society,NA,https://clinicaltrials.gov/ct2/show/NCT04611269,0,7,7,0,3,0,Argentina,0,"NA","Journal Article/Journal Article|Research Support, Non-U.S. Gov't/Journal Article|Research Support, Non-U.S. Gov't/Journal Article/Editorial|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't/Journal Article|Observational Study/Journal Article|Multicenter Study|Observational Study|Research Support, Non-U.S. Gov't"
NCT04577105,2020-04-01,2020-08-31,Observational,Risk Factors and Computed Tomography Findings in COVID-19.,Completed,NA,Instituto Nacional de Cardiologia Ignacio Chavez,NA,https://clinicaltrials.gov/ct2/show/NCT04577105,0,12,12,0,1,0,Mexico,0,simple chest tomography,"Journal Article/Journal Article/Journal Article/Journal Article|Multicenter Study|Observational Study/Journal Article|Research Support, Non-U.S. Gov't|Validation Study"
NCT04627467,2020-03-28,2020-07-09,Interventional,Prevention With Chloroquine in Health Personnel Exposed to Infection With Coronavirus Disease 2019 (COVID-19) (TS-COVID),"Active, not recruiting",Phase 2,Fundacion Clinica Valle del Lili,NA,https://clinicaltrials.gov/ct2/show/NCT04627467,0,20,20,0,1,0,Colombia,0,chloroquine,"Journal Article/Journal Article|Research Support, Non-U.S. Gov't/Journal Article|Meta-Analysis|Systematic Review/Journal Article/Journal Article/Letter|Comment/Clinical Trial|Journal Article/Historical Article|Journal Article|Review"
NCT04344951,2020-04-06,2021-04-01,Interventional,"Chloroquine Phosphate Against Infection by the Novel Coronavirus SARS-CoV-2 (COVID-19): The HOPE Open-Label, Non Randomized Clinical Trial",Recruiting,Phase 2,Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.,NA,https://clinicaltrials.gov/ct2/show/NCT04344951,0,3,3,0,1,0,Greece,0,chloroquine,Journal Article/Journal Article/Clinical Trial|Journal Article
NCT04385043,2020-05-01,2020-10-15,Interventional,Hyperimmune Plasma in Patients With COVID-19 Severe Infection,Recruiting,Phase 2/Phase 3,University of Catanzaro,NA,https://clinicaltrials.gov/ct2/show/NCT04385043,0,3,3,0,0,0,Italy,0,convalescent plasma|standard care,"Clinical Trial, Phase I|Journal Article|Research Support, N.I.H., Extramural"
NCT04321369,2020-03-09,2020-03-23,Observational,Impact of Swab Site and Sample Collector on Testing Sensitivity for COVID-19 Virus in Symptomatic Individuals,Completed,NA,UnitedHealth Group,NA,https://clinicaltrials.gov/ct2/show/NCT04321369,0,2,2,0,1,1,United States,0,testing sensitivity for sars-cov-2 virus in symptomatic individuals,Journal Article
NCT04494724,2020-07-13,2020-12-31,Interventional,Clazakizumab vs. Placebo - COVID-19 Infection,Recruiting,Phase 2,The Methodist Hospital System,NA,https://clinicaltrials.gov/ct2/show/NCT04494724,0,8,8,0,0,1,United States,0,clazakizumab|placebo,"Journal Article|Research Support, Non-U.S. Gov't/Journal Article|Published Erratum"
NCT04479202,2020-02-08,2020-04-18,Interventional,The Effect of Berberine on Intestinal Function and Inflammatory Mediators in Severe Patients With Covid-19,Completed,Phase 4,Chinese Medical Association,NA,https://clinicaltrials.gov/ct2/show/NCT04479202,0,3,3,0,0,0,China,0,berberine|montmorrillonite,"Journal Article/Journal Article|Research Support, Non-U.S. Gov't/Letter"
NCT04333875,2020-03-20,2020-12-31,Observational [Patient Registry],Morbidity and Mortality Due to Deferral of Aortic Valve Replacement in Patients With Severe Aortic Stenosis,"Active, not recruiting",NA,"University Hospital Inselspital, Berne",NA,https://clinicaltrials.gov/ct2/show/NCT04333875,0,4,4,0,2,0,Switzerland,0,tavr/savr|tavr|savr,Journal Article/Journal Article
NCT04384380,2020-04-01,2020-05-31,Interventional,Efficacy and Tolerability of Hydroxychloroquine in Adult Patients With COVID-19,Completed,N/A,Taoyuan General Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04384380,0,5,5,0,1,0,Taiwan,0,hydroxychloroquine,Journal Article|Systematic Review/Clinical Trial|Journal Article
NCT04342637,2020-04-10,2020-04-25,Observational,COVID-19 Endoscopy Survey,Completed,NA,Al-Azhar University,NA,https://clinicaltrials.gov/ct2/show/NCT04342637,0,6,6,0,3,1,"United States|Egypt|Iran, Islamic Republic of",0,practice details,Journal Article|Review/Journal Article/Journal Article|Review
NCT04623697,2020-11-01,2023-10-30,Observational [Patient Registry],Covid-19 Infection and New Onset Type 1 Diabetes,Recruiting,NA,Hospital of South West Jutland,NA,https://clinicaltrials.gov/ct2/show/NCT04623697,0,10,10,0,0,0,Denmark,0,"NA",Journal Article
NCT04516811,2020-09-21,2021-12-30,Interventional,Therapeutic Use of Convalescent Plasma in the Treatment of Patients With Moderate to Severe COVID-19,Recruiting,Phase 3,South African National Blood Service,NA,https://clinicaltrials.gov/ct2/show/NCT04516811,0,1,1,0,2,0,South Africa,0,convalescent plasma/standard care|standard care/placebo|convalescent plasma|standard care|placebo,Journal Article
NCT04567979,2020-06-11,2020-09-30,Observational,Prospective Determination of COVID-19 Infection Rate in a Chemotherapy Unit in Mexico.,"Active, not recruiting",NA,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,NA,https://clinicaltrials.gov/ct2/show/NCT04567979,0,12,12,0,0,0,Mexico,0,"NA","Journal Article|Research Support, Non-U.S. Gov't/Journal Article|Video-Audio Media/Journal Article/Journal Article|Multicenter Study|Research Support, Non-U.S. Gov't/Journal Article|Research Support, Non-U.S. Gov't/Letter|Comment"
NCT04712292,2020-09-08,2021-01-31,Observational,Effects of COVID-19 Pandemic on the Diagnosis and Outcomes of Colorectal Cancer (COVID-CRC),Recruiting,NA,University of Bologna,NA,https://clinicaltrials.gov/ct2/show/NCT04712292,0,5,5,0,0,0,Italy,0,surgical procedure for cancer,Journal Article|Video-Audio Media/Journal Article/Journal Article/Editorial
NCT04353583,2020-04-21,2021-12-31,Observational [Patient Registry],Renal Outcome in Patients With COVID-19,Recruiting,NA,University of Giessen,NA,https://clinicaltrials.gov/ct2/show/NCT04353583,0,1,1,0,9,0,Germany,0,"NA",Editorial
NCT04392323,2020-05-13,2020-07-01,Interventional,Incidence of COVID-19 Test Conversion in Post-surgical Patients,Recruiting,N/A,Northwell Health,NA,https://clinicaltrials.gov/ct2/show/NCT04392323,0,12,12,0,0,1,United States,0,pcr/serology|pcr|serology test,"Journal Article/Journal Article|Observational Study|Research Support, Non-U.S. Gov't/Journal Article/Case Reports|Journal Article/Journal Article/Journal Article/Journal Article"
NCT04418557,2020-04-28,2021-07-31,Observational [Patient Registry],COVID-19 and Obstetric Transmission,Recruiting,NA,University Hospitals Cleveland Medical Center,NA,https://clinicaltrials.gov/ct2/show/NCT04418557,0,2,2,0,2,1,United States,0,pcr/serology|pcr|serology test,"Case Reports|Journal Article|Research Support, Non-U.S. Gov't"
NCT04515108,2020-03-10,2020-08-05,Observational,Perinatal Outcomes and Hematologic Parameters in COVID-19 Pregnancies,Completed,NA,Ankara City Hospital Bilkent,NA,https://clinicaltrials.gov/ct2/show/NCT04515108,0,4,4,0,0,0,Turkey,0,clinical assessment,Journal Article|Review/Journal Article/Journal Article|Multicenter Study/Journal Article
NCT04356482,2020-05-20,2020-11-30,Interventional,CONVALESCENT PLASMA FOR ILL PATIENTS BY COVID-19,Recruiting,Phase 1/Phase 2,Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado,NA,https://clinicaltrials.gov/ct2/show/NCT04356482,0,6,6,0,3,0,Mexico,0,convalescent plasma,"Case Reports|Journal Article|Research Support, Non-U.S. Gov't"
NCT04393727,2020-05-01,2020-09-30,Interventional,Transfusion of Convalescent Plasma for the Early Treatment of Patients With COVID-19,Terminated,Phase 2,"Azienda Ospedaliero, Universitaria Pisana","Study was stopped because the Promoter was changed and a new study on convalescent plasma
    promoted by AIFA was started in Italy.",https://clinicaltrials.gov/ct2/show/NCT04393727,0,1,1,0,2,0,Italy,0,convalescent plasma,"Case Reports|Journal Article|Research Support, Non-U.S. Gov't"
NCT04798677,2020-10-29,2021-04-30,Interventional,Efficacy and Tolerability of ABBC1 in Volunteers Receiving the Influenza or Covid-19 Vaccine,Recruiting,N/A,AB Biotek,NA,https://clinicaltrials.gov/ct2/show/NCT04798677,0,19,19,1,1,0,Spain,0,abbc1 immunoessential|placebo,"Journal Article|Review|Research Support, Non-U.S. Gov't/Letter/Journal Article/Clinical Trial, Phase II|Clinical Trial, Phase III|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't/Journal Article|Research Support, Non-U.S. Gov't"
NCT04366089,2020-03-26,2020-10-30,Interventional,Oxygen-Ozone as Adjuvant Treatment in Early Control of COVID-19 Progression and Modulation of the Gut Microbial Flora,Recruiting,Phase 2,Azienda Policlinico Umberto I,NA,https://clinicaltrials.gov/ct2/show/NCT04366089,0,3,3,0,0,0,Italy,0,oxygen-ozone|sivomixx|azithromycin|hydroxychloroquine|standard care,Editorial/Journal Article
NCT04374123,2020-04-20,2020-05-20,Observational,COVID-19 Serology Screening and Strict Protocol in the Endoscopy Unit,Completed,NA,Instituto Ecuatoriano de Enfermedades Digestivas,NA,https://clinicaltrials.gov/ct2/show/NCT04374123,0,3,3,0,1,0,Ecuador,0,igm/igg rapid test|igg antibody test|igm antibodytest,Letter|Comment/Letter|Comment/Journal Article|Multicenter Study
NCT04368897,2020-05-01,2021-04-01,Observational,In-vitro Diagnostic Test to Predict COVID-19 Mortality and Disease Severity,Recruiting,NA,"Applied Biology, Inc.",NA,https://clinicaltrials.gov/ct2/show/NCT04368897,0,4,4,0,3,0,Spain,0,cag,Letter/Journal Article/Letter/Letter
NCT04437940,2020-06-15,2020-07-10,Observational,Evaluation of Vaginal Fluid for Covid-19 Positivity in Women With Positive Nasofarengeal Covid-19 Test,Completed,NA,Acibadem University,NA,https://clinicaltrials.gov/ct2/show/NCT04437940,0,1,1,0,1,0,Turkey,0,pcr,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04378738,2020-05-01,2020-05-07,Interventional,Social Media and Covid19 Pandemic,Enrolling by invitation,N/A,Acibadem University,NA,https://clinicaltrials.gov/ct2/show/NCT04378738,0,1,1,0,0,0,Turkey,0,questionnaire,"Journal Article|Research Support, N.I.H., Extramural"
NCT04763213,2018-01-01,2019-12-31,Observational,New Predictors in Determining the Need for Invasive Treatment in Non-STEMI,Completed,NA,Kahramanmaras Sutcu Imam University,NA,https://clinicaltrials.gov/ct2/show/NCT04763213,0,9,9,0,0,0,Turkey,0,coronary angiography,Journal Article/Journal Article/Journal Article
NCT04360837,2020-05-06,2021-06-01,Interventional,PEEP Incremental and Decremental Alveolar Recruitment of Critically Ill Corona Virus Disease-19 (COVID-19) Patients,Recruiting,N/A,Szeged University,NA,https://clinicaltrials.gov/ct2/show/NCT04360837,0,1,1,0,2,0,Hungary,0,alveolar,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04424836,2020-05-15,2020-06-04,Observational,HFNC Treatment in COVID-19 Pneumonia,Completed,NA,Sisli Hamidiye Etfal Training and Research Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04424836,0,3,3,0,2,0,Turkey,0,high flow nasal cannula,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04346264,2020-04-27,2020-06-01,Observational,CoVid-19 - Infection and Antibody Formation in the Viennese Population,Enrolling by invitation,NA,Ludwig Boltzmann Institute for Lung Health,NA,https://clinicaltrials.gov/ct2/show/NCT04346264,0,1,1,0,1,0,Austria,0,no intervention planned due to the observational study design only a diagnostic testing,"Comparative Study|Letter|Research Support, Non-U.S. Gov't"
NCT04361942,2020-05-01,2021-11-30,Interventional,Treatment of Severe COVID-19 Pneumonia With Allogeneic Mesenchymal Stromal Cells (COVID_MSV),Recruiting,Phase 2,Red de Terapia Celular,NA,https://clinicaltrials.gov/ct2/show/NCT04361942,0,4,4,0,3,0,Spain,0,mesenchymal stem cells|placebo,Journal Article
NCT04480593,2020-06-02,2020-08-30,Interventional,The Use of Brazilian Green Propolis Extract (EPP-AF) in Patients Affected by COVID-19.,Completed,Phase 2/Phase 3,D'Or Institute for Research and Education,NA,https://clinicaltrials.gov/ct2/show/NCT04480593,0,8,8,0,1,0,Brazil,0,brazilian green propolis extract (epp-af)|standard care,Journal Article|Review/Journal Article|Review/Journal Article|Review
NCT04861402,2020-04-30,2021-07-15,Observational,Non-Invasive Intracranial Pressure in COVID-19 Individuals,Recruiting,NA,Federal University of SÃ£o Paulo,NA,https://clinicaltrials.gov/ct2/show/NCT04861402,0,7,7,0,0,0,Brazil,0,the icp monitoring will be performed in a non-invasive method developed by brain4care,Letter|Comment/Case Reports|Journal Article
NCT04392713,2020-04-15,2020-07-31,Interventional,Efficacy of Ivermectin in COVID-19,Recruiting,N/A,"Combined Military Hospital, Pakistan",NA,https://clinicaltrials.gov/ct2/show/NCT04392713,0,1,1,0,0,0,Pakistan,0,ivermectin,Journal Article|Review
NCT04453579,2020-03-09,2020-05-04,Observational [Patient Registry],"Bariatric Surgery During Lockdown, Impact of COVID-19 on Physical and Mental Health",Completed,NA,University of Rome Tor Vergata,NA,https://clinicaltrials.gov/ct2/show/NCT04453579,0,1,1,0,0,0,Italy,0,telehealth,Journal Article|Comment
NCT04468035,2020-06-01,2021-12-31,Observational,Early Cognitive Assessment and Evolutionary Monitoring of Patients With Severe ARDS on COVID-19 Pneumonia Requiring Mechanical Ventilation,Recruiting,NA,Groupe Hospitalier Paris Saint Joseph,NA,https://clinicaltrials.gov/ct2/show/NCT04468035,0,4,4,0,2,0,France,0,"NA",Letter/Case Reports|Journal Article
NCT04530617,2020-10-05,2021-04-30,Interventional,Camostat and Artemisia Annua vs Placebo in COVID-19 Outpatients,Recruiting,Phase 2,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,NA,https://clinicaltrials.gov/ct2/show/NCT04530617,0,28,28,0,4,0,Mexico,0,camostat mesilate|artemisia annua leaf,Published Erratum
NCT04819165,2020-03-01,2020-12-31,Observational,Healthcare-associated Infections in Severe COVID-19 During 2020,Completed,NA,Sanatorio Anchorena San Martin,NA,https://clinicaltrials.gov/ct2/show/NCT04819165,0,8,8,0,0,0,Argentina,0,covid-19,"Journal Article|Review/Journal Article/Journal Article|Multicenter Study|Research Support, Non-U.S. Gov't"
NCT04526405,2020-07-14,2020-11-03,Observational,Frequency of COVID-19 Antibodies in Patients With Hereditary Hematological Diseases,Completed,NA,University of Milano Bicocca,NA,https://clinicaltrials.gov/ct2/show/NCT04526405,0,4,4,0,1,0,Italy,0,sars-cov-2 s1/s2 igg|sars-cov-2 s1|igg test,Letter/Letter
NCT04568356,2020-04-24,2020-06-12,Interventional,A Clinical Evaluation of COVID-19 Rapid Point of Care Antigen Tests,Completed,N/A,"E25Bio, Inc.",NA,https://clinicaltrials.gov/ct2/show/NCT04568356,0,17,17,0,1,1,United States,0,direct antigen tests for covid-19,"Comparative Study|Journal Article/Journal Article/Evaluation Study|Letter/Journal Article|Research Support, N.I.H., Extramural|Research Support, N.I.H., Intramural|Review/Journal Article/Evaluation Study|Journal Article/Journal Article|Comment/Journal Article|Research Support, Non-U.S. Gov't|Review/Preprint/Evaluation Study|Journal Article/Journal Article|Research Support, Non-U.S. Gov't/Journal Article/Comparative Study|Journal Article|Validation Study/Journal Article/Journal Article|Meta-Analysis|Research Support, Non-U.S. Gov't|Systematic Review/Journal Article|Meta-Analysis|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04367896,2020-03-24,2020-04-17,Observational,COVID-19 OUTBREAK AND SOLID ORGAN TRANSPLANTATION (SOT) : AN INTERNATIONAL WEB-BASED SURVEY,Completed,NA,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,NA,https://clinicaltrials.gov/ct2/show/NCT04367896,0,3,3,0,0,0,Italy,0,questionnaire,"Journal Article/Letter|Research Support, Non-U.S. Gov't/Journal Article|Review"
NCT04402853,2020-02-01,2020-03-01,Observational,SARS Cov-2 in Conjunctival Secretion in COVID-19 Patients,Completed,NA,UniversitÃ  degli Studi dell'Insubria,NA,https://clinicaltrials.gov/ct2/show/NCT04402853,0,1,1,0,1,0,Italy,0,tears swab,Journal Article
NCT04470648,2020-07-22,2021-08-31,Observational,COVID-19 Infection at Samusocial in Paris: Descriptive and Serological Survey,Recruiting,NA,"Institut National de la SantÃ© Et de la Recherche MÃ©dicale, France",NA,https://clinicaltrials.gov/ct2/show/NCT04470648,0,8,8,0,2,0,France,0,blood test for sars-cov2 serology,Journal Article
NCT04616950,2020-12-01,2021-06-30,Observational,Impact of the COVID-19 Epidemic on the Hospital Journey of Patients With Cancer of the Digestive System,Recruiting,NA,Groupe Hospitalier Paris Saint Joseph,NA,https://clinicaltrials.gov/ct2/show/NCT04616950,0,5,5,0,2,0,France,0,"NA",Journal Article|Review/Journal Article
NCT04488484,2020-07-01,2021-12-31,Interventional,Medical and Serological Follow-up of the Staff of the Paris Saint-Joseph Hospital Group Infected With Severe Acute Respiratory Syndrome Coronavirus 2.,"Active, not recruiting",N/A,Groupe Hospitalier Paris Saint Joseph,NA,https://clinicaltrials.gov/ct2/show/NCT04488484,0,5,5,0,1,0,France,0,serology test follow-up,"Journal Article|Systematic Review/Journal Article|Research Support, Non-U.S. Gov't"
NCT04522492,2020-08-11,2021-03-31,Interventional,Impact of COVID-19 on Mental Health of Patients With Skin Picking,"Active, not recruiting",N/A,Hospital de Clinicas de Porto Alegre,NA,https://clinicaltrials.gov/ct2/show/NCT04522492,0,2,2,0,1,0,Brazil,0,internet-based cognitive behavioral therapy|quality of life promotion,Journal Article|Randomized Controlled Trial
NCT04841681,2020-06-07,2020-08-25,Interventional,Video-based Psychotherapy for COVID-19 Patients in Isolation Ward in Jakarta,Completed,N/A,Indonesia University,NA,https://clinicaltrials.gov/ct2/show/NCT04841681,0,7,7,0,0,0,Indonesia,0,video-based psychotherapy,Journal Article/Journal Article|Comment/Journal Article/Journal Article
NCT04689672,2020-12-16,2021-05-10,Observational,Predictivity of Hemogasanalysis and Lung UltraSound in Determining COVID-19 Severity,Recruiting,NA,IRCCS San Raffaele,NA,https://clinicaltrials.gov/ct2/show/NCT04689672,0,5,5,0,0,0,Italy,0,lung ultrasound,Letter
NCT04647695,2020-11-20,2021-07-31,Interventional,IFN-beta 1b and Remdesivir for COVID19,Recruiting,Phase 2,The University of Hong Kong,NA,https://clinicaltrials.gov/ct2/show/NCT04647695,0,2,2,0,2,0,Hong Kong,0,interferon|remdesivir,"Clinical Trial, Phase III|Journal Article|Randomized Controlled Trial|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't"
NCT04454606,2020-05-01,2020-05-15,Interventional,The New Silicone N99 Half-Piece Respirator,Completed,N/A,Bangkok Metropolitan Administration Medical College and Vajira Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04454606,0,1,1,0,0,0,Thailand,0,fit test|filtration test,Journal Article|Published Erratum
NCT04733729,2020-03-01,2021-01-30,Observational [Patient Registry],Covid-19 in Hematological Malignancies,Recruiting,NA,Sorveglianza Epidemiologica Infezioni Fungine Emopatie Maligne,NA,https://clinicaltrials.gov/ct2/show/NCT04733729,0,3,3,0,1,0,Italy,0,"NA","Journal Article|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't/Journal Article|Multicenter Study|Observational Study/Journal Article|Multicenter Study|Observational Study|Research Support, Non-U.S. Gov't"
NCT04443140,2020-03-15,2020-07-01,Observational [Patient Registry],Preeclampsia-like Syndrome Induced by COVID-19: Is it a Real Public Health Issue in Pregnancy During the Pandemic?,Completed,NA,Zeynep Kamil Maternity and Pediatric Research and Training Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04443140,0,1,1,0,2,0,Turkey,0,pcr,Journal Article|Observational Study
NCT04558996,2020-03-01,2020-12-31,Observational [Patient Registry],Spanish Registry of Pregnant Women With COVID-19,Recruiting,NA,Puerta de Hierro University Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04558996,0,1,1,0,0,0,Spain,0,"NA",Letter
NCT04840940,2020-12-21,2021-12-21,Observational,Presepsin Biomarker for Ventilator-associated Pneumonia Diagnosis in COVID-19 Patients,Recruiting,NA,San Luigi Gonzaga Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04840940,0,21,21,0,1,0,Italy,0,"NA",Letter/Journal Article
NCT04449731,2020-03-20,2020-08-30,Observational,Changes in Dietary Behaviours During the COVID-19 Outbreak Confinement in the Adult Population (COVIDiet_Int),Recruiting,NA,Universidad de Granada,NA,https://clinicaltrials.gov/ct2/show/NCT04449731,0,3,3,0,4,0,Spain,0,"NA",Journal Article/Journal Article/Journal Article
NCT04643522,2020-01-07,2020-10-05,Observational,Semen Parameters and COVID-19 in Infertile Men,Completed,NA,Ankara City Hospital Bilkent,NA,https://clinicaltrials.gov/ct2/show/NCT04643522,0,4,4,0,1,0,Turkey,0,clinical assessment,"Journal Article/Journal Article|Research Support, Non-U.S. Gov't/Journal Article/Journal Article"
NCT04517422,2020-08-19,2021-02-02,Interventional,Efficacy of L. Plantarum and P. Acidilactici in Adults With SARS-CoV-2 and COVID-19,Completed,N/A,"AB Biotics, SA",NA,https://clinicaltrials.gov/ct2/show/NCT04517422,0,7,7,0,7,0,Mexico,0,probiotics|placebo,Journal Article/Journal Article/Journal Article|Review/Journal Article/Journal Article/Journal Article/Journal Article|Review
NCT04343898,2020-04-01,2020-08-01,Observational,Study of the Treatment and Outcomes in Critically Ill Patients With COVID-19,"Active, not recruiting",NA,Brigham and Women's Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04343898,0,14,14,0,11,1,United States,0,no intervention,"Clinical Trial|Letter|Multicenter Study|Research Support, N.I.H., Extramural/Journal Article|Multicenter Study|Research Support, N.I.H., Extramural/Journal Article|Multicenter Study/Journal Article|Research Support, N.I.H., Extramural/Journal Article|Multicenter Study|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't/Letter|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't/Journal Article|Multicenter Study/Journal Article|Research Support, N.I.H., Extramural/Journal Article/Journal Article|Multicenter Study|Research Support, N.I.H., Extramural/Journal Article|Multicenter Study/Journal Article/Journal Article/Journal Article"
NCT04476589,2020-07-01,2022-06-30,Observational,Prognostication of Recovery in Early Disorders of Consciousness After COVID-19,Recruiting,NA,Massachusetts General Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04476589,0,1,1,0,1,1,United States,0,functional mri,"Case Reports|Journal Article|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't"
NCT04679168,2020-06-01,2021-12-31,Observational [Patient Registry],Study on Kidney Disease and EnviromenTal Chemical,Recruiting,NA,Seoul National University Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04679168,0,3,3,0,1,0,"Korea, Republic of",0,"NA","Journal Article|Research Support, Non-U.S. Gov't"
NCT04685512,2020-11-18,2021-04-01,Interventional,Effect of Tenofovir/Emtricitabine in Patients Recently Infected With SARS-COV2 (Covid-19) Discharged Home,Recruiting,Phase 2/Phase 3,"University Hospital, Caen",NA,https://clinicaltrials.gov/ct2/show/NCT04685512,0,5,5,0,0,0,France,0,tenofovir disoproxil/emtricitabine|tenofovir disoproxil|emtricitabine,"Journal Article|Research Support, N.I.H., Extramural"
NCT04514705,2020-08-11,2021-12-31,Interventional,Characteristics in Post Covid-19 Patients,Recruiting,N/A,Universidade Metodista de Piracicaba,NA,https://clinicaltrials.gov/ct2/show/NCT04514705,0,6,6,0,0,0,Brazil,0,exercise,"Editorial/Case Reports|Journal Article/Journal Article|Research Support, Non-U.S. Gov't|Systematic Review/Journal Article/Journal Article"
NCT04662437,2020-09-10,2020-12-01,Observational,The Status of Parathyroid Hormone Secretion in Covid-19 Patients,Completed,NA,Bezmialem Vakif University,NA,https://clinicaltrials.gov/ct2/show/NCT04662437,0,3,3,0,0,0,Turkey,0,venous blood was collected for biochemistry testing,Journal Article|Review/Letter
NCT04578158,2020-09-29,2021-03-28,Interventional,Trial to Study the Adjuvant Benefits of Quercetin Phytosome in Patients With COVID-19,Completed,Phase 3,Liaquat University of Medical & Health Sciences,NA,https://clinicaltrials.gov/ct2/show/NCT04578158,0,3,3,0,9,0,Pakistan,0,standard covid-19 care|quercetin phytosome,Journal Article/Journal Article
NCT04753476,2020-06-08,2021-06-08,Interventional,Treatment of Severe COVID-19 Patients Using Secretome of Hypoxia-Mesenchymal Stem Cells in Indonesia,Recruiting,Phase 2,Stem Cell and Cancer Research Indonesia,NA,https://clinicaltrials.gov/ct2/show/NCT04753476,0,2,2,0,1,0,Indonesia,0,injection of secretome-mscs|standard treatment of covid-19,Journal Article|Review/Journal Article|Review
NCT04604249,2020-10-26,2021-11-30,Observational,Prevalence of COVID-19 in High Altitude : Insights From the Highest City of the World,"Active, not recruiting",NA,Centre d'Expertise sur l'Altitude EXALT,NA,https://clinicaltrials.gov/ct2/show/NCT04604249,0,6,6,0,1,0,Peru,0,"sars-cov-2 rapid diagnostic test (covid-prestoâ® igm/igg, aaz, boulogne-billancourt, france)|sars-cov-2 rapid diagnostic test (covid-prestoâ® igm|igg, aaz, boulogne-billancourt, france)",Letter|Comment/Journal Article/Journal Article/Letter|Comment
NCT04818866,2020-02-01,2021-12-30,Observational,International Study of Inflammation in COVID-19,Recruiting,NA,University of Michigan,NA,https://clinicaltrials.gov/ct2/show/NCT04818866,0,1,1,0,1,1,United States,0,"supar, c-reactive protein, ferritin, d-dimer, procalcitonin, interleukin-6, lactate dehydrogenase","Journal Article|Multicenter Study|Observational Study|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't"
NCT04700254,2020-12-28,2021-01-11,Observational,"Anxiety, Depression and Eating Attitudes of Diabetes Mellitus Patients During COVID-19 Lockdown in Greece",Completed,NA,"Chania General Hospital ""St. George""",NA,https://clinicaltrials.gov/ct2/show/NCT04700254,0,5,5,0,4,0,Greece,0,dass questionnaire|eat-26 questionnaire,Journal Article
NCT04715477,2021-01-17,2021-04-01,Observational,Intensive Care Anxiety in SARS-CoV-2 Patients,Recruiting,NA,Derince Training and Research Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04715477,0,2,2,0,0,0,Turkey,0,hospital anxiety depression measure,Journal Article|Meta-Analysis|Systematic Review
NCT04659200,2020-09-01,2020-12-05,Observational,Thyroid Function Tests and Status of Thyroid Autoantibodies in Covid-19 Patients,Completed,NA,Bezmialem Vakif University,NA,https://clinicaltrials.gov/ct2/show/NCT04659200,0,1,1,0,2,0,Turkey,0,venous blood was collected for biochemistry testing.,Journal Article
NCT04824664,2020-01-01,2020-07-30,Observational,The ALIGHIERI Survey: an Italian Overview of Global Impact of tHe COVID-19 pandemIc on General surgERy practIce,Completed,NA,Associazione Chirurghi Ospedalieri Italiani,NA,https://clinicaltrials.gov/ct2/show/NCT04824664,0,1,1,0,0,0,Italy,0,questionnaire,Journal Article
NCT04348214,2020-04-22,2020-10-01,Observational,Screening & Risk Assessment of Healthcare Workers & Infection Control in University & COVID-19 Quarantine Hospitals,Completed,NA,Ain Shams University,NA,https://clinicaltrials.gov/ct2/show/NCT04348214,0,2,2,0,4,0,Egypt,0,"NA",Journal Article/Journal Article
NCT04407273,2020-05-14,2020-08-20,Observational,Statin Therapy and COVID-19 Infection,Completed,NA,Institut Investigacio Sanitaria Pere Virgili,NA,https://clinicaltrials.gov/ct2/show/NCT04407273,0,1,1,0,2,0,Spain,0,observational,Journal Article
NCT04799600,2020-09-01,2021-06-15,Observational,The Effect of the Severity of COVID-19 Disease on the Incidence of Acute Renal Failure in ICU,Recruiting,NA,Ankara City Hospital Bilkent,NA,https://clinicaltrials.gov/ct2/show/NCT04799600,0,3,3,0,0,0,Turkey,0,brescä°a-covä°d respiratory severity scale|brescä°a-covä°d respiratory severity scale,Journal Article
NCT04834102,2021-01-27,2021-04-27,Observational,COVID-19 Induced Telogen Effluvium,Recruiting,NA,Istanbul Medeniyet University,NA,https://clinicaltrials.gov/ct2/show/NCT04834102,0,4,4,0,0,0,Turkey,0,blood test,Case Reports|Journal Article/Letter/Journal Article|Multicenter Study
NCT04331795,2020-04-04,2020-06-05,Interventional,"Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis",Completed,Phase 2,University of Chicago,NA,https://clinicaltrials.gov/ct2/show/NCT04331795,0,1,1,0,8,1,United States,0,tocilizumab,"Clinical Trial, Phase II|Journal Article|Research Support, Non-U.S. Gov't"
NCT04721457,2021-01-03,2021-02-28,Interventional,The Efficacy of Pre-procedural Mouth Rinses on COVID-19 Saliva Viral Load,Recruiting,Phase 4,King Abdulaziz University,NA,https://clinicaltrials.gov/ct2/show/NCT04721457,0,17,17,0,1,0,Saudi Arabia,0,distilled water|1% povidone iodine (pvp-i)|1.5% hydrogen peroxide (h2o2)|0.075% cetylpyridinium chloride (cpc)|0.1% sodium hypochlorite,Journal Article
NCT04728828,2021-01-25,2023-02-15,Observational,COVADIAL - Immunogenicity of COVID-19 Vaccine in Hemodialysis Patients,Recruiting,NA,Centre Hospitalier de Cornouaille,NA,https://clinicaltrials.gov/ct2/show/NCT04728828,0,3,3,0,1,0,France,0,serological covid-19 vaccine immunogenicity,Journal Article|Comment
NCT04404244,2020-01-01,2022-01-01,Observational,Extraordinary Measures for Egyptian Children With Hemato-Oncological Disorders During COVID-19 Pandemic,Recruiting,NA,Ain Shams University,NA,https://clinicaltrials.gov/ct2/show/NCT04404244,0,1,1,0,1,0,Egypt,0,"NA",Journal Article
NCT04705753,2020-04-01,2020-10-15,Interventional,"Assessment of the Clinical Effectiveness of a Herbal Extract (Cretan IAMA) in Patients With Viral Respiratory Infections, Including COVID-19, in Primary Healthcare Settings, and Co-assessment of Its Prophylactic Effect in People Cohabiting With These Patients",Completed,Phase 2/Phase 3,University of Crete,NA,https://clinicaltrials.gov/ct2/show/NCT04705753,0,4,4,0,0,0,Greece,0,cretan iama,Journal Article|Review
NCT04340349,2021-02-01,2021-05-30,Interventional,Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals,Enrolling by invitation,Early Phase 1,Instituto Nacional de Rehabilitacion,NA,https://clinicaltrials.gov/ct2/show/NCT04340349,0,19,19,0,3,0,Mexico,0,hydroxychloroquine|bromhexine hydrochloride,Journal Article/Journal Article
NCT04598581,2020-11-02,2021-04-09,Interventional,"Low Dose Radiation Therapy for Severe-Acute-Respiratory-Syndrome-Coronavirus-2 (SARS-CoV-2), COVID-19",Completed,N/A,"University Hospital, Basel, Switzerland",NA,https://clinicaltrials.gov/ct2/show/NCT04598581,0,1,1,0,4,0,Switzerland,0,radiotherapy|placebo,Journal Article
NCT04467931,2020-01-19,2020-10-21,Observational,ACEI or ARB and COVID-19 Severity and Mortality in US Veterans,Completed,NA,University of Utah,NA,https://clinicaltrials.gov/ct2/show/NCT04467931,0,1,1,0,2,1,United States,0,ace inhibitor/arb|non-acei/arb|ace inhibitor|arb|non-acei,"Journal Article|Research Support, U.S. Gov't, Non-P.H.S.|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't"
NCT04320862,2020-04-03,2021-12-31,Observational,COVID-19 Pandemic Response Network,Recruiting,NA,Duke University,NA,https://clinicalzeros.gov/ct2/show/NCT04320862,0,0,0,0,4,1,United States,0,"NA",NA
NCT04716465,2021-01-19,2023-01-31,Observational,Dysautonomia in Patients Post COVID-19 Infection,Recruiting,NA,Universitair Ziekenhuis Brussel,NA,https://clinicalzeros.gov/ct2/show/NCT04716465,0,0,0,0,1,0,Belgium,0,dysautonomia,NA
NCT04727294,2021-01-22,2021-06-30,Observational,"MGUS, SMM, and MM Patient Experience With Coronavirus 19 (COVID-19) Survey",Recruiting,NA,HealthTree Foundation,NA,https://clinicalzeros.gov/ct2/show/NCT04727294,0,0,0,0,0,1,United States,0,questionnaire,NA
NCT04726111,2020-12-30,2021-07-30,Interventional,COVID-19 and Pregnancy: Placental and Immunological Impacts,Recruiting,N/A,Hopital Foch,NA,https://clinicalzeros.gov/ct2/show/NCT04726111,0,0,0,0,0,0,France,0,specimens specific for the study,NA
NCT04726098,2021-01-15,2021-06-30,Interventional,Low or High Dose of Dexamethasone in Patients With Respiratory Failure by COVID-19,Recruiting,Phase 4,Hospital Clinico Universitario de Santiago,NA,https://clinicalzeros.gov/ct2/show/NCT04726098,0,0,0,0,0,0,Spain,0,dexamethasone high dose|dexamethasone low dose,NA
NCT04320953,2020-03-16,2020-03-26,Interventional,Non-contact Endoscopy at Covid-19 Outbreak,Completed,N/A,Changhai Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04320953,0,0,0,0,1,0,China,0,non-contact mce system,NA
NCT04726865,2020-10-01,2020-12-20,Observational,COVID-19 Pandemic and Medical Students,Completed,NA,University of Jordan,NA,https://clinicalzeros.gov/ct2/show/NCT04726865,0,0,0,0,0,0,Jordan,0,naser al-husban,NA
NCT04726371,2021-01-08,2022-10-31,Interventional,Best Practices to Prevent COVID-19 Illness in Staff and People With Serious Mental Illness and Developmental Disabilities in Congregate Living Settings,Recruiting,N/A,Massachusetts General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04726371,0,0,0,0,0,1,United States,0,generic best practices|tailored best practices,NA
NCT04724707,2020-09-11,2021-12-31,Observational [Patient Registry],Russian Cardiovascular Registry of COVID-19,Recruiting,NA,"Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health",NA,https://clinicalzeros.gov/ct2/show/NCT04724707,0,0,0,0,0,0,Russian Federation,0,"NA",NA
NCT04724681,2021-02-01,2021-12-31,Interventional,Continuous Wireless Monitoring of Vital Signs and Automated Alerts of Patient Deterioration in Patients Admitted With COVID-19 Infection,Recruiting,N/A,University Hospital Bispebjerg and Frederiksberg,NA,https://clinicalzeros.gov/ct2/show/NCT04724681,0,0,0,0,0,0,Denmark,0,ward css,NA
NCT04724629,2021-01-05,2021-03-31,Interventional,Survival TRial Using CytoKines in COVID-19 (STRUCK Trial),Recruiting,Phase 3,University of Sao Paulo,NA,https://clinicalzeros.gov/ct2/show/NCT04724629,0,0,0,0,0,0,Brazil,0,ixekizumab|aldesleukin|colchicine|standard care,NA
NCT04724616,2021-01-06,2021-06-30,Interventional,CARTOON: CoronAviRus (COVID-19) educaTional prOgram fOr childreN,Recruiting,N/A,Medical University of Vienna,NA,https://clinicalzeros.gov/ct2/show/NCT04724616,0,0,0,0,0,0,Austria,0,educational program (cartoon),NA
NCT04725097,2020-12-10,2021-07-31,Observational,A Study to Evaluate Rapid Throughput Screening for Human COVID-19 Infection,Recruiting,NA,Mayo Clinic,NA,https://clinicalzeros.gov/ct2/show/NCT04725097,0,0,0,0,0,1,United States|India|Spain|United Kingdom,0,"NA",NA
NCT04725084,2020-07-01,2020-12-15,Observational,Comparison of Non-invasive Oxygenation Strategies in Patients Admitted for Covid-19 Acute Respiratory Distress Syndrome,Completed,NA,Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer,NA,https://clinicalzeros.gov/ct2/show/NCT04725084,0,0,0,0,0,0,France,0,use of high flow nasal cannula alone|use of non-invasive ventilation|use of continuous positive airway pressure,NA
NCT04724538,2020-10-15,2021-02-10,Interventional,Inhalation Low Dose Radionuclide Therapy in Treatment COVID-19,Recruiting,Phase 1/Phase 2,National Medical Research Radiological Centre of the Ministry of Health of Russia,NA,https://clinicalzeros.gov/ct2/show/NCT04724538,0,0,0,0,0,0,Russian Federation,0,99mtc-pertechnetate|99mtc-pertechnetate aerosol,NA
NCT04723576,2020-12-03,2022-02-28,Interventional,Mental and Physical Well-Being of Frontline Health Care Workers During Coronavirus Disease 2019 (COVID-19),Recruiting,N/A,RAND,NA,https://clinicalzeros.gov/ct2/show/NCT04723576,0,0,0,0,0,1,United States,0,stress first aid,NA
NCT04723550,2021-01-05,2021-11-05,Interventional,COVID-19 Lockdown Related Telemedicine for Type 2 Diabetes,Recruiting,N/A,Xuzhou No.1 Peoples Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04723550,0,0,0,0,1,0,China,0,hospital telemedicine management system|standard care,NA
NCT04720794,2020-09-25,2020-10-20,Interventional,A Study To Evaluate The Performance of the Lucira Health All-In-One COVID-19 Test Kit vs Hologic Panther Fusion,Completed,N/A,Lucira Health Inc,NA,https://clinicalzeros.gov/ct2/show/NCT04720794,0,0,0,0,1,1,United States,0,lucira covid-19 all-in-one test kit,NA
NCT04721236,2020-11-19,2021-11-19,Interventional,Early Use of Hyperimmune Plasma in COVID-19,Recruiting,N/A,IRCCS Policlinico S. Matteo,NA,https://clinicalzeros.gov/ct2/show/NCT04721236,0,0,0,0,0,0,Italy,0,convalescent plasma,NA
NCT04718506,2021-01-12,2021-06-12,Interventional,Rehabilitation for Post-COVID-19 Syndrome Through a Supervised Exercise Intervention,Recruiting,N/A,Universidad de Murcia,NA,https://clinicalzeros.gov/ct2/show/NCT04718506,0,0,0,0,0,0,Spain,0,exercise|controls,NA
NCT04720404,2020-06-23,2022-02-28,Interventional,Mindful Prevention of Psychopathology in Healthcare Workers During the COVID-19 Crisis (COVID-19 MindPreP),Recruiting,N/A,Radboud University,NA,https://clinicalzeros.gov/ct2/show/NCT04720404,0,0,0,0,0,0,Netherlands,0,mindfulness-based stress reduction|self-help mindfulness/compassion exercises|support as usual|self-help mindfulness|compassion exercises,NA
NCT04719208,2020-10-06,2021-05-31,Interventional,[COVID-19] Reduction of Sars-CoV-2 Oral Viral Load With Prophylactic Mouth Rinse,Recruiting,N/A,Augusta University,NA,https://clinicalzeros.gov/ct2/show/NCT04719208,0,0,0,0,0,1,United States,0,water (e) mouth rinse with the solution provided|chlorhexidine gluconate (a) mouth rinse with the solution provided|hydrogen peroxide (b) mouth rinse with the solution provided|betadine (c) mouth rinse with the solution provided|alcohol mouthwash (listerine) (d) mouth rinse with the solution provided,NA
NCT04719182,2020-09-01,2021-01-01,Observational,Practice of Adjunctive Treatments in Intensive Care Unit Patients With COVID-19,"Active, not recruiting",NA,Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA),NA,https://clinicalzeros.gov/ct2/show/NCT04719182,0,0,0,0,0,0,Netherlands,0,adjunctive therapies,NA
NCT04718480,2020-11-27,2021-08-31,Interventional,Fluvoxamine Administration in Moderate SARS-CoV-2 (COVID-19) Infected Patients,Recruiting,Phase 2,SigmaDrugs Research Ltd.,NA,https://clinicalzeros.gov/ct2/show/NCT04718480,0,0,0,0,0,0,Hungary,0,placebo|fluvoxamine,NA
NCT04717024,2020-09-15,2021-12-31,Observational,The Nanowear Wearable Covid-19 Observational and Analysis Trend,Recruiting,NA,Nanowear Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04717024,0,0,0,0,0,1,United States,0,observational study - no intervention,NA
NCT04716998,2021-01-31,2022-01-31,Interventional,Safety and the Efficacy of MesenCure for the Treatment of Pulmonary Manifestations of COVID-19,Recruiting,Phase 1/Phase 2,BonusBio Group Ltd,NA,https://clinicalzeros.gov/ct2/show/NCT04716998,0,0,0,0,1,0,Israel,0,mesencure,NA
NCT04716985,2021-01-22,2021-07-22,Interventional,Evaluation of the Daily Intake of 0.5 L of Water Saturated With Molecular Hydrogen for 21 Days in COVID-19 Patients Treated in Ambulatory Care,Recruiting,N/A,AGIR Ã  Dom,NA,https://clinicalzeros.gov/ct2/show/NCT04716985,0,0,0,0,2,0,France,0,molecular hydrogen|placebo magnesium,NA
NCT04716179,2021-01-18,2021-05-18,Interventional,Prospective Two-arm Study of Fertility in Men With COVID-19,Recruiting,N/A,I.M. Sechenov First Moscow State Medical University,NA,https://clinicalzeros.gov/ct2/show/NCT04716179,0,0,0,0,0,0,Russian Federation,0,"sperm test|hormone levels (testosterone, fsh, lh, prolactin)|sars-cov-2 ig g levels|testis pathology samples",NA
NCT04716647,2020-10-09,2020-12-12,Interventional,Feasibility of Ayurveda in Patients With Mild-to-Moderate COVID-19: A Community-Based Participatory Research,Completed,N/A,Aarogyam UK,NA,https://clinicalzeros.gov/ct2/show/NCT04716647,0,0,0,0,0,0,United Kingdom,0,ayurveda,NA
NCT04715997,2020-12-30,2021-05-30,Interventional,"Safety and Immunogenicity Study of GX-19N, a COVID-19 Preventive DNA Vaccine in Healthy Adults",Recruiting,Phase 1/Phase 2,"Genexine, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04715997,0,0,0,1,0,0,"Korea, Republic of",0,gx-19n,NA
NCT04716088,2020-11-18,2020-12-02,Observational,Rapid Antigen Testing for SARS-CoV-2 Among Healthcare Workers to Prevent Spread of COVID-19,Completed,NA,The University Clinic of Pulmonary and Allergic Diseases Golnik,NA,https://clinicalzeros.gov/ct2/show/NCT04716088,0,0,0,0,1,0,Slovenia,0,rapid antigen test for sars cov2,NA
NCT04715919,2021-01-15,2021-06-01,Observational,Long Term Outcomes of Coronavirus Disease-19 (COVID-19),Recruiting,NA,Izmir Dr Suat Seren Chest Diseases and Surgery Education and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04715919,0,0,0,0,0,0,Turkey,0,chest computed tomography|pulmonary function tests|six minutes walk test|quality of life,NA
NCT04716023,2019-08-23,2021-08-22,Observational,Physiology and Structure of the Small Airways in Patients With Chronic Airflow Obstruction or COVID-19,Recruiting,NA,Imperial College London,NA,https://clinicalzeros.gov/ct2/show/NCT04716023,0,0,0,0,0,0,United Kingdom,0,"NA",NA
NCT04715295,2020-10-05,2021-05-30,Interventional,Safety and Efficacy of Doxycycline and Rivaroxaban in COVID-19,Recruiting,Phase 4,Yaounde Central Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04715295,0,0,0,0,0,0,Cameroon,0,doxycycline tablets|rivaroxaban 15mg tab|hydroxychloroquine / azithromycin|hydroxychloroquine|azithromycin,NA
NCT04715243,2021-01-31,2021-04-30,Interventional,"Comparison of High Flow Nasal Cannula (HFNC), Face-mask Non-Invasive Ventilation (NIV) & Helmet NIV in COVID-19 ARDS Patients",Recruiting,N/A,Sultan Qaboos University,NA,https://clinicalzeros.gov/ct2/show/NCT04715243,0,0,0,0,1,0,Oman,0,high flow nasal cannula (hfnc)|helmet niv|face-mask niv,NA
NCT04715360,2020-12-29,2021-11-29,Interventional,Management of Cytokine Storms in Severe COVID-19 Patients With Autologous Activated Platelet-rich Plasma Therapy,Recruiting,Phase 1/Phase 2,Hayandra Peduli Foundation,NA,https://clinicalzeros.gov/ct2/show/NCT04715360,0,0,0,0,0,0,Indonesia,0,autologous activated platelet-rich plasma|avigan,NA
NCT04714515,2020-02-20,2020-03-30,Observational,Montelukast - a Treatment Choice for COVID-19,Completed,NA,University of Sargodha,NA,https://clinicalzeros.gov/ct2/show/NCT04714515,0,0,0,0,0,0,China|Pakistan,0,montelukast|hydroxychloroquine|ivermectin,NA
NCT04714333,2020-05-06,2021-05-05,Observational,Detection of Covid-19 by Volatile Organic Compounds in Exhaled Breath,Enrolling by invitation,NA,British Columbia Cancer Agency,NA,https://clinicalzeros.gov/ct2/show/NCT04714333,0,0,0,0,1,0,Canada,0,"NA",NA
NCT04714125,2020-06-19,2021-02-01,Observational,Prognostic Value of Flow-mediated Dilation in Hospitalized COVID-19 Patients,Recruiting,NA,University of Sao Paulo General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04714125,0,0,0,0,0,0,Brazil,0,"NA",NA
NCT04714008,2020-12-01,2022-12-31,Observational,Covid-19 and ONline GAmbling,Recruiting,NA,Nantes University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04714008,0,0,0,0,0,0,France,0,"NA",NA
NCT04713852,2020-03-13,2020-09-30,Observational,Predictive Value of SOFA and APACHE Scores for In-hospital Mortality in COVID-19 ICU Patients,Completed,NA,Jessa Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04713852,0,0,0,0,0,0,Belgium,0,"NA",NA
NCT04711954,2020-11-01,2021-11-01,Observational [Patient Registry],HIV/COV in Ukraine-NL,Recruiting,NA,Erasmus Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04711954,0,0,0,0,0,0,Netherlands|Ukraine,0,"NA",NA
NCT04713878,2020-05-08,2020-06-30,Interventional,Mesenchymal Stem Cells Therapy in Patients With COVID-19 Pneumonia,Completed,N/A,Kanuni Sultan Suleyman Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04713878,0,0,0,0,1,0,Turkey,0,mesenchymal stem cells,NA
NCT04713540,2021-01-01,2021-04-01,Observational,Rehabilitation in Intensive Care Unit,Recruiting,NA,Bakirkoy Dr. Sadi Konuk Research and Training Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04713540,0,0,0,0,1,0,Turkey,0,"NA",NA
NCT04712357,2020-11-09,2022-01-31,Interventional,Clinical Experimentation With Tenofovir Disoproxyl Fumarate and Emtricitabine for COVID-19,Recruiting,N/A,Universidade Federal do Ceara,NA,https://clinicalzeros.gov/ct2/show/NCT04712357,0,0,0,0,0,0,Brazil,0,vitamin c 500 mg oral tablet|tenofovir disoproxyl fumarate 300 mg oral tablet|tenofovir disoproxyl fumarate 300 mg/emtricitabine 200 mg oral tablet|tenofovir disoproxyl fumarate 300 mg|emtricitabine 200 mg oral tablet,NA
NCT04712344,2021-01-18,2021-09-30,Interventional,Assessment of Efficacy and Safety of Therapy With COVID-19 Convalescent Plasma in Subjects With Severe COVID-19 (IPCO),Recruiting,Phase 2,University of Erlangen-NÃ¼rnberg Medical School,NA,https://clinicalzeros.gov/ct2/show/NCT04712344,0,0,0,0,2,0,Germany,0,convalescent plasma,NA
NCT04694742,2020-09-01,2021-03-31,Observational,Ventilatory Efficiency in Critically Ill COVID-19 Patients,Recruiting,NA,ASST Fatebenefratelli Sacco,NA,https://clinicalzeros.gov/ct2/show/NCT04694742,0,0,0,0,0,0,Italy,0,data collecting,NA
NCT04714138,2021-01-05,2021-02-20,Observational,Remote Video Consultation for Quality of Life Assessment in Patients Hospitalised After COVID-19 Infection,Recruiting,NA,Groupe Hospitalier du Havre,NA,https://clinicalzeros.gov/ct2/show/NCT04714138,0,0,0,0,1,0,France,0,"NA",NA
NCT04713150,2020-10-05,2021-09-30,Observational,HEALthy Brain and Child Development Study - COVID-19 Supplement,Recruiting,NA,Boston Children's Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04713150,0,0,0,0,0,1,United States,0,no intervention,NA
NCT04712045,2020-08-01,2020-12-12,Interventional,Rational Use of Personal Protective Equipment During COVID-19 Pandemic,Completed,N/A,University of Oxford,NA,https://clinicalzeros.gov/ct2/show/NCT04712045,0,0,0,0,0,0,United Kingdom,0,new ppe|old ppe,NA
NCT04709744,2020-04-01,2020-12-25,Observational,Impact of Vitamin D Level and Supplement on SLE Patients During COVID-19 Pandemic,Completed,NA,Mansoura University,NA,https://clinicalzeros.gov/ct2/show/NCT04709744,0,0,0,0,1,0,Egypt,0,vitamin d|elisa,NA
NCT04709003,2020-12-23,2022-06-30,Observational,Covid-19 Vaccine Effectiveness in Healthcare Personnel in Clalit Health Services in Israel (CoVEHPI),Recruiting,NA,Clalit Health Services,NA,https://clinicalzeros.gov/ct2/show/NCT04709003,0,0,0,0,0,0,Israel,0,serologic test|respiratory swabs,NA
NCT04709302,2021-02-28,2022-06-30,Observational [Patient Registry],Effects of COVID-19 on Endothelium in HIV-Positive Patients in Sub-Saharan Africa,Recruiting,NA,Medical University of Graz,NA,https://clinicalzeros.gov/ct2/show/NCT04709302,0,0,0,0,0,0,Nigeria|South Africa,0,covid-19|hiv|art,NA
NCT04709172,2021-01-05,2021-04-05,Interventional,Pilot Study of Cefditoren Pivoxil in COVID-19 Patients With Mild to Moderate Pneumonia,Recruiting,Phase 4,Meiji Pharma Spain S.A.,NA,https://clinicalzeros.gov/ct2/show/NCT04709172,0,0,0,0,1,0,Spain,0,cefditoren pivoxil 400mg,NA
NCT04709120,2021-01-11,2021-03-31,Observational [Patient Registry],Analysis of Health Status of Ð¡omorbid Adult COVID-19 Patients Hospitalised in Second Wave of SARS-CoV-2 Infection,Recruiting,NA,Eurasian Association of Therapists,NA,https://clinicalzeros.gov/ct2/show/NCT04709120,0,0,0,0,1,0,Russian Federation,0,"NA",NA
NCT04705831,2020-12-30,2022-01-31,Interventional,Study to Evaluate the Benefit of RUCONEST in Improving Neurological Symptoms in Post COVID-19 Infection,Recruiting,Phase 4,IMMUNOe Research Centers,NA,https://clinicalzeros.gov/ct2/show/NCT04705831,0,0,0,0,0,1,United States,0,ruconest,NA
NCT04707833,2020-11-26,2023-12-01,Interventional,Evaluation of Serological Techniques for Screening for COVID-19 Infection at the University Hospital of Rouen,Recruiting,N/A,"University Hospital, Rouen",NA,https://clinicalzeros.gov/ct2/show/NCT04707833,0,0,0,0,0,0,France,0,serological testing for covid-19 infection,NA
NCT04707820,2020-04-16,2021-06-10,Interventional,Antiviral T Lymphocyte Immunity During Acute COVID-19 Infection,Recruiting,N/A,"University Hospital, Rouen",NA,https://clinicalzeros.gov/ct2/show/NCT04707820,0,0,0,0,0,0,France,0,elispot,NA
NCT04707742,2020-06-15,2020-11-18,Interventional,Antiseptic Mouth Rinses to Reduce Salivary Viral Load in COVID-19 Patients,Completed,N/A,FundaciÃ³n para el Fomento de la InvestigaciÃ³n Sanitaria y BiomÃ©dica de la Comunitat Valenciana,NA,https://clinicalzeros.gov/ct2/show/NCT04707742,0,0,0,0,0,0,Spain,0,betadineâ© bucal 100 mg/ml|oximenâ® 3%|clorhexidine dental phbâ©|vitis xtra forteâ©|distilled water|betadineâ© bucal 100 mg|methylprednisolone|oximenâ® 3%|clorhexidine dental phbâ©|vitis xtra forteâ©,NA
NCT04706416,2020-11-14,2021-01-15,Interventional,N-Acetyl Glucosamine as Therapeutic Intervention for Coronavirus Disease-19 (COVID-19),"Active, not recruiting",Phase 1,Quantinosis.ai LLC,NA,https://clinicalzeros.gov/ct2/show/NCT04706416,0,0,0,0,0,1,United States,0,n-acetyl glucosamine (nag),NA
NCT04706390,2021-01-12,2022-01-12,Observational,Comparison of the Immune Response to Natural COVID-19 Infection and Vaccination,Recruiting,NA,University of Bergen,NA,https://clinicalzeros.gov/ct2/show/NCT04706390,0,0,0,0,0,0,Norway,0,covid-19 vaccine,NA
NCT04706325,2021-01-01,2021-05-01,Observational,COVID-19 RELATED KIDNEY DAMAGE,Recruiting,NA,Kocaeli Derince Education and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04706325,0,0,0,0,0,0,Turkey,0,acute kidney injury,NA
NCT04706260,2020-04-14,2021-04-14,Observational,Clinical Evolution and Becoming of Adult Patients Infected With Covid-19 Hospitalized at Strasbourg University Hospitals,Recruiting,NA,"University Hospital, Strasbourg, France",NA,https://clinicalzeros.gov/ct2/show/NCT04706260,0,0,0,0,0,0,France,0,"NA",NA
NCT04703907,2020-12-03,2021-08-31,Interventional,Auricular Stimulation for Relief of Stress and Anxiety,Recruiting,N/A,University Medicine Greifswald,NA,https://clinicalzeros.gov/ct2/show/NCT04703907,0,0,0,0,0,0,Germany,0,auricular stimulation,NA
NCT04703777,2020-04-04,2021-04-04,Observational,Relationship Between Social Status and Use of Healthcare Services During the Confinement Period Linked to the COVID-19 Epidemic,Recruiting,NA,"University Hospital, Strasbourg, France",NA,https://clinicalzeros.gov/ct2/show/NCT04703777,0,0,0,0,0,0,France,0,"NA",NA
NCT04703452,2021-01-19,2022-01-31,Observational,poSt Covid-19 Infection centraL sENsitisaTion,Recruiting,NA,Universitair Ziekenhuis Brussel,NA,https://clinicalzeros.gov/ct2/show/NCT04703452,0,0,0,0,1,0,Belgium,0,indicators of central sensitisation,NA
NCT04703270,2021-01-04,2023-01-03,Observational,Understanding COVID-19 Infection in Pregnant Women and Their Babies,Recruiting,NA,"St George's, University of London",NA,https://clinicalzeros.gov/ct2/show/NCT04703270,0,0,0,0,0,0,United Kingdom,0,"NA",NA
NCT04701944,2020-04-21,2021-04-21,Observational,Clinical Study of Pregnant Women With COVID-19,Recruiting,NA,"University Hospital, Strasbourg, France",NA,https://clinicalzeros.gov/ct2/show/NCT04701944,0,0,0,0,0,0,France,0,"NA",NA
NCT04701905,2020-04-30,2021-04-30,Observational,The Offer of Neurosurgery Care in the Grand Est of France During the Health Crisis Linked to Covid-19,Recruiting,NA,"University Hospital, Strasbourg, France",NA,https://clinicalzeros.gov/ct2/show/NCT04701905,0,0,0,0,0,0,France,0,"NA",NA
NCT04701892,2021-01-19,2023-01-31,Observational,poSt Covid-19 Infection centraL Sensitisation 2,Recruiting,NA,Universitair Ziekenhuis Brussel,NA,https://clinicalzeros.gov/ct2/show/NCT04701892,0,0,0,0,1,0,Belgium,0,indicators of central sensitisation,NA
NCT04701528,2020-11-15,2022-03-25,Interventional,Anti-Viral Effects of Voclosporin in COVID-19 Positive Kidney Transplant Recipients,Recruiting,Phase 2,Leiden University Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04701528,0,0,0,0,0,0,Netherlands,0,voclosporin|tacrolimus,NA
NCT04701515,2020-06-10,2022-12-31,Observational,Cardiovascular Manifestations of COVID-19,Recruiting,NA,Methodist Health System,NA,https://clinicalzeros.gov/ct2/show/NCT04701515,0,0,0,0,0,1,United States,0,chart review,NA
NCT04699097,2020-07-01,2020-09-01,Observational,The Effect of Azithromycin Use on Conduction System of Heart in COVID-19 Positive Children,Completed,NA,Kayseri City Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04699097,0,0,0,0,0,0,Turkey,0,azithromycin,NA
NCT04701996,2020-09-23,2021-11-20,Observational,Transmission Dynamics of COVID-19 in a Rural Setting of the Democratic Republic of the Congo,Recruiting,NA,"Institute of Tropical Medicine, Belgium",NA,https://clinicalzeros.gov/ct2/show/NCT04701996,0,0,0,0,1,0,"Congo, The Democratic Republic of the",0,serological surveillance,NA
NCT04699851,2020-11-18,2021-04-18,Interventional,Optimization of the Management of COVID-19 Through Tailored Recommendations to the Citizens,Recruiting,N/A,Laval University,NA,https://clinicalzeros.gov/ct2/show/NCT04699851,0,0,0,0,1,0,Canada,0,tailored recommendations|general recommendation,NA
NCT04699227,2020-04-23,2021-04-30,Interventional,Can RIC Prevent Deterioration to Critical Care in Covid19,Recruiting,N/A,University College London Hospitals,NA,https://clinicalzeros.gov/ct2/show/NCT04699227,0,0,0,0,0,0,United Kingdom,0,cuff application with inflation|sham inflation,NA
NCT04699578,2020-12-28,2021-12-31,Observational,COVID-19 Infection and Fetal-neonatal Outcomes,Recruiting,NA,"University of Campania ""Luigi Vanvitelli""",NA,https://clinicalzeros.gov/ct2/show/NCT04699578,0,0,0,0,0,0,Italy,0,covid-19 positive,NA
NCT04698083,2020-07-22,2020-10-15,Observational,"Electrocardiographic QRS Axis Shift ,Rotation and COVÄ°D-19",Completed,NA,Ankara Education and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04698083,0,0,0,0,0,0,Turkey,0,"electrocardiography ,tomographic imaging",NA
NCT04698044,2020-05-08,2020-06-25,Observational,Anxiety and Depression Perceived by Individuals With and Without Cancer During the COVID-19 Pandemic Period,Completed,NA,"Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey",NA,https://clinicalzeros.gov/ct2/show/NCT04698044,0,0,0,0,1,0,Turkey,0,hospital anxiety depression scale,NA
NCT04697927,2020-12-30,2022-12-31,Observational,A Study of Risk Factors for the COVID-19 Virus Infection,Recruiting,NA,Memorial Sloan Kettering Cancer Center,NA,https://clinicalzeros.gov/ct2/show/NCT04697927,0,0,0,0,2,1,United States,0,questionnaire,NA
NCT04697030,2020-09-15,2020-10-15,Observational,Burnout Among Adolescent Population During Covid-19 Lockdown in Pakistan,Completed,NA,Sialkott College of Physical Therapy,NA,https://clinicalzeros.gov/ct2/show/NCT04697030,0,0,0,0,0,0,Pakistan,0,"NA",NA
NCT04695756,2020-12-15,2021-06-15,Observational,Liver Transplantation and Coronavirus Disease 2019 (COVID-19),Recruiting,NA,Hospital Italiano de Buenos Aires,NA,https://clinicalzeros.gov/ct2/show/NCT04695756,0,0,0,0,1,0,Argentina,0,covid-19 pandemic,NA
NCT04695743,2020-09-01,2022-06-01,Interventional,Group CST Using Zoom: A Proof of Concept Study,Recruiting,N/A,"University College, London",NA,https://clinicalzeros.gov/ct2/show/NCT04695743,0,0,0,0,0,0,United Kingdom,0,online cognitive stimulation therapy,NA
NCT04695678,2020-07-01,2021-01-31,Observational,Epidemiological Multicohort Study of Latent COVID-19 Infections,"Active, not recruiting",NA,Wissenschaftliches Institut Bethanien e.V,NA,https://clinicalzeros.gov/ct2/show/NCT04695678,0,0,0,0,0,0,Germany,0,covid-19 nasal/pharyngeal swab|covid-19 nasal|pharyngeal swab,NA
NCT04694638,2020-05-21,2021-05-31,Interventional,"Use of Combined Prone Positioning and High-Flow Nasal Cannula, and Non-invasive Positive Pressure Ventilation to Prevent Intubation in COVID-19 Infection",Recruiting,N/A,Mayo Clinic,NA,https://clinicalzeros.gov/ct2/show/NCT04694638,0,0,0,0,0,1,United States,0,body position change,NA
NCT04695457,2020-07-15,2020-11-16,Observational,Correlation Between the Incidence of COVID-19 in Nursing-homes and the Profile of Nursing Homes in the French Alps,Completed,NA,Centre Hospitalier Annecy Genevois,NA,https://clinicalzeros.gov/ct2/show/NCT04695457,0,0,0,0,0,0,France,0,"NA",NA
NCT04695379,2020-05-26,2022-11-26,Observational,Follow-up of a Cohort of Patients With Myasthenic Syndrome and COVID-19 Infection,Recruiting,NA,"University Hospital, Bordeaux",NA,https://clinicalzeros.gov/ct2/show/NCT04695379,0,0,0,0,0,0,France,0,"NA",NA
NCT04694612,2021-01-01,2021-03-31,Interventional,Efficacy of Favipiravir in Treatment of Mild & Moderate COVID-19 Infection in Nepal,Recruiting,Phase 3,Nepal Health Research Council,NA,https://clinicalzeros.gov/ct2/show/NCT04694612,0,0,0,0,0,0,Nepal,0,favipiravir|placebo|remdesivir,NA
NCT04694573,2020-12-28,2021-12-28,Observational [Patient Registry],Multicenter CTS Pre-and Post-Transplantation Covid-19 Serum Studies,Recruiting,NA,Heidelberg University,NA,https://clinicalzeros.gov/ct2/show/NCT04694573,0,0,0,0,1,0,Germany,0,"NA",NA
NCT04694768,2020-07-01,2021-01-01,Observational,Implementation of Rehabilitation Program for Post COVID-19,Recruiting,NA,Assiut University,NA,https://clinicalzeros.gov/ct2/show/NCT04694768,0,0,0,0,0,0,Egypt,0,rehabilitation,NA
NCT04694482,2020-11-12,2021-01-31,Observational,The Impact of the COVID-19 (SARS-CoV-2 Disease) on Psychopathology,Recruiting,NA,University of Milano Bicocca,NA,https://clinicalzeros.gov/ct2/show/NCT04694482,0,0,0,0,2,0,Italy,0,psychometric scale administration,NA
NCT04694664,2020-10-01,2020-12-01,Observational,COVID-19 Vaccine Confidence Among Pregnant Women and Mothers,Completed,NA,Pregistry,NA,https://clinicalzeros.gov/ct2/show/NCT04694664,0,0,0,0,0,1,United States,0,survey,NA
NCT04694651,2020-12-15,2021-01-30,Observational [Patient Registry],Potential Acceptance of COVID-19 Vaccines in Healthcare Workers in Egypt,Recruiting,NA,Assiut University,NA,https://clinicalzeros.gov/ct2/show/NCT04694651,0,0,0,0,0,0,Egypt,0,"NA",NA
NCT04694014,2020-10-15,2021-05-30,Observational,Emotional Intelligence Skills Health Leaders Need During Covid-19,Enrolling by invitation,NA,African Wood Inc,NA,https://clinicalzeros.gov/ct2/show/NCT04694014,0,0,0,0,0,0,Kenya,0,ei open ended pre-survey/semi structured interview|behavioral/cognitive assessment|geneva emotional competence test (geco)|ei open ended pre-survey|semi structured interview|behavioral|cognitive assessment,NA
NCT04693975,2020-10-16,2022-10-31,Observational [Patient Registry],Social Distancing During the COVID-19 Pandemic and People Living With Chronic Respiratory Diseases,Recruiting,NA,Universidade Estadual de Londrina,NA,https://clinicalzeros.gov/ct2/show/NCT04693975,0,0,0,0,0,0,Brazil,0,"NA",NA
NCT04688840,2020-01-01,2020-09-01,Observational,Smartphone Application: A Possible Solution for Follow up of Patients With Hip Arthroplasty,Completed,NA,Tanta University,NA,https://clinicalzeros.gov/ct2/show/NCT04688840,0,0,0,0,0,0,Egypt,0,hip arthropalsty,NA
NCT04691947,2020-11-05,2021-03-01,Interventional,Safety and Immunogenicity of Two Different Strengths of the Inactivated COVID-19 Vaccine ERUCOV-VAC,Recruiting,Phase 1,Health Institutes of Turkey,NA,https://clinicalzeros.gov/ct2/show/NCT04691947,0,0,0,1,1,0,Turkey,0,erucov-vac|placebo,NA
NCT04691934,2020-03-11,2020-12-25,Observational,Obstetric Anesthesia Experiences in COVID-19 Positive Patients,Completed,NA,Turkiye Yuksek Ihtisas Education and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04691934,0,0,0,0,0,0,Turkey,0,anesthesia management,NA
NCT04691895,2020-05-01,2020-09-30,Observational [Patient Registry],Gastrointestinal Symptoms in COVID-19,"Active, not recruiting",NA,University of Bologna,NA,https://clinicalzeros.gov/ct2/show/NCT04691895,0,0,0,0,1,0,Italy,0,sars-cov2 infection,NA
NCT04690920,2020-07-23,2020-12-10,Interventional,Theranostic Implication of Complementary Medicines Against Interleukin Receptors and Gp-130 Proteins,Completed,N/A,University of Lahore,NA,https://clinicalzeros.gov/ct2/show/NCT04690920,0,0,0,0,0,0,Pakistan,0,tocilizumab,NA
NCT04690114,2020-10-01,2021-05-31,Observational [Patient Registry],COVID-10 in the Pediatric Population: SARS-CoV-2 Seropositivity,Recruiting,NA,Shaare Zedek Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04690114,0,0,0,0,1,0,Israel,0,"NA",NA
NCT04689490,2020-08-01,2020-12-31,Observational,Prospective Study of Persistent Dyspnea in Recovered COVID-19 Patients,Recruiting,NA,Hospital ClÃ­nico Universitario de Valladolid,NA,https://clinicalzeros.gov/ct2/show/NCT04689490,0,0,0,0,0,0,Spain,0,cardiopulmonary exercise test,NA
NCT04689477,2020-05-25,2021-12-31,Observational [Patient Registry],Non-invasive Characterization of Systemic Microvascular Reactivity by Near-infrared Diffuse Optical Spectroscopy in COVID-19 Patients,Recruiting,NA,Corporacion Parc Tauli,NA,https://clinicalzeros.gov/ct2/show/NCT04689477,0,0,0,0,0,0,Brazil|Mexico|Spain,0,vascular occlusion test,NA
NCT04693052,2020-12-10,2021-02-01,Observational,Attitudes Towards Receiving Mental Health Care Using Telehealth During the COVID-19 Pandemic,Enrolling by invitation,NA,Northwestern University,NA,https://clinicalzeros.gov/ct2/show/NCT04693052,0,0,0,0,0,1,United States,0,no intervention,NA
NCT04693026,2020-09-10,2021-02-15,Interventional,Efficacy of Ramdicivir and Baricitinib for the Treatment of Severe COVID 19 Patients,Recruiting,Phase 3,M Abdur Rahim Medical College and Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04693026,0,0,0,0,0,0,Bangladesh,0,remdesivir|baricitinib|tocilizumab,NA
NCT04691609,2020-03-01,2023-03-31,Observational,Assiut University Registry for ACS Patients During COVID-19 Pandemic,Recruiting,NA,Assiut University,NA,https://clinicalzeros.gov/ct2/show/NCT04691609,0,0,0,0,0,0,Egypt,0,"NA",NA
NCT04689711,2020-12-07,2021-08-31,Observational,Prognostic Models for COVID-19 Care,Enrolling by invitation,NA,Tufts Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04689711,0,0,0,0,0,1,United States,0,"NA",NA
NCT04687488,2020-07-23,2020-11-09,Interventional,Aerosol and Droplet Dispersion During Gastrointestinal Motility Investigations,Completed,N/A,Universitaire Ziekenhuizen Leuven,NA,https://clinicalzeros.gov/ct2/show/NCT04687488,0,0,0,0,0,0,Belgium,0,fluorescein|particle measurement,NA
NCT04686760,2020-11-15,2021-01-15,Interventional,Efficacy of Inhaled Nitroglycerin in Moderate to Critically Ill COVID-19 Patients,Recruiting,N/A,University of Lahore,NA,https://clinicalzeros.gov/ct2/show/NCT04686760,0,0,0,0,0,0,Pakistan,0,nitroglycerin,NA
NCT04686747,2021-01-31,2021-03-01,Observational,COVID - 19 and Advanced Gastro-intestinal Cancer Treatment,Enrolling by invitation,NA,S.M. Misericordia Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04686747,0,0,0,0,0,0,Italy,0,"NA",NA
NCT04686708,2019-03-11,2020-09-11,Observational,COVID-19 Pandemic and General Surgery Emergencies,Completed,NA,Gulhane Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04686708,0,0,0,0,0,0,Turkey,0,emergency general surgical admissions,NA
NCT04685603,2020-12-07,2021-01-31,Interventional,Dendritic Cell Vaccine to Prevent COVID-19,Recruiting,Phase 1,Indonesia-MoH,NA,https://clinicalzeros.gov/ct2/show/NCT04685603,0,0,0,1,1,0,Indonesia,0,av-covid-19,NA
NCT04682873,2020-05-15,2021-06-01,Interventional,A Clinical Study to Assess the Efficacy and Safety of AmizonÂ® Max in the Treatment of Moderate Covid-19,Recruiting,Phase 3,"Joint Stock Company ""Farmak""",NA,https://clinicalzeros.gov/ct2/show/NCT04682873,0,0,0,0,0,0,Ukraine,0,enisamium iodide|placebo,NA
NCT04682574,2020-11-02,2020-12-30,Interventional,Role of Mega Dose of Vitamin C in Critical COVID-19 Patients,Recruiting,N/A,University of Lahore,NA,https://clinicalzeros.gov/ct2/show/NCT04682574,0,0,0,0,1,0,Pakistan,0,vitamin c,NA
NCT04681950,2020-11-24,2020-12-30,Observational,Assessment of Self-Collected Sample Compared to Clinician Collected Sample in COVID-19 and Influenza Program,Recruiting,NA,Biocerna LLC,NA,https://clinicalzeros.gov/ct2/show/NCT04681950,0,0,0,0,0,1,United States,0,"NA",NA
NCT04682093,2020-03-09,2021-01-31,Observational,Risk Stratification of Patients With Suspected COVID-19 Presenting to the ED,Enrolling by invitation,NA,European Society for Emergency Medicine (EUSEM) Research Network,NA,https://clinicalzeros.gov/ct2/show/NCT04682093,0,0,0,0,1,0,Croatia|Finland|France|Greece|Italy,0,"NA",NA
NCT04681001,2020-12-20,2021-05-30,Interventional,"Prophylactic Treatment With Carragelose Nasal Spary to Prevent SARS-CoV-2, COVID-19, Infections in Health Care Workers",Recruiting,N/A,Marinomed Biotech AG,NA,https://clinicalzeros.gov/ct2/show/NCT04681001,0,0,0,0,1,0,Austria,0,nasal rinse,NA
NCT04680858,2020-07-01,2021-01-31,Interventional,Impact of Digital Communication Assist Tools in Endoscopic Team Communication During COVID-19,Enrolling by invitation,N/A,University of Ulm,NA,https://clinicalzeros.gov/ct2/show/NCT04680858,0,0,0,0,1,0,Germany,0,dect,NA
NCT04679584,2020-11-16,2021-12-31,Observational,COVIDOM: Longterm Morbidity of SARS-CoV-2 Infection and COVID-19 Disease - Consequences for Health Status and Quality of Life,Recruiting,NA,University Hospital Schleswig-Holstein,NA,https://clinicalzeros.gov/ct2/show/NCT04679584,0,0,0,0,0,0,Germany,0,observation of different courses of sars-cov-2 infection in different phases (acute vs. post-acute)/settings|observation of different courses of sars-cov-2 infection in different phases (acute vs. post-acute)|settings,NA
NCT04678024,2020-11-18,2021-08-31,Observational,Sensitivity Evaluation of Serological Tests for Covid-19,Enrolling by invitation,NA,Istituto Ortopedico Galeazzi,NA,https://clinicalzeros.gov/ct2/show/NCT04678024,0,0,0,0,1,0,Italy,0,"NA",NA
NCT04337996,2020-07-13,2021-01-13,Interventional,Dynamic Evaluation of COVID-19 Diagnostic Tests,Completed,N/A,Tourcoing Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04337996,0,0,0,0,3,0,France,0,covid-19 diagnostic test,NA
NCT04677283,2020-04-05,2020-12-31,Observational,"Study of Symptoms Linked to Covid-19 in Residents and Professionals in EHPAD, Associated With a Dual Diagnostic Approach by PCR and Serology: a Cohort in ÃŽle-de-France.",Recruiting,NA,GÃ©rond'if,NA,https://clinicalzeros.gov/ct2/show/NCT04677283,0,0,0,0,0,0,France,0,"NA",NA
NCT04677270,2020-08-31,2020-11-30,Interventional,Evaluation of Two Versions of a Digital Problem Solving Tool for the General Public Specific for the COVID-19 Pandemic,Completed,N/A,Karolinska Institutet,NA,https://clinicalzeros.gov/ct2/show/NCT04677270,0,0,0,0,0,0,Sweden,0,digital problem solving tool,NA
NCT04676971,2020-12-11,2021-07-07,Interventional,Efficacy and Safety of hzVSF-v13 in Patients With COVID-19 Pneumonia,Recruiting,Phase 2,"ImmuneMed, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04676971,0,0,0,0,2,0,Italy|Russian Federation,0,hzvsf-v13|placebo (normal saline solution),NA
NCT04674553,2020-11-10,2020-12-10,Observational,Effect of Obesity Among COVID-19 Patients in Critical Care Settings,Completed,NA,"Services Institute of Medical Sciences, Pakistan",NA,https://clinicalzeros.gov/ct2/show/NCT04674553,0,0,0,0,0,0,Pakistan,0,"NA",NA
NCT04674189,2020-12-23,2021-06-30,Interventional,A Study to Evaluate the Safety and Immunogenicity of Vaccine CVnCoV in Healthy Adults in Germany for COVID-19,Recruiting,Phase 3,CureVac AG,NA,https://clinicalzeros.gov/ct2/show/NCT04674189,0,0,0,1,1,0,Germany,0,cvncov vaccine|placebo,NA
NCT04673279,2020-12-02,2021-04-10,Observational [Patient Registry],Long-term COVID-19 Immune Response in a Vulnerable Neighbourhood in Argentina,Recruiting,NA,Hospital Italiano de Buenos Aires,NA,https://clinicalzeros.gov/ct2/show/NCT04673279,0,0,0,0,0,0,Argentina,0,serology test,NA
NCT04673149,2020-12-23,2022-07-31,Interventional,GLS-5310 Vaccine for the Prevention of SARS-CoV-2 (COVID-19),Recruiting,Phase 1/Phase 2,"GeneOne Life Science, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04673149,0,0,0,1,2,0,"Korea, Republic of",0,gls-5310|placebo,NA
NCT04672343,2020-10-19,2021-04-30,Observational,Prognostic Impact of the Nutritional Status of Individuals Aged 70 Years and Older With SARS-CoV-2,Recruiting,NA,Centre Hospitalier Universitaire Dijon,NA,https://clinicalzeros.gov/ct2/show/NCT04672343,0,0,0,0,0,0,France,0,data collection|querying the insee database,NA
NCT04669990,2020-11-19,2021-10-31,Observational,Remdesivir and Convalescent Plasma Therapy for Treatment of COVID-19 Infection in Nepal : A Registry Study,Recruiting,NA,Nepal Health Research Council,NA,https://clinicalzeros.gov/ct2/show/NCT04669990,0,0,0,0,0,0,Nepal,0,remdesivir,NA
NCT04669938,2020-12-04,2022-03-31,Observational,"Role of the Microbiota in the Evolution of the SARS-CoV-2 Disease,COVID-19, in Hospitalized Patients",Recruiting,NA,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04669938,0,0,0,0,0,0,France,0,oropharyngeal/intestinal microbiota|host genotype|host immune factors|viral sequence|oropharyngeal|intestinal microbiota,NA
NCT04669509,2020-04-01,2020-10-01,Observational,Effect of Liver Injury on Mortality in Coronavirus Disease-2019 Patients Admitted to Intensive Care Unit,Completed,NA,Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04669509,0,0,0,0,0,0,Turkey,0,liver function tests,NA
NCT04669054,2020-12-01,2021-05-30,Observational,Hospital Interns Psychological State During the COVID-19,"Active, not recruiting",NA,"University Hospital, Montpellier",NA,https://clinicalzeros.gov/ct2/show/NCT04669054,0,0,0,0,0,0,France,0,"NA",NA
NCT04668937,2020-03-18,2020-03-18,Observational,ConsÃ©quences of the COVID-19 Lockdown Measures on the CHRU Nancy Pediatric Emergency Services,Completed,NA,"Central Hospital, Nancy, France",NA,https://clinicalzeros.gov/ct2/show/NCT04668937,0,0,0,0,0,0,France,0,"NA",NA
NCT04668469,2020-06-08,2020-09-15,Interventional,Efficacy and Safety of Ivermectin for Treatment and Prophylaxis of COVID-19 Pandemic,Completed,N/A,Benha University,NA,https://clinicalzeros.gov/ct2/show/NCT04668469,0,0,0,0,0,0,Egypt,0,ivermectin|hydroxychloroquine|personal protective measures,NA
NCT04667936,2020-03-01,2020-12-15,Observational,Evaluation of Sedation in COVID-19 ARDS,Recruiting,NA,Goethe University,NA,https://clinicalzeros.gov/ct2/show/NCT04667936,0,0,0,0,0,0,Germany,0,treatment group,NA
NCT04667442,2020-12-01,2021-03-31,Observational,Investigational Performance Evaluation of the Nanomix eLabÂ® COVID-19 Rapid Antigen Panel With Samples From COVID-19 Positive and Negative Human Subjects,Recruiting,NA,Nanomix,NA,https://clinicalzeros.gov/ct2/show/NCT04667442,0,0,0,0,1,1,United States,0,nanomix elabâ® covid-19 rapid antigen panel (non-interventional)|nanomix elabâ® covid-19 rapid antigen panel (non-interventional),NA
NCT04666558,2020-11-30,2021-12-17,Interventional,Heal-Me Personalized Online Nutrition and Exercise Routines,Recruiting,N/A,University of Alberta,NA,https://clinicalzeros.gov/ct2/show/NCT04666558,0,0,0,0,0,0,Canada,0,exercise/nutrition|exercise|nutrition,NA
NCT04666493,2020-12-04,2021-11-30,Interventional,Adapting Anxiety Intervention for Youth With Autism for Rapid Response to COVID-19,Recruiting,N/A,"Anagnostou, Evdokia, M.D.",NA,https://clinicalzeros.gov/ct2/show/NCT04666493,0,0,0,0,0,0,Canada,0,"cognitive behavior therapy (cbt), specifically using the facing your fears (fyf) curriculum",NA
NCT04666116,2020-04-01,2020-12-31,Interventional,Changes in Viral Load in COVID-19 After Probiotics,Recruiting,N/A,Hospital de Sagunto,NA,https://clinicalzeros.gov/ct2/show/NCT04666116,0,0,0,0,1,0,Spain,0,dietary supplementation in patients with covid disease admitted to hospital,NA
NCT04666064,2020-12-10,2021-06-30,Observational,Validation of COVILUS Score in Patients Suspected of COVID-19 Infection in the Emergency Room,Recruiting,NA,"Centre Hospitalier Universitaire, Amiens",NA,https://clinicalzeros.gov/ct2/show/NCT04666064,0,0,0,0,0,0,France,0,covid19 rt-pcr|lung ultrasound,NA
NCT04666025,2020-09-23,2022-09-23,Observational,SARS-CoV-2 Donor-Recipient Immunity Transfer,Recruiting,NA,City of Hope Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04666025,0,0,0,0,0,1,United States,0,biospecimen collection|biospeciman collection|diagnostic laboratory biomarker analysis|electronic health record review|questionnaire,NA
NCT04665245,2020-12-15,2021-04-30,Observational,Symptom-Based Markers for COVID-19 Transmission,Enrolling by invitation,NA,University of Iowa,NA,https://clinicalzeros.gov/ct2/show/NCT04665245,0,0,0,0,2,1,United States,0,"NA",NA
NCT04663659,2020-03-15,2020-05-15,Observational,The Effect of Diabetes Mellitus on Mortality of Patients With COVID-19,Completed,NA,Sisli Hamidiye Etfal Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04663659,0,0,0,0,1,0,Turkey,0,no intervention,NA
NCT04662684,2020-10-16,2021-04-30,Interventional,Medically Ill Hospitalized Patients for COVID-19 THrombosis Extended ProphyLaxis With Rivaroxaban ThErapy: The MICHELLE Trial,Recruiting,Phase 3,Science Valley Research Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04662684,0,0,0,0,0,0,Brazil,0,rivaroxaban 10 mg,NA
NCT04662021,2020-12-10,2021-02-10,Interventional,Aerobic Training Versus Cognitive Behavioral Therapy in Management of Anxiety,Enrolling by invitation,N/A,Cairo University,NA,https://clinicalzeros.gov/ct2/show/NCT04662021,0,0,0,0,1,0,Egypt,0,aerobic exercises,NA
NCT04661930,2020-12-13,2021-04-01,Interventional,Fenofibrate for Patients With COVID-19 Requiring Hospitalization,Recruiting,Phase 3,Hebrew University of Jerusalem,NA,https://clinicalzeros.gov/ct2/show/NCT04661930,0,0,0,0,0,0,Israel,0,tricorâ® 145mg tablets|standard care|placebo|tricorâ® 145mg tablets,NA
NCT04661527,2020-04-22,2020-12-30,Interventional,Sarilumab Treatment In cytoKinE Storm Caused by Infection With COVID-19,Recruiting,Phase 2,"Clinica Universidad de Navarra, Universidad de Navarra",NA,https://clinicalzeros.gov/ct2/show/NCT04661527,0,0,0,0,1,0,Spain,0,sarilumab,NA
NCT04661462,2020-09-30,2021-09-30,Observational,Health After Covid-19 in Tyrol,Recruiting,NA,Medical University Innsbruck,NA,https://clinicalzeros.gov/ct2/show/NCT04661462,0,0,0,0,0,0,Austria,0,online survey,NA
NCT04659876,2020-03-22,2020-09-01,Observational,Factors Affecting Mortality in Critical Patients Admitted to Intensive Care Unit Due to COVID 19,Completed,NA,Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04659876,0,0,0,0,0,0,Turkey,0,clinical features/laboratory values|clinical features|laboratory values,NA
NCT04659746,2020-12-09,2021-02-28,Interventional,MejoraCare-Paraguay: mHealth Solution for Chronic Patients During the COVID-19 Outbreak in Paraguay,Recruiting,N/A,Universidad AutÃ³noma de EncarnaciÃ³n,NA,https://clinicalzeros.gov/ct2/show/NCT04659746,0,0,0,0,2,0,Paraguay,0,mejoracare,NA
NCT04659187,2020-03-26,2021-05-30,Observational,CORONA Germany- Clinical Outcome and Risk in Hospitalized COVID-19 Patients - An Epidemiological Study From Germany,Recruiting,NA,Asklepios proresearch,NA,https://clinicalzeros.gov/ct2/show/NCT04659187,0,0,0,0,2,0,Germany,0,"NA",NA
NCT04659135,2020-04-19,2022-12-31,Observational [Patient Registry],ASCO Survey on COVID-19 in Oncology (ASCO) Registry,Recruiting,NA,American Society of Clinical Oncology,NA,https://clinicalzeros.gov/ct2/show/NCT04659135,0,0,0,0,0,1,United States,0,"NA",NA
NCT04658433,2020-12-05,2021-02-15,Interventional,The Effect of Omega -3 Supplements on the Serum Levels of ACE/ACE2 Ratio as a Potential Key in Cardiovascular Disease and COVID-19; A Randomized Clinical Trial in the Covid-19 Uninfected Jordanian People,Recruiting,N/A,Applied Science Private University,NA,https://clinicalzeros.gov/ct2/show/NCT04658433,0,0,0,0,0,0,Jordan,0,300 mg of omega3-fa,NA
NCT04655612,2020-12-01,2021-07-01,Observational,Seroprevalence Study of CoV-2-SARS (COVID-19) Infection in Patients With Chronic Inflammatory Rheumatic Diseases,Recruiting,NA,"University Hospital, Montpellier",NA,https://clinicalzeros.gov/ct2/show/NCT04655612,0,0,0,0,2,0,France,0,"NA",NA
NCT04655521,2020-12-02,2021-08-31,Observational,Dynamics of the Immune Response to COVID-19 / Infection by SARS-CoV-2,Recruiting,NA,UniversitÃ¤t des Saarlandes,NA,https://clinicalzeros.gov/ct2/show/NCT04655521,0,0,0,0,2,0,Germany,0,"NA",NA
NCT04651413,2020-11-24,2021-03-31,Observational,PCR Cycle Threshold Values and COVID-19 Outcomes,Recruiting,NA,University Hospitals of North Midlands NHS Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04651413,0,0,0,0,1,0,United Kingdom,0,pcr value,NA
NCT04649840,2020-10-01,2021-12-31,Observational,Estimation of Dynamics of Humoral and Cellular Immunity in COVID-19 Patients,Enrolling by invitation,NA,Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus,NA,https://clinicalzeros.gov/ct2/show/NCT04649840,0,0,0,0,0,0,Belarus,0,humoral/cellular immunity|humoral|cellular immunity,NA
NCT04649827,2020-04-02,2020-06-30,Observational,A Clinical Trial for Hospitalized Patients With COVID-19 in CearÃ¡: ResCOVID Study,Recruiting,NA,Escola de SaÃºde PÃºblica do CearÃ¡,NA,https://clinicalzeros.gov/ct2/show/NCT04649827,0,0,0,0,0,0,Brazil,0,clinical observation,NA
NCT04649515,2020-12-04,2021-08-31,Interventional,"Efficacy and Safety of TY027, a Treatment for COVID-19, in Humans",Recruiting,Phase 3,Tychan Pte Ltd.,NA,https://clinicalzeros.gov/ct2/show/NCT04649515,0,0,0,0,1,0,Singapore,0,ty027|saline,NA
NCT04648800,2020-07-07,2020-12-31,Interventional,Clinical Trial Evaluating the Effect of BCG Vaccination on the Incidence and Severity of SARS-CoV-2 Infections Among Healthcare Professionals During the COVID-19 Pandemic in Poland,Recruiting,Phase 3,University of Rzeszow,NA,https://clinicalzeros.gov/ct2/show/NCT04648800,0,0,0,1,0,0,Poland,0,bcg-10 vaccine|saline,NA
NCT04646655,2020-07-27,2021-05-31,Interventional,Enoxaparin at Prophylactic or Therapeutic Doses in COVID-19,Recruiting,Phase 3,ASST Fatebenefratelli Sacco,NA,https://clinicalzeros.gov/ct2/show/NCT04646655,0,0,0,0,0,0,Italy,0,enoxaparin,NA
NCT04645433,2020-03-15,2020-05-15,Observational,Effect of Favipiravir on Mortality in Patients With COVID-19 at a Tertiary Center Intensive Care Unit,Completed,NA,Sisli Hamidiye Etfal Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04645433,0,0,0,0,0,0,Turkey,0,"NA",NA
NCT04645407,2020-02-01,2020-04-15,Interventional,Effects of Fuzheng Huayu Tablets on COVID-19,Completed,Phase 4,ShuGuang Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04645407,0,0,0,0,0,0,China,0,fuzheng huayu,NA
NCT04644172,2020-11-01,2023-11-30,Interventional,Improving Thinking in Everyday Life After Covid-19,Recruiting,Phase 1/Phase 2,University of Alabama at Birmingham,NA,https://clinicalzeros.gov/ct2/show/NCT04644172,0,0,0,0,0,1,United States,0,speed of processing training|instrumental activities of daily living shaping|transfer package from ci therapy|standard care,NA
NCT04644159,2020-11-13,2022-06-30,Observational,"Longitudinal Follow-up of a Population Cohort in a French City With High SARS-CoV-2 Circulation, in Early 2020 [COVID-19]",Recruiting,NA,Institut Pasteur,NA,https://clinicalzeros.gov/ct2/show/NCT04644159,0,0,0,0,1,0,France,0,biological samples,NA
NCT04644146,2020-12-01,2021-06-01,Observational,Genetic Predisposition to Severe Forms of COVID-19 (SARS-CoV2 Infection),Recruiting,NA,Hospices Civils de Lyon,NA,https://clinicalzeros.gov/ct2/show/NCT04644146,0,0,0,0,0,0,France,0,genetic,NA
NCT04643964,2020-11-30,2020-11-30,Interventional,Brief Video Interventions for Depression,Recruiting,N/A,Ohio State University,NA,https://clinicalzeros.gov/ct2/show/NCT04643964,0,0,0,0,0,1,United States,0,entrã©e: cognitive skills|entrã©e: behavioral skills|entrã©e: interpersonal skills|sampler skills|entrã©e: cognitive skills|entrã©e: behavioral skills|entrã©e: interpersonal skills,NA
NCT04643691,2020-09-11,2022-09-30,Interventional,Losartan and Spironolactone Treatment for ICU Patients With COVID-19 Suffering From ARDS,Recruiting,Phase 2,Assistance Publique Hopitaux De Marseille,NA,https://clinicalzeros.gov/ct2/show/NCT04643691,0,0,0,0,0,0,France,0,losartan 50 mg/spironolactone 25 mg pillules oral use|losartan 50 mg|spironolactone 25 mg pillules oral use,NA
NCT04643561,2020-11-01,2020-12-31,Interventional,Using Travelan to Boost Immune Response in Vitro to COVID-19,"Active, not recruiting",Phase 1/Phase 2,Hadassah Medical Organization,NA,https://clinicalzeros.gov/ct2/show/NCT04643561,0,0,0,0,1,0,Israel,0,travelan otc,NA
NCT04643548,2020-10-13,2021-06-13,Observational,WHO Covid 19 - Neurological Abnormalities in SARS-CoV-2 ICU Patients,Recruiting,NA,"University Hospital, Clermont-Ferrand",NA,https://clinicalzeros.gov/ct2/show/NCT04643548,0,0,0,0,1,0,France,0,"NA",NA
NCT04642040,2020-06-30,2021-01-31,Interventional,Effectiveness of Pulmonary Rehabilitation Program in Patients With SARS-CoV-2 Pneumonia,Recruiting,N/A,Sisli Hamidiye Etfal Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04642040,0,0,0,0,0,0,Turkey,0,pulmonary rehabilitation,NA
NCT04641988,2020-02-01,2020-03-01,Observational,Cardiac Biomarkers and Mortality in Critically Ill Patients With SARS-CoV-2 (COVID-19),Completed,NA,"University Hospital, Montpellier",NA,https://clinicalzeros.gov/ct2/show/NCT04641988,0,0,0,0,0,0,France,0,"NA",NA
NCT04641858,2020-12-03,2022-02-28,Interventional,BCG to Reduce Absenteeism Among Health Care Workers During the COVID-19 Pandemic,Recruiting,Phase 4,University of Southern Denmark,NA,https://clinicalzeros.gov/ct2/show/NCT04641858,0,0,0,1,1,0,Cape Verde|Guinea-Bissau|Mozambique,0,bcg-denmark|saline,NA
NCT04640038,2020-12-18,2022-12-31,Interventional,Contrast Enhanced Ultrasound in COVID-19,Recruiting,Phase 3,Children's Hospital of Philadelphia,NA,https://clinicalzeros.gov/ct2/show/NCT04640038,0,0,0,0,2,1,United States,0,sulfur hexafluoride lipid-type a microspheres,NA
NCT04639466,2020-12-11,2022-11-10,Interventional,"A Synthetic MVA-based SARS-CoV-2 Vaccine, COH04S1, for the Prevention of COVID-19",Recruiting,Phase 1,City of Hope Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04639466,0,0,0,1,4,1,United States,0,placebo|vaccine therapy,NA
NCT04639349,2020-11-19,2021-03-01,Interventional,Effect of Home Exercise Activity on Cortisol and Depression in COPD During the Pandemic COVID,Recruiting,N/A,Cairo University,NA,https://clinicalzeros.gov/ct2/show/NCT04639349,0,0,0,0,0,0,Egypt,0,exercise|control,NA
NCT04638842,2020-12-24,2021-06-01,Interventional,Online Multi-component Psychological Intervention for Prevention of Grief Disorder Due to COVID-19,Recruiting,N/A,Universidad Internacional de Valencia,NA,https://clinicalzeros.gov/ct2/show/NCT04638842,0,0,0,0,2,0,Mexico,0,online intervention grief covid-19,NA
NCT04638673,2020-11-19,2021-06-30,Interventional,NeuroCovid Rehab and Recovery Related to COVID-19 Diagnosis,Recruiting,Phase 2,Medical University of South Carolina,NA,https://clinicalzeros.gov/ct2/show/NCT04638673,0,0,0,0,1,1,United States,0,soterix tavns model 0125-lte stimulator - active-active group|soterix tavns model 0125-lte stimulator - sham-active group,NA
NCT04637828,2020-11-18,2021-07-30,Interventional,A Study to Compare the Efficacy of GNS561 Versus Standard of Care in Patients With SARS-CoV-2 (COVID-19) Infection,Recruiting,Phase 2,Genoscience Pharma,NA,https://clinicalzeros.gov/ct2/show/NCT04637828,0,0,0,0,0,0,France,0,gns561,NA
NCT04636034,2021-01-12,2021-08-31,Interventional,The Effect of Ganglion Sphenopalatine Block Versus Placebo on Persistent Headache Following COVID-19 Infection,Recruiting,Phase 3,University Hospital Bispebjerg and Frederiksberg,NA,https://clinicalzeros.gov/ct2/show/NCT04636034,0,0,0,0,3,0,Denmark,0,"sphenopalatine ganglion block with local anesthetic|sphenopalatine ganglion block with placebo (isotone nacl)|""sham""-block with placebo (isotone nacl)",NA
NCT04636021,2020-08-01,2021-12-31,Observational [Patient Registry],Restoring Non-Emergent Cardiovascular Care in the Peri- COVID-19 Era,Recruiting,NA,Pinnacle Health Cardiovascular Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04636021,0,0,0,0,0,1,United States,0,covid-19 testing,NA
NCT04629001,2020-09-01,2021-09-01,Observational [Patient Registry],Effect of Covid-19 on Outcomes of Pregnancy,"Active, not recruiting",NA,Assiut University,NA,https://clinicalzeros.gov/ct2/show/NCT04629001,0,0,0,0,0,0,Egypt,0,"covid-19 pcr , igm",NA
NCT04681755,2020-05-19,2021-05-19,Observational,Rehabilitation Required Due to Clinical Disorders After Severe Covid-19 Infection,Recruiting,NA,"University Hospital, Strasbourg, France",NA,https://clinicalzeros.gov/ct2/show/NCT04681755,0,0,0,0,1,0,France,0,"NA",NA
NCT04681157,2020-04-03,2021-04-03,Observational,Retrospective Study on Anosmias and Ageusias Linked to Infection by Covid-19,Recruiting,NA,"University Hospital, Strasbourg, France",NA,https://clinicalzeros.gov/ct2/show/NCT04681157,0,0,0,0,1,0,France,0,"NA",NA
NCT04679428,2020-05-07,2022-05-07,Observational,Immunological Characteristics of COVID-19 Patients,Recruiting,NA,The University Clinic of Pulmonary and Allergic Diseases Golnik,NA,https://clinicalzeros.gov/ct2/show/NCT04679428,0,0,0,0,0,0,Slovenia,0,"NA",NA
NCT04679415,2020-12-17,2021-04-30,Interventional,Efficacy and Safety of hzVSF-v13 in Moderate to Severe Patients With COVID-19 Pneumonia,Recruiting,Phase 2,"ImmuneMed, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04679415,0,0,0,0,1,0,Indonesia,0,hzvsf-v13|placebo (normal saline solution),NA
NCT04678193,2020-12-24,2021-06-30,Observational [Patient Registry],COVID-19 Risk Assessment for Hospitalization Outcomes and Epidemiology Efficacy,Enrolling by invitation,NA,"Aventyn, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04678193,0,0,0,0,1,1,United States|India|Sweden,0,coromec registry with ecl-19,NA
NCT04673331,2020-11-04,2021-11-04,Observational,"Physical Activity, Exercise Capacity and Coronavirus Phobia of Adult Cystic Fibrosis Patients During COVID-19 Pandemic",Recruiting,NA,Hacettepe University,NA,https://clinicalzeros.gov/ct2/show/NCT04673331,0,0,0,0,0,0,Turkey,0,exercise,NA
NCT04670328,2020-05-01,2020-07-31,Observational,Role of Hematological Parameters in the Stratification of COVID-19 Disease Severity,Completed,NA,FMH College of Medicine and Dentistry,NA,https://clinicalzeros.gov/ct2/show/NCT04670328,0,0,0,0,0,0,Pakistan,0,not required,NA
NCT04668313,2020-09-29,2020-12-30,Observational [Patient Registry],COVID-19 Advanced Respiratory Physiology (CARP) Study,Recruiting,NA,NHS Greater Glasgow and Clyde,NA,https://clinicalzeros.gov/ct2/show/NCT04668313,0,0,0,0,0,0,United Kingdom,0,"NA",NA
NCT04668170,2020-05-05,2021-12-31,Observational,Predictive Immune Biomarkers of COVID-19 Pathogenesis to Influence Therapeutic Management,Recruiting,NA,"University Hospital, Toulouse",NA,https://clinicalzeros.gov/ct2/show/NCT04668170,0,0,0,0,0,0,France,0,blood sample|blood collection on their first consultation/10 to 14 days later|longitudinally|10 to 14 days later,NA
NCT04667780,2020-12-10,2021-05-09,Interventional,Study to Investigate the Treatment Effect of Colchicine in Patients With COVID-19,Recruiting,Phase 3,Ayub Teaching Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04667780,0,0,0,0,0,0,Pakistan,0,colchicine|standard covid-19 care,NA
NCT04666753,2020-07-02,2020-09-29,Observational,Retrospective Study of ImmunoFormulation for COVID-19,Completed,NA,Fagron Iberica S.A.U.,NA,https://clinicalzeros.gov/ct2/show/NCT04666753,0,0,0,0,0,0,Spain,0,immunoformulation,NA
NCT04666246,2020-03-01,2021-02-01,Observational,Inspiratory Effort in COVID-19,Recruiting,NA,University of Modena and Reggio Emilia,NA,https://clinicalzeros.gov/ct2/show/NCT04666246,0,0,0,0,0,0,Italy,0,"NA",NA
NCT04666207,2020-05-25,2021-01-31,Observational,"Viral Shedding, Symptoms and Exposure of SARS-CoV-2 in Non-hospitalized Children With COVID-19",Recruiting,NA,"Rigshospitalet, Denmark",NA,https://clinicalzeros.gov/ct2/show/NCT04666207,0,0,0,0,0,0,Denmark,0,pcr,NA
NCT04665258,2020-12-14,2021-06-14,Observational,COVID-19 Vaccine and Impact on Fertility Study,Recruiting,NA,University of Miami,NA,https://clinicalzeros.gov/ct2/show/NCT04665258,0,0,0,0,1,1,United States,0,"NA",NA
NCT04664049,2020-12-23,2022-12-31,Observational,The Outcomes of NRICM101 on SARS-COV-2 (COVID-19) Infection,Recruiting,NA,"National Research Institute of Chinese Medicine, Ministry of Health and Welfare",NA,https://clinicalzeros.gov/ct2/show/NCT04664049,0,0,0,0,1,0,Taiwan,0,nricm101,NA
NCT04664023,2020-12-09,2022-07-30,Observational,"Description of Immunologic, Enzymatic and Metabolic Biomarkers Associated to the Severity of COVID-19 (SARS-CoV-2) and Its Resolution",Recruiting,NA,Poitiers University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04664023,0,0,0,0,1,0,France,0,"blood collection at day 8, day 16, day 24, month 6/month 12 after first symptoms from sars-cov-2 infection|blood collection at day 8, day 16, day 24, month 6|month 12 after first symptoms from sars-cov-2 infection",NA
NCT04664010,2020-02-06,2021-01-14,Interventional,Efficacy and Safety of High-dose Vitamin C Combined With Chinese Medicine Against Coronavirus Pneumonia (COVID-19),"Active, not recruiting",N/A,Xi'an International Medical Center Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04664010,0,0,0,0,0,0,China,0,"alpha-interferon alpha, abidol, ribavirin, buzhong yiqi plus/minus formula, huhuang detoxicity paste, baimu qingre jiedu paste, fumigation/inhalation of vitamin c|alpha-interferon, abidol, ribavirin, buzhong yiqi plus/minus formula, huhuang detoxicity paste, baimu qingre jiedu paste/5% glucose|alpha-interferon, abidol, ribavirin, buzhong yiqi plus/minus formula, huhuang detoxicity paste, baimu qingre jiedu paste/high-dose vitamin c treatment|alpha-interferon alpha, abidol, ribavirin, buzhong yiqi plus|minus formula, huhuang detoxicity paste, baimu qingre jiedu paste, fumigation|inhalation of vitamin c|alpha-interferon, abidol, ribavirin, buzhong yiqi plus|minus formula, huhuang detoxicity paste, baimu qingre jiedu paste|5% glucose|high-dose vitamin c treatment",NA
NCT04663594,2020-12-04,2021-03-31,Interventional,Online Culture for Mental Health in People Aged 16-24,Recruiting,N/A,University of Oxford,NA,https://clinicalzeros.gov/ct2/show/NCT04663594,0,0,0,0,1,0,United Kingdom,0,wofb|ashmolean website,NA
NCT04661410,2020-12-01,2021-12-01,Interventional,Reward Re-Training: A New Treatment to Address Reward Imbalance During the COVID-19 Pandemic,Recruiting,N/A,Drexel University,NA,https://clinicalzeros.gov/ct2/show/NCT04661410,0,0,0,0,1,1,United States,0,reward re-training|supportive therapy,NA
NCT04659941,2020-10-01,2021-10-01,Interventional,Use of BCG Vaccine as a Preventive Measure for COVID-19 in Health Care Workers,Recruiting,Phase 2,Universidade Federal do Rio de Janeiro,NA,https://clinicalzeros.gov/ct2/show/NCT04659941,0,0,0,1,0,0,Brazil,0,bcg,NA
NCT04659889,2020-12-31,2021-06-30,Observational,Clinical and Haematological Phenotypes in Long COVID,Recruiting,NA,HCA International Limited,NA,https://clinicalzeros.gov/ct2/show/NCT04659889,0,0,0,0,0,0,United Kingdom,0,blood sampling (venesection),NA
NCT04659486,2020-09-24,2021-04-30,Interventional,Adolescents With COVID-19/MIS-C at HCFMUSP,Enrolling by invitation,N/A,University of Sao Paulo,NA,https://clinicalzeros.gov/ct2/show/NCT04659486,0,0,0,0,0,0,Brazil,0,home-based exercise training,NA
NCT04658979,2020-12-31,2021-03-31,Interventional,Pulmonary TELE-REHABilitation Program : Feasibility and Safety Study,Recruiting,N/A,Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec,NA,https://clinicalzeros.gov/ct2/show/NCT04658979,0,0,0,0,1,0,Canada,0,pulmonary tele-rehabilitation,NA
NCT04657510,2020-11-14,2020-12-01,Observational,Femoral frACturEs and COVID-19.,Recruiting,NA,Istituto Ortopedico Galeazzi,NA,https://clinicalzeros.gov/ct2/show/NCT04657510,0,0,0,0,0,0,Italy,0,covid-19,NA
NCT04657445,2020-11-17,2021-05-31,Observational,"EFFECT OF COVID-19 DISEASE IN SMELL AND TASTE OF PATIENTS WITH MILD, MODERATE OR SEVERE SYMPTOMATOLOGY",Recruiting,NA,"University Hospital, Ioannina",NA,https://clinicalzeros.gov/ct2/show/NCT04657445,0,0,0,0,3,0,Greece,0,visual analogue scale,NA
NCT04657263,2020-11-01,2021-05-01,Observational,Impact of the COVID-19 Pandemic on Vaccination,Recruiting,NA,"University Hospital, Montpellier",NA,https://clinicalzeros.gov/ct2/show/NCT04657263,0,0,0,0,1,0,France,0,vaccine coverage assessment,NA
NCT04656626,2020-07-07,2020-07-21,Interventional,Brief Mindfulness Based Intervention to Improve Psychological Wellbeing,Completed,N/A,Imam Abdulrahman Bin Faisal University,NA,https://clinicalzeros.gov/ct2/show/NCT04656626,0,0,0,0,2,0,Saudi Arabia,0,brief mindfulness based intervention|progressive muscle relaxation,NA
NCT04654481,2020-12-31,2021-02-28,Interventional,Study of AffloVest in At-Risk Respiratory Patients During COVID-19 Pandemic,Recruiting,N/A,Icahn School of Medicine at Mount Sinai,NA,https://clinicalzeros.gov/ct2/show/NCT04654481,0,0,0,0,0,1,United States,0,hcfwo|standard care/monitoring|standard care|monitoring,NA
NCT04654416,2020-03-20,2020-08-07,Observational,Clinical Outcome of Patients With COVID-19 Pneumonia Treated With Corticosteroids and Colchicine,Completed,NA,ClÃ­nica MedellÃ­n - Grupo QuirÃ³nsalud,NA,https://clinicalzeros.gov/ct2/show/NCT04654416,0,0,0,0,0,0,Colombia,0,corticosteroid with/without colchicine|corticosteroid with|without colchicine,NA
NCT04653857,2020-04-01,2020-04-30,Observational,Cardiac Assessment After Covid-19 Disease in Elite Altheltic Population,"Active, not recruiting",NA,"University Hospital, Montpellier",NA,https://clinicalzeros.gov/ct2/show/NCT04653857,0,0,0,0,1,0,France,0,"NA",NA
NCT04653844,2020-02-01,2021-02-20,Observational,RT-PCR Database Analysis for COVID-19 Infections and Re-infection,"Active, not recruiting",NA,"University Hospital, Montpellier",NA,https://clinicalzeros.gov/ct2/show/NCT04653844,0,0,0,0,1,0,France,0,"NA",NA
NCT04653831,2020-11-08,2021-11-30,Interventional,Treatment With Pirfenidone for COVID-19 Related Severe ARDS,Recruiting,N/A,Soroka University Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04653831,0,0,0,0,0,0,Israel,0,pirfenidone|standard care,NA
NCT04559035,2020-09-24,2020-12-31,Interventional,Nasal Irrigation to Reduce COVID-19 Morbidity,Enrolling by invitation,N/A,Augusta University,NA,https://clinicalzeros.gov/ct2/show/NCT04559035,0,0,0,0,0,1,United States,0,nasal lavage,NA
NCT04652648,2020-05-27,2020-10-31,Interventional,Rapid Development and Implementation of a Remote ECG-monitored Prospective Randomized Clinical Trial During a Pandemic: Hydroxychloroquine Prophylaxis in COVID-19 Household Contacts,Completed,Phase 4,Bryn Mawr Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04652648,0,0,0,0,0,1,United States,0,hydroxychloroquine,NA
NCT04652505,2020-07-13,2021-03-31,Observational,"Effect of the COVID-19 Public Health Crisis on the Mental Health and Physical Well-Being of Cancer Patients, the Coping With COVID Study",Recruiting,NA,M.D. Anderson Cancer Center,NA,https://clinicalzeros.gov/ct2/show/NCT04652505,0,0,0,0,0,1,United States,0,questionnaire,NA
NCT04650191,2020-03-01,2021-06-30,Observational [Patient Registry],Surfactant Protein Genetic Variants in COVID-19 Infection,Recruiting,NA,Milton S. Hershey Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04650191,0,0,0,0,0,1,United States,0,identification of genetic variants,NA
NCT04650178,2020-05-26,2021-07-01,Observational,Well-being in Cancer Patients With Neuropathy During COVID-19 Who Participated in Prior Clinical Trials,Recruiting,NA,M.D. Anderson Cancer Center,NA,https://clinicalzeros.gov/ct2/show/NCT04650178,0,0,0,0,0,1,United States,0,quality-of-life assessment|questionnaire,NA
NCT04650035,2020-11-01,2020-11-04,Observational,The Impact of COVID-19 on Surgical Practice in Jordan During the Second Outbreak,Completed,NA,Yarmouk University,NA,https://clinicalzeros.gov/ct2/show/NCT04650035,0,0,0,0,1,0,Jordan,0,"NA",NA
NCT04649736,2020-10-26,2021-03-30,Interventional,Home-based Respiratory Physiotherapy and Telephone-Based Psychological Support in Severe COVID-19 Patients,Recruiting,N/A,Universidad Peruana Cayetano Heredia,NA,https://clinicalzeros.gov/ct2/show/NCT04649736,0,0,0,0,0,0,Peru,0,respiratory/psychological rehabilitation|respiratory|psychological rehabilitation,NA
NCT04649658,2020-03-01,2020-06-01,Observational,Pronation in COVID-19 Patients Undergoing Non Invasive Respiratory Support,Completed,NA,University of Modena and Reggio Emilia,NA,https://clinicalzeros.gov/ct2/show/NCT04649658,0,0,0,0,1,0,Italy,0,prone positioning,NA
NCT04649333,2020-06-15,2020-08-31,Observational,COVID-19 and Sports - an Online Survey on the Impact of the Pandemic and Possible Preventive Measures,Completed,NA,Medical University Innsbruck,NA,https://clinicalzeros.gov/ct2/show/NCT04649333,0,0,0,0,1,0,Austria,0,"NA",NA
NCT04649320,2020-11-23,2020-12-31,Observational,Perception of the COVID-19 Pandemic in Patients With Haematological or Solid Neoplasias,Recruiting,NA,Medical University Innsbruck,NA,https://clinicalzeros.gov/ct2/show/NCT04649320,0,0,0,0,0,0,Austria,0,questionnaire,NA
NCT04647994,2020-09-21,2021-07-01,Observational,Exploratory Study: COVID-19 and Pregnancy,Recruiting,NA,University of Sao Paulo General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04647994,0,0,0,0,1,0,Brazil,0,sars-cov-2 serology,NA
NCT04646525,2020-10-01,2021-02-01,Observational,The Relationship Between Covid-19 Infection in Pediatric Patients and Secondary Lymphoid Organs,Recruiting,NA,Selcuk University,NA,https://clinicalzeros.gov/ct2/show/NCT04646525,0,0,0,0,0,0,Turkey,0,physical examination,NA
NCT04646109,2020-05-11,2020-09-02,Interventional,Ivermectin for Severe COVID-19 Management,Completed,Phase 3,Afyonkarahisar Health Sciences University,NA,https://clinicalzeros.gov/ct2/show/NCT04646109,0,0,0,0,1,0,Turkey,1,ivermectin,NA
NCT04645368,2020-07-01,2021-04-30,Observational,"Study of Longidaze in the Prevention & Treatment of Pulmonary Fibrosis, Interstitial Lung Diseases Caused by COVID-19",Recruiting,NA,NPO Petrovax,NA,https://clinicalzeros.gov/ct2/show/NCT04645368,0,0,0,0,0,0,Russian Federation,0,bovhyaluronidase azoxymer,NA
NCT04644705,2020-11-02,2021-05-31,Interventional,Safety and Pharmacokinetics of a Novel Niclosamide Solution in Combination With Camostat,Recruiting,Phase 1,CharitÃ© Research Organisation GmbH,NA,https://clinicalzeros.gov/ct2/show/NCT04644705,0,0,0,0,0,0,Germany,0,niclosamide|placebo,NA
NCT04644302,2020-02-01,2021-07-31,Observational,Circulatory Coherence in COVID-19 and Non-COVID-19 Patients With Sepsis,Recruiting,NA,University Hospital Hradec Kralove,NA,https://clinicalzeros.gov/ct2/show/NCT04644302,0,0,0,0,1,0,Czechia,0,microcirculation recording,NA
NCT04642703,2020-03-03,2020-11-30,Observational,Mortality in Patients With Severe COVID-19 Pneumonia Who Underwent Tracheostomy,Recruiting,NA,University of Chile,NA,https://clinicalzeros.gov/ct2/show/NCT04642703,0,0,0,0,1,0,Chile,0,"NA",NA
NCT04641182,2020-07-06,2020-08-16,Observational [Patient Registry],Prone Position for Nonintubated Patients With COVID-19 and Hypoxemic Respiratory Failure,Completed,NA,Pontificia Universidad Catolica de Chile,NA,https://clinicalzeros.gov/ct2/show/NCT04641182,0,0,0,0,0,0,Chile,0,prone positioning,NA
NCT04637867,2020-11-23,2021-11-01,Interventional,COVID-19 - Multicentre Study on Nosocomial Transmission of SARS-CoV-2 Virus: an Ancillary Study (NOSO-COR IMMUNO),Recruiting,N/A,Hospices Civils de Lyon,NA,https://clinicalzeros.gov/ct2/show/NCT04637867,0,0,0,0,1,0,France,0,"collection of blood, salivary/nasopharyngeal samples.|collection of blood, salivary|nasopharyngeal samples.",NA
NCT04636333,2020-10-30,2021-04-07,Interventional,Phase I Trial of a Recombinant COVID-19 Vaccine (CHO Cell),Recruiting,Phase 1,Jiangsu Province Centers for Disease Control and Prevention,NA,https://clinicalzeros.gov/ct2/show/NCT04636333,0,0,0,1,2,0,China,0,"two doses of middle-dose recombinant sars-cov-2 vaccine (cho cell) at the schedule of day 0, 14|three doses of middle-dose recombinant sars-cov-2 vaccine (cho cell) at the schedule of day 0, 14, 28|two doses of high-dose recombinant sars-cov-2 vaccine (cho cell) at the schedule of day 0, 14|three doses of high-dose recombinant sars-cov-2 vaccine (cho cell) at the schedule of day 0, 14, 28|two doses of placebo at the schedule of day 0, 14 #middle-dose group#|three doses of placebo at the schedule of day 0, 14, 28 #middle-dose group#|two doses of placebo at the schedule of day 0, 14 #high-dose group#|three doses of placebo at the schedule of day 0, 14, 28 #high-dose group#",NA
NCT04636320,2020-06-13,2021-01-13,Interventional,Prevalence of Myocardial Scars on CMR After COVID-19 Infection,Recruiting,N/A,"University Hospital, Bordeaux",NA,https://clinicalzeros.gov/ct2/show/NCT04636320,0,0,0,0,0,0,France,0,contrast-enhanced cmr|exercise test ecg|blood sample|resting 12 lead ecg|24 hour holter ecg,NA
NCT04635813,2020-03-10,2020-09-30,Observational,The Impact of COVID-19 Pandemic on Thyroid Surgery in Italy: Results From a Nation-wide Multicentric Study,Completed,NA,University of Cagliari,NA,https://clinicalzeros.gov/ct2/show/NCT04635813,0,0,0,0,0,0,Italy,0,thyroidectomy,NA
NCT04635787,2020-11-05,2022-09-30,Observational,Vital Sensor Monitors for CV19 Detection,Enrolling by invitation,NA,Northwestern University,NA,https://clinicalzeros.gov/ct2/show/NCT04635787,0,0,0,0,0,1,United States,0,anne one,NA
NCT04635618,2020-11-05,2021-07-13,Interventional,Psychotherapy Strategies for the Treatment of Professionals and Students From Essential Services With High Levels of Emotional Distress in the Context of COVID-19,Enrolling by invitation,N/A,Hospital de Clinicas de Porto Alegre,NA,https://clinicalzeros.gov/ct2/show/NCT04635618,0,0,0,0,0,0,Brazil,0,cognitive behavioral brief-telepsychotherapy|brief interpersonal telepsychotherapy|telepsychoeducation,NA
NCT04634903,2020-11-19,2021-05-01,Interventional,"Testing Scalable, Single-Session Interventions for Adolescent Depression in the Context of COVID-19","Active, not recruiting",N/A,Stony Brook University,NA,https://clinicalzeros.gov/ct2/show/NCT04634903,0,0,0,0,2,1,United States,0,supportive therapy ssi|behavioral activation ssi|growth mindset ssi,NA
NCT04634799,2021-01-08,2021-11-30,Interventional,Study To antagOnize Plasminogen Activator Inhibitor-1 in Severe COVID-19,Recruiting,Phase 1/Phase 2,Northwestern University,NA,https://clinicalzeros.gov/ct2/show/NCT04634799,0,0,0,0,2,1,United States,0,tm5614|placebo,NA
NCT04634422,2020-11-16,2021-06-30,Interventional,Plasma Exchange (PLEX) and Convalescent Plasma (CCP) in COVID-19 Patients With Multiorgan Failure,Recruiting,N/A,"Rigshospitalet, Denmark",NA,https://clinicalzeros.gov/ct2/show/NCT04634422,0,0,0,0,1,0,Denmark,0,plasma exchange/convalescent plasma|plasma|convalescent plasma,NA
NCT04634318,2020-12-10,2021-12-31,Interventional,Organization of Pulmonary Rehabilitation of Post-COVID-19 Patient With Sequelae (REHABCOVID),Recruiting,N/A,Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer,NA,https://clinicalzeros.gov/ct2/show/NCT04634318,0,0,0,0,4,0,France,0,respiratory rehabilitation program (rr).|respiratory tele-rehabilitation program (trr).,NA
NCT04633941,2020-06-01,2020-07-30,Observational,Impact of Social Distancing on Bariatric Versus Non-Surgical Obese Patients During COVID-19 Pandemic,Completed,NA,Singapore General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04633941,0,0,0,0,1,0,Singapore,0,standard care,NA
NCT04633772,2020-08-05,2021-02-01,Interventional,Use of Angiotensin-(1-7) in COVID-19,Recruiting,Phase 1/Phase 2,Erasme University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04633772,0,0,0,0,1,0,Brazil,0,angiotensin-(1-7)|placebo,NA
NCT04632732,2020-10-26,2021-10-07,Observational [Patient Registry],Apelin; ACE2 and Biomarkers of Alveolar-capillary Permeability in SARS-cov-2 (COVID-19).,Recruiting,NA,Centre de recherche du Centre hospitalier universitaire de Sherbrooke,NA,https://clinicalzeros.gov/ct2/show/NCT04632732,0,0,0,0,1,0,Canada,0,covid-19 test|blood sample,NA
NCT04632719,2020-11-08,2020-12-29,Interventional,The MentalPlusÂ® for Assessment and Rehabilitation of Cognitive Function After Remission of the Symptoms of COVID-19,Recruiting,N/A,University of Sao Paulo,NA,https://clinicalzeros.gov/ct2/show/NCT04632719,0,0,0,0,0,0,Brazil,0,the use of the mentalplusâ® digital game for assessment/rehabilitation of cognitive function after remission of the symptoms of covid-19|the use of the mentalplusâ® digital game for assessment|rehabilitation of cognitive function after remission of the symptoms of covid-19,NA
NCT04632706,2020-09-22,2021-02-28,Interventional,Exploratory Ph I Trial of the Active IMP in Healthy Volunteers in Relation to COVID-19,Recruiting,Early Phase 1,MedinCell S.A,NA,https://clinicalzeros.gov/ct2/show/NCT04632706,0,0,0,0,0,0,United Kingdom,0,ivermectin|placebo,NA
NCT04632602,2020-04-04,2020-12-31,Interventional,Awake Prone Position to Reduce Ventilation Inhomogeneity in COVID-19 Acute Respiratory Failure,Recruiting,N/A,Assistance Publique Hopitaux De Marseille,NA,https://clinicalzeros.gov/ct2/show/NCT04632602,0,0,0,0,0,0,France,0,physiological effects of awake prone position in covid 19 patients,NA
NCT04632368,2020-11-20,2021-04-30,Interventional,Targeting the Health Care Provider (HCP) Burnout Crisis During the COVID-19 Pandemic,Recruiting,N/A,Duke University,NA,https://clinicalzeros.gov/ct2/show/NCT04632368,0,0,0,0,1,1,United States,0,transcendental meditation,NA
NCT04632082,2020-11-05,2021-07-13,Interventional,Telepsychoeducation for the Prevention of Emotional Distress in Professionals and Students From Essential Services in the Context of COVID-19,Enrolling by invitation,N/A,Hospital de Clinicas de Porto Alegre,NA,https://clinicalzeros.gov/ct2/show/NCT04632082,0,0,0,0,1,0,Brazil,0,telepsychoeducation with personalized videos|telepsychoeducation without personalized videos,NA
NCT04631380,2020-08-01,2021-01-31,Interventional,Prayer in Commbate to Corona Virus - Covid -19,Recruiting,N/A,Hospital do Coracao,NA,https://clinicalzeros.gov/ct2/show/NCT04631380,0,0,0,0,0,0,Brazil,0,prayer,NA
NCT04631172,2020-05-01,2020-09-30,Observational [Patient Registry],Covid-19 Anxiety and Phobia Levels of the Parents,Completed,NA,Selcuk University,NA,https://clinicalzeros.gov/ct2/show/NCT04631172,0,0,0,0,1,0,Turkey,0,"coronavirus anxiety scale , covid-19 phobia scale",NA
NCT04630054,2020-11-15,2021-02-15,Interventional,Face Masks to Reduce COVID-19 in Bangladesh,Recruiting,N/A,Yale University,NA,https://clinicalzeros.gov/ct2/show/NCT04630054,0,0,0,0,1,0,Bangladesh,0,face mask|face mask awareness,NA
NCT04630015,2020-08-31,2023-08-01,Observational,Expanded Evaluation of the Survivorship Wellness Group Program in the Context of COVID-19 and Telehealth,Recruiting,NA,"University of California, San Francisco",NA,https://clinicalzeros.gov/ct2/show/NCT04630015,0,0,0,0,1,1,United States,0,questionnaire,NA
NCT04629638,2020-08-01,2020-11-15,Observational,Maternal Attachment and Depression Anxiety Score Evaluation in COVID-19 Positive Pregnant Women,Completed,NA,Kanuni Sultan Suleyman Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04629638,0,0,0,0,3,0,Turkey,0,"maternal attachment, edinburgh depression scoring/postpartum anxiety scale scores|maternal attachment, edinburgh depression scoring|postpartum anxiety scale scores",NA
NCT04629222,2020-03-11,2020-07-20,Observational,Tracheobronchitis in Respiratory Involvement on the Lung SPECT/CT Images of COVID-19 Patients,Completed,NA,"Central Hospital, Nancy, France",NA,https://clinicalzeros.gov/ct2/show/NCT04629222,0,0,0,0,0,0,France,0,"NA",NA
NCT04629157,2020-11-05,2020-11-19,Interventional,The LAVA (Lateral Flow Antigen Validation and Applicability) Study for COVID-19,Recruiting,N/A,Alder Hey Children's NHS Foundation Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04629157,0,0,0,0,0,0,United Kingdom,0,innova lateral flow device,NA
NCT04629105,2020-07-24,2021-08-31,Interventional,Regenerative Medicine for COVID-19 and Flu-Elicited ARDS Using Longeveron Mesenchymal Stem Cells (LMSCs) (RECOVER),Recruiting,Phase 1,Longeveron LLC,NA,https://clinicalzeros.gov/ct2/show/NCT04629105,0,0,0,0,0,1,United States,0,longeveron mesenchymal stem cells (lmscs)|placebo,NA
NCT04628637,2020-04-16,2020-10-01,Observational,High GRP78 Levels in Covid-19 Infection: A Case-Control Study,Completed,NA,Kafkas University,NA,https://clinicalzeros.gov/ct2/show/NCT04628637,0,0,0,0,0,0,Turkey,0,serum protein level analysis,NA
NCT04628208,2020-11-17,2021-01-31,Observational,Clinical Study Spartan COVID-19 V2 System (Canada Alternate),Recruiting,NA,Spartan Bioscience Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04628208,0,0,0,0,2,0,Canada,0,spartan covid-19 v2 system,NA
NCT04628195,2020-04-01,2020-06-30,Observational,Cardiac Performance in Mechanically Ventilated COVID-19 Patients,Completed,NA,Pontificia Universidad Catolica de Chile,NA,https://clinicalzeros.gov/ct2/show/NCT04628195,0,0,0,0,0,0,Chile,0,"NA",NA
NCT04627623,2020-06-22,2021-03-22,Observational,Prevalence and Risk Factors of COVID-19 in the Upper Silesian Agglomeration,Recruiting,NA,Medical University of Silesia,NA,https://clinicalzeros.gov/ct2/show/NCT04627623,0,0,0,0,1,0,Poland,0,igm/igg antibodies assay|igm|igg antibodies assay,NA
NCT04628000,2020-10-27,2021-10-14,Observational,Baseline Vitamin D Deficiency and COVID-19 Disease Severity,Recruiting,NA,Parkview Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04628000,0,0,0,0,1,1,United States,0,vitamin d,NA
NCT04627194,2020-02-20,2020-04-30,Observational,Characteristics of COVID-19 Patients in Kazakhstan in Early 2020,"Active, not recruiting",NA,Semey State Medical University,NA,https://clinicalzeros.gov/ct2/show/NCT04627194,0,0,0,0,0,0,Kazakhstan,0,"NA",NA
NCT04624997,2020-06-08,2020-12-31,Observational,Coagulopathy and Vasculopathy Assessment as a Predictor of the Severity of SARS-CoV-2 / COVID-19 Infection,Recruiting,NA,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04624997,0,0,0,0,0,0,France,0,biological samples,NA
NCT04626076,2020-08-13,2021-06-30,Observational [Patient Registry],International Registry of Healthcare Workers Exposed to COVID-19 Patients,Recruiting,NA,Certara,NA,https://clinicalzeros.gov/ct2/show/NCT04626076,0,0,0,0,0,0,Pakistan,0,comparative observational cohort study,NA
NCT04625296,2020-09-17,2021-01-31,Observational,Behaviour and Experience of Communities Healthcare Professionals Facing the SARS CoV-2 (COVID-19) Epidemic,Recruiting,NA,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04625296,0,0,0,0,0,0,France,0,semi-directive interview|questionnaire : preparedness for caregiving scale,NA
NCT04625114,2020-11-04,2022-10-01,Interventional,The Potential of Oral Camostat in Early COVID-19 Disease in an Ambulatory Setting to Reduce Viral Load and Disease Burden,Recruiting,Phase 2,"University Hospital, Ghent",NA,https://clinicalzeros.gov/ct2/show/NCT04625114,0,0,0,0,0,0,Belgium,0,camostat|placebo,NA
NCT04625075,2020-06-10,2021-06-10,Observational,Manganese-Enhanced Magnetic Resonance Imaging of MyOcardial injuRY in COVID 19 (COVID-19),Recruiting,NA,University of Edinburgh,NA,https://clinicalzeros.gov/ct2/show/NCT04625075,0,0,0,0,0,0,United Kingdom,0,cardiac mri|cardiac ct|electrocardiogram (ecg)|blood sample,NA
NCT04624503,2020-10-01,2021-06-01,Observational,Prognostic and Clinical Impact of Cardiovascular Involvement in Patients With COVID-19,Recruiting,NA,"Humanitas Hospital, Italy",NA,https://clinicalzeros.gov/ct2/show/NCT04624503,0,0,0,0,0,0,Italy,0,"NA",NA
NCT04623346,2020-03-11,2020-11-01,Observational,Orthopaedic Conservative Treatment in the Time of Covid-19 Pandemic,"Active, not recruiting",NA,Prof. Dr. Cemil TascÄ±oglu Education and Research Hospital Organization,NA,https://clinicalzeros.gov/ct2/show/NCT04623346,0,0,0,0,1,0,Turkey,0,observation for study group,NA
NCT04623255,2020-10-16,2021-10-15,Interventional,Randomised Study of Plasma Exchange in Severe COVID-19,Recruiting,Phase 2,"University College, London",NA,https://clinicalzeros.gov/ct2/show/NCT04623255,0,0,0,0,0,0,United Kingdom,0,octaplas,NA
NCT04623177,2020-03-01,2020-09-30,Observational,Thromboprophylaxis for Patients in ICU With COVID-19,"Active, not recruiting",NA,Instituto de Investigacion Sanitaria La Fe,NA,https://clinicalzeros.gov/ct2/show/NCT04623177,0,0,0,0,0,0,Spain,0,"NA",NA
NCT04622891,2020-04-01,2020-07-30,Interventional,Clarithromycin Versus Azithromycin in Treatment of Mild COVID-19 Infection,Completed,N/A,South Valley University,NA,https://clinicalzeros.gov/ct2/show/NCT04622891,0,0,0,0,0,0,Egypt,0,clarithromycin 500mg|azithromycin|placebo,NA
NCT04622865,2020-06-01,2021-06-30,Interventional,Masitinib Combined With Isoquercetin and Best Supportive Care in Hospitalized Patients With Moderate and Severe COVID-19,Recruiting,Phase 2,AB Science,NA,https://clinicalzeros.gov/ct2/show/NCT04622865,0,0,0,0,0,0,France,0,masitinib|isoquercetin|best supportive care,NA
NCT04622826,2020-05-15,2020-12-31,Interventional,plasmApuane CoV-2 : Efficacy and Safety of Immune Covid-19 Plasma in Covid-19 Pneumonia in Non ITU Patients,Recruiting,Phase 2,Azienda USL Toscana Nord Ovest,NA,https://clinicalzeros.gov/ct2/show/NCT04622826,0,0,0,0,0,0,Italy,0,immune plasma,NA
NCT04621214,2020-03-21,2020-04-28,Observational,Innovation of Audio-Visual Triage System in Combating the Spread of COVID-19 Infection and Its Efficacy: A Novel Strategy,Completed,NA,University of Lahore,NA,https://clinicalzeros.gov/ct2/show/NCT04621214,0,0,0,0,0,0,Pakistan,0,audio-visual triage system (avt),NA
NCT04622748,2020-07-10,2020-12-10,Observational,Neurocognitive Functions of Recovered COVID-19 Patients,Recruiting,NA,"National Institute on Drug Dependence, China",NA,https://clinicalzeros.gov/ct2/show/NCT04622748,0,0,0,0,0,0,China,0,trier social stress test,NA
NCT04621903,2020-10-08,2020-10-27,Interventional,A Pilot Study on Efficacy and Safety of Ayurveda Combination in Patients With Mild-to-Moderate COVID-19,Completed,N/A,Aarogyam UK,NA,https://clinicalzeros.gov/ct2/show/NCT04621903,0,0,0,0,1,0,United Kingdom,0,shanshamani vati plus,NA
NCT04621058,2020-11-09,2021-11-30,Interventional,Efficacy of Vitamin D Treatment in Mortality Reduction Due to COVID-19.,Recruiting,Phase 3,Bioaraba Health Research Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04621058,0,0,0,0,2,0,Spain,0,vitamin d|placebo,NA
NCT04621149,2020-11-15,2021-03-31,Interventional,An Outpatient Study Investigating Non-prescription Treatments for COVID-19,Recruiting,Phase 2,"Profact, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04621149,0,0,0,0,3,1,United States,0,"chlorine dioxide|zinc acetate|famotidine|placebo|lactoferrin, green tea extract",NA
NCT04621084,2020-04-01,2025-12-31,Observational,Influence of the COVId-19 Pandemic on STRESS and Eating Habits,Recruiting,NA,"University Hospital, Clermont-Ferrand",NA,https://clinicalzeros.gov/ct2/show/NCT04621084,0,0,0,0,0,0,France,0,eating habits,NA
NCT04619693,2020-11-18,2021-09-18,Observational,Biomarkers for Dexamethasone Response in Sars-Cov-2 / COVID-19 Pneumonia,Recruiting,NA,"University Hospital, Montpellier",NA,https://clinicalzeros.gov/ct2/show/NCT04619693,0,0,0,0,3,0,France,0,"NA",NA
NCT04620798,2020-09-14,2020-12-31,Interventional,Longitudinal COVID-19 Antibody Testing in Indiana University Undergraduate Students,"Active, not recruiting",N/A,Indiana University,NA,https://clinicalzeros.gov/ct2/show/NCT04620798,0,0,0,0,0,1,United States,0,immediate vs. delayed provision of antibody test results,NA
NCT04619368,2020-07-27,2022-07-31,Observational [Patient Registry],Post-intensive Care Follow-up of Patients Hospitalized for an Acute Respiratory Distress Syndrome Caused by COVID-19,Recruiting,NA,"University Hospital, Toulouse",NA,https://clinicalzeros.gov/ct2/show/NCT04619368,0,0,0,0,0,0,France,0,follow up calls,NA
NCT04619290,2020-10-12,2020-11-30,Interventional,Outpatient Treatment With CoVid-19 With Prexablu,Recruiting,Phase 1,Hospital Reg. Lic. Adolfo Lopez Mateos,NA,https://clinicalzeros.gov/ct2/show/NCT04619290,0,0,0,0,1,0,Mexico,0,sublingual methylene blue|control patients,NA
NCT04618341,2020-03-30,2020-06-30,Observational,A Clinical Study of Online Active Play Program With Adolescents,Completed,NA,Revival Active,NA,https://clinicalzeros.gov/ct2/show/NCT04618341,0,0,0,0,0,0,United Kingdom,0,"NA",NA
NCT04618042,2020-11-13,2021-07-31,Interventional,FX06 to Rescue Acute Respiratory Distress Syndrome During Covid-19 Pneumonia,Recruiting,Phase 2,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04618042,0,0,0,0,1,0,France,0,fx06|placebo of fx06,NA
NCT04617483,2020-10-31,2020-11-28,Interventional,"Study of the Commercial Scale SARS-CoV-2 Vaccine Against the Pilot Scale Among Adults, and Bridging Study of the Immunogenicity in Elderly Against That in Adults",Recruiting,Phase 3,"Sinovac Biotech Co., Ltd",NA,https://clinicalzeros.gov/ct2/show/NCT04617483,0,0,0,1,0,0,China,0,"two doses of commercial scale inactivated sars-cov-2 vaccine at the schedule of day 0,14|two doses of pilot scale inactivated sars-cov-2 vaccine at the schedule of day 0,14|two doses of pilot scale inactivated sars-cov-2 vaccine at the schedule of day 0,14 in elderly",NA
NCT04619576,2020-06-01,2025-12-21,Observational,Influence of the COVId-19 Pandemic on STRESS of Occupational Health Workers,Recruiting,NA,"University Hospital, Clermont-Ferrand",NA,https://clinicalzeros.gov/ct2/show/NCT04619576,0,0,0,0,0,0,France,0,occupational health workers,NA
NCT04618861,2020-10-13,2020-11-02,Observational,Surfactant Protein D Levels in Covid-19 Infection: Case-Control Study,Completed,NA,Kafkas University,NA,https://clinicalzeros.gov/ct2/show/NCT04618861,0,0,0,0,0,0,Turkey,0,"NA",NA
NCT04616846,2020-08-04,2021-09-15,Interventional,Thromboembolic Risk Screening in Patients With Cancer and COVID-19,Recruiting,N/A,Centre Antoine Lacassagne,NA,https://clinicalzeros.gov/ct2/show/NCT04616846,0,0,0,0,0,0,France|Monaco,0,peripheral venous ultrasound,NA
NCT04616976,2020-01-01,2020-02-29,Observational,COVID-19 With Convalescent Plasma,Completed,NA,"Southeast University, China",NA,https://clinicalzeros.gov/ct2/show/NCT04616976,0,0,0,0,0,0,China,0,convalescent plasma,NA
NCT04615975,2020-11-01,2021-07-30,Interventional,Ketogenic Diet as Protective Factor During COVID-19,Recruiting,N/A,University of Padova,NA,https://clinicalzeros.gov/ct2/show/NCT04615975,0,0,0,0,0,0,Italy,0,ketogenic diet with phytoextracts,NA
NCT04615936,2020-07-10,2021-05-31,Interventional,Nasal Photodisinfection COVID Proof of Concept Study,Recruiting,N/A,Sunnybrook Health Sciences Centre,NA,https://clinicalzeros.gov/ct2/show/NCT04615936,0,0,0,0,0,0,Canada,0,methylene-blue photodisinfection,NA
NCT04615728,2019-11-01,2020-07-05,Observational,MANAGEMENT OF APPENDICITIS DURING THE COVID-19 PANDEMIC,Completed,NA,Cambridge University Hospitals NHS Foundation Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04615728,0,0,0,0,0,0,United Kingdom,0,laparoscopic/open appendicectomy|laparoscopic|open appendicectomy,NA
NCT04615195,2020-06-10,2020-07-02,Observational,Effect of COVID19-related COntainment in ChildreN,Recruiting,NA,"University Hospital, Toulouse",NA,https://clinicalzeros.gov/ct2/show/NCT04615195,0,0,0,0,0,0,France,0,cries 13 questionnaire,NA
NCT04615676,2020-04-27,2020-07-17,Observational [Patient Registry],Prospective Evaluation of the Predictive Criteria of Severity for Respiratory Infection Due to COVID-19 Virus,Completed,NA,"University Hospital, Toulouse",NA,https://clinicalzeros.gov/ct2/show/NCT04615676,0,0,0,0,1,0,France,0,follow-up phone call,NA
NCT04615416,2020-05-01,2021-01-31,Interventional,Emotion Regulation Training Via Telehealth During the COVID-19 Pandemic,Recruiting,N/A,"Teachers College, Columbia University",NA,https://clinicalzeros.gov/ct2/show/NCT04615416,0,0,0,0,0,1,United States,0,emotion regulation training via telehealth,NA
NCT04615390,2020-03-30,2021-06-03,Observational,Recovery Profiles in Patients With SARS-CoV-2 Outcomes Undergoing Rehabilitation,Recruiting,NA,University Hospital of Ferrara,NA,https://clinicalzeros.gov/ct2/show/NCT04615390,0,0,0,0,0,0,Italy,0,early rehabilitation|subacute rehabilitation|mindfulness training|personalized ambulatory training,NA
NCT04615052,2020-09-26,2021-10-31,Interventional,Home-based Exercise in COVID-19 Survivors,Recruiting,N/A,University of Sao Paulo,NA,https://clinicalzeros.gov/ct2/show/NCT04615052,0,0,0,0,1,0,Brazil,0,exercise training,NA
NCT04615026,2020-11-04,2021-06-30,Observational [Patient Registry],Prevalence of Thrombosis in COVID-Patients,Recruiting,NA,University Hospital Augsburg,NA,https://clinicalzeros.gov/ct2/show/NCT04615026,0,0,0,0,0,0,Germany,0,duplex sonography,NA
NCT04615000,2020-10-29,2021-11-01,Observational [Patient Registry],SeroCovid<19: A Prospective Covid-19 Seroconversion Study in a Tertiary Pediatric Patient Cohort,Recruiting,NA,"University Hospital, Ghent",NA,https://clinicalzeros.gov/ct2/show/NCT04615000,0,0,0,0,0,0,Belgium,0,sars-cov-2 serological assessment (igg),NA
NCT04609501,2020-06-01,2023-06-30,Observational [Patient Registry],"Delivery During Covid-19 Pandemic: Implications for Obstetrics, Maternal Psychopathology, and Mother-Infant Relationship","Active, not recruiting",NA,Hillel Yaffe Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04609501,0,0,0,0,0,0,Israel,0,"NA",NA
NCT04614883,2020-10-21,2021-10-31,Interventional,Analysis of Volatile Organic Compounds in Exhaled Air and in Sweat in the Context of Suspicion of COVID-19 Infection,Recruiting,N/A,Hopital Foch,NA,https://clinicalzeros.gov/ct2/show/NCT04614883,0,0,0,0,0,0,France,0,volatile organic compounds analysis|canine odor detection of volatile organic compounds,NA
NCT04614025,2020-11-30,2021-05-31,Interventional,Open-label Multicenter Study to Evaluate the Efficacy of PLX-PAD for the Treatment of COVID-19,Recruiting,Phase 2,Pluristem Ltd.,NA,https://clinicalzeros.gov/ct2/show/NCT04614025,0,0,0,0,0,0,Germany|Israel,0,plx-pad,NA
NCT04614012,2020-07-02,2022-07-02,Interventional,Hyperimmune Plasma for Patients With COVID-19,Recruiting,N/A,A.O. Ospedale Papa Giovanni XXIII,NA,https://clinicalzeros.gov/ct2/show/NCT04614012,0,0,0,0,0,0,Italy,0,treated with hyperimmune plasma,NA
NCT04613310,2020-09-25,2020-12-31,Interventional,PCR and Rapid Diagnostic Test on Saliva and Nasopharyngeal Swabs for the Detection of SARS-CoV-2 (COVID-19),Recruiting,N/A,"Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland",NA,https://clinicalzeros.gov/ct2/show/NCT04613310,0,0,0,0,1,0,Switzerland,0,rapid diagnostic test vs pcr,NA
NCT04613297,2020-10-19,2021-10-31,Interventional,HLA-G Immuno-Inhibitor Checkpoint Study in Patients With COVID-19 Infection: Molecular and Cellular Assessment,Recruiting,N/A,Hopital Foch,NA,https://clinicalzeros.gov/ct2/show/NCT04613297,0,0,0,0,0,0,France,0,baseline/during hospitalization blood samples|baseline blood sample|baseline|during hospitalization blood samples,NA
NCT04613245,2020-05-01,2021-01-30,Observational [Patient Registry],Health-Related Quality of Life of Patients With Asthma During the Pandemic of COVID-19,Recruiting,NA,Cairo University,NA,https://clinicalzeros.gov/ct2/show/NCT04613245,0,0,0,0,1,0,Egypt,0,"NA",NA
NCT04475575,2020-04-06,2020-06-30,Interventional,Can the Electronic Nose Smell COVID-19 Antibodies?,Completed,N/A,Maastricht University Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04475575,0,0,0,0,0,0,Netherlands,0,aeonose,NA
NCT04611256,2020-08-01,2020-11-30,Interventional,Mesenchymal Stem Cells in Patients Diagnosed With COVID-19,Recruiting,Phase 1,Hospital Reg. Lic. Adolfo Lopez Mateos,NA,https://clinicalzeros.gov/ct2/show/NCT04611256,0,0,0,0,1,0,Mexico,0,msc|control,NA
NCT04610801,2020-08-08,2021-08-08,Interventional,Evaluation of the Efficacy of Xylitol Nasal Spray Against SARS-CoV-2,Recruiting,Phase 3,Larkin Community Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04610801,0,0,0,0,1,1,United States,0,nasal rinse,NA
NCT04609969,2020-10-13,2020-10-17,Interventional,Diagnostic Performance Evaluation of a Novel SARS-CoV-2 (COVID-19) Antigen Detection Test,Completed,N/A,Centre Hospitalier RÃ©gional d'OrlÃ©ans,NA,https://clinicalzeros.gov/ct2/show/NCT04609969,0,0,0,0,3,0,France,0,rt-qpcr test|covid-viroâ® test|covid-viroâ® test,NA
NCT04609839,2020-10-27,2023-04-27,Observational,FOLLOW-UP OF PATIENTS WITH COVID-19.,Recruiting,NA,"University Hospital, Strasbourg, France",NA,https://clinicalzeros.gov/ct2/show/NCT04609839,0,0,0,0,0,0,France,0,follow-up of patients with covid-19,NA
NCT04609722,2020-07-01,2021-02-01,Interventional,Effect of Solution-Focused Support Program on Anxiety Levels of Parents During the COVID-19 Pandemic,Recruiting,N/A,Adiyaman University Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04609722,0,0,0,0,2,0,Turkey,0,solution-focused support program,NA
NCT04609423,2020-11-10,2021-05-31,Interventional,Cod Liver Oil for Covid-19 Prevention Study,Recruiting,Phase 4,Oslo University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04609423,0,0,0,0,3,0,Norway,0,cod liver oil|corn oil (placebo),NA
NCT04609371,2020-10-21,2021-03-01,Interventional,PanDirect: Self-care Tools and Telephone Coaching for Depression and Anxiety During Pandemics,Enrolling by invitation,N/A,"St. Mary's Research Center, Canada",NA,https://clinicalzeros.gov/ct2/show/NCT04609371,0,0,0,0,1,0,Canada,0,self-care tools|lay telephone coaching,NA
NCT04609332,2020-11-10,2021-08-31,Observational [Patient Registry],Endothelial Damage and Angiogenesis Biomarkers During COVID-19,Recruiting,NA,University of Chile,NA,https://clinicalzeros.gov/ct2/show/NCT04609332,0,0,0,0,2,0,Chile,0,endothelial damage/angiogenic biomarkers|endothelial damage|angiogenic biomarkers,NA
NCT04613050,2020-07-02,2021-12-24,Interventional,Effect of Respiratory Versus Aerobic Training on Respiratory and Immunity Efficiency in Recovered COVID- 19 Patients,Recruiting,N/A,Cairo University,NA,https://clinicalzeros.gov/ct2/show/NCT04613050,0,0,0,0,1,0,Egypt,0,respiratory training|aerobic training,NA
NCT04611841,2020-07-21,2022-12-31,Observational,Medical-biological Research of the Pathogenesis of COVID-19 Disease Caused by SARS-CoV-2,Enrolling by invitation,NA,Federal Research and Clinical Center of Physical-Chemical Medicine,NA,https://clinicalzeros.gov/ct2/show/NCT04611841,0,0,0,0,0,0,Russian Federation,0,"NA",NA
NCT04611243,2020-05-22,2022-05-21,Observational,"Lung Function, Exercise Capacity, and Serology Responses in Patients With COVID-19",Recruiting,NA,Chinese University of Hong Kong,NA,https://clinicalzeros.gov/ct2/show/NCT04611243,0,0,0,0,0,0,Hong Kong,0,kaletra/beta interferon|kaletra|beta interferon,NA
NCT04611230,2020-11-05,2021-09-24,Observational,"A Study to Assess Infection Rate of Severe Acute Respiratory Syndrome - CoronaVirus 2 (SARS-CoV-2) and It's Affect on Quality of Life in Adult Volunteers in Lake County, Illinois",Recruiting,NA,AbbVie,NA,https://clinicalzeros.gov/ct2/show/NCT04611230,0,0,0,0,1,1,United States,0,"NA",NA
NCT04610567,2020-10-27,2021-03-15,Interventional,Treatment of Patients With Mild Coronavirus-19 (COVID-19) Disease With Methotrexate Associated to LDL Like Nanoparticles (Nano-COVID19),Recruiting,Phase 1/Phase 2,University of Sao Paulo General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04610567,0,0,0,0,2,0,Brazil,0,methotrexate-lde phase 1|methotrexate-lde phase 2|placebo-lde phase 2,NA
NCT04610541,2020-10-12,2021-10-30,Interventional,REMdesivir-HU Clinical Study and Severe Covid-19 Patients,"Active, not recruiting",Phase 3,University of Pecs,NA,https://clinicalzeros.gov/ct2/show/NCT04610541,0,0,0,0,1,0,Hungary,0,remdesivir-hu,NA
NCT04607941,2020-10-27,2021-06-04,Observational,"Study of Socio-demographic Factors, Behaviors and Practices Associated With Infection With SARS-CoV-2 Responsible for COVID-19",Recruiting,NA,Institut Pasteur,NA,https://clinicalzeros.gov/ct2/show/NCT04607941,0,0,0,0,1,0,France,0,questionnaire|phone interviews,NA
NCT04608201,2020-12-09,2021-12-31,Interventional,Evaluation of the Efficacy of Nicotine Patches in SARS-CoV2 (COVID-19) Infection in Hospitalized Patients,Recruiting,Phase 3,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04608201,0,0,0,0,2,0,France,0,nicotine 7 mg/ 24h transdermal patch - 24 hour|placebo of nicotine transdermal patch|nicotine 7 mg|24h transdermal patch - 24 hour,NA
NCT04607928,2020-08-01,2021-08-01,Interventional,Pirfenidone Compared to Placebo in Post-COVID19 Pulmonary Fibrosis COVID-19,Recruiting,Phase 2,Institut d'InvestigaciÃ³ BiomÃ¨dica de Bellvitge,NA,https://clinicalzeros.gov/ct2/show/NCT04607928,0,0,0,0,2,0,Spain,0,pirfenidone|placebo,NA
NCT04606563,2020-10-09,2021-06-30,Interventional,Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan on Outcomes of Coronavirus Infection?,Recruiting,Phase 3,University of British Columbia,NA,https://clinicalzeros.gov/ct2/show/NCT04606563,0,0,0,0,0,1,United States|Belgium|Canada|France|Japan|Spain,0,losartan,NA
NCT04605952,2020-07-01,2020-08-30,Observational,Study to Find the Percentage of Cases Retaining COVID-19 IgG Antibodies 45-65 After They Have Tested Positive,Completed,NA,Tata Main Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04605952,0,0,0,0,0,0,India,0,repeat sars-cov-2 igg antibodies at 45-65 days,NA
NCT04605887,2021-01-18,2023-11-30,Interventional,Angiotensin 1-7 as a Therapy in the Treatment of COVID-19,Recruiting,Phase 2,Rambam Health Care Campus,NA,https://clinicalzeros.gov/ct2/show/NCT04605887,0,0,0,0,2,0,Israel,0,angiotensin,NA
NCT04605757,2020-07-30,2021-04-30,Observational,Long-term Evolution of Pulmonary Involvement of Novel SARS-COV-2 Infection (COVID-19): Follow the Covid Study,Recruiting,NA,Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi,NA,https://clinicalzeros.gov/ct2/show/NCT04605757,0,0,0,0,1,0,Italy,0,"clinical, functional/radiological lung involvement evolution|clinical, functional|radiological lung involvement evolution",NA
NCT04605965,2020-06-09,2022-06-30,Observational [Patient Registry],WEAICOR: Wearables to Investigate the Long Term Cardiovascular and Behavioral Impacts of COVID-19,Recruiting,NA,Tulane University,NA,https://clinicalzeros.gov/ct2/show/NCT04605965,0,0,0,0,1,1,United States,0,"NA",NA
NCT04475562,2020-04-06,2020-05-06,Interventional,Can the Electronic Nose Smell COVID-19?,Completed,N/A,Maastricht University Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04475562,0,0,0,0,0,0,Netherlands,0,aeonose,NA
NCT04605588,2020-12-02,2021-04-30,Interventional,A Triple Combination Antiviral Coronavirus Therapy (TriACT) for COVID-19,Recruiting,Phase 2,"Rutgers, The State University of New Jersey",NA,https://clinicalzeros.gov/ct2/show/NCT04605588,0,0,0,0,3,1,United States,0,nitazoxanide|placebo nitazoxanide|ribavirin|placebo ribavirin|hydroxychloroquine|placebo hydroxychloroquine,NA
NCT04605172,2020-11-02,2021-04-30,Observational,Lockdown Impact on Spontaneous Premature Birth in a Level III NICU,Enrolling by invitation,NA,"Central Hospital, Nancy, France",NA,https://clinicalzeros.gov/ct2/show/NCT04605172,0,0,0,0,1,0,France,0,hospitalization for premature birth,NA
NCT04604327,2020-10-26,2021-05-31,Interventional,Comparison of Two Different Doses of Bemiparin in COVID-19,Recruiting,Phase 3,"Clinica Universidad de Navarra, Universidad de Navarra",NA,https://clinicalzeros.gov/ct2/show/NCT04604327,0,0,0,0,0,0,Spain,0,bemiparin sodium,NA
NCT04604977,2020-09-15,2021-10-31,Interventional,Feasibility and Effectiveness of Home-behavioral Program for Adolescents With Migraine,Recruiting,N/A,Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta,NA,https://clinicalzeros.gov/ct2/show/NCT04604977,0,0,0,0,0,0,Italy,0,mindfulness,NA
NCT04604769,2019-06-26,2020-09-01,Observational,Perceived Stress Among ICU Medical Staff During COVID-19 Crisis,Completed,NA,University of Liege,NA,https://clinicalzeros.gov/ct2/show/NCT04604769,0,0,0,0,0,0,Belgium,0,"NA",NA
NCT04604119,2020-05-01,2020-05-30,Observational [Patient Registry],Anxiety and Burnout in Anesthetists and Intensive Care Unit Nurses During Covid-19 Pandemic,Completed,NA,Sisli Hamidiye Etfal Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04604119,0,0,0,0,1,0,Turkey,0,"NA",NA
NCT04604080,2020-11-01,2020-11-18,Observational,Post-COVID-19 Epidemic Depression Assessment in Adults in South Punjab Pakistan,Completed,NA,Islamia University of Bahawalpur,NA,https://clinicalzeros.gov/ct2/show/NCT04604080,0,0,0,0,4,0,Pakistan,0,service of questionnaire,NA
NCT04602260,2020-06-09,2021-09-30,Observational,Functional Recovery of Hospitalised Patients With COVID-19: The COREG Extension Study,Recruiting,NA,McMaster University,NA,https://clinicalzeros.gov/ct2/show/NCT04602260,0,0,0,0,0,0,Canada,0,"NA",NA
NCT04603794,2020-10-01,2020-11-30,Interventional,Efficacy of Mouthwash in Reducing Salivary Carriage of COVID-19,Recruiting,Phase 4,Ohio State University,NA,https://clinicalzeros.gov/ct2/show/NCT04603794,0,0,0,0,0,1,United States,0,0.12% chlorhexidine gluconate mouth rinse|0.5% povidone iodine|1% hydrogen peroxide|0.9% normal saline,NA
NCT04603729,2020-05-30,2020-06-30,Interventional,Comparison of Efficacy of Dexamethasone and Methylprednisolone in Moderate to Severe Covid 19 Disease,Completed,Phase 3,Fatima Memorial Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04603729,0,0,0,0,0,0,Pakistan,0,dexamethasone 2 mg/ml|methylprednisolone injection|dexamethasone 2 mg|methylprednisolone,NA
NCT04603677,2020-07-08,2022-07-30,Observational,Northern Colorado COVID-19 Biobank,Enrolling by invitation,NA,Colorado State University,NA,https://clinicalzeros.gov/ct2/show/NCT04603677,0,0,0,0,0,1,United States,0,"NA",NA
NCT04602507,2020-12-07,2021-03-31,Interventional,Ivermectin in Adults With Severe COVID-19.,Recruiting,Phase 2,CES University,NA,https://clinicalzeros.gov/ct2/show/NCT04602507,0,0,0,0,1,0,Colombia,0,ivermectin|placebo,NA
NCT04602481,2020-05-31,2022-05-31,Observational,COVID-19 in People With Primary Ciliary Dyskinesia,Recruiting,NA,University of Bern,NA,https://clinicalzeros.gov/ct2/show/NCT04602481,0,0,0,0,0,0,Switzerland,0,"NA",NA
NCT04602442,2020-10-01,2021-08-01,Interventional,Safety and Efficiency of Method of Exosome Inhalation in COVID-19 Associated Pneumonia,Enrolling by invitation,Phase 2,"State-Financed Health Facility ""Samara Regional Medical Center Dinasty""",NA,https://clinicalzeros.gov/ct2/show/NCT04602442,0,0,0,0,0,0,Russian Federation,0,exo 1 inhalation|exo 2 inhalation|placebo,NA
NCT04603963,2020-06-01,2020-10-10,Interventional,Inspiratory Muscle Training in Patients With COVID-19,Terminated,N/A,Hospital Israelita Albert Einstein,There was a change in the institutional flow reducing the cases of covid 19,https://clinicalzeros.gov/ct2/show/NCT04603963,0,0,0,0,1,0,Brazil,0,power breathe,NA
NCT04603664,2020-10-30,2021-02-28,Observational,Role of NGAL and Cystatin C in Prediction of Acute Kidney Injury Covid-19 Infection,Recruiting,NA,Ain Shams University,NA,https://clinicalzeros.gov/ct2/show/NCT04603664,0,0,0,0,1,0,Egypt,0,serum ngal/cystatin c|serum ngal|cystatin c,NA
NCT04602832,2020-10-14,2020-12-31,Interventional,Enduring Happiness and Continued Self-Enhancement (ENHANCE) for COVID-19,Enrolling by invitation,N/A,University of British Columbia,NA,https://clinicalzeros.gov/ct2/show/NCT04602832,0,0,0,0,1,0,Canada,0,enduring happiness/continued self-enhancement (enhance) for covid-19|enduring happiness|continued self-enhancement (enhance) for covid-19,NA
NCT04602637,2019-12-15,2020-12-15,Observational,Training Load Management in Three Professional Tennis Players During COVID-19 Lockdown: a Case Series Study,"Active, not recruiting",NA,Kine Kinesiologia Deportiva y Funcional,NA,https://clinicalzeros.gov/ct2/show/NCT04602637,0,0,0,0,0,0,Argentina,0,training load,NA
NCT04601090,2020-09-16,2022-09-30,Observational [Patient Registry],Survival Rates and Longterm Outcomes After COVID-19,Recruiting,NA,Oslo University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04601090,0,0,0,0,1,0,Norway,0,icu treatment,NA
NCT04602000,2020-09-25,2020-12-31,Interventional,To Evaluate the Safety and Efficacy of CT-P59 in Patients With Mild to Moderate Syptoms of Severe Acute Respiratory Syndrome COVID-19,Recruiting,Phase 2/Phase 3,Celltrion,NA,https://clinicalzeros.gov/ct2/show/NCT04602000,0,0,0,0,0,0,"Korea, Republic of",0,ct-p59/placebo|ct-p59|placebo,NA
NCT04601077,2020-11-01,2021-06-01,Interventional,The Evaluation of Nitric Oxide Generating Lozenges on Outcome in Newly Diagnosed COVID-19 Patient of African Americans,Recruiting,Phase 1/Phase 2,Nitric Oxide Innovations LLC,NA,https://clinicalzeros.gov/ct2/show/NCT04601077,0,0,0,0,1,1,United States,0,"nitric oxide lozenges, 30 mg|placebo",NA
NCT04601012,2020-09-20,2020-10-20,Observational,OCTA Study: Retinal Vascular Changes in Patients With SARS-CoV-2 Infection,Completed,NA,Federico II University,NA,https://clinicalzeros.gov/ct2/show/NCT04601012,0,0,0,0,2,0,Italy,0,optical coherence tomography angiography,NA
NCT04600999,2020-10-07,2021-06-30,Interventional,Clinical Trial of Favipiravir Treatment of Patients With COVID-19,Recruiting,Phase 3,University of Pecs,NA,https://clinicalzeros.gov/ct2/show/NCT04600999,0,0,0,0,0,0,Hungary,0,favipiravir,NA
NCT04600440,2020-04-25,2021-12-31,Interventional,Convalescent Plasma in the Treatment of Covid-19,Recruiting,N/A,Skane University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04600440,0,0,0,0,0,0,Sweden,0,convalescent plasma,NA
NCT04599998,2020-10-15,2021-02-15,Observational,Long-term Follow-up Findings of Inpatients for COVID-19 Pneumonia,Enrolling by invitation,NA,Koc University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04599998,0,0,0,0,0,0,Turkey,0,"spirometry, thoracic ct, cpet, 6 minute walking test, sf-36 questionnaire",NA
NCT04598347,2020-08-08,2022-01-08,Observational [Patient Registry],Evaluation of the Possible Vertical Transmission of SARS-CoV-2 Through Study of Amniotic Fluid and Chorionic Villi of Affected Pregnant Women for the COVID-19,Recruiting,NA,FundaciÃ³ Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau,NA,https://clinicalzeros.gov/ct2/show/NCT04598347,0,0,0,0,1,0,Spain,0,"NA",NA
NCT04599959,2020-10-26,2021-01-20,Interventional,COVID-19 Tests: Nasopharyngeal Swab vs Saliva Collected With SalivetteÂ® Cortisol for Viral RNA Sampling for RT-qPCR,Completed,N/A,Boehringer Ingelheim,NA,https://clinicalzeros.gov/ct2/show/NCT04599959,0,0,0,0,2,0,Mexico,0,sampling of sars-cov-2 rna from nasopharyngeal swab specimen/saliva collected via salivette cortisol|sampling of sars-cov-2 rna from nasopharyngeal swab specimen|saliva collected via salivette cortisol,NA
NCT04598620,2020-09-19,2021-10-01,Observational,Non-invasive Prognostication of COVID-19 Patients by Use of Biomarkers in Exhaled Breath Condensate,Recruiting,NA,Aalborg University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04598620,0,0,0,0,1,0,Denmark,0,"NA",NA
NCT04598256,2020-06-01,2020-08-31,Observational [Patient Registry],Endoscopic Procedures of Children in the Normalization Process of Covid-19 Pandemic,Completed,NA,Tepecik Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04598256,0,0,0,0,2,0,Turkey,0,endoscopic procedure,NA
NCT04596839,2020-09-04,2021-02-28,Interventional,Antiviral Activity and Safety of Remdesivir in Bangladeshi Patients With Severe Coronavirus Disease (COVID-19),Recruiting,N/A,Beximco Pharmaceuticals Ltd.,NA,https://clinicalzeros.gov/ct2/show/NCT04596839,0,0,0,0,3,0,Bangladesh,0,remdesivir|standard care,NA
NCT04597047,2020-08-20,2022-10-31,Interventional,Research & Evaluation of LumiraDx SARS-CoV-2 (COVID-19) Point of Care Ab Test,Recruiting,N/A,LumiraDx UK Limited,NA,https://clinicalzeros.gov/ct2/show/NCT04597047,0,0,0,0,0,1,United States,0,capillary collection/testing|venous draw/testing|capillary collection|testing|venous draw,NA
NCT04597034,2020-10-02,2021-12-30,Interventional,Efficacy and Safety of a Highly Selective Semipermeable Membrane (AN-69 Oxiris) vs (Standard AN-69) in COVID-19,Recruiting,N/A,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,NA,https://clinicalzeros.gov/ct2/show/NCT04597034,0,0,0,0,0,0,Mexico,0,an69-oxiris|an69-standard,NA
NCT04594668,2020-04-24,2021-04-24,Interventional,Senicapoc in COVID-19 Patients With Severe Respiratory Insufficiency,Recruiting,Phase 2,University of Aarhus,NA,https://clinicalzeros.gov/ct2/show/NCT04594668,0,0,0,0,0,0,Denmark,0,senicapoc,NA
NCT04595110,2020-03-25,2021-04-25,Observational,Hemostatic Profile in Patients Affected by COVID-19,Recruiting,NA,A.O. Ospedale Papa Giovanni XXIII,NA,https://clinicalzeros.gov/ct2/show/NCT04595110,0,0,0,0,0,0,Italy,0,observational,NA
NCT04596098,2020-04-30,2021-06-30,Observational,Immune Responses to COVID-19; Isolation of Neutralizing Antibodies for Therapeutics and Vaccine.,Recruiting,NA,"University Hospital, Grenoble",NA,https://clinicalzeros.gov/ct2/show/NCT04596098,0,0,0,0,1,0,France,0,blood sample,NA
NCT04596085,2020-09-16,2020-11-30,Interventional,"Study to Evaluate Efficacy and Safety of ""VIRACIDE"" IN THE MANAGEMENT OF CORONA VIRUS DISEASE 2019 (COVID-19)",Recruiting,N/A,"The Herb, Inc",NA,https://clinicalzeros.gov/ct2/show/NCT04596085,0,0,0,0,4,0,India,0,investigational product - viracide|placebo,NA
NCT04595240,2020-05-01,2020-10-15,Observational,Semen Analysis Changes in Covid-19 Positivepatients,Completed,NA,Assiut University,NA,https://clinicalzeros.gov/ct2/show/NCT04595240,0,0,0,0,0,0,Egypt,0,semen analysis,NA
NCT04594330,2020-06-01,2020-12-31,Interventional,Virgin Coconut Oil (VCO) as a Potential Adjuvant Therapy in COVID-19 Patients,Recruiting,Phase 2,Gadjah Mada University,NA,https://clinicalzeros.gov/ct2/show/NCT04594330,0,0,0,0,0,0,Indonesia,0,virgin coconut oil (vco)|placebo,NA
NCT04594291,2020-10-07,2023-09-30,Observational,MRI Changes of Acute Kidney Injury in COVID-19,Recruiting,NA,University Hospitals of Derby and Burton NHS Foundation Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04594291,0,0,0,0,0,0,United Kingdom,0,mri scans,NA
NCT04593641,2020-09-04,2020-10-22,Interventional,"This is a Phase 1 Study to Evaluate the Safety,Tolerability and Virology of CT P59 in Patients With Mild Symptoms of Symptoms of Coronavirus Disease (COVID-19)","Active, not recruiting",Phase 1,Celltrion,NA,https://clinicalzeros.gov/ct2/show/NCT04593641,0,0,0,0,0,0,"Korea, Republic of",0,ct-p59,NA
NCT04593069,2020-10-07,2021-02-28,Interventional,The COGCOV Study in ICU Patients,Recruiting,N/A,Ziekenhuis Oost-Limburg,NA,https://clinicalzeros.gov/ct2/show/NCT04593069,0,0,0,0,1,0,Belgium,0,neurocognitive assessment,NA
NCT04592549,2020-12-04,2021-09-30,Interventional,"This is a Phase 1 Clinical Trial to Evaluate the Safety, Pharmacokinetics, and Immunogenicity of ADM03820, a Monoclonal Antibody Cocktail Being Tested for the Treatment and Prevention of COVID-19",Recruiting,Phase 1,Ology Bioservices,NA,https://clinicalzeros.gov/ct2/show/NCT04592549,0,0,0,0,2,1,United States,0,adm03820|placebo,NA
NCT04591600,2020-07-01,2020-09-30,Interventional,Effectiveness of Ivermectin and Doxycycline on COVID-19 Patients,Completed,Phase 1/Phase 2,Alkarkh Health Directorate-Baghdad,NA,https://clinicalzeros.gov/ct2/show/NCT04591600,0,0,0,0,0,0,Iraq,0,ivermectin/doxycyline|standard care|ivermectin|doxycyline,NA
NCT04593654,2020-03-01,2020-08-15,Observational,Dosing of Thromboprophylaxis and Mortality in Critically Ill COVID-19 Patients,Completed,NA,Karolinska Institutet,NA,https://clinicalzeros.gov/ct2/show/NCT04593654,0,0,0,0,0,0,Sweden,0,tinzaparin/dalteparin|tinzaparin|dalteparin,NA
NCT04592354,2020-10-15,2021-04-15,Interventional,Anhydrous Enol-Oxaloacetate (AEO) on Improving Fatigue in Post-COVID-19 Survivors,Recruiting,N/A,Terra Biological LLC,NA,https://clinicalzeros.gov/ct2/show/NCT04592354,0,0,0,0,0,1,United States,0,oxaloacetate medical food/dietary supplement|oxaloacetate medical food|dietary supplement,NA
NCT04591158,2020-09-15,2021-09-30,Interventional,COVID-19 and Lung Ultrasound Utility,Recruiting,N/A,Bridge to Health Medical and Dental USA,NA,https://clinicalzeros.gov/ct2/show/NCT04591158,0,0,0,0,0,0,Canada,0,butterfly iq,NA
NCT04590053,2020-10-20,2021-02-28,Interventional,"Allocetra-OTS in COVID-19, Phase II",Recruiting,Phase 2,Hadassah Medical Organization,NA,https://clinicalzeros.gov/ct2/show/NCT04590053,0,0,0,0,2,0,Israel,0,allocetra-ots,NA
NCT04590170,2020-10-30,2022-10-30,Observational,French Cohort of COVID-19 Patients With Post-intensive Care Syndrome,Recruiting,NA,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04590170,0,0,0,0,1,0,France,0,post-intensive care unit syndrome,NA
NCT04588909,2020-03-23,2020-09-22,Observational,Outcomes of Elective Colorectal Cancer Surgery During COVID 19 Pandemic: Implications for Cancer Care Policy,"Active, not recruiting",NA,Sheri Kashmir Institute of Medical Sciences,NA,https://clinicalzeros.gov/ct2/show/NCT04588909,0,0,0,0,0,0,India,0,colorectal resections,NA
NCT04589117,2020-05-27,2020-08-02,Interventional,Expressive Writing for COVID-19 Resilience for Parents,Completed,N/A,Duke University,NA,https://clinicalzeros.gov/ct2/show/NCT04589117,0,0,0,0,0,1,United States,0,expressive writing,NA
NCT04589104,2020-05-26,2020-08-17,Interventional,Expressive Writing for COVID-19 Resilience,Completed,N/A,Duke University,NA,https://clinicalzeros.gov/ct2/show/NCT04589104,0,0,0,0,0,1,United States,0,expressive writing,NA
NCT04589949,2020-10-12,2022-11-01,Interventional,Early Convalescent Plasma Therapy for High-risk Patients With COVID-19 in Primary Care (the CoV-Early Study),Recruiting,Phase 3,Erasmus Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04589949,0,0,0,0,0,0,Netherlands,0,convp|ffp,NA
NCT04589936,2020-09-03,2021-06-30,Interventional,Prone Position to Improve Oxygenation in COVID-19 Patients Outside Critical Care,Recruiting,N/A,Cambridge University Hospitals NHS Foundation Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04589936,0,0,0,0,0,0,United Kingdom,0,prone positioning,NA
NCT04587258,2020-08-28,2022-09-01,Observational,Improving Cancer Screening and Prevention During the COVID-19 Pandemic in Underserved Populations of Rhode Island,Recruiting,NA,Rhode Island Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04587258,0,0,0,0,0,1,United States,0,informational videos/social media campaigns encouraging cancer screening.|informational videos|social media campaigns encouraging cancer screening.,NA
NCT04587921,2020-06-22,2021-01-22,Interventional,Feasibility and Impact of Remote Oximetry in Patients Hospitalized With Covid-19,Recruiting,N/A,University of Sao Paulo General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04587921,0,0,0,0,0,0,Brazil,0,digital oximeter monitoring,NA
NCT04587414,2019-03-06,2020-10-31,Interventional,eHealth Intervention on Physical Activity for Type 2 Diabetics - Frustrated by COVID-19,"Active, not recruiting",N/A,UKK Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04587414,0,0,0,0,0,0,Finland,0,telehealth/counselling|telehealth|standard care|counselling,NA
NCT04587375,2020-03-01,2020-05-01,Observational,Diagnosis of Endocrine Dysfunctions in Covid-19,Completed,NA,"University Hospital, Montpellier",NA,https://clinicalzeros.gov/ct2/show/NCT04587375,0,0,0,0,0,0,France,0,"NA",NA
NCT04587323,2020-05-22,2023-03-20,Observational,VEGF and sFlt-1 Levels in the Pathogenesis and Severity of COVID-19 Disease,Recruiting,NA,University of Alabama at Birmingham,NA,https://clinicalzeros.gov/ct2/show/NCT04587323,0,0,0,0,0,1,United States,0,"NA",NA
NCT04587219,2020-10-22,2021-03-30,Interventional,"The Study of ""Gam-COVID-Vac"" Vaccine Against COVID-19 With the Participation of Volunteers of 60 y.o and Older","Active, not recruiting",Phase 2,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",NA,https://clinicalzeros.gov/ct2/show/NCT04587219,0,0,0,1,5,0,Russian Federation,0,gam-covid-vac,NA
NCT04586413,2020-10-07,2022-10-31,Observational,Post Acute COVID-19 Quality of Life (PAC-19QoL) Tool Development and Patient Registry (PAC-19QoLReg),Recruiting,NA,Medialis Ltd.,NA,https://clinicalzeros.gov/ct2/show/NCT04586413,0,0,0,0,1,0,United Kingdom,0,no intervention,NA
NCT04586140,2020-11-09,2021-04-30,Observational,Operation of the GHPSJ Clinical Ethical Reflection Assistance Group During the COVID-19 Period,Recruiting,NA,Groupe Hospitalier Paris Saint Joseph,NA,https://clinicalzeros.gov/ct2/show/NCT04586140,0,0,0,0,1,0,France,0,"NA",NA
NCT04586114,2020-03-01,2020-05-31,Observational,Effect of Corticosteroid Treatment on Prognosis in ARDS Secondary to Covid-19,"Active, not recruiting",NA,"Central Hospital, Nancy, France",NA,https://clinicalzeros.gov/ct2/show/NCT04586114,0,0,0,0,1,0,France,0,corticosteroids/derivatives|corticosteroids|derivatives,NA
NCT04584658,2020-09-15,2021-10-31,Observational,Dysphagia and Dysphonia Outcomes in SARS CoV-2 (COVID-19) Infection (DYADS Study),Recruiting,NA,Cambridge University Hospitals NHS Foundation Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04584658,0,0,0,0,2,0,United Kingdom,0,fibreoptic endoscopic evaluation of swallowing (fees)|videofluoroscopy|dysphagia handicap index (dhi)|voice symptom scale (voiss),NA
NCT04584606,2020-06-27,2020-10-31,Observational,Ain Shams University Experience: Clinical Determinants of Hospitalized COVID-19 Patients,Recruiting,NA,Ain Shams University,NA,https://clinicalzeros.gov/ct2/show/NCT04584606,0,0,0,0,0,0,Egypt,0,lab workup (on admission/regularly during follow up).|lab workup (on admission|regularly during follow up).,NA
NCT04584593,2020-10-02,2022-02-28,Interventional,Pilot Study to Detect SARS-CoV-2 Virus in Sperm,Recruiting,N/A,"University Hospital, Toulouse",NA,https://clinicalzeros.gov/ct2/show/NCT04584593,0,0,0,0,2,0,France,0,sample,NA
NCT04584580,2020-08-01,2020-10-31,Interventional,D-dimer Adjusted Versus Therapeutic Dose Low-molecular-weight Heparin in Patients With COVID-19 Pneumonia,Recruiting,Phase 4,Ain Shams University,NA,https://clinicalzeros.gov/ct2/show/NCT04584580,0,0,0,0,0,0,Egypt,0,low-molecular-weight heparin,NA
NCT04583995,2020-09-28,2021-01-31,Interventional,"A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom",Recruiting,Phase 3,Novavax,NA,https://clinicalzeros.gov/ct2/show/NCT04583995,0,0,0,1,2,0,United Kingdom,0,sars-cov-2 rs/matrix m1-adjuvant|placebo|licensed seasonal influenza vaccine|sars-cov-2 rs|matrix m1-adjuvant,NA
NCT04583982,2020-10-09,2020-12-04,Observational,ImmuneSenseâ„¢ COVID-19 Study,Completed,NA,Adaptive Biotechnologies,NA,https://clinicalzeros.gov/ct2/show/NCT04583982,0,0,0,0,2,1,United States,0,t-detectâ„¢ sars-cov-2 assay|t-detectâ„¢ sars-cov-2 assay,NA
NCT04583865,2020-10-07,2021-09-14,Observational,Feasibility and Quality of TeleConsultation in Pediatric Anesthesia,"Active, not recruiting",NA,"University Hospital, Toulouse",NA,https://clinicalzeros.gov/ct2/show/NCT04583865,0,0,0,0,0,0,France,0,teleconsultation,NA
NCT04583761,2020-10-12,2021-02-28,Observational,Tobacco and Nicotine Consumption and the Risk of Acquisition of Coronavirus Disease 2019 (COVID-19),"Active, not recruiting",NA,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04583761,0,0,0,0,1,0,France,0,questionnaire,NA
NCT04583293,2020-12-08,2022-10-31,Observational,Acute kIDnEy Injury in coviD-19,Recruiting,NA,University Hospitals of Derby and Burton NHS Foundation Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04583293,0,0,0,0,2,0,United Kingdom,0,no intervention,NA
NCT04583566,2020-10-04,2021-10-03,Observational [Patient Registry],"Differential Expression of Cytokines, Transcriptome and miRNA in Coronavirus Disease 2019 (COVID-19) Egyptian's Patients",Recruiting,NA,Tanta University,NA,https://clinicalzeros.gov/ct2/show/NCT04583566,0,0,0,0,1,0,Egypt,0,covid-19 diagnostic/assessment tests|covid-19 diagnostic|assessment tests,NA
NCT04583449,2020-08-19,2020-12-01,Interventional,Mental Imagery to Increase Face Covering Use in UK-based Public Places During the COVID-19 Pandemic,Recruiting,N/A,University of East London,NA,https://clinicalzeros.gov/ct2/show/NCT04583449,0,0,0,0,0,0,United Kingdom,0,mental imagery,NA
NCT04583189,2020-10-01,2020-11-25,Interventional,Evaluation of the Performance of the Covid-19 Ag BSS Rapid Antigenic Test in Symptomatic Children in a Pediatric Emergency Department,Completed,N/A,Centre Hospitalier Intercommunal Creteil,NA,https://clinicalzeros.gov/ct2/show/NCT04583189,0,0,0,0,2,0,France,0,performance of the test antigenic/test rt-pcr|performance of the test antigenic|test rt-pcr,NA
NCT04581889,2020-07-02,2021-07-31,Observational,Prevalence of Antibodies Against SARS-CoV-2 Virus That Causes COVID-19 in TÃ¼bingen Children,Recruiting,NA,University Hospital Tuebingen,NA,https://clinicalzeros.gov/ct2/show/NCT04581889,0,0,0,0,1,0,Germany,0,diagnostic test,NA
NCT04583319,2020-10-31,2020-11-30,Observational,"Validation of a Rapid, Non-invasive Point-of-care IVD Test for Diagnosis of SARS-COV-2 (COVID-19) Infection",Recruiting,NA,Firalis SA,NA,https://clinicalzeros.gov/ct2/show/NCT04583319,0,0,0,0,1,0,Turkey,0,easycov poc,NA
NCT04583306,2020-06-01,2020-12-15,Observational [Patient Registry],The Salivary Raman COVID-19 Fingerprint,Recruiting,NA,Fondazione Don Carlo Gnocchi Onlus,NA,https://clinicalzeros.gov/ct2/show/NCT04583306,0,0,0,0,0,0,Italy,0,"raman analysis of saliva, characterization of the raman database/building of the classification model|raman analysis of saliva, characterization of the raman database|building of the classification model",NA
NCT04429724,2020-07-06,2021-04-30,Interventional,Health Professional Exposure Assessment to Covid-19,"Active, not recruiting",N/A,Tourcoing Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04429724,0,0,0,0,2,0,France,0,diagnostic test covid-19,NA
NCT04582318,2020-11-08,2021-06-30,Interventional,"A Phase 1/2 Study to Assess the Safety, Tolerability and Pharmacokinetics of NGM621 in Healthy Subjects, and to Assess the Safety, PK and Efficacy in Subjects With Moderate to Severe ARDS Caused by COVID-19",Recruiting,Phase 1/Phase 2,"NGM Biopharmaceuticals, Inc",NA,https://clinicalzeros.gov/ct2/show/NCT04582318,0,0,0,0,1,0,Australia,0,ngm621|placebo,NA
NCT04582214,2020-09-28,2021-01-01,Interventional,Oscillation and Lung Expansion Therapy in Patients With COVID-19,Recruiting,N/A,Hill-Rom,NA,https://clinicalzeros.gov/ct2/show/NCT04582214,0,0,0,0,0,1,United States,0,metanebâ® system|metanebâ® system,NA
NCT04581811,2020-11-10,2021-05-31,Interventional,Prolonged Prone Positioning for COVID-19-induced Acute Respiratory Distress Syndrome (ARDS),Recruiting,N/A,University of Alabama at Birmingham,NA,https://clinicalzeros.gov/ct2/show/NCT04581811,0,0,0,0,1,1,United States,0,prolonged proned positioning|traditional proning arm,NA
NCT04581746,2020-11-25,2021-12-31,Interventional,Impact of the Epidemic of COVID-19 Infection Among People Living With HIV (SARS-CoV-2),Recruiting,N/A,Tourcoing Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04581746,0,0,0,0,1,0,France,0,questionnaire,NA
NCT04581291,2020-01-01,2020-06-01,Interventional,The Effect of Aerobic Exercise on Immune Biomarkers and Symptoms Severity and Progression in Patients With COVID-19: A Pilot Randomized Control Trial,Completed,N/A,Istanbul Gelisim University,NA,https://clinicalzeros.gov/ct2/show/NCT04581291,0,0,0,0,0,0,Turkey,0,moderate intensity aerobic exercises,NA
NCT04579640,2020-10-27,2021-06-30,Interventional,Trial of Vitamin D to Reduce Risk and Severity of COVID-19 and Other Acute Respiratory Infections,"Active, not recruiting",Phase 3,Queen Mary University of London,NA,https://clinicalzeros.gov/ct2/show/NCT04579640,0,0,0,0,2,0,United Kingdom,0,vitamin d,NA
NCT04579627,2020-05-14,2020-06-08,Observational,"Facial Hair, PPE and COVID-19",Completed,NA,Royal Cornwall Hospitals Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04579627,0,0,0,0,0,0,United Kingdom,0,questionnaire,NA
NCT04579588,2020-10-29,2022-12-01,Observational,Understanding Immunity to the Flu Vaccine in COVID-19 Patients,Enrolling by invitation,NA,Stanford University,NA,https://clinicalzeros.gov/ct2/show/NCT04579588,0,0,0,0,2,1,United States,0,flu shot,NA
NCT04581161,2020-08-28,2020-10-31,Interventional,Proportional Open Ventilation (POV) Device and Its Efficacy in Managing Acute Respiratory Failure in COVID-19 Patients,Recruiting,N/A,Hill-Rom,NA,https://clinicalzeros.gov/ct2/show/NCT04581161,0,0,0,0,0,1,United States,0,life2000â® ventilator|life2000â® ventilator,NA
NCT04581135,2020-05-01,2023-04-30,Observational [Patient Registry],Study to Investigate Long-term Pulmonary and Extrapulmonary Effects of COVID-19,Recruiting,NA,"University Hospital Inselspital, Berne",NA,https://clinicalzeros.gov/ct2/show/NCT04581135,0,0,0,0,0,0,Switzerland,0,covid-19,NA
NCT04581096,2020-10-02,2021-02-15,Observational [Patient Registry],Mapping COVID-19 Spread in a Tertiary Hospital,Recruiting,NA,Hospital General Universitario de Valencia,NA,https://clinicalzeros.gov/ct2/show/NCT04581096,0,0,0,0,1,0,Spain,0,no intervention,NA
NCT04581083,2020-10-08,2020-10-10,Observational,"Validation of Laboratory Techniques, Strategies, and Types of Samples for Epidemiological Control in the Covid-19 Pandemic",Completed,NA,Hunter College of City University of New York,NA,https://clinicalzeros.gov/ct2/show/NCT04581083,0,0,0,0,2,0,Bolivia,0,pcr|lamp|pool rt-pcr|pool lamp,NA
NCT04581070,2020-04-29,2020-10-09,Observational,"The COVID-IYON Study - Study Examining Data Pertaining to Clinical Outcomes and Organisational Responses to the 2020 SARS-CoV-2 Pandemic""",Terminated,NA,Cancer Trials Ireland,Study stopped due to low accrual,https://clinicalzeros.gov/ct2/show/NCT04581070,0,0,0,0,1,0,Ireland,0,"NA",NA
NCT04581044,2020-09-17,2020-10-23,Observational,Impact of COVID-19 on Psoriasis Practice,Completed,NA,Cairo University,NA,https://clinicalzeros.gov/ct2/show/NCT04581044,0,0,0,0,1,0,Egypt,0,"NA",NA
NCT04581018,2020-08-13,2021-10-30,Interventional,An Evaluation of a Synbiotic Formula for Patients With COVID-19 Infection,Recruiting,N/A,Chinese University of Hong Kong,NA,https://clinicalzeros.gov/ct2/show/NCT04581018,0,0,0,0,1,0,Hong Kong,0,health supplements,NA
NCT04579549,2020-09-29,2021-09-30,Interventional,Repeat Testing for SARS-CoV-2,Enrolling by invitation,N/A,"University of Wisconsin, Madison",NA,https://clinicalzeros.gov/ct2/show/NCT04579549,0,0,0,0,2,1,United States,0,saliva assay,NA
NCT04579471,2020-07-01,2021-12-31,Observational,Prevalence and Outcome of SARS-CoV-2 Infection & COVID-19 in Transplant Recipients: The COVITRA Study,Recruiting,NA,Universitaire Ziekenhuizen Leuven,NA,https://clinicalzeros.gov/ct2/show/NCT04579471,0,0,0,0,1,0,Belgium,0,sars-cov-2 igg,NA
NCT04579289,2020-06-15,2020-09-01,Observational,Managerial and Environmental Risk for COVID 19 in French Long Term Care Institutions,Completed,NA,Rennes University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04579289,0,0,0,0,1,0,France,0,questionnaire,NA
NCT04578197,2020-08-18,2022-06-30,Observational,NeuroCovid - a Study of Intensive Care-requiring Covid-19 Patients,Recruiting,NA,Karolinska University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04578197,0,0,0,0,0,0,Sweden,0,"NA",NA
NCT04577235,2020-06-05,2020-08-05,Interventional,Correlation Between Thoracic Ultrasound and Thorax Computed Tomography Scores.,Completed,N/A,Gaziosmanpasa Taksim Research and Education Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04577235,0,0,0,0,0,0,Turkey,0,severity of lung involvement with covid-19.,NA
NCT04576312,2020-06-29,2020-12-31,Interventional,Study to Assess the Safety of Ascending Doses of UNI911 INHALATION in Healthy Volunteers in Preparation for Evaluation in Adults With COVID-19,"Active, not recruiting",Phase 1,UNION therapeutics,NA,https://clinicalzeros.gov/ct2/show/NCT04576312,0,0,0,0,1,0,Denmark,0,uni911 inhalation,NA
NCT04576299,2020-09-01,2020-10-30,Observational,Health Care Workers' Perception of Patient Safety During COVID-19 Pandemic,"Active, not recruiting",NA,Universidad Miguel Hernandez de Elche,NA,https://clinicalzeros.gov/ct2/show/NCT04576299,0,0,0,0,0,0,Chile|Colombia|Ecuador|Spain,0,group 1,NA
NCT04575168,2020-10-30,2020-11-30,Observational,Clinical Study Spartan COVID-19 V2 System,Recruiting,NA,Spartan Bioscience Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04575168,0,0,0,0,2,1,United States,0,spartan covid-19 test,NA
NCT04577534,2020-08-14,2021-12-31,Interventional,COVID-19: Salvage TOcilizumab as a Rescue Measure,Recruiting,Phase 3,Turku University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04577534,0,0,0,0,1,0,Finland,0,iv tocillizumab (tcz),NA
NCT04575610,2020-11-30,2021-03-31,Interventional,IRAK4 Inhibition in Treatment of COVID-19 With ARDS (I-RAMIC),Recruiting,Phase 2,Yale University,NA,https://clinicalzeros.gov/ct2/show/NCT04575610,0,0,0,0,2,1,United States,0,pf-06650833|placebo,NA
NCT04575571,2020-04-29,2025-04-29,Observational,MAVIPAN: My Life and the COVID-19 Pandemic,Recruiting,NA,Laval University,NA,https://clinicalzeros.gov/ct2/show/NCT04575571,0,0,0,0,0,0,Canada,0,no intervention|qualitative interviews..,NA
NCT04425720,2020-09-01,2021-06-01,Interventional,Use of Remote Monitoring for COVID-19 Patient,Recruiting,N/A,Montefiore Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04425720,0,0,0,0,4,1,United States,0,lifesignals biosensor 1ax*|standard care,NA
NCT04575064,2020-06-29,2022-03-31,Interventional,An International Randomized Trial of Additional Treatments for COVID-19 in Hospitalized Patients Who Are All Receiving the Local Standard of Care - WHO-SOLIDARITY-GERMANY,"Active, not recruiting",Phase 2/Phase 3,"Klinikum Bremen-Mitte, gGmbH",NA,https://clinicalzeros.gov/ct2/show/NCT04575064,0,0,0,0,0,0,Germany,0,standard care|remdesivir,NA
NCT04574219,2020-11-03,2022-10-31,Interventional,Virtual Parental Presence on Induction,Recruiting,N/A,"Children's Hospital Medical Center, Cincinnati",NA,https://clinicalzeros.gov/ct2/show/NCT04574219,0,0,0,0,1,1,United States|Canada,0,use of facetime with child/parents during induction|use of facetime with child|parents during induction,NA
NCT04573361,2020-05-02,2020-05-27,Interventional,Access to Chiropractic Care During the COVID-19 Healthcare Emergency in Spain,Completed,N/A,Real Centro Universitario Maria Cristina,NA,https://clinicalzeros.gov/ct2/show/NCT04573361,0,0,0,0,0,0,Spain,0,chiropractic care (one visit)|chiropractic care (more than one visit),NA
NCT04573868,2020-03-01,2020-06-30,Observational [Patient Registry],"National Study ""AEC COVID-19""",Recruiting,NA,Hospitales Universitarios Virgen del RocÃ­o,NA,https://clinicalzeros.gov/ct2/show/NCT04573868,0,0,0,0,0,0,Spain,0,"NA",NA
NCT04573335,2020-06-01,2020-07-15,Observational,Diabetes Outcomes in COVID-19 Pandemic,Completed,NA,"Services Institute of Medical Sciences, Pakistan",NA,https://clinicalzeros.gov/ct2/show/NCT04573335,0,0,0,0,0,0,Pakistan,0,"NA",NA
NCT04573322,2020-09-10,2021-11-14,Interventional,Safety and Efficacy of Trans Sodium Crocetinate (TSC) in SARS-CoV-2 (COVID-19) Infected Subjects,Recruiting,Phase 1/Phase 2,Diffusion Pharmaceuticals Inc,NA,https://clinicalzeros.gov/ct2/show/NCT04573322,0,0,0,0,0,0,Romania,0,trans sodium crocetinate|saline,NA
NCT04573270,2020-04-24,2020-08-20,Interventional,Mesenchymal Stem Cells for the Treatment of COVID-19,Completed,Phase 1,Thomas Advanced Medical LLC,NA,https://clinicalzeros.gov/ct2/show/NCT04573270,0,0,0,0,0,1,United States,0,primepro|placebo,NA
NCT04573634,2020-05-15,2023-12-31,Observational,A Registry Study of COVID-19 Serologic and Virologic Testing to Accelerate Recovery and Transition,Recruiting,NA,University of Kentucky,NA,https://clinicalzeros.gov/ct2/show/NCT04573634,0,0,0,0,1,1,United States,0,"NA",NA
NCT04570462,2020-05-18,2020-12-31,Interventional,Mild Hypothermia for COVID-19 ARDS,Recruiting,N/A,Northwell Health,NA,https://clinicalzeros.gov/ct2/show/NCT04570462,0,0,0,0,0,1,United States,0,hypothermia via cooling machine- arctic sun 5000,NA
NCT04572399,2020-10-30,2020-12-28,Interventional,UVA Light Device to Treat COVID-19,Completed,N/A,Cedars-Sinai Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04572399,0,0,0,0,3,1,United States,0,uv light treatment,NA
NCT04570982,2020-07-30,2020-10-30,Observational,Clinical Protocol for Convalescent Plasma and Remdesivir Therapy in Nepal,Recruiting,NA,Nepal Health Research Council,NA,https://clinicalzeros.gov/ct2/show/NCT04570982,0,0,0,0,0,0,Nepal,0,convalescent plasma,NA
NCT04573153,2020-09-21,2021-01-31,Interventional,Metabolic Cofactor Supplementation and Hydroxychloroquine Combination in Covid-19 Patients,Recruiting,Phase 2/Phase 3,ScandiBio Therapeutics AB,NA,https://clinicalzeros.gov/ct2/show/NCT04573153,0,0,0,0,1,0,Turkey,0,hydroxychloroquine / metabolic cofactor supplementation|hydroxychloroquine / sorbitol|hydroxychloroquine|metabolic cofactor supplementation|sorbitol,NA
NCT04572438,2020-08-01,2021-04-01,Observational,A Cohort Study of Mechanically Ventilated COVID-19 Patients Undergoing Tracheostomy,Recruiting,NA,"University College, London",NA,https://clinicalzeros.gov/ct2/show/NCT04572438,0,0,0,0,0,0,United Kingdom,0,tracheostomy,NA
NCT04572412,2020-11-25,2021-04-30,Interventional,Low Dose Lung Radiotherapy to Treat COVID-19 Pneumonia,Recruiting,N/A,Lancashire Teaching Hospitals NHS Foundation Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04572412,0,0,0,0,2,0,United Kingdom,0,radiotherapy,NA
NCT04570397,2020-12-18,2021-05-31,Interventional,Ravulizumab and COVID-19,Recruiting,Phase 3,Brigham and Women's Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04570397,0,0,0,0,1,1,United States,0,ravulizumab,NA
NCT04570254,2020-08-19,2020-10-15,Interventional,Antioxidants as Adjuvant Therapy to Standard Therapy in Patients With COVID-19,"Active, not recruiting",N/A,Unidad Temporal COVID-19 en Centro Citibanamex,NA,https://clinicalzeros.gov/ct2/show/NCT04570254,0,0,0,0,1,0,Mexico,0,vitamin c|vitamin e|melatonin|n-acetyl cysteine|pentoxifylline,NA
NCT04568876,2020-10-23,2021-11-30,Interventional,Micronized and Ultramicronized Palmitoylethanolamide in COVID-19 Patients,Recruiting,Phase 4,Epitech Group SpA,NA,https://clinicalzeros.gov/ct2/show/NCT04568876,0,0,0,0,2,0,Italy,0,"micronized/ultra-micronized palmitoylethanolamide (mpea/umpea, 300mg / 600mg) oral suspension|standard care|micronized|ultra-micronized palmitoylethanolamide (mpea|umpea, 300mg|600mg) oral suspension",NA
NCT04569877,2020-09-24,2022-12-25,Interventional,GM-CSF Inhalation to Prevent ARDS in COVID-19 Pneumonia,Recruiting,Phase 2,University of Giessen,NA,https://clinicalzeros.gov/ct2/show/NCT04569877,0,0,0,0,1,0,Germany,0,molgramostim nebuliser solution|placebo,NA
NCT04569851,2020-01-01,2021-10-01,Observational,Clinical Characteristics and Prognostic Factors of Patients With COVID-19 (Coronavirus Disease 2019),Enrolling by invitation,NA,Medsavana,NA,https://clinicalzeros.gov/ct2/show/NCT04569851,0,0,0,0,0,0,Spain,0,"NA",NA
NCT04569383,2020-10-05,2021-05-31,Interventional,"Safety, Tolerability and Immunogenicity of the Candidate Vaccine MVA-SARS-2-S Against COVID-19",Recruiting,Phase 1,UniversitÃ¤tsklinikum Hamburg-Eppendorf,NA,https://clinicalzeros.gov/ct2/show/NCT04569383,0,0,0,1,1,0,Germany,0,mva-sars-2-s vaccinations (days 0/28)|mva-sars-2-s vaccinations (days 0|28),NA
NCT04569344,2020-01-01,2021-03-31,Observational,COVID-19 and Venous Thromboembolism Risk,Enrolling by invitation,NA,"University of California, San Francisco",NA,https://clinicalzeros.gov/ct2/show/NCT04569344,0,0,0,0,3,1,United States,0,laboratory test positive for sars-cov-2 virus,NA
NCT04569292,2020-01-01,2021-04-30,Observational,COVID-19 Infection in Cancer Pantients,Recruiting,NA,Ospedale Andrea Tortora di Pagani,NA,https://clinicalzeros.gov/ct2/show/NCT04569292,0,0,0,0,0,0,Italy,0,no intervention,NA
NCT04570189,2020-10-01,2021-01-31,Observational,"Evaluating Auscul-X, a Touch Free Digital Stethoscope",Recruiting,NA,AusculSciences Canada Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04570189,0,0,0,0,1,0,Canada,0,auscul-x,NA
NCT04569266,2020-08-07,2021-11-07,Interventional,Effectiveness of an Exercise Re-training Program on Dyspnea in Patients After Acute Respiratory Distress Syndrome Secondary to Severe COVID-19 Pneumonia in Post-ICU,Recruiting,N/A,Groupe Hospitalier Paris Saint Joseph,NA,https://clinicalzeros.gov/ct2/show/NCT04569266,0,0,0,0,0,0,France,0,specific exercise rehabilitation treatment,NA
NCT04568655,2020-02-01,2020-07-01,Observational,The Noninvasive Ventilation to COVID-19 Patients,Completed,NA,The First Affiliated Hospital of Guangzhou Medical University,NA,https://clinicalzeros.gov/ct2/show/NCT04568655,0,0,0,0,0,0,China,0,noninvasive ventilation,NA
NCT04568148,2020-04-15,2021-12-31,Observational,COVID-19 Biorepository,Recruiting,NA,University of Kansas Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04568148,0,0,0,0,0,1,United States,0,"NA",NA
NCT04568564,2020-10-01,2021-05-01,Interventional,Telerehabilitation in Lung Surgery Patients,Recruiting,N/A,Istanbul Medipol University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04568564,0,0,0,0,2,0,Turkey,0,"breathing exercise, intensive spirometry use, supported cough, progressive mobilisation/ambulation|exercise booklet|breathing exercise, intensive spirometry use, supported cough, progressive mobilisation|ambulation",NA
NCT04567953,2020-07-28,2021-01-30,Interventional,COVID-19 Tests With Saliva Specimens,"Active, not recruiting",N/A,Paradigm Laboratories LLC,NA,https://clinicalzeros.gov/ct2/show/NCT04567953,0,0,0,0,0,1,United States,0,saliva,NA
NCT04568421,2020-08-18,2021-12-31,Observational [Patient Registry],Argentinian Registry of Patients With Rheumatic Diseases and COVID-19 Infection,Recruiting,NA,Sociedad Argentina de Reumatologia,NA,https://clinicalzeros.gov/ct2/show/NCT04568421,0,0,0,0,0,0,Argentina,0,immunosuppressive agents,NA
NCT04567810,2020-09-18,2020-12-14,Interventional,"Safety, Tolerability, and Pharmacokinetics of Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Chicken Egg Antibody (IgY) (COVID-19)",Completed,Phase 1,Stanford University,NA,https://clinicalzeros.gov/ct2/show/NCT04567810,0,0,0,0,2,0,Australia,0,anti-sars-cov-2 igy|placebo,NA
NCT04568018,2020-07-03,2020-12-31,Observational,Surfactant-BL in Adult Acute Respiratory Distress Syndrome Due to COVID-19,Recruiting,NA,Biosurf LLC.,NA,https://clinicalzeros.gov/ct2/show/NCT04568018,0,0,0,0,0,0,Russian Federation,0,surfactant,NA
NCT04568005,2020-06-01,2020-08-01,Observational [Patient Registry],Evaluation of Lymphedema Patients Status During Covid-19 Pandemic,Completed,NA,Fatih Sultan Mehmet Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04568005,0,0,0,0,1,0,Turkey,0,"NA",NA
NCT04567173,2020-09-21,2021-06-30,Interventional,Convalescent Plasma as Adjunctive Therapy for Hospitalized Patients With COVID-19,Recruiting,Phase 2/Phase 3,University of the Philippines,NA,https://clinicalzeros.gov/ct2/show/NCT04567173,0,0,0,0,1,0,Philippines,0,convalescent plasma,NA
NCT04564716,2020-09-28,2021-03-28,Interventional,"Clinical Trial of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Vaccine Against COVID-19 in Belarus","Active, not recruiting",Phase 3,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",NA,https://clinicalzeros.gov/ct2/show/NCT04564716,0,0,0,1,3,0,Belarus,0,gam-covid-vac|placebo,NA
NCT04566965,2020-08-18,2022-12-31,Observational,Serology to Covid for Recording Exposures and Evaluating Needs,Recruiting,NA,"Children's Hospital Medical Center, Cincinnati",NA,https://clinicalzeros.gov/ct2/show/NCT04566965,0,0,0,0,0,1,United States,0,sars-cov-2,NA
NCT04565782,2020-09-15,2020-11-01,Observational,Corona Virus Infection Among Liver Transplant Recipients,Recruiting,NA,Assiut University,NA,https://clinicalzeros.gov/ct2/show/NCT04565782,0,0,0,0,0,0,Egypt,0,"NA",NA
NCT04565509,2020-11-20,2022-06-30,Interventional,Supporting the Health and Well-being of Children With Intellectual and Developmental Disability During COVID-19 Pandemic,Recruiting,N/A,Washington University School of Medicine,NA,https://clinicalzeros.gov/ct2/show/NCT04565509,0,0,0,0,1,1,United States,0,general communication message|focused/targeted message|best message alone|best message / augmented message/implementation strategy|focused|targeted message|best message|augmented message|implementation strategy,NA
NCT04565197,2020-05-01,2020-12-30,Interventional,Convalescent Plasma Therapy for COVID-19 Patients,"Active, not recruiting",Early Phase 1,Lahore General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04565197,0,0,0,0,1,0,Pakistan,0,convalescent plasma,NA
NCT04565106,2020-04-15,2020-05-31,Observational,Automatic Oxygen Titration With O2maticÂ® to Patients Admitted With COVID-19 and Hypoxemic Respiratory Failure,Completed,NA,Hvidovre University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04565106,0,0,0,0,0,0,Denmark,0,closed-loop control of oxygen supplementation by o2matic,NA
NCT04566770,2020-09-24,2021-08-21,Interventional,A Clinical Trial of A COVID-19 Vaccine Named Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector),Recruiting,Phase 2,CanSino Biologics Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04566770,0,0,0,1,1,0,China,0,adenovirus type 5 vector|recombinant novel coronavirus vaccine (adenovirus type 5 vector) -placebo,NA
NCT04425707,2020-06-09,2020-07-01,Interventional,Ivermectin In Treatment of COVID 19 Patients,Recruiting,N/A,"Ministry of Health and Population, Egypt",NA,https://clinicalzeros.gov/ct2/show/NCT04425707,0,0,0,0,0,0,Egypt,0,ivermectin,NA
NCT04563208,2020-12-09,2021-02-28,Interventional,Study of Oral Administration of Ribavirin and Nitazoxamide Versus Placebo in COVID-19,Recruiting,Phase 2,"University of Witwatersrand, South Africa",NA,https://clinicalzeros.gov/ct2/show/NCT04563208,0,0,0,0,3,0,South Africa,0,placebo|duact,NA
NCT04563689,2020-06-18,2020-10-22,Interventional,Pilot Study to Evaluate Effect of CHX0.12/CPC 0.05 of SARS-CoV-2 Viral Load in COVID-19 Patients,Completed,N/A,Dentaid SL,NA,https://clinicalzeros.gov/ct2/show/NCT04563689,0,0,0,0,1,0,Colombia,0,chx0.12/cpc0.05 oral rinse (perioaidactive control)|placebo|chx0.12|cpc0.05 oral rinse (perioaidactive control),NA
NCT04563676,2020-09-22,2021-03-31,Interventional,Physiopathology and Sequelae of COVID-19 Infection,Recruiting,N/A,"Centre Hospitalier Universitaire, Amiens",NA,https://clinicalzeros.gov/ct2/show/NCT04563676,0,0,0,0,0,0,France,0,blood test,NA
NCT04563650,2020-09-18,2021-05-31,Interventional,COVID-19 Serology and Immunosenescence,Recruiting,N/A,"Centre Hospitalier Universitaire, Amiens",NA,https://clinicalzeros.gov/ct2/show/NCT04563650,0,0,0,0,0,0,France,0,blood sample,NA
NCT04564287,2020-10-28,2021-12-01,Observational,An Observational Study of Neurologic Function After COVID-19 Infection,Enrolling by invitation,NA,National Institutes of Health Clinical Center (CC),NA,https://clinicalzeros.gov/ct2/show/NCT04564287,0,0,0,0,36,1,United States,0,"NA",NA
NCT04563156,2020-06-23,2021-06-30,Observational,Follow-up and Rehabilitation of Survivors of Severe Coronavirus Disease 2019 (COVID-19) Infection,Enrolling by invitation,NA,University of Sao Paulo General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04563156,0,0,0,0,0,0,Brazil,0,lung function test,NA
NCT04562285,2020-06-23,2021-06-30,Observational,Sustained Immunity to SARS-CoV-2,Recruiting,NA,Henry Ford Health System,NA,https://clinicalzeros.gov/ct2/show/NCT04562285,0,0,0,0,0,1,United States,0,serologic immunoassays to sars-cov-2 antibodies,NA
NCT04561219,2020-04-19,2020-10-02,Interventional,Nitazoxanide Therapy for Patients With COVID-19 Pneumonia,Completed,Phase 2,Universidade Federal do Rio de Janeiro,NA,https://clinicalzeros.gov/ct2/show/NCT04561219,0,0,0,0,2,0,Brazil,0,nitazoxanide|placebo,NA
NCT04562246,2020-08-14,2021-08-31,Observational,SARS-CoV-2 IgG and IgM Serologic Assays,Recruiting,NA,Henry Ford Health System,NA,https://clinicalzeros.gov/ct2/show/NCT04562246,0,0,0,0,0,1,United States,0,serologic assays for antibodies to sars-cov-2,NA
NCT04561024,2020-03-01,2020-10-30,Observational,Evaluation of a COVID-19 Pneumonia CXR AI Detection Algorithm,"Active, not recruiting",NA,"Ensemble Group Holdings, LLC",NA,https://clinicalzeros.gov/ct2/show/NCT04561024,0,0,0,0,1,0,Hong Kong,0,ai model,NA
NCT04561193,2020-05-30,2020-12-31,Observational,Investigation of Subsequent and Co-infections Associated With SARS-CoV-2 (COVID-19),Recruiting,NA,Methodist Health System,NA,https://clinicalzeros.gov/ct2/show/NCT04561193,0,0,0,0,0,1,United States,0,observational,NA
NCT04561154,2020-06-11,2021-06-11,Interventional,Identifying Functional and Psycho-social Complaints After Hospitalization for SARS-CoV-2 Infection( COVID 19)- REPERCOV,Recruiting,N/A,Centre Hospitalier le Mans,NA,https://clinicalzeros.gov/ct2/show/NCT04561154,0,0,0,0,0,0,France,0,questionnaire,NA
NCT04561063,2020-12-08,2021-07-31,Interventional,COVID-19 Prophylaxis South Africa (COVER HCW),Recruiting,Phase 2,"University of Witwatersrand, South Africa",NA,https://clinicalzeros.gov/ct2/show/NCT04561063,0,0,0,0,2,0,South Africa,0,nitazoxanide|sofosbuvir/daclatasvir|sofosbuvir|daclatasvir,NA
NCT04560608,2020-03-15,2021-01-31,Observational [Patient Registry],"Elucidating the Symptomatic, Explanatory and Prognostic Characteristics of GERIAtric Patients Hospitalized for COVID-19",Recruiting,NA,"University Hospital, Angers",NA,https://clinicalzeros.gov/ct2/show/NCT04560608,0,0,0,0,1,0,France,0,"NA",NA
NCT04560881,2020-09-16,2021-12-01,Interventional,"Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (COVID-19)","Active, not recruiting",Phase 3,Laboratorio Elea Phoenix S.A.,NA,https://clinicalzeros.gov/ct2/show/NCT04560881,0,0,0,1,2,0,Argentina,0,inactivated sars-cov-2 vaccine|placebo/aluminum adjuvant of inactivated sars-cov-2 vaccine|placebo|aluminum adjuvant of inactivated sars-cov-2 vaccine,NA
NCT04560855,2020-09-14,2021-06-14,Observational,Secure Self-monitoring Through a Combination of Connected Objects: Implementation in COVID-19 Patients Monitored at Home,Recruiting,NA,Withings,NA,https://clinicalzeros.gov/ct2/show/NCT04560855,0,0,0,0,0,0,France,0,connected devices measurements,NA
NCT04560530,2020-03-01,2020-07-30,Observational,The Role of CT Chest Scan in the Pre-anesthetic Assessment of Suspected or Confirmed COVID -19 Patients,Completed,NA,Tanta University,NA,https://clinicalzeros.gov/ct2/show/NCT04560530,0,0,0,0,0,0,Saudi Arabia,0,radiotherapy,NA
NCT04560413,2020-06-01,2020-07-25,Observational,"Depression, Anxiety and SARS-CoV-2 (Covid-19) Phobia in Post-stroke Patients",Completed,NA,Fatih Sultan Mehmet Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04560413,0,0,0,0,1,0,Turkey,0,"NA",NA
NCT04560257,2020-05-01,2020-12-30,Interventional,High Flow Nasal Cannula HFNC In Covid-19 Patients,Recruiting,N/A,Lahore General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04560257,0,0,0,0,3,0,Pakistan,0,high flow nasal cannula,NA
NCT04560231,2020-06-01,2020-11-30,Interventional,Remdesivir in COVID-19 Lahore General Hospital,Recruiting,Early Phase 1,Lahore General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04560231,0,0,0,0,1,0,Pakistan,0,remdesivir,NA
NCT04558645,2020-09-18,2020-12-18,Observational,Evaluation of Quality of Life in Patients With Type 1 Diabetes Mellitus During the Covid-19 Pandemic,Completed,NA,Gazi University,NA,https://clinicalzeros.gov/ct2/show/NCT04558645,0,0,0,0,3,0,Turkey,0,online survey,NA
NCT04560205,2020-05-01,2020-12-30,Interventional,Tocilizumab in COVID-19 Lahore General Hospital,Recruiting,Phase 1,Lahore General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04560205,0,0,0,0,1,0,Pakistan,0,tocilizumab,NA
NCT04559113,2020-05-01,2020-12-30,Interventional,Methylprednisolone in COVID-19 Patients (Methyl19LGH),Recruiting,N/A,Lahore General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04559113,0,0,0,0,1,0,Pakistan,0,methylprednisolone injectable product,NA
NCT04559074,2020-10-23,2021-04-30,Interventional,Personalised Electronic Record Supported Optimisation When Alone for Patients With Hypertension- Pilot Study for Remote Medical Management of Hypertension During the COVID-19 Pandemic,Recruiting,Phase 4,Queen Mary University of London,NA,https://clinicalzeros.gov/ct2/show/NCT04559074,0,0,0,0,2,0,United Kingdom,0,amlodipine,NA
NCT04559009,2020-10-15,2023-12-31,Observational [Patient Registry],COVID-19 Amyotrophic Lateral Sclerosis (ALS) Registry,Recruiting,NA,Atrium Health,NA,https://clinicalzeros.gov/ct2/show/NCT04559009,0,0,0,0,1,1,United States,0,"NA",NA
NCT04558437,2020-06-12,2020-12-31,Observational,"COVID-Impact ""Psychological IMPACT of Covid-19 on AP-HP Staff""",Recruiting,NA,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04558437,0,0,0,0,0,0,France,0,questionnaire,NA
NCT04558411,2020-09-12,2020-12-15,Interventional,"Pilot Study of a Brief, Scaleable Intervention for Coronavirus (COVID-19) Mental Health Sequelae in College Students",Recruiting,N/A,"Rutgers, The State University of New Jersey",NA,https://clinicalzeros.gov/ct2/show/NCT04558411,0,0,0,0,0,1,United States,0,dialectical behavioral therapy (dbt) skills,NA
NCT04558372,2020-04-01,2020-12-12,Interventional,Genosvid Diagnostic Test for Early Detection of COVID-19,Completed,N/A,Gadjah Mada University,NA,https://clinicalzeros.gov/ct2/show/NCT04558372,0,0,0,0,3,0,Indonesia,0,exhaled breath sampling,NA
NCT04558749,2020-10-01,2021-04-30,Observational,Anxiety and Depression Among Pregnant Women During COVID-19 Pandemic,Recruiting,NA,Assiut University,NA,https://clinicalzeros.gov/ct2/show/NCT04558749,0,0,0,0,1,0,Egypt,0,state-trait anxiety inventory scale|edinburgh postnatal depression scale (edps),NA
NCT04558320,2020-07-02,2021-04-01,Observational,COVID-19 and Lactating Mothers,Recruiting,NA,University of Rochester,NA,https://clinicalzeros.gov/ct2/show/NCT04558320,0,0,0,0,1,1,United States,0,"NA",NA
NCT04558307,2020-06-03,2021-06-01,Observational,Feasibility of Rapid COVID-19 Testing in Disadvantaged Populations,Enrolling by invitation,NA,Mayo Clinic,NA,https://clinicalzeros.gov/ct2/show/NCT04558307,0,0,0,0,0,1,United States,0,pilot a rapid sars-cov-2 testing strategy|community-driven messages to promote covid-19 testing,NA
NCT04558463,2020-04-16,2020-09-30,Interventional,The Effectivity and Safety of Favipiravir Compared to Oseltamivir as Adjuvant Therapy for COVID-19,Recruiting,Phase 3,Indonesia University,NA,https://clinicalzeros.gov/ct2/show/NCT04558463,0,0,0,0,0,0,Indonesia,0,favipiravir|oseltamivir 75mg,NA
NCT04558021,2020-10-08,2021-01-30,Interventional,A Study To Evaluate The Efficacy And Safety Of a Novel Niclosamide Suspension Formulation For COVID-19,Recruiting,Phase 3,Imuneks Farma ilac San. Tic. A.S.,NA,https://clinicalzeros.gov/ct2/show/NCT04558021,0,0,0,0,1,0,Turkey,0,niclosamide suspension|placebo,NA
NCT04556149,2020-10-01,2020-12-02,Observational,"imPulseâ„¢ Una Full-spectrum, Over Clothing E-stethoscope",Completed,NA,"Level 42 AI, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04556149,0,0,0,0,3,1,United States,0,impulseâ„¢ una e-stethoscope|philips lumify ultrasound system|impulseâ„¢ una e-stethoscope,NA
NCT04556604,2020-04-10,2020-08-14,Observational,Surgical Consent During the COVID-19 Pandemic,Completed,NA,Medway Primary Care Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04556604,0,0,0,0,0,0,United Kingdom,0,educational meetings/visual prompts|education|visual prompts,NA
NCT04556565,2020-05-08,2021-05-31,Observational,MIND/COVID-19: Mental Health Impact and NeeDs Associated With COVID-19: a Comprehensive National Evaluation in Spain,Recruiting,NA,Hospital del Mar Research Institute (IMIM),NA,https://clinicalzeros.gov/ct2/show/NCT04556565,0,0,0,0,1,0,Spain,0,"NA",NA
NCT04553575,2020-09-25,2022-09-30,Observational [Patient Registry],CoViD-19 Patient in Reims University Hospital in March to April 2020,Recruiting,NA,CHU de Reims,NA,https://clinicalzeros.gov/ct2/show/NCT04553575,0,0,0,0,1,0,France,0,serology test,NA
NCT04555109,2020-06-30,2021-06-30,Observational,Convalescent Plasma for COVID-19 Research Donor Study,Recruiting,NA,The Hospital for Sick Children,NA,https://clinicalzeros.gov/ct2/show/NCT04555109,0,0,0,0,0,0,Canada,0,"NA",NA
NCT04554992,2020-03-20,2022-06-30,Interventional,Convalescent Plasma for the Treatment of COVID-19 (Coronavirus Disease 2019),"Active, not recruiting",Phase 1,The Methodist Hospital System,NA,https://clinicalzeros.gov/ct2/show/NCT04554992,0,0,0,0,1,1,United States,0,convalescent plasma,NA
NCT04554979,2020-06-01,2020-07-15,Observational,COVID-19 Disease Duration and GIT Manifestations. A New Disease Severity Classification. An Egyptian Experience,Completed,NA,Cairo University,NA,https://clinicalzeros.gov/ct2/show/NCT04554979,0,0,0,0,1,0,Egypt,0,hydroxychloroquine,NA
NCT04554264,2020-09-01,2021-09-30,Interventional,Complicated Grief in ICU in the Aftermath of COVID-19,Recruiting,N/A,"Centre Hospitalier Universitaire, Amiens",NA,https://clinicalzeros.gov/ct2/show/NCT04554264,0,0,0,0,0,0,France,0,questionnaire,NA
NCT04554251,2020-09-01,2020-12-01,Observational,Global Impact of COVID-19 on Pulmonology Special Units,Enrolling by invitation,NA,Assiut University,NA,https://clinicalzeros.gov/ct2/show/NCT04554251,0,0,0,0,0,0,Egypt,0,questionnaire,NA
NCT04555954,2020-04-11,2020-07-31,Observational,Determining the Physical Activity Level of Healthy Adults During Pandemic,Completed,NA,Pamukkale University,NA,https://clinicalzeros.gov/ct2/show/NCT04555954,0,0,0,0,0,0,Turkey,0,surveys/questionnaires|survey|questionnaire,NA
NCT04555187,2020-06-08,2021-12-31,Observational,Cardiovascular Risk Stratification in Covid-19,"Active, not recruiting",NA,Oregon Health and Science University,NA,https://clinicalzeros.gov/ct2/show/NCT04555187,0,0,0,0,1,1,United States,0,"NA",NA
NCT04555148,2020-09-20,2020-12-30,Interventional,COVIDIG (COVID-19 Hyper-ImmunoGlobulin),Recruiting,Phase 2,Green Cross Corporation,NA,https://clinicalzeros.gov/ct2/show/NCT04555148,0,0,0,0,0,0,"Korea, Republic of",0,gc5131|placebo,NA
NCT04553705,2020-09-20,2020-11-04,Interventional,"Omega-3, Nigella Sativa, Indian Costus, Quinine, Anise Seed, Deglycyrrhizinated Licorice, Artemisinin, Febrifugine on Immunity of Patients With (COVID-19)",Recruiting,Phase 2/Phase 3,Beni-Suef University,NA,https://clinicalzeros.gov/ct2/show/NCT04553705,0,0,0,0,1,0,Saudi Arabia,0,omega 3/nigella sativa oil|omega 3/nigella sativa oil/indian costus|omega 3/nigella sativa oil/quinine pills|omega 3/nigella sativa oil/anise seed capsule|omega 3/nigella sativa oil/deglycyrrhizinated licorice|active comparator|omega-3|nigella sativa oil|indian costus|quinine|anise|deglycyrrhizinated licorice,NA
NCT04551547,2020-10-31,2021-02-28,Interventional,Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of COVID-19,Recruiting,Phase 1/Phase 2,"Sinovac Biotech Co., Ltd",NA,https://clinicalzeros.gov/ct2/show/NCT04551547,0,0,0,1,2,0,China,0,"two doses of low dosage inactivated sars-cov-2 vaccine at the schedule of day 0,28|two doses of medium dosage inactivated sars-cov-2 vaccine at the schedule of day 0,28|placebo",NA
NCT04553055,2020-07-20,2020-09-15,Observational [Patient Registry],Antibiotic Misuse During COVID-19 Pandemic,Completed,NA,Beni-Suef University,NA,https://clinicalzeros.gov/ct2/show/NCT04553055,0,0,0,0,1,0,Egypt,0,online questionnaires,NA
NCT04552951,2020-04-04,2020-09-14,Interventional,Effect of Vitamin D on Morbidity and Mortality of the COVID-19,Recruiting,Phase 4,FundaciÃ³n para la InvestigaciÃ³n Biosanitaria del Principado de Asturias,NA,https://clinicalzeros.gov/ct2/show/NCT04552951,0,0,0,0,0,0,Spain,0,cholecalciferol,NA
NCT04552483,2020-06-08,2020-08-20,Interventional,Effects of Early Use of Nitazoxanide in Patients With COVID-19,Completed,Phase 2,Universidade Federal do Rio de Janeiro,NA,https://clinicalzeros.gov/ct2/show/NCT04552483,0,0,0,0,2,0,Brazil,0,nitazoxanide|placebo,NA
NCT04552379,2020-12-01,2021-04-30,Interventional,The Containing Coronavirus Disease 19 (COVID-19) Trial,Recruiting,Phase 3,Pontificia Universidad Catolica de Chile,NA,https://clinicalzeros.gov/ct2/show/NCT04552379,0,0,0,0,1,0,Chile,0,peginterferon beta-1a,NA
NCT04552366,2020-09-29,2020-12-31,Interventional,A Clinical Trial of a Recombinant Adenovirus 5 Vectored COVID-19 Vaccine (Ad5-nCoV) With Two Doses in Healthy Adults,"Active, not recruiting",Phase 1,"Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China",NA,https://clinicalzeros.gov/ct2/show/NCT04552366,0,0,0,1,2,0,China,0,ad5-ncov,NA
NCT04552340,2020-03-16,2023-03-31,Observational,"Epidemiologic, Clinical and Molecular Characteristics of Patients With Acute Respiratory Failure Affected by 2019-NCOV.",Recruiting,NA,Istituto Clinico Humanitas,NA,https://clinicalzeros.gov/ct2/show/NCT04552340,0,0,0,0,0,0,Italy,0,patient with sar-cov-2 infection,NA
NCT04551690,2020-04-15,2020-07-15,Observational,Prevalence of COVID-19 (Coronavirus Disease 19) in Pregnant Women on Labor in a Public Hospital in Chile (COroNavirus diSease Covid-19 pandEmic iN ChilE),Completed,NA,"Hospital San Juan de Dios, Santiago",NA,https://clinicalzeros.gov/ct2/show/NCT04551690,0,0,0,0,0,0,Chile,0,"NA",NA
NCT04551781,2020-04-01,2020-07-30,Interventional,Short Term Low Dose Corticosteroids for Management of Post covid19 Pulmonary Fibrosis,Completed,N/A,South Valley University,NA,https://clinicalzeros.gov/ct2/show/NCT04551781,0,0,0,0,0,0,Egypt,0,prednisone|control,NA
NCT04550325,2020-08-05,2020-11-26,Interventional,"Safety, PK and PD of Kamada Anti-SARS-CoV-2 in COVID-19",Completed,Phase 1/Phase 2,"Kamada, Ltd.",NA,https://clinicalzeros.gov/ct2/show/NCT04550325,0,0,0,0,1,0,Israel,0,kamada anti-sars-cov-2,NA
NCT04550312,2020-09-30,2020-10-31,Observational,The Impact of Lifestyle Changes on Non-COVID Deaths,Recruiting,NA,The First Affiliated Hospital with Nanjing Medical University,NA,https://clinicalzeros.gov/ct2/show/NCT04550312,0,0,0,0,0,0,China,0,"NA",NA
NCT04550403,2020-07-30,2021-05-30,Observational,Clinical Phenotype and Outcomes of Inpatients With COVID-19 and Diabetes,Recruiting,NA,Azienda Ospedaliero-Universitaria di Parma,NA,https://clinicalzeros.gov/ct2/show/NCT04550403,0,0,0,0,1,0,Italy,0,"NA",NA
NCT04550351,2020-08-19,2020-12-18,Interventional,Recombinant New Coronavirus Vaccine (CHO Cells) to Prevent SARS-CoV-2 Phase I Clinical Trial (â‰¥60 Years Old),"Active, not recruiting",Phase 1,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",NA,https://clinicalzeros.gov/ct2/show/NCT04550351,0,0,0,1,3,0,China,0,biological/vaccine: recombinant new coronavirus vaccine (cho cell) low-dose group|biological/vaccine: recombinant new coronavirus vaccine (cho cells) high-dose group|biological/vaccine: recombinant new coronavirus vaccine (cho cells) placebo group|biological|vaccine: recombinant new coronavirus vaccine (cho cell) low-dose group|vaccine: recombinant new coronavirus vaccine (cho cells) high-dose group|placebo,NA
NCT04549337,2020-09-25,2021-05-01,Interventional,Feasibility and Safety of High-intensity Exercise Training in Patients Surviving COVID-19,Recruiting,N/A,"Rigshospitalet, Denmark",NA,https://clinicalzeros.gov/ct2/show/NCT04549337,0,0,0,0,2,0,Denmark,0,exercise training,NA
NCT04549636,2020-09-18,2021-12-31,Observational,COVID-19 Related Lung Ventilation and Perfusion Injury,Recruiting,NA,McMaster University,NA,https://clinicalzeros.gov/ct2/show/NCT04549636,0,0,0,0,1,0,Canada,0,v/q spect-ct|st. george's respiratory questionnaire (sgrq)|mmrc (modified medical research council) dyspnea scale|six-minute walk test (6mwt)|spirometry|plethysmography/dlco|airwave oscillometry|v|q spect-ct|plethysmography|dlco,NA
NCT04548908,2020-08-03,2021-04-30,Observational,Prevalence Of COVID-19 Among Health-workers in a French General Hospital,Recruiting,NA,Centre Hospitalier Sud Essonne,NA,https://clinicalzeros.gov/ct2/show/NCT04548908,0,0,0,0,0,0,France,0,pcr/serology,NA
NCT04548895,2020-12-30,2021-06-30,Observational,Non-invasive Biometric Monitoring in Nursing Homes to Fight COVID-19,Recruiting,NA,"Health Stream Analytics, LLC",NA,https://clinicalzeros.gov/ct2/show/NCT04548895,0,0,0,0,1,1,United States,0,observational measurement of biometric data. no change to health care provided.,NA
NCT04549350,2020-05-19,2020-08-18,Observational,Sleep Quality Among HCWs,Completed,NA,Zagazig University,NA,https://clinicalzeros.gov/ct2/show/NCT04549350,0,0,0,0,1,0,Egypt,0,psqi,NA
NCT04548544,2019-10-18,2020-05-20,Interventional,A Randomized Controlled Feasibility Study of Emotional Well-being of Adolescents Undergoing a Mindfulness Training During COVID-19,Completed,N/A,"University of California, San Francisco",NA,https://clinicalzeros.gov/ct2/show/NCT04548544,0,0,0,0,0,1,United States,0,"training for awareness, resilience,/action (tara)|training for awareness, resilience,|action (tara)",NA
NCT04548531,2020-09-10,2021-04-30,Interventional,Engaging Patients in Colon Cancer Screening Decisions During COVID-19,Enrolling by invitation,N/A,Massachusetts General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04548531,0,0,0,0,1,1,United States,0,shared decision making,NA
NCT04547634,2020-07-01,2020-11-30,Interventional,Telerehabilitation in Oncology Patients,Enrolling by invitation,N/A,University of Malaga,NA,https://clinicalzeros.gov/ct2/show/NCT04547634,0,0,0,0,0,0,Spain,0,therapeutic exercise/education|therapeutic exercise|education,NA
NCT04546841,2020-11-27,2021-09-30,Interventional,Safety and Immunogenicity Trial of Multi-peptide Vaccination to Prevent COVID-19 Infection in Adults,Recruiting,Phase 1,University Hospital Tuebingen,NA,https://clinicalzeros.gov/ct2/show/NCT04546841,0,0,0,1,1,0,Germany,0,multipeptide cocktail,NA
NCT04547283,2020-06-14,2020-09-20,Interventional,Awake-Prone Positioning Strategy for Hypoxic Patients With COVID-19,Recruiting,N/A,Atrium Health,NA,https://clinicalzeros.gov/ct2/show/NCT04547283,0,0,0,0,0,1,United States,0,standard care|apps,NA
NCT04547218,2020-06-22,2020-12-31,Observational,Study on Incidence of Elective Surgery Postponed During COVID-19 Pandemic in Geriatric Population,Completed,NA,University of Malaya,NA,https://clinicalzeros.gov/ct2/show/NCT04547218,0,0,0,0,1,0,Malaysia,0,"NA",NA
NCT04546737,2020-09-08,2021-07-31,Interventional,"Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients",Recruiting,N/A,"Centre Hospitalier Universitaire, Amiens",NA,https://clinicalzeros.gov/ct2/show/NCT04546737,0,0,0,0,1,0,France,0,magnetic resonance spectroscopy (mrs).,NA
NCT04546776,2020-09-08,2022-06-30,Observational,COVID-19 Persistence in Stool,Enrolling by invitation,NA,Quadram Institute Bioscience,NA,https://clinicalzeros.gov/ct2/show/NCT04546776,0,0,0,0,0,0,United Kingdom,0,"NA",NA
NCT04547114,2020-09-14,2020-12-31,Observational,Breath Analysis for SARS-CoV-2 in Infected and Healthy Subjects,Recruiting,NA,Klinikum Bayreuth GmbH,NA,https://clinicalzeros.gov/ct2/show/NCT04547114,0,0,0,0,0,0,Germany,0,multicapillary column coupled ion mobility spectrometry,NA
NCT04546191,2020-07-01,2020-09-01,Observational [Patient Registry],Symptoms and Wellbeing of People Infected With Covid-19 Virus in Iceland,Completed,NA,Landspitali University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04546191,0,0,0,0,1,0,Iceland,0,"NA",NA
NCT04545541,2020-11-01,2022-04-30,Interventional,Nebulised Heparin in Patients With Severe COVID-19,Recruiting,Phase 2/Phase 3,Australian National University,NA,https://clinicalzeros.gov/ct2/show/NCT04545541,0,0,0,0,2,1,United States,0,nebulised unfractionated heparin (ufh),NA
NCT04544605,2020-09-07,2021-09-30,Observational,Special Chinese Medicine Out-patient Programme for Discharged COVID-19 Patients,Recruiting,NA,Hong Kong Baptist University,NA,https://clinicalzeros.gov/ct2/show/NCT04544605,0,0,0,0,1,0,China,0,individualized-chinese herbal medicine,NA
NCT04544878,2020-03-26,2021-06-01,Observational [Patient Registry],Pediatric Intensive Care and COVID-19,Recruiting,NA,Bicetre Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04544878,0,0,0,0,0,0,France,0,"NA",NA
NCT04545047,2020-05-01,2021-12-31,Observational,Observational Study of Convalescent Plasma for Treatment of Veterans With COVID-19,"Active, not recruiting",NA,VA Office of Research and Development,NA,https://clinicalzeros.gov/ct2/show/NCT04545047,0,0,0,0,1,1,United States,0,convalescent plasma,NA
NCT04544150,2020-06-01,2020-09-01,Observational,Gastrointestinal Manifestations Among Patients With COVID19,Completed,NA,Assiut University,NA,https://clinicalzeros.gov/ct2/show/NCT04544150,0,0,0,0,0,0,Egypt,0,"NA",NA
NCT04404179,2020-03-27,2020-05-02,Observational,Setting up a COVID-19 Care Facility at a Prison in Pakistan,Completed,NA,"Services Institute of Medical Sciences, Pakistan",NA,https://clinicalzeros.gov/ct2/show/NCT04404179,0,0,0,0,1,0,Pakistan,0,covid-19 facility,NA
NCT04544072,2020-05-01,2020-12-01,Observational,Analysis of the Quality and Quantity of Antibiotic Prescriptions for Bacterial Respiratory Tract Superinfection in Patients Hospitalized in COVID-19 Wards,Recruiting,NA,Universitair Ziekenhuis Brussel,NA,https://clinicalzeros.gov/ct2/show/NCT04544072,0,0,0,0,0,0,Belgium,0,"NA",NA
NCT04543760,2020-10-01,2021-03-31,Interventional,Effect of Prone Positioning Combined With High Flow Oxygen Therapy on Oxygenation During Acute Respiratory Failure Due to COVID-19,Recruiting,N/A,"Hospital St. Joseph, Marseille, France",NA,https://clinicalzeros.gov/ct2/show/NCT04543760,0,0,0,0,2,0,France,0,prone positioning|supine position,NA
NCT04542967,2020-06-23,2020-09-02,Interventional,Study on the Safety and Efficacy of Convalescent Plasma in Patients With Severe COVID-19 Disease,Recruiting,Phase 2,Hospital Central Militar,NA,https://clinicalzeros.gov/ct2/show/NCT04542967,0,0,0,0,1,0,Mexico,0,biological,NA
NCT04542954,2020-03-01,2020-08-31,Observational [Patient Registry],Optimized Management of Covid-19 Positive Kidney Transplant Recipients: Single Center Experience From the Middle East,Completed,NA,Hamid Al-Essa Organ Transplant Center,NA,https://clinicalzeros.gov/ct2/show/NCT04542954,0,0,0,0,0,0,Kuwait,0,optimized management of covid-19 positive kidney transplant recipients: single center experience from the middle east,NA
NCT04542941,2020-06-16,2020-12-31,Interventional,Assessment of Safety and Efficacy of CCP,Completed,N/A,Makerere University,NA,https://clinicalzeros.gov/ct2/show/NCT04542941,0,0,0,0,1,0,Uganda,0,convalescent plasma,NA
NCT04542694,2020-05-21,2020-08-10,Interventional,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Completed,Phase 3,"Promomed, LLC",NA,https://clinicalzeros.gov/ct2/show/NCT04542694,0,0,0,0,3,0,Russian Federation,1,favipiravir|standard care,NA
NCT04542876,2020-05-01,2020-07-31,Interventional,Efficacy and Safety of Guduchi Ghan Vati in the Management of Asymptomatic COVID-19 Infection,Completed,N/A,Aarogyam UK,NA,https://clinicalzeros.gov/ct2/show/NCT04542876,0,0,0,0,0,0,India,0,guduchi ghan vati,NA
NCT04542421,2020-07-01,2021-07-01,Interventional,Lung Ultrasound Implementation in the Management of Patients Hospitalized With COVID-19,Recruiting,N/A,"University of Colorado, Denver",NA,https://clinicalzeros.gov/ct2/show/NCT04542421,0,0,0,0,1,1,United States,0,lung ultrasound use in patients hospitalized with covid,NA
NCT04542408,2020-11-12,2021-05-31,Interventional,Hamburg Edoxaban for Anticoagulation in COVID-19 Study,Recruiting,Phase 3,UniversitÃ¤tsklinikum Hamburg-Eppendorf,NA,https://clinicalzeros.gov/ct2/show/NCT04542408,0,0,0,0,2,0,Germany,0,anticoagulation agents (edoxaban and/or high dose lmwh)|low dose low molecular weight heparin/placebo|anticoagulation agents (edoxaban and|or high dose lmwh)|low dose low molecular weight heparin|placebo,NA
NCT04542343,2020-11-01,2021-09-30,Interventional,COVID-19 Risk Reduction Among African American Parishioners,Recruiting,N/A,Charles Drew University of Medicine and Science,NA,https://clinicalzeros.gov/ct2/show/NCT04542343,0,0,0,0,1,1,United States,0,"change in knowledge, motivation, skills, resources",NA
NCT04542447,2020-09-01,2020-09-30,Interventional,To Evaluate Safety and Efficacy of Nuvastatic as an Immunomodulator Adjuvant Therapy in COVID-19 Patients.,Recruiting,Phase 1,Natureceuticals Sdn Bhd,NA,https://clinicalzeros.gov/ct2/show/NCT04542447,0,0,0,0,1,0,India,0,nuvastatic,NA
NCT04542044,2020-04-02,2020-05-05,Observational,Evaluation of the Safety and Outcomes of Outpatient Management With Mild to Moderate COVID-19 Pneumonia,Completed,NA,"University Hospital, Geneva",NA,https://clinicalzeros.gov/ct2/show/NCT04542044,0,0,0,0,0,0,Switzerland,0,management strategy of outpatient with mild to moderate sars-cov-2 pneumonia,NA
NCT04542330,2020-09-15,2022-01-31,Interventional,Using BCG to Protect Senior Citizens During the COVID-19 Pandemic,Recruiting,Phase 3,Bandim Health Project,NA,https://clinicalzeros.gov/ct2/show/NCT04542330,0,0,0,1,2,0,Denmark,0,bcg-denmark|saline,NA
NCT04542226,2020-03-31,2020-07-15,Observational,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Completed,NA,NPO Petrovax,NA,https://clinicalzeros.gov/ct2/show/NCT04542226,0,0,0,0,6,0,Belarus|Russian Federation,1,polyoxidonium,NA
NCT04541472,2020-05-01,2020-12-01,Observational,Influence of the COVId-19 Pandemic on the STRESS of Dental Surgeons (COVISTRESS - Dental Surgery),Recruiting,NA,"University Hospital, Clermont-Ferrand",NA,https://clinicalzeros.gov/ct2/show/NCT04541472,0,0,0,0,0,0,France,0,"NA",NA
NCT04540939,2020-10-19,2021-12-31,Interventional,Neural Mechanisms of Mindfulness-based Cognitive Therapy (MBCT) for Posttraumatic Stress Disorder (PTSD) - COVID Related Substudy,Recruiting,N/A,University of Michigan,NA,https://clinicalzeros.gov/ct2/show/NCT04540939,0,0,0,0,2,1,United States,0,mindfulness-based cognitive therapy|muscle relaxation therapy,NA
NCT04540185,2020-11-01,2022-11-01,Interventional,A Phase 3 Randomized Double Blind Efficacy and Safety Study of Oral Polio Vaccine and NA-831 for Covid-19,Enrolling by invitation,Phase 3,"NeuroActiva, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04540185,0,0,0,1,1,1,United States|New Zealand,0,oral polio vaccine|placebo|na-831|polio vaccine/na-831|polio vaccine,NA
NCT04540484,2020-08-26,2021-09-24,Observational,COVID-19 IgG Formation in Physicians at ALGH and Their Household Members,Recruiting,NA,Advocate Health Care,NA,https://clinicalzeros.gov/ct2/show/NCT04540484,0,0,0,0,1,1,United States,0,"NA",NA
NCT04539834,2020-05-01,2020-08-01,Observational,Electrolyte State in Patients With COVID-19,"Active, not recruiting",NA,Zagazig University,NA,https://clinicalzeros.gov/ct2/show/NCT04539834,0,0,0,0,0,0,Egypt,0,electrolytes,NA
NCT04539275,2020-11-16,2022-06-20,Interventional,COVID-19 (VA CURES-1),Recruiting,Phase 3,VA Office of Research and Development,NA,https://clinicalzeros.gov/ct2/show/NCT04539275,0,0,0,0,6,1,United States,0,convalescent plasma|masked saline placebo,NA
NCT04538586,2020-05-01,2020-12-01,Observational,"Influence of the COVId-19 Pandemic on STRESS, and Screening Procedures (COVISTRESS Screening)",Recruiting,NA,"University Hospital, Clermont-Ferrand",NA,https://clinicalzeros.gov/ct2/show/NCT04538586,0,0,0,0,0,0,France,0,"NA",NA
NCT04537962,2020-06-11,2020-09-30,Interventional,"Evaluationof the Load of SARS-CoV-2 Virus in Oral Cavity, Oropharinge and Saliva of Patients With Covid-19 After Disinfection With Oral Antimicrobial Solutions: a Pilot Study",Enrolling by invitation,N/A,Hospital Israelita Albert Einstein,NA,https://clinicalzeros.gov/ct2/show/NCT04537962,0,0,0,0,0,0,Brazil,0,colgate periogard mouthwash|colgate peroxyl mouthwash|colgate total mouthwash|placebo,NA
NCT04537351,2020-08-24,2021-03-31,Interventional,The MEseNchymal coviD-19 Trial: a Pilot Study to Investigate Early Efficacy of MSCs in Adults With COVID-19,Recruiting,Phase 1/Phase 2,Cynata Therapeutics Limited,NA,https://clinicalzeros.gov/ct2/show/NCT04537351,0,0,0,0,2,0,Australia,0,cyp-001,NA
NCT04537663,2020-08-25,2020-11-30,Interventional,Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults,Recruiting,Phase 4,UMC Utrecht,NA,https://clinicalzeros.gov/ct2/show/NCT04537663,0,0,0,1,0,0,Netherlands,0,bacille calmette-guã©rin (bcg)|placebo|bacille calmette-guã©rin (bcg),NA
NCT04537559,2020-03-01,2020-07-31,Observational,Impact of COVID-19 Outbreak on Non-COVID-19 Patients,Enrolling by invitation,NA,"University Hospital, Geneva",NA,https://clinicalzeros.gov/ct2/show/NCT04537559,0,0,0,0,1,0,Switzerland,0,"NA",NA
NCT04537117,2020-04-20,2020-05-05,Observational,"Knowledge, Attitudes and Clinical Practices of Pediatric Dentists Regarding Covid-19",Completed,NA,Fayoum University,NA,https://clinicalzeros.gov/ct2/show/NCT04537117,0,0,0,0,0,0,Egypt,0,questionaire,NA
NCT04536441,2020-04-01,2020-05-30,Interventional,Ultra-brief Online Mindfulness-based Intervention During COVID-19 Movement Control Order,Completed,N/A,Universiti Tunku Abdul Rahman,NA,https://clinicalzeros.gov/ct2/show/NCT04536441,0,0,0,0,0,0,Malaysia,0,ultra brief online mindfulness-based intervention|control,NA
NCT04536285,2020-05-01,2020-08-31,Observational,Hospitalized Children and Adolescent Patients With Type 1 Diabetes During the COVID-19 Pandemic in Egypt,Completed,NA,Ain Shams University,NA,https://clinicalzeros.gov/ct2/show/NCT04536285,0,0,0,0,0,0,Egypt,0,"NA",NA
NCT04536051,2020-06-02,2021-09-30,Interventional,A Study of a Candidate COVID-19 Vaccine (COV003),Recruiting,Phase 3,University of Oxford,NA,https://clinicalzeros.gov/ct2/show/NCT04536051,0,0,0,1,2,0,Brazil,0,chadox1 ncov-19 single dose / paracetamol|menacwy single dose / paracetamol|chadox1 ncov-19 two dose / paracetamol|menacwy prime/saline placebo boost / paracetamol|chadox1 ncov-19 single dose|paracetamol|menacwy single dose|chadox1 ncov-19 two dose|menacwy prime|saline placebo boost,NA
NCT04535856,2020-11-14,2021-01-14,Interventional,Therapeutic Study to Evaluate the Safety and Efficacy of DW-MSC in COVID-19 Patients,Completed,Phase 1,Ina-Respond,NA,https://clinicalzeros.gov/ct2/show/NCT04535856,0,0,0,0,6,0,Indonesia,0,allogeneic mesenchymal stem cell|placebo,NA
NCT04535791,2020-07-15,2021-05-31,Interventional,Efficacy of Vitamin D Supplementation to Prevent the Risk of Acquiring COVID-19 in Healthcare Workers,Recruiting,Phase 3,"CoordinaciÃ³n de InvestigaciÃ³n en Salud, Mexico",NA,https://clinicalzeros.gov/ct2/show/NCT04535791,0,0,0,0,0,0,Mexico,0,cholecalciferol,NA
NCT04535297,2020-05-10,2020-05-30,Observational,Consequences of the COVID-19 Lockdown on Health and Well-being of Patients With Parkinson Disease and Post-stroke,Completed,NA,University of Haifa,NA,https://clinicalzeros.gov/ct2/show/NCT04535297,0,0,0,0,0,0,Israel,0,exposure,NA
NCT04535700,2020-09-18,2021-03-10,Interventional,Clinical Trial of Pioglitazone Treatment in Patients With Type 2 Diabetes Mellitus and Covid-19,Recruiting,Phase 4,Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal,NA,https://clinicalzeros.gov/ct2/show/NCT04535700,0,0,0,0,1,0,Spain,0,pioglitazone 30 mg|standard care,NA
NCT04535063,2020-04-18,2020-12-30,Interventional,Convalescent Plasma as Potential Therapy for Severe COVID-19 Pneumonia,Recruiting,Phase 3,Centro de EducaciÃ³n Medica e Investigaciones ClÃ­nicas Norberto Quirno,NA,https://clinicalzeros.gov/ct2/show/NCT04535063,0,0,0,0,1,0,Argentina,0,convalescent plasma,NA
NCT04535154,2020-03-31,2021-06-01,Observational,Patient-reported Outcomes and Lung Function After Hospitalization for COVID-19,"Active, not recruiting",NA,"University Hospital, Akershus",NA,https://clinicalzeros.gov/ct2/show/NCT04535154,0,0,0,0,0,0,Norway,0,no intervention,NA
NCT04535128,2020-03-24,2020-12-31,Observational [Patient Registry],"COVID-19 Registry to Assess Frequency, Risk Factors, Management, and Outcomes of Arterial and Venous Thromboembolic Complications",Recruiting,NA,Brigham and Women's Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04535128,0,0,0,0,0,1,United States,0,no intervention,NA
NCT04534725,2020-12-17,2021-12-31,Interventional,COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomised Trial;,Recruiting,Phase 3,"Peter MacCallum Cancer Centre, Australia",NA,https://clinicalzeros.gov/ct2/show/NCT04534725,0,0,0,0,4,0,Australia,0,interferon alfa|selinexor|lenzilumab,NA
NCT04534673,2020-08-05,2021-12-31,Interventional,Pegylated Interferon Lambda for Treatment of COVID-19 Infection,Recruiting,Phase 2,Soroka University Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04534673,0,0,0,0,0,0,Israel,0,lambda 180 mcg s.c,NA
NCT04534608,2020-05-11,2020-06-30,Observational,COVID-19 Child Health Investigation of Latent Disease in Hamburg,"Active, not recruiting",NA,UniversitÃ¤tsklinikum Hamburg-Eppendorf,NA,https://clinicalzeros.gov/ct2/show/NCT04534608,0,0,0,0,0,0,Germany,0,"NA",NA
NCT04534400,2020-09-01,2021-01-15,Observational,Automated Quantification of Radiologic Pulmonary Alteration During Acute Respiratory Failure,Recruiting,NA,"University Hospital, Strasbourg, France",NA,https://clinicalzeros.gov/ct2/show/NCT04534400,0,0,0,0,1,0,France,0,thoracic ct-scan,NA
NCT04532931,2020-09-03,2021-06-30,Interventional,COVID-19 Treatment in South Africa,Recruiting,Phase 2,Shin Poong Pharmaceutical Co. Ltd.,NA,https://clinicalzeros.gov/ct2/show/NCT04532931,0,0,0,0,4,0,South Africa,0,standard care|artesunate-amodiaquine|pyronaridine-artesunate|favipiravir/nitazoxanide|sofosbuvir/daclatasvir|favipiravir|nitazoxanide|sofosbuvir|daclatasvir,NA
NCT04532294,2020-09-08,2021-02-19,Interventional,"Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants",Recruiting,Phase 1,BeiGene,NA,https://clinicalzeros.gov/ct2/show/NCT04532294,0,0,0,0,4,0,Australia,0,bgb dxp593|placebo,NA
NCT04531774,2020-08-28,2021-06-01,Interventional,RECHARGE: A Brief Psychological Intervention to Build Resilience in Healthcare Workers During COVID-19,Recruiting,N/A,University of Zurich,NA,https://clinicalzeros.gov/ct2/show/NCT04531774,0,0,0,0,2,0,Switzerland,0,recharge|self study,NA
NCT04532632,2020-09-01,2020-10-01,Observational [Patient Registry],Taste and Smell Impairment in Critically Ill COVID-19 Patients,Completed,NA,Sisli Hamidiye Etfal Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04532632,0,0,0,0,3,0,Turkey,0,"NA",NA
NCT04531735,2020-03-01,2020-08-01,Observational,Respiratory Syncytial Virus Infection May be More Dangerous in Neonate,"Active, not recruiting",NA,Dr. Behcet Uz Children's Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04531735,0,0,0,0,0,0,Turkey,0,"NA",NA
NCT04531618,2020-08-13,2021-12-31,Interventional,Mother-infant Bonding During COVID-19,Recruiting,N/A,Columbia University,NA,https://clinicalzeros.gov/ct2/show/NCT04531618,0,0,0,0,1,1,United States,0,family nurture intervention (fni),NA
NCT04531345,2020-10-01,2020-11-01,Observational,Cytokine Status of Covid-19 Patients,Completed,NA,Istanbul Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04531345,0,0,0,0,1,0,Turkey,0,flow cytometry,NA
NCT04531501,2020-06-29,2020-09-29,Observational,COVID-19 Saliva Test Research Study,Recruiting,NA,Chronomics Limited,NA,https://clinicalzeros.gov/ct2/show/NCT04531501,0,0,0,0,0,0,United Kingdom,0,saliva/nps test|saliva|nps test,NA
NCT04531319,2020-08-15,2020-10-01,Observational,Immune Cell Subgroups in Covid 19 Patients,Completed,NA,Istanbul Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04531319,0,0,0,0,1,0,Turkey,0,flow cytometry,NA
NCT04531202,2020-03-02,2020-09-30,Observational [Patient Registry],CORE Study COVID-19,Recruiting,NA,D'Or Institute for Research and Education,NA,https://clinicalzeros.gov/ct2/show/NCT04531202,0,0,0,0,0,0,Brazil,0,"NA",NA
NCT04531111,2020-07-07,2020-08-31,Observational,Glycemic Control Among Children and Adolescents With Type 1 Diabetes During COVID-19 Pandemic in Egypt,Recruiting,NA,Ain Shams University,NA,https://clinicalzeros.gov/ct2/show/NCT04531111,0,0,0,0,0,0,Egypt,0,"NA",NA
NCT04530604,2020-10-01,2021-10-01,Interventional,Defibrotide Therapy for SARS-CoV2 (COVID-19) Acute Respiratory Distress Syndrome (ARDS),Recruiting,Phase 1,University of Michigan,NA,https://clinicalzeros.gov/ct2/show/NCT04530604,0,0,0,0,1,1,United States,0,defibrotide,NA
NCT04530578,2020-06-01,2020-10-30,Interventional,Nebulized Heparin in Severe Acute Respiratory Syndrome COVID-19,Recruiting,Phase 4,"Clinica San Camilo, Argentina",NA,https://clinicalzeros.gov/ct2/show/NCT04530578,0,0,0,0,1,0,Argentina,0,heparin|enoxaparin,NA
NCT04530500,2020-08-13,2023-06-24,Observational,COVID-19 In-vitro Diagnostic Test and Androgen Receptor Gene Expression,Enrolling by invitation,NA,"University of California, Irvine",NA,https://clinicalzeros.gov/ct2/show/NCT04530500,0,0,0,0,1,1,United States,0,covid-19 androgen sensitivity test (covast),NA
NCT04530461,2020-06-01,2020-11-30,Observational,Serologic Profile of SARS CoV2 in COVID-19 Patients With Systemic Diseases,Recruiting,NA,Military Hospital of Tunis,NA,https://clinicalzeros.gov/ct2/show/NCT04530461,0,0,0,0,1,0,Tunisia,0,serology test,NA
NCT04530422,2020-04-15,2020-07-08,Interventional,Efficacy of Sofosbuvir Plus Ledipasvir in Egyptian Patients With COVID-19 Compared to Standard Treatment,Completed,Phase 3,Almaza Military Fever Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04530422,0,0,0,0,0,0,Egypt,0,sofosbuvir/ledipasvir|sofosbuvir|ledipasvir,NA
NCT04530370,2020-05-29,2020-09-30,Interventional,Efficacy and Safety of Recovered Covid 19 Plasma Transfusion to Covid 19 Severly Ill Patients,Recruiting,Early Phase 1,South Valley University,NA,https://clinicalzeros.gov/ct2/show/NCT04530370,0,0,0,0,0,0,Egypt,0,convalescent plasma,NA
NCT04529408,2020-08-26,2020-08-26,Observational,EARSATS-19: In-ear Measurement of Blood Oxygen Saturation in COVID-19 Follow up,Recruiting,NA,Imperial College London,NA,https://clinicalzeros.gov/ct2/show/NCT04529408,0,0,0,0,0,0,United Kingdom,0,earsats pulse oximeter probe,NA
NCT04530136,2020-11-30,2021-08-15,Interventional,Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19,Recruiting,Phase 2,Pharming Technologies B.V.,NA,https://clinicalzeros.gov/ct2/show/NCT04530136,0,0,0,0,2,1,United States,0,ruconest,NA
NCT04394208,2020-08-16,2021-01-30,Interventional,Silymarin in COVID-19 Pneumonia,Recruiting,Phase 3,Cairo University,NA,https://clinicalzeros.gov/ct2/show/NCT04394208,0,0,0,0,3,0,Egypt,0,silymarin|placebo,NA
NCT04529447,2020-06-10,2020-08-10,Observational,Response of Korean Medicine Hospital to COVID-19,Completed,NA,Jaseng Hospital of Korean Medicine,NA,https://clinicalzeros.gov/ct2/show/NCT04529447,0,0,0,0,0,0,"Korea, Republic of",0,questionnaire,NA
NCT04527562,2020-07-14,2020-11-15,Interventional,Colchicine in Moderate Symptomatic COVID-19 Patients,Completed,N/A,Dhaka Medical College,NA,https://clinicalzeros.gov/ct2/show/NCT04527562,0,0,0,0,2,0,Bangladesh,0,colchicine|placebo,NA
NCT04528901,2020-09-04,2022-12-31,Observational,Study of seroPREvalence Vis-Ã -vis SARS-CoV2 and Correlation With Clinical Forms of COVID-19 in Patients Followed in Pneumology in the Cluster Area of the Grand-Est Region (Strasbourg University Hospital),Recruiting,NA,"University Hospital, Strasbourg, France",NA,https://clinicalzeros.gov/ct2/show/NCT04528901,0,0,0,0,2,0,France,0,"NA",NA
NCT04527497,2020-08-01,2021-05-30,Observational,Clinical Course and Treatment of COVID-19 Inpatients in Hospital,Recruiting,NA,Wissenschaftliches Institut Bethanien e.V,NA,https://clinicalzeros.gov/ct2/show/NCT04527497,0,0,0,0,0,0,Germany,0,"NA",NA
NCT04527458,2020-02-24,2020-08-02,Observational,Case Fatalities in Hospitalised COVID-19 Patients in the UK,Completed,NA,University of Edinburgh,NA,https://clinicalzeros.gov/ct2/show/NCT04527458,0,0,0,0,0,0,United Kingdom,0,patient characteristics|covid-19 treatments|differences in triage|surge capacity,NA
NCT04527614,2020-09-24,2021-05-30,Interventional,Influence of Prior Infection With COVID-19 on Occurrence of Influenza-like Illness or Acute Respiratory Infection,Enrolling by invitation,N/A,Sciensano,NA,https://clinicalzeros.gov/ct2/show/NCT04527614,0,0,0,0,1,0,Belgium,0,qrt-pcr/serology|qrt-pcr|serology test,NA
NCT04527601,2020-08-21,2020-09-13,Observational,Extremely Premature Births During the Peak of the COVID-19 Pandemic: an International Study of the Active SafeBoosC III Departments,Completed,NA,"Rigshospitalet, Denmark",NA,https://clinicalzeros.gov/ct2/show/NCT04527601,0,0,0,0,3,0,Denmark,0,"NA",NA
NCT04527133,2020-06-11,2020-08-11,Interventional,An Open Non-comparative Study of the Efficacy and Safety of Aprotinin in Patients Hospitalized With COVID-19,"Active, not recruiting",N/A,Aviron LLC,NA,https://clinicalzeros.gov/ct2/show/NCT04527133,0,0,0,0,0,0,Russian Federation,0,aprotinin,NA
NCT04527081,2020-08-31,2020-11-09,Interventional,Study of COVID-19 DNA Vaccine (AG0302-COVID19),"Active, not recruiting",Phase 1/Phase 2,"AnGes, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04527081,0,0,0,1,4,0,Japan,0,ag0302-covid19,NA
NCT04526990,2020-09-15,2021-12-30,Interventional,Phase III Trial of A COVID-19 Vaccine of Adenovirus Vector in Adults 18 Years Old and Above,Recruiting,Phase 3,CanSino Biologics Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04526990,0,0,0,1,11,0,Mexico|Argentina|Chile|Pakistan|Russian Federation,0,adenovirus type 5 vector|placebo,NA
NCT04526977,2021-01-10,2021-06-30,Observational,Differences in Immune Response Among HIV-1-infected Individuals With Previous or Current COVID-19 (CoVIHDis).,Recruiting,NA,Asociacion para el Estudio de las Enfermedades Infecciosas,NA,https://clinicalzeros.gov/ct2/show/NCT04526977,0,0,0,0,1,0,Spain,0,immune response study,NA
NCT04527315,2020-07-17,2023-08-31,Observational [Patient Registry],COVID-19 Survivorship Registry,Recruiting,NA,NYU Langone Health,NA,https://clinicalzeros.gov/ct2/show/NCT04527315,0,0,0,0,2,1,United States,0,questionnaire,NA
NCT04526054,2020-09-03,2021-09-03,Interventional,Morphological Abnormalities of the Olfactory Bulb on MRI and Olfactometry in Anosmic Versus Normosmic COVID-19 Patients,Recruiting,N/A,Hopital Foch,NA,https://clinicalzeros.gov/ct2/show/NCT04526054,0,0,0,0,1,0,France,0,ent exam|olfactometry|brain mri,NA
NCT04525742,2020-07-05,2020-08-30,Interventional,COVID-19 Pandemic and Parents of Disabled Children,Completed,N/A,Gaziosmanpasa Taksim Research and Education Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04525742,0,0,0,0,1,0,Turkey,0,difficulties lived by disabled children's parents in the period of covid-19 pandemic,NA
NCT04525716,2020-03-01,2020-08-31,Observational,The Effect of Covid-19 on Patient Outcomes Among Operated Patients,Recruiting,NA,Karolinska Institutet,NA,https://clinicalzeros.gov/ct2/show/NCT04525716,0,0,0,0,0,0,Sweden,0,covid-19 infection status,NA
NCT04524234,2020-04-20,2020-08-31,Observational,Cardiac Dysfunction in Critically Ill Patients With COVID-19,Completed,NA,"Sahlgrenska University Hospital, Sweden",NA,https://clinicalzeros.gov/ct2/show/NCT04524234,0,0,0,0,3,0,Sweden,0,echocardiography,NA
NCT04525287,2020-02-20,2020-08-20,Observational,Prediction Models for Diagnosis and Prognosis of Severe COVID-19,Recruiting,NA,"Second Affiliated Hospital, School of Medicine, Zhejiang University",NA,https://clinicalzeros.gov/ct2/show/NCT04525287,0,0,0,0,0,0,China,0,"NA",NA
NCT04524754,2020-07-11,2020-09-11,Observational,Prevalence and Outcomes of Olfactory and Gustatory Dysfunctions in Patients With COVID-19,Recruiting,NA,Ain Shams University,NA,https://clinicalzeros.gov/ct2/show/NCT04524754,0,0,0,0,2,0,Egypt,0,"NA",NA
NCT04525404,2020-11-12,2021-09-01,Observational,MOIST Study: Multi-Organ Imaging With Serial Testing in COVID-19 Infected Patients,Recruiting,NA,University of Alberta,NA,https://clinicalzeros.gov/ct2/show/NCT04525404,0,0,0,0,2,0,Canada,0,"mri (heart, brain, lungs, liver)|bloodwork|cognitive testing|olfaction testing|spirometry|walk test",NA
NCT04525378,2020-07-01,2020-09-30,Interventional,MSC-based Therapy in COVID-19-associated Acute Respiratory Distress Syndrome,Recruiting,Phase 1,D'Or Institute for Research and Education,NA,https://clinicalzeros.gov/ct2/show/NCT04525378,0,0,0,0,1,0,Brazil,0,mesenchymal stromal cell-based therapy,NA
NCT04524520,2020-05-05,2021-05-08,Observational,"COVID19-OR (SARS-CoV-2): Observation,Risk & Recovery",Recruiting,NA,Western Sussex Hospitals NHS Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04524520,0,0,0,0,0,0,United Kingdom,0,"NA",NA
NCT04524507,2020-08-27,2021-05-31,Interventional,COVID-19 Antibody Plasma Research Study in Hospitalized Patients,Recruiting,Phase 2,"University of North Carolina, Chapel Hill",NA,https://clinicalzeros.gov/ct2/show/NCT04524507,0,0,0,0,1,1,United States,0,convalescent plasma,NA
NCT04523051,2020-04-01,2021-04-01,Observational,Rehabilitation After Admission in Intensive Care Unit for COVID-19,Recruiting,NA,Centre Hospitalier RÃ©gional Metz-Thionville,NA,https://clinicalzeros.gov/ct2/show/NCT04523051,0,0,0,0,1,0,France,0,"NA",NA
NCT04523571,2020-07-28,2020-09-30,Interventional,Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b1) in Chinese Healthy Subjects,"Active, not recruiting",Phase 1,BioNTech SE,NA,https://clinicalzeros.gov/ct2/show/NCT04523571,0,0,0,1,2,0,China,0,bnt162b1|placebo,NA
NCT04523831,2020-06-01,2020-08-22,Interventional,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Completed,Phase 3,Dhaka Medical College,NA,https://clinicalzeros.gov/ct2/show/NCT04523831,0,0,0,0,5,0,Bangladesh,1,ivermectin/doxycycline|standard care|ivermectin|doxycycline,NA
NCT04523012,2020-07-01,2021-06-30,Observational,COVID-19 and HIV Patients,Recruiting,NA,Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida,NA,https://clinicalzeros.gov/ct2/show/NCT04523012,0,0,0,0,0,0,France,0,seroprevalence of sars-cov-2 infection in patients with hiv infection,NA
NCT04522128,2020-05-22,2022-03-31,Interventional,Does Quality of Life Decline During the COVID-19 Pandemic and Can we Change Behaviour to Improve Poor Quality of Life?,Recruiting,N/A,University of Manchester,NA,https://clinicalzeros.gov/ct2/show/NCT04522128,0,0,0,0,0,0,United Kingdom,0,behaviour change technique intervention to improve quality of life,NA
NCT04522037,2020-06-01,2020-09-30,Observational,Measurement of the Efficacy of MORPHINE in the Early Management of Dyspnea in COVID-19 Positive Patients,Recruiting,NA,Hospices Civils de Lyon,NA,https://clinicalzeros.gov/ct2/show/NCT04522037,0,0,0,0,0,0,France,0,no intervention|compare the difference in respiratory rate between h0|h12 of the initiation of morphine between the control|interventional groups,NA
NCT04522466,2020-04-03,2020-05-28,Interventional,Evaluation of the Pharmacokinetics and Pharmacodynamics of Hydroxychloroquine in COVID-19 Intensive Care Unit Patients,Terminated,Phase 3,Centre Hospitalier Universitaire de Saint Etienne,Stop of the study by competent authority (ANSM),https://clinicalzeros.gov/ct2/show/NCT04522466,0,0,0,0,1,0,France,0,hydroxychloroquine,NA
NCT04522089,2020-08-24,2020-11-20,Interventional,A Study to Evaluate the Safety and Immunogenicity of COVID-19 (AdimrSC-2f) Vaccine,Recruiting,Phase 1,Adimmune Corporation,NA,https://clinicalzeros.gov/ct2/show/NCT04522089,0,0,0,1,3,0,Taiwan,0,adimrsc-2f,NA
NCT04522076,2020-04-06,2022-05-01,Observational,Prospective Hospital Registry of Patients With Suspected or Confirmed Coronavirus Infection (COVID-19) and Community-acquired Pneumonia,"Active, not recruiting",NA,National Medical Research Center for Therapy and Preventive Medicine,NA,https://clinicalzeros.gov/ct2/show/NCT04522076,0,0,0,0,0,0,Russian Federation,0,"NA",NA
NCT04521322,2020-07-24,2020-10-30,Interventional,Efficacy of a Nasal Spray Containing Iota-Carrageenan in the Prophylaxis of COVID-19 Disease in Health Personnel Dedicated to Patients Care With COVID-19 Disease,Recruiting,Phase 4,Centro de EducaciÃ³n Medica e Investigaciones ClÃ­nicas Norberto Quirno,NA,https://clinicalzeros.gov/ct2/show/NCT04521322,0,0,0,0,1,0,Argentina,0,iota-carrageenan,NA
NCT04521010,2020-01-01,2020-04-30,Observational,Staff Absenteeism and Delivery of Healthcare Services During the COVID-19 Pandemic,Completed,NA,Poznan University of Medical Sciences,NA,https://clinicalzeros.gov/ct2/show/NCT04521010,0,0,0,0,0,0,Poland,0,covid-19 pandemic,NA
NCT04521088,2020-07-02,2020-12-31,Observational [Patient Registry],Epidemiological Analysis of Ambulant Patients in a COVID-19 Outpatient Clinic,Recruiting,NA,Wissenschaftliches Institut Bethanien e.V,NA,https://clinicalzeros.gov/ct2/show/NCT04521088,0,0,0,0,1,0,Germany,0,"NA",NA
NCT04519372,2020-04-01,2020-06-14,Observational,SARS-CoV-2 /COVID-19 Admission Screening in a University Hospital Setting,"Active, not recruiting",NA,"University Hospital, Basel, Switzerland",NA,https://clinicalzeros.gov/ct2/show/NCT04519372,0,0,0,0,1,0,Switzerland,0,testing for sars-cov-2,NA
NCT04519502,2020-06-23,2021-03-31,Observational,Maternal Morbidity and Mortality During the COVID-19 Pandemic,Recruiting,NA,The George Washington University Biostatistics Center,NA,https://clinicalzeros.gov/ct2/show/NCT04519502,0,0,0,0,1,1,United States,0,"NA",NA
NCT04519320,2020-05-18,2021-08-18,Interventional,Medium and Long Term Follow-up of COVID-19 Infected Patients: Research and Characterization of Pulmonary Sequelae,Recruiting,N/A,Centre Hospitalier Universitaire de Besancon,NA,https://clinicalzeros.gov/ct2/show/NCT04519320,0,0,0,0,1,0,France,0,pulmonary function testing,NA
NCT04519437,2020-07-26,2021-10-25,Interventional,"Study Assessing the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Repeated Subcutaneous Doses of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (REGN10933+REGN10987) in Adult Volunteers as Related to COVID-19","Active, not recruiting",Phase 1,Regeneron Pharmaceuticals,NA,https://clinicalzeros.gov/ct2/show/NCT04519437,0,0,0,0,3,1,United States,0,regn10933 / regn10987|placebo|regn10933|regn10987,NA
NCT04519398,2020-08-18,2021-02-17,Observational,Investigating the Involvement of ACE and Angiotensinogen Genes' Polymorphism Along With Other Thrombophilic Genotypes in Severe Forms of COVID-19 With/Without Thrombotic Events,Recruiting,NA,Grigore T. Popa University of Medicine and Pharmacy,NA,https://clinicalzeros.gov/ct2/show/NCT04519398,0,0,0,0,0,0,Romania,0,complete thrombophilic profile testing by multiplex pcr,NA
NCT04519385,2020-03-01,2020-07-01,Interventional,Toclizumam Versus Dexamethasone in Severe Covid-19 Cases,Completed,N/A,South Valley University,NA,https://clinicalzeros.gov/ct2/show/NCT04519385,0,0,0,0,1,0,Egypt,0,tocilizumab|dexamethasone,NA
NCT04519307,2020-03-01,2020-08-01,Observational,Evaluation of Newborns Presenting With Suspected COVID 19,"Active, not recruiting",NA,Dr. Behcet Uz Children's Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04519307,0,0,0,0,0,0,Turkey,0,"NA",NA
NCT04519216,2020-07-31,2021-06-30,Interventional,Breastfeeding Education in the Time of COVID-19,Recruiting,N/A,"University of California, Davis",NA,https://clinicalzeros.gov/ct2/show/NCT04519216,0,0,0,0,0,1,United States,0,telesimulation,NA
NCT04518735,2020-04-01,2020-06-30,Observational,Evolution of COVID-19 in Anticoagulated or Antiaggregated Patients (CORONA Study),Completed,NA,FundaciÃ³ Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau,NA,https://clinicalzeros.gov/ct2/show/NCT04518735,0,0,0,0,0,0,Spain,0,antithrombotic therapy (anticoagulant and/or antiplatelet) before admission for covid19|antithrombotic therapy (anticoagulant and|or antiplatelet) before admission for covid19,NA
NCT04518969,2020-05-03,2020-12-01,Interventional,Determination of the Hemoadsorption Impact as Adjunctive Treatment Upon the Support Therapy of COVID-19,Recruiting,N/A,Brugmann University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04518969,0,0,0,0,0,0,Belgium,0,cytosorb,NA
NCT04518514,2020-04-20,2020-10-31,Interventional,Telemedical Risk Assessment and Preoperative Evaluation (TAPE),Recruiting,N/A,RWTH Aachen University,NA,https://clinicalzeros.gov/ct2/show/NCT04518514,0,0,0,0,0,0,Germany,0,tape-software,NA
NCT04516564,2020-09-30,2021-03-31,Interventional,"A Study of AK119 (Anti-CD73 Antibody), a Treatment for COVID-19, in Healthy Subjects",Recruiting,Phase 1,Akeso,NA,https://clinicalzeros.gov/ct2/show/NCT04516564,0,0,0,0,2,0,New Zealand,0,ak119|placebo,NA
NCT04517123,2020-09-01,2021-12-31,Interventional,"Prone Position and Respiratory Outcomes in Non-Intubated COVID-19 PatiEnts The ""PRONE"" Study",Recruiting,N/A,Johns Hopkins University,NA,https://clinicalzeros.gov/ct2/show/NCT04517123,0,0,0,0,2,1,United States,0,prone positioning,NA
NCT04517097,2020-05-12,2020-06-30,Observational,Study of the Specific Seroprevalence of SARS-CoV-2 in a Sample of Patients and Salaried Staff From a French Anti-cancer Center at the End of the Containment Period of the SARS-CoV-2 Pandemic,Completed,NA,Centre Georges Francois Leclerc,NA,https://clinicalzeros.gov/ct2/show/NCT04517097,0,0,0,0,0,0,France,0,blood sample,NA
NCT04517695,2020-08-01,2021-02-01,Observational,Blood Volume Assessment in COVID-19 ICU Patients - BVAC19,Recruiting,NA,NYU Langone Health,NA,https://clinicalzeros.gov/ct2/show/NCT04517695,0,0,0,0,0,1,United States,0,bva-100,NA
NCT04517682,2020-05-21,2020-12-15,Observational,COVID-19 and SARS-CoV-2 Detection in Saliva,Enrolling by invitation,NA,Ambry Genetics,NA,https://clinicalzeros.gov/ct2/show/NCT04517682,0,0,0,0,1,1,United States,0,pcr,NA
NCT04516954,2020-08-01,2020-11-30,Interventional,Convalescent Plasma for COVID-19 Patients,Enrolling by invitation,Early Phase 1,Vinmec Research Institute of Stem Cell and Gene Technology,NA,https://clinicalzeros.gov/ct2/show/NCT04516954,0,0,0,0,2,0,Vietnam,0,convalescent plasma,NA
NCT04516915,2020-06-15,2021-05-31,Interventional,IMU-838 and Oseltamivir in the Treatment of COVID-19,Recruiting,Phase 2,University Hospitals Coventry and Warwickshire NHS Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04516915,0,0,0,0,1,0,United Kingdom,0,imu-838|oseltamivir,NA
NCT04516837,2020-08-31,2021-08-31,Interventional,Eltrombopag Plus rhTPO Versus Eltrombopag for ITP During the COVID-19 Pandemic (ELABORATE-19),Recruiting,Phase 2,Peking University People's Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04516837,0,0,0,0,2,0,China,0,eltrombopag|rhtpo,NA
NCT04516824,2020-03-19,2020-07-13,Observational,Experience of Orthopaedic and Spine Center Pakistan During COVID-19,Completed,NA,Ghurki Trust and Teaching Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04516824,0,0,0,0,0,0,Pakistan,0,orthopaedic surgical procedures,NA
NCT04516486,2020-03-09,2020-05-24,Observational,Coronavirus Studied by Metagenomics in ARDS COVID-19 Patients,"Active, not recruiting",NA,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04516486,0,0,0,0,0,0,France,0,retrospective metagenomics on clinical samples collected during hospitalization,NA
NCT04515147,2020-09-28,2021-11-09,Interventional,"A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19","Active, not recruiting",Phase 2,CureVac AG,NA,https://clinicalzeros.gov/ct2/show/NCT04515147,0,0,0,1,8,0,Panama|Peru,0,cvncov 6 î¼g|cvncov 12 î¼g|hepatitis a vaccine|pneumococcal vaccine|cvncov 12î¼g|cvncov 6 î¼g|cvncov 12 î¼g|cvncov 12î¼g,NA
NCT04515199,2020-07-01,2021-01-31,Observational [Patient Registry],Home Management of Adult Egyptian Mild COVID-19 Cases,Recruiting,NA,Cairo University,NA,https://clinicalzeros.gov/ct2/show/NCT04515199,0,0,0,0,0,0,Egypt,0,"NA",NA
NCT04514003,2020-07-01,2023-12-31,Observational,The Corona and COVID-19 Study in Telemark and Agder,Recruiting,NA,Sykehuset Telemark,NA,https://clinicalzeros.gov/ct2/show/NCT04514003,0,0,0,0,1,0,Norway,0,"NA",NA
NCT04514627,2020-07-13,2021-07-31,Interventional,Neuromodulation With Percutaneous Electrical Nerve Field Stimulation for Adults With COVID-19,Recruiting,N/A,Olive View-UCLA Education & Research Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04514627,0,0,0,0,1,1,United States,0,auricular percutaneous neurostimulation,NA
NCT04513990,2020-04-09,2021-04-30,Interventional,Novel Point-of-Care Diagnostic Test for SARS-CoV-2 (COVID-19),Recruiting,N/A,M.D. Anderson Cancer Center,NA,https://clinicalzeros.gov/ct2/show/NCT04513990,0,0,0,0,1,1,United States,0,biospecimen collection|biospeciman collection|questionnaire,NA
NCT04513470,2020-08-01,2021-01-31,Interventional,Allocetra-OTS in COVID-19,"Active, not recruiting",Phase 1,Hadassah Medical Organization,NA,https://clinicalzeros.gov/ct2/show/NCT04513470,0,0,0,0,1,0,Israel,0,allocetra-ots,NA
NCT04513847,2020-08-13,2020-09-13,Observational,PsoVac: Educational Needs re Vaccines for Biologic Patients With Psoriasis,Completed,NA,Dermatrials Research,NA,https://clinicalzeros.gov/ct2/show/NCT04513847,0,0,0,0,2,0,Canada,0,"NA",NA
NCT04513210,2020-10-10,2021-10-30,Observational,Reliability of Standardized Protocol of Ultrasound of the Lungs in Prediction of Severity of Covid-19 Infection,Enrolling by invitation,NA,Jagiellonian University,NA,https://clinicalzeros.gov/ct2/show/NCT04513210,0,0,0,0,3,0,Poland,0,"NA",NA
NCT04513184,2020-07-14,2021-03-30,Interventional,Randomized Clinical Trial of Intranasal Dexamethasone as an Adjuvant in Patients With COVID-19,Recruiting,Phase 2,Universidad Nacional Autonoma de Mexico,NA,https://clinicalzeros.gov/ct2/show/NCT04513184,0,0,0,0,3,0,Mexico,0,dexamethasone,NA
NCT04513158,2020-08-14,2021-08-01,Interventional,Convalescent Plasma in the Early Treatment of High-Risk Patients With SARS-CoV-2 (COVID-19) Infection,Recruiting,Phase 2,Norton Healthcare,NA,https://clinicalzeros.gov/ct2/show/NCT04513158,0,0,0,0,2,1,United States,0,convalescent plasma,NA
NCT04512027,2020-09-15,2020-09-19,Interventional,Prolectin-M in COVID-19 Patients Having Mild to Moderate Symptoms Not Requiring Oxygen Support.,Completed,N/A,Composite Interceptive Med Science,NA,https://clinicalzeros.gov/ct2/show/NCT04512027,0,0,0,0,3,0,India,0,prolectin-m; a (1-6)-alpha-d-mannopyranose class|standard care,NA
NCT04512300,2020-06-15,2020-06-25,Observational,Parental Attitude Toward Children Dental Treatment During COVID-19 Pandemic,Completed,NA,Cairo University,NA,https://clinicalzeros.gov/ct2/show/NCT04512300,0,0,0,0,0,0,Egypt,0,"NA",NA
NCT04511650,2020-10-21,2021-02-28,Interventional,"A Study to Evaluate the Safety and Efficacy of Razuprotafib, a Novel Tie 2 Activator, in Hospitalized Subjects With Moderate to Severe Coronavirus Disease 2019 (COVID-19)",Recruiting,Phase 2,Aerpio Therapeutics,NA,https://clinicalzeros.gov/ct2/show/NCT04511650,0,0,0,0,7,1,United States,0,razuprotafib subcutaneous solution|placebo,NA
NCT04512118,2020-03-15,2020-06-30,Observational,CT Abnormalities Evocative of Lung Infection Are Associated With Lower 18F-FDG Uptake in Confirmed COVID-19 Patients,Completed,NA,"Central Hospital, Nancy, France",NA,https://clinicalzeros.gov/ct2/show/NCT04512118,0,0,0,0,0,0,France,0,pet-ct of 18f-fdg,NA
NCT04508439,2020-06-20,2020-08-30,Interventional,Effect of the Use of Anticoagulant Therapy During Hospitalization and Discharge in Patients With COVID-19 Infection,Recruiting,N/A,Hospital Regional de Alta especialidad de Ixtapaluca,NA,https://clinicalzeros.gov/ct2/show/NCT04508439,0,0,0,0,0,0,Mexico,0,enoxaparin,NA
NCT04509713,2020-07-02,2020-09-30,Observational,Canine COVID-19 Detection,Recruiting,NA,ARCTEC,NA,https://clinicalzeros.gov/ct2/show/NCT04509713,0,0,0,0,0,0,United Kingdom,0,collection of odour samples,NA
NCT04508972,2020-07-01,2020-10-01,Observational,The VOICE-COVID-19,Recruiting,NA,McGill University Health Centre/Research Institute of the McGill University Health Centre,NA,https://clinicalzeros.gov/ct2/show/NCT04508972,0,0,0,0,4,0,Canada,0,alexa amazon,NA
NCT04508712,2020-08-10,2021-08-31,Observational [Patient Registry],Long-term Outcomes in Patients With COVID-19,Recruiting,NA,RenJi Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04508712,0,0,0,0,2,0,China,0,"NA",NA
NCT04510662,2020-08-31,2021-03-31,Interventional,Telmisartan in Respiratory Failure Due to COVID-19,Recruiting,Phase 2,Hospital Regional de Alta Especialidad de Zumpango,NA,https://clinicalzeros.gov/ct2/show/NCT04510662,0,0,0,0,0,0,Mexico,0,telmisartan,NA
NCT04510493,2020-10-23,2023-09-30,Interventional,Canakinumab in Patients With COVID-19 and Type 2 Diabetes,Recruiting,Phase 3,"University Hospital, Basel, Switzerland",NA,https://clinicalzeros.gov/ct2/show/NCT04510493,0,0,0,0,4,0,Switzerland,0,canakinumab|placebo,NA
NCT04510441,2020-05-26,2022-05-01,Observational,Artificial Intelligence-assisted Diagnosis and Prognostication in COVID-19 Using Electrocardiograms,Recruiting,NA,Imperial College London,NA,https://clinicalzeros.gov/ct2/show/NCT04510441,0,0,0,0,0,0,United Kingdom,0,no intervention,NA
NCT04510025,2020-05-13,2023-05-01,Observational,Capturing MultiORgan Effects of COVID-19,Recruiting,NA,University of Oxford,NA,https://clinicalzeros.gov/ct2/show/NCT04510025,0,0,0,0,1,0,United Kingdom,0,magnetic resonance imaging,NA
NCT04510012,2020-03-05,2021-03-05,Observational,Characterizing the Immune Response and Neuronal Damage in COVID-19,Recruiting,NA,"University Hospital Inselspital, Berne",NA,https://clinicalzeros.gov/ct2/show/NCT04510012,0,0,0,0,0,0,Switzerland,0,"analysis of cytokine response, innate/adaptive immune response, complement activation,/serum neurofilaments as a marker of neurological damage.|analysis of cytokine response, innate|adaptive immune response, complement activation,|serum neurofilaments as a marker of neurological damage.",NA
NCT04509999,2020-10-26,2022-09-30,Interventional,Bicalutamide to Block TMPRSS2 in Males With COVID-19 Infection,Recruiting,Phase 3,University of Florida,NA,https://clinicalzeros.gov/ct2/show/NCT04509999,0,0,0,0,5,1,United States,0,bicalutamide 150 mg oral tablet|placebo,NA
NCT04508959,2020-04-15,2021-07-31,Observational [Patient Registry],The McMaster Multi-Regional COVID-19 Hospital Case Registry,Recruiting,NA,McMaster University,NA,https://clinicalzeros.gov/ct2/show/NCT04508959,0,0,0,0,1,0,Canada,0,"NA",NA
NCT04508920,2019-05-15,2021-06-15,Observational [Patient Registry],A Survey to Assess Effects of Covid-19 on Cardiovascular Patients,Recruiting,NA,"Centro en Insuficiencia Cardiaca, Mexico",NA,https://clinicalzeros.gov/ct2/show/NCT04508920,0,0,0,0,0,0,Mexico,0,"survey|symptomatology, treatment. daily activities",NA
NCT04508868,2020-08-31,2020-12-23,Interventional,Treatment of Depressive Symptoms in Older Individuals in Isolation During Covid-19,Terminated,N/A,Uppsala University,"Study terminated due to changes in government restrictions. Collected data to be presented as a
    pilot study.",https://clinicalzeros.gov/ct2/show/NCT04508868,0,0,0,0,2,0,Sweden,0,behavioral|minimal attention control intervention,NA
NCT04506229,2020-08-20,2021-08-31,Observational,Genetic Mechanisms Underlying SARS-CoV-2 Infection and the Impact of COVID-19 on Cognitive Function,Recruiting,NA,Texas Cardiac Arrhythmia Research Foundation,NA,https://clinicalzeros.gov/ct2/show/NCT04506229,0,0,0,0,2,1,United States,0,whole exome sequencing,NA
NCT04506528,2020-08-10,2023-01-31,Observational [Patient Registry],The C3I COVID-19 Project,Recruiting,NA,"University of Wisconsin, Madison",NA,https://clinicalzeros.gov/ct2/show/NCT04506528,0,0,0,0,3,1,United States,0,"NA",NA
NCT04506515,2020-04-09,2020-04-19,Observational,Psychological Impact of COVID-19 Pandemic in Healthcare Workers,Completed,NA,Hospital General Universitario de Valencia,NA,https://clinicalzeros.gov/ct2/show/NCT04506515,0,0,0,0,0,0,Spain,0,psychological stress/adaptation at work score (psas)|psychological stress|adaptation at work score (psas),NA
NCT04506632,2020-06-02,2021-04-02,Observational,Burden for STaff Working in the NHS,Recruiting,NA,Sheffield Teaching Hospitals NHS Foundation Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04506632,0,0,0,0,0,0,United Kingdom,0,"NA",NA
NCT04505592,2020-09-25,2021-06-30,Interventional,Tenecteplase in Patients With COVID-19,Recruiting,Phase 2,Icahn School of Medicine at Mount Sinai,NA,https://clinicalzeros.gov/ct2/show/NCT04505592,0,0,0,0,3,1,United States,0,tenecteplase|placebo,NA
NCT04505709,2020-08-01,2021-08-01,Observational [Patient Registry],"Clinical, Immunological, Genomic, Virological and Bioethical Actors of COVID-19",Enrolling by invitation,NA,Instituto de InvestigaciÃ³n Sanitaria de la FundaciÃ³n JimÃ©nez DÃ­az,NA,https://clinicalzeros.gov/ct2/show/NCT04505709,0,0,0,0,0,0,Spain,0,"NA",NA
NCT04504877,2020-06-16,2020-11-16,Interventional,Burnout and Distress preventiOn With caNnabidiol in Front-line Health Care workerS deAling wIth COVID-19,"Active, not recruiting",Phase 2/Phase 3,University of Sao Paulo,NA,https://clinicalzeros.gov/ct2/show/NCT04504877,0,0,0,0,3,0,Brazil,0,cannabidiol,NA
NCT04505631,2020-06-10,2021-06-30,Observational,Follow-up of Respiratory Sequelae of Hospitalized Patients With COVID-19,Recruiting,NA,Groupe Hospitalier de la Region de Mulhouse et Sud Alsace,NA,https://clinicalzeros.gov/ct2/show/NCT04505631,0,0,0,0,0,0,France,0,"NA",NA
NCT04505605,2020-05-14,2020-11-30,Observational,Study of a Possible Respiratory Degradation Prognosis Caused by Biomarkers in Severe Forms of COVID-19 Pneumonia,"Active, not recruiting",NA,Groupe Hospitalier Paris Saint Joseph,NA,https://clinicalzeros.gov/ct2/show/NCT04505605,0,0,0,0,1,0,France,0,blood sample,NA
NCT04337983,2020-03-13,2020-10-31,Observational,Hemodynamic Characteristics of Patients With SARS-CoV-2,Recruiting,NA,Bicetre Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04337983,0,0,0,0,1,0,France,0,transpulmonary thermodilution|echocardiography,NA
NCT04503525,2020-05-25,2021-05-25,Observational,Nutritional Assessment of Hospitalized Patients With COVID-19,Recruiting,NA,Lille Catholic University,NA,https://clinicalzeros.gov/ct2/show/NCT04503525,0,0,0,0,0,0,France,0,nutritional assessment,NA
NCT04503447,2020-08-01,2020-09-09,Observational,COVID-19 Seroprevalence Study in ITM Staff,Completed,NA,"Institute of Tropical Medicine, Belgium",NA,https://clinicalzeros.gov/ct2/show/NCT04503447,0,0,0,0,1,0,Belgium,0,"NA",NA
NCT04502472,2020-06-06,2021-12-31,Interventional,Open-label Treatment of Severe Coronavirus Disease 2019 (COVID-19) With Convalescent Plasma,Recruiting,Phase 2/Phase 3,Inova Health Care Services,NA,https://clinicalzeros.gov/ct2/show/NCT04502472,0,0,0,0,0,1,United States,0,convalescent plasma,NA
NCT04502667,2020-07-15,2021-02-28,Interventional,Efficacy of Vitamin D Treatment in Pediatric Patients Hospitalized by COVID-19,Recruiting,Phase 3,"CoordinaciÃ³n de InvestigaciÃ³n en Salud, Mexico",NA,https://clinicalzeros.gov/ct2/show/NCT04502667,0,0,0,0,0,0,Mexico,0,cholecalciferol,NA
NCT04503057,2020-05-01,2023-05-01,Observational [Patient Registry],Exhaled Breath Particles as a Clinical Indicator for Lung Injury and Acute Respiratory Distress Syndrome (ARDS),Recruiting,NA,Lund University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04503057,0,0,0,0,0,0,Sweden,0,"NA",NA
NCT04502433,2021-01-06,2021-07-31,Interventional,Poractant Alfa - Curosurf and SARS-COV-19 ARDS (Covid-19),Recruiting,Phase 2,Chiesi Farmaceutici S.p.A.,NA,https://clinicalzeros.gov/ct2/show/NCT04502433,0,0,0,0,1,0,United Kingdom,0,curosurfâ® (poractant alfa)|curosurfâ® (poractant alfa),NA
NCT04502342,2020-06-01,2020-08-30,Interventional,"Add on to Azythromycine, Phytomedicine and/or Antimalarial Drug vs Hydroxychloroquine in Uncomplicated COVID-19 Patients",Enrolling by invitation,Phase 2,Institute for Research and Development of Medicinal and Food Plants of Guinea,NA,https://clinicalzeros.gov/ct2/show/NCT04502342,0,0,0,0,1,0,Guinea,0,hydroxychloroquine / azithromycin|cospherunate/azythromycine|cospherunate/phytomedicine/azythromycien|hydroxychloroquine|azithromycin|cospherunate|phytomedicine,NA
NCT04502056,2020-07-31,2020-09-21,Interventional,Covid-19 Messaging to Underserved Communities - 2nd Experiment,"Active, not recruiting",N/A,"National Bureau of Economic Research, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04502056,0,0,0,0,1,1,United States,0,acknowledgement racial injustice ama|african american sender acknowledgement|african american sender in informational videos.|racial inequality highlighted|ama acknowledgement drug pricing|white sender in acknowledgement|white sender in informational videos|no racial inequality highlighting|placebo videos,NA
NCT04501991,2020-03-11,2020-05-04,Observational,Short-term Impact of COVID-19 Lockdown on Metabolic Control of Type 2 Diabetes,Completed,NA,University of Pisa,NA,https://clinicalzeros.gov/ct2/show/NCT04501991,0,0,0,0,0,0,Italy,0,antidiabetic treatment,NA
NCT04500132,2020-05-28,2021-08-31,Interventional,To Evaluate Safety and Efficacy of EC-18 in COVID-19 Infection to Pneumonia,Recruiting,Phase 2,Enzychem Lifesciences Corporation,NA,https://clinicalzeros.gov/ct2/show/NCT04500132,0,0,0,0,1,0,"Korea, Republic of",0,ec-18|placebo,NA
NCT04501822,2020-07-19,2021-07-19,Observational,One-year Cardiac Follow-up of Patients With COVID-19 Pneumonia,Recruiting,NA,Tomsk National Research Medical Center of the Russian Academy of Sciences,NA,https://clinicalzeros.gov/ct2/show/NCT04501822,0,0,0,0,0,0,Russian Federation,0,"evaluation of clinical, instrumental/laboratory diagnostics tests|evaluation of clinical, instrumental|laboratory diagnostics tests",NA
NCT04501783,2020-05-20,2020-07-29,Interventional,Study of Efficacy and Safety of TL-FVP-t vs. SOC in Patients With Mild to Moderate COVID-19,"Active, not recruiting",Phase 3,R-Pharm,NA,https://clinicalzeros.gov/ct2/show/NCT04501783,0,0,0,0,0,0,Russian Federation,0,favipiravir|standard care,NA
NCT04500652,2020-06-27,2020-08-30,Observational,Mental Health Status and Related Factors Among Physical Medicine & Rehabilitation Physicians in the Covid-19 Pandemic,Recruiting,NA,Dokuz Eylul University,NA,https://clinicalzeros.gov/ct2/show/NCT04500652,0,0,0,0,0,0,Turkey,0,"NA",NA
NCT04500600,2020-06-11,2021-07-01,Observational,Well-Being and Health-Related Quality of Life in Cancer Patients and Survivors During the COVID-19 Pandemic,Recruiting,NA,M.D. Anderson Cancer Center,NA,https://clinicalzeros.gov/ct2/show/NCT04500600,0,0,0,0,0,1,United States,0,quality-of-life assessment|questionnaire,NA
NCT04501445,2020-09-14,2021-08-01,Interventional,Psychological Symptoms and Families of COVID-19 Patients,Recruiting,N/A,Rush University Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04501445,0,0,0,0,2,1,United States,0,written summary of rounds,NA
NCT04501432,2020-07-14,2020-10-24,Observational,Cardiac Rehabilitation and Ongoing Physical Activity During COVID-19,Completed,NA,Ludwig Boltzmann Institute for Digital Health and Prevention,NA,https://clinicalzeros.gov/ct2/show/NCT04501432,0,0,0,0,1,0,Austria,0,no intervention,NA
NCT04500418,2020-08-25,2021-09-30,Interventional,CharitÃ© Trial of Cenicriviroc (CVC) Treatment for COVID-19 Patients,Recruiting,Phase 2,"Charite University, Berlin, Germany",NA,https://clinicalzeros.gov/ct2/show/NCT04500418,0,0,0,0,2,0,Germany,0,cenicriviroc|placebo,NA
NCT04500366,2020-08-26,2021-04-30,Interventional,GERAS Frailty Rehabilitation at Home During COVID-19,Recruiting,N/A,McMaster University,NA,https://clinicalzeros.gov/ct2/show/NCT04500366,0,0,0,0,1,0,Canada,0,socialization|virtual group exercise|nutrition consult/protein supplementation|medication review|nutrition consult|protein supplementation,NA
NCT04500067,2020-05-07,2020-09-15,Interventional,"Intravenous Immunoglobulin (IVIG, Bioven) Efficacy Assess for COVID-19 / SARS-CoV-2 Severe Pneumonia Complex Treatment",Completed,Phase 3,Biopharma Plasma LLC,NA,https://clinicalzeros.gov/ct2/show/NCT04500067,0,0,0,0,1,0,Ukraine,0,ivig,NA
NCT04499391,2020-12-04,2022-07-31,Interventional,COVID-19 Project ECHO in Nursing Homes,Recruiting,N/A,Milton S. Hershey Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04499391,0,0,0,0,3,1,United States,0,project echo,NA
NCT04499313,2020-08-02,2020-11-15,Interventional,Dexamethasone Vs Methylprednisolone for the Treatment of Patients With ARDS Caused by COVID-19,Recruiting,Phase 3,Chattogram General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04499313,0,0,0,0,4,0,Bangladesh,0,dexamethasone|methylprednisolone,NA
NCT04499300,2020-06-09,2020-12-31,Observational,Elderly Patients and COVID-19 Infection: a Cohort of Fifty Patients Over Ninety Years of Age,Recruiting,NA,Brugmann University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04499300,0,0,0,0,1,0,Belgium,0,data collection from medical files,NA
NCT04497948,2020-09-21,2020-11-18,Interventional,Acalabrutinib Study With Best Supportive Care in Participants Hospitalized With COVID-19,Terminated,Phase 1,Acerta Pharma BV,"Data from the CALAVI Phase II trials for Acalabrutinib in patients hospitalized with COVID-19
    did not meet their primary efficacy endpoints.

    Based on this higher management made the decision to prematurely terminate the D822FC00005 PK
    study.",https://clinicalzeros.gov/ct2/show/NCT04497948,0,0,0,0,2,1,Brazil|United States,0,acalabrutinib,NA
NCT04498936,2020-07-15,2020-10-30,Interventional,Sofosbuvir/Ledipasvir and Nitazoxanide for Treatment of COVID-19,Completed,Phase 4,Assiut University,NA,https://clinicalzeros.gov/ct2/show/NCT04498936,0,0,0,0,1,0,Egypt,0,sofosbuvir/ledipasvir|nitazoxanide|sofosbuvir|ledipasvir,NA
NCT04498299,2020-09-01,2020-10-01,Observational,Stress Echocardiography in Patients Recovery From Mild COVID-19 Illness,Recruiting,NA,Hospital Beneficencia Espanola de Puebla,NA,https://clinicalzeros.gov/ct2/show/NCT04498299,0,0,0,0,0,0,Mexico,0,echocardiogram,NA
NCT04498507,2020-04-16,2020-10-30,Observational,Psychosocial Outcomes in Families of COVID-19 ICU Patients,Completed,NA,University of Liege,NA,https://clinicalzeros.gov/ct2/show/NCT04498507,0,0,0,0,1,0,Belgium,0,questionnaire,NA
NCT04497649,2020-07-01,2021-04-01,Interventional,Sofosbuvir Containing Regimens in Treatment of COVID 19 Patients,Recruiting,Phase 2/Phase 3,Tanta University,NA,https://clinicalzeros.gov/ct2/show/NCT04497649,0,0,0,0,2,0,Egypt,0,sofosbuvir|daclatasvir,NA
NCT04498091,2020-03-15,2020-07-01,Observational,EPIdemiological Approaches to the Cardiovascular Consequences of COVID-19,"Active, not recruiting",NA,Centre Hospitalier Universitaire Dijon,NA,https://clinicalzeros.gov/ct2/show/NCT04498091,0,0,0,0,0,0,France,0,biological data|clinical data,NA
NCT04498065,2020-03-01,2020-07-01,Observational,MYocardial DOmmages Related to COVID-19,"Active, not recruiting",NA,Centre Hospitalier Universitaire Dijon,NA,https://clinicalzeros.gov/ct2/show/NCT04498065,0,0,0,0,0,0,France,0,biological data|clinical data,NA
NCT04497415,2020-10-21,2020-11-30,Interventional,The COVID-19 and Healthcare Workers: An Active Intervention,Recruiting,N/A,"Research Foundation for Mental Hygiene, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04497415,0,0,0,0,4,1,United States,0,video-based intervention,NA
NCT04497402,2020-09-01,2021-09-01,Observational [Patient Registry],Sex-Informed Data in the COVID-19 Pandemic.,Recruiting,NA,University of Roma La Sapienza,NA,https://clinicalzeros.gov/ct2/show/NCT04497402,0,0,0,0,2,0,Italy,0,"NA",NA
NCT04497623,2020-07-28,2020-08-13,Interventional,"Clinical Evaluation of Ventilador Innovation Product in Colombia in the SARS COVID 19 Pandemic, Unisabana Herons.",Completed,N/A,FundaciÃ³n Neumologica Colombiana,NA,https://clinicalzeros.gov/ct2/show/NCT04497623,0,0,0,0,1,0,Colombia,0,invasive mechanical ventilation using the unisabana-herons ventilator during 24 hours,NA
NCT04497818,2020-06-16,2020-07-16,Observational,Correlation Fear of COVID-19 & Dental Treatment Anxiety,Completed,NA,Qassim University,NA,https://clinicalzeros.gov/ct2/show/NCT04497818,0,0,0,0,0,0,Saudi Arabia,0,cross sectional study using scientifically validated psychometric scales,NA
NCT04497467,2020-08-01,2020-12-31,Observational,Changes in Out-patient Visits in Taiwan During the Time of Global COVID-19 Pandemic,Recruiting,NA,National Taiwan University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04497467,0,0,0,0,0,0,Taiwan,0,"NA",NA
NCT04497779,2020-07-13,2021-08-21,Observational,Analysis of Coronavirus Disease 19 (COVID-19) Convalescent Plasma,Recruiting,NA,City of Hope Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04497779,0,0,0,0,1,1,United States,0,biospecimen collection|biospeciman collection|diagnostic laboratory biomarker analysis|electronic health record review|questionnaire,NA
NCT04497272,2020-08-07,2021-08-07,Interventional,Assesment of the Metabolomic Signature in COVID-19 Patients,Recruiting,N/A,Centre Hospitalier Universitaire de Nice,NA,https://clinicalzeros.gov/ct2/show/NCT04497272,0,0,0,0,1,0,France,0,covid-19 patients,NA
NCT04497246,2020-05-29,2020-12-31,Observational,"Psychological Impact, Mental Health and Sleep Disorder Among Patients Hospitalized and Health Care Workers During the 2019 Coronavirus Outbreak (COVID-19)",Recruiting,NA,Brugmann University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04497246,0,0,0,0,0,0,Belgium,0,questionnaire,NA
NCT04497194,2020-03-01,2020-08-30,Observational [Patient Registry],Registry of COVID-19 Patients at AOUI Verona,Recruiting,NA,Azienda Ospedaliera Universitaria Integrata Verona,NA,https://clinicalzeros.gov/ct2/show/NCT04497194,0,0,0,0,0,0,Italy,0,not applicable (observational study),NA
NCT04497454,2020-05-08,2021-07-01,Interventional,Mechanical Ventilation Strategy for Coronavirus Disease 2019 (COVID-19),Recruiting,N/A,University of Sao Paulo General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04497454,0,0,0,0,0,0,Brazil,0,eit-group|ardsnet,NA
NCT04497441,2020-06-10,2020-08-10,Observational,Netizens' Perception of COVID-19 Information & Information Sources.,Recruiting,NA,Qassim University,NA,https://clinicalzeros.gov/ct2/show/NCT04497441,0,0,0,0,0,0,Saudi Arabia,0,questionnaire,NA
NCT04495907,2020-08-06,2021-03-31,Observational,COVID-19 Progression in End-Stage Kidney Disease,Recruiting,NA,Davita Clinical Research,NA,https://clinicalzeros.gov/ct2/show/NCT04495907,0,0,0,0,5,1,United States,0,"NA",NA
NCT04496141,2020-07-27,2020-11-30,Observational,Evaluation of Commercial SARS-CoV-2 Antibody Immunoassays for COVID-19,"Active, not recruiting",NA,Hong Kong Sanatorium & Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04496141,0,0,0,0,0,0,Hong Kong,0,sars-cov-2 antibody immunoassays,NA
NCT04495842,2020-10-01,2021-03-31,Interventional,The Effect of Aromatherapy on COVID-19-induced Anxiety,Recruiting,N/A,Franklin School of Integrative Health Sciences,NA,https://clinicalzeros.gov/ct2/show/NCT04495842,0,0,0,0,1,1,United States,0,essential oil blend|control blend,NA
NCT04495543,2020-12-01,2021-08-31,Interventional,Mitigating Suicide Risk With Single Session 'Brief Skills for Safer Living',Recruiting,N/A,"St. Michael's Hospital, Toronto",NA,https://clinicalzeros.gov/ct2/show/NCT04495543,0,0,0,0,1,0,Canada,0,brief skills for safer living,NA
NCT04494399,2020-07-29,2022-07-01,Interventional,IFN Beta-1b and Ribavirin for Covid-19,Recruiting,Phase 2,The University of Hong Kong,NA,https://clinicalzeros.gov/ct2/show/NCT04494399,0,0,0,0,0,0,Hong Kong,0,interferon|ribavirin,NA
NCT04494867,2020-08-19,2020-12-31,Interventional,Core Warming in COVID-19 Patients Undergoing Mechanical Ventilation,Recruiting,N/A,Sharp HealthCare,NA,https://clinicalzeros.gov/ct2/show/NCT04494867,0,0,0,0,3,1,United States,0,core warming|standard care,NA
NCT04493359,2020-07-25,2022-02-14,Interventional,Switch of Renin-Angiotensin System Inhibitors in Patients With Covid-19,Recruiting,Phase 2/Phase 3,University of Sao Paulo,NA,https://clinicalzeros.gov/ct2/show/NCT04493359,0,0,0,0,1,0,Brazil,0,renin-angiotensin system inhibitors,NA
NCT04494204,2020-08-07,2020-12-01,Interventional,Effect of a Combination of Treatment of Reginmune Capsule and Immunofree Tablets in the Treatment of Mild to Moderate COVID-19 Patients,Completed,Phase 2/Phase 3,Nutrin GmbH,NA,https://clinicalzeros.gov/ct2/show/NCT04494204,0,0,0,0,4,0,India,0,immunofree tablets/reginmune capsule|immunofree tablets|reginmune,NA
NCT04493307,2020-06-30,2021-02-28,Observational,The Evaluation of Hemostasis in Hospitalized COVID-19 Patients,Recruiting,NA,LifeBridge Health,NA,https://clinicalzeros.gov/ct2/show/NCT04493307,0,0,0,0,2,1,United States,0,phlebotomy,NA
NCT04493268,2020-03-07,2020-07-20,Observational,HYPONATREMIA IN COVID-19 PATIENTS,Completed,NA,Hospital Nacional Profesor Alejandro Posadas,NA,https://clinicalzeros.gov/ct2/show/NCT04493268,0,0,0,0,0,0,Argentina,0,"NA",NA
NCT04491994,2020-04-10,2020-05-31,Interventional,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Completed,Phase 3,UNICEF,NA,https://clinicalzeros.gov/ct2/show/NCT04491994,0,0,0,0,1,0,Pakistan,1,hydroxychloroquine,NA
NCT04492267,2020-07-07,2021-01-07,Observational,Inflammatory Bowel Disease (IBD) and Covid-19 Infection,Recruiting,NA,"University Hospital, Strasbourg, France",NA,https://clinicalzeros.gov/ct2/show/NCT04492267,0,0,0,0,0,0,France,0,"NA",NA
NCT04492228,2020-09-01,2020-12-31,Interventional,Eucaloric Ketogenic Diet in COVID-19 Cytokine Storm Syndrome,Recruiting,N/A,Ospedale Policlinico San Martino,NA,https://clinicalzeros.gov/ct2/show/NCT04492228,0,0,0,0,1,0,Italy,0,ketogenic diet,NA
NCT04492943,2020-04-20,2020-06-30,Observational,To Observe Whether Isoflurane Can Treat COVID-19 Patients,Completed,NA,Massachusetts General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04492943,0,0,0,0,1,1,United States,0,"NA",NA
NCT04492891,2020-11-23,2025-11-23,Interventional,Cyclosporine For The Treatment Of COVID-19(+),Recruiting,Phase 2,Baylor College of Medicine,NA,https://clinicalzeros.gov/ct2/show/NCT04492891,0,0,0,0,1,1,United States,0,cyclosporine|standard care,NA
NCT04492527,2020-07-28,2021-06-30,Interventional,Student-delivered Telehealth Program for COVID-19 Education and Health Promotion,Recruiting,N/A,University of British Columbia,NA,https://clinicalzeros.gov/ct2/show/NCT04492527,0,0,0,0,1,0,Canada,0,telehealth,NA
NCT04492501,2020-04-01,2020-07-20,Interventional,Investigational Treatments for COVID-19 in Tertiary Care Hospital of Pakistan,Completed,N/A,UNICEF,NA,https://clinicalzeros.gov/ct2/show/NCT04492501,0,0,0,0,0,0,Pakistan,0,therapeutic plasma exchange (tpe)|convalescent plasma|tocilizumab|remdesivir|mesenchymal stem cells,NA
NCT04492371,2020-07-01,2021-07-31,Observational,COVID-19 Infection and Multiple Myeloma,Recruiting,NA,European Myeloma Network,NA,https://clinicalzeros.gov/ct2/show/NCT04492371,0,0,0,0,0,0,Austria|Belgium|Czechia|Germany|Greece|Italy|Netherlands|United Kingdom,0,"NA",NA
NCT04492358,2020-10-22,2021-10-31,Interventional,"Treatment for Moderate/Severe COVID-19 in a Fragile and Vulnerable Population, Admitted to a Geriatric Hospital Unit or in a Transicional Care Center",Recruiting,Phase 2/Phase 3,Fundacion Clinic per a la Recerca BiomÃ©dica,NA,https://clinicalzeros.gov/ct2/show/NCT04492358,0,0,0,0,1,0,Spain,0,colchicine|prednisone tablet|standard care,NA
NCT04491318,2020-07-01,2020-07-25,Observational,COVID-19 Quarantine on Musculoskeletal Status in Hemophilia,Recruiting,NA,InvestigaciÃ³n en Hemofilia y Fisioterapia,NA,https://clinicalzeros.gov/ct2/show/NCT04491318,0,0,0,0,0,0,Spain,0,observational,NA
NCT04491292,2020-05-18,2021-04-30,Observational,Assessment of the Psychosocial Impact of the COVID-19 Pandemic on the MD Anderson Cancer Center Workforce,Recruiting,NA,M.D. Anderson Cancer Center,NA,https://clinicalzeros.gov/ct2/show/NCT04491292,0,0,0,0,0,1,United States,0,questionnaire,NA
NCT04491240,2020-07-20,2020-10-01,Interventional,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Completed,Phase 1/Phase 2,"State-Financed Health Facility ""Samara Regional Medical Center Dinasty""",NA,https://clinicalzeros.gov/ct2/show/NCT04491240,0,0,0,0,4,0,Russian Federation,1,exo 1 inhalation|exo 2 inhalation|placebo,NA
NCT04491227,2020-05-05,2022-04-30,Observational,Global Assessment of Acute and Chronic Kidney Disease Incidence and Outcomes in Patients With COVID-19 Infection,Enrolling by invitation,NA,"University of California, San Diego",NA,https://clinicalzeros.gov/ct2/show/NCT04491227,0,0,0,0,0,1,United States|Bolivia|Canada|Chile|India|United Kingdom,0,"NA",NA
NCT04491201,2020-07-27,2020-09-27,Observational,National Survey of the Impact of COVID-19 Pandemics,Recruiting,NA,Peking Union Medical College Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04491201,0,0,0,0,0,0,China,0,questionnaire,NA
NCT04488588,2020-03-15,2020-05-01,Observational,Survival and 30-days Hospital Outcome in COVID-19 Patients in Upper Egypt,Completed,NA,Assiut University,NA,https://clinicalzeros.gov/ct2/show/NCT04488588,0,0,0,0,0,0,Egypt,0,immunoglobulin,NA
NCT04490278,2020-09-29,2021-07-30,Interventional,CoV-PICS: A Virtual Post-ICU Clinic,Recruiting,N/A,Washington University School of Medicine,NA,https://clinicalzeros.gov/ct2/show/NCT04490278,0,0,0,0,3,1,United States,0,medical record review - inpatient treatment|online questionnaires,NA
NCT04488549,2020-05-20,2020-06-10,Observational,Delayed Colorectal Cancer Care During Coronavirus Disease (COVID-19) Pandemic (DECOR-19),Completed,NA,Treviso Regional Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04488549,0,0,0,0,0,0,Italy,0,questionnaire,NA
NCT04490850,2020-07-15,2021-07-15,Interventional,COVID-19 Seroprevalence Study in French Guiana,Recruiting,N/A,Institut Pasteur,NA,https://clinicalzeros.gov/ct2/show/NCT04490850,0,0,0,0,0,0,French Guiana,0,blood sample,NA
NCT04490837,2020-06-22,2020-07-31,Observational [Patient Registry],Rapid Diagnostic Test for COVID-19 Based on Antibody Detection (YCOVID),"Active, not recruiting",NA,Corporacion Parc Tauli,NA,https://clinicalzeros.gov/ct2/show/NCT04490837,0,0,0,0,0,0,Spain,0,elisa/rapid test to detect antibodies against covid-19|elisa|rapid test,NA
NCT04490811,2020-04-09,2021-12-31,Observational,Seroprevalence and Immunoprotection Against COVID-19 in Parisian Children,Recruiting,NA,HÃ´pital Necker-Enfants Malades,NA,https://clinicalzeros.gov/ct2/show/NCT04490811,0,0,0,0,0,0,France,0,no intervention,NA
NCT04490473,2020-07-24,2021-03-24,Interventional,Turkish of the SARS-CoV-2 Anxiety Scale,Recruiting,N/A,Eskisehir Osmangazi University,NA,https://clinicalzeros.gov/ct2/show/NCT04490473,0,0,0,0,1,0,Turkey,0,survey,NA
NCT04488562,2020-05-08,2021-12-01,Observational [Patient Registry],Home Monitoring and Evaluation After Admission for COVID-19 in the Netherlands,Recruiting,NA,Erasmus Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04488562,0,0,0,0,0,0,Netherlands,0,"NA",NA
NCT04488510,2020-05-06,2020-05-06,Observational,Pathogens Involved in Secondary Infections During Severe Forms of Covid-19 Pneumonia:,"Active, not recruiting",NA,Groupe Hospitalier Paris Saint Joseph,NA,https://clinicalzeros.gov/ct2/show/NCT04488510,0,0,0,0,1,0,France,0,"NA",NA
NCT04488471,2020-06-30,2022-06-30,Observational,Impact of Isolation in Patients With IBD During the COVID-19 Crisis,Recruiting,NA,Sheffield Teaching Hospitals NHS Foundation Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04488471,0,0,0,0,0,0,United Kingdom,0,"NA",NA
NCT04487977,2020-04-22,2020-09-30,Observational,Survey on COVID-19 Airway Management,Recruiting,NA,Spanish Society of Anesthesia and Critical Care (SEDAR),NA,https://clinicalzeros.gov/ct2/show/NCT04487977,0,0,0,0,0,0,Spain,0,questionnaire,NA
NCT04487951,2020-07-01,2020-11-01,Observational,N-terminal Pro B-type Natriuretic Peptide and Vitamin D Levels as Prognostic Markers in COVID-19 Pneumonia,Recruiting,NA,Cairo University,NA,https://clinicalzeros.gov/ct2/show/NCT04487951,0,0,0,0,0,0,Egypt,0,"pro bnp , vitamin d",NA
NCT04487886,2020-11-18,2022-02-28,Interventional,Duvelisib Ameliorates Manifestations of Pneumonia in Established Novel Coronavirus Infection (COVID-19),Recruiting,Phase 2,Emory University,NA,https://clinicalzeros.gov/ct2/show/NCT04487886,0,0,0,0,2,1,United States,0,duvelisib|placebo,NA
NCT04487873,2020-07-23,2020-12-18,Observational,COVID-19 Phobia in Patients With Bronchiectasis During Covid-19 Pandemic,Recruiting,NA,Hacettepe University,NA,https://clinicalzeros.gov/ct2/show/NCT04487873,0,0,0,0,2,0,Turkey,0,"NA",NA
NCT04487769,2020-06-01,2021-08-31,Observational,Lung Ultrasound in COVID-19 Patients,Recruiting,NA,Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA),NA,https://clinicalzeros.gov/ct2/show/NCT04487769,0,0,0,0,2,0,Netherlands,0,"NA",NA
NCT04487444,2020-09-10,2021-03-31,Interventional,Thymalfasin (Thymosin Alpha 1) to Treat COVID-19 Infection,Recruiting,Phase 2,Rhode Island Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04487444,0,0,0,0,3,1,United States,0,thymalfasin,NA
NCT04487171,2020-07-21,2021-07-31,Interventional,Screening for Postpartum Depression and Associated Risk Factors Among Women Who Deliver in Four Hospital in France During the COVID-19 Epidemic,Recruiting,N/A,"Centre Hospitalier Universitaire, Amiens",NA,https://clinicalzeros.gov/ct2/show/NCT04487171,0,0,0,0,0,0,France,0,questionnaire,NA
NCT04487639,2020-07-10,2021-07-31,Interventional,Presence of SARS-CoV-2 in Semen: Impact on Fertility Preservation in Male Oncological Patients ?,Recruiting,N/A,"University Hospital, Clermont-Ferrand",NA,https://clinicalzeros.gov/ct2/show/NCT04487639,0,0,0,0,0,0,France,0,"sars-cov-2 research in nasopharyngeal swab, sperm/serologics|sars-cov-2 research in nasopharyngeal swab, sperm|serology test",NA
NCT04487119,2020-08-12,2020-08-20,Observational,Hematology and Clinical Picture in Pediatric COVID-19 Infection,Completed,NA,Benha University,NA,https://clinicalzeros.gov/ct2/show/NCT04487119,0,0,0,0,4,0,Egypt,0,"NA",NA
NCT04487574,2020-07-25,2020-10-29,Interventional,A Study to Assess the Efficacy and Safety of XC221 in Patients With COVID-19,Completed,Phase 3,RSV Therapeutics LLC,NA,https://clinicalzeros.gov/ct2/show/NCT04487574,0,0,0,0,2,0,Russian Federation,0,xc221|placebo,NA
NCT04485169,2020-04-01,2020-07-31,Interventional,Therapeutic Plasma Exchange for Coronavirus Disease-2019 Triggered Cytokine Release Storm;,Completed,N/A,UNICEF,NA,https://clinicalzeros.gov/ct2/show/NCT04485169,0,0,0,0,1,0,Pakistan,0,therapeutic plasma exchange (tpe),NA
NCT04486729,2020-07-01,2020-10-10,Observational,Respiratory Mechanics and Gas Exchange Characteristics in Patient With SARS-CoV-2,Recruiting,NA,Sanatorio Anchorena San Martin,NA,https://clinicalzeros.gov/ct2/show/NCT04486729,0,0,0,0,0,0,Argentina,0,high peep with end inspiratory pause|low peep - fio2 high|high peep without end inspiratory pause|low peep - fio2 low,NA
NCT04485429,2020-07-20,2020-12-31,Interventional,Efficacy Assessment of Methylprednisolone and Heparin in Patients With COVID-19 Pneumonia,Recruiting,Phase 3,D'Or Institute for Research and Education,NA,https://clinicalzeros.gov/ct2/show/NCT04485429,0,0,0,0,0,0,Brazil,0,methylprednisolone|heparin,NA
NCT04485364,2020-04-14,2020-04-14,Observational,Place of Circulating Biomarkers and Respiratory Eicosanoids in the Prognosis of Severe Forms of Covid-19 Pneumonia,"Active, not recruiting",NA,Groupe Hospitalier Paris Saint Joseph,NA,https://clinicalzeros.gov/ct2/show/NCT04485364,0,0,0,0,0,0,France,0,"NA",NA
NCT04485351,2020-07-31,2020-08-31,Observational,Assessing the Impact of the COVID-19 Lockdown on Metabolic Control and Access to Health Care in Patients With Diabetes,Recruiting,NA,"Central Hospital, Nancy, France",NA,https://clinicalzeros.gov/ct2/show/NCT04485351,0,0,0,0,0,0,France,0,no intervention,NA
NCT04485338,2020-08-01,2020-12-31,Observational,Chest Radiography in COVID-19 Patients,Recruiting,NA,Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA),NA,https://clinicalzeros.gov/ct2/show/NCT04485338,0,0,0,0,1,0,Netherlands,0,"NA",NA
NCT04486417,2020-06-01,2020-07-22,Observational,Feasibility of a Telematics Pre-operative Assessment in a Bariatric Surgery During Covid-19,Recruiting,NA,University of Roma La Sapienza,NA,https://clinicalzeros.gov/ct2/show/NCT04486417,0,0,0,0,0,0,Italy,0,"NA",NA
NCT04483960,2020-07-28,2021-12-31,Interventional,Australasian COVID-19 Trial (ASCOT) ADAptive Platform Trial,Recruiting,Phase 3,University of Melbourne,NA,https://clinicalzeros.gov/ct2/show/NCT04483960,0,0,0,0,2,0,Australia,0,nafamostat mesilate|convalescent plasma|enoxaparin|dalteparin|tinzaparin|aspirin,NA
NCT04484597,2020-03-15,2020-08-15,Observational,Predictors of COVID-19 Infection and Disease Progression,Recruiting,NA,Port Said University,NA,https://clinicalzeros.gov/ct2/show/NCT04484597,0,0,0,0,0,0,Egypt,0,pct,NA
NCT04484545,2020-04-01,2021-06-01,Observational,Prognostic Factors in Patients Admitted to an Urban Teaching Hospital With COVID-19 Infection,"Active, not recruiting",NA,Glasgow Royal Infirmary,NA,https://clinicalzeros.gov/ct2/show/NCT04484545,0,0,0,0,0,0,United Kingdom,0,prognostic score,NA
NCT04483752,2020-06-08,2021-02-08,Interventional,Predicting the Progression to Chronic Fibrosis of Lung Lesions Related to Covid-19 Infection From Chest CT Images,Recruiting,N/A,Centre Chirurgical Marie Lannelongue,NA,https://clinicalzeros.gov/ct2/show/NCT04483752,0,0,0,0,0,0,France,0,chest ct,NA
NCT04484207,2020-07-06,2020-10-20,Interventional,Addressing COVID-19 Mental Health Problems Among US Veterans,Recruiting,N/A,"Research Foundation for Mental Hygiene, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04484207,0,0,0,0,2,1,United States,0,a short video intervention|a vignette intervention,NA
NCT04483908,2020-04-10,2022-05-30,Observational,COVID-19 in Baselland: Investigation and Validation of Serological Diagnostic Assays and Epidemiological Study of Sars-CoV-2 Specific Antibody Responses,Recruiting,NA,"University Hospital, Basel, Switzerland",NA,https://clinicalzeros.gov/ct2/show/NCT04483908,0,0,0,0,0,0,Switzerland,0,blood sample|fingertip tests for poc assays|saliva|collection of swabs,NA
NCT04483830,2020-06-05,2020-08-06,Interventional,Suloexide in the Treatment of Early Stages of COVID-19,Completed,Phase 2/Phase 3,Clinedem,NA,https://clinicalzeros.gov/ct2/show/NCT04483830,0,0,0,0,2,0,Mexico,0,sulodexide|placebo,NA
NCT04483622,2020-06-12,2021-01-13,Observational,Immunoglobulin G Antibody Immune Response Profile Following Infection With SARS-CoV-2 in COVID-19 Egyptian Patients,Recruiting,NA,Sohag University,NA,https://clinicalzeros.gov/ct2/show/NCT04483622,0,0,0,0,0,0,Egypt,0,"NA",NA
NCT04482686,2020-12-09,2021-05-31,Interventional,Trial of Combination Therapy to Treat COVID-19 Infection,Recruiting,Phase 2,ProgenaBiome,NA,https://clinicalzeros.gov/ct2/show/NCT04482686,0,0,0,0,6,1,United States,0,ivermectin|doxycycline hcl|zinc|vitamin d|vitamin c,NA
NCT04483271,2020-10-02,2020-12-15,Interventional,The Effect of Omega-3 on Selected Cytokines Involved in Cytokine Storm,Enrolling by invitation,N/A,Applied Science Private University,NA,https://clinicalzeros.gov/ct2/show/NCT04483271,0,0,0,0,1,0,Jordan,0,300 mg of omega3-fa,NA
NCT04482673,2020-07-31,2021-12-31,Interventional,Vitamin D Supplementation in the Prevention and Mitigation of COVID-19 Infection,Recruiting,Phase 4,Medical University of South Carolina,NA,https://clinicalzeros.gov/ct2/show/NCT04482673,0,0,0,0,1,1,United States,0,vitamin d|placebo,NA
NCT04482621,2020-09-14,2021-05-31,Interventional,Decitabine for Coronavirus (COVID-19) Pneumonia- Acute Respiratory Distress Syndrome (ARDS) Treatment: DART Trial,Recruiting,Phase 2,Johns Hopkins University,NA,https://clinicalzeros.gov/ct2/show/NCT04482621,0,0,0,0,2,1,United States,0,decitabine|placebo,NA
NCT04482595,2020-11-11,2021-08-31,Interventional,BIO 300 Oral Suspension in Discharged COVID-19 Patients,Recruiting,Phase 2,Humanetics Corporation,NA,https://clinicalzeros.gov/ct2/show/NCT04482595,0,0,0,0,3,1,United States,0,bio 300 oral suspension|placebo,NA
NCT04481529,2020-07-29,2020-12-15,Observational,COVID-19 Serological Status of Hospital Staff Working or Not in the COVID-19 Sector,"Active, not recruiting",NA,"University Hospital, Limoges",NA,https://clinicalzeros.gov/ct2/show/NCT04481529,0,0,0,0,1,0,France,0,health questionnaire,NA
NCT04482387,2020-07-24,2021-07-01,Interventional,DigiVis: Self-testing Vision App for Telephone Consultations,Recruiting,N/A,Cambridge University Hospitals NHS Foundation Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04482387,0,0,0,0,1,0,United Kingdom,0,digivis visual acuity app,NA
NCT04482361,2020-08-06,2020-12-22,Observational [Patient Registry],SERO-EPIDEMIOLOGY OF SARS-COV2 INFECTION IN THE AUTONOMOUS CITY OF BUENOS AIRES,Completed,NA,Ministerio de Salud de Ciudad AutÃ³noma de Buenos Aires,NA,https://clinicalzeros.gov/ct2/show/NCT04482361,0,0,0,0,1,0,Argentina,0,presence of specific anti-sars-cov-2 antibodies,NA
NCT04482205,2020-03-16,2020-05-31,Observational,Covid -19 Pandemic: Economic Burden on Patients Operated for Traumatic Close Fractures,Completed,NA,Aga Khan University,NA,https://clinicalzeros.gov/ct2/show/NCT04482205,0,0,0,0,0,0,Pakistan,0,"NA",NA
NCT04481516,2020-07-01,2020-12-31,Observational,Yoga in NHS Health Care Workers With COVID-19 Related Stress,Recruiting,NA,Doncaster And Bassetlaw Hospitals NHS Foundation Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04481516,0,0,0,0,0,0,United Kingdom,0,yoga,NA
NCT04480957,2020-08-04,2020-12-31,Interventional,Ascending Dose Study of Investigational SARS-CoV-2 Vaccine ARCT-021 in Healthy Adult Subjects,Recruiting,Phase 1/Phase 2,"Arcturus Therapeutics, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04480957,0,0,0,1,1,0,Singapore,0,arct-021 dose 1|arct-021 dose 2|arct-021 dose 3|arct-021 dose 4|arct-021 dose regimen 1|arct-021 dose regimen 2|placebo,NA
NCT04481646,2020-06-12,2022-06-30,Observational [Patient Registry],Novel Face Mask Sampling for COVID-19: A Diagnostic and Public Health Tool,Recruiting,NA,University of Leicester,NA,https://clinicalzeros.gov/ct2/show/NCT04481646,0,0,0,0,0,0,United Kingdom,0,face mask sampling,NA
NCT04481633,2020-09-09,2021-09-30,Interventional,Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection,Recruiting,N/A,"University Hospital, Toulouse",NA,https://clinicalzeros.gov/ct2/show/NCT04481633,0,0,0,0,2,0,France,0,covid 19 serology|covid 19 self-questionnaire,NA
NCT04480580,2020-03-30,2020-04-30,Observational,Seroprevalence of SARS-Cov-2 in the Setting of a Non-dedicated COVID-19 Hospital in a Low CoV-2 Incidence Area: Implications for Surgery,Completed,NA,University of Cagliari,NA,https://clinicalzeros.gov/ct2/show/NCT04480580,0,0,0,0,0,0,Italy,0,sars-cov-2 ab,NA
NCT04480515,2020-03-11,2020-06-15,Observational,Does COVID-19 Pandemic Reduce In-hospital Mortality?,Completed,NA,Kanuni Sultan Suleyman Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04480515,0,0,0,0,0,0,Turkey,0,in-hospital mortality rate,NA
NCT04479982,2020-09-24,2020-12-31,Observational,Microbial Infection and AMR in Hospitalized Patients With Covid 19,Recruiting,NA,Assiut University,NA,https://clinicalzeros.gov/ct2/show/NCT04479982,0,0,0,0,3,0,Egypt,0,"NA",NA
NCT04480398,2020-05-12,2020-06-15,Observational,Efficacy and Safety of Guduchi Ghan Vati for Covid-19 Asymptomatic Patients,Completed,NA,Aarogyam UK,NA,https://clinicalzeros.gov/ct2/show/NCT04480398,0,0,0,0,1,0,India,0,guduchi ghan vati,NA
NCT04480112,2020-06-02,2021-05-31,Interventional,Impact of Covid-19 on Frequent Social Interaction Through Communication Technologies in the Cognitive Status of Socially-isolated Older Adults,Enrolling by invitation,N/A,Boston University,NA,https://clinicalzeros.gov/ct2/show/NCT04480112,0,0,0,0,3,1,United States,0,technology based social interactions|no research related technology based social interactions,NA
NCT04480060,2020-03-10,2020-06-30,Observational,Experience of an Emergency Intensive Care Unit During COVID-19 Pandemic,Completed,NA,Kanuni Sultan Suleyman Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04480060,0,0,0,0,0,0,Turkey,0,pcr,NA
NCT04479540,2020-05-26,2021-05-26,Interventional,Assessment of the Risk of Pulmonary Embolism and Coagulation Profile in Patients With COVID-19 Lung Disease,Recruiting,N/A,Hopital Foch,NA,https://clinicalzeros.gov/ct2/show/NCT04479540,0,0,0,0,1,0,France,0,angiography scanner,NA
NCT04479358,2020-09-10,2020-12-01,Interventional,Low-dose Tocilizumab Versus Standard of Care in Hospitalized Patients With COVID-19,Recruiting,Phase 2,University of Chicago,NA,https://clinicalzeros.gov/ct2/show/NCT04479358,0,0,0,0,1,1,United States,0,tocilizumab|standard care,NA
NCT04479319,2020-12-31,2021-06-30,Observational,Decision Support System Algorithm for COVID-19 Diagnosis,Recruiting,NA,Ankara University,NA,https://clinicalzeros.gov/ct2/show/NCT04479319,0,0,0,0,1,0,Turkey,0,thorax ct,NA
NCT04479293,2020-07-01,2020-10-30,Observational,Post COVID-19 Functional Status in Egypt,Recruiting,NA,Assiut University,NA,https://clinicalzeros.gov/ct2/show/NCT04479293,0,0,0,0,1,0,Egypt,0,post covid-19 functional satus scale,NA
NCT04479280,2020-07-20,2020-08-16,Observational,Evaluation of Coagulopathy in Critically Ill COVID-19 Patients.,Completed,NA,Assiut University,NA,https://clinicalzeros.gov/ct2/show/NCT04479280,0,0,0,0,2,0,Egypt,0,"sonclot coagulation/platelet function analyzer scp1, sienco, usa|sonclot coagulation|platelet function analyzer scp1, sienco, usa",NA
NCT04479137,2020-03-10,2020-06-30,Observational,Possible Predictors of Mortality Based on COVID-19 for Patients Under 50 Years Old: A Multi-Center Experience of Istanbul,Completed,NA,Kanuni Sultan Suleyman Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04479137,0,0,0,0,1,0,Turkey,0,pcr,NA
NCT04479124,2020-03-10,2020-06-30,Observational,The Impact of COVID-19 Pandemic to Trauma Patients in Emergency Department: A Multicenter Experience of Istanbul,Completed,NA,Kanuni Sultan Suleyman Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04479124,0,0,0,0,0,0,Turkey,0,pcr,NA
NCT04478539,2020-06-01,2021-06-01,Interventional,Extracorporeal Blood Purification as a Treatment Modality for COVID-19,Recruiting,N/A,Zan Mitrev Clinic,NA,https://clinicalzeros.gov/ct2/show/NCT04478539,0,0,0,0,0,0,North Macedonia,0,extracorporeal blood purification using the oxirisâ® (an69st) hemofilter|extracorporeal blood purification using the oxirisâ® (an69st) hemofilter,NA
NCT04477473,2020-06-30,2020-07-30,Observational,Perceived Impact of the COVID-19 Pandemic on Medical Management and Symptoms in a High Risk Group,Recruiting,NA,"University Hospital, Geneva",NA,https://clinicalzeros.gov/ct2/show/NCT04477473,0,0,0,0,1,0,Switzerland,0,questionnaire,NA
NCT04477954,2020-07-06,2020-11-06,Interventional,Hyperbaric Oxygen as an Adjuvant Treatment for Patients With Covid-19 Severe Hypoxemia,Terminated,Phase 2,AsociaciÃ³n Argentina de Medicina HiperbÃ¡rica e InvestigaciÃ³n,"Investigators and Ethic Committee endorsed early suspension of the protocol because of
    superiority and safety. For the interim analysys, the statistical methodology presented by
    Pocock was followed.",https://clinicalzeros.gov/ct2/show/NCT04477954,0,0,0,0,2,0,Argentina,0,oxygen,NA
NCT04477889,2020-06-20,2025-12-31,Observational,Methodist Health System COVID-19 Patient Registry,Recruiting,NA,Methodist Health System,NA,https://clinicalzeros.gov/ct2/show/NCT04477889,0,0,0,0,1,1,United States,0,treatment for covid-19,NA
NCT04478071,2020-08-22,2022-08-01,Interventional,Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19),Recruiting,Phase 2,"The University of Texas Health Science Center, Houston",NA,https://clinicalzeros.gov/ct2/show/NCT04478071,0,0,0,0,1,1,United States,0,vadadustat|placebo,NA
NCT04476888,2020-04-26,2020-09-15,Interventional,Convalescent Plasma Treatment in COVID-19,Completed,N/A,Aga Khan University,NA,https://clinicalzeros.gov/ct2/show/NCT04476888,0,0,0,0,2,0,Pakistan,0,convalescent plasma|drugs/supportive care|drugs|supportive care,NA
NCT04476823,2020-03-15,2020-05-31,Observational,European Pathology Laboratories and COVID-19,Completed,NA,Centre Hospitalier Universitaire de Nice,NA,https://clinicalzeros.gov/ct2/show/NCT04476823,0,0,0,0,0,0,France,0,activity,NA
NCT04477083,2020-07-15,2020-08-15,Interventional,"Development and Validation of ""Ready-to-Use"" Inhalable Forms of Hydroxychloroquine for Treatment of COVID-19","Active, not recruiting",N/A,Mansoura University,NA,https://clinicalzeros.gov/ct2/show/NCT04477083,0,0,0,0,0,0,Egypt,0,hydroxychloroquine|supportive/symptomatic treatment|supportive care|symptomatic treatment,NA
NCT04476745,2020-10-05,2020-12-15,Interventional,The Effect of D3 on Selected Cytokines Involved in Cytokine Storm in the Covid-19 Uninfected Jordanian People,Enrolling by invitation,N/A,Applied Science Private University,NA,https://clinicalzeros.gov/ct2/show/NCT04476745,0,0,0,0,2,0,Jordan,0,vitamin d,NA
NCT04475484,2020-06-10,2020-12-31,Observational,Online Survey on Psychological Impact of COVID-19 Epidemic on School-age Children,Recruiting,NA,Hospices Civils de Lyon,NA,https://clinicalzeros.gov/ct2/show/NCT04475484,0,0,0,0,0,0,France,0,online survey,NA
NCT04476602,2020-04-27,2020-12-31,Observational,Ambulatory Management of Moderate to High Risk COVID-19 (SARS-CoV-2) Patients - The Coronavirus Related Outpatient Work Navigators (CROWN) Protocol,Recruiting,NA,Northwell Health,NA,https://clinicalzeros.gov/ct2/show/NCT04476602,0,0,0,0,1,1,United States,0,"NA",NA
NCT04474249,2020-06-25,2022-12-31,Observational,Follow-up of Critical COVID-19 Patients,Recruiting,NA,Uppsala University,NA,https://clinicalzeros.gov/ct2/show/NCT04474249,0,0,0,0,1,0,Sweden,0,"NA",NA
NCT04475588,2020-05-01,2020-07-08,Interventional,Efficacy and Safety of Itolizumab in COVID-19 Complications,Completed,Phase 2,Biocon Limited,NA,https://clinicalzeros.gov/ct2/show/NCT04475588,0,0,0,0,0,0,India,0,itolizumab|best supportive care|antibiotics|hydroxychloroquine / oxygen,NA
NCT04475120,2020-04-15,2020-07-02,Interventional,Efficacy and Safety of Liposomal Lactoferrin in COVID-19 Patients With Mild-to-Moderate Disease and in COVID-19 Asymptomatic Patients,Completed,Phase 2/Phase 3,University of Rome Tor Vergata,NA,https://clinicalzeros.gov/ct2/show/NCT04475120,0,0,0,0,0,0,Italy,0,liposomal,NA
NCT04475068,2020-07-17,2020-09-30,Observational,Postural Recruitment Maneuver in Patients With Acute Respiratory Distress Syndrome Due to COVID-19 Infection,Recruiting,NA,Hospital Nacional Edgardo Rebagliati Martins,NA,https://clinicalzeros.gov/ct2/show/NCT04475068,0,0,0,0,1,0,Peru,0,lateral position (left/right lateral decubitus)|lateral position (left|right lateral decubitus),NA
NCT04474444,2019-03-23,2021-03-23,Observational,Ambulance Calls for Substance Use and Alcohol in a Pandemic (ASAP),Recruiting,NA,University of Lincoln,NA,https://clinicalzeros.gov/ct2/show/NCT04474444,0,0,0,0,0,0,United Kingdom,0,attendance by ambulance crew,NA
NCT04474340,2020-05-21,2020-09-30,Interventional,COVID-19 Convalescent Plasma Treatment in SARS-CoV-2 Infected Patients,Recruiting,Phase 1,"Ministry of Health, Kuwait",NA,https://clinicalzeros.gov/ct2/show/NCT04474340,0,0,0,0,1,0,Kuwait,0,convalscent plasma,NA
NCT04474301,2020-06-11,2021-07-01,Observational,Well-Being and Health-Related Quality of Life in Melanoma Patients During COVID-19 Pandemic,Recruiting,NA,M.D. Anderson Cancer Center,NA,https://clinicalzeros.gov/ct2/show/NCT04474301,0,0,0,0,0,1,United States,0,questionnaire,NA
NCT04474288,2020-07-16,2021-07-31,Observational,The COVID-19 PUI Reality Check (CPRC) Study,Recruiting,NA,Bassett Healthcare,NA,https://clinicalzeros.gov/ct2/show/NCT04474288,0,0,0,0,1,1,United States,0,sars-cov-2 antibody testing,NA
NCT04475302,2020-07-01,2021-01-31,Interventional,BCG Vaccine in Reducing Morbidity and Mortality in Elderly Individuals in COVID-19 Hotspots,Recruiting,Phase 3,"Tuberculosis Research Centre, India",NA,https://clinicalzeros.gov/ct2/show/NCT04475302,0,0,0,1,2,0,India,0,bcg,NA
NCT04475211,2020-08-10,2022-08-31,Observational,LILLE COVID RESEARCH NETWORK (Covid-19),Recruiting,NA,"University Hospital, Lille",NA,https://clinicalzeros.gov/ct2/show/NCT04475211,0,0,0,0,1,0,France,0,"NA",NA
NCT04475185,2020-07-20,2020-12-31,Interventional,Safety and Effectiveness Assessment of the MakAir Artificial Ventilator,Recruiting,N/A,Nantes University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04475185,0,0,0,0,4,0,France,0,makair,NA
NCT04474483,2020-11-06,2021-03-31,Interventional,Safety and Efficacy of Melatonin in Outpatients Infected With COVID-19,Recruiting,Phase 2,State University of New York at Buffalo,NA,https://clinicalzeros.gov/ct2/show/NCT04474483,0,0,0,0,2,1,United States,0,melatonin|placebo (methylcellulose) capsule,NA
NCT04474236,2020-05-27,2021-02-27,Observational,Lung Ultrasound for COVID-19 Initial Triage and Monitoring,Recruiting,NA,"University Hospital, Toulouse",NA,https://clinicalzeros.gov/ct2/show/NCT04474236,0,0,0,0,0,0,France,0,thoracic lung ultrasound,NA
NCT04474067,2020-06-28,2021-03-31,Observational,COVID-19 - Cytokine Storm,Recruiting,NA,Hadassah Medical Organization,NA,https://clinicalzeros.gov/ct2/show/NCT04474067,0,0,0,0,2,0,Israel,0,no intervention,NA
NCT04473105,2020-05-01,2020-12-31,Observational,Optimising Resource Allocation Via Prediction of Outcomes for Covid-19,Recruiting,NA,Nottingham University Hospitals NHS Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04473105,0,0,0,0,1,0,United Kingdom,0,"NA",NA
NCT04473274,2020-05-21,2020-11-01,Interventional,"GlitazOne Treatment for Coronavirus HypoxiA, a Safety and Tolerability Open Label With Matching Cohort Pilot Study",Completed,Phase 4,Samaritan Health Services,NA,https://clinicalzeros.gov/ct2/show/NCT04473274,0,0,0,0,2,1,United States,0,pioglitazone,NA
NCT04473248,2020-06-28,2020-08-30,Interventional,Spartan COVID-19 System: Evaluation of Clinical Sample Collection,Completed,N/A,Spartan Bioscience Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04473248,0,0,0,0,1,0,Canada,0,spartan covid-19 system,NA
NCT04473300,2020-05-11,2020-08-31,Observational,Assessment of Lung Recruitablity of Acute Respiratory Distress Syndrome With SARS-CoV-2 Pneumonia by Electrical Impedance Tomography,Recruiting,NA,Osaka University,NA,https://clinicalzeros.gov/ct2/show/NCT04473300,0,0,0,0,0,0,Japan,0,"NA",NA
NCT04473183,2020-07-21,2022-01-31,Observational,Epidemiologic Assessment of SARS-CoV-2 (COVID-19) Prevalence in Minnesota,Recruiting,NA,University of Minnesota,NA,https://clinicalzeros.gov/ct2/show/NCT04473183,0,0,0,0,2,1,United States,0,specimen collection|survey,NA
NCT04473170,2020-04-04,2020-05-20,Interventional,Study Evaluating the Safety and Efficacy of Autologous Non-Hematopoietic Peripheral Blood Stem Cells in COVID-19,Completed,Phase 1/Phase 2,Abu Dhabi Stem Cells Center,NA,https://clinicalzeros.gov/ct2/show/NCT04473170,0,0,0,0,0,0,United Arab Emirates,0,autologous non-hematopoietic peripheral blood stem cells (nhpbsc)|standard care,NA
NCT04473157,2020-07-01,2020-11-30,Observational,COVID-19 in Patients With Anosmia in Egypt,Completed,NA,Ain Shams University,NA,https://clinicalzeros.gov/ct2/show/NCT04473157,0,0,0,0,2,0,Egypt,0,"NA",NA
NCT04473131,2020-04-27,2022-06-30,Observational,Immune Profiling of COVID19-patients Admitted to ICU,Recruiting,NA,Hamad Medical Corporation,NA,https://clinicalzeros.gov/ct2/show/NCT04473131,0,0,0,0,0,0,Qatar,0,no intervention,NA
NCT04473118,2020-07-11,2020-09-30,Observational,Assessment of Mental Health in Healthcare Workers Exposed to COVID-19 Patients,Recruiting,NA,Hamad Medical Corporation,NA,https://clinicalzeros.gov/ct2/show/NCT04473118,0,0,0,0,0,0,Qatar,0,questionnaire,NA
NCT04473053,2020-07-03,2021-07-03,Interventional,Rapid Experimental Medicine for COVID-19,Recruiting,Phase 2/Phase 3,University of Edinburgh,NA,https://clinicalzeros.gov/ct2/show/NCT04473053,0,0,0,0,1,0,United Kingdom,0,standard care|nafamostat mesilate|td139,NA
NCT04472078,2020-06-10,2020-06-26,Observational [Patient Registry],"Seroprevalence of Coronavirus Disease 2019 (COVID-19) Antibodies in a Vulnerable Neighbourhood, Buenos Aries Argentina",Completed,NA,Hospital Italiano de Buenos Aires,NA,https://clinicalzeros.gov/ct2/show/NCT04472078,0,0,0,0,1,0,Argentina,0,serology test|igg,NA
NCT04472052,2020-03-16,2020-05-31,Observational,Frequency of Perforated Appendicitis in Times of COVID-19,Completed,NA,University Hospital Tuebingen,NA,https://clinicalzeros.gov/ct2/show/NCT04472052,0,0,0,0,0,0,Germany,0,appendectomy,NA
NCT04472013,2020-08-12,2022-12-31,Observational,"Systematic Assessment of SARS-CoV-2 Neurotropic Capacity in Modestly and Critically Ill Patients, and Patients Who Died From COVID-19",Recruiting,NA,"University Hospital, Basel, Switzerland",NA,https://clinicalzeros.gov/ct2/show/NCT04472013,0,0,0,0,3,0,Switzerland,0,data collection from lumbar puncture|data collection from blood draw|cns magnetic resonance imaging (mri) imaging|microscopy of defined brain regions on autopsy specimens,NA
NCT04472494,2020-08-24,2021-01-13,Interventional,Study of Abatacept in the Treatment of Hospitalized COVID-19 Participants With Respiratory Compromise,Recruiting,Phase 2,Bristol-Myers Squibb,NA,https://clinicalzeros.gov/ct2/show/NCT04472494,0,0,0,0,4,1,United States|Puerto Rico,0,abatacept|placebo,NA
NCT04471649,2020-06-15,2020-10-31,Observational,Hydroxy Chloroquine and Covid in RA Patients,Recruiting,NA,Tanta University,NA,https://clinicalzeros.gov/ct2/show/NCT04471649,0,0,0,0,3,0,Egypt,0,"NA",NA
NCT04470869,2020-06-12,2021-04-12,Interventional,Impact on the OLAF Intervention to Prevent Post Traumatic Disorders During the Confinement.,Recruiting,N/A,"University Hospital, Toulouse",NA,https://clinicalzeros.gov/ct2/show/NCT04470869,0,0,0,0,0,0,France,0,phone call,NA
NCT04471051,2020-04-30,2021-04-30,Observational,An Observational Cohort Trial of Outcomes and Antibody Responses Following Treatment With COVID19 Convalescent Plasma in Hospitalized COVID-19 Patients,Recruiting,NA,"University of Colorado, Denver",NA,https://clinicalzeros.gov/ct2/show/NCT04471051,0,0,0,0,0,1,United States,0,"NA",NA
NCT04470739,2020-05-30,2020-09-30,Interventional,Is Thymus Size of Infants Who Born to COVID-19 Positive Mothers Associated With Neonatal Morbidities?,Recruiting,N/A,Kanuni Sultan Suleyman Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04470739,0,0,0,0,0,0,Turkey,0,chest x-ray,NA
NCT04470531,2020-07-12,2020-10-12,Interventional,Role of Co-trimoxazole in Severe COVID-19 Patients,Recruiting,Phase 2,"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh",NA,https://clinicalzeros.gov/ct2/show/NCT04470531,0,0,0,0,1,0,Bangladesh,0,trimoxazole,NA
NCT04468802,2020-02-01,2020-06-30,Observational,Do Childhood Measles and DTaP Vaccination Decrease the Mortality Rate Caused by COVID-19 in OECD Countries?,Completed,NA,Kanuni Sultan Suleyman Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04468802,0,0,0,0,1,0,Turkey,0,case fatality rate,NA
NCT04470323,2020-07-22,2020-10-31,Observational,Functional Exhaustion of T Cells in COVID19 Patients,Recruiting,NA,Assiut University,NA,https://clinicalzeros.gov/ct2/show/NCT04470323,0,0,0,0,2,0,Egypt,0,flow cytometry,NA
NCT04469660,2020-05-18,2020-08-30,Observational,Impact of COVID-19 Pandemic on the Psychological Wellbeing of Healthcare Professionals in India,Recruiting,NA,Max Healthcare Insititute Limited,NA,https://clinicalzeros.gov/ct2/show/NCT04469660,0,0,0,0,0,0,India,0,"NA",NA
NCT04469647,2020-07-19,2021-01-15,Observational,COVID 19 Seroprevalence Amongst Healthcare Workers in JHAH,Enrolling by invitation,NA,Johns Hopkins Aramco Healthcare,NA,https://clinicalzeros.gov/ct2/show/NCT04469647,0,0,0,0,1,0,Saudi Arabia,0,serology test,NA
NCT04469634,2020-07-31,2021-07-31,Interventional,Are SARS-CoV-2 Specific Antibodies a Correlate for Protection?,"Active, not recruiting",N/A,"Institute of Tropical Medicine, Belgium",NA,https://clinicalzeros.gov/ct2/show/NCT04469634,0,0,0,0,2,0,Belgium,0,"assessing antibody responses, neutralizing capacity/memory b-cell function|assessing antibody responses, neutralizing capacity|memory b-cell function",NA
NCT04469621,2020-07-17,2020-10-23,Interventional,A Phase 1b Trial to Evaluate Safety and Effect of SAR443122 on Immune System in Severe COVID-19,Completed,Phase 1,Sanofi,NA,https://clinicalzeros.gov/ct2/show/NCT04469621,0,0,0,0,9,0,Argentina|Brazil|Chile|Mexico|Russian Federation,0,sar443122|placebo,NA
NCT04468971,2020-09-29,2021-09-30,Interventional,REgulatory T Cell infuSion fOr Lung Injury Due to COVID-19 PnEumonia,Recruiting,Phase 1,"Cellenkos, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04468971,0,0,0,0,4,1,United States,0,ck0802|placebo,NA
NCT04470609,2020-07-10,2020-11-30,Interventional,Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19 in People Aged â©¾60 Years,Enrolling by invitation,Phase 1/Phase 2,Chinese Academy of Medical Sciences,NA,https://clinicalzeros.gov/ct2/show/NCT04470609,0,0,0,1,0,0,China,0,inactivated sars-cov-2 vaccine|medium dosage inactivated sars-cov-2 vaccine on a 0-/28-day schedule|placebo|28-day schedule|medium dosage inactivated sars-cov-2 vaccine on a 0-,NA
NCT04470583,2020-10-09,2021-11-30,Observational,Evaluating Clinical Parameters of COVID-19 in Pregnancy,Recruiting,NA,Chelsea and Westminster NHS Foundation Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04470583,0,0,0,0,2,0,United Kingdom,0,"NA",NA
NCT04470544,2020-07-28,2022-09-15,Interventional,Camostat Mesilate Treating Patients With Hospitalized Patients With COVID-19,Recruiting,Phase 2,Academic and Community Cancer Research United,NA,https://clinicalzeros.gov/ct2/show/NCT04470544,0,0,0,0,3,1,United States,0,camostat mesilate|standard care,NA
NCT04469153,2020-06-29,2020-09-01,Observational,Interest of the Dosage of Ferritin / Glycosylated Ferritin in COVID-19,Recruiting,NA,Hospices Civils de Lyon,NA,https://clinicalzeros.gov/ct2/show/NCT04469153,0,0,0,0,0,0,France,0,no intervention|evaluation of the ferritin|glycosylated ferritin by standard approved serological tests,NA
NCT04468412,2020-07-14,2021-09-30,Observational,Influence of COVID-19 on Vascular Endothelial Function,"Active, not recruiting",NA,Radboud University,NA,https://clinicalzeros.gov/ct2/show/NCT04468412,0,0,0,0,2,0,Netherlands,0,carotid artery reactivity testing,NA
NCT04468308,2020-09-08,2021-03-31,Observational,VRQOL in Cataract Patients During the COVID-19 Pandemic,Recruiting,NA,Medical University Innsbruck,NA,https://clinicalzeros.gov/ct2/show/NCT04468308,0,0,0,0,1,0,Austria,0,questionnaire,NA
NCT04468646,2020-06-15,2020-07-15,Interventional,To Determine the Efficacy of Neurokinin 1 Receptor Antagonist as a Therapeutic Tool Against Cytokine Storm and Respiratory Failure in Covid-19 Patients,Recruiting,Phase 3,University of Health Sciences Lahore,NA,https://clinicalzeros.gov/ct2/show/NCT04468646,0,0,0,0,0,0,Pakistan,0,nk-1r antagonist,NA
NCT04468139,2020-06-20,2020-07-20,Interventional,"The Study of Quadruple Therapy Zinc, Quercetin, Bromelain and Vitamin C on the Clinical Outcomes of Patients Infected With COVID-19",Recruiting,Phase 4,"Ministry of Health, Saudi Arabia",NA,https://clinicalzeros.gov/ct2/show/NCT04468139,0,0,0,0,0,0,Saudi Arabia,0,quercetin|bromelain|zinc|vitamin c,NA
NCT04468256,2020-07-26,2022-07-31,Observational,The Heart Hive COVID-19 Study,Recruiting,NA,Imperial College London,NA,https://clinicalzeros.gov/ct2/show/NCT04468256,0,0,0,0,1,0,United Kingdom,0,covid-19 experience surveys,NA
NCT04468217,2020-06-02,2020-09-15,Observational,Evaluation of an Alternative Method of Obtaining Viral RNA for the Detection of SARS-CoV-2 Virus Using PCR,Recruiting,NA,Neurognos,NA,https://clinicalzeros.gov/ct2/show/NCT04468217,0,0,0,0,0,0,Chile,0,"obtainment of nasopharyngeal, oropharyngeal, buccal, nasal/saliva samples|obtainment of nasopharyngeal, oropharyngeal, buccal, nasal|saliva",NA
NCT04467918,2020-07-06,2020-11-16,Interventional,CANnabiDiol for CoviD-19 pATiEnts With Mild to Moderate Symptoms,"Active, not recruiting",Phase 2/Phase 3,University of Sao Paulo,NA,https://clinicalzeros.gov/ct2/show/NCT04467918,0,0,0,0,5,0,Brazil,0,cannabidiol|placebo,NA
NCT04468009,2020-06-25,2021-01-19,Interventional,Treatment of Critically Ill Patients With Covid-19 With Convalescent Plasma,Recruiting,Phase 2,Hospital de Infecciosas Francisco Javier Muniz,NA,https://clinicalzeros.gov/ct2/show/NCT04468009,0,0,0,0,4,0,Argentina,0,convalescent plasma,NA
NCT04467008,2020-07-15,2020-08-15,Observational,Covid-19 Rapid Diagnostic Tests on Blood Drop,Completed,NA,CMC Ambroise ParÃ©,NA,https://clinicalzeros.gov/ct2/show/NCT04467008,0,0,0,0,1,0,France,0,"NA",NA
NCT04466982,2020-07-02,2021-08-31,Observational,Assessment of Olfactory Dysfunction in SARS CoV-2 (COVID-19) Infection,Recruiting,NA,Cambridge University Hospitals NHS Foundation Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04466982,0,0,0,0,2,0,United Kingdom,0,"NA",NA
NCT04466540,2020-05-12,2021-01-28,Interventional,Randomized Placebo-controlled Trial of Hydroxychloroquine in Outpatient Cases With Coronavirus Disease 2019 (COVID-19),Recruiting,Phase 4,Hospital AlemÃ£o Oswaldo Cruz,NA,https://clinicalzeros.gov/ct2/show/NCT04466540,0,0,0,0,1,0,Brazil,0,hydroxychloroquine|placebo,NA
NCT04466462,2020-05-26,2020-06-30,Observational,Cross-sectional Study of COVID-19 Infection in Hospital Health Personnel,Completed,NA,"FundaciÃ³n FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la PromociÃ³n de la Salud y la Ciencia",NA,https://clinicalzeros.gov/ct2/show/NCT04466462,0,0,0,0,0,0,Spain,0,"NA",NA
NCT04466644,2020-06-08,2020-08-24,Observational,COVID-19: A Prevalence Study of Two ART Centres After the Pandemic Lockdown in the USA (COVID-19 Free Clinics),Completed,NA,Igenomix,NA,https://clinicalzeros.gov/ct2/show/NCT04466644,0,0,0,0,1,1,United States,0,elisa|pcr,NA
NCT04466605,2020-03-30,2020-06-30,Interventional,Effect of Tele-Yoga Therapy on Patients With Chronic Musculoskeletal Pain During Covid-19 Lockdown,Completed,N/A,Aarogyam UK,NA,https://clinicalzeros.gov/ct2/show/NCT04466605,0,0,0,0,0,0,India,0,tele-yoga|primary care,NA
NCT04465981,2020-07-31,2020-12-31,Observational,Investigation of Antibody and Immune Responses to SARS-CoV-2 Proteins,Recruiting,NA,INanoBio Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04465981,0,0,0,0,1,1,United States,0,sampling,NA
NCT04466306,2020-04-15,2020-07-08,Observational [Patient Registry],Pediatric Acute Kidney Injury in COVID-19,Enrolling by invitation,NA,Children's Healthcare of Atlanta,NA,https://clinicalzeros.gov/ct2/show/NCT04466306,0,0,0,0,0,1,United States|Canada|Israel|Japan|Serbia|Spain|United Kingdom,0,"NA",NA
NCT04466280,2020-07-15,2020-11-15,Interventional,"Efficacy and Safety of Mucoadhesive Sustained Release, Mucodentol, in Comparison With Hydroxychloroquine to Prevent COVID-19",Recruiting,N/A,Baqiyatallah Medical Sciences University,NA,https://clinicalzeros.gov/ct2/show/NCT04466280,0,0,0,0,0,0,"Iran, Islamic Republic of",0,hydroxychloroquine|mucodentol|personal protective equipment,NA
NCT04465058,2020-07-08,2020-08-08,Observational,Characteristics of Critically Ill COVID 19 Patients,Recruiting,NA,Assiut University,NA,https://clinicalzeros.gov/ct2/show/NCT04465058,0,0,0,0,0,0,Egypt,0,covid-19,NA
NCT04465695,2020-07-14,2021-06-30,Interventional,Dual Therapy With Interferon Beta-1b and Clofazimine for COVID-19,Recruiting,Phase 2,The University of Hong Kong,NA,https://clinicalzeros.gov/ct2/show/NCT04465695,0,0,0,0,3,0,China,0,interferon|clofazimine,NA
NCT04465656,2020-07-07,2020-10-31,Observational,Registry of the Evolution of Diagnosed and/or Hospitalized Patients for Pulmonary Embolism During the Covid-19 Pandemic,Recruiting,NA,"Hospital St. Joseph, Marseille, France",NA,https://clinicalzeros.gov/ct2/show/NCT04465656,0,0,0,0,1,0,France,0,serology test for covid-19,NA
NCT04465474,2020-05-01,2022-04-30,Observational [Patient Registry],"Coronavirus Disease 2019 (COVID-19) During Pregnancy: Prevalence of Seroconversion, Effect on Maternal and Perinatal Outcomes and Risk of Vertical Transmission (COVID-MAP)",Recruiting,NA,Chinese University of Hong Kong,NA,https://clinicalzeros.gov/ct2/show/NCT04465474,0,0,0,0,3,0,China|Hong Kong|Spain,0,non intervention,NA
NCT04464486,2020-04-21,2021-03-31,Interventional,Remote COVID-19 Symptom Tracking for Cancer Patients at Home During the Pandemic,Enrolling by invitation,N/A,University of Utah,NA,https://clinicalzeros.gov/ct2/show/NCT04464486,0,0,0,0,0,1,United States,0,sch intervention,NA
NCT04463433,2020-02-01,2021-12-31,Interventional,Psychological Intervention for Parent-child Relationship and Couple Relationship Under COVID-19 in China,Recruiting,N/A,Beijing Normal University,NA,https://clinicalzeros.gov/ct2/show/NCT04463433,0,0,0,0,0,0,China,0,behavior|problem-solving/relationship improvement intervention.|cognitive|problem-solving|relationship improvement intervention.,NA
NCT04463758,2020-05-11,2022-02-28,Observational,Covid-19 in Pregnancy: a French Population-based Cohort of Women and Newborns,Recruiting,NA,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04463758,0,0,0,0,0,0,France,0,questionnaire,NA
NCT04463628,2020-05-15,2020-11-30,Observational,"Impacts of the Covid-19 Epidemic and Associated Lockdown Measures on the Management, Health and Behaviors of Cystic Fibrosis Patients During the 2020 Epidemic",Recruiting,NA,Centre Hospitalier Intercommunal Creteil,NA,https://clinicalzeros.gov/ct2/show/NCT04463628,0,0,0,0,0,0,France,0,questionnaire|interview,NA
NCT04463862,2020-06-04,2020-09-04,Observational [Patient Registry],COVID - AirPollution,Recruiting,NA,"University Hospital, Strasbourg, France",NA,https://clinicalzeros.gov/ct2/show/NCT04463862,0,0,0,0,1,0,Belgium|France,0,"NA",NA
NCT04463420,2020-08-15,2020-11-15,Interventional,Safety and Efficacy of PHR 160 Spray on the Outcomes of Patients With COVID-19,Recruiting,N/A,Baqiyatallah Medical Sciences University,NA,https://clinicalzeros.gov/ct2/show/NCT04463420,0,0,0,0,2,0,"Iran, Islamic Republic of",0,phr160 spray|placebo|standard care,NA
NCT04463264,2020-06-26,2020-11-15,Interventional,Efficacy and Safety Study of Nitazoxanide (NTX) in the Treatment of Patients With SARS-CoV-2 Virus Infection (COVID-19),Recruiting,Phase 2/Phase 3,Laboratorios Roemmers S.A.I.C.F.,NA,https://clinicalzeros.gov/ct2/show/NCT04463264,0,0,0,0,4,0,Argentina,0,nitazoxanide|placebo,NA
NCT04463472,2020-06-29,2020-09-28,Interventional,Study of COVID-19 DNA Vaccine (AG0301-COVID19),"Active, not recruiting",Phase 1/Phase 2,"AnGes, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04463472,0,0,0,1,3,0,Japan,0,ag0301-covid19,NA
NCT04460664,2020-08-14,2021-01-31,Observational,Coagulation Changes Associated With COVID-19 Infection,Enrolling by invitation,NA,HemoSonics LLC,NA,https://clinicalzeros.gov/ct2/show/NCT04460664,0,0,0,0,1,1,United States,0,quantra system,NA
NCT04462120,2020-06-16,2020-06-18,Observational,IL-12RB and TNF-alpha Gene Polymorphism and Susceptibility and Progress of Covid-19 SARS-CoV-2: A Case Control Study,"Active, not recruiting",NA,Assiut University,NA,https://clinicalzeros.gov/ct2/show/NCT04462120,0,0,0,0,0,0,Egypt,0,"NA",NA
NCT04461925,2020-05-02,2021-05-02,Interventional,Treatment of Coronavirus COVID-19 Pneumonia (Pathogen SARS-CoV-2) With Cryopreserved Allogeneic P_MMSCs and UC-MMSCs,Recruiting,Phase 1/Phase 2,Institute of Cell Therapy,NA,https://clinicalzeros.gov/ct2/show/NCT04461925,0,0,0,0,0,0,Ukraine,0,mesenchymalÂ stem cells|antibiotics|hormones|anticoagulation|ðžxygen therapy|ðžxygen therapy,NA
NCT04461379,2020-07-21,2021-01-01,Interventional,"Prevention, Efficacy and Safety of BCG Vaccine in COVID-19 Among Healthcare Workers","Active, not recruiting",Phase 3,Hospital Universitario Dr. Jose E. Gonzalez,NA,https://clinicalzeros.gov/ct2/show/NCT04461379,0,0,0,1,3,0,Mexico,0,bcg|placebo,NA
NCT04461340,2020-08-15,2020-10-30,Interventional,Efficacy and Safety of Sirolimus in COVID-19 Infection,Recruiting,Phase 2,Alexandria University,NA,https://clinicalzeros.gov/ct2/show/NCT04461340,0,0,0,0,3,0,Egypt,0,sirolimus,NA
NCT04460651,2020-08-14,2021-01-31,Interventional,PREPARE-IT. Prevention of COVID19 With EPA in Healthcare Providers at Risk - Intervention Trial,Recruiting,Phase 3,Estudios ClÃ­nicos Latino AmÃ©rica,NA,https://clinicalzeros.gov/ct2/show/NCT04460651,0,0,0,0,1,0,Argentina,0,icosapent ethyl (ipe)|placebo,NA
NCT04460599,2020-03-08,2020-07-30,Observational,Neurological Features During COVID19,Recruiting,NA,Centre d'Investigation Clinique et Technologique 805,NA,https://clinicalzeros.gov/ct2/show/NCT04460599,0,0,0,0,1,0,France,0,observation,NA
NCT04460703,2020-07-03,2020-07-08,Interventional,"COVID-19 Vaccine Messaging, Part 1",Completed,N/A,Yale University,NA,https://clinicalzeros.gov/ct2/show/NCT04460703,0,0,0,1,1,1,United States,0,control message|baseline message|personal freedom message|economic freedom message|self-interest message|community interest message|economic benefit message|guilt message|embarrassment message|anger message|trust in science message|not bravery message,NA
NCT04460690,2020-07-13,2021-07-31,Interventional,"Rapid, Onsite COVID-19 Detection",Enrolling by invitation,N/A,"University of Wisconsin, Madison",NA,https://clinicalzeros.gov/ct2/show/NCT04460690,0,0,0,0,4,1,United States,0,rapid test,NA
NCT04460677,2020-08-12,2021-03-31,Interventional,ASD (Autism Spectrum Disorder) Telehealth for Distress Related to COVID-19,Recruiting,N/A,"Rutgers, The State University of New Jersey",NA,https://clinicalzeros.gov/ct2/show/NCT04460677,0,0,0,0,4,1,United States,0,emotional support plan|daily monitoring,NA
NCT04460534,2020-05-07,2021-07-31,Interventional,Detection of COVID-19 (SARS-CoV-2) in the Semen of COVID+ Patients (Positive RT-PCR on a Nasopharyngeal Swab),Recruiting,N/A,GCS Ramsay SantÃ© pour l'Enseignement et la Recherche,NA,https://clinicalzeros.gov/ct2/show/NCT04460534,0,0,0,0,0,0,France,0,diagnostic,NA
NCT04460196,2020-07-08,2020-09-18,Observational [Patient Registry],Healthcare Renunciation During the Confinement Period in Connection With the COVID-19 Epidemic in Adult Emergency Departments,Completed,NA,"University Hospital, Angers",NA,https://clinicalzeros.gov/ct2/show/NCT04460196,0,0,0,0,2,0,France,0,questionnaire,NA
NCT04460183,2020-07-29,2021-01-27,Interventional,A Study to Assess Efficacy and Safety of RESP301 Plus Standard of Care (SOC) Compared to SOC Alone in Hospitalized Participants With COVID-19,Recruiting,Phase 2/Phase 3,Thirty Respiratory Limited,NA,https://clinicalzeros.gov/ct2/show/NCT04460183,0,0,0,0,4,0,United Kingdom,0,"resp301, a nitric oxide generating solution|standard care",NA
NCT04460170,2020-07-01,2022-02-01,Observational [Patient Registry],COVID-19 Follow up Intensive Care Studies,Recruiting,NA,University Medical Center Groningen,NA,https://clinicalzeros.gov/ct2/show/NCT04460170,0,0,0,0,1,0,Netherlands,0,"NA",NA
NCT04460469,2020-07-01,2020-09-30,Observational,Anxiety Level and Oral Hygiene Practice in Dental Students During Covid-19 Pandemic,Recruiting,NA,Cairo University,NA,https://clinicalzeros.gov/ct2/show/NCT04460469,0,0,0,0,1,0,Egypt,0,"NA",NA
NCT04460274,2019-12-31,2020-06-15,Observational,Forecast Number of Covid-19 Cases Worldwide,Completed,NA,Turkish Ministry of Health Izmir Teaching Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04460274,0,0,0,0,1,0,Turkey,0,model building|model validation,NA
NCT04460443,2020-08-01,2021-08-01,Interventional,Sofosbuvir in Treatment of COVID 19,Recruiting,Phase 2/Phase 3,Tanta University,NA,https://clinicalzeros.gov/ct2/show/NCT04460443,0,0,0,0,2,0,Egypt,0,sofosbuvir|sofosbuvir ledipsavir|daclatasvir,NA
NCT04460014,2020-09-30,2021-03-01,Interventional,Simple Cognitive Task Intervention After Trauma During COVID-19 In Hospital Staff EKUT-P RCT,Recruiting,N/A,Karolinska Institutet,NA,https://clinicalzeros.gov/ct2/show/NCT04460014,0,0,0,0,4,0,Sweden,0,simple cognitive task intervention|placebo,NA
NCT04459975,2020-04-01,2020-10-31,Observational,Acute Kidney Injury and Renal Outcomes for COVID-19 Patients in Intensive Care Units,Recruiting,NA,Hospices Civils de Lyon,NA,https://clinicalzeros.gov/ct2/show/NCT04459975,0,0,0,0,0,0,France,0,non interventional study,NA
NCT04458948,2020-03-24,2021-03-24,Interventional,Open Label Non-comparative Trial of the Combination of Hydroxychloroquine and Azithromycin in the Treatment of Hospitalized Patients,"Active, not recruiting",Phase 2,University of New Mexico,NA,https://clinicalzeros.gov/ct2/show/NCT04458948,0,0,0,0,0,1,United States,0,hydroxychloroquine|azithromycin,NA
NCT04459533,2020-06-01,2020-06-01,Observational,Sparing in Neuromuscular Blockade in COVID 19 ICU,Completed,NA,Hospices Civils de Lyon,NA,https://clinicalzeros.gov/ct2/show/NCT04459533,0,0,0,0,0,0,France,0,tof protocol,NA
NCT04459520,2020-07-23,2020-07-28,Interventional,Effect of Availability of COVID-19 Testing on Choice to Isolate and Socially Distance,Completed,N/A,"University of California, Los Angeles",NA,https://clinicalzeros.gov/ct2/show/NCT04459520,0,0,0,0,2,1,United States,0,no intervention|unavailable covid test result - hypothetical scenario,NA
NCT04459455,2020-08-19,2020-10-15,Interventional,"Project H-COVID: Evaluating Hyper-Brief, Online Materials During the COVID-19 Pandemic",Completed,N/A,Stony Brook University,NA,https://clinicalzeros.gov/ct2/show/NCT04459455,0,0,0,0,2,1,United States,0,remain covid free ssi|contain covid anxiety ssi,NA
NCT04459390,2020-07-20,2020-10-20,Observational,Association of Comorbidities With COVID19,Recruiting,NA,Assiut University,NA,https://clinicalzeros.gov/ct2/show/NCT04459390,0,0,0,0,1,0,Egypt,0,pcr,NA
NCT04459364,2020-06-01,2020-07-07,Observational [Patient Registry],The Prevalence of Pulmonary Hypertension in Patients With COVID-19.,Completed,NA,Attgeno AB,NA,https://clinicalzeros.gov/ct2/show/NCT04459364,0,0,0,0,1,0,Sweden,0,"NA",NA
NCT04459351,2020-06-19,2023-05-31,Observational,PHenotyping patiENts Admitted to Hospital With cOvid-19 Infection and idenTifYing Prognostic markErs,Recruiting,NA,Chelsea and Westminster NHS Foundation Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04459351,0,0,0,0,1,0,United Kingdom,0,"NA",NA
NCT04459325,2020-06-01,2020-07-20,Interventional,TigeraseÂ® Efficacy and Safety as Part of Complex Therapy in Patients With COVID-19,Completed,Phase 3,AO GENERIUM,NA,https://clinicalzeros.gov/ct2/show/NCT04459325,0,0,0,0,1,0,Russian Federation,0,tigeraseâ®/best available care|best available therapy|tigeraseâ®,NA
NCT04459312,2020-06-01,2020-07-10,Observational,National Covid-19 Surveillance Physicians,Recruiting,NA,"Heinrich-Heine University, Duesseldorf",NA,https://clinicalzeros.gov/ct2/show/NCT04459312,0,0,0,0,1,0,Germany,0,serology test,NA
NCT04459689,2020-03-15,2022-03-31,Observational [Patient Registry],COVID-19 in PID Survey,Recruiting,NA,Imagine Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04459689,0,0,0,0,0,0,France,0,"NA",NA
NCT04458246,2020-07-31,2020-12-31,Interventional,Home-based Aerobic Training Among Adolescents With Chronic Diseases During COVID-19 Pandemic,Recruiting,N/A,University of Sao Paulo,NA,https://clinicalzeros.gov/ct2/show/NCT04458246,0,0,0,0,0,0,Brazil,0,exercise,NA
NCT04458519,2020-07-16,2021-04-30,Interventional,Efficacy of Intranasal Probiotic Treatment to Reduce Severity of Symptoms in COVID19 Infection,Recruiting,N/A,Centre hospitalier de l'UniversitÃ© de MontrÃ©al (CHUM),NA,https://clinicalzeros.gov/ct2/show/NCT04458519,0,0,0,0,3,0,Canada,0,probiorinse|saline,NA
NCT04457609,2020-07-31,2020-08-31,Interventional,Administration of Allogenic UC-MSCs as Adjuvant Therapy for Critically-Ill COVID-19 Patients,Recruiting,Phase 1,Indonesia University,NA,https://clinicalzeros.gov/ct2/show/NCT04457609,0,0,0,0,0,0,Indonesia,0,oseltamivir|azithromycin|mesenchymal stem cells,NA
NCT04458363,2020-07-04,2020-09-01,Interventional,Convalescent Plasma in Pediatric COVID-19,Completed,Early Phase 1,Emory University,NA,https://clinicalzeros.gov/ct2/show/NCT04458363,0,0,0,0,1,1,United States,0,convalescent plasma|standard care,NA
NCT04457817,2020-12-01,2021-07-31,Interventional,Compensatory Reserve Index (CRI) for Management of COVID-19,Enrolling by invitation,N/A,"University of Colorado, Denver",NA,https://clinicalzeros.gov/ct2/show/NCT04457817,0,0,0,0,3,1,United States,0,cri management,NA
NCT04457726,2020-07-01,2021-03-31,Interventional,Part Two of Novel Adoptive Cellular Therapy With SARS-CoV-2 Specific T Cells in Patients With Severe COVID-19,Recruiting,Phase 1/Phase 2,KK Women's and Children's Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04457726,0,0,0,0,1,0,Singapore,0,sars-cov-2 specific t cells,NA
NCT04457505,2020-05-08,2021-05-31,Observational [Patient Registry],One Year Follow-ups of Patients Admitted to Spanish Intensive Care Units Due to COVID-19,Recruiting,NA,"Consorcio Centro de InvestigaciÃ³n BiomÃ©dica en Red, M.P.",NA,https://clinicalzeros.gov/ct2/show/NCT04457505,0,0,0,0,0,0,Spain,0,"NA",NA
NCT04457570,2020-06-15,2020-12-15,Observational,Excess Risk of Morbi-mortality Due to COVID-19 in Patients With Cancer,Recruiting,NA,Hospices Civils de Lyon,NA,https://clinicalzeros.gov/ct2/show/NCT04457570,0,0,0,0,0,0,France,0,mortality,NA
NCT04457388,2020-03-25,2020-06-15,Interventional,Tele-Yoga Therapy for Chronic Pain,Completed,N/A,Aarogyam UK,NA,https://clinicalzeros.gov/ct2/show/NCT04457388,0,0,0,0,2,0,United Kingdom,0,tele-yoga,NA
NCT04456933,2020-06-29,2021-12-31,Observational,Intracorporeal Anastomosis in Laparoscopic Left Colectomy. Cohort Comparative Study,Recruiting,NA,Corporacion Parc Tauli,NA,https://clinicalzeros.gov/ct2/show/NCT04456933,0,0,0,0,2,0,Spain,0,extracorporeal left hemicolectomy anastomosis|intracorporeal left hemicolectomy anastomosis,NA
NCT04457349,2020-07-25,2020-12-29,Interventional,Therapeutic Plasma Exchange in Resistant Cytokine Storm of COVID 19,Recruiting,N/A,Alexandria University,NA,https://clinicalzeros.gov/ct2/show/NCT04457349,0,0,0,0,4,0,Egypt,0,therapeutic plasma exchange (tpe),NA
NCT04452695,2020-03-10,2020-08-03,Observational,Acceptability of Telehealth Triage Using Robotic Systems in COVID-19,Completed,NA,Brigham and Women's Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04452695,0,0,0,0,2,1,United States,0,doctor spot,NA
NCT04456062,2020-08-04,2021-03-31,Interventional,Using Caring Contacts to Reduce Psychiatric Morbidity Following Hospitalization During the COVID-19 Pandemic,Recruiting,N/A,Sunnybrook Health Sciences Centre,NA,https://clinicalzeros.gov/ct2/show/NCT04456062,0,0,0,0,2,0,Canada,0,caring contacts,NA
NCT04456556,2020-04-27,2020-06-20,Observational,Combined Endophthalmitis and Orbital Cellulitis in Patients With Novel Coronavirus Disease (COVID-19),Completed,NA,Minia University,NA,https://clinicalzeros.gov/ct2/show/NCT04456556,0,0,0,0,0,0,Egypt,0,"NA",NA
NCT04456452,2020-07-27,2020-09-08,Interventional,Study of Ampion for the Treatment of Adult COVID-19 Patients Requiring Oxygen Supplementation,Completed,Phase 1,Ampio Pharmaceuticals. Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04456452,0,0,0,0,5,1,United States,0,ampion|standard care,NA
NCT04456361,2020-04-16,2020-10-15,Interventional,Use of Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Caused by COVID-19,"Active, not recruiting",Early Phase 1,Instituto de Medicina Regenerativa,NA,https://clinicalzeros.gov/ct2/show/NCT04456361,0,0,0,0,1,0,Mexico,0,mesenchymal stem cells,NA
NCT04456010,2020-06-01,2020-07-30,Observational,COVID-19 in ART: Perception and Experience,Completed,NA,"University Hospital, Montpellier",NA,https://clinicalzeros.gov/ct2/show/NCT04456010,0,0,0,0,1,0,France,0,questionnaire,NA
NCT04455815,2020-09-25,2021-08-31,Interventional,A Trial Looking at the Use of Camostat to Reduce Progression of Symptoms of Coronavirus (COVID-19) in People Who Have Tested Positive But Are Able to Stay at Home,Recruiting,Phase 2/Phase 3,Cancer Research UK,NA,https://clinicalzeros.gov/ct2/show/NCT04455815,0,0,0,0,5,0,United Kingdom,0,camostat,NA
NCT04456101,2020-06-19,2020-12-01,Observational,"Study on the Recovery of Pulmonary Function, Chest CT, Hematologic, and Immune & Inflammatory Conditions in COVID-19 Rehabilitation Patients",Recruiting,NA,"Wuhan Union Hospital, China",NA,https://clinicalzeros.gov/ct2/show/NCT04456101,0,0,0,0,1,0,China,0,"NA",NA
NCT04456075,2020-04-01,2022-04-30,Observational,Risk Prediction and Therapy Monitoring in Patients With SARS-Cov-2 Infection / COVID 19,Recruiting,NA,Heidelberg University,NA,https://clinicalzeros.gov/ct2/show/NCT04456075,0,0,0,0,0,0,Germany,0,"NA",NA
NCT04455451,2020-08-06,2022-12-31,Observational,Intensive Care Therapy of Covid-19 Disease in Germany,Recruiting,NA,University Hospital Tuebingen,NA,https://clinicalzeros.gov/ct2/show/NCT04455451,0,0,0,0,8,0,Germany,0,"NA",NA
NCT04455347,2020-06-15,2022-06-30,Observational [Patient Registry],Cardiac and Thoracic Imaging in Pediatric Patients With Evidence of Systemic Inflammation COVID19 Linked,Recruiting,NA,Imagine Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04455347,0,0,0,0,0,0,France,0,"NA",NA
NCT04455308,2020-07-21,2020-10-19,Interventional,COVID-19 and Chilblains,Completed,N/A,Rennes University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04455308,0,0,0,0,2,0,France,0,biological samples,NA
NCT04453527,2020-05-28,2021-05-31,Observational,The CASCADE Study - Measures of Complement Activation and Inflammation in Patients With Covid-19,Recruiting,NA,Portsmouth Hospitals NHS Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04453527,0,0,0,0,0,0,United Kingdom,0,"NA",NA
NCT04453514,2020-07-21,2020-10-31,Interventional,Feasibility of a Brief Trauma-informed Yoga Intervention for Anxiety During the Coronavirus Disease (COVID-19) Pandemic,Recruiting,N/A,National University of Natural Medicine,NA,https://clinicalzeros.gov/ct2/show/NCT04453514,0,0,0,0,1,1,United States,0,trauma-informed yoga video recording,NA
NCT04453501,2020-03-02,2020-04-25,Observational,Anti Infective Agents Impact in COVID-19 Pneumonia,Completed,NA,Centre d'Investigation Clinique et Technologique 805,NA,https://clinicalzeros.gov/ct2/show/NCT04453501,0,0,0,0,0,0,France,0,favorable outcome,NA
NCT04453475,2020-07-01,2021-07-31,Interventional,Feasibility and Benefits of Digital Services During the COVID19 Pandemic,Recruiting,N/A,Jacobs University Bremen gGmbH,NA,https://clinicalzeros.gov/ct2/show/NCT04453475,0,0,0,0,1,0,Germany,0,training session adressing information/health literacy|training session adressing information|health literacy,NA
NCT04453748,2020-06-08,2021-10-31,Observational [Patient Registry],"The Assessment of the Prevalence, Clinical Course and Treatment of COVID-19 Complications",Enrolling by invitation,NA,Silesian Centre for Heart Diseases,NA,https://clinicalzeros.gov/ct2/show/NCT04453748,0,0,0,0,1,0,Poland,0,complex diagnostic panel,NA
NCT04453670,2020-03-10,2020-05-11,Observational,Neuropathology in Adults Intensive Care Unit Patients With COVID 19,Completed,NA,University of Versailles,NA,https://clinicalzeros.gov/ct2/show/NCT04453670,0,0,0,0,0,0,France,0,autopsy,NA
NCT04452422,2020-06-23,2020-09-23,Observational,Deep Venous Thrombosis in Non-severe COVID-19 Patients Hospitalized for a Neurovascular Pathology,Recruiting,NA,"University Hospital, Strasbourg, France",NA,https://clinicalzeros.gov/ct2/show/NCT04452422,0,0,0,0,0,0,France,0,"NA",NA
NCT04453280,2020-05-18,2020-06-03,Observational,Antibody Detection in COVID-19 Cured Patients (SARS-CoV-2-CZ-Immunity),Completed,NA,Institute of Health Information and Statistics of the Czech Republic,NA,https://clinicalzeros.gov/ct2/show/NCT04453280,0,0,0,0,0,0,Czechia,0,quantitative analysis of anti-sars-cov-2-antibodies|rapid test,NA
NCT04452773,2020-07-14,2020-09-30,Interventional,Clinical Trial to Evaluate the Efficacy of Food Supplement ManremycÂ® Against SARS- COV-2 Infection (COVID-19) in Healthcare Workers,Recruiting,N/A,Reig Jofre Group,NA,https://clinicalzeros.gov/ct2/show/NCT04452773,0,0,0,0,2,0,Spain,0,manremyc|placebo,NA
NCT04452708,2020-06-11,2021-06-10,Observational,HFNC and NIV for COVID-19 Complicated by Respiratory Failure,Recruiting,NA,Chinese University of Hong Kong,NA,https://clinicalzeros.gov/ct2/show/NCT04452708,0,0,0,0,0,0,Hong Kong,0,oxygen,NA
NCT04452682,2020-05-25,2020-06-21,Observational,The Impact of COVID-19 Pandemic on Critical Limb Threatening Ischemia and Emergency Vascular Practice,Completed,NA,Mansoura University,NA,https://clinicalzeros.gov/ct2/show/NCT04452682,0,0,0,0,0,0,Egypt,0,covid 19 impact,NA
NCT04452630,2020-06-23,2020-07-23,Observational,Cardiovascular Consequences After COVID-19,Recruiting,NA,Assistance Publique Hopitaux De Marseille,NA,https://clinicalzeros.gov/ct2/show/NCT04452630,0,0,0,0,0,0,France,0,infectious disease/cardiology clinical consultations|infectious disease|cardiology clinical consultations,NA
NCT04452617,2020-03-19,2020-04-08,Observational,Safety of Short-term Hydroxychloroquine Plus Azithromycin Treatment in Critically Ill Patients With Severe COVID-19,Completed,NA,Institut Mutualiste Montsouris,NA,https://clinicalzeros.gov/ct2/show/NCT04452617,0,0,0,0,1,0,France,0,"NA",NA
NCT04452565,2020-10-15,2020-12-31,Interventional,"NA-831, Atazanavir and Dexamethasone Combination Therapy for the Treatment of COVID-19 Infection",Recruiting,Phase 2/Phase 3,"NeuroActiva, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04452565,0,0,0,0,4,1,United States,0,na-831|na-831/atazanavir|na-831/dexamethasone|atazanavir/dexamethasone|atazanavir|dexamethasone,NA
NCT04452487,2020-06-01,2021-06-30,Observational,Study of the Consequences of Infection on Compliance of Modalities of Decisions of Limitations and Stops of Treatments (COVID-19-LAT),Recruiting,NA,"University Hospital, Clermont-Ferrand",NA,https://clinicalzeros.gov/ct2/show/NCT04452487,0,0,0,0,0,0,France,0,decisions of limitations/stop processing|decisions of limitations|stop processing,NA
NCT04451577,2020-06-01,2021-06-01,Observational,"Epidemiologic, Clinical, Molecular Characteristics of Hospital Employees With or Without Covid-19 Infection",Recruiting,NA,Istituto Clinico Humanitas,NA,https://clinicalzeros.gov/ct2/show/NCT04451577,0,0,0,0,0,0,Italy,0,no intervention,NA
NCT04451889,2020-08-01,2021-07-01,Interventional,Probe-based Confocal Laser Endomicroscopy in Critically Ill COVID-19 Patients,Recruiting,N/A,"Federal Research Clinical Center of Federal Medical & Biological Agency, Russia",NA,https://clinicalzeros.gov/ct2/show/NCT04451889,0,0,0,0,1,0,Russian Federation,0,miniprobe alveoflex,NA
NCT04450017,2020-04-06,2020-07-31,Observational,Clinical Features of Severe Patients With COVID-19,Recruiting,NA,"Federal Research Clinical Center of Federal Medical & Biological Agency, Russia",NA,https://clinicalzeros.gov/ct2/show/NCT04450017,0,0,0,0,0,0,Russian Federation,0,"the demographic, clinical, laboratory,/instrumental data|the demographic, clinical, laboratory,|data",NA
NCT04451694,2020-04-01,2020-07-30,Observational,Nutritional Follow up After Hospital Discharge for Coronavirus Disease-19,Recruiting,NA,"Central Hospital, Nancy, France",NA,https://clinicalzeros.gov/ct2/show/NCT04451694,0,0,0,0,0,0,France,0,nutritional intervention,NA
NCT04451317,2020-06-12,2021-08-31,Observational,Physical Activity Following the Containment Period Imposed by the COVID-19 Pandemic in Patients,Recruiting,NA,"University Hospital, Toulouse",NA,https://clinicalzeros.gov/ct2/show/NCT04451317,0,0,0,0,2,0,France,0,"questionnaire, phone call",NA
NCT04450277,2020-04-01,2020-05-31,Observational [Patient Registry],Delivery of Protocolised Emergency Surgical Care During COVID-19 Pandemic,Completed,NA,Khoo Teck Puat Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04450277,0,0,0,0,1,0,Singapore,0,emergency surgery,NA
NCT04450004,2020-07-10,2021-09-20,Interventional,"Safety, Tolerability and Immunogenicinity of a Coronavirus-Like Particle COVID-19 Vaccine in Adults Aged 18-55 Years.","Active, not recruiting",Phase 1,Medicago,NA,https://clinicalzeros.gov/ct2/show/NCT04450004,0,0,0,1,3,0,Canada,0,intramuscular vaccine,NA
NCT04449978,2020-04-09,2022-06-30,Observational,TARGet Kids! COVID-19 Study of Children and Families,Recruiting,NA,The Hospital for Sick Children,NA,https://clinicalzeros.gov/ct2/show/NCT04449978,0,0,0,0,0,0,Canada,0,"NA",NA
NCT04448782,2020-03-09,2020-06-30,Observational,Characterization of Reverse Triggering and Other Asynchronies in COVID-19 Patients Under Invasive Mechanical Ventilation,Completed,NA,Corporacion Parc Tauli,NA,https://clinicalzeros.gov/ct2/show/NCT04448782,0,0,0,0,1,0,Spain,0,asynchronies detection,NA
NCT04449276,2020-06-18,2021-12-31,Interventional,"A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults","Active, not recruiting",Phase 1,CureVac AG,NA,https://clinicalzeros.gov/ct2/show/NCT04449276,0,0,0,1,3,0,Belgium|Germany,0,cvncov vaccine|placebo,NA
NCT04449783,2020-06-25,2020-08-25,Observational,Preoperative Shielding and N/T RT-PCR Swabbing for Elective Cancer Surgery,Recruiting,NA,Liverpool University Hospitals NHS Foundation Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04449783,0,0,0,0,1,0,United Kingdom,0,pre-operative screening|telephone consult,NA
NCT04449094,2020-02-28,2020-03-30,Observational,Emergence of the COVID 19 Epidemic in the City of Nice,Completed,NA,Centre Hospitalier Universitaire de Nice,NA,https://clinicalzeros.gov/ct2/show/NCT04449094,0,0,0,0,0,0,France,0,"NA",NA
NCT04449081,2020-04-25,2020-06-10,Observational,"Knowledge, Attitude and Practice of Dental Students About COVID-19",Completed,NA,Melaka Manipal Medical College,NA,https://clinicalzeros.gov/ct2/show/NCT04449081,0,0,0,0,1,0,Malaysia,0,"knowledge, attitude, practice, awareness, preference",NA
NCT04449042,2020-04-01,2025-12-31,Observational [Patient Registry],The PAWS-COVID-19 (Pediatric AirWay complicationS COVID-19) Registry,Recruiting,NA,Boston Children's Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04449042,0,0,0,0,0,1,United States,0,airway management during sedation/general anesthesia|airway management during sedation|general anesthesia,NA
NCT04448769,2020-06-26,2020-07-24,Interventional,Epidemiological Study of Seroprevalence Against the SARS-CoV-2 Virus (COVID-19),Completed,N/A,"Central Hospital, Nancy, France",NA,https://clinicalzeros.gov/ct2/show/NCT04448769,0,0,0,0,3,0,France,0,anti-sars-cov-2 igt seropositivity,NA
NCT04448119,2020-10-16,2021-03-31,Interventional,Control of COVID-19 Outbreaks in Long Term Care,Recruiting,Phase 2,Appili Therapeutics Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04448119,0,0,0,0,2,0,Canada,0,favipiravir|placebo,NA
NCT04448054,2020-05-20,2021-11-20,Observational,"Imaging SARS-CoV-2 Involvement of Leptomeninges, Olfactory and Limbic Areas",Recruiting,NA,Fondation Ophtalmologique Adolphe de Rothschild,NA,https://clinicalzeros.gov/ct2/show/NCT04448054,0,0,0,0,2,0,France,0,mri,NA
NCT04447638,2020-03-20,2020-06-01,Observational,Percutaneous Tracheostomy With COVID-19,Completed,NA,Ã‡anakkale Onsekiz Mart University,NA,https://clinicalzeros.gov/ct2/show/NCT04447638,0,0,0,0,1,0,Turkey,0,tracheostomy with aerosol box in covid-19 positive patients,NA
NCT04448405,2020-06-18,2020-10-01,Observational,Covid-19 Lockdown and Deviant Sexual Fantasies,Completed,NA,"University Hospital, Montpellier",NA,https://clinicalzeros.gov/ct2/show/NCT04448405,0,0,0,0,2,0,France,0,questionnaire,NA
NCT04447781,2020-07-15,2022-02-22,Interventional,"Safety, Tolerability and Immunogenicity of INO-4800 Followed by Electroporation in Healthy Volunteers for COVID19",Recruiting,Phase 1/Phase 2,International Vaccine Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04447781,0,0,0,1,1,0,"Korea, Republic of",0,ino-4800|cellectraâ® 2000|saline-sodium citrate (ssc) buffer|cellectraâ® 2000,NA
NCT04447131,2020-04-29,2021-06-30,Observational,Effect of COVID-19 on Platelet Aggregation,Recruiting,NA,University of Sao Paulo,NA,https://clinicalzeros.gov/ct2/show/NCT04447131,0,0,0,0,1,0,Brazil,0,venipuncture in peripheral vein,NA
NCT04447235,2020-07-23,2020-12-31,Interventional,Early Treatment With Ivermectin and LosarTAN for Cancer Patients With COVID-19 Infection,Recruiting,Phase 2,Instituto do Cancer do Estado de SÃ£o Paulo,NA,https://clinicalzeros.gov/ct2/show/NCT04447235,0,0,0,0,1,0,Brazil,0,placebo|ivermectin|losartan,NA
NCT04447222,2020-05-12,2021-07-21,Observational,Impact of the COVID-19 Pandemic and HRQOL in Cancer Patients and Survivors,Recruiting,NA,M.D. Anderson Cancer Center,NA,https://clinicalzeros.gov/ct2/show/NCT04447222,0,0,0,0,0,1,United States,0,quality-of-life assessment|questionnaire,NA
NCT04447144,2020-06-01,2020-08-01,Observational,"Nutritional Habits, and Coronavirus Disease 2019 (COVID-19) Outcome",Recruiting,NA,Cairo University,NA,https://clinicalzeros.gov/ct2/show/NCT04447144,0,0,0,0,2,0,Egypt,0,"NA",NA
NCT04446377,2020-07-15,2021-03-31,Interventional,A Study of LAM-002A for the Prevention of Progression of COVID-19,Recruiting,Phase 2,"AI Therapeutics, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04446377,0,0,0,0,2,1,United States,0,apilimod dimesylate|placebo,NA
NCT04446338,2020-05-13,2020-06-30,Observational,Immune Status SARS-CoV-2 in a Sample of a Tertiary Eye Health Centre,Recruiting,NA,University Hospital Tuebingen,NA,https://clinicalzeros.gov/ct2/show/NCT04446338,0,0,0,0,0,0,Germany,0,antibody test,NA
NCT04446286,2020-06-18,2020-08-18,Observational,Bicentric Study on the Use of ECMO-VV or VA for Severe ARDS Associated With Covid-19,Recruiting,NA,"University Hospital, Strasbourg, France",NA,https://clinicalzeros.gov/ct2/show/NCT04446286,0,0,0,0,2,0,France,0,"NA",NA
NCT04446104,2020-05-13,2020-08-31,Interventional,A Preventive Treatment for Migrant Workers at High-risk of COVID-19,Completed,Phase 3,"National University Hospital, Singapore",NA,https://clinicalzeros.gov/ct2/show/NCT04446104,0,0,0,0,2,0,Singapore,0,hydroxychloroquine|ivermectin|zinc|povidone/iodine|vitamin c,NA
NCT04445597,2020-05-07,2022-12-31,Interventional,ANalyzing Olfactory Dysfunction Mechanisms In COVID-19,Recruiting,N/A,Universitaire Ziekenhuizen Leuven,NA,https://clinicalzeros.gov/ct2/show/NCT04445597,0,0,0,0,1,0,Belgium,0,sampling,NA
NCT04445506,2020-04-01,2020-05-31,Observational,Short Term Corticosteroids in SARS-CoV2 Patients,Completed,NA,The Miriam Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04445506,0,0,0,0,0,1,United States,0,dexamethasone,NA
NCT04445389,2020-06-17,2021-03-17,Interventional,"Safety and Immunogenicity Study of GX-19, a COVID-19 Preventive DNA Vaccine in Healthy Adults",Recruiting,Phase 1/Phase 2,"Genexine, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04445389,0,0,0,1,2,0,"Korea, Republic of",0,gx-19|saline,NA
NCT04445376,2020-07-03,2020-09-10,Interventional,Effect of Physical Therapy Exercises on Cardiorespiratory Fitness Level in COVID19 Patients After Recovery.,Completed,N/A,Government College University Faisalabad,NA,https://clinicalzeros.gov/ct2/show/NCT04445376,0,0,0,0,6,0,Pakistan,0,exercise,NA
NCT04445311,2020-05-31,2020-07-30,Interventional,Ivermectin in Treatment of COVID-19,Recruiting,Phase 2/Phase 3,Zagazig University,NA,https://clinicalzeros.gov/ct2/show/NCT04445311,0,0,0,0,0,0,Egypt,0,ivermectin,NA
NCT04445285,2020-04-28,2020-11-30,Interventional,Phase 2 Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure,Recruiting,Phase 2,University of South Alabama,NA,https://clinicalzeros.gov/ct2/show/NCT04445285,0,0,0,0,2,1,United States,0,pulmozyme/ recombinant human deoxyribonuclease (rh-dnase)|saline|pulmozyme|rh-dnase,NA
NCT04445259,2020-06-20,2021-05-31,Observational,Study of the Treatment and Outcomes in Critically Ill Patients With COVID-19 and High Risk of Acute Kidney Injury,Recruiting,NA,Guy's and St Thomas' NHS Foundation Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04445259,0,0,0,0,0,0,United Kingdom,0,"NA",NA
NCT04445246,2020-05-23,2021-05-31,Interventional,Inhaled Iloprost for Suspected COVID-19 Respiratory Failure,Recruiting,Phase 2,Hamad Medical Corporation,NA,https://clinicalzeros.gov/ct2/show/NCT04445246,0,0,0,0,0,0,Qatar,0,iloprost,NA
NCT04445233,2020-04-29,2021-06-30,Observational,COVID-19 Household Transmission Study,"Active, not recruiting",NA,"University of North Carolina, Chapel Hill",NA,https://clinicalzeros.gov/ct2/show/NCT04445233,0,0,0,0,1,1,United States,0,"NA",NA
NCT04445454,2020-06-12,2022-09-30,Interventional,Mesenchymal Stromal Cell Therapy for Severe Covid-19 Infection,Recruiting,Phase 1/Phase 2,University of Liege,NA,https://clinicalzeros.gov/ct2/show/NCT04445454,0,0,0,0,0,0,Belgium,0,mesenchymal stem cells,NA
NCT04445441,2020-04-24,2020-09-03,Observational,An Observational Study to Assess the Protocol for the COVID-19 Treatment in Burkina Faso,Completed,NA,Centre Muraz,NA,https://clinicalzeros.gov/ct2/show/NCT04445441,0,0,0,0,2,0,Burkina Faso,0,"NA",NA
NCT04445402,2020-04-30,2021-05-01,Observational [Patient Registry],Pediatrics HOT COVID-19 Database in NY Tristate,Recruiting,NA,Columbia University,NA,https://clinicalzeros.gov/ct2/show/NCT04445402,0,0,0,0,0,1,United States,0,"NA",NA
NCT04444596,2020-06-17,2021-03-31,Interventional,Conjunctival Swab vs Nasopharyngeal Swab in Patients With COVID-19,Recruiting,N/A,Medical University Innsbruck,NA,https://clinicalzeros.gov/ct2/show/NCT04444596,0,0,0,0,0,0,Austria,0,conjunctival swab/nasopharyngeal swab|conjunctival swab|nasopharyngeal swab,NA
NCT04444609,2020-06-18,2021-06-30,Observational,PROSAIC-19 - Prospective Longitudinal Assessment in a COVID-19 Infected Cohort,Recruiting,NA,Imperial College London,NA,https://clinicalzeros.gov/ct2/show/NCT04444609,0,0,0,0,1,0,United Kingdom,0,"blood tests sputum, nasal lavage/brushing|blood tests sputum, nasal lavage|brushing",NA
NCT04444557,2020-04-17,2020-05-01,Observational,Effect of COvid-19 on Mental Health in Syrian and Turkish Maintenance HemoDialysis Patients: COST-HD Study,Completed,NA,Sisli Hamidiye Etfal Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04444557,0,0,0,0,0,0,Turkey,0,beck depression inventory (bdi),NA
NCT04444700,2020-07-04,2020-11-30,Interventional,A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care as a Rapid Response to (SARS-CoV-2) COVID-19 Pandemic,Recruiting,Phase 3,University of Sao Paulo General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04444700,0,0,0,0,1,0,Brazil,0,anticoagulation,NA
NCT04443881,2020-05-08,2020-12-31,Interventional,Clinical Trial of the Use of Anakinra in Cytokine Storm Syndrome Secondary to Covid-19 (ANA-COVID-GEAS),Recruiting,Phase 2/Phase 3,Fundacion Miguel Servet,NA,https://clinicalzeros.gov/ct2/show/NCT04443881,0,0,0,0,0,0,Spain,0,anakinra|ml prefilled syringe [kineret],NA
NCT04442958,2020-05-15,2020-06-15,Interventional,Effectiveness of Convalescent Immune Plasma Therapy,Completed,N/A,Bagcilar Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04442958,0,0,0,0,1,0,Turkey,0,convalescent plasma,NA
NCT04442230,2020-10-10,2021-02-28,Interventional,NasoVAX in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19),Recruiting,Phase 2,"Altimmune, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04442230,0,0,0,0,4,1,United States,0,nasovax|placebo,NA
NCT04442191,2020-05-05,2021-05-05,Interventional,Convalescent Plasma as a Possible Treatment for COVID-19,Recruiting,Phase 2,University of Illinois at Chicago,NA,https://clinicalzeros.gov/ct2/show/NCT04442191,0,0,0,0,0,1,United States,0,convalescent plasma|placebo,NA
NCT04442152,2020-06-30,2020-08-31,Interventional,Impact of COVID-19 on Family Dynamics on Bandebereho Study Participants,Enrolling by invitation,N/A,"Promundo, United States",NA,https://clinicalzeros.gov/ct2/show/NCT04442152,0,0,0,0,0,0,Rwanda,0,mencare//bandebereho fathers'/couples' group education|mencare|NA|bandebereho fathers'|couples' group education,NA
NCT04441710,2020-10-27,2022-04-30,Observational [Patient Registry],Caregiver Serological Monitoring Extended Secondarily to Patients With the SARS-CoV-2 Coronavirus,Recruiting,NA,Hospices Civils de Lyon,NA,https://clinicalzeros.gov/ct2/show/NCT04441710,0,0,0,0,1,0,France,0,questionnaire,NA
NCT04441684,2020-04-17,2020-05-07,Interventional,"Seroprevalence of SARS-CoV-2 in Strasbourg University Hospital, Strasbourg, France (COVID-19)",Recruiting,N/A,"University Hospital, Strasbourg, France",NA,https://clinicalzeros.gov/ct2/show/NCT04441684,0,0,0,0,0,0,France,0,blood sample,NA
NCT04441632,2020-06-15,2020-07-26,Interventional,Effect of Positive Attitudes on Behavior and Wellness,Completed,N/A,Cedars-Sinai Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04441632,0,0,0,0,1,1,United States,0,positive feedback,NA
NCT04441385,2020-06-26,2020-11-30,Interventional,Study to Evaluate the Efficacy and Safety of Maraviroc in SARS-CoV-2 Infection (COVID-19).,Recruiting,Phase 2,Hospital Universitario Infanta Leonor,NA,https://clinicalzeros.gov/ct2/show/NCT04441385,0,0,0,0,1,0,Spain,0,maraviroc|standard care,NA
NCT04439006,2020-07-22,2021-12-31,Interventional,Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization,Recruiting,Phase 2,Ohio State University Comprehensive Cancer Center,NA,https://clinicalzeros.gov/ct2/show/NCT04439006,0,0,0,0,3,1,United States,0,best available therapy|ibrutinib,NA
NCT04438993,2020-05-29,2020-10-31,Observational,The COVID-19 Disease and CARdiac Events Study,Recruiting,NA,NHS Lanarkshire,NA,https://clinicalzeros.gov/ct2/show/NCT04438993,0,0,0,0,0,0,United Kingdom,0,"NA",NA
NCT04438967,2020-06-16,2021-12-31,Observational,Brain Health in the Time of COVID-19,Recruiting,NA,Miro Health,NA,https://clinicalzeros.gov/ct2/show/NCT04438967,0,0,0,0,3,1,United States,0,"NA",NA
NCT04438954,2020-05-05,2020-06-05,Observational,"Investigation of Fatigue, Physical Activity, Sleep Quality and Anxiety Levels",Completed,NA,Ankara Yildirim BeyazÄ±t University,NA,https://clinicalzeros.gov/ct2/show/NCT04438954,0,0,0,0,1,0,Turkey,0,"NA",NA
NCT04438941,2020-03-25,2020-06-20,Observational,Contribution of a Prone Team in Intensive Care During the Covid-19 Epidemic,Recruiting,NA,"University Hospital, Strasbourg, France",NA,https://clinicalzeros.gov/ct2/show/NCT04438941,0,0,0,0,1,0,France,0,"NA",NA
NCT04438850,2020-07-31,2021-02-28,Interventional,COVidIVERmectin: Ivermectin for Treatment of Covid-19,Recruiting,Phase 2,IRCCS Sacro Cuore Don Calabria di Negrar,NA,https://clinicalzeros.gov/ct2/show/NCT04438850,0,0,0,0,3,0,Italy|Spain,0,ivermectin|placebo,NA
NCT04438057,2020-08-12,2020-08-12,Interventional,Evaluating the Efficacy of Convalescent Plasma in Symptomatic Outpatients Infected With COVID-19,Recruiting,Phase 2,Metro Infectious Disease Consultants,NA,https://clinicalzeros.gov/ct2/show/NCT04438057,0,0,0,0,2,1,United States,0,ccp,NA
NCT04437719,2020-06-29,2021-12-29,Interventional,"Prospective Cohort Study to Describe the Clinical Characteristics of COVID-19, the Acquired Immune Response and the Biological and Clinical Parameters of Patients Followed in Oncology by the Saint-Joseph Hospital Group for a Period of 6 Months During the COVID-19 Pandemic",Recruiting,N/A,Groupe Hospitalier Paris Saint Joseph,NA,https://clinicalzeros.gov/ct2/show/NCT04437719,0,0,0,0,2,0,France,0,obvio-19 app,NA
NCT04437706,2020-12-11,2022-06-30,Observational,Network-Targeted Strategies for Efficient Community SARS-CoV-2 (COVID-19) Sampling,Enrolling by invitation,NA,Duke University,NA,https://clinicalzeros.gov/ct2/show/NCT04437706,0,0,0,0,6,1,United States,0,"NA",NA
NCT04437342,2020-06-30,2020-08-30,Observational,Postpartum Depression in the Covid-19 Pandemic and the Impact of Anaesthesia,Completed,NA,General and Maternity Hospital of Athens Elena Venizelou,NA,https://clinicalzeros.gov/ct2/show/NCT04437342,0,0,0,0,5,0,Greece,0,questionnaire|gad-7 (general anxiety disorder) scale|epds (edinburgh postnatal depression scale),NA
NCT04436484,2020-04-29,2021-02-19,Observational,Immune Biomarkers of Outcome From COVID-19,Recruiting,NA,University Hospital Plymouth NHS Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04436484,0,0,0,0,2,0,United Kingdom,0,blood sample,NA
NCT04435717,2020-05-04,2020-08-04,Interventional,Efficacy of Tocilizumab in Modifying the Inflammatory Parameters of Patients With COVID-19 (COVITOZ-01),Recruiting,Phase 2,Hospital Universitario Ramon y Cajal,NA,https://clinicalzeros.gov/ct2/show/NCT04435717,0,0,0,0,0,0,Spain,0,tocilizumab 20 mg/ml intravenous solution [actemra]_#1|tocilizumab 20 mg/ml intravenous solution [actemra]_#1 (2 doses)|tocilizumab|ml intravenous solution [actemra]_#1|ml intravenous solution [actemra]_#1 (2 doses),NA
NCT04435587,2020-07-13,2021-06-30,Interventional,Ivermectin vs Combined Hydroxychloroquine and Antiretroviral Drugs (ART) Among Asymptomatic COVID-19 Infection,Recruiting,Phase 4,Mahidol University,NA,https://clinicalzeros.gov/ct2/show/NCT04435587,0,0,0,0,2,0,Thailand,0,ivermectin pill|combined art/hydroxychloroquine|combined art|hydroxychloroquine,NA
NCT04435275,2021-01-02,2021-03-31,Interventional,Virtual Assistant for COVID-19 PPE,Recruiting,N/A,"University Health Network, Toronto",NA,https://clinicalzeros.gov/ct2/show/NCT04435275,0,0,0,0,1,0,Canada,0,"virtual assistant first, then human coach|human coach first, then virtual assistant",NA
NCT04435223,2020-04-07,2020-05-07,Observational,Lipid Metabolism in COVID-19 Severe Pneumonia Compared With Severe Pneumonia Caused by Other Pathogen,Completed,NA,Centre Hospitalier Universitaire Dijon,NA,https://clinicalzeros.gov/ct2/show/NCT04435223,0,0,0,0,1,0,France,0,biological assays in particular on the lipid metabolism,NA
NCT04435119,2020-03-15,2020-05-15,Observational,Covid-19 and Vitamin D in Nursing-home,Completed,NA,"University Hospital, Angers",NA,https://clinicalzeros.gov/ct2/show/NCT04435119,0,0,0,0,0,0,France,0,"NA",NA
NCT04431908,2020-06-15,2020-09-01,Observational,Validation of a Rapid Quantitative Test for Loss of Smell in COVID-19 Subjects,Recruiting,NA,Yale University,NA,https://clinicalzeros.gov/ct2/show/NCT04431908,0,0,0,0,2,1,United States,0,olfactory device,NA
NCT04434248,2020-04-23,2020-07-31,Interventional,An Adaptive Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,"Active, not recruiting",Phase 2/Phase 3,Chromis LLC,NA,https://clinicalzeros.gov/ct2/show/NCT04434248,0,0,0,0,0,0,Russian Federation,0,favipiravir|standard care,NA
NCT04434157,2020-03-28,2020-05-05,Observational,Association of the Neutrophil/Lymphocyte Ratio With Clinical Complications and Mortality in COVID-19 Patients,Completed,NA,Hospital Regional de Alta especialidad de Ixtapaluca,NA,https://clinicalzeros.gov/ct2/show/NCT04434157,0,0,0,0,0,0,Mexico,0,"NA",NA
NCT04434144,2020-05-02,2020-06-05,Observational [Patient Registry],A Comparative Study on Ivermectin and Hydroxychloroquine on the COVID19 Patients in Bangladesh,Completed,NA,"Upazila Health & Family Planning Officer's (UHFPO) Office, Chakoria, Cox's Bazar",NA,https://clinicalzeros.gov/ct2/show/NCT04434144,0,0,0,0,0,0,Bangladesh,0,ivermectin / doxycycline|hydroxychloroquine / azithromycin|ivermectin|doxycycline|hydroxychloroquine|azithromycin,NA
NCT04433949,2020-06-12,2022-05-30,Interventional,Best Supportive Care With or Without Low Dose Whole Lung Radiation Therapy for the Treatment of COVID-19,Recruiting,Phase 3,Emory University,NA,https://clinicalzeros.gov/ct2/show/NCT04433949,0,0,0,0,0,1,United States,0,best available therapy|low,NA
NCT04433754,2020-03-01,2020-06-11,Observational,The Development of Pancreatic Injury in the Course of Severe Acute Respiratory Syndrome Coronavirus 2 Infection,Completed,NA,UÅŸak University,NA,https://clinicalzeros.gov/ct2/show/NCT04433754,0,0,0,0,0,0,Turkey,0,biochemical analysis,NA
NCT04433364,2020-06-02,2021-06-02,Observational [Patient Registry],COPE - COVID-19 in Pregnancy and Early Childhood,Recruiting,NA,"Sahlgrenska University Hospital, Sweden",NA,https://clinicalzeros.gov/ct2/show/NCT04433364,0,0,0,0,0,0,Sweden,0,questionnaire|interview,NA
NCT04433039,2020-05-22,2020-06-12,Observational,COVID19 Versus H1N1: Radiological Challenge During Next Influenza Season Rising,Completed,NA,Alexandria University,NA,https://clinicalzeros.gov/ct2/show/NCT04433039,0,0,0,0,0,0,Egypt,0,"NA",NA
NCT04433000,2020-03-15,2020-06-10,Observational,Reliability of a Pocket Sized Ultrasound Scanner in the Evaluation Covid-19 Pneumonia,Recruiting,NA,University of Siena,NA,https://clinicalzeros.gov/ct2/show/NCT04433000,0,0,0,0,0,0,Italy,0,butterfly,NA
NCT04432987,2020-05-25,2020-08-25,Interventional,Dornase Alpha for the Treatment of COVID-19,Recruiting,Phase 2,Acibadem University,NA,https://clinicalzeros.gov/ct2/show/NCT04432987,0,0,0,0,0,0,Turkey,0,pulmozyme,NA
NCT04432948,2020-05-15,2020-08-31,Observational,Maternal Psychological Implications of Covid-19 Pandemic and Possible Effect on Anaesthetic Management.,Recruiting,NA,General and Maternity Hospital of Athens Elena Venizelou,NA,https://clinicalzeros.gov/ct2/show/NCT04432948,0,0,0,0,0,0,Greece,0,phq-9 depression scale|gad-7 general anxiety disorder scale|questionnaire,NA
NCT04432870,2020-06-09,2021-05-30,Observational,Patients' Preferences About Rescheduling Colonoscopies Delayed Due to COVID-19: Cross Sectional Study,Enrolling by invitation,NA,Massachusetts General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04432870,0,0,0,0,2,1,United States,0,"NA",NA
NCT04432805,2020-06-15,2021-06-15,Interventional,Descriptive and Evaluation Study of the Use of Pulmonary Ultrasound in the Initial Management of Pregnant Women in the Context of COVID-19,Recruiting,N/A,Assistance Publique Hopitaux De Marseille,NA,https://clinicalzeros.gov/ct2/show/NCT04432805,0,0,0,0,0,0,France,0,performing of lung ultrasound,NA
NCT04432779,2020-05-25,2024-06-30,Observational,Impact of COVID-19 Infection During Pregnancy on Newborns and Young Children,Recruiting,NA,Centre Hospitalier Universitaire Saint Pierre,NA,https://clinicalzeros.gov/ct2/show/NCT04432779,0,0,0,0,2,0,Belgium,0,no intervention,NA
NCT04431869,2020-08-18,2022-07-31,Observational [Patient Registry],In-Utero Vascular Accidents in Neonates From COVID-19 Infected Mothers,Recruiting,NA,"University of Colorado, Denver",NA,https://clinicalzeros.gov/ct2/show/NCT04431869,0,0,0,0,2,1,United States,0,"NA",NA
NCT04431856,2020-05-15,2020-11-17,Interventional,CO-PARENT: COVID-19 - Parent Action in Response to Emotions and Needs for Treatment,Completed,N/A,University of Miami,NA,https://clinicalzeros.gov/ct2/show/NCT04431856,0,0,0,0,3,1,United States,0,unified protocol for covid-19 parenting stress (up-covid)|shg,NA
NCT04431310,2020-03-27,2025-08-01,Observational,Seroconversion Among Staff at a Large Acute Care Hospital in Denmark During the COVID-19 Pandemic,Recruiting,NA,Nordsjaellands Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04431310,0,0,0,0,0,0,Denmark,0,serial seroconversion measurements in hospital employees during the covid-19 pandemic,NA
NCT04444401,2020-06-15,2021-06-15,Observational,Registry on NEN Patients and COVID-19,Recruiting,NA,European Institute of Oncology,NA,https://clinicalzeros.gov/ct2/show/NCT04444401,0,0,0,0,2,0,Italy,0,"NA",NA
NCT04444310,2020-06-15,2020-06-18,Observational [Patient Registry],Antibody Responses in Contacts of COVID-19 Patients,"Active, not recruiting",NA,Assiut University,NA,https://clinicalzeros.gov/ct2/show/NCT04444310,0,0,0,0,0,0,Egypt,0,"NA",NA
NCT04444271,2020-05-01,2020-08-30,Interventional,Mesenchymal Stem Cell Infusion for COVID-19 Infection,Recruiting,Phase 2,"National Institute of Blood and Marrow Transplant (NIBMT), Pakistan",NA,https://clinicalzeros.gov/ct2/show/NCT04444271,0,0,0,0,3,0,Pakistan,0,mesenchymal stem cells|placebo,NA
NCT04443712,2020-05-29,2021-06-01,Observational,Screening for Patients Admitted to Ain-Shams University Hospitals for SARS-COV-2 (COVID19),Recruiting,NA,Ain Shams University,NA,https://clinicalzeros.gov/ct2/show/NCT04443712,0,0,0,0,0,0,Egypt,0,"NA",NA
NCT04443673,2020-08-20,2021-02-28,Interventional,Glycine Supplement for Severe COVID-19,Recruiting,N/A,Instituto Nacional de Enfermedades Respiratorias,NA,https://clinicalzeros.gov/ct2/show/NCT04443673,0,0,0,0,2,0,Mexico,0,glycine,NA
NCT04443257,2020-07-08,2021-07-25,Observational,REassessement After Hospitalization for Sars-COV-2 disordER,Enrolling by invitation,NA,"University Hospital, Montpellier",NA,https://clinicalzeros.gov/ct2/show/NCT04443257,0,0,0,0,3,0,France,0,assessment of the sequelae after hospitalization for sars-cov-2,NA
NCT04441918,2020-06-05,2020-12-11,Interventional,"Tolerability,Safety,Pharmacokinetic Profile and Immunogenicity of a Recombinant Humanized Anti-SARS-CoV-2 Monoclonal Antibody (JS016) for Injection in Chinese Health Subjects",Recruiting,Phase 1,"Shanghai Junshi Bioscience Co., Ltd.",NA,https://clinicalzeros.gov/ct2/show/NCT04441918,0,0,0,0,0,0,China,0,monoclonal antibody,NA
NCT04438694,2020-06-01,2021-05-31,Interventional,Assessment of the Effect of Convalescent Plasma Therapy in Patients With Life-threatening COVID19 Infection,Recruiting,Phase 1/Phase 2,Cairo University,NA,https://clinicalzeros.gov/ct2/show/NCT04438694,0,0,0,0,1,0,Egypt,0,convalescent plasma|standard care,NA
NCT04438239,2020-06-22,2020-12-31,Observational,Rehabilitation Needs After COVID-19 Hospital Treatment,Completed,NA,Azienda UnitÃ  Sanitaria Locale Reggio Emilia,NA,https://clinicalzeros.gov/ct2/show/NCT04438239,0,0,0,0,2,0,Italy,0,"none, this study is observational",NA
NCT04437823,2020-06-01,2021-05-31,Interventional,Efficacy of Intravenous Infusions of Stem Cells in the Treatment of COVID-19 Patients,Recruiting,Phase 2,Jinnah Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04437823,0,0,0,0,0,0,Pakistan,0,mesenchymal stem cells,NA
NCT04437121,2020-04-30,2020-05-24,Observational,Dietary and Lifestyle Habits During the Pandemic of COVID-19 in Greece,Completed,NA,University of Thessaly,NA,https://clinicalzeros.gov/ct2/show/NCT04437121,0,0,0,0,0,0,Greece,0,survey|lifestyle habits,NA
NCT04435808,2020-04-14,2020-07-15,Interventional,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Terminated,Phase 1/Phase 2,University of New Mexico,Stopped for futility by DSMB,https://clinicalzeros.gov/ct2/show/NCT04435808,0,0,0,0,2,1,United States,1,hydroxychloroquine,NA
NCT04435795,2020-09-14,2021-02-25,Interventional,Inhaled Ciclesonide for Outpatients With COVID19,Recruiting,Phase 2/Phase 3,McGill University Health Centre/Research Institute of the McGill University Health Centre,NA,https://clinicalzeros.gov/ct2/show/NCT04435795,0,0,0,0,1,0,Canada,0,normal saline intranasal,NA
NCT04435353,2020-03-22,2020-12-31,Interventional,Assessment of the Effectiveness of Vibroacoustic Therapy for Respiratory Failure Caused by COVID 19,Recruiting,N/A,Astana Medical University,NA,https://clinicalzeros.gov/ct2/show/NCT04435353,0,0,0,0,0,0,Kazakhstan,0,vibrolung,NA
NCT04435327,2020-08-17,2021-04-30,Observational,Lung Damage Caused by SARS-CoV-2 Pneumonia (COVID-19),Recruiting,NA,University of Milano Bicocca,NA,https://clinicalzeros.gov/ct2/show/NCT04435327,0,0,0,0,1,0,Italy,0,"NA",NA
NCT04435106,2020-04-03,2020-05-01,Observational,Compassionate Use of Opaganib in Patients With Coronavirus Disease 2019 (COVID-19),Completed,NA,Shaare Zedek Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04435106,0,0,0,0,0,0,Israel,0,opaganib|standard care,NA
NCT04435080,2020-03-15,2020-06-11,Observational,Physical Rehabilitation in ICU in ARDS Patients With COVID-19,Completed,NA,KoÃ§ University,NA,https://clinicalzeros.gov/ct2/show/NCT04435080,0,0,0,0,0,0,Turkey,0,"NA",NA
NCT04435028,2019-01-14,2019-08-13,Observational,Ketotifen: as a Cardioprotective Agent in Breast Cancer Patients Receiving Anthracycline-containing Chemotherapy,Completed,NA,Horus University,NA,https://clinicalzeros.gov/ct2/show/NCT04435028,0,0,0,0,0,0,Egypt,0,ketotifen,NA
NCT04434014,2020-06-08,2020-06-18,Observational,Proper Nutrition And Its Relation To Oral Diseases In Covid -19 Era,Recruiting,NA,October University for Modern Sciences and Arts,NA,https://clinicalzeros.gov/ct2/show/NCT04434014,0,0,0,0,0,0,Egypt,0,proper diet,NA
NCT04433871,2020-04-27,2022-04-27,Observational [Patient Registry],COVID-19 in Pediatric Oncology and Hematology Centers in France,Recruiting,NA,"University Hospital, Caen",NA,https://clinicalzeros.gov/ct2/show/NCT04433871,0,0,0,0,0,0,France,0,no intervention,NA
NCT04433546,2020-07-15,2020-12-02,Interventional,"Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).",Terminated,Phase 2,PhaseBio Pharmaceuticals Inc.,Company no longer pursing indication,https://clinicalzeros.gov/ct2/show/NCT04433546,0,0,0,0,7,1,United States,0,pemziviptadil (pb1046)|control,NA
NCT04432051,2020-05-26,2020-08-08,Interventional,The Use of Lung Ultrasonography in COVID-19 Patients,Recruiting,N/A,Gaziosmanpasa Taksim Research and Education Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04432051,0,0,0,0,2,0,Turkey,0,mechanical ventilation|position,NA
NCT04431180,2020-06-13,2020-06-13,Interventional,Recruit Blood Donors Via SMS During Epidemic of COVID-19 #Second Repeat Trial#,Enrolling by invitation,N/A,Guangzhou Blood Center,NA,https://clinicalzeros.gov/ct2/show/NCT04431180,0,0,0,0,0,0,China,0,blood donation sms,NA
NCT04430374,2020-06-02,2020-12-31,Observational [Patient Registry],Registry for a Cardiovascular Patient Who COVID-19 Infection in Qatar and Gulf,Recruiting,NA,Hamad Medical Corporation,NA,https://clinicalzeros.gov/ct2/show/NCT04430374,0,0,0,0,1,0,Qatar,0,no intervention,NA
NCT04430322,2020-03-01,2020-12-31,Observational,Covid-19 at the Regional Medical Center Metz-Thionville: a Descriptive Study,Recruiting,NA,Centre Hospitalier RÃ©gional Metz-Thionville,NA,https://clinicalzeros.gov/ct2/show/NCT04430322,0,0,0,0,1,0,France,0,"NA",NA
NCT04429867,2020-05-07,2020-12-07,Interventional,Hydroxychloroquine Use in Hospitalized Patients With COVID-19: Impact on Progression to Severe or Critical Disease,"Active, not recruiting",Phase 4,WellStar Health System,NA,https://clinicalzeros.gov/ct2/show/NCT04429867,0,0,0,0,1,1,United States,0,hydroxychloroquine|placebo,NA
NCT04429711,2020-05-12,2020-09-30,Interventional,Ivermectin vs. Placebo for the Treatment of Patients With Mild to Moderate COVID-19,Recruiting,N/A,Sheba Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04429711,0,0,0,0,1,0,Israel,0,ivermectin,NA
NCT04430062,2020-05-01,2020-05-20,Observational,Short-term Outcome of Covid-19 Surgical Patients: Case-series of a High-risk Area Community Hospital,Completed,NA,Azienda Socio Sanitaria Territoriale di Lodi,NA,https://clinicalzeros.gov/ct2/show/NCT04430062,0,0,0,0,1,0,Italy,0,surgical procedures performed under general anesthesia,NA
NCT04430023,2020-05-15,2020-06-03,Observational,Epidemiological and Demographic Data From 150 Patients Diagnosed With Coronavirus Disease 2019 Pneumonia,Completed,NA,Sisli Hamidiye Etfal Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04430023,0,0,0,0,1,0,Turkey,0,epidemiological/demographic characteristics|epidemiological|demographic characteristics,NA
NCT04429477,2020-05-01,2020-07-15,Observational [Patient Registry],Cerebral Compliance Impairment in COVID-19,Completed,NA,University of Sao Paulo,NA,https://clinicalzeros.gov/ct2/show/NCT04429477,0,0,0,0,1,0,Brazil,0,cerebral compliance/hemodynamics monitoring|cerebral compliance|hemodynamics monitoring,NA
NCT04429620,2020-05-30,2020-12-31,Observational,Prospective Assay for SARS-CoV-2 (COVID-19) Antibody Detection Indirectly by Immunofluorescence: SARS-CoV2 IIF Method,Recruiting,NA,Szeged University,NA,https://clinicalzeros.gov/ct2/show/NCT04429620,0,0,0,0,1,0,Hungary,0,immunfluorescence,NA
NCT04429594,2020-07-28,2025-07-15,Interventional,Study of the Incidence of SARS-CoV-2 Infection (COVID-19),Recruiting,N/A,Centre Hospitalier Universitaire de Nice,NA,https://clinicalzeros.gov/ct2/show/NCT04429594,0,0,0,0,2,0,France,0,blood sample,NA
NCT04427969,2020-06-15,2020-06-25,Observational,Early Prone Position on Coronavirus Disease 2019 Pneumonia,Completed,NA,Sisli Hamidiye Etfal Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04427969,0,0,0,0,2,0,Turkey,0,prone positioning,NA
NCT04427735,2019-01-24,2021-07-24,Observational,Effect of Covid-19 Epidemic on Primary PCI in Patients With STEMI,Recruiting,NA,Beijing Friendship Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04427735,0,0,0,0,0,0,China,0,"NA",NA
NCT04427358,2020-05-07,2020-08-07,Observational,RT-PCR SARS-CoV-2 at 1 Month of COVID-19 Infection in the Geriatric Population,Completed,NA,"University Hospital, Strasbourg, France",NA,https://clinicalzeros.gov/ct2/show/NCT04427358,0,0,0,0,1,0,France,0,"NA",NA
NCT04427345,2020-04-30,2021-04-30,Observational,Predictive Factors COVID-19 Patients,Recruiting,NA,University of Milano Bicocca,NA,https://clinicalzeros.gov/ct2/show/NCT04427345,0,0,0,0,1,0,Italy,0,predictive factors for clinical response in patients with covid-19.,NA
NCT04427176,2020-04-29,2020-05-28,Observational,Evaluation of ARFC Masks Equipped With CF5 Filter in the Care Unit to Allow a Wider Distribution of FFP2 Masks (Covid-19).,Completed,NA,Centre Hospitalier Universitaire de Saint Etienne,NA,https://clinicalzeros.gov/ct2/show/NCT04427176,0,0,0,0,1,0,France,0,mask,NA
NCT04427280,2020-05-26,2020-10-31,Observational,Cancer: Rapid Diagnostics and Immune Assessment for SARS-CoV-2 (COVID-19),Recruiting,NA,Royal Marsden NHS Foundation Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04427280,0,0,0,0,0,0,United Kingdom,0,"NA",NA
NCT04427137,2020-06-09,2022-06-30,Interventional,Accelerated LFR for Bipolar Patients During the COVID-19 Pandemic,Recruiting,N/A,Centre for Addiction and Mental Health,NA,https://clinicalzeros.gov/ct2/show/NCT04427137,0,0,0,0,1,0,Canada,0,"magpro x100 stimulator, b70 fluid-cooled coil",NA
NCT04427098,2020-05-22,2020-10-30,Interventional,Enoxaparin in COVID-19 Moderate to Severe Hospitalized Patients,Recruiting,Phase 2,Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi,NA,https://clinicalzeros.gov/ct2/show/NCT04427098,0,0,0,0,1,0,Italy,0,enoxaparin|sodium,NA
NCT04427267,2020-06-03,2020-06-27,Observational,Assessment of Thermal Condition of Health Workers Who Use Personal Protective Equipment From Biological Hazards During Their Work With COVID-19 Patients,Completed,NA,"Federal State Budgetary Scientific Institution ""Izmerov Research Institute of Occupational Health""",NA,https://clinicalzeros.gov/ct2/show/NCT04427267,0,0,0,0,3,0,Russian Federation,0,personal protective equipment from biological hazard,NA
NCT04426305,2020-05-21,2020-06-20,Interventional,Community Health Workers Against COVID19,Enrolling by invitation,N/A,University Ghent,NA,https://clinicalzeros.gov/ct2/show/NCT04426305,0,0,0,0,0,0,Belgium,0,community health worker support|care as usual,NA
NCT04426292,2020-05-12,2020-10-23,Interventional,SARS-COV-2 Seroprevalence and Seroconversion Among Employees of the Universitair Ziekenhuis Brussel During the 2020 COVID-19 Outbreak,Recruiting,N/A,Universitair Ziekenhuis Brussel,NA,https://clinicalzeros.gov/ct2/show/NCT04426292,0,0,0,0,0,0,Belgium,0,serology test,NA
NCT04426279,2020-08-18,2021-02-28,Observational,Morbimortality of Covid-19 in Patients With Chronic Inflammatory Rheumatism Treated With Immunosuppressants,Recruiting,NA,"University Hospital, Lille",NA,https://clinicalzeros.gov/ct2/show/NCT04426279,0,0,0,0,3,0,France,0,questionnaire,NA
NCT04426266,2020-05-01,2020-09-28,Observational,Psychological Effects of the COVID-19 Pandemic on the Hungarian Adult Population,Completed,NA,Szeged University,NA,https://clinicalzeros.gov/ct2/show/NCT04426266,0,0,0,0,2,0,Hungary,0,"NA",NA
NCT04426253,2020-06-05,2020-12-31,Observational,"Identification of Genetic Factors Determining Disease Course in the New Type of Coronavirus Infection, COVID-19","Active, not recruiting",NA,Szeged University,NA,https://clinicalzeros.gov/ct2/show/NCT04426253,0,0,0,0,0,0,Hungary,0,"NA",NA
NCT04425889,2020-05-05,2020-05-30,Observational,COVID-19 Antibodies Among Healthcare Workers,Completed,NA,Hospital Universitario Dr. Jose E. Gonzalez,NA,https://clinicalzeros.gov/ct2/show/NCT04425889,0,0,0,0,1,0,Mexico,0,igm/igg rapid test|igg|igm antibodytest,NA
NCT04426006,2020-06-01,2021-06-30,Interventional,Serological Response to SARS-Cov-2 Virus in Personnel of the Institut BergoniÃ© in the Context of the COVID-19 Pandemic,"Active, not recruiting",N/A,Institut BergoniÃ©,NA,https://clinicalzeros.gov/ct2/show/NCT04426006,0,0,0,0,1,0,France,0,pro-sero-cov,NA
NCT04426318,2020-06-14,2021-01-12,Interventional,COVID-19 and the Healthy Minds Program for Educators,Completed,N/A,"University of Wisconsin, Madison",NA,https://clinicalzeros.gov/ct2/show/NCT04426318,0,0,0,0,4,1,United States,0,healthy minds program foundations training,NA
NCT04425915,2020-06-14,2021-05-30,Interventional,Efficacy of Convalescent Plasma Therapy in Patients With COVID-19,Recruiting,Phase 3,"Institute of Liver and Biliary Sciences, India",NA,https://clinicalzeros.gov/ct2/show/NCT04425915,0,0,0,0,1,0,India,0,convalescent plasma|standard care,NA
NCT04425863,2020-05-01,2020-08-30,Observational,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Completed,NA,Eurnekian Public Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04425863,0,0,0,0,4,0,Argentina,1,"ivermectin 5 mg/ml oral solution, aspirin 250 mg tablets|ivermectin/deamethisone/aspirin|ivermectin/deamethisone/exoparin|ivermectin|ml oral solution, aspirin 250 mg tablets|ml oral solution, dexamethasone 4-mg injection, aspirin 250 mg tablets|ml oral solution, dexamethasone 4-mg injection, enoxaparin injection. inpatient treatment with mechanical ventilation in icu.",NA
NCT04425850,2020-06-01,2020-08-10,Observational,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Completed,NA,Eurnekian Public Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04425850,0,0,0,0,4,0,Argentina,1,iota carrageenan nasal spray/ivermectin oral drops (used as buccal drops)|iota carrageenan nasal spray|ivermectin,NA
NCT04425616,2020-06-04,2021-11-30,Interventional,SafeFit Trial: Virtual Clinics to Deliver Universal Interventions in People With Cancer,Recruiting,N/A,University Hospital Southampton NHS Foundation Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04425616,0,0,0,0,1,0,United Kingdom,0,exercise|psychological/behaviour change support|nutrition|psychological|behavior,NA
NCT04425759,2020-06-08,2021-06-30,Observational [Patient Registry],Prevalence and Risk Factors of SARS-CoV-2 Antibody Responses (COVID-19),Recruiting,NA,Hospital de MatarÃ³,NA,https://clinicalzeros.gov/ct2/show/NCT04425759,0,0,0,0,1,0,Spain,0,blood sample,NA
NCT04425382,2020-03-01,2020-07-31,Observational,Darunavir/Cobicistat vs. Lopinavir/Ritonavir in COVID-19 Pneumonia in Qatar,Recruiting,NA,Hamad Medical Corporation,NA,https://clinicalzeros.gov/ct2/show/NCT04425382,0,0,0,0,0,0,Qatar,0,darunavir/cobicistat|lopinavir/ritonavir|darunavir|cobicistat|lopinavir|ritonavir,NA
NCT04425317,2020-06-24,2021-06-15,Interventional,Detection of SARS-CoV-2 in Follicular Fluid and Cumulus-oocyte-complexes in COVID-19 Patients,Recruiting,N/A,CRG UZ Brussel,NA,https://clinicalzeros.gov/ct2/show/NCT04425317,0,0,0,0,1,0,Belgium,0,blood sample,NA
NCT04425252,2020-08-01,2020-12-29,Interventional,Safety and Anti-coronavirus Response of Suppression of Host Nucleotide Synthesis in Patients With COVID-19,Completed,Phase 1/Phase 2,"Clear Creek Bio, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04425252,0,0,0,0,9,1,United States,0,brequinar|standard care,NA
NCT04425213,2020-05-12,2020-05-25,Observational,Obesity and Mortality of Critically Ill Patients With COVID-19,Completed,NA,"Central Hospital, Nancy, France",NA,https://clinicalzeros.gov/ct2/show/NCT04425213,0,0,0,0,1,0,France,0,"NA",NA
NCT04424849,2020-03-15,2020-06-15,Observational,Thorax Computed Tomography Severity Score and Outcome in COVID-19 Patients,Recruiting,NA,Tepecik Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04424849,0,0,0,0,0,0,Turkey,0,ct-scan,NA
NCT04424797,2020-07-13,2020-12-31,Interventional,Prone Positioning on Admission for Hospitalized COVID-19 Pneumonia Protocol,Recruiting,N/A,Poudre Valley Health System,NA,https://clinicalzeros.gov/ct2/show/NCT04424797,0,0,0,0,1,1,United States,0,prone positioning|supine positioning,NA
NCT04425044,2020-04-12,2020-05-18,Observational,AiM Covid Self Monitoring,Completed,NA,Aarogyam UK,NA,https://clinicalzeros.gov/ct2/show/NCT04425044,0,0,0,0,0,0,India,0,other,NA
NCT04425031,2020-08-25,2022-12-01,Interventional,Handling Oxygenation Targets in COVID-19,Recruiting,Phase 4,Aalborg University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04425031,0,0,0,0,2,0,Denmark,0,oxygen,NA
NCT04425005,2020-05-10,2020-12-07,Interventional,Home-based Exercise Training During Covid-19 Pandemic in Post-bariatric,Completed,N/A,University of Sao Paulo,NA,https://clinicalzeros.gov/ct2/show/NCT04425005,0,0,0,0,1,0,Brazil,0,exercise,NA
NCT04424771,2020-03-01,2020-06-30,Observational,Post-traumatic Stress Disease in Health Workers During COVID-19 Pandemia,Completed,NA,Piazza della Vittoria 14 Studio Medico - Ginecologia e Ostetricia,NA,https://clinicalzeros.gov/ct2/show/NCT04424771,0,0,0,0,1,0,Italy,0,maslach burnout inventory (mbi),NA
NCT04424355,2020-05-19,2021-07-19,Observational,Magnetic Resonance Imaging to Detect Signs of Viral Pneumonia in Patients With Coronavirus Infection.,Recruiting,NA,Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department,NA,https://clinicalzeros.gov/ct2/show/NCT04424355,0,0,0,0,2,0,Russian Federation,0,chest mri,NA
NCT04423692,2020-06-01,2020-08-15,Observational,Knowledge About Covid-19 Infection in Pregnant Women,Recruiting,NA,Aljazeera Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04423692,0,0,0,0,1,0,Egypt,0,labs,NA
NCT04424446,2020-07-13,2021-06-01,Observational,Saliva as Source of Detection for SARS-CoV-2,Recruiting,NA,National Institutes of Health Clinical Center (CC),NA,https://clinicalzeros.gov/ct2/show/NCT04424446,0,0,0,0,27,1,United States,0,"NA",NA
NCT04424082,2020-06-09,2020-11-07,Interventional,External Dead Space in Ventilated COVID-19 Patients,Recruiting,N/A,Karolinska Institutet,NA,https://clinicalzeros.gov/ct2/show/NCT04424082,0,0,0,0,2,0,Sweden,0,removal of dead space filter,NA
NCT04424004,2020-06-09,2021-06-30,Observational,MURDOCK Cabarrus County COVID-19 Prevalence and Immunity (C3PI) Study,"Active, not recruiting",NA,Duke University,NA,https://clinicalzeros.gov/ct2/show/NCT04424004,0,0,0,0,2,1,United States,0,pct/serology|pcr|serology test,NA
NCT04423991,2020-03-10,2020-06-04,Interventional,Identification of a Responsive Subpopulation to Hydroxychloroquine in COVID-19 Patients Using Machine Learning,Completed,N/A,Dascena,NA,https://clinicalzeros.gov/ct2/show/NCT04423991,0,0,0,0,0,1,United States,0,coviage,NA
NCT04423978,2020-05-04,2020-06-15,Observational,Implications of Covid-19 on the Lifestyle Changes,Completed,NA,Azienda UnitÃ  Sanitaria Locale Reggio Emilia,NA,https://clinicalzeros.gov/ct2/show/NCT04423978,0,0,0,0,2,0,Italy,0,"NA",NA
NCT04423640,2020-04-15,2020-06-15,Observational,Analysis of the Inflammatory Response and the Development of Humoral and Cellular Immunity in Patients With COVID-19,Recruiting,NA,"CoordinaciÃ³n de InvestigaciÃ³n en Salud, Mexico",NA,https://clinicalzeros.gov/ct2/show/NCT04423640,0,0,0,0,1,0,Mexico,0,active covid-19 disease,NA
NCT04423315,2020-06-08,2020-07-15,Observational,Thrombosis Risk Assessment and Clinical Presentation of Covid-19 Pneumonia,Completed,NA,Nisantasi University,NA,https://clinicalzeros.gov/ct2/show/NCT04423315,0,0,0,0,1,0,Turkey,0,"NA",NA
NCT04423289,2020-03-31,2020-05-04,Interventional,Telematic Monitoring Through a Mobile Application of Patients With COVID-19,Completed,N/A,Hospital Universitari Vall d'Hebron Research Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04423289,0,0,0,0,0,0,Spain,0,farmalarm,NA
NCT04422691,2020-07-01,2020-12-31,Observational,Ultrasonography in Norwegian Emergency Department Patients With Suspected Covid-19 Infection,Recruiting,NA,St. Olavs Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04422691,0,0,0,0,2,0,Norway,0,lung ultrasound,NA
NCT04423003,2020-03-01,2020-05-15,Observational [Patient Registry],Endoscopic Interventions in Patients With COVID-19,Completed,NA,University Hospital Tuebingen,NA,https://clinicalzeros.gov/ct2/show/NCT04423003,0,0,0,0,0,0,Germany,0,endoscopic intervention,NA
NCT04422470,2020-06-22,2021-01-22,Observational [Patient Registry],Registry of Patients With Hematologic Disease and COVID-19 in Russia,Recruiting,NA,"National Research Center for Hematology, Russia",NA,https://clinicalzeros.gov/ct2/show/NCT04422470,0,0,0,0,2,0,Russian Federation,0,non-interventional study,NA
NCT04422613,2020-05-28,2021-05-31,Interventional,Characterization of Persistent Pulmonary Abnormalities Following COVID-19 Pneumonia,"Active, not recruiting",N/A,"University Hospital, Toulouse",NA,https://clinicalzeros.gov/ct2/show/NCT04422613,0,0,0,0,1,0,France,0,pulmonary anomalies 4 months after documented covid-19 pneumonia,NA
NCT04422262,2020-06-08,2021-05-31,Observational,Analysis of Long Term Risk of Coronavirus Disease-19 Emergency,Recruiting,NA,Neuromed IRCCS,NA,https://clinicalzeros.gov/ct2/show/NCT04422262,0,0,0,0,1,0,Italy,0,"NA",NA
NCT04422587,2020-03-13,2020-06-05,Observational [Patient Registry],Evaluation of the COVID-19 Infection Response in Patients Admitted to the Emergency Department for Dyspnea,Completed,NA,"University Hospital, Toulouse",NA,https://clinicalzeros.gov/ct2/show/NCT04422587,0,0,0,0,1,0,France,0,recop unit patient,NA
NCT04422574,2020-05-01,2020-05-01,Observational,COVID 19 Serology in Pulmonologists,Completed,NA,"University Hospital, Montpellier",NA,https://clinicalzeros.gov/ct2/show/NCT04422574,0,0,0,0,0,0,France,0,"NA",NA
NCT04422561,2020-05-31,2020-07-14,Interventional,Prophylactic Ivermectin in COVID-19 Contacts,Completed,Phase 2/Phase 3,Zagazig University,NA,https://clinicalzeros.gov/ct2/show/NCT04422561,0,0,0,0,5,0,Egypt,1,ivermectin,NA
NCT04422522,2020-03-15,2020-05-15,Observational,Fibromyalgia During the COVID-19 Pandemic,"Active, not recruiting",NA,Al-Azhar University,NA,https://clinicalzeros.gov/ct2/show/NCT04422522,0,0,0,0,1,0,Egypt,0,"NA",NA
NCT04422444,2020-06-01,2021-05-01,Observational [Patient Registry],Post Intensive Care Syndrome in COVID19 Patients,Recruiting,NA,Corporacion Parc Tauli,NA,https://clinicalzeros.gov/ct2/show/NCT04422444,0,0,0,0,1,0,Spain,0,questionnaire,NA
NCT04422769,2020-05-22,2021-03-31,Observational,Needs of Persons With Spinal Cord Injury (SCI),"Active, not recruiting",NA,Washington University School of Medicine,NA,https://clinicalzeros.gov/ct2/show/NCT04422769,0,0,0,0,2,1,United States,0,"NA",NA
NCT04421664,2020-03-25,2020-08-17,Interventional,Preemptive Therapy for SARS-Coronavirus-2 (COVID-19 PEP Canada),Terminated,Phase 3,McGill University Health Centre/Research Institute of the McGill University Health Centre,Request of Health Canada after publication of https://doi.org/10.7326/M20-4207,https://clinicalzeros.gov/ct2/show/NCT04421664,0,0,0,0,1,1,United States|Canada,0,hydroxychloroquine|placebo,NA
NCT04422353,2020-05-01,2020-12-30,Interventional,Video Dance Class and Unsupervised Physical Activity During Covid-19 Pandemic in People With Parkinson's Disease,Recruiting,N/A,Federal University of Rio Grande do Sul,NA,https://clinicalzeros.gov/ct2/show/NCT04422353,0,0,0,0,1,0,Brazil,0,video dance classes|unsupervised physical activities,NA
NCT04422340,2020-04-01,2020-08-15,Observational,Senior-COVID-Rea Multicentric Survey,Recruiting,NA,Hospices Civils de Lyon,NA,https://clinicalzeros.gov/ct2/show/NCT04422340,0,0,0,0,2,0,France,0,group1,NA
NCT04421391,2020-06-08,2020-11-01,Interventional,QuadraMune(TM) for Prevention of COVID-19,Recruiting,N/A,Therapeutic Solutions International,NA,https://clinicalzeros.gov/ct2/show/NCT04421391,0,0,0,0,0,1,United States,0,quadramune(tm),NA
NCT04420338,2020-06-05,2020-12-15,Interventional,"SeroCOVIDial Study: Assessment of COVID-19 Seroconversion in Patients on Chronic Hemodialysis and in Their Caregivers, a Cohort Study",Recruiting,N/A,Assistance Publique Hopitaux De Marseille,NA,https://clinicalzeros.gov/ct2/show/NCT04420338,0,0,0,0,2,0,France,0,blood sample|serum test,NA
NCT04420676,2020-09-24,2021-12-31,Interventional,Synbiotic Therapy of Gastrointestinal Symptoms During Covid-19 Infection,Recruiting,N/A,Medical University of Graz,NA,https://clinicalzeros.gov/ct2/show/NCT04420676,0,0,0,0,2,0,Austria,0,omnibiotic aad|placebo,NA
NCT04420182,2020-08-17,2021-06-30,Interventional,COVID-19 Virtual Care at Home,Recruiting,N/A,Lawson Health Research Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04420182,0,0,0,0,3,0,Canada,0,virtual care at home,NA
NCT04420312,2020-03-01,2020-04-20,Observational,Prevalence and Characteristics of Pulmonary Embolism on COVID-19 Patients Presenting Respiratory Symptoms,Completed,NA,Groupe Hospitalier Paris Saint Joseph,NA,https://clinicalzeros.gov/ct2/show/NCT04420312,0,0,0,0,1,0,France,0,"NA",NA
NCT04420299,2020-06-04,2021-03-31,Interventional,Clinical Trial on the Efficacy and Safety of Bemiparin in Patients Hospitalized Because of COVID-19,Recruiting,Phase 2,FundaciÃ³n de investigaciÃ³n HM,NA,https://clinicalzeros.gov/ct2/show/NCT04420299,0,0,0,0,1,0,Spain,0,bemiparin,NA
NCT04420286,2020-05-06,2021-06-05,Observational,Study of the Increase in ICU Beds Capacity During COVID-19 Pandemic in France,Recruiting,NA,Centre Hospitalier Universitaire de NÄ«mes,NA,https://clinicalzeros.gov/ct2/show/NCT04420286,0,0,0,0,1,0,France,0,"NA",NA
NCT04419571,2020-03-23,2020-06-16,Observational,Outcomes in Emergency Laparotomies During COVID-19 Pandemic,Completed,NA,"Barking, Havering and Redbridge University Hospitals NHS Trust",NA,https://clinicalzeros.gov/ct2/show/NCT04419571,0,0,0,0,3,0,United Kingdom,0,emergency laparotomy,NA
NCT04419545,2020-03-24,2020-12-31,Observational,Covid Radiographic Images Data-set for A.I,Recruiting,NA,Azienda Ospedaliera CittÃ  della Salute e della Scienza di Torino,NA,https://clinicalzeros.gov/ct2/show/NCT04419545,0,0,0,0,0,0,Italy,0,neural network diagnosis algorithm,NA
NCT04420416,2020-04-01,2020-07-30,Observational,Mental Health and Academic Performance in COVID-19,Recruiting,NA,Instituto Mexicano del Seguro Social,NA,https://clinicalzeros.gov/ct2/show/NCT04420416,0,0,0,0,1,0,Mexico,0,questionnaire,NA
NCT04420390,2020-05-01,2020-07-31,Interventional,Low Dose Radiotherapy for COVID-19 Pneumonitis,Recruiting,N/A,"Hospital San Carlos, Madrid",NA,https://clinicalzeros.gov/ct2/show/NCT04420390,0,0,0,0,0,0,Spain,0,radiotherapy,NA
NCT04419623,2020-07-09,2021-07-31,Interventional,A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer,Recruiting,Phase 1/Phase 2,"Telios Pharma, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04419623,0,0,0,0,2,1,United States,0,part 1 - tl-895|part 2 - tl-895|placebo,NA
NCT04418947,2020-06-15,2020-07-17,Interventional,Project Resurgence Communication Trial,Completed,N/A,University of Pennsylvania,NA,https://clinicalzeros.gov/ct2/show/NCT04418947,0,0,0,0,1,1,United States,0,communication type,NA
NCT04418375,2020-06-08,2021-02-28,Observational,Establishment of a Biological Collection During COVID-19 Serological Screening in APHP Professionals (COVID-HOP),Recruiting,NA,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04418375,0,0,0,0,1,0,France,0,"NA",NA
NCT04418609,2020-05-01,2022-04-30,Observational,Neuro-COVID-19: Neurological Complications of COVID-19,Recruiting,NA,University of Zurich,NA,https://clinicalzeros.gov/ct2/show/NCT04418609,0,0,0,0,0,0,Switzerland,0,further processing of health data,NA
NCT04418544,2020-06-01,2020-12-31,Observational,Vocal Feature Analysis Algorithm for COVID-19 Detection,Recruiting,NA,Soniphi LLC,NA,https://clinicalzeros.gov/ct2/show/NCT04418544,0,0,0,0,1,1,United States,0,device used to record voice for screening,NA
NCT04418518,2020-06-24,2021-06-30,Interventional,A Trial of CONvalescent Plasma for Hospitalized Adults With Acute COVID-19 Respiratory Illness,Recruiting,Phase 3,Weill Medical College of Cornell University,NA,https://clinicalzeros.gov/ct2/show/NCT04418518,0,0,0,0,1,1,United States,0,convalescent plasma,NA
NCT04418206,2020-06-01,2020-12-01,Interventional,Validating an ELISpot for Early Detection of an Active Immune Response Against COVID-19,Recruiting,N/A,Centre Hospitalier Universitaire de Nice,NA,https://clinicalzeros.gov/ct2/show/NCT04418206,0,0,0,0,1,0,France,0,patients covid 19,NA
NCT04418245,2020-03-01,2020-06-30,Observational,CT Biomarkers Identification by Artificial Intelligence for COVID-19 Prognosis,"Active, not recruiting",NA,Centre Hospitalier Universitaire de NÄ«mes,NA,https://clinicalzeros.gov/ct2/show/NCT04418245,0,0,0,0,0,0,France|Martinique,0,imaging by thoracic scanner,NA
NCT04417374,2020-05-01,2020-05-30,Observational,"Caracteristics of the Patients Hospitalized With Unvonluntary Commitment Procedure, in the Context COVID-19",Completed,NA,"University Hospital, Montpellier",NA,https://clinicalzeros.gov/ct2/show/NCT04417374,0,0,0,0,2,0,France,0,description of groups caracteristics,NA
NCT04417335,2020-04-16,2021-05-31,Interventional,Reducing COVID-19 Related Hospital Admission in Elderly by BCG Vaccination,"Active, not recruiting",Phase 4,Radboud University,NA,https://clinicalzeros.gov/ct2/show/NCT04417335,0,0,0,1,0,0,Netherlands,0,bcg|placebo,NA
NCT04416438,2020-05-18,2020-12-31,Observational,COVID-19 Epidemic and Patients With Myeloproliferative Neoplasias,Recruiting,NA,French Innovative Leukemia Organisation,NA,https://clinicalzeros.gov/ct2/show/NCT04416438,0,0,0,0,1,0,France,0,"NA",NA
NCT04416373,2020-03-22,2023-12-31,Observational,COVID-19 and Pregnancy Outcomes,Recruiting,NA,Universidade Nova de Lisboa,NA,https://clinicalzeros.gov/ct2/show/NCT04416373,0,0,0,0,0,0,Portugal,0,pcr,NA
NCT04416360,2020-05-05,2020-07-31,Interventional,Autism Spectrum Disorder or Attention Deficit Hyperactivity Disorder in Covid-19 Outbreak,Recruiting,N/A,"University Hospital, Toulouse",NA,https://clinicalzeros.gov/ct2/show/NCT04416360,0,0,0,0,0,0,France,0,interview by psychologists,NA
NCT04416347,2020-06-15,2022-04-30,Observational,COVID19 Clinical Predictors and Outcome,Recruiting,NA,"St George's, University of London",NA,https://clinicalzeros.gov/ct2/show/NCT04416347,0,0,0,0,2,0,United Kingdom,0,sars-cov2 infection,NA
NCT04416139,2020-05-01,2021-04-30,Interventional,Mesenchymal Stem Cell for Acute Respiratory Distress Syndrome Due for COVID-19,Recruiting,Phase 2,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,NA,https://clinicalzeros.gov/ct2/show/NCT04416139,0,0,0,0,0,0,Mexico,0,mesenchymal stem cells,NA
NCT04416334,2020-08-19,2021-08-25,Interventional,PREEMPTIVE THERAPY WITH COLCHICINE IN PATIENTS OLDER THAN 60 YEARS WITH HIGH RISK OF SEVERE PNEUMONIAE DUE TO CORONAVIRUS,Recruiting,Phase 3,Instituto de InvestigaciÃ³n MarquÃ©s de Valdecilla,NA,https://clinicalzeros.gov/ct2/show/NCT04416334,0,0,0,0,3,0,Spain,0,colchicine/symptomatic treatment (paracetamol)|symptomatic treatment (paracetamol/best symptomatic treatment based on doctor recommendations)|colchicine|symptomatic treatment (paracetamol)|symptomatic treatment (paracetamol|best symptomatic treatment based on doctor recommendations),NA
NCT04416256,2020-02-01,2022-02-28,Observational,COVID-19 Pandemic and Worldwide Organ Procurement,Recruiting,NA,Paris Translational Research Center for Organ Transplantation,NA,https://clinicalzeros.gov/ct2/show/NCT04416256,0,0,0,0,0,0,France,0,"NA",NA
NCT04414124,2020-08-02,2021-02-28,Interventional,A Clinical Study to Assess the Natural History of COVID-19 and Effects of KB109 and Supportive Self-care in Outpatients With Mild-to-moderate COVID-19,"Active, not recruiting",N/A,Kaleido Biosciences,NA,https://clinicalzeros.gov/ct2/show/NCT04414124,0,0,0,0,2,1,United States,0,kb109 / self supportive care (ssc)|self supportive care (ssc) alone|kb109|self supportive care (ssc),NA
NCT04416061,2020-05-25,2020-07-31,Observational,The Role of a Private Hospital in Hong Kong Amid COVID-19 Pandemic,"Active, not recruiting",NA,Hong Kong Sanatorium & Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04416061,0,0,0,0,0,0,Hong Kong,0,covid 19 diagnostic test,NA
NCT04416009,2020-07-05,2020-12-20,Observational [Patient Registry],Extracellular Water in Covid 19 Pneumonia,Recruiting,NA,Gaziosmanpasa Taksim Research and Education Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04416009,0,0,0,0,0,0,Turkey,0,nä°cas|nä°cas,NA
NCT04414371,2020-05-20,2020-12-31,Interventional,Tools for Wellbeing COVID-19 National Study of Undergraduate Students,Recruiting,N/A,"Rutgers, The State University of New Jersey",NA,https://clinicalzeros.gov/ct2/show/NCT04414371,0,0,0,0,0,1,United States,0,yoga,NA
NCT04414319,2020-04-15,2021-04-15,Observational,Severe Acute Respiratory Syndrome-Coronavirus-2 and Loss of Autonomy in the Elderly,Recruiting,NA,University Hospital Center of Martinique,NA,https://clinicalzeros.gov/ct2/show/NCT04414319,0,0,0,0,0,0,France|Guadeloupe|Martinique,0,"NA",NA
NCT04414267,2020-05-26,2021-05-25,Interventional,Bacillus Calmette-guÃ©rin Vaccination to Prevent COVID-19,Recruiting,Phase 4,Hellenic Institute for the Study of Sepsis,NA,https://clinicalzeros.gov/ct2/show/NCT04414267,0,0,0,1,3,0,Greece,0,bcg|placebo,NA
NCT04415086,2020-06-01,2022-04-20,Interventional,Treatment of Patients With COVID-19 With Convalescent Plasma,Recruiting,Phase 2,University of Sao Paulo General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04415086,0,0,0,0,2,0,Brazil,0,convalescent plasma,NA
NCT04414657,2020-04-09,2022-04-30,Observational,USZ BioResource COVID,Recruiting,NA,University of Zurich,NA,https://clinicalzeros.gov/ct2/show/NCT04414657,0,0,0,0,0,0,Switzerland,0,blood sample,NA
NCT04413955,2020-06-01,2021-12-31,Observational [Patient Registry],Registry of SeraphÂ®-100 MicrobindÂ® Affinity Blood Filter for COVID-19 Under EUA,Recruiting,NA,"Children's Hospital Medical Center, Cincinnati",NA,https://clinicalzeros.gov/ct2/show/NCT04413955,0,0,0,0,2,1,United States,0,seraphâ®-100 microbindâ® affinity blood filter|seraphâ®-100 microbindâ® affinity blood filter,NA
NCT04413435,2020-10-30,2020-12-15,Observational,Clinical Characteristics of Critically Ill Patients With COVID-19,Completed,NA,Nevsehir Public Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04413435,0,0,0,0,3,0,Turkey,0,file scanning,NA
NCT04413864,2020-04-24,2021-02-28,Interventional,Immunomodulatory Profile of Dexmedetomidine Sedation in Patients Recovering After ARDS Covid-19,Recruiting,N/A,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04413864,0,0,0,0,0,0,France,0,inflammatory cytokines/chemokines profiles of patients with dexmedetomidine administration|inflammatory cytokines|chemokines profiles of patients with dexmedetomidine administration,NA
NCT04412772,2020-06-12,2021-12-31,Interventional,Trial of Tocilizumab for Treatment of Severe COVID-19: ARCHITECTS,Recruiting,Phase 3,Queen's Medical Centre,NA,https://clinicalzeros.gov/ct2/show/NCT04412772,0,0,0,0,1,1,United States,0,tocilizumab|placebo,NA
NCT04413071,2020-05-25,2020-06-12,Observational,Cardiac COVID-19 Health Care Workers,Completed,NA,AORTICA Group,NA,https://clinicalzeros.gov/ct2/show/NCT04413071,0,0,0,0,2,0,Spain,0,passed infection of sars-cov-2,NA
NCT04413058,2020-04-10,2020-09-10,Observational,Menstrual Cycle Characteristics of Healthcare Professionals,Completed,NA,Haydarpasa Numune Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04413058,0,0,0,0,1,0,Turkey,0,"NA",NA
NCT04413045,2020-05-20,2020-07-28,Observational,"Novel COVID-19, A National Analysis",Completed,NA,Assiut University,NA,https://clinicalzeros.gov/ct2/show/NCT04413045,0,0,0,0,1,0,Egypt,0,prevalence of covid-19,NA
NCT04413006,2020-05-25,2020-12-31,Interventional,Self-compassion for Chronic Pain Virtual Group Treatment Program,Recruiting,N/A,University of Manitoba,NA,https://clinicalzeros.gov/ct2/show/NCT04413006,0,0,0,0,0,0,Canada,0,self-compassion for chronic pain virtual group treatment program,NA
NCT04412551,2020-05-20,2020-12-31,Observational [Patient Registry],Lung Ultrasound for Assessment of Patients With Moderate to Severe Covid-19,Recruiting,NA,"Dalarna County Council, Sweden",NA,https://clinicalzeros.gov/ct2/show/NCT04412551,0,0,0,0,0,0,Sweden,0,"NA",NA
NCT04412343,2020-05-23,2020-10-05,Interventional,The Seniors COvid-19 Pandemic and Exercise Study,Completed,N/A,University of British Columbia,NA,https://clinicalzeros.gov/ct2/show/NCT04412343,0,0,0,0,2,0,Canada,0,virtual group intervention|exercise,NA
NCT04412330,2020-05-01,2021-05-01,Interventional,Optimizing Outcomes With Physical Therapy Treatment for IndividuALs Surviving an ICU Admission for Covid-19,Recruiting,N/A,University of Kentucky,NA,https://clinicalzeros.gov/ct2/show/NCT04412330,0,0,0,0,2,1,United States,0,icu recovery / physical therapy|icu recovery|physical therapy,NA
NCT04412278,2020-06-01,2020-06-08,Observational,Impact of COVID-19 Pandemic on Perceived Exercise Benefits and Barriers,Completed,NA,Okan University,NA,https://clinicalzeros.gov/ct2/show/NCT04412278,0,0,0,0,1,0,Turkey,0,online survey,NA
NCT04412239,2020-04-20,2020-12-20,Interventional,To Assess the Efficiency and Satisfaction of Pharmacist Giving Patient-centred Advice on Telephone Consultation in TB Patients: Experience of the COVID-19 Pandemic,Recruiting,N/A,Health Science Center of Xi'an Jiaotong University,NA,https://clinicalzeros.gov/ct2/show/NCT04412239,0,0,0,0,1,0,Pakistan,0,patient-centred advice on telephone consultation in tb patients:,NA
NCT04412226,2020-06-10,2020-06-30,Observational,Effect of Using Barrier Devices for Intubation in COVID-19 Patients,Completed,NA,Derince Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04412226,0,0,0,0,1,0,Turkey,0,aerosol box|transparent sheet,NA
NCT04412486,2020-06-01,2022-05-31,Interventional,COVID-19 Convalescent Plasma (CCP) Transfusion,Recruiting,Early Phase 1,University of Mississippi Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04412486,0,0,0,0,1,1,United States,0,convalescent plasma,NA
NCT04412473,2020-04-30,2021-06-30,Observational,COVID-19 Respiratory Distress and Antithrombotic Drugs in Subject's Habits,Recruiting,NA,"University Hospital, Strasbourg, France",NA,https://clinicalzeros.gov/ct2/show/NCT04412473,0,0,0,0,1,0,France,0,"NA",NA
NCT04412460,2020-03-20,2021-12-31,Observational,Echocardiography in Patients With Covid-19,Recruiting,NA,University Hospital Tuebingen,NA,https://clinicalzeros.gov/ct2/show/NCT04412460,0,0,0,0,0,0,Germany,0,"NA",NA
NCT04412382,2020-06-01,2020-12-31,Observational [Patient Registry],Covid-19: Possible Role of Neutrophil Extracellular Traps,Recruiting,NA,Azienda Ospedaliera Universitaria Integrata Verona,NA,https://clinicalzeros.gov/ct2/show/NCT04412382,0,0,0,0,1,0,Italy,0,netosis markers,NA
NCT04412746,2020-04-01,2020-06-30,Observational,Covid-19 and Diabetes in West of Algeria,Recruiting,NA,"Laboratoire De Recherche Sur Le Diabete, UniversitÃ© de Tlemcen",NA,https://clinicalzeros.gov/ct2/show/NCT04412746,0,0,0,0,0,0,Algeria,0,management of covid-19,NA
NCT04412031,2019-11-11,2020-05-14,Observational,Prediction of Unfavourable Outcome in Newly Covid-19 Hospitalized Patient,Completed,NA,Hospices Civils de Lyon,NA,https://clinicalzeros.gov/ct2/show/NCT04412031,0,0,0,0,0,0,France,0,no intervention,NA
NCT04412018,2020-06-04,2020-12-31,Interventional,An Investigation on the Effects of Icosapent Ethyl (VascepaTM) on Inflammatory Biomarkers in Individuals With COVID-19,Recruiting,Phase 2,Canadian Medical and Surgical Knowledge Translation Research Group,NA,https://clinicalzeros.gov/ct2/show/NCT04412018,0,0,0,0,3,0,Canada,0,icosapent ethyl,NA
NCT04411667,2020-04-28,2020-11-01,Interventional,Study of SOC Plus IVIG Compared to SOC Alone in the Treatment of COVID-19,"Active, not recruiting",Phase 4,Sharp HealthCare,NA,https://clinicalzeros.gov/ct2/show/NCT04411667,0,0,0,0,1,1,United States,0,octagam,NA
NCT04411628,2020-05-28,2020-08-26,Interventional,A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19,Completed,Phase 1,Eli Lilly and Company,NA,https://clinicalzeros.gov/ct2/show/NCT04411628,0,0,0,0,10,1,United States,0,ly3819253|placebo,NA
NCT04411563,2020-05-21,2020-09-30,Observational [Patient Registry],Epigenetic Tools as Prognostic Predictors in Covid19,Recruiting,NA,Bakirkoy Dr. Sadi Konuk Research and Training Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04411563,0,0,0,0,0,0,Turkey,0,taking biological samples,NA
NCT04410939,2020-04-10,2020-05-20,Observational,COVID-19 PCR Test Results in Asymptomatic Pregnants,Completed,NA,Istanbul Medipol University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04410939,0,0,0,0,0,0,Turkey,0,reverse transcription polymerase chain reaction,NA
NCT04410835,2020-04-28,2020-12-31,Observational,Psychological Impact of the Corona Virus (SARS-CoV-2) and COVID-19 Pandemic in Individuals With Psychiatric Disorders,Recruiting,NA,Medical University of Graz,NA,https://clinicalzeros.gov/ct2/show/NCT04410835,0,0,0,0,1,0,Austria,0,online survey,NA
NCT04410692,2020-05-15,2020-05-16,Interventional,Can the Prediction Market Improve Predictions of COVID-19?,Completed,N/A,"National University, Singapore",NA,https://clinicalzeros.gov/ct2/show/NCT04410692,0,0,0,0,1,0,Singapore,0,prediction market,NA
NCT04410263,2020-04-09,2023-12-30,Observational,Microbiota in COVID-19 Patients for Future Therapeutic and Preventive Approaches,Recruiting,NA,University of Zurich,NA,https://clinicalzeros.gov/ct2/show/NCT04410263,0,0,0,0,0,0,Switzerland,0,"sampling|nose swabs, bronchoalveolar lavage ,urine)",NA
NCT04410432,2020-09-29,2021-08-31,Observational,Immune Response and Risk of Serious Infection to SARS-Cov2,Recruiting,NA,Centre Hospitalier Universitaire Dijon,NA,https://clinicalzeros.gov/ct2/show/NCT04410432,0,0,0,0,4,0,France,0,blood sample,NA
NCT04410354,2020-06-16,2020-12-01,Interventional,Study of Merimepodib in Combination With Remdesivir in Adult Patients With Advanced COVID-19,Terminated,Phase 2,"ViralClear Pharmaceuticals, Inc.",Failure to meet primary endpoint,https://clinicalzeros.gov/ct2/show/NCT04410354,0,0,0,0,6,1,United States,0,merimepodib|placebo|remdesivir,NA
NCT04410536,2020-06-15,2021-12-31,Interventional,Home Detox in Medication Overuse Headache (MOH) During Covid-19 Emergency,Recruiting,N/A,Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta,NA,https://clinicalzeros.gov/ct2/show/NCT04410536,0,0,0,0,1,0,Italy,0,symptomatic drugs|bridge therapy|mindfulness,NA
NCT04410510,2020-09-30,2020-12-31,Interventional,P2Et Extract in the Symptomatic Treatment of Subjects With COVID-19,Recruiting,Phase 2/Phase 3,Hospital Universitario San Ignacio,NA,https://clinicalzeros.gov/ct2/show/NCT04410510,0,0,0,0,3,0,Colombia,0,p2et (caesalpinia spinosa extract)|placebo,NA
NCT04410484,2020-05-22,2020-08-31,Observational,PREPARE-IBD: Physician Responses to Disease Flares and Patient Adaptation in Relation to Events in Inflammatory Bowel Disease During COVID-19 Pandemic,"Active, not recruiting",NA,Hull University Teaching Hospitals NHS Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04410484,0,0,0,0,1,0,United Kingdom,0,"NA",NA
NCT04410471,2020-05-29,2020-05-29,Observational [Patient Registry],Humoral Immunity Against SARS-CoV-2 in Liver Transplanted Patients After COVID-19 in Comparison With Immunocompetent Patients,Recruiting,NA,Hospital General Universitario Gregorio MaraÃ±on,NA,https://clinicalzeros.gov/ct2/show/NCT04410471,0,0,0,0,1,0,Spain,0,igm/igg rapid test|igg test|igm,NA
NCT04410458,2020-05-31,2020-05-31,Interventional,Recruit Blood Donors Via SMS During Epidemic of COVID-19 ï¼ˆRepeat Trialï¼‰,Enrolling by invitation,N/A,Guangzhou Blood Center,NA,https://clinicalzeros.gov/ct2/show/NCT04410458,0,0,0,0,0,0,China,0,blood donation sms,NA
NCT04410159,2020-06-22,2020-06-29,Interventional,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Completed,Phase 2,Universiti Sains Islam Malaysia,NA,https://clinicalzeros.gov/ct2/show/NCT04410159,0,0,0,0,5,0,Malaysia,1,povidone/iodine|essential oils|water,NA
NCT04409925,2020-12-25,2021-04-30,Interventional,DISmantling COvid iNduced Neutrophil ExtraCellular Traps (DISCONNECT-1),Recruiting,Phase 1,McGill University Health Centre/Research Institute of the McGill University Health Centre,NA,https://clinicalzeros.gov/ct2/show/NCT04409925,0,0,0,0,7,0,Canada,0,rhdnase i,NA
NCT04409899,2020-03-20,2020-06-30,Observational,The Utility of Enhanced Pre and Post-surgical Work-out to Prevent the Spread of COVID-19 in a Large Urology Department,"Active, not recruiting",NA,Fundacio Puigvert,NA,https://clinicalzeros.gov/ct2/show/NCT04409899,0,0,0,0,1,0,Spain,0,blood test,NA
NCT04410016,2020-05-25,2020-07-31,Interventional,Evaluation of Staff COVID-19 Wellbeing Centres in a Healthcare Workplace: COVID-WELL Study,Recruiting,N/A,University of Nottingham,NA,https://clinicalzeros.gov/ct2/show/NCT04410016,0,0,0,0,2,0,United Kingdom,0,staff wellbeing centres,NA
NCT04409834,2020-08-05,2021-05-31,Interventional,Prevention of Arteriovenous Thrombotic Events in Critically-Ill COVID-19 Patients Trial,Recruiting,Phase 4,The TIMI Study Group,NA,https://clinicalzeros.gov/ct2/show/NCT04409834,0,0,0,0,2,1,United States,0,unfractionated heparin iv|enoxaparin|clopidogrel|unfractionated heparin sc|kg|sodium,NA
NCT04409275,2020-05-21,2020-12-31,Observational,LUNG FIBROTIC CHANGES ASSOCIATED WITH SARS-CoV-2 INFECTION,Recruiting,NA,FundaciÃ³n para la InvestigaciÃ³n del Hospital ClÃ­nico de Valencia,NA,https://clinicalzeros.gov/ct2/show/NCT04409275,0,0,0,0,1,0,Spain,0,"NA",NA
NCT04409535,2020-05-07,2021-02-25,Observational,Effects of the COVID-19 Health Emergency on Biopsychosocial Health,"Active, not recruiting",NA,University of New Mexico,NA,https://clinicalzeros.gov/ct2/show/NCT04409535,0,0,0,0,0,1,United States,0,survey,NA
NCT04409522,2020-05-12,2020-06-05,Interventional,Evaluation of Therapeutic Effects of Melatonin by Inhibition of NLRP3 Inflammasome in COVID19 Patients,Recruiting,N/A,Baqiyatallah Medical Sciences University,NA,https://clinicalzeros.gov/ct2/show/NCT04409522,0,0,0,0,0,0,"Iran, Islamic Republic of",0,melatonin|standard care,NA
NCT04409509,2020-07-01,2021-01-12,Interventional,Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19),Completed,Phase 2,CSL Behring,NA,https://clinicalzeros.gov/ct2/show/NCT04409509,0,0,0,0,11,1,United States,0,"garadacimab, factor xiia antagonist monoclonal antibody|placebo",NA
NCT04409249,2020-03-15,2020-05-25,Observational,Prognosis in Pregnant With COVID-19,Completed,NA,Kanuni Sultan Suleyman Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04409249,0,0,0,0,2,0,Turkey,0,"imaging, blood tests",NA
NCT04409197,2020-05-08,2020-06-08,Observational,"Evaluation of Changes in Weight, Sleep, and Other Psycho-behavioural Parameters During Covid-19 Confinement in Subjects Monitored by the RNPC Network",Completed,NA,"University Hospital, Grenoble",NA,https://clinicalzeros.gov/ct2/show/NCT04409197,0,0,0,0,1,0,France,0,"NA",NA
NCT04408456,2020-03-01,2020-07-31,Interventional,Efficacy of Hydroxychloroquine (HCQ) as Post Exposure Prophylaxis (PEP) for Prevention of COVID-19,Completed,Phase 3,Postgraduate Institute of Medical Education and Research,NA,https://clinicalzeros.gov/ct2/show/NCT04408456,0,0,0,0,2,0,India,0,hydroxychloroquine|standard care,NA
NCT04408339,2020-04-15,2021-04-14,Observational [Patient Registry],COVID-19 in Cancer Patients: Evaluation of Clinical Course and Impact on Oncological Care Including Biobanking,Recruiting,NA,UniversitÃ¤tsklinikum Hamburg-Eppendorf,NA,https://clinicalzeros.gov/ct2/show/NCT04408339,0,0,0,0,1,0,Germany,0,no intervention,NA
NCT04408326,2020-06-01,2021-05-01,Observational,Efficacy and Safety of Angiotensin II Use in Coronavirus Disease(COVID)-19 Patients With Acute Respiratory Distress Syndrome,Recruiting,NA,Guy's and St Thomas' NHS Foundation Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04408326,0,0,0,0,3,0,United Kingdom,0,angiotensin ii|interleukin,NA
NCT04408248,2020-08-20,2021-05-31,Observational,AKI Biomarkers in Coronavirus(COVID)-19,Recruiting,NA,Guy's and St Thomas' NHS Foundation Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04408248,0,0,0,0,4,0,United Kingdom,0,"NA",NA
NCT04408222,2020-04-16,2021-04-30,Observational,Awake Proning in COVID-19 Patients With Hypoxemic Respiratory Failure,"Active, not recruiting",NA,Columbia University,NA,https://clinicalzeros.gov/ct2/show/NCT04408222,0,0,0,0,0,1,United States,0,prone positioning,NA
NCT04408131,2020-05-28,2021-01-27,Interventional,Morbi-mortality by COVID-19 Among Homeless People in Marseille: a Cohort Study,Recruiting,N/A,Assistance Publique Hopitaux De Marseille,NA,https://clinicalzeros.gov/ct2/show/NCT04408131,0,0,0,0,0,0,France,0,blood sample,NA
NCT04408066,2020-04-30,2022-04-30,Interventional,COVID-19: A POC Test Under Research & Evaluation,Recruiting,N/A,LumiraDx UK Limited,NA,https://clinicalzeros.gov/ct2/show/NCT04408066,0,0,0,0,1,0,United Kingdom,0,sample collection/performance evaluation (a)|sample collection/performance evaluation (b)|sample collection|performance evaluation,NA
NCT04407923,2020-05-25,2020-11-25,Observational,Drug Management of Juvenile Idiopathic Arthritis in Covid-19 Context : Impact on Therapeutical Managment,Recruiting,NA,"University Hospital, Brest",NA,https://clinicalzeros.gov/ct2/show/NCT04407923,0,0,0,0,0,0,France,0,"NA",NA
NCT04408378,2020-06-05,2020-07-20,Observational,Change in the Ratio of Mean Platelet Volume (MPV) to Platellet(PLT) in Covid-19 Pneumonia Patients,Recruiting,NA,Gaziosmanpasa Taksim Research and Education Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04408378,0,0,0,0,0,0,Turkey,0,observation of covid 19 pneumonia,NA
NCT04408365,2020-08-05,2021-05-31,Observational,"Endothelial Function, Inflammation and Organ Dysfunction in COVID-19",Recruiting,NA,Guy's and St Thomas' NHS Foundation Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04408365,0,0,0,0,1,0,United Kingdom,0,"NA",NA
NCT04407598,2020-05-01,2020-06-08,Observational,COPD in the Time of COVID-19,"Active, not recruiting",NA,University of Leicester,NA,https://clinicalzeros.gov/ct2/show/NCT04407598,0,0,0,0,1,0,United Kingdom,0,"NA",NA
NCT04407429,2020-05-27,2021-06-27,Observational,Vienna Versus SARS-CoV-2 Virus Study,Recruiting,NA,Medical University of Vienna,NA,https://clinicalzeros.gov/ct2/show/NCT04407429,0,0,0,0,0,0,Austria,0,laboratory analyses,NA
NCT04407585,2020-06-01,2021-05-10,Observational,Testing the Accuracy of a Digital Test to Diagnose Covid-19,Recruiting,NA,King's College London,NA,https://clinicalzeros.gov/ct2/show/NCT04407585,0,0,0,0,1,0,United Kingdom,0,pcr,NA
NCT04407390,2020-06-01,2021-05-01,Interventional,Effects of Nicotinamide Riboside on the Clinical Outcome of Covid-19 in the Elderly,Recruiting,Phase 2,University of Copenhagen,NA,https://clinicalzeros.gov/ct2/show/NCT04407390,0,0,0,0,1,0,Denmark,0,nicotinamide riboside|placebo,NA
NCT04407572,2020-04-20,2020-06-01,Observational,Evaluation of the Relationship Between Zinc Vitamin D and b12 Levels in the Covid-19 Positive Pregnant Women,Completed,NA,Kanuni Sultan Suleyman Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04407572,0,0,0,0,1,0,Turkey,0,serum test,NA
NCT04407559,2020-05-01,2020-09-01,Observational,COVID-SErology in Rheumatoid Arthritis (COVID-19),Completed,NA,"University Hospital, Montpellier",NA,https://clinicalzeros.gov/ct2/show/NCT04407559,0,0,0,0,2,0,France,0,serology test,NA
NCT04407663,2020-03-03,2020-05-04,Observational,"Outpatient Clinic in Obesity Care During COVID-19 Outbreak: Physically Far, Virtually Near",Completed,NA,"University of Campania ""Luigi Vanvitelli""",NA,https://clinicalzeros.gov/ct2/show/NCT04407663,0,0,0,0,0,0,Italy,0,telehealth,NA
NCT04407494,2020-03-01,2020-04-01,Observational,Diagnostic Value of Patient - Reported and Clinically Verified Olfactory Disorders (COVID-19),Completed,NA,"University Hospital, Montpellier",NA,https://clinicalzeros.gov/ct2/show/NCT04407494,0,0,0,0,1,0,France,0,"reporting of anosmia, ageusia/other clinical symptoms|reporting of anosmia, ageusia|other clinical symptoms",NA
NCT04407221,2020-06-16,2024-05-01,Observational,COVID-19 Research in Organ Transplant Recipients,Enrolling by invitation,NA,Vastra Gotaland Region,NA,https://clinicalzeros.gov/ct2/show/NCT04407221,0,0,0,0,1,0,Sweden,0,"NA",NA
NCT04407208,2020-05-01,2020-06-22,Interventional,Convalescent Plasma Therapy in Patients With COVID-19,Completed,Phase 1,Biofarma,NA,https://clinicalzeros.gov/ct2/show/NCT04407208,0,0,0,0,2,0,Indonesia,0,convalescent plasma,NA
NCT04407195,2020-06-01,2021-06-01,Observational,COVID-19 and Mental Health,"Active, not recruiting",NA,Northeastern University,NA,https://clinicalzeros.gov/ct2/show/NCT04407195,0,0,0,0,2,1,United States,0,exposure,NA
NCT04407182,2020-05-04,2020-08-01,Interventional,Safety and Efficacy of Viusid and Asbrip in Hospitalized Patients Infected by SARS-Cov-2 With COVID-19,Completed,Phase 2,Catalysis SL,NA,https://clinicalzeros.gov/ct2/show/NCT04407182,0,0,0,0,4,0,Ecuador,0,viusid/asbrip|viusid|asbrip,NA
NCT04407117,2017-03-23,2020-04-19,Observational,Appendicitis During the National Lockdown During the COVID-19 Pandemic,Completed,NA,Nordsjaellands Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04407117,0,0,0,0,1,0,Denmark,0,lock-down/social distancing|lock-down|social distancing,NA
NCT04407299,2020-04-20,2020-05-10,Observational,COVID-19 Impact on Rheumatic Patients,Completed,NA,Cairo University,NA,https://clinicalzeros.gov/ct2/show/NCT04407299,0,0,0,0,1,0,Egypt,0,questionnaire,NA
NCT04407286,2020-05-19,2020-08-30,Interventional,Vitamin D Testing and Treatment for COVID 19,Completed,Phase 1,Arizona State University,NA,https://clinicalzeros.gov/ct2/show/NCT04407286,0,0,0,0,2,1,United States,0,vitamin d,NA
NCT04406844,2020-05-09,2021-06-30,Observational,Issues and Challenges in Cancer Patients on Active Treatment During the COVID-19 Pandemic,Recruiting,NA,Max Healthcare Insititute Limited,NA,https://clinicalzeros.gov/ct2/show/NCT04406844,0,0,0,0,1,0,India,0,"NA",NA
NCT04406688,2020-06-22,2021-02-28,Observational,Prediction of Acute Kidney Injury in Patients With COVID-19,Recruiting,NA,University Hospital Muenster,NA,https://clinicalzeros.gov/ct2/show/NCT04406688,0,0,0,0,1,0,Germany|Portugal|Spain|United Kingdom,0,"NA",NA
NCT04406493,2020-04-28,2021-04-28,Interventional,Monitoring COVID-19 Patients' Lung Fluid Using Impedance Technique,Recruiting,N/A,Hillel Yaffe Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04406493,0,0,0,0,0,0,Israel,0,lung impedance,NA
NCT04406389,2020-10-13,2021-06-30,Interventional,Anticoagulation in Critically Ill Patients With COVID-19 (The IMPACT Trial),Recruiting,Phase 4,Weill Medical College of Cornell University,NA,https://clinicalzeros.gov/ct2/show/NCT04406389,0,0,0,0,4,1,United States,0,enoxaparin|heparin|fondapariniux|argatroban,NA
NCT04406324,2020-06-01,2021-03-05,Observational,COVID-19: Respiratory and Sleep Follow-up,Recruiting,NA,"University Hospital, Grenoble",NA,https://clinicalzeros.gov/ct2/show/NCT04406324,0,0,0,0,1,0,France,0,no intervention,NA
NCT04406571,2020-04-01,2021-11-30,Observational,Reorganization of the Healthcare System During COVID-19 Pandemic: Impact on Management of Patients With Exocrine Pancreatic Cancer,Recruiting,NA,CHU de Reims,NA,https://clinicalzeros.gov/ct2/show/NCT04406571,0,0,0,0,0,0,France,0,data record,NA
NCT04406558,2020-05-27,2021-03-31,Observational,Psychological Impact of the Health Measures Generated by the COVID19 in Adolescents,Recruiting,NA,Centre Hospitalier Intercommunal Creteil,NA,https://clinicalzeros.gov/ct2/show/NCT04406558,0,0,0,0,1,0,France,0,questionnaire,NA
NCT04406233,2020-05-23,2022-05-23,Observational,Muscle Mass and Strength as Predictors of Time to Discharge in Patients With COVID-19,Recruiting,NA,University of Sao Paulo,NA,https://clinicalzeros.gov/ct2/show/NCT04406233,0,0,0,0,0,0,Brazil,0,"NA",NA
NCT04406181,2020-05-18,2020-12-31,Interventional,Psychological Well-being of Patients Awaiting for Cardiac Surgery During the COVID-19 Pandemic,Recruiting,N/A,Universitair Ziekenhuis Brussel,NA,https://clinicalzeros.gov/ct2/show/NCT04406181,0,0,0,0,1,0,Belgium,0,hads|survey,NA
NCT04405999,2020-05-14,2020-08-09,Interventional,Prevention of Infection and Incidence of COVID-19 in Medical Personnel Assisting Patients With New Coronavirus Disease,Completed,Phase 4,"Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health",NA,https://clinicalzeros.gov/ct2/show/NCT04405999,0,0,0,0,1,0,Russian Federation,0,bromhexine hydrochloride,NA
NCT04405973,2020-05-19,2020-09-30,Observational,Clinical Scores for Outcome Prediction in Patients With Severe COVID-19 Pneumonia Requiring ECMO,Completed,NA,University Hospital Freiburg,NA,https://clinicalzeros.gov/ct2/show/NCT04405973,0,0,0,0,2,0,Germany,0,vv-ecmo,NA
NCT04405310,2020-05-20,2020-11-20,Interventional,Convalescent Plasma of Covid-19 to Treat SARS-COV-2 a Randomized Doble Blind 2 Center Trial,Completed,Phase 2,Grupo Mexicano para el Estudio de la Medicina Intensiva,NA,https://clinicalzeros.gov/ct2/show/NCT04405310,0,0,0,0,2,0,Mexico,0,convalescent plasma|placebo|albumine,NA
NCT04405466,2020-04-22,2020-08-28,Observational,A Study to Assess the Feasibility of Screening for SARS-CoV-2 Among Healthy Workers,Recruiting,NA,Miltenyi Biomedicine GmbH,NA,https://clinicalzeros.gov/ct2/show/NCT04405466,0,0,0,0,2,0,Germany,0,blood sample|throat swab,NA
NCT04405284,2020-06-04,2020-06-30,Observational,The Use of Disinfectants Among Women in Egypt and the Toxicity by Bleach During the Coronavirus Lock-down.,Completed,NA,Helwan University,NA,https://clinicalzeros.gov/ct2/show/NCT04405284,0,0,0,0,1,0,Egypt,0,use/exposure to disinfectants during the coronavirus pandemic|use|exposure to disinfectants during the coronavirus pandemic,NA
NCT04405232,2020-05-25,2021-04-25,Observational,Coagulopathy in COVID19 - A Multi-Centre Observational Study in UK,Recruiting,NA,Imperial College London,NA,https://clinicalzeros.gov/ct2/show/NCT04405232,0,0,0,0,2,0,United Kingdom,0,non-interventional,NA
NCT04405102,2020-09-16,2023-01-01,Interventional,COVID-19 Ozanimod Intervention Study,Recruiting,Phase 2,Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec,NA,https://clinicalzeros.gov/ct2/show/NCT04405102,0,0,0,0,2,0,Canada,0,ozanimod|standard care,NA
NCT04405544,2020-05-22,2020-07-22,Interventional,Determination of Acute Encephalopathy Predictors in Patients With COVID-19,Completed,N/A,"State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia",NA,https://clinicalzeros.gov/ct2/show/NCT04405544,0,0,0,0,2,0,Russian Federation,0,ct-scan|eeg|ep|pulse oximetry|blood test,NA
NCT04404218,2020-08-04,2021-03-31,Interventional,The AÃ§aÃ­ Berry COVID-19 Anti-Inflammation Trial,Recruiting,Phase 2,"University Health Network, Toronto",NA,https://clinicalzeros.gov/ct2/show/NCT04404218,0,0,0,0,1,0,Canada,0,aã§aã­ palm berry extract - natural product|placebo|aã§aã­ palm berry extract - natural product,NA
NCT04403672,2020-05-18,2020-07-24,Observational [Patient Registry],Performance Evaluation of RealDetectâ„¢ COVID-19 RT-PCR Kit for the Detection of SARS-CoV-2 Virus,Recruiting,NA,Bangladesh Medical Research Council (BMRC),NA,https://clinicalzeros.gov/ct2/show/NCT04403672,0,0,0,0,1,0,Bangladesh,0,performance evaluation study of realdetect rt-pcr kit for covid-19 detection,NA
NCT04403828,2020-05-20,2020-06-01,Observational,Impact of COVID-19 on Personal Protection Among Dentist in Egypt,Completed,NA,Fayoum University,NA,https://clinicalzeros.gov/ct2/show/NCT04403828,0,0,0,0,2,0,Egypt,0,questionnaire,NA
NCT04403269,2020-05-05,2021-05-05,Interventional,"NORMAL HUMAN IMMUNOGLOBULINS (IVIG) IN PATIENTS AGED 75 YEARS AND OVER, COVID-19 WITH SEVERE ACUTE RESPIRATORY FAILURE",Recruiting,Phase 2,Versailles Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04403269,0,0,0,0,0,0,France,0,igiv,NA
NCT04403438,2020-04-01,2020-05-01,Observational,Familial Mediterranean Fever and BehÃ§et: Analysis Before and After Covid19 Pandemic,Enrolling by invitation,NA,Istanbul University,NA,https://clinicalzeros.gov/ct2/show/NCT04403438,0,0,0,0,0,0,Turkey,0,"ä±t will be compared pain, sleep, fatigue, physical activity level/quality of life/questioning exercise habits before/after the covid-19 outbreak in patients with behã§et/fmf.|ä±t will be compared pain, sleep, fatigue, physical activity level|quality of life|exercise|after the covid-19 outbreak in patients with behã§et|fmf.",NA
NCT04403061,2020-05-22,2020-12-22,Observational,Th1/Th2/Th17/TREG and TLRs Activation/KIR for COVID 19 Prediction of Outcome,Completed,NA,Asociacion para el Estudio de las Enfermedades Infecciosas,NA,https://clinicalzeros.gov/ct2/show/NCT04403061,0,0,0,0,1,0,Spain,0,cytokines measurement|cellular response|tlrs activation measurement|kir phenotype evaluation,NA
NCT04403035,2020-05-10,2020-07-01,Observational,Comparison of the ID NOW and Accula Point-of-Care Assays for Detection of COVID-19,Recruiting,NA,Ascension South East Michigan,NA,https://clinicalzeros.gov/ct2/show/NCT04403035,0,0,0,0,1,1,United States,0,id now vs. accula,NA
NCT04403009,2020-02-01,2020-06-06,Observational,The Clinical Difference Between the Nonfatal Patients and the Fatal Patients With Severe COVID-19,Recruiting,NA,The First Affiliated Hospital of Guangzhou Medical University,NA,https://clinicalzeros.gov/ct2/show/NCT04403009,0,0,0,0,0,0,China,0,no intervention,NA
NCT04402983,2020-05-27,2020-12-01,Interventional,The Effectiveness of Telerehabilitation-Based Physiotherapy in COVID 19 Patients,Completed,N/A,Istanbul Medipol University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04402983,0,0,0,0,2,0,Turkey,0,physiotherapy,NA
NCT04402879,2020-11-10,2021-12-01,Interventional,CORONA (COvid pRONe hypoxemiA): Prone Positioning for Hypoxemic COVID-19 Patients With Do-not-intubate Goals,Recruiting,N/A,University of Calgary,NA,https://clinicalzeros.gov/ct2/show/NCT04402879,0,0,0,0,5,0,Canada,0,prone positioning,NA
NCT04402840,2020-04-24,2021-12-31,Interventional,Stellate Ganglion Block (SGB) for COVID-19 Acute Respiratory Distress Syndrome (ARDS),Recruiting,N/A,West Virginia University,NA,https://clinicalzeros.gov/ct2/show/NCT04402840,0,0,0,0,1,1,United States,0,stellate ganglion block,NA
NCT04402827,2020-08-01,2020-12-30,Observational,Different Susceptibility to SARS CoV-2 Infection Among Health Care Workers Highly Exposed to COVID-19.,Recruiting,NA,Asociacion para el Estudio de las Enfermedades Infecciosas,NA,https://clinicalzeros.gov/ct2/show/NCT04402827,0,0,0,0,2,0,Spain,0,susceptibility to infection,NA
NCT04402814,2020-05-05,2020-10-01,Observational,IgG/IgM Antibody Test in Patients Who Have Tested Negative or Positive for COVID-19 With the Standard Method of COVID19 Testing.,Recruiting,NA,Sharp HealthCare,NA,https://clinicalzeros.gov/ct2/show/NCT04402814,0,0,0,0,1,1,United States,0,clungene rapid test cassette,NA
NCT04402229,2020-05-12,2020-07-31,Observational,Psychological Impact of the Covid-19 Pandemic on Student Nurses,Completed,NA,Versailles Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04402229,0,0,0,0,1,0,France,0,"NA",NA
NCT04402203,2020-05-31,2020-07-31,Interventional,Study on Safety and Efficacy of Favipiravir (Favipira) for COVID-19 Patient in Selected Hospitals of Bangladesh,Recruiting,Phase 2/Phase 3,Bangladesh Medical Research Council (BMRC),NA,https://clinicalzeros.gov/ct2/show/NCT04402203,0,0,0,0,0,0,Bangladesh,0,favipiravir|standard care,NA
NCT04402060,2020-05-28,2021-01-31,Interventional,A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19,Recruiting,Phase 1/Phase 2,"Apellis Pharmaceuticals, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04402060,0,0,0,0,3,1,United States|Brazil,0,apl-9|vehicle control,NA
NCT04401371,2020-05-01,2020-05-10,Observational,Distance Learning for Dental Student During COVID-19 Pandemic,Completed,NA,Cairo University,NA,https://clinicalzeros.gov/ct2/show/NCT04401371,0,0,0,0,1,0,Egypt,0,"NA",NA
NCT04401254,2020-07-01,2021-12-31,Observational,Recovery of Patients From COVID-19 After Critical Illness,Recruiting,NA,Australian and New Zealand Intensive Care Research Centre,NA,https://clinicalzeros.gov/ct2/show/NCT04401254,0,0,0,0,2,0,Australia,0,"NA",NA
NCT04400929,2020-06-02,2021-06-30,Interventional,Using GM-CSF as a Host Directed Therapeutic Against COVID-19,Recruiting,Phase 2,Singapore General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04400929,0,0,0,0,1,0,Singapore,0,sargramostim|saline,NA
NCT04401111,2020-06-16,2021-06-15,Observational,One-year Outcomes in Survivors of the Severe COVID-19 Pneumonia (CO-Qo-ICU),Recruiting,NA,Centre Hospitalier Universitaire de Nice,NA,https://clinicalzeros.gov/ct2/show/NCT04401111,0,0,0,0,1,0,France,0,"NA",NA
NCT04401098,2020-05-02,2020-10-01,Observational,Changing Of Egyptian Population Behaviour Towards COVID 19 Outbreak,Recruiting,NA,Damanhour University,NA,https://clinicalzeros.gov/ct2/show/NCT04401098,0,0,0,0,0,0,Egypt,0,"NA",NA
NCT04401085,2020-04-23,2020-05-01,Observational,COVID-19: Herd Immunity Study in the Czech Republic,Completed,NA,Institute of Health Information and Statistics of the Czech Republic,NA,https://clinicalzeros.gov/ct2/show/NCT04401085,0,0,0,0,2,0,Czechia,0,rapid test|quantitative analysis of sars-cov-2 antibodies,NA
NCT04401072,2020-04-24,2020-05-22,Observational,Attitude of Egyptian Population Toward COVID 19 in Ramadan,Recruiting,NA,Damanhour University,NA,https://clinicalzeros.gov/ct2/show/NCT04401072,0,0,0,0,0,0,Egypt,0,"NA",NA
NCT04401241,2020-02-01,2020-05-01,Observational,How Routine Biomarkers and Blood Leucocytes Count Can Assist Diagnosis of COVID-19 in Emergency Department,Completed,NA,Centre Hospitalier Princesse Grace,NA,https://clinicalzeros.gov/ct2/show/NCT04401241,0,0,0,0,0,0,Monaco,0,"NA",NA
NCT04401228,2020-03-01,2020-05-01,Observational,Predictive Models for Intensive Care Admission and Death of COVID-19,"Active, not recruiting",NA,Clinique Saint Pierre Ottignies,NA,https://clinicalzeros.gov/ct2/show/NCT04401228,0,0,0,0,0,0,Belgium,0,"predict admission of covid-19 patients to icu/death with routine/quickly avalaible clinical, biological/radiological variables?|predict admission of covid-19 patients to icu|death with routine|quickly avalaible clinical, biological|radiological variables?",NA
NCT04401046,2020-05-20,2020-10-30,Interventional,COVID-19 and Reorganisation of Cancer Patient Care: Self- Evaluation of Potential Post-traumatic Stress Disorder,Recruiting,N/A,Institut Paoli-Calmettes,NA,https://clinicalzeros.gov/ct2/show/NCT04401046,0,0,0,0,2,0,France,0,survey|anxiety|6 months later,NA
NCT04401033,2020-05-11,2020-06-30,Observational [Patient Registry],Increased Risk of SARS-CoronaVirus-2 (SARS-CoV-2) Infection Associated With Endoscopy (DECORE Study),Completed,NA,Hospital del RÃ­o Hortega,NA,https://clinicalzeros.gov/ct2/show/NCT04401033,0,0,0,0,2,0,Spain,0,telehealth|gastrointestinal endoscopy|abdominal ultrasound,NA
NCT04400877,2020-06-08,2020-07-30,Observational,Prevalence and Severity of Venous Thromboembolism in a General Population During the COVID-19 Pandemic,Completed,NA,"University Hospital, Linkoeping",NA,https://clinicalzeros.gov/ct2/show/NCT04400877,0,0,0,0,3,0,Sweden,0,diagnostic examination for venous thromboembolism,NA
NCT04400812,2020-05-19,2020-09-30,Observational,Attitude and Perception Towards COVID-19 Pandemic,Enrolling by invitation,NA,Zagazig University,NA,https://clinicalzeros.gov/ct2/show/NCT04400812,0,0,0,0,1,0,Egypt,0,questionnaire,NA
NCT04400279,2020-06-01,2020-11-28,Interventional,The COVID-19 Pandemic and Exercise Study,Completed,N/A,University of British Columbia,NA,https://clinicalzeros.gov/ct2/show/NCT04400279,0,0,0,0,4,0,Canada,0,yoga group|high intensity interval training|combination,NA
NCT04399889,2020-06-18,2021-04-01,Interventional,hCT-MSCs for COVID19 ARDS,Recruiting,Phase 1/Phase 2,Duke University,NA,https://clinicalzeros.gov/ct2/show/NCT04399889,0,0,0,0,1,1,United States,0,mesenchymalÂ stem cells,NA
NCT04399681,2020-05-10,2020-08-10,Interventional,The Utility of Bedside Lung Ultrasonography on Diagnosis of COVID-19,Recruiting,N/A,Kanuni Sultan Suleyman Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04399681,0,0,0,0,0,0,Turkey,0,lung ultrasound,NA
NCT04400006,2020-05-06,2020-05-16,Observational,Ozone Therapy in the Prevention of COVID-19 Infection,Completed,NA,Marmara University,NA,https://clinicalzeros.gov/ct2/show/NCT04400006,0,0,0,0,0,0,Turkey,0,"NA",NA
NCT04399967,2020-06-13,2021-06-30,Interventional,"COVID-19 Brief Advice and Chat-based Support for Smoking Cessation Via ""Quit to Win"" Contest 2020",Recruiting,N/A,The University of Hong Kong,NA,https://clinicalzeros.gov/ct2/show/NCT04399967,0,0,0,0,5,0,China,0,chat-based support|award/covid-specific advice|award advice|covid-19 related health warning leaflet|health warning leaflet|sms-based support|referral card|cosh self-help smoking cessation booklet|award|covid-specific advice,NA
NCT04399746,2020-03-15,2020-05-20,Interventional,Ivermectin-Azithromycin-Cholecalciferol (IvAzCol) Combination Therapy for COVID-19,Recruiting,N/A,Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado,NA,https://clinicalzeros.gov/ct2/show/NCT04399746,0,0,0,0,0,0,Mexico,0,ivermectin|azithromycin|cholecalciferol,NA
NCT04399109,2020-05-20,2021-05-19,Interventional,Evaluation of a Remote Monitoring Smartphone Application and Care Model of COVID-19 Patients in the Community (ReCOVER),Recruiting,N/A,"Prince of Wales Hospital, Sydney",NA,https://clinicalzeros.gov/ct2/show/NCT04399109,0,0,0,0,0,0,Australia,0,tcc-covid mhealth,NA
NCT04399005,2020-05-25,2020-06-05,Interventional,The Efficacy Comparing Daily and After-each-case Room Disinfection.,Completed,N/A,The First Affiliated Hospital of Zhejiang Chinese Medical University,NA,https://clinicalzeros.gov/ct2/show/NCT04399005,0,0,0,0,1,0,China,0,after-each-case room disinfection|daily room disinfection,NA
NCT04397848,2020-05-14,2020-07-03,Observational,Mental Health Outcomes in Healthcare Workers During COVID-19,Completed,NA,"University Health Network, Toronto",NA,https://clinicalzeros.gov/ct2/show/NCT04397848,0,0,0,0,1,0,Canada,0,"NA",NA
NCT04398277,2020-05-01,2021-04-30,Interventional,A Daily Coping Toolkit for Medical Personnel and First-Responders During COVID-19 Pandemic,Recruiting,N/A,Kent State University,NA,https://clinicalzeros.gov/ct2/show/NCT04398277,0,0,0,0,0,1,United States,0,daily coping toolkit,NA
NCT04398004,2020-05-06,2020-11-30,Interventional,Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early,Completed,Phase 2,Hellenic Institute for the Study of Sepsis,NA,https://clinicalzeros.gov/ct2/show/NCT04398004,0,0,0,0,3,0,Greece,0,clarithromycin,NA
NCT04397835,2020-04-17,2021-04-20,Observational,Psychological Impact of COVID-19 Quarantine and Worsening of Cardiovascular Risk in the French General Population,Recruiting,NA,"University Hospital, Toulouse",NA,https://clinicalzeros.gov/ct2/show/NCT04397835,0,0,0,0,0,0,France,0,"NA",NA
NCT04397822,2020-04-16,2021-10-31,Observational,COVID-19 : Study of INFLAmmasome and PLAtelets Functions,Recruiting,NA,"University Hospital, Toulouse",NA,https://clinicalzeros.gov/ct2/show/NCT04397822,0,0,0,0,1,0,France,0,blood sample,NA
NCT04397692,2020-06-13,2020-09-30,Interventional,Inhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2 (US Trial),Recruiting,N/A,Beyond Air Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04397692,0,0,0,0,2,1,United States,0,nitric oxide delivered via lungfitâ„¢ system|nitric oxide delivered via lungfitâ„¢ system,NA
NCT04397588,2020-04-21,2020-10-21,Observational,Extracorporeal Membrane Oxygenation (ECMO) and Coronavirus Disease (COVID) 19,Recruiting,NA,Rennes University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04397588,0,0,0,0,1,0,France,0,"NA",NA
NCT04397562,2020-04-29,2020-07-03,Interventional,A Clinical Trial of the Efficacy and Safety of Levilimab (BCD-089) in Patients With Severe COVID-19,Completed,Phase 3,Biocad,NA,https://clinicalzeros.gov/ct2/show/NCT04397562,0,0,0,0,4,0,Russian Federation,0,levilimab|placebo,NA
NCT04397666,2020-05-15,2020-09-15,Interventional,RT-PCR on Conjunctival Sample for the Detection of SARS-CoV-2 in Patients With Covid-19,Recruiting,N/A,Versailles Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04397666,0,0,0,0,1,0,France,0,pcr,NA
NCT04397172,2020-04-09,2021-04-30,Observational,Intensive Care Associated Complications and Outcome of Acute Respiratory Distress Syndrome Due to COVID-19,Recruiting,NA,"University Hospital Inselspital, Berne",NA,https://clinicalzeros.gov/ct2/show/NCT04397172,0,0,0,0,1,0,Switzerland,0,study arm,NA
NCT04396106,2020-05-26,2021-03-31,Interventional,Safety and Efficacy of AT-527 in Subjects With Moderate Coronavirus Disease (COVID-19),Recruiting,Phase 2,"Atea Pharmaceuticals, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04396106,0,0,0,0,6,1,"United States|Belgium|Brazil|Moldova, Republic of|Romania|South Africa|Ukraine",0,at-527|placebo,NA
NCT04396210,2020-05-14,2020-06-18,Observational,Patients Perspectives on Discontinuation of Their Fertility Treatment Due to the COVID-19 Pandemic,Completed,NA,"University Hospital, Ghent",NA,https://clinicalzeros.gov/ct2/show/NCT04396210,0,0,0,0,3,0,Belgium,0,questionnaire,NA
NCT04396353,2020-06-04,2020-10-01,Observational,EXercise TRAining and Sedentary Lifestyle on Clinical Outcomes in Patients With COVID-19,Completed,NA,University of Sao Paulo General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04396353,0,0,0,0,5,0,Brazil,0,questionnaire,NA
NCT04395859,2020-05-27,2021-12-31,Observational,Collateral Damage From the COVID-19 Pandemic Observed in Patients Treated With Intravitreal Injections (IVT) of Anti-angiogenic Agents,Recruiting,NA,Fondation Ophtalmologique Adolphe de Rothschild,NA,https://clinicalzeros.gov/ct2/show/NCT04395859,0,0,0,0,1,0,France,0,questionnaire|data collection up to 1 year,NA
NCT04395833,2020-04-07,2020-05-11,Observational,National Survey on the Lockdown of Children With Disabilities,Completed,NA,"University Hospital, Brest",NA,https://clinicalzeros.gov/ct2/show/NCT04395833,0,0,0,0,0,0,France,0,"NA",NA
NCT04396600,2020-06-08,2022-05-25,Observational,The Professional Peer Resilience Initiative,Enrolling by invitation,NA,University of Minnesota,NA,https://clinicalzeros.gov/ct2/show/NCT04396600,0,0,0,0,2,1,United States,0,peer support,NA
NCT04395794,2020-05-07,2020-08-31,Observational [Patient Registry],SARS-CoV-2 Disguise Study,Recruiting,NA,Meshalkin Research Institute of Pathology of Circulation,NA,https://clinicalzeros.gov/ct2/show/NCT04395794,0,0,0,0,0,0,Russian Federation,0,sars-cov-2-test|questionnaire,NA
NCT04395781,2020-05-18,2022-12-31,Observational [Patient Registry],Pediatric Acute and Critical Care COVID-19 Registry of Asia,Recruiting,NA,KK Women's and Children's Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04395781,0,0,0,0,3,0,China|India|Indonesia|Japan|Malaysia|Pakistan|Singapore,0,"NA",NA
NCT04395768,2020-09-09,2021-09-30,Interventional,International ALLIANCE Study of Therapies to Prevent Progression of COVID-19,Recruiting,Phase 2,"National Institute of Integrative Medicine, Australia",NA,https://clinicalzeros.gov/ct2/show/NCT04395768,0,0,0,0,1,0,Australia,0,vitamin c|hydroxychloroquine|azithromycin|zinc citrate|vitamin d|vitamin b,NA
NCT04395755,2020-04-01,2020-05-15,Observational,Impact of COVID-19 on Psychological Status in Case of IVF Interrupted or Postponed,Completed,NA,Ospedale Policlinico San Martino,NA,https://clinicalzeros.gov/ct2/show/NCT04395755,0,0,0,0,1,0,Italy,0,generalized anxiety disorder-7 (gad-7)|questionnaire,NA
NCT04395664,2020-04-16,2020-09-01,Observational,Arrhythmias in Patients With COVID-19,Completed,NA,Herlev and Gentofte Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04395664,0,0,0,0,1,0,Denmark,0,c3/ holter monitor|c3|holter monitor,NA
NCT04395391,2020-05-18,2020-05-21,Observational,Home Usability Study of the SARS-CoV-2 (COVID-19) Test,Completed,NA,Exact Sciences Corporation,NA,https://clinicalzeros.gov/ct2/show/NCT04395391,0,0,0,0,2,1,United States,0,sars-cov-2,NA
NCT04395924,2020-05-05,2021-05-31,Observational,Maternal-foetal Transmission of SARS-Cov-2,Recruiting,NA,Centre Hospitalier RÃ©gional d'OrlÃ©ans,NA,https://clinicalzeros.gov/ct2/show/NCT04395924,0,0,0,0,3,0,France,0,"diagnosis of sars-cov2 by rt-pcr/: igg, ig m serologies in the amniotoc fluid, the blood cord/the placenta|pcr|: igg, ig m serologies in the amniotoc fluid, the blood cord|the placenta",NA
NCT04395300,2020-03-30,2020-04-30,Observational,Sleep Quality in Healthcare Personnel During COVID-19,Completed,NA,Assiut University,NA,https://clinicalzeros.gov/ct2/show/NCT04395300,0,0,0,0,1,0,Egypt,0,survey,NA
NCT04395885,2020-06-01,2020-08-31,Observational,Sexual Function During COVID 19 Pandemic,Completed,NA,Assiut University,NA,https://clinicalzeros.gov/ct2/show/NCT04395885,0,0,0,0,3,0,Egypt,0,questionnaire,NA
NCT04394793,2020-06-13,2020-08-27,Interventional,Low Dose Radiation Therapy for Covid-19 Pneumonia,"Active, not recruiting",N/A,"All India Institute of Medical Sciences, New Delhi",NA,https://clinicalzeros.gov/ct2/show/NCT04394793,0,0,0,0,4,0,India,0,low,NA
NCT04394455,2020-06-30,2020-11-30,Interventional,Brief Cognitive Behavioral Therapy Versus Crisis Intervention Therapy Through Telepsychiatry on Psychiatric Symptoms,Enrolling by invitation,N/A,Universidad Nacional Autonoma de Honduras,NA,https://clinicalzeros.gov/ct2/show/NCT04394455,0,0,0,0,2,0,Honduras,0,behavioral|crisis intervention therapy,NA
NCT04394442,2020-03-21,2020-08-31,Interventional,Hydroxychloroquine in COVID-19 Patients,Recruiting,Phase 2,Zagazig University,NA,https://clinicalzeros.gov/ct2/show/NCT04394442,0,0,0,0,0,0,Saudi Arabia,0,hydroxychloroquine,NA
NCT04394429,2020-04-24,2021-06-24,Observational,Endotracheal Tube Obstruction in Covid-19 Patients Requiring Mechanical Ventilation,Recruiting,NA,"University Hospital, Strasbourg, France",NA,https://clinicalzeros.gov/ct2/show/NCT04394429,0,0,0,0,1,0,France,0,"NA",NA
NCT04394390,2020-05-01,2020-06-15,Observational [Patient Registry],Do Vitamin D Levels Really Correlated With Disease Severity in COVID-19 Patients?,Enrolling by invitation,NA,Bursa City Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04394390,0,0,0,0,0,0,Turkey,0,vitamin d,NA
NCT04395482,2020-05-07,2021-06-15,Observational,Lung CT Scan Analysis of SARS-CoV2 Induced Lung Injury,Recruiting,NA,University of Milano Bicocca,NA,https://clinicalzeros.gov/ct2/show/NCT04395482,0,0,0,0,2,0,Italy|San Marino,0,lung ct scan analysis in covid-19 patients,NA
NCT04394117,2020-06-19,2021-06-30,Interventional,Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease,Recruiting,Phase 4,The George Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04394117,0,0,0,0,3,0,Australia|India,0,arb|placebo,NA
NCT04394104,2020-05-27,2020-05-31,Observational,COVID-19 Wellness Survey,Terminated,NA,"Rutgers, The State University of New Jersey",Study has concluded.,https://clinicalzeros.gov/ct2/show/NCT04394104,0,0,0,0,2,1,United States,0,questionnaire,NA
NCT04394078,2020-05-06,2020-05-18,Observational,Impact of COVID-19 Pandemic on Depression and Quality of Life,Completed,NA,Okan University,NA,https://clinicalzeros.gov/ct2/show/NCT04394078,0,0,0,0,3,0,Turkey,0,online survey,NA
NCT04394169,2020-05-25,2020-09-25,Interventional,Early Care Program for the Management of Post-ICU Syndrome and Chronic Pain After COVID-19 Infection.,Recruiting,N/A,Hospital Clinic of Barcelona,NA,https://clinicalzeros.gov/ct2/show/NCT04394169,0,0,0,0,1,0,Spain,0,intervention program,NA
NCT04393974,2020-03-24,2022-03-24,Observational,COVID-19 and Cancer Patients,Recruiting,NA,Imperial College London,NA,https://clinicalzeros.gov/ct2/show/NCT04393974,0,0,0,0,1,0,United Kingdom,0,"NA",NA
NCT04393961,2020-04-05,2020-07-29,Interventional,At-Home COVID-19 Antibody Test Usability Assessment & Behavior Change Study,Recruiting,N/A,ProofPilot,NA,https://clinicalzeros.gov/ct2/show/NCT04393961,0,0,0,0,0,1,United States,0,igm/igg rapid test|igg|igm antibodytest,NA
NCT04393948,2020-06-30,2020-10-31,Interventional,Lung Irradiation for COVID-19 Pneumonia,Recruiting,N/A,Brigham and Women's Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04393948,0,0,0,0,2,1,United States,0,phase 1|phase 2,NA
NCT04393636,2020-06-05,2022-12-31,Interventional,Digital Cardiac Counseling Trial: DCC Trial,Recruiting,N/A,Academisch Ziekenhuis Maastricht,NA,https://clinicalzeros.gov/ct2/show/NCT04393636,0,0,0,0,1,0,Netherlands,0,digital cardiac counseling,NA
NCT04393428,2020-03-01,2020-06-01,Observational,Urinary Biomarkers for AKI Diagnosis in Patients With SARS-CoV-2 (COVID-19),Completed,NA,"University Hospital, Montpellier",NA,https://clinicalzeros.gov/ct2/show/NCT04393428,0,0,0,0,2,0,France,0,[timp-2]*[igfbp-7],NA
NCT04393415,2020-05-25,2020-08-25,Interventional,Using PRP and Cord Blood in Treatment of Covid -19,Recruiting,N/A,Aljazeera Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04393415,0,0,0,0,2,0,Egypt,0,mesenchymal stem cells,NA
NCT04393402,2020-03-20,2020-12-31,Observational,Lung Ultrasound Score in Covid 19 Infectious Disease in Critical Care (LUS-COVID19),Recruiting,NA,Centre Hospitalier Universitaire de Nice,NA,https://clinicalzeros.gov/ct2/show/NCT04393402,0,0,0,0,0,0,France,0,lung ultrasound (lus),NA
NCT04393792,2020-05-31,2020-08-31,Interventional,SINUS WASH Pilot Study in Adults Testing Positive for COVID-19,Recruiting,Phase 1,Hampshire Hospitals NHS Foundation Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04393792,0,0,0,0,0,0,United Kingdom,0,povidone/iodine|saline,NA
NCT04393233,2020-04-23,2020-05-23,Observational,Drug Management of Rheumatoid Arthritis in Covid-19 Context : Impact on Therapeutic De-escalation,Recruiting,NA,"University Hospital, Brest",NA,https://clinicalzeros.gov/ct2/show/NCT04393233,0,0,0,0,1,0,France,0,"NA",NA
NCT04393558,2020-04-20,2022-12-31,Observational,Wearable Sensor to Monitor COVID-19 Like Signs and Symptoms,Recruiting,NA,Shirley Ryan AbilityLab,NA,https://clinicalzeros.gov/ct2/show/NCT04393558,0,0,0,0,1,1,United States,0,adam sensor,NA
NCT04393324,2020-04-24,2020-05-31,Observational [Patient Registry],The Critical Care Response to the COVID-19 Pandemic in Madrid,Recruiting,NA,"Hospital San Carlos, Madrid",NA,https://clinicalzeros.gov/ct2/show/NCT04393324,0,0,0,0,2,0,Spain,0,"NA",NA
NCT04393038,2020-05-01,2020-12-30,Interventional,ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19,Recruiting,Phase 2/Phase 3,Abivax S.A.,NA,https://clinicalzeros.gov/ct2/show/NCT04393038,0,0,0,0,2,0,Belgium|Brazil|France|Germany|Italy|Mexico|Spain|United Kingdom,0,abx464|placebo,NA
NCT04392778,2020-04-01,2020-07-31,Interventional,Clinical Use of Stem Cells for the Treatment of Covid-19,Recruiting,Phase 1/Phase 2,SBÃœ Dr. Sadi Konuk EÄŸitim ve AraÅŸtÄ±rma Hastanesi,NA,https://clinicalzeros.gov/ct2/show/NCT04392778,0,0,0,0,0,0,Turkey,0,mesenchymal stem cells|saline,NA
NCT04392414,2020-05-01,2020-07-10,Interventional,Hyperimmune Convalescent Plasma in Moderate and Severe COVID-19 Disease,Completed,Phase 2,"Federal Research Clinical Center of Federal Medical & Biological Agency, Russia",NA,https://clinicalzeros.gov/ct2/show/NCT04392414,0,0,0,0,2,0,Russian Federation,0,convalescent plasma|plasma,NA
NCT04392401,2020-05-11,2021-02-28,Observational,COVID-19 - Study of the Kinetics of the Immune Response During the Intensive Care Unit Stay in Adult Patients Infected With SARS-CoV-2: Multicentric Non Interventional Study,Recruiting,NA,Hospices Civils de Lyon,NA,https://clinicalzeros.gov/ct2/show/NCT04392401,0,0,0,0,0,0,France,0,blood sample,NA
NCT04392388,2020-05-01,2020-12-31,Observational,"Health, Perception, Practices, Relations and Social Inequalities in the General Population During the Covid-19 Crisis",Recruiting,NA,"Institut National de la SantÃ© Et de la Recherche MÃ©dicale, France",NA,https://clinicalzeros.gov/ct2/show/NCT04392388,0,0,0,0,1,0,France,0,no intervention,NA
NCT04393077,2020-05-10,2020-05-15,Interventional,Emotional Freedom Technique (EFT) Effect on Nurses,Completed,N/A,Istanbul Saglik Bilimleri University,NA,https://clinicalzeros.gov/ct2/show/NCT04393077,0,0,0,0,2,0,Turkey,0,emotional freedom technique,NA
NCT04391712,2020-04-30,2020-05-15,Interventional,Photobiomodulation Laser Therapy for COVID-19 Positive Patients With Pulmonary Disease,Completed,Phase 2,Lowell General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04391712,0,0,0,0,1,1,United States,0,mls laser|standard care,NA
NCT04392232,2020-05-05,2020-12-31,Interventional,A Study of COVID 19 Convalescent Plasma in High Risk Patients With COVID 19 Infection,Recruiting,Phase 2,TriHealth Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04392232,0,0,0,0,1,1,United States,0,convalescent plasma,NA
NCT04392219,2020-04-10,2020-08-11,Interventional,"COVID-19 First In Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of EIDD-2801 in Healthy Volunteers",Completed,Phase 1,"Ridgeback Biotherapeutics, LP",NA,https://clinicalzeros.gov/ct2/show/NCT04392219,0,0,0,0,3,0,United Kingdom,0,eidd-2801|placebo,NA
NCT04391686,2020-07-03,2021-11-02,Observational [Patient Registry],Resting Energy Expenditure of the COronaVirus (COVID19) Patient in Reanimation Context,Recruiting,NA,Centre Hospitalier Arras,NA,https://clinicalzeros.gov/ct2/show/NCT04391686,0,0,0,0,3,0,France,0,indirect calorimetry,NA
NCT04392089,2020-05-01,2021-05-01,Observational,Effects of Cardiovascular and Pulmonary Optimization on Cerebral Oxygenation in COVID-19 Patients With Severe ARDS,Recruiting,NA,Hvidovre University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04392089,0,0,0,0,0,0,Denmark,0,"masimo, lidco",NA
NCT04391946,2020-03-14,2022-05-01,Observational [Patient Registry],Observatory of Patients With Chronic Lymphocytic Leukemia / Lymphocytic Lymphoma or Waldenstrom Disease Infected With COVID-19,Recruiting,NA,French Innovative Leukemia Organisation,NA,https://clinicalzeros.gov/ct2/show/NCT04391946,0,0,0,0,1,0,France,0,data registry,NA
NCT04391881,2020-05-30,2020-08-30,Observational,Oral Manifestation of COVID 19 Patient: A Cross Sectional Study on Egyptian Population,Recruiting,NA,Cairo University,NA,https://clinicalzeros.gov/ct2/show/NCT04391881,0,0,0,0,2,0,Egypt,0,"NA",NA
NCT04391829,2020-08-31,2021-08-31,Interventional,Detection of SARS-CoV-2 in Semen of COVID-19 Positive Males,Recruiting,N/A,Universitair Ziekenhuis Brussel,NA,https://clinicalzeros.gov/ct2/show/NCT04391829,0,0,0,0,1,0,Belgium,0,ejaculated semen sample,NA
NCT04391127,2020-05-04,2020-11-06,Interventional,Hydroxychloroquine and Ivermectin for the Treatment of COVID-19 Infection,Completed,Phase 3,Centenario Hospital Miguel Hidalgo,NA,https://clinicalzeros.gov/ct2/show/NCT04391127,0,0,0,0,4,0,Mexico,0,hydroxychloroquine|ivermectin|placebo,NA
NCT04390178,2020-04-10,2020-06-30,Interventional,Convalescent Plasma as Treatment for Acute Coronavirus Disease (COVID-19),"Active, not recruiting",Phase 1/Phase 2,Karolinska University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04390178,0,0,0,0,0,0,Sweden,0,convalescent plasma,NA
NCT04390594,2020-08-13,2021-02-12,Interventional,Efficacy and Safety Evaluation of Treatment Regimens in Adult COVID-19 Patients in Senegal,Recruiting,Phase 3,Institut Pasteur de Dakar,NA,https://clinicalzeros.gov/ct2/show/NCT04390594,0,0,0,0,4,0,Senegal,0,nafamostat mesilate,NA
NCT04390555,2020-04-30,2020-12-31,Observational [Patient Registry],The Global PCHF-COVICAV Registry,Recruiting,NA,University of Zurich,NA,https://clinicalzeros.gov/ct2/show/NCT04390555,0,0,0,0,0,0,Switzerland,0,"NA",NA
NCT04390516,2020-03-24,2020-05-04,Interventional,Respiratory Decompensation and Model for the Triage of COVID-19 Patients,Completed,N/A,Dascena,NA,https://clinicalzeros.gov/ct2/show/NCT04390516,0,0,0,0,3,1,United States,0,coviage,NA
NCT04390477,2020-05-04,2021-07-31,Interventional,Study to Evaluate the Effect of a Probiotic in COVID-19,Recruiting,N/A,Bioithas SL,NA,https://clinicalzeros.gov/ct2/show/NCT04390477,0,0,0,0,1,0,Spain,0,probiotic,NA
NCT04390412,2020-05-04,2020-08-30,Interventional,Low Dose Radiotherapy in COVID-19 Pneumonia,"Active, not recruiting",Phase 1/Phase 2,Shahid Beheshti University of Medical Sciences,NA,https://clinicalzeros.gov/ct2/show/NCT04390412,0,0,0,0,2,0,"Iran, Islamic Republic of",0,radiotherapy,NA
NCT04390074,2020-05-27,2020-06-04,Observational,COVID-19 in the Swedish ICU-cohort: Risk Factors of Critical Care Admission and Intensive Care Mortality,Completed,NA,Uppsala University,NA,https://clinicalzeros.gov/ct2/show/NCT04390074,0,0,0,0,2,0,Sweden,0,covid-19/intensive care|covid-19|intensive care,NA
NCT04389996,2020-05-14,2020-07-21,Observational [Patient Registry],COVID-19 Pandemic Impact on Patients With Cancer - a Danish Survey,"Active, not recruiting",NA,Odense University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04389996,0,0,0,0,3,0,Denmark,0,no intervention,NA
NCT04389944,2020-03-31,2020-06-30,Interventional,Amotosalen-Ultraviolet A Pathogen-Inactivated Convalescent Plasma in Addition to Best Supportive Care and Antiviral Therapy on Clinical Deterioration in Adults Presenting With Moderate to Severe COVID-19,Completed,N/A,"University Hospital, Basel, Switzerland",NA,https://clinicalzeros.gov/ct2/show/NCT04389944,0,0,0,0,2,0,Switzerland,0,convalescent plasma,NA
NCT04390152,2020-01-13,2021-12-31,Interventional,Safety and Efficacy of Intravenous Wharton's Jelly Derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Due to COVID 19,Recruiting,Phase 1/Phase 2,BioXcellerator,NA,https://clinicalzeros.gov/ct2/show/NCT04390152,0,0,0,0,3,0,Colombia,0,"wharton's jelly derived mesenchymal stem cells.|hydroxychloroquine, lopinavir/ritonavir/azithromycin/placebo (standard therapy)|hydroxychloroquine, lopinavir|ritonavir|azithromycin|placebo (standard therapy)",NA
NCT04390126,2020-04-20,2021-05-07,Observational,COVID-19 Related Lockdown Effects On Chronic Diseases,"Active, not recruiting",NA,Centre Hospitalier Universitaire Dijon,NA,https://clinicalzeros.gov/ct2/show/NCT04390126,0,0,0,0,3,0,France,0,questionnaire,NA
NCT04389515,2020-05-14,2020-09-25,Observational,"Postoperative Recovery Index, Patient Expectations and Satisfaction With Prenatal Care Instrument in Pregnant Patients With COVID-19",Recruiting,NA,Kanuni Sultan Suleyman Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04389515,0,0,0,0,3,0,Turkey,0,"NA",NA
NCT04389710,2020-04-15,2021-04-14,Interventional,Convalescent Plasma for the Treatment of COVID-19,Recruiting,Phase 2,Thomas Jefferson University,NA,https://clinicalzeros.gov/ct2/show/NCT04389710,0,0,0,0,1,1,United States,0,convalescent plasma,NA
NCT04389684,2020-05-27,2021-07-27,Observational,Clinical and Psycho-social Impact of COVID-19 Related Confinement on Patients With Digestive Tumors,Recruiting,NA,Poitiers University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04389684,0,0,0,0,1,0,France,0,questionnaire,NA
NCT04389658,2020-05-07,2020-06-10,Observational,Contagiousness and Immunogenicity Status of COVID-19 in Asymptomatic Population (COVID-19 CONDITION),Completed,NA,Igenomix,NA,https://clinicalzeros.gov/ct2/show/NCT04389658,0,0,0,0,2,0,Spain,0,"NA",NA
NCT04389489,2020-05-14,2020-09-25,Observational,Postpartum Sexual Function in Pregnant Women With COVID-19,Recruiting,NA,Kanuni Sultan Suleyman Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04389489,0,0,0,0,3,0,Turkey,0,"NA",NA
NCT04389567,2020-05-12,2020-05-25,Observational,Famotidine Outpatient COVID-19 Treatment Study,Completed,NA,Northwell Health,NA,https://clinicalzeros.gov/ct2/show/NCT04389567,0,0,0,0,1,1,United States,0,famotidine,NA
NCT04389554,2020-05-14,2020-05-28,Observational [Patient Registry],D-dimer Levels in Pregnant With COVID-19,Completed,NA,Kanuni Sultan Suleyman Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04389554,0,0,0,0,2,0,Turkey,0,blood d-dimer assay,NA
NCT04389463,2020-05-11,2022-05-11,Observational,Patient Outcome of Cardiac Surgery During the COVID-19 Pandemic,Recruiting,NA,Nantes University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04389463,0,0,0,0,2,0,France,0,no intervention,NA
NCT04389450,2020-10-01,2021-05-31,Interventional,"Double-Blind, Multicenter, Study to Evaluate the Efficacy of PLX PAD for the Treatment of COVID-19",Recruiting,Phase 2,Pluristem Ltd.,NA,https://clinicalzeros.gov/ct2/show/NCT04389450,0,0,0,0,8,1,United States,0,plx-pad|placebo,NA
NCT04389333,2020-03-26,2020-04-26,Interventional,Feasibility of Non-contact Magnetically-controlled Capsule Endoscopy During COVID-19 Pandemic,Completed,N/A,Changhai Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04389333,0,0,0,0,1,0,China,0,endoscopy,NA
NCT04389320,2020-03-15,2020-05-01,Observational,Antimalarial and Covid 19 in Rheumatoid Arthritis,Completed,NA,Assiut University,NA,https://clinicalzeros.gov/ct2/show/NCT04389320,0,0,0,0,0,0,Egypt,0,hydroxychloroquine,NA
NCT04389385,2020-05-01,2020-09-30,Interventional,COVID-19 Specific T Cell Derived Exosomes (CSTC-Exo),"Active, not recruiting",Phase 1,TC Erciyes University,NA,https://clinicalzeros.gov/ct2/show/NCT04389385,0,0,0,0,0,0,Turkey,0,t cell derived exosom,NA
NCT04389372,2020-03-15,2021-03-31,Interventional,"Effectiveness and Acceptability of MINDFULNESS by Smartphone, for Patients With Chronic Migraine and Medication Overuse",Recruiting,N/A,Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta,NA,https://clinicalzeros.gov/ct2/show/NCT04389372,0,0,0,0,1,0,Italy,0,mindfulness,NA
NCT04387409,2020-05-25,2021-05-01,Interventional,Study to Assess VPM1002 in Reducing Healthcare Professionals' Absenteeism in COVID-19 Pandemic,"Active, not recruiting",Phase 3,Vakzine Projekt Management GmbH,NA,https://clinicalzeros.gov/ct2/show/NCT04387409,0,0,0,0,3,0,Germany,0,vpm1002|placebo,NA
NCT04388657,2020-05-01,2020-09-01,Observational,"COVID-19, bLOod Coagulation and Thrombosis",Recruiting,NA,Ramsay GÃ©nÃ©rale de SantÃ©,NA,https://clinicalzeros.gov/ct2/show/NCT04388657,0,0,0,0,0,0,France,0,echo-doppler,NA
NCT04388644,2020-02-20,2020-05-20,Observational,Survey of Satisfaction on Traditional Chinese Medicine Jing-Guan-Fang (JGF) for COVID-19 Prevention,Recruiting,NA,Taipei City Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04388644,0,0,0,0,0,0,Taiwan,0,"NA",NA
NCT04388631,2020-05-10,2021-05-01,Observational [Patient Registry],Detection Rate of SARS-CoV-2 in Male Genitourinary System and Its Impact on Male Reproductive Health.,Recruiting,NA,Tongji Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04388631,0,0,0,0,1,0,China,0,coronavirus disease 2019,NA
NCT04388605,2020-04-21,2021-09-30,Observational [Patient Registry],Assessing the Safety of Pregnancy In the CoRonavirus (COVID-19) pandEmic,Recruiting,NA,"University of California, San Francisco",NA,https://clinicalzeros.gov/ct2/show/NCT04388605,0,0,0,0,1,1,United States,0,"NA",NA
NCT04388579,2020-03-20,2020-03-27,Observational,Screening Patients for a Strategic Shift to Pulmonary Telerehabilitation Because of COVID-19,Completed,NA,University of Lisbon,NA,https://clinicalzeros.gov/ct2/show/NCT04388579,0,0,0,0,0,0,Portugal,0,pulmonary rehabilitation,NA
NCT04387968,2020-08-24,2021-03-24,Observational,"Epidemiological Study of the Covid-19 Presto Test - The ""COVIDOR"" Study",Recruiting,NA,OrlÃ©ans MÃ©tropole Service de MÃ©decine PrÃ©ventive,NA,https://clinicalzeros.gov/ct2/show/NCT04387968,0,0,0,0,2,0,France,0,covid-19 presto test,NA
NCT04387955,2020-04-30,2021-05-31,Interventional,Analysis of Chilblains pROfile During coVID-19 Epidemic (ACROVID),Recruiting,N/A,Poitiers University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04387955,0,0,0,0,1,0,France,0,biological samples,NA
NCT04387643,2020-03-01,2020-04-02,Observational,Protecting Health Care Workers During the COVID-19 Outbreak,Completed,NA,Aarogyam UK,NA,https://clinicalzeros.gov/ct2/show/NCT04387643,0,0,0,0,0,0,India,0,ayurvedic kadha,NA
NCT04388514,2020-04-08,2020-10-08,Interventional,Blood Ozonization in Patients With SARS-CoV-2 Respiratory Failure,Recruiting,N/A,Azienda Sanitaria-Universitaria Integrata di Udine,NA,https://clinicalzeros.gov/ct2/show/NCT04388514,0,0,0,0,0,0,Italy,0,ozone,NA
NCT04388436,2020-05-11,2021-07-10,Observational [Patient Registry],Post Covid-19 Cardiopulmonary and Immunological Changes,"Active, not recruiting",NA,Mansoura University,NA,https://clinicalzeros.gov/ct2/show/NCT04388436,0,0,0,0,1,0,Egypt,0,"NA",NA
NCT04388410,2020-08-25,2020-11-30,Interventional,Safety and Efficacy of Convalescent Plasma Transfusion for Patients With COVID-19,Recruiting,Phase 2/Phase 3,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,NA,https://clinicalzeros.gov/ct2/show/NCT04388410,0,0,0,0,2,0,Mexico,0,convalescent plasma,NA
NCT04387799,2020-05-13,2020-06-12,Observational,Determinants of COVID-19 Pneumonia (MC-19),Completed,NA,Catholic University of the Sacred Heart,NA,https://clinicalzeros.gov/ct2/show/NCT04387799,0,0,0,0,2,0,Italy,0,serology test,NA
NCT04387786,2020-03-31,2020-04-24,Observational,Dornase Alfa Administered to Patients With COVID-19 (DACOVID),Completed,NA,Northwell Health,NA,https://clinicalzeros.gov/ct2/show/NCT04387786,0,0,0,0,1,1,United States,0,dornase alfa,NA
NCT04387279,2020-04-24,2021-03-30,Observational,The Impact of COVID-19 on the Health Care Utilization of Inflammatory Bowel Disease,Recruiting,NA,Keimyung University Dongsan Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04387279,0,0,0,0,0,0,"Korea, Republic of",0,interview,NA
NCT04387253,2020-05-23,2021-07-23,Interventional,Study of Late Fetal Loss in Poitou-Charentes. GYNE-COVID,Recruiting,N/A,Poitiers University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04387253,0,0,0,0,3,0,France,0,pcr,NA
NCT04387214,2020-04-13,2020-08-10,Observational,COVID-19 Pandemic and Academic Performance of Veterinary Students,Completed,NA,South Valley University,NA,https://clinicalzeros.gov/ct2/show/NCT04387214,0,0,0,0,5,0,Egypt,0,questionnaire,NA
NCT04387292,2020-09-07,2021-05-31,Interventional,Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic,Recruiting,N/A,Fondation Ophtalmologique Adolphe de Rothschild,NA,https://clinicalzeros.gov/ct2/show/NCT04387292,0,0,0,0,2,0,France,0,ophthalmologic exam,NA
NCT04386850,2020-04-14,2020-11-15,Interventional,Oral 25-hydroxyvitamin D3 and COVID-19,Recruiting,Phase 2/Phase 3,Tehran University of Medical Sciences,NA,https://clinicalzeros.gov/ct2/show/NCT04386850,0,0,0,0,1,0,"Iran, Islamic Republic of",0,hydroxyvitamin,NA
NCT04386668,2020-05-26,2020-07-12,Interventional,Let It Out (LIO) and COVID19: Testing an Online Emotional Disclosure-based Intervention During the COVID19 Pandemic,Terminated,N/A,"University College, London",Interim analysis indicated adaptations to intervention may be required.,https://clinicalzeros.gov/ct2/show/NCT04386668,0,0,0,0,4,0,United Kingdom,0,let it out (lio)-c|neutral writing control,NA
NCT04386551,2020-05-06,2020-08-05,Observational,Detection of COVID-19 in Saliva Collection,Completed,NA,"Centre Hospitalier Universitaire, Amiens",NA,https://clinicalzeros.gov/ct2/show/NCT04386551,0,0,0,0,3,0,France,0,"NA",NA
NCT04386798,2020-07-25,2020-12-22,Interventional,Stress and Anxiety Levels of Mothers Lying in the Baby Newborn Intensive Care Unit,Recruiting,N/A,Eskisehir Osmangazi University,NA,https://clinicalzeros.gov/ct2/show/NCT04386798,0,0,0,0,2,0,Turkey,0,survey,NA
NCT04386720,2020-05-25,2021-05-25,Observational,Measurement of Airway Opening Pressure (AOP) in Patients With Acute Respiratory Distress Syndrom and With or Without Covid 19.,Recruiting,NA,"University Hospital, Bordeaux",NA,https://clinicalzeros.gov/ct2/show/NCT04386720,0,0,0,0,3,0,France,0,"NA",NA
NCT04386512,2020-05-15,2020-06-01,Observational,Clinical Epidemiology and Characteristics Of Covid-19 Cases Occurred In A Lymphoma Setting In The First Epidemic Phase (LymphoCov1),Completed,NA,Versailles Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04386512,0,0,0,0,1,0,France,0,"NA",NA
NCT04386694,2020-05-18,2020-09-17,Interventional,Photobiomodulation Therapy Combined With Static Magnetic Field in Patients With COVID-19,Completed,N/A,University of Nove de Julho,NA,https://clinicalzeros.gov/ct2/show/NCT04386694,0,0,0,0,6,0,Brazil,0,pbmt/smf|placebo|pbmt|smf,NA
NCT04386460,2020-05-11,2020-06-05,Observational,Covid-19 and Prevention of Malnutrition After Confinement by Dentists,Recruiting,NA,Centre Hospitalier Universitaire de Nice,NA,https://clinicalzeros.gov/ct2/show/NCT04386460,0,0,0,0,0,0,France,0,"NA",NA
NCT04386291,2020-05-25,2021-05-19,Interventional,Meditation and Kundalini Yoga for Heightened Anxiety Related to COVID-19,Recruiting,N/A,"Research Foundation for Mental Hygiene, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04386291,0,0,0,0,4,1,United States,0,anxiety reduction training|kundalini yoga/anxiety reduction training|meditation/anxiety reduction training|kundalini yoga|meditation,NA
NCT04386265,2020-04-15,2022-05-11,Observational [Patient Registry],Compassionate Use of Hyperbaric Oxygen Therapy,Enrolling by invitation,NA,"SerenaGroup, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04386265,0,0,0,0,2,1,United States|Poland,0,"NA",NA
NCT04386239,2021-01-31,2021-01-31,Interventional,Study on the Use of Sarilumab in Patients With COVID-19 Infection,Recruiting,Early Phase 1,ASST Fatebenefratelli Sacco,NA,https://clinicalzeros.gov/ct2/show/NCT04386239,0,0,0,0,1,0,Italy,0,sarilumab prefilled syringe,NA
NCT04386369,2020-04-15,2020-06-01,Observational,Evaluation of Airway Pressure Release Ventilation in COVID-19 ARDS,Completed,NA,"Central Hospital, Nancy, France",NA,https://clinicalzeros.gov/ct2/show/NCT04386369,0,0,0,0,2,0,France,0,airway pressure release ventilation,NA
NCT04385836,2020-06-01,2020-09-01,Interventional,Trial of Alpha One Antitrypsin Inhalation in Treating Patient With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2),Recruiting,Early Phase 1,"Ministry of Health, Saudi Arabia",NA,https://clinicalzeros.gov/ct2/show/NCT04385836,0,0,0,0,0,0,Saudi Arabia,0,alpha one antitrypsin,NA
NCT04385823,2020-03-01,2020-05-04,Observational,Use of High Flow Nasal Cannula Oxygen and Covid-19 Acute Hypoxemic Respiratory Failure,Completed,NA,HÃ´pital Louis Mourier,NA,https://clinicalzeros.gov/ct2/show/NCT04385823,0,0,0,0,0,0,France,0,nasal high flow,NA
NCT04385810,2020-04-27,2020-07-29,Interventional,Description of Ophthalmologic Injuries in Intensive Care During the SARS-CoV2 Epidemic - COVID19,Completed,N/A,Fondation Ophtalmologique Adolphe de Rothschild,NA,https://clinicalzeros.gov/ct2/show/NCT04385810,0,0,0,0,1,0,France,0,ophthalmologic exam,NA
NCT04386109,2020-04-01,2021-03-31,Observational,Neonatal Complications of Coronavirus Disease (COVID-19),Recruiting,NA,University of Oxford,NA,https://clinicalzeros.gov/ct2/show/NCT04386109,0,0,0,0,0,0,United Kingdom,0,no intervention,NA
NCT04385251,2020-06-18,2021-06-30,Observational,International SARS-CoV-2 (COVID-19) Infection Observational Study,Recruiting,NA,University of Minnesota,NA,https://clinicalzeros.gov/ct2/show/NCT04385251,0,0,0,0,3,1,United States|Argentina|Denmark|United Kingdom,0,data collection,NA
NCT04385238,2020-05-15,2020-06-20,Observational,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Completed,NA,Pregistry,NA,https://clinicalzeros.gov/ct2/show/NCT04385238,0,0,0,0,5,1,United States,1,survey,NA
NCT04385212,2020-03-13,2020-04-14,Observational,Outcomes in Hospitalized Older Patients With COVID-19,Completed,NA,"University Hospital, Geneva",NA,https://clinicalzeros.gov/ct2/show/NCT04385212,0,0,0,0,0,0,Switzerland,0,"NA",NA
NCT04385199,2020-05-04,2020-08-01,Interventional,Convalescent Plasma for Patients With COVID-19,Recruiting,Phase 2,Henry Ford Health System,NA,https://clinicalzeros.gov/ct2/show/NCT04385199,0,0,0,0,0,1,United States,0,convalescent plasma,NA
NCT04385147,2020-05-18,2020-07-01,Observational,Advanced Endoscopy During COVID-19,Completed,NA,Al-Azhar University,NA,https://clinicalzeros.gov/ct2/show/NCT04385147,0,0,0,0,3,1,United States|Egypt|Germany|Peru|Singapore,0,endoscopic management according to standard of care,NA
NCT04385108,2020-03-04,2021-12-31,Interventional,Predictive Immune Biomarkers for COVID-19 Pathogenesis,Recruiting,N/A,"University Hospital, Toulouse",NA,https://clinicalzeros.gov/ct2/show/NCT04385108,0,0,0,0,2,0,France,0,blood sample|blood collection on their first consultation/10 to 14 days later|longitudinally|10 to 14 days later,NA
NCT04385069,2020-04-16,2020-07-05,Observational,COVID-19 Hyperinflammation Syndrome (COV-HI): Protocol for a Rapidly Executed Cohort Study,Recruiting,NA,"University College, London",NA,https://clinicalzeros.gov/ct2/show/NCT04385069,0,0,0,0,0,0,United Kingdom,0,"NA",NA
NCT04385004,2020-04-27,2020-07-31,Observational,"Clinical, Biological and Histological Pulmonary and Renal Damage Associated With the SARS-CoV-2 Syndrome in Patients Admitted in ICU",Recruiting,NA,"University Hospital, Strasbourg, France",NA,https://clinicalzeros.gov/ct2/show/NCT04385004,0,0,0,0,1,0,France,0,"NA",NA
NCT04384900,2020-05-11,2020-11-30,Interventional,Accelerated Prone Position Ventilation of Patients With COVID-19,Recruiting,N/A,Nordsjaellands Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04384900,0,0,0,0,1,0,Denmark,0,prone positioning,NA
NCT04384887,2020-04-25,2020-08-25,Observational,"""Investigation of the Relationship Between New Coronary Virus Disease (COVID-19) and Anxiety and Depressive Symptoms in Pregnant Women""",Completed,NA,Kanuni Sultan Suleyman Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04384887,0,0,0,0,1,0,Turkey,0,covid-19 positive pregnant women,NA
NCT04384419,2020-05-29,2021-05-30,Observational,"Death Number Perception in Depression, Anxiety, and Schizoypal Personnality in General Population (Covid-19 Pandemic)",Recruiting,NA,"University Hospital, Montpellier",NA,https://clinicalzeros.gov/ct2/show/NCT04384419,0,0,0,0,1,0,France,0,"NA",NA
NCT04384588,2020-04-07,2021-04-06,Interventional,COVID19-Convalescent Plasma for Treating Patients With Active Symptomatic COVID 19 Infection (FALP-COVID),Recruiting,Phase 2/Phase 3,Fundacion Arturo Lopez Perez,NA,https://clinicalzeros.gov/ct2/show/NCT04384588,0,0,0,0,0,0,Chile,0,convalescent plasma,NA
NCT04384549,2020-05-20,2021-02-20,Interventional,Efficacy of BCG Vaccination in the Prevention of COVID19 Via the Strengthening of Innate Immunity in Health Care Workers,Recruiting,Phase 3,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04384549,0,0,0,1,1,0,France,0,bcg|placebo,NA
NCT04384497,2020-05-07,2020-06-30,Interventional,Convalescent Plasma for Treatment of COVID-19: An Exploratory Dose Identifying Study,Recruiting,Phase 1/Phase 2,Karolinska University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04384497,0,0,0,0,1,0,Sweden,0,convalescent plasma,NA
NCT04384458,2020-07-20,2020-09-10,Interventional,Comparative Study of Hydroxychloroquine and Ivermectin in COVID-19 Prophylaxis,Recruiting,N/A,Nucleo De Pesquisa E Desenvolvimento De Medicamentos Da Universidade Federal Do Ceara,NA,https://clinicalzeros.gov/ct2/show/NCT04384458,0,0,0,0,3,0,Brazil,0,hydroxychloroquine|ivermectin,NA
NCT04384406,2020-04-01,2020-05-01,Observational,COVID-19 Outbreak Consequences for Outpatients Followed in PRM,Completed,NA,"University Hospital, Montpellier",NA,https://clinicalzeros.gov/ct2/show/NCT04384406,0,0,0,0,1,0,France,0,"NA",NA
NCT04384705,2020-06-17,2021-06-30,Observational,HDL Target of CoViD19 ? Analysis on the Caregivers of the Reunion University Hospital,Recruiting,NA,Centre Hospitalier Universitaire de la RÃ©union,NA,https://clinicalzeros.gov/ct2/show/NCT04384705,0,0,0,0,1,0,France,0,research specific blood sample,NA
NCT04384250,2020-05-10,2020-08-31,Observational,Genetic Basis of COVID-19 Infection,Recruiting,NA,Mansoura University,NA,https://clinicalzeros.gov/ct2/show/NCT04384250,0,0,0,0,0,0,Egypt,0,whole exome sequencing,NA
NCT04384055,2020-03-21,2021-12-31,Observational,Predicting Outcomes for Covid-19 Using Sonography,Enrolling by invitation,NA,Stanford University,NA,https://clinicalzeros.gov/ct2/show/NCT04384055,0,0,0,0,4,1,United States,0,lung ultrasound,NA
NCT04384029,2020-03-24,2021-03-31,Observational,The Geneva Covid-19 CVD Study,"Active, not recruiting",NA,"University Hospital, Geneva",NA,https://clinicalzeros.gov/ct2/show/NCT04384029,0,0,0,0,0,0,Switzerland,0,covid-19 / patients|covid-19|patients,NA
NCT04383886,2020-04-18,2020-08-18,Observational,Evaluation of Emergency Department (ED) Staff Stress Level During COVID-19 Pandemic,Recruiting,NA,Hospices Civils de Lyon,NA,https://clinicalzeros.gov/ct2/show/NCT04383886,0,0,0,0,0,0,France,0,stress/anxiety questionnaire|stress|anxiety questionnaire,NA
NCT04383626,2020-03-02,2020-04-05,Observational,Fear Among Dentists During COVID-19 Pandemic,Completed,NA,Cairo University,NA,https://clinicalzeros.gov/ct2/show/NCT04383626,0,0,0,0,0,0,Egypt,0,"NA",NA
NCT04383470,2020-04-26,2021-12-31,Observational,Collaborative Outcomes Study on Health and Functioning During Infection Times During COVID-19 Pandemic,Recruiting,NA,University of Padova,NA,https://clinicalzeros.gov/ct2/show/NCT04383470,0,0,0,0,1,0,Greece,0,"NA",NA
NCT04383457,2020-06-15,2020-10-08,Observational [Patient Registry],Covid-19 Triage Using Camera-based AI,Completed,NA,Vastra Gotaland Region,NA,https://clinicalzeros.gov/ct2/show/NCT04383457,0,0,0,0,2,0,Sweden,0,ria-device (remote investigation/assessment)|ria-device (remote investigation|assessment),NA
NCT04383652,2020-05-06,2021-06-30,Observational,Collection of Coronavirus COVID-19 Outbreak Samples in New South Wales,Recruiting,NA,Kirby Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04383652,0,0,0,0,0,0,Australia,0,biological sample/clinical data collection|biological samples|clinical data collection,NA
NCT04382924,2020-08-05,2022-01-31,Interventional,Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patient With Confirmed COVID-19 Disease,"Active, not recruiting",Phase 2/Phase 3,Algernon Pharmaceuticals,NA,https://clinicalzeros.gov/ct2/show/NCT04382924,0,0,0,0,4,1,United States|Australia|Philippines|Romania,0,np-120 (ifenprodil),NA
NCT04382794,2020-05-14,2020-06-15,Observational,Sitagliptin Treatment in Diabetic COVID-19 Positive Patients,Completed,NA,University of Milan,NA,https://clinicalzeros.gov/ct2/show/NCT04382794,0,0,0,0,4,0,Italy,0,retrospective case-control analysis,NA
NCT04382781,2020-05-31,2020-05-31,Observational,Immunosupressive Treatment in COVID-19 Patients,Recruiting,NA,Spanish Network for Research in Infectious Diseases,NA,https://clinicalzeros.gov/ct2/show/NCT04382781,0,0,0,0,2,0,Spain,0,no-immunosuppressive|immunosuppressive|immunoglubulins,NA
NCT04382729,2020-04-17,2020-07-31,Interventional,Neuromuscular Electrical Stimulation in Patients With COVID19 Associated Pneumonia,Recruiting,N/A,"University of Turin, Italy",NA,https://clinicalzeros.gov/ct2/show/NCT04382729,0,0,0,0,0,0,Italy,0,neuromuscular electrical stimulation|exercise,NA
NCT04382534,2020-03-10,2020-09-30,Observational,A Cross-sectional and Cohort Study of COVID-19 Patients With Post - Discharge Dysfunction,Recruiting,NA,Peking University Third Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04382534,0,0,0,0,0,0,China,0,respiratory rehabilitation,NA
NCT04382846,2020-05-08,2030-12-01,Interventional,Novel Regimens in COVID-19 Treatment,Recruiting,Phase 3,Tanta University,NA,https://clinicalzeros.gov/ct2/show/NCT04382846,0,0,0,0,1,0,Egypt,0,nitazoxanide,NA
NCT04382469,2020-02-01,2020-04-30,Observational,Egyptian Initial Experience About 2019 Novel Corona Virus: Study of 48 Patients in Alexandria-Egypt Using Chest CT,Completed,NA,Alexandria University,NA,https://clinicalzeros.gov/ct2/show/NCT04382469,0,0,0,0,1,0,Egypt,0,"NA",NA
NCT04382196,2020-04-17,2022-12-31,Observational,Impact of COVID-19 on Mental Health of Health Care Workers,"Active, not recruiting",NA,"University Hospital, Ghent",NA,https://clinicalzeros.gov/ct2/show/NCT04382196,0,0,0,0,0,0,Belgium,0,online survey,NA
NCT04382547,2020-05-11,2021-06-30,Interventional,Treatment of Covid-19 Associated Pneumonia With Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells,Enrolling by invitation,Phase 1/Phase 2,Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus,NA,https://clinicalzeros.gov/ct2/show/NCT04382547,0,0,0,0,1,0,Belarus,0,mesenchymal stem cells|standard care,NA
NCT04382131,2020-06-23,2020-10-31,Interventional,Hypertonic Saline Nasal Irrigation and Gargling in Suspected or Confirmed COVID-19 (ELVIS COVID-19),Recruiting,N/A,University of Edinburgh,NA,https://clinicalzeros.gov/ct2/show/NCT04382131,0,0,0,0,2,0,United Kingdom,0,saline,NA
NCT04381884,2020-05-18,2020-09-29,Interventional,Ivermectin Effect on SARS-CoV-2 Replication in Patients With COVID-19,Completed,Phase 2,Laboratorio Elea Phoenix S.A.,NA,https://clinicalzeros.gov/ct2/show/NCT04381884,0,0,0,0,7,0,Argentina,0,ivermectin (iver pâ®) arm will receive ivm 600 âµg / kg once daily/standard care. control arm will receive standard care.|ivermectin (iver pâ®) arm will receive ivm 600 âµg|kg once daily|standard care,NA
NCT04381858,2020-05-06,2020-11-26,Interventional,Convalescent Plasma vs Human Immunoglobulin to Treat COVID-19 Pneumonia,Completed,Phase 3,Centenario Hospital Miguel Hidalgo,NA,https://clinicalzeros.gov/ct2/show/NCT04381858,0,0,0,0,2,0,Mexico,0,convalescent plasma|immunoglobulin,NA
NCT04381819,2020-03-02,2022-02-28,Observational,"Norwegian SARS-CoV-2 Study - Virological, Clinical and Immunological Characterisation of COVID-19",Recruiting,NA,Oslo University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04381819,0,0,0,0,0,0,Norway,0,pcr,NA
NCT04382092,2020-03-23,2020-04-24,Interventional,Co-infection Management in COVID-19 Critically Ill,Completed,N/A,Cliniques universitaires Saint-Luc- UniversitÃ© Catholique de Louvain,NA,https://clinicalzeros.gov/ct2/show/NCT04382092,0,0,0,0,0,0,Belgium,0,filmarray pneumonia,NA
NCT04382066,2020-05-12,2020-12-23,Interventional,Proof of Concept Study to Evaluate the Safety Profile of Plitidepsin in Patients With COVID-19,Completed,Phase 1,PharmaMar,NA,https://clinicalzeros.gov/ct2/show/NCT04382066,0,0,0,0,10,0,Spain,0,plitidepsin|day,NA
NCT04381351,2020-04-16,2021-03-01,Observational,Noncoding RNAs in COVID-19 and COVID-19 Related Kidney Dysfunction,Recruiting,NA,"Heinrich-Heine University, Duesseldorf",NA,https://clinicalzeros.gov/ct2/show/NCT04381351,0,0,0,0,1,0,Germany,0,"NA",NA
NCT04381312,2020-04-09,2021-07-09,Observational,Direct and Indirect Impact of COVID-19 In Older Populations,Recruiting,NA,"University Hospital, Grenoble",NA,https://clinicalzeros.gov/ct2/show/NCT04381312,0,0,0,0,0,0,France,0,"NA",NA
NCT04381286,2019-04-01,2021-04-01,Observational,Transpulmonary Driving Pressure in ARDS COVID19 Patients,Recruiting,NA,"University Hospital, Montpellier",NA,https://clinicalzeros.gov/ct2/show/NCT04381286,0,0,0,0,1,0,France,0,"NA",NA
NCT04381000,2020-04-01,2020-05-29,Interventional,Quarantine and Telerehabilitation in Chronic Pain Patients During COVID-19 Pandemic.,Completed,N/A,Clinical Exercise Physiology and Rehabilitation Reasearch Laboratory,NA,https://clinicalzeros.gov/ct2/show/NCT04381000,0,0,0,0,2,0,Greece,0,exercise,NA
NCT04380935,2020-05-18,2020-10-31,Interventional,Effectiveness and Safety of Convalescent Plasma Therapy on COVID-19 Patients With Acute Respiratory Distress Syndrome,Recruiting,Phase 2/Phase 3,Indonesia University,NA,https://clinicalzeros.gov/ct2/show/NCT04380935,0,0,0,0,1,0,Indonesia,0,convalescent plasma|standard care,NA
NCT04380896,2020-04-27,2026-07-27,Observational,COVID-19 Staff Testing of Antibody Responses Study (Co-Stars),Recruiting,NA,Great Ormond Street Hospital for Children NHS Foundation Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04380896,0,0,0,0,1,0,United Kingdom,0,blood test|standard care,NA
NCT04380792,2020-04-13,2020-10-13,Observational,Prevalence of DVT or PE in Patients Infected With COVID-19 Admitted to Hospital,Completed,NA,Foundation for the study of VTE diseases. (FUENTE),NA,https://clinicalzeros.gov/ct2/show/NCT04380792,0,0,0,0,1,0,Spain,0,"NA",NA
NCT04380779,2020-04-13,2020-10-13,Observational,Prevalence of Severe Bleeding in COVID-19 Patients Treated With Higher Than Recommended Thromboprophylaxis Doses,Completed,NA,Foundation for the study of VTE diseases. (FUENTE),NA,https://clinicalzeros.gov/ct2/show/NCT04380779,0,0,0,0,1,0,Spain,0,"NA",NA
NCT04380766,2019-01-01,2020-07-31,Observational [Patient Registry],Covid-19 Pandemic and Pancreatic Surgery in Italy,Completed,NA,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,NA,https://clinicalzeros.gov/ct2/show/NCT04380766,0,0,0,0,3,0,Italy,0,evaluation of changes in the diagnostic-therapeutic pathway,NA
NCT04380727,2020-03-20,2020-04-14,Observational [Patient Registry],Almitrine and COVID-19 Related Hypoxemia,Completed,NA,"Central Hospital, Nancy, France",NA,https://clinicalzeros.gov/ct2/show/NCT04380727,0,0,0,0,1,0,France,0,"NA",NA
NCT04380714,2020-05-01,2020-05-30,Observational,Changes in the Consumption of Psychoactive Substances During Containment Linked to COVID-19,Completed,NA,"University Hospital, Montpellier",NA,https://clinicalzeros.gov/ct2/show/NCT04380714,0,0,0,0,2,0,France,0,"NA",NA
NCT04380688,2020-06-13,2020-11-16,Interventional,Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.,Completed,Phase 2,AstraZeneca,NA,https://clinicalzeros.gov/ct2/show/NCT04380688,0,0,0,0,3,1,United States,0,acalabrutinib,NA
NCT04729491,2020-06-30,2020-09-15,Interventional,EAT-DUTA AndroCoV Trial,Completed,Phase 2/Phase 3,Corpometria Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04729491,0,0,0,0,0,0,Brazil,0,dutasteride 0.5 mg|azithromycin|nitazoxanide|placebo,NA
NCT04380532,2020-05-15,2021-05-15,Interventional,Tableted COVID-19 Therapeutic Vaccine,"Active, not recruiting",Phase 1/Phase 2,Immunitor LLC,NA,https://clinicalzeros.gov/ct2/show/NCT04380532,0,0,0,1,1,0,Canada|Mongolia,0,v-sars,NA
NCT04380519,2020-04-23,2020-07-10,Interventional,Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19),Completed,Phase 2/Phase 3,R-Pharm,NA,https://clinicalzeros.gov/ct2/show/NCT04380519,0,0,0,0,2,0,Russian Federation,0,rph-104|olokizumab|placebo,NA
NCT04380376,2020-04-30,2020-10-30,Interventional,Low-doses Melphalan Inhalation in Patients With COVID-19 (CoronavIrus Disease 2019) Pneumonia,Recruiting,Phase 2,"Federal State Budgetary Institution, Pulmonology Scientific Research Institute",NA,https://clinicalzeros.gov/ct2/show/NCT04380376,0,0,0,0,1,0,Russian Federation,0,standard care|melphalan,NA
NCT04729452,2020-06-01,2023-10-01,Observational,Characterisation of the Immune Response to SARS-CoV-2,Recruiting,NA,Cwm Taf University Health Board (NHS),NA,https://clinicalzeros.gov/ct2/show/NCT04729452,0,0,0,0,0,0,United Kingdom,0,blood test,NA
NCT04379466,2020-05-05,2020-10-11,Observational,Effector and Regulatory T Cell Receptor Repertoire Analyses in Patients Affected by COVID-19,Recruiting,NA,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04379466,0,0,0,0,1,0,France,0,"NA",NA
NCT04379661,2020-05-07,2020-07-07,Interventional,SUNLIGHT Study: Online Support Groups for MS to Address COVID-19,Completed,N/A,Columbia University,NA,https://clinicalzeros.gov/ct2/show/NCT04379661,0,0,0,0,2,1,United States,0,online support group,NA
NCT04379544,2020-04-23,2020-09-01,Observational [Patient Registry],Prognostic Value of Point of Care Cardiac and Lung Ultrasound in COVID-19,"Active, not recruiting",NA,University of Pennsylvania,NA,https://clinicalzeros.gov/ct2/show/NCT04379544,0,0,0,0,2,1,United States,0,no intervention,NA
NCT04379531,2020-04-25,2020-05-22,Interventional,LDCT in COVID-19 Pneumonia: a Prospective Moscow Study,Completed,N/A,Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department,NA,https://clinicalzeros.gov/ct2/show/NCT04379531,0,0,0,0,2,0,Russian Federation,0,chest ct,NA
NCT04379310,2020-05-01,2020-05-05,Observational,Evaluation of Clinical Parameters on Admission and Medications in Covid-19 Pneumonia (Corona Virus Disease 2019),Completed,NA,Nisantasi University,NA,https://clinicalzeros.gov/ct2/show/NCT04379310,0,0,0,0,1,0,Turkey,0,ace inhibitors/calcium channel blockers|ace inhibitor|calcium channel blockers,NA
NCT04379297,2020-04-10,2021-05-28,Observational,COvid-19 National Survey for Assessing VIral Spread by Nonaffected CarriErs (CON-VINCE),"Active, not recruiting",NA,Luxembourg Institute of Health,NA,https://clinicalzeros.gov/ct2/show/NCT04379297,0,0,0,0,0,0,Luxembourg,0,"NA",NA
NCT04379284,2020-05-08,2021-04-30,Observational,Risks of COVID19 in the Pregnant Population,Recruiting,NA,Mayo Clinic,NA,https://clinicalzeros.gov/ct2/show/NCT04379284,0,0,0,0,2,1,United States,0,biospecimen collection|biospeciman collection,NA
NCT04379245,2020-04-30,2020-04-30,Observational,COVID-19 Infection in Patients Infected With HIV and/or on PrEP,Completed,NA,Hospices Civils de Lyon,NA,https://clinicalzeros.gov/ct2/show/NCT04379245,0,0,0,0,0,0,France,0,"data research, database analysis",NA
NCT04379232,2020-03-19,2020-04-20,Observational,Surgical Activity During the Covid-19 Pandemic: Results for 112 Patients in a French Tertiary Care Center,Completed,NA,Hospices Civils de Lyon,NA,https://clinicalzeros.gov/ct2/show/NCT04379232,0,0,0,0,0,0,France,0,pcr/chest ct|pcr|chest ct,NA
NCT04379375,2020-07-27,2020-09-30,Interventional,Nudges to Improve Health Behaviors That Limit COVID-19 Spread,Terminated,N/A,Medical College of Wisconsin,Slow enrollment rate,https://clinicalzeros.gov/ct2/show/NCT04379375,0,0,0,0,6,1,United States,0,nudge,NA
NCT04379063,2020-05-13,2021-05-31,Observational,COVID-19 Pandemic Short Interval National Survey Gauging Psychological Distress,"Active, not recruiting",NA,Nova Scotia Health Authority,NA,https://clinicalzeros.gov/ct2/show/NCT04379063,0,0,0,0,3,0,Canada,0,covid-19 pandemic,NA
NCT04379336,2020-05-04,2021-04-28,Interventional,BCG Vaccination for Healthcare Workers in COVID-19 Pandemic,Recruiting,Phase 3,TASK Applied Science,NA,https://clinicalzeros.gov/ct2/show/NCT04379336,0,0,0,1,0,0,South Africa,0,bacille calmette-guã©rin (bcg)|placebo|bacille calmette-guã©rin (bcg),NA
NCT04379037,2020-06-27,2020-09-01,Interventional,Vagus Nerve Stimulation ARDS Prevention Trial for COVID-19 Hospitalized Patients,Recruiting,N/A,Nemechek Technologies,NA,https://clinicalzeros.gov/ct2/show/NCT04379037,0,0,0,0,1,0,Argentina,0,transcutaneous auricular vagus nerve stimulation,NA
NCT04378686,2020-04-23,2021-05-01,Observational,Serological Testing for COVID-19 (SARS-CoV-2) in ESKD,Recruiting,NA,Universitaire Ziekenhuizen Leuven,NA,https://clinicalzeros.gov/ct2/show/NCT04378686,0,0,0,0,1,0,Belgium,0,dialysis,NA
NCT04378881,2020-06-01,2020-12-30,Observational,Simulation of Risk of Adverse Drug Events Associated With the Initiation of Drugs Repurposed for the Treatment of COVID-19 in Adults With Polypharmacy Using Data From Large Medicare and Commercially Insured Populations,"Active, not recruiting",NA,Tabula Rasa HealthCare,NA,https://clinicalzeros.gov/ct2/show/NCT04378881,0,0,0,0,1,1,United States,0,"NA",NA
NCT04378842,2020-05-18,2021-05-31,Observational,COVID-19 and ICU-acquired MDR Bacteria,Recruiting,NA,"University Hospital, Lille",NA,https://clinicalzeros.gov/ct2/show/NCT04378842,0,0,0,0,1,0,France,0,"NA",NA
NCT04378829,2020-09-12,2020-10-11,Observational,"Platelet Count, Platelet, Mean Platelet Volume and Platelet Distribution Width in COVID-19",Recruiting,NA,Konya Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04378829,0,0,0,0,1,0,Turkey,0,"platelet count, platelet, mean platelet volume/platelet distribution width in covid-19|platelet count, platelet, mean platelet volume|platelet distribution width in covid-19",NA
NCT04378803,2020-05-13,2020-08-04,Interventional,Mindfulness Training for Seniors,Completed,N/A,University of Miami,NA,https://clinicalzeros.gov/ct2/show/NCT04378803,0,0,0,0,3,1,United States,0,mindfullness training,NA
NCT04378712,2020-01-21,2020-03-23,Interventional,Hydrogen/Oxygen Mixed Gas Inhalation for Coronavirus Disease 2019 (COVID-19),Completed,N/A,Guangzhou Institute of Respiratory Disease,NA,https://clinicalzeros.gov/ct2/show/NCT04378712,0,0,0,0,2,0,China,0,hydrogen oxygen generator with nebulizer|standard care,NA
NCT04377724,2020-04-27,2021-06-30,Observational,Spread and Course of COVID-19 Infections,"Active, not recruiting",NA,ETH Zurich,NA,https://clinicalzeros.gov/ct2/show/NCT04377724,0,0,0,0,3,0,Switzerland,0,"NA",NA
NCT04377685,2020-03-01,2021-06-30,Observational,Prediction of Clinical Course in COVID19 Patients,Recruiting,NA,Centre Hospitalier Universitaire de Saint Etienne,NA,https://clinicalzeros.gov/ct2/show/NCT04377685,0,0,0,0,4,0,France,0,ct-scan,NA
NCT04377672,2020-05-28,2021-05-28,Interventional,Human Convalescent Plasma for High Risk Children Exposed or Infected With SARS-CoV-2 (COVID-19),Recruiting,Phase 1,Johns Hopkins University,NA,https://clinicalzeros.gov/ct2/show/NCT04377672,0,0,0,0,2,1,United States,0,convalescent plasma,NA
NCT04728919,2021-01-15,2022-01-15,Observational,Nasal and Pulmonary Nitric Oxide Output in COVID-19 Infection,Recruiting,NA,Tampere University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04728919,0,0,0,0,0,0,Finland,0,"NA",NA
NCT04728880,2021-01-26,2021-03-31,Observational,Remdesivir in Adults With Covid-19: Mansoura University Hospital Experience,Recruiting,NA,Mansoura University,NA,https://clinicalzeros.gov/ct2/show/NCT04728880,0,0,0,0,0,0,Egypt,0,remdesivir,NA
NCT04377490,2020-05-04,2020-10-31,Observational,Thrombo Embolic Events in Hospitalized Patients With Covid-19 Serious Acute Pneumopathy,Recruiting,NA,"Centre Hospitalier Universitaire, Amiens",NA,https://clinicalzeros.gov/ct2/show/NCT04377490,0,0,0,0,1,0,France,0,ultrasound|blood sample,NA
NCT04377477,2020-05-10,2021-08-10,Interventional,COVID-19 Pneumonitis Low Dose Lung Radiotherapy (COLOR-19),Recruiting,N/A,Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia,NA,https://clinicalzeros.gov/ct2/show/NCT04377477,0,0,0,0,2,0,Italy,0,radiological,NA
NCT04729075,2021-01-19,2021-01-19,Observational [Patient Registry],"Associations Between COVID-19 ARDS Treatment, Clinical Trajectories and Liberation From Mechanical Ventilator - an Analysis of the NorthCARDS Dataset",Completed,NA,Northwell Health,NA,https://clinicalzeros.gov/ct2/show/NCT04729075,0,0,0,0,0,1,United States,0,ards/covid19 treatments|ards|covid19 treatments,NA
NCT04377776,2020-05-04,2020-05-18,Observational,"Observational Study Concerning COVID-19 Infection in Transplanted Kidney, Pancreas or Pancreatic Islet Patients",Completed,NA,IRCCS San Raffaele,NA,https://clinicalzeros.gov/ct2/show/NCT04377776,0,0,0,0,1,0,Italy,0,practice details,NA
NCT04377750,2020-04-08,2020-04-29,Interventional,The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation,Recruiting,Phase 4,Hadassah Medical Organization,NA,https://clinicalzeros.gov/ct2/show/NCT04377750,0,0,0,0,0,0,Israel,0,tocilizumab,NA
NCT04377659,2020-05-01,2022-05-01,Interventional,Tocilizumab for Prevention of Respiratory Failure in Patients With Severe COVID-19 Infection,"Active, not recruiting",Phase 2,Memorial Sloan Kettering Cancer Center,NA,https://clinicalzeros.gov/ct2/show/NCT04377659,0,0,0,0,5,1,United States,0,tocilizumab,NA
NCT04377607,2020-11-01,2020-11-20,Observational,Haemoglobin Concentration on COVID-19,Recruiting,NA,Nevsehir Public Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04377607,0,0,0,0,2,0,Turkey,0,file scanning,NA
NCT04377581,2020-04-09,2020-07-10,Observational,"COVID-19 Health Messaging Efficacy and Its Impact on Public Perception, Anxiety, and Behavior",Completed,NA,Milton S. Hershey Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04377581,0,0,0,0,2,1,United States,0,"NA",NA
NCT04377412,2020-05-01,2020-08-31,Observational,Risk Factors for Anxiety and Depression Among Pregnant Women During the COVID-19 Pandemic,Recruiting,NA,"Å»elazna Medical Centre, LLC",NA,https://clinicalzeros.gov/ct2/show/NCT04377412,0,0,0,0,0,1,United States|Albania|Australia|Czechia|France|Germany|Hong Kong|Israel|Italy|Lebanon|Norway|Poland|Spain|Sweden|Taiwan,0,pandemic control measures,NA
NCT04377308,2020-05-01,2021-04-20,Interventional,Fluoxetine to Reduce Intubation and Death After COVID19 Infection,Recruiting,Phase 4,University of Toledo Health Science Campus,NA,https://clinicalzeros.gov/ct2/show/NCT04377308,0,0,0,0,0,1,United States,0,fluoxetine,NA
NCT04376398,2020-04-06,2020-06-30,Observational [Patient Registry],Survey: COVID-19 Patients Managed in the Operating Theatre of Belgian Hospitals,Completed,NA,Cliniques universitaires Saint-Luc- UniversitÃ© Catholique de Louvain,NA,https://clinicalzeros.gov/ct2/show/NCT04376398,0,0,0,0,1,0,Belgium,0,"NA",NA
NCT04377074,2020-03-31,2020-04-07,Observational,Parental Stress During the COVID-19 Pandemic and Its Association With Depression and Anxiety,Completed,NA,University of Oslo,NA,https://clinicalzeros.gov/ct2/show/NCT04377074,0,0,0,0,0,0,Norway,0,"NA",NA
NCT04377035,2020-03-31,2021-03-01,Observational,The Role of Ultrasound in COVID-19,Recruiting,NA,"University Hospital, Gentofte, Copenhagen",NA,https://clinicalzeros.gov/ct2/show/NCT04377035,0,0,0,0,2,0,Denmark,0,"NA",NA
NCT04376853,2020-04-15,2020-06-30,Observational,CoronaWatch - Early Detection of Cardiovascular Risks in COVID-19 Via SmartWatch,Recruiting,NA,University Hospital Heidelberg,NA,https://clinicalzeros.gov/ct2/show/NCT04376853,0,0,0,0,0,0,Germany,0,apple watch,NA
NCT04376996,2020-04-20,2020-10-31,Observational,Slovenian National COVID-19 Prevalence Study,Recruiting,NA,University of Ljubljana,NA,https://clinicalzeros.gov/ct2/show/NCT04376996,0,0,0,0,1,0,Slovenia,0,no intervention,NA
NCT04376593,2020-05-01,2021-05-31,Interventional,PET/CT Imaging in COVID-19 Patients,Enrolling by invitation,Early Phase 1,"University of California, Davis",NA,https://clinicalzeros.gov/ct2/show/NCT04376593,0,0,0,0,1,1,United States,0,18f-î±vî²6-bp|18f-î±vî²6-bp,NA
NCT04376580,2020-04-30,2020-10-31,Observational,Use of the Nasal Cannula During COVID-19,Enrolling by invitation,NA,Tiva Group,NA,https://clinicalzeros.gov/ct2/show/NCT04376580,0,0,0,0,2,0,Argentina,0,"NA",NA
NCT04376476,2020-05-05,2021-06-05,Interventional,Host-pathogen Interactions During SARS-CoV-2 Infection,Recruiting,N/A,Hospices Civils de Lyon,NA,https://clinicalzeros.gov/ct2/show/NCT04376476,0,0,0,0,1,0,France,0,blood sample|low/upper respiratory tract sample|stool collection|phone call|low|respiratory tract sample|swab,NA
NCT04376944,2020-04-01,2020-12-01,Observational,Barrier Measures to Limit Covid-19.Nosocomial Transmission: a Cross-sectional Evaluation,Recruiting,NA,"University Hospital, Montpellier",NA,https://clinicalzeros.gov/ct2/show/NCT04376944,0,0,0,0,0,0,France,0,questionnaire,NA
NCT04376905,2020-04-01,2020-09-01,Observational,Extra Vascular Lung Water and Pulmonary Permeability in Critically Ill Patients With SARS-CoV-2 (COVID-19),Completed,NA,"University Hospital, Montpellier",NA,https://clinicalzeros.gov/ct2/show/NCT04376905,0,0,0,0,2,0,France,0,"NA",NA
NCT04376879,2020-05-16,2022-05-31,Observational,Predicting the Need for Intubation in Hospitalised COVID-19 Patients (PRED ICU COVID19),Recruiting,NA,"Central Hospital, Nancy, France",NA,https://clinicalzeros.gov/ct2/show/NCT04376879,0,0,0,0,3,0,France,0,data monitoring for 48h within the first 24 hours of admission for covid-19,NA
NCT04376840,2020-05-28,2022-01-28,Interventional,Prevalence of Long-term Respiratory Complications of Severe SARS-CoV-2 Pneumonia - COVID-19,Recruiting,N/A,CHU de Reims,NA,https://clinicalzeros.gov/ct2/show/NCT04376840,0,0,0,0,1,0,France,0,blood sample/data record|blood sample|data record,NA
NCT04376814,2020-03-29,2020-04-05,Interventional,Favipiravir Plus Hydroxychloroquine and Lopinavir/Ritonavir Plus Hydroxychloroquine in COVID-19,Completed,N/A,Baqiyatallah Medical Sciences University,NA,https://clinicalzeros.gov/ct2/show/NCT04376814,0,0,0,0,2,0,"Iran, Islamic Republic of",0,favipiravir|hydroxychloroquine|lopinavir/ritonavir|lopinavir|ritonavir,NA
NCT04376788,2020-05-20,2020-07-01,Interventional,Exchange Transfusion Versus Plasma From Convalescent Patients With Methylene Blue in Patients With COVID-19,Recruiting,Phase 2,Ain Shams University,NA,https://clinicalzeros.gov/ct2/show/NCT04376788,0,0,0,0,1,0,Egypt,0,plasma|convalescent plasma|methylene blue|methylprednisolone,NA
NCT04376775,2020-05-11,2020-12-11,Observational,Assessment of the Impact of COVID-19 on Transplant Patients and on Patients Awaiting Transplantation,"Active, not recruiting",NA,"University Hospital, Bordeaux",NA,https://clinicalzeros.gov/ct2/show/NCT04376775,0,0,0,0,2,0,France,0,transplant patient,NA
NCT04376710,2020-07-01,2020-10-01,Observational,Surgical Telemedicine in the COVID-19 Pandemic Era,Completed,NA,"University of Colorado, Denver",NA,https://clinicalzeros.gov/ct2/show/NCT04376710,0,0,0,0,2,1,United States,0,completion of pre-pandemic survey|completion of survey after peak of pandemic|completion of post telemedicine encounter survey,NA
NCT04375501,2020-02-01,2020-04-15,Observational,A Study of Outcomes in Patients With Fractured Neck of Femur During the COVID-19 Pandemic,Completed,NA,Barts & The London NHS Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04375501,0,0,0,0,1,0,United Kingdom,0,"surgery: dynamic hip screw, hemiarthroplasty, hip replacement, intramedullary nail",NA
NCT04374019,2020-05-01,2021-05-31,Interventional,Novel Agents for Treatment of High-risk COVID-19 Positive Patients,Recruiting,Phase 2,University of Kentucky,NA,https://clinicalzeros.gov/ct2/show/NCT04374019,0,0,0,0,3,1,United States,0,ivermectin|camostat mesilate|artemesia annua|artesunate,NA
NCT04376034,2020-04-16,2021-03-30,Interventional,Convalescent Plasma Collection and Treatment in Pediatrics and Adults,Recruiting,Phase 3,West Virginia University,NA,https://clinicalzeros.gov/ct2/show/NCT04376034,0,0,0,0,0,1,United States,0,convalescent plasma|standard care,NA
NCT04375774,2020-05-31,2020-05-31,Interventional,Verification of Alternative Do-it-yourself Equipment Respirators for the COVID-19 Personal Protective Equipment (PPE),Recruiting,N/A,Cliniques universitaires Saint-Luc- UniversitÃ© Catholique de Louvain,NA,https://clinicalzeros.gov/ct2/show/NCT04375774,0,0,0,0,0,0,Belgium,0,ffp2|facial mask|mfs,NA
NCT04375748,2020-04-15,2021-10-15,Observational,Hospital Registry of Acute Myocarditis: Evolution of the Proportion of Positive SARS-COV-2 (COVID19) Cases,Recruiting,NA,"University Hospital, Toulouse",NA,https://clinicalzeros.gov/ct2/show/NCT04375748,0,0,0,0,1,0,France|Martinique|Mayotte|RÃ©union,0,standard care|examinations for the research:|paraclinical test,NA
NCT04375709,2020-03-15,2021-06-30,Observational,Quality of Life and Physical Performance After Novel Coronavirus Infection (COVID-19);,Recruiting,NA,Kantonsspital Winterthur KSW,NA,https://clinicalzeros.gov/ct2/show/NCT04375709,0,0,0,0,1,0,Switzerland,0,exercise|education sessions,NA
NCT04375670,2020-05-11,2020-12-31,Observational,COVID19-FOIE National Observatory,Recruiting,NA,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04375670,0,0,0,0,1,0,France,0,"NA",NA
NCT04375644,2020-05-07,2020-07-15,Observational,Impact of the COVID-19 Pandemic on the Quality of Psychological Life (COVID-PRO-IMPACT),Completed,NA,Hospices Civils de Lyon,NA,https://clinicalzeros.gov/ct2/show/NCT04375644,0,0,0,0,1,0,France,0,questionnaires on psychological quality of life,NA
NCT04374084,2020-05-10,2021-12-31,Interventional,Moxibustion Plus Cupping in Convalescent Patients With COVID-19,Recruiting,N/A,Guang'anmen Hospital of China Academy of Chinese Medical Sciences,NA,https://clinicalzeros.gov/ct2/show/NCT04374084,0,0,0,0,2,0,China,0,moxibustion/cupping|moxibustion|cupping,NA
NCT04375202,2020-04-18,2021-06-30,Interventional,Colchicine in COVID-19: a Pilot Study,Recruiting,Phase 2,University Of Perugia,NA,https://clinicalzeros.gov/ct2/show/NCT04375202,0,0,0,0,1,0,Italy,0,colchicine,NA
NCT04375176,2020-04-27,2020-06-30,Observational,Monocytes and NK Cells Activity in Covid-19 Patients,Recruiting,NA,UniversitÃ  degli Studi dell'Insubria,NA,https://clinicalzeros.gov/ct2/show/NCT04375176,0,0,0,0,0,0,Italy,0,study of immune-mediated mechanisms in patients tested positive for sars-cov-2,NA
NCT04375124,2020-04-25,2020-08-31,Interventional,Treatment of Angiotensin Peptide (1-7) for COVID-19,Recruiting,N/A,Kanuni Sultan Suleyman Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04375124,0,0,0,0,2,0,Turkey,0,angiotensin peptide (1-7) derived plasma|biological,NA
NCT04374656,2020-05-18,2021-05-31,Observational,Prevalence of SARS-CoV-2 in Conjunctival Swab Samples Among Patients With Conjunctivitis During the COVID-19 Pandemic,Recruiting,NA,Johns Hopkins University,NA,https://clinicalzeros.gov/ct2/show/NCT04374656,0,0,0,0,1,1,United States,0,"NA",NA
NCT04374617,2020-04-01,2020-04-25,Observational,Risk of Venous Thromboembolism in Critically Ill Patients With Severe COVID-19,Completed,NA,Hospital Universitari Vall d'Hebron Research Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04374617,0,0,0,0,1,0,Spain,0,duplex ultrasound/computed tomography angiography|ultrasound|tomography angiography,NA
NCT04374591,2020-08-01,2020-11-01,Interventional,The Role of Sodium Bicarbonate as Adjuvant Treatment of Computed Tomography Identified COVID-19 Pneumonia,"Active, not recruiting",N/A,Mansoura University,NA,https://clinicalzeros.gov/ct2/show/NCT04374591,0,0,0,0,3,0,Egypt,0,sodium bicarbonate,NA
NCT04374565,2020-05-05,2021-04-05,Interventional,Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia,"Active, not recruiting",Phase 2,University of Virginia,NA,https://clinicalzeros.gov/ct2/show/NCT04374565,0,0,0,0,4,1,United States,0,convalescent plasma,NA
NCT04374539,2020-04-29,2021-05-05,Interventional,Plasma Exchange in Patients With COVID-19 Disease and Invasive Mechanical Ventilation: a Randomized Controlled Trial,Recruiting,Phase 2,Fundacion Clinic per a la Recerca BiomÃ©dica,NA,https://clinicalzeros.gov/ct2/show/NCT04374539,0,0,0,0,1,0,Spain,0,plasma|standard care,NA
NCT04374487,2020-05-09,2021-08-09,Interventional,Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications,"Active, not recruiting",Phase 2,Max Healthcare Insititute Limited,NA,https://clinicalzeros.gov/ct2/show/NCT04374487,0,0,0,0,1,0,India,0,convalescent plasma|standard care,NA
NCT04374838,2020-05-15,2020-08-01,Observational,Effect of COVID-19 Pandemic on Pediatric Cancer Care,Recruiting,NA,South Egypt Cancer Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04374838,0,0,0,0,2,0,Egypt,0,"NA",NA
NCT04374058,2020-03-20,2021-03-31,Observational,Less Frequency Hemodialysis and COVID-19,"Active, not recruiting",NA,Dialisis Madariaga,NA,https://clinicalzeros.gov/ct2/show/NCT04374058,0,0,0,0,0,0,Argentina,0,dialysis,NA
NCT04374045,2020-04-30,2020-06-17,Observational [Patient Registry],Testing for Dysautonomia in Patients Hospitalized for SARS-CoV-2 Infection (COVID-19) : COVIDANS Study,Completed,NA,Centre Hospitalier Universitaire de Saint Etienne,NA,https://clinicalzeros.gov/ct2/show/NCT04374045,0,0,0,0,3,0,France,0,ecg-holter,NA
NCT04374032,2020-05-01,2020-10-07,Interventional,Clinical Trial to Evaluate the Efficacy and Safety of an Immunomodulatory Therapy for the Treatment of Patients With Moderate to Severe COVID-19 Infection,Completed,Phase 2/Phase 3,Bosnalijek D.D,NA,https://clinicalzeros.gov/ct2/show/NCT04374032,0,0,0,0,3,0,Bosnia and Herzegovina,0,metenkefalin / tridecactide|standard care|metenkefalin|tridecactide,NA
NCT04373382,2020-07-27,2022-02-28,Interventional,Peer Champion Support for Hospital Staff During and After the COVID-19 Pandemic,"Active, not recruiting",N/A,"Mount Sinai Hospital, Canada",NA,https://clinicalzeros.gov/ct2/show/NCT04373382,0,0,0,0,3,0,Canada,0,peer resilience champion|enriched survey feedback,NA
NCT04374110,2020-05-05,2020-06-24,Observational [Patient Registry],Drug Safety and the Occurrence of Complications During Hospitalization in Patients With COVID-19,Recruiting,NA,"Institute of Cardiology, Warsaw, Poland",NA,https://clinicalzeros.gov/ct2/show/NCT04374110,0,0,0,0,1,0,Poland,0,clinical data,NA
NCT04374097,2020-03-31,2020-04-07,Observational,Level and Predictors of Trauma-symptoms Among Health Workers and Public Service Providers During the COVID-19 Outbreak,Completed,NA,University of Oslo,NA,https://clinicalzeros.gov/ct2/show/NCT04374097,0,0,0,0,1,0,Norway,0,"NA",NA
NCT04373161,2020-03-20,2020-04-22,Interventional,Home Pulse Oximeter Use in Patients With COVID-19,Completed,N/A,Swedish Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04373161,0,0,0,0,2,1,United States,0,home pulse oximetry monitoring,NA
NCT04373824,2020-04-25,2020-07-25,Interventional,Max Ivermectin- COVID 19 Study Versus Standard of Care Treatment for COVID 19 Cases. A Pilot Study,Recruiting,N/A,Max Healthcare Insititute Limited,NA,https://clinicalzeros.gov/ct2/show/NCT04373824,0,0,0,0,0,0,India,0,ivermectin,NA
NCT04373798,2020-05-04,2020-11-30,Observational,C-reactive Protein Levels Among Individuals With COVID-19,Recruiting,NA,Frederiksberg University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04373798,0,0,0,0,1,0,Denmark,0,c-reactive protein,NA
NCT04373759,2020-05-02,2020-09-30,Observational [Patient Registry],Cardiac Arrest Incidence and Outcome Among Patients With COVID-19 in French ICUs,Completed,NA,Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer,NA,https://clinicalzeros.gov/ct2/show/NCT04373759,0,0,0,0,9,0,France|Martinique,0,cardiopulmonary resuscitation|modified rankin score,NA
NCT04373135,2020-05-08,2021-02-28,Interventional,"Understanding Community Considerations, Opinions, Values, Impacts, and Decisions for COVID-19","Active, not recruiting",N/A,"University of California, Los Angeles",NA,https://clinicalzeros.gov/ct2/show/NCT04373135,0,0,0,0,3,1,United States,0,educational video,NA
NCT04373109,2020-04-16,2020-10-12,Observational,Stroke Rehabilitation Outcome During COVID-19 Lockdown,Completed,NA,University of Zurich,NA,https://clinicalzeros.gov/ct2/show/NCT04373109,0,0,0,0,1,0,Switzerland,0,observation,NA
NCT04373096,2020-12-07,2021-08-31,Interventional,Enhanced Hood PPE to Minimize COVID-19 Transmission to Front-line Health Care Workers,Recruiting,N/A,"University Health Network, Toronto",NA,https://clinicalzeros.gov/ct2/show/NCT04373096,0,0,0,0,3,0,Canada,0,current ipac-uhn ppe|modified ipac-uhn ppe,NA
NCT04373044,2020-05-01,2021-05-01,Interventional,"Baricitinib, Placebo and Antiviral Therapy for the Treatment of Patients With Moderate and Severe COVID-19",Recruiting,Phase 2,University of Southern California,NA,https://clinicalzeros.gov/ct2/show/NCT04373044,0,0,0,0,3,1,United States,0,baricitinib|hydroxychloroquine|placebo,NA
NCT04373486,2020-03-03,2020-04-30,Observational,Incidence of Acute Pulmonary Embolism in Covid-19 Patients on CT Angiography and Relationship to D-dimer Levels,Completed,NA,"University Hospital, Strasbourg, France",NA,https://clinicalzeros.gov/ct2/show/NCT04373486,0,0,0,0,1,0,France,0,"NA",NA
NCT04373005,2020-05-11,2021-06-30,Observational,Screening of Cancer Patients to Assess Impact of COVID-19,"Active, not recruiting",NA,"University Health Network, Toronto",NA,https://clinicalzeros.gov/ct2/show/NCT04373005,0,0,0,0,1,0,Canada,0,nasopharyngeal (np) swab,NA
NCT04372979,2020-09-14,2021-05-31,Interventional,Efficacy of Convalescent Plasma Therapy in the Early Care of COVID-19 Patients.,Recruiting,Phase 3,Direction Centrale du Service de SantÃ© des ArmÃ©es,NA,https://clinicalzeros.gov/ct2/show/NCT04372979,0,0,0,0,3,0,France,0,transfusion of sars-cov-2 convalescent plasma.|transfusion of standard plasma.,NA
NCT04372693,2020-09-01,2021-01-30,Interventional,Unplanned Shifting to Online Distance Learning: Nursing Students' Perception and Achievement,Enrolling by invitation,N/A,Cairo University,NA,https://clinicalzeros.gov/ct2/show/NCT04372693,0,0,0,0,5,0,Egypt,0,distance learning,NA
NCT04372576,2020-04-16,2020-08-31,Observational,Epidemiology and Outcome of Ventilator-associated Pneumonia Among Critically Ill COVID-19 Patients,Recruiting,NA,Semmelweis University,NA,https://clinicalzeros.gov/ct2/show/NCT04372576,0,0,0,0,0,0,Hungary,0,assessment of ventilator-associated pneumonia criteria,NA
NCT04372199,2020-04-29,2020-05-27,Observational [Patient Registry],SEVERITY SCORE FOR COVID-19 PNEUMONIA,Recruiting,NA,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,NA,https://clinicalzeros.gov/ct2/show/NCT04372199,0,0,0,0,0,0,Italy,0,"NA",NA
NCT04372472,2020-04-07,2020-05-29,Observational,SQuISH-COVID: A Pilot Study,"Active, not recruiting",NA,"Cytovale, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04372472,0,0,0,0,0,1,United States,0,"NA",NA
NCT04372017,2020-05-14,2020-06-04,Interventional,Hydroxychloroquine as Post-Exposure Prophylaxis Against COVID-19 Infection,"Active, not recruiting",Phase 3,Sanford Health,NA,https://clinicalzeros.gov/ct2/show/NCT04372017,0,0,0,0,2,1,United States,0,hydroxychloroquine|vitamin d,NA
NCT04372004,2020-05-08,2021-05-31,Interventional,Comparison of the Efficacy of Rapid Tests to Identify COVID-19 Infection (CATCh COVID-19),Recruiting,Phase 1,Texas Cardiac Arrhythmia Research Foundation,NA,https://clinicalzeros.gov/ct2/show/NCT04372004,0,0,0,0,2,1,United States,0,diagnostic tests for covid-19 infection,NA
NCT04724642,2020-12-28,2021-05-28,Observational,"COVID-19 Vaccine in Patients After Allogeneic HCT, CAR-T Therapy and With Primary Immune Deficiency",Recruiting,NA,Tel-Aviv Sourasky Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04724642,0,0,0,0,1,0,Israel,0,"NA",NA
NCT04371601,2020-03-01,2021-12-31,Interventional,Safety and Effectiveness of Mesenchymal Stem Cells in the Treatment of Pneumonia of Coronavirus Disease 2019,"Active, not recruiting",Early Phase 1,Fuzhou General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04371601,0,0,0,0,0,0,China,0,oseltamivir|hormones|oxygen|mesenchymal stem cells,NA
NCT04371562,2020-03-01,2020-03-31,Observational,Predicting Death and ICU Admission in COVID-19 Patients in ED,Completed,NA,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,NA,https://clinicalzeros.gov/ct2/show/NCT04371562,0,0,0,0,1,0,Italy,0,"NA",NA
NCT04371679,2020-04-01,2020-10-01,Observational,Changes in Cardiac and Pulmonary Hemodynamics as Predictor of Outcome in Hospitalized COVID-19 Patients,Recruiting,NA,Hasselt University,NA,https://clinicalzeros.gov/ct2/show/NCT04371679,0,0,0,0,0,0,Belgium,0,no intervention,NA
NCT04371510,2020-04-22,2020-10-22,Interventional,Blood Biomarkers as Predictors of COVID-19 Disease Progression in Recently Infected Chronic Haemodialysis Patients,Recruiting,N/A,Centre Hospitalier Universitaire de Nice,NA,https://clinicalzeros.gov/ct2/show/NCT04371510,0,0,0,0,0,0,France,0,blood sample,NA
NCT04371471,2020-03-01,2020-04-30,Observational,Covid-19 Pandemic Triage Score,Completed,NA,Groupe Hospitalier de la Rochelle RÃ© Aunis,NA,https://clinicalzeros.gov/ct2/show/NCT04371471,0,0,0,0,1,0,France,0,stc-19,NA
NCT04371315,2020-04-27,2021-06-01,Observational,"Risk Factors, Clinical Characteristics and Outcomes of Acute Infection With Coronavirus 2019 (COVID-19) In Children",Recruiting,NA,St. Jude Children's Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04371315,0,0,0,0,1,1,United States,0,"NA",NA
NCT04371367,2020-04-27,2021-03-01,Interventional,"Avdoralimab an Anti-C5aR Antibody, in Patients With COVID-19 Severe Pneumonia ( FORCE )","Active, not recruiting",Phase 2,Assistance Publique Hopitaux De Marseille,NA,https://clinicalzeros.gov/ct2/show/NCT04371367,0,0,0,0,2,0,France,0,avdoralimab|placebo,NA
NCT04371328,2020-03-13,2020-06-05,Observational [Patient Registry],Emergency Management in a Dedicated Respiratory Unit of Patients With a Possible COVID-19 Infection,"Active, not recruiting",NA,"University Hospital, Toulouse",NA,https://clinicalzeros.gov/ct2/show/NCT04371328,0,0,0,0,1,0,France,0,recop unit patient,NA
NCT04371250,2020-04-30,2020-05-31,Observational,Study of Resilience and Loneliness in Youth (18 - 25 Years Old) During the COVID-19 Pandemic Lock-down Measures.,"Active, not recruiting",NA,Erasme University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04371250,0,0,0,0,2,0,Belgium,0,survey/questionnaire|questionnaire,NA
NCT04370886,2020-04-30,2020-04-30,Interventional,Recruit Blood Donors Via SMS During Epidemic of COVID-19,Completed,N/A,Guangzhou Blood Center,NA,https://clinicalzeros.gov/ct2/show/NCT04370886,0,0,0,0,2,0,China,0,blood donation sms,NA
NCT04371029,2020-04-28,2020-09-28,Interventional,Impact of Neck Inspiratory Muscle Activation During Sleep in ICU Patients After a COVID 19 ARDS,Recruiting,N/A,"University Hospital, Bordeaux",NA,https://clinicalzeros.gov/ct2/show/NCT04371029,0,0,0,0,2,0,France,0,psg,NA
NCT04370834,2020-05-28,2021-01-14,Interventional,Tocilizumab for Patients With Cancer and COVID-19 Disease,Terminated,Phase 2,National Cancer Institute (NCI),Other - Randomized data no longer support continuation,https://clinicalzeros.gov/ct2/show/NCT04370834,0,0,0,0,14,1,United States,0,tocilizumab,NA
NCT04370821,2020-05-09,2040-04-27,Observational [Patient Registry],"COVID-19 CHAMPS Study of Healthcare, First Responder and Service Workers",Recruiting,NA,Villanova University,NA,https://clinicalzeros.gov/ct2/show/NCT04370821,0,0,0,0,3,1,United States,0,"NA",NA
NCT04370782,2020-04-28,2020-09-30,Interventional,Hydroxychloroquine and Zinc With Either Azithromycin or Doxycycline for Treatment of COVID-19 in Outpatient Setting,Completed,Phase 4,"St. Francis Hospital, New York",NA,https://clinicalzeros.gov/ct2/show/NCT04370782,0,0,0,0,2,1,United States,0,hydroxychloroquine|azithromycin|zinc|doxycycline,NA
NCT04370275,2020-04-23,2020-05-23,Observational,Accuracy of Lung Ultrasound in the Diagnosis of covid19 Pneumonia,Recruiting,NA,Ospedale di Latisana,NA,https://clinicalzeros.gov/ct2/show/NCT04370275,0,0,0,0,0,0,Italy,0,"NA",NA
NCT04370262,2020-04-07,2020-09-07,Interventional,Multi-site Adaptive Trials for COVID-19,Completed,Phase 3,Northwell Health,NA,https://clinicalzeros.gov/ct2/show/NCT04370262,0,0,0,0,3,1,United States,0,soc / intravenous famotidine|soc / placebo|standard care|famotidine|placebo,NA
NCT04370210,2020-05-04,2020-06-04,Observational,Sleep Quality During COVID-19 Containment in Children Whether or Not Usually Followed in Child Psychiatry,Completed,NA,Centre Hospitalier RenÃ© Dubos,NA,https://clinicalzeros.gov/ct2/show/NCT04370210,0,0,0,0,3,0,France,0,questionnaire,NA
NCT04370197,2020-03-03,2020-04-30,Observational,Covid-19 Epidemic on Acute Stroke Management,Recruiting,NA,"University Hospital, Strasbourg, France",NA,https://clinicalzeros.gov/ct2/show/NCT04370197,0,0,0,0,0,0,France,0,"NA",NA
NCT04370171,2020-05-04,2020-05-29,Observational,Management of Diabetic Patients With Telemedicine in the Context of the Covid-19 Epidemic,Completed,NA,"University Hospital, Strasbourg, France",NA,https://clinicalzeros.gov/ct2/show/NCT04370171,0,0,0,0,2,0,France,0,care modalities|teleconsultation either by phone/by computer consultation|teleconsultation either by phone|by computer consultation,NA
NCT04370678,2020-04-17,2020-04-24,Observational,Changes in Preference for Surgery of Patients Signed up for Arthroscopic Procedures,Completed,NA,Region Zealand,NA,https://clinicalzeros.gov/ct2/show/NCT04370678,0,0,0,0,1,0,Denmark,0,change in preference to surgery under covid-19 pandemic.,NA
NCT04369859,2020-04-23,2021-04-22,Observational,Obstetric and Perinatal Outcomes of Women With COVID-19,Recruiting,NA,Assistance Publique Hopitaux De Marseille,NA,https://clinicalzeros.gov/ct2/show/NCT04369859,0,0,0,0,1,0,France,0,examine the impact of covid-19 during pregnancy,NA
NCT04369820,2020-03-31,2020-09-30,Interventional,C5a Receptor Expression - COVID-19 (C5-COV),Recruiting,N/A,Assistance Publique Hopitaux De Marseille,NA,https://clinicalzeros.gov/ct2/show/NCT04369820,0,0,0,0,1,0,France,0,blood draw,NA
NCT04369989,2020-04-14,2021-04-14,Observational,Observational Study of COVID-19 Treatment Efficacy,Enrolling by invitation,NA,OSF Healthcare System,NA,https://clinicalzeros.gov/ct2/show/NCT04369989,0,0,0,0,0,1,United States,0,no intervention,NA
NCT04369794,2020-08-10,2021-06-30,Interventional,"COVID-19: BCG As Therapeutic Vaccine, Transmission Limitation, and Immunoglobulin Enhancement",Recruiting,Phase 4,"University of Campinas, Brazil",NA,https://clinicalzeros.gov/ct2/show/NCT04369794,0,0,0,1,1,0,Brazil,0,bcg|placebo,NA
NCT04369365,2020-04-27,2020-08-27,Interventional,"A Single-blinded, Randomized, Placebo Controlled Phase II Trial of Prophylactic Treatment With Oral Azithromycin Versus Placebo in Cancer Patients Undergoing Antineoplastic Treatment During the Corona Virus Disease 19 (COVID-19) Pandemic",Recruiting,Phase 2,Medical University of Vienna,NA,https://clinicalzeros.gov/ct2/show/NCT04369365,0,0,0,0,1,0,Austria,0,azithromycin|placebo,NA
NCT04369300,2020-04-24,2020-11-24,Observational [Patient Registry],Anxiety And Depression During COVID-19 IN INDIA,Recruiting,NA,Max Healthcare Insititute Limited,NA,https://clinicalzeros.gov/ct2/show/NCT04369300,0,0,0,0,1,0,India,0,registery data collection,NA
NCT04368793,2020-04-06,2020-12-31,Observational,Clinical Effects of Internet Assisted Pulmonary Rehabilitation of COVID-2019 Pneumonia Patients After Discharge,Recruiting,NA,China-Japan Friendship Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04368793,0,0,0,0,2,0,China,0,remote pulmonary rehabilitation,NA
NCT04369456,2020-04-22,2020-10-22,Interventional,Blood Biomarkers as Predictors of COVID-19 Disease Progression in Recently Infected Kidney Transplant Patients,Recruiting,N/A,Centre Hospitalier Universitaire de Nice,NA,https://clinicalzeros.gov/ct2/show/NCT04369456,0,0,0,0,1,0,France,0,blood sample,NA
NCT04368637,2020-05-03,2020-07-30,Observational,Acute Cardiovascular Events Triggered by COVID-19-Related Stress,Recruiting,NA,Jordan Collaborating Cardiology Group,NA,https://clinicalzeros.gov/ct2/show/NCT04368637,0,0,0,0,1,0,Jordan,0,"NA",NA
NCT04368884,2020-04-22,2021-06-30,Observational,Assess the Seroconversion Status of Health Care Workers Suspected or Confirmed Cases of COVID-19 Patients,Recruiting,NA,Max Healthcare Insititute Limited,NA,https://clinicalzeros.gov/ct2/show/NCT04368884,0,0,0,0,1,0,India,0,"NA",NA
NCT04368871,2020-04-28,2020-06-30,Observational,Radiographic Findings and Their Temporal Changes in COVID-19 Positive Changes Patients: A Prospective Study,Recruiting,NA,Max Healthcare Insititute Limited,NA,https://clinicalzeros.gov/ct2/show/NCT04368871,0,0,0,0,2,0,India,0,"NA",NA
NCT04368260,2020-04-24,2020-07-31,Interventional,Clinical Validation of New Injection Molded Flocked Nasopharyngeal Swabs in Response to the COVID-19 Pandemic,Recruiting,N/A,University of Virginia,NA,https://clinicalzeros.gov/ct2/show/NCT04368260,0,0,0,0,0,1,United States,0,control swab|prototype,NA
NCT04707534,2021-01-21,2021-05-21,Interventional,Dexamethasone for COVID-19,Recruiting,Phase 4,University of Oklahoma,NA,https://clinicalzeros.gov/ct2/show/NCT04707534,0,0,0,0,1,1,United States,0,dexamethasone,NA
NCT04368208,2020-04-29,2020-10-21,Observational,Impact of Giving Birth During the Covid 19 Pandemia on Postnatal Women's Depression,Completed,NA,Poitiers University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04368208,0,0,0,0,3,0,France,0,assessment of postnatal depression using the the edinburgh questionnaire between 4/6 weeks after delivery|assessment of postnatal depression using the the edinburgh questionnaire between 4|6 weeks after delivery,NA
NCT04368299,2020-05-01,2021-10-31,Interventional,Telemedicine for Follow-up of Systemic Lupus Erythematosus,Recruiting,N/A,Chinese University of Hong Kong,NA,https://clinicalzeros.gov/ct2/show/NCT04368299,0,0,0,0,1,0,Hong Kong,0,telehealth|standard care,NA
NCT04367857,2020-04-18,2021-10-31,Observational [Patient Registry],ARMOR Study: COVID-19 Seroprevalence Among Healthcare Workers,Recruiting,NA,Columbia University,NA,https://clinicalzeros.gov/ct2/show/NCT04367857,0,0,0,0,1,1,United States,0,serology test|health care worker survey,NA
NCT04367805,2020-04-27,2020-10-31,Observational,COVID-19 Infection in Patients With Hepatocellular Carcinoma,Recruiting,NA,"Centre Hospitalier Universitaire, Amiens",NA,https://clinicalzeros.gov/ct2/show/NCT04367805,0,0,0,0,0,0,France,0,pcr,NA
NCT04367792,2020-04-23,2020-10-31,Observational,Cardiac Injury in COVID-19: a Pathology Study,"Active, not recruiting",NA,A.O. Ospedale Papa Giovanni XXIII,NA,https://clinicalzeros.gov/ct2/show/NCT04367792,0,0,0,0,2,0,Italy,0,"NA",NA
NCT04367714,2020-03-15,2021-12-01,Observational [Patient Registry],Antibody Response Against SARS-CoV-2 in Dialysis Patients During COVID-19,Recruiting,NA,Region MidtJylland Denmark,NA,https://clinicalzeros.gov/ct2/show/NCT04367714,0,0,0,0,1,0,Denmark,0,"NA",NA
NCT04367662,2020-04-09,2020-05-14,Interventional,Study of the Vascular Compartment and Hypercoagulability During Coronavirus Infection COVID-19,Completed,N/A,"University Hospital, Rouen",NA,https://clinicalzeros.gov/ct2/show/NCT04367662,0,0,0,0,1,0,France,0,blood sample,NA
NCT04368000,2020-04-29,2020-08-06,Interventional,Prone Positioning in Awake Patients With COVID-19 Requiring Hospitalization,Terminated,N/A,University of Utah,Study was terminated due to lack of adherence to the protocol in the intervention arm.,https://clinicalzeros.gov/ct2/show/NCT04368000,0,0,0,0,3,1,United States,0,intermittent|usual care positioning with no instructions,NA
NCT04367350,2020-03-20,2021-03-31,Observational [Patient Registry],Prospective Registry of Corona Virus Disease 2019 (Covid-19) Patients With Neuromuscular Involvement,Recruiting,NA,University Hospital Tuebingen,NA,https://clinicalzeros.gov/ct2/show/NCT04367350,0,0,0,0,0,0,Germany,0,laboratory|muscle,NA
NCT04367337,2020-03-25,2021-03-24,Observational,Health Behavior Change During COVID-19 Pandemic,"Active, not recruiting",NA,"University of Social Sciences and Humanities, Warsaw",NA,https://clinicalzeros.gov/ct2/show/NCT04367337,0,0,0,0,4,0,China|Australia|Canada|France|Gambia|Germany|Israel|Italy|Malaysia|Poland|Portugal|Romania|Singapore|Switzerland,0,no intervention,NA
NCT04367207,2020-05-01,2020-12-01,Observational [Patient Registry],African Covid-19 Critical Care Outcomes Study,Recruiting,NA,University of Cape Town,NA,https://clinicalzeros.gov/ct2/show/NCT04367207,0,0,0,0,2,0,South Africa,0,"NA",NA
NCT04367545,2020-04-16,2020-05-17,Interventional,Development of a Molecular Diagnostic Strategy for SARS-CoV2 Based on Saliva in the Context of the COVID-19 Pandemic,Completed,N/A,"University Hospital, Rouen",NA,https://clinicalzeros.gov/ct2/show/NCT04367545,0,0,0,0,2,0,France,0,saliva,NA
NCT04367168,2020-05-27,2021-04-27,Interventional,Colchicine Twice Daily During 10 Days as an Option for the Treatment of Symptoms Induced by Inflammation in Patients With Mild and Severe Coronavirus Disease,Recruiting,Phase 2,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,NA,https://clinicalzeros.gov/ct2/show/NCT04367168,0,0,0,0,2,0,Mexico,0,colchicine|placebo,NA
NCT04367064,2020-04-25,2020-11-25,Observational,To Study the Clinical Characteristics and Treatment Outcome of COVID-19 Patients Admitted in Hospitals of Max Healthcare (SCOPe Study),Recruiting,NA,Max Healthcare Insititute Limited,NA,https://clinicalzeros.gov/ct2/show/NCT04367064,0,0,0,0,1,0,India,0,"NA",NA
NCT04367402,2020-03-30,2020-04-24,Observational,"COST (COvid STudio) ACTION: Study for the Evaluation of Specific Antibodies Anti Covid-19 Linked to Covid-19 Infection, Symptoms and Genetic Expression of ACE2 Polymorphisms in Patients (COST ACTION)",Recruiting,NA,Azienda Ospedaliera San Paolo,NA,https://clinicalzeros.gov/ct2/show/NCT04367402,0,0,0,0,1,0,Italy,0,igm/igg rapid test,NA
NCT04366947,2020-04-14,2020-09-20,Interventional,Intravascular Access in Suspected/Confirmed COVID-19 Patient,Completed,N/A,Lazarski University,NA,https://clinicalzeros.gov/ct2/show/NCT04366947,0,0,0,0,1,0,Poland,0,nioâ® (intraosseous access)|standard care|nioâ® (intraosseous access),NA
NCT04366921,2020-04-10,2021-04-30,Observational,European/Euro-ELSO Survey on Adult and Neonatal/ Pediatric COVID-19 Patients in ECMO,Recruiting,NA,Maastricht University Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04366921,0,0,0,0,0,0,Germany|Austria|Belgium|Czechia|Denmark|France|Greece|Hungary|Israel|Italy|Lithuania|Netherlands|Poland|Portugal|Russian Federation|Spain|Sweden|Switzerland|United Kingdom,0,"NA",NA
NCT04689542,2021-01-01,2021-08-01,Interventional,Surgical Face Mask Effects in Patients With COVID-19,Recruiting,N/A,Cliniques universitaires Saint-Luc- UniversitÃ© Catholique de Louvain,NA,https://clinicalzeros.gov/ct2/show/NCT04689542,0,0,0,0,2,0,Belgium,0,sit-to-stand test,NA
NCT04367363,2020-03-17,2020-05-07,Observational,Social Media and COVID-19,Completed,NA,Yale-NUS College,NA,https://clinicalzeros.gov/ct2/show/NCT04367363,0,0,0,0,2,0,Singapore,0,social media/news consumption|social media|news,NA
NCT04366778,2020-05-01,2021-01-01,Observational,Thrombosis and Covid-19,Completed,NA,Hospices Civils de Lyon,NA,https://clinicalzeros.gov/ct2/show/NCT04366778,0,0,0,0,4,0,France,0,tem-tpa,NA
NCT04366765,2020-03-19,2021-06-30,Observational,COVID-19 Survival - The COVIVA Study,Recruiting,NA,"University Hospital, Basel, Switzerland",NA,https://clinicalzeros.gov/ct2/show/NCT04366765,0,0,0,0,1,0,Switzerland,0,"NA",NA
NCT04366752,2020-04-22,2020-08-22,Observational,Thrombo Embolic Events in Critical Care Patients With Covid-19 Serious Acute Pneumopathy,Recruiting,NA,"Centre Hospitalier Universitaire, Amiens",NA,https://clinicalzeros.gov/ct2/show/NCT04366752,0,0,0,0,0,0,France,0,ultrasound|blood sample,NA
NCT04366986,2020-06-23,2024-04-30,Observational [Patient Registry],International Registry of Coronavirus (COVID-19) Exposure in Pregnancy,Recruiting,NA,Pregistry,NA,https://clinicalzeros.gov/ct2/show/NCT04366986,0,0,0,0,1,1,United States,0,tested for sars-cov-2 (regardless of the result)|clinical diagnosis of covid-19 by a health care professional,NA
NCT04366856,2020-06-26,2020-12-31,Interventional,PROne Positioning in coVID-19 Oxygeno-dependent Patients in Spontaneous Ventilation (PROVID Study),Recruiting,N/A,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04366856,0,0,0,0,1,0,France,0,prone positioning|no instruction regarding positioning,NA
NCT04366323,2020-04-27,2021-10-31,Interventional,Clinical Trial to Assess the Safety and Efficacy of Intravenous Administration of Allogeneic Adult Mesenchymal Stem Cells of Expanded Adipose Tissue in Patients With Severe Pneumonia Due to COVID-19,"Active, not recruiting",Phase 1/Phase 2,Andalusian Network for Design and Translation of Advanced Therapies,NA,https://clinicalzeros.gov/ct2/show/NCT04366323,0,0,0,0,2,0,Spain,0,mesenchymal stem cells|allogeneic,NA
NCT04682041,2020-12-22,2021-06-30,Interventional,Evaluating the Impact of EnteraGam In People With COVID-19,Recruiting,N/A,"Entera Health, Inc",NA,https://clinicalzeros.gov/ct2/show/NCT04682041,0,0,0,0,1,0,Spain,0,bovine plasma-derived immunoglobulin concentrate|standard care,NA
NCT04366245,2020-04-23,2021-12-31,Interventional,Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection,Recruiting,Phase 1/Phase 2,Andalusian Network for Design and Translation of Advanced Therapies,NA,https://clinicalzeros.gov/ct2/show/NCT04366245,0,0,0,0,3,0,Spain,0,convalescent plasma|standard care,NA
NCT04366206,2020-03-14,2020-07-31,Observational [Patient Registry],Factors Associated With Clinical Outcomes in Patients Hospitalized for Covid-19 in GHT-93 Est,Recruiting,NA,Centre Hospitalier Intercommunal Robert Ballanger,NA,https://clinicalzeros.gov/ct2/show/NCT04366206,0,0,0,0,0,0,France,0,"NA",NA
NCT04366180,2020-04-24,2020-06-30,Interventional,Evaluation of the Probiotic Lactobacillus Coryniformis K8 on COVID-19 Prevention in Healthcare Workers,Recruiting,N/A,Biosearch S.A.,NA,https://clinicalzeros.gov/ct2/show/NCT04366180,0,0,0,0,1,0,Spain,0,probiotic|control,NA
NCT04366167,2020-04-18,2021-04-19,Observational,Patient Recovery From Heart Surgery During the Covid-19 Pandemic,Recruiting,NA,Barts & The London NHS Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04366167,0,0,0,0,0,0,United Kingdom,0,cardiac surgery,NA
NCT04366154,2020-04-15,2020-07-15,Observational,Impact of the COVID-19 Infectious Epidemic on the Management of Oncology and Onco-hematology Patients and on the Psychological Consequences for Patients and Caregivers,"Active, not recruiting",NA,Centre Francois Baclesse,NA,https://clinicalzeros.gov/ct2/show/NCT04366154,0,0,0,0,2,0,France,0,questionnaire,NA
NCT04366063,2020-04-05,2020-06-06,Interventional,Mesenchymal Stem Cell Therapy for SARS-CoV-2-related Acute Respiratory Distress Syndrome,Recruiting,Phase 2/Phase 3,Royan Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04366063,0,0,0,0,1,0,"Iran, Islamic Republic of",0,cell therapy protocol 1|cell therapy protocol 2,NA
NCT04366024,2020-01-17,2020-08-30,Observational,A Novel Nomogram to Predict Severity of COVID-19,Recruiting,NA,Xinqiao Hospital of Chongqing,NA,https://clinicalzeros.gov/ct2/show/NCT04366024,0,0,0,0,1,0,China,0,other,NA
NCT04365985,2020-04-29,2021-05-31,Interventional,Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19,Recruiting,Phase 2,William Beaumont Hospitals,NA,https://clinicalzeros.gov/ct2/show/NCT04365985,0,0,0,0,3,1,United States,0,naltrexone|ketamine|placebo,NA
NCT04365972,2020-04-23,2020-04-30,Interventional,Attention Bias Modification for Reducing Health Anxiety During the Coronavirus Pandemic,Completed,N/A,Tel Aviv University,NA,https://clinicalzeros.gov/ct2/show/NCT04365972,0,0,0,0,1,0,Israel,0,attention bias modification (abm),NA
NCT04365816,2020-04-30,2020-07-10,Observational,NutriCovid30 : Nutritional Evaluation for Covid-19 Infection at D30,Completed,NA,"University Hospital, Grenoble",NA,https://clinicalzeros.gov/ct2/show/NCT04365816,0,0,0,0,2,0,France,0,interview,NA
NCT04366297,2020-01-12,2020-02-25,Interventional,Intravascular Access of COVID-19 Patient Under Personal Protective Equipment,Completed,N/A,Lazarski University,NA,https://clinicalzeros.gov/ct2/show/NCT04366297,0,0,0,0,0,0,Poland,0,intravenous|intraosseous,NA
NCT04366271,2020-05-07,2020-07-31,Interventional,Clinical Trial of Allogeneic Mesenchymal Cells From Umbilical Cord Tissue in Patients With COVID-19,Recruiting,Phase 2,"Hospital Infantil Universitario NiÃ±o JesÃºs, Madrid, Spain",NA,https://clinicalzeros.gov/ct2/show/NCT04366271,0,0,0,0,1,0,Spain,0,mesenchymal stem cells|standard care,NA
NCT04365738,2020-03-11,2020-04-10,Interventional,Pulmonary Rehabilitation in Post-Acute Period of COVID-19 Infection,Completed,N/A,Istanbul Bilgi University,NA,https://clinicalzeros.gov/ct2/show/NCT04365738,0,0,0,0,0,0,Turkey,0,rehabilitation,NA
NCT04365881,2020-03-31,2020-04-07,Observational,Loneliness During the NPIs for the COVID-19 Pandemic in Norway: Risk Factors and Associations With Psychopathology,Completed,NA,Modum Bad,NA,https://clinicalzeros.gov/ct2/show/NCT04365881,0,0,0,0,0,0,Norway,0,cross-sectional observational study,NA
NCT04365361,2020-04-26,2020-12-30,Observational,The Psychological Impact of the COVID-19 on Students.,Recruiting,NA,The University of Hong Kong,NA,https://clinicalzeros.gov/ct2/show/NCT04365361,0,0,0,0,2,0,Hong Kong,0,"NA",NA
NCT04365257,2020-05-13,2021-06-30,Interventional,Prazosin to Prevent COVID-19 (PREVENT-COVID Trial),Recruiting,Phase 2,Johns Hopkins University,NA,https://clinicalzeros.gov/ct2/show/NCT04365257,0,0,0,0,3,1,United States,0,prazosin|standard care,NA
NCT04365608,2020-03-20,2020-11-30,Interventional,Prehospital Intubation of COVID-19 Patient With Personal Protective Equipment,Completed,N/A,Lazarski University,NA,https://clinicalzeros.gov/ct2/show/NCT04365608,0,0,0,0,2,0,Poland,0,laryngoscopy,NA
NCT04365348,2020-04-27,2021-03-31,Observational,The Psychological Impact of COVID-19 Outbreak on COVID-19 Survivors and Their Families,Recruiting,NA,The University of Hong Kong,NA,https://clinicalzeros.gov/ct2/show/NCT04365348,0,0,0,0,1,0,Hong Kong,0,"NA",NA
NCT04365322,2020-04-20,2020-09-01,Observational [Patient Registry],Study of Specific Viral Immune Responses Induced by SARS-CoV-2 (COVID-19),Recruiting,NA,Centre Hospitalier Universitaire de Besancon,NA,https://clinicalzeros.gov/ct2/show/NCT04365322,0,0,0,0,3,0,France,0,biological samples,NA
NCT04365309,2020-02-10,2020-04-30,Interventional,Protective Effect of Aspirin on COVID-19 Patients,Enrolling by invitation,Phase 2/Phase 3,Xijing Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04365309,0,0,0,0,0,0,China,0,aspirin,NA
NCT04364698,2020-05-07,2020-06-30,Observational,Observational Cohort of COVID-19 Patients at Raymond-Poincare,Recruiting,NA,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04364698,0,0,0,0,1,0,France,0,"NA",NA
NCT04364594,2020-03-26,2020-04-24,Interventional,COVID-19 Search in Conjunctival Cells,Completed,N/A,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,NA,https://clinicalzeros.gov/ct2/show/NCT04364594,0,0,0,0,2,0,Italy,0,conjunctival swab,NA
NCT04359602,2020-04-08,2022-04-20,Observational [Patient Registry],COVID-19 Recovered Volunteer Research Participant Pool Registry,Recruiting,NA,"University of California, Los Angeles",NA,https://clinicalzeros.gov/ct2/show/NCT04359602,0,0,0,0,2,1,United States,0,"NA",NA
NCT04364763,2020-08-05,2021-06-30,Interventional,A Study to Evaluate the Effect of RBT-9 on Progression of COVID-19 in High-Risk Individuals (The PREVENT Study),Recruiting,Phase 2,"Renibus Therapeutics, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04364763,0,0,0,0,13,1,United States,0,rbt-9 (90 mg)|saline,NA
NCT04364009,2020-04-27,2020-10-20,Interventional,Anakinra for COVID-19 Respiratory Symptoms,Terminated,Phase 3,"University Hospital, Tours",Efficiency and safety reasons,https://clinicalzeros.gov/ct2/show/NCT04364009,0,0,0,0,5,0,France,0,anakinra/osoc|osoc|anakinra,NA
NCT04363450,2020-04-27,2021-03-31,Interventional,Hydroxychloroquine as Prophylaxis for COVID-19 in Healthcare Workers (HCQPreP),Recruiting,Phase 3,Louisiana State University Health Sciences Center in New Orleans,NA,https://clinicalzeros.gov/ct2/show/NCT04363450,0,0,0,0,2,1,United States,0,hydroxychloroquine|placebo,NA
NCT04363853,2020-06-01,2021-06-01,Interventional,Tocilizumab Treatment in Patients With COVID-19,"Active, not recruiting",Phase 2,Instituto Nacional de Cancerologia de Mexico,NA,https://clinicalzeros.gov/ct2/show/NCT04363853,0,0,0,0,3,0,Mexico,0,tocilizumab,NA
NCT04363814,2020-06-10,2021-07-01,Interventional,Clinical Impact of BACTEK-R in Subject With Mild Pneumonia Due to COVID-19 Infection,Recruiting,Phase 3,Inmunotek S.L.,NA,https://clinicalzeros.gov/ct2/show/NCT04363814,0,0,0,0,3,0,Dominican Republic,0,bactek-r,NA
NCT04363788,2020-02-28,2020-04-24,Observational,Needle Stick Injuries in Emergency Medical Service Practice,Completed,NA,Lazarski University,NA,https://clinicalzeros.gov/ct2/show/NCT04363788,0,0,0,0,1,0,Poland,0,gloves,NA
NCT04363736,2020-05-05,2020-08-12,Interventional,A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,Completed,Phase 2,Hoffmann-La Roche,NA,https://clinicalzeros.gov/ct2/show/NCT04363736,0,0,0,0,3,1,United States,0,tociliuzumab,NA
NCT04363541,2020-08-27,2022-04-30,Interventional,Local Thermotherapy for Patients With Mild-to-moderate COVID-19,Recruiting,N/A,Instituto Nacional de Perinatologia,NA,https://clinicalzeros.gov/ct2/show/NCT04363541,0,0,0,0,2,0,Mexico,0,electric pad for human external pain therapy,NA
NCT04363632,2020-04-02,2020-06-30,Observational [Patient Registry],Prospective Analysis of Morbi-mortality of Patients With Cancers in Active Phase of Treatment Suspected or Diagnosed of a SARS-CoV-2 Infection,Completed,NA,Centre Leon Berard,NA,https://clinicalzeros.gov/ct2/show/NCT04363632,0,0,0,0,3,0,France,0,"NA",NA
NCT04363593,2020-05-04,2020-11-16,Interventional,Serology COVID-19 From the Cornwall Hospital Union,Completed,N/A,Centre Hospitalier de Cornouaille,NA,https://clinicalzeros.gov/ct2/show/NCT04363593,0,0,0,0,2,0,France,0,serology test|serum test,NA
NCT04363437,2020-04-26,2020-05-31,Interventional,COlchicine in Moderate-severe Hospitalized Patients Before ARDS to Treat COVID-19,Recruiting,Phase 2,Maimonides Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04363437,0,0,0,0,2,1,United States,0,standard care|colchicine,NA
NCT04363385,2020-05-31,2021-05-31,Interventional,Collection of Biological Samples With Clinical Characterization of Covid-19 Patients,Recruiting,N/A,Centre Hospitalier Intercommunal Creteil,NA,https://clinicalzeros.gov/ct2/show/NCT04363385,0,0,0,0,4,0,France,0,biological test,NA
NCT04363528,2020-04-24,2020-10-30,Interventional,Incidence of Deep Vein Thrombosis at Doppler Echo in Covid-19 Patients With SARS-Cov-2 Pneumopathy Hospitalized in ICU,Recruiting,N/A,Versailles Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04363528,0,0,0,0,1,0,France,0,doppler echo,NA
NCT04363047,2020-10-01,2021-05-01,Observational,"Immune Cells in Inflammatory Arthritis With Coronaviruses, Including COVID-19",Enrolling by invitation,NA,University of Manchester,NA,https://clinicalzeros.gov/ct2/show/NCT04363047,0,0,0,0,2,0,United Kingdom,0,40ml blood sample,NA
NCT04363372,2020-06-30,2020-08-31,Interventional,A Study for Efficacy and Safety of Live Biotherapeutic MRx4DP0004 to Treat COVID-19,Recruiting,Phase 2,4D pharma plc,NA,https://clinicalzeros.gov/ct2/show/NCT04363372,0,0,0,0,1,0,United Kingdom,0,mrx-4dp0004|placebo,NA
NCT04363268,2020-04-20,2030-04-20,Observational,ACCESS A Master Digital Surveillance Protocol for COVID-19,Recruiting,NA,Medable Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04363268,0,0,0,0,1,1,United States,0,"NA",NA
NCT04363008,2020-03-30,2020-04-30,Observational,COVID 19 Biomarkers,Recruiting,NA,University of British Columbia,NA,https://clinicalzeros.gov/ct2/show/NCT04363008,0,0,0,0,1,0,Canada,0,serum test,NA
NCT04362943,2020-04-20,2020-05-15,Observational,Clinical-epidemiological Characterization of COVID-19 Disease in Hospitalized Older Adults,Recruiting,NA,Complejo Hospitalario Universitario de Albacete,NA,https://clinicalzeros.gov/ct2/show/NCT04362943,0,0,0,0,0,0,Spain,0,baricitinib/anakinra|baricitinib|anakinra,NA
NCT04362930,2020-04-27,2022-04-24,Observational,Cohort of Patients With Covid-19 Presenting Neurological or Psychiatric Disorders (CoCo-Neurosciences),Recruiting,NA,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04362930,0,0,0,0,2,0,France,0,"NA",NA
NCT04363099,2020-03-01,2020-06-30,Observational,Multicentre Observational Study on Management COVID 19 Positive Outpatients in a French Cluster.,Recruiting,NA,Maison de Sante Pluridisciplinaire de Creil,NA,https://clinicalzeros.gov/ct2/show/NCT04363099,0,0,0,0,0,0,France,0,observational,NA
NCT04362345,2020-04-09,2021-01-09,Observational,Clinical Features and Risk Factors Associated With Worse Outcome in Patients Hospitalized for Covid-19 Pneumonia,Recruiting,NA,"University Hospital, Strasbourg, France",NA,https://clinicalzeros.gov/ct2/show/NCT04362345,0,0,0,0,2,0,France,0,"NA",NA
NCT04362332,2020-04-14,2020-06-08,Interventional,"Chloroquine, Hydroxychloroquine or Only Supportive Care in Patients AdmItted With Moderate to Severe COVID-19",Terminated,Phase 4,UMC Utrecht,"Currently, almost no patients admitted to Dutch hospitals. If any effect of HCQ is to be
    expected we need more than 1000 inclusions",https://clinicalzeros.gov/ct2/show/NCT04362332,0,0,0,0,1,0,Netherlands,0,chloroquine|hydroxychloroquine|standard care,NA
NCT04362319,2020-05-15,2020-05-31,Observational,Burnout and Medical Errors in the Anaesthesiology Fraternity During Covid-19 Pandemic,Completed,NA,University of Malaya,NA,https://clinicalzeros.gov/ct2/show/NCT04362319,0,0,0,0,1,0,Malaysia,0,questionnaire,NA
NCT04362267,2020-06-15,2020-09-30,Observational,Longitudinal Study of Covid-19 Infection Among HCW in a French University Hospital,Recruiting,NA,"University Hospital, Lille",NA,https://clinicalzeros.gov/ct2/show/NCT04362267,0,0,0,0,2,0,France,0,questionnaire|sars-cov2 testing,NA
NCT04362150,2020-04-21,2022-12-31,Observational,Long-term Impact of Infection With Novel Coronavirus (COVID-19),"Active, not recruiting",NA,"University of California, San Francisco",NA,https://clinicalzeros.gov/ct2/show/NCT04362150,0,0,0,0,3,1,United States,0,"NA",NA
NCT04362137,2020-05-02,2020-10-17,Interventional,"Phase 3 Randomized, Double-blind, Placebo-controlled Multi-center Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID)",Completed,Phase 3,Novartis,NA,https://clinicalzeros.gov/ct2/show/NCT04362137,0,0,0,0,18,1,United States|Argentina|Brazil|Colombia|France|Germany|Mexico|Peru|Russian Federation|Spain|Turkey|United Kingdom,0,ruxolitinib|placebo,NA
NCT04362111,2020-07-29,2021-01-31,Interventional,Early Treatment of Cytokine Storm Syndrome in Covid-19,Recruiting,Phase 3,University of Alabama at Birmingham,NA,https://clinicalzeros.gov/ct2/show/NCT04362111,0,0,0,0,1,1,United States,0,anakinra|saline,NA
NCT04361786,2020-04-01,2020-06-30,Observational,Acral Cutaneous Thrombotic Vasculopathy and Covid-19 Infection,Completed,NA,"University Hospital, Montpellier",NA,https://clinicalzeros.gov/ct2/show/NCT04361786,0,0,0,0,2,0,France,0,"NA",NA
NCT04361916,2020-04-21,2020-06-30,Interventional,Home Care for Patients With COVID-19: Active Monitoring in Two Italian Health Units (Casale Monferrato and Torino),Terminated,N/A,Mario Negri Institute for Pharmacological Research,interrupted early due to the drastic reduction in the number of cases,https://clinicalzeros.gov/ct2/show/NCT04361916,0,0,0,0,2,0,Italy,0,home care monitoring,NA
NCT04361591,2020-03-01,2021-03-01,Observational [Patient Registry],COVID-19 in Liver Transplant Recipients,Recruiting,NA,Hospital Clinic of Barcelona,NA,https://clinicalzeros.gov/ct2/show/NCT04361591,0,0,0,0,0,0,Spain,0,observational,NA
NCT04361565,2020-03-20,2020-04-10,Observational,Frequency and Clinical Evolution of Olfactory and Taste Disorders in COVID-19 Patients,Enrolling by invitation,NA,Centre Hospitalier Universitaire de Nice,NA,https://clinicalzeros.gov/ct2/show/NCT04361565,0,0,0,0,2,0,France,0,"NA",NA
NCT04361526,2020-04-17,2020-07-31,Interventional,Pilot Study on Cytokine Filtration in COVID-19 ARDS,Recruiting,N/A,Hospital Clinic of Barcelona,NA,https://clinicalzeros.gov/ct2/show/NCT04361526,0,0,0,0,0,0,Spain,0,cytokine adsorption,NA
NCT04361500,2020-04-15,2020-10-01,Observational [Patient Registry],Registry of COVID-19 Patients Treated With the Seraph 100 Microbind Affinity Blood Filter,Recruiting,NA,Hannover Medical School,NA,https://clinicalzeros.gov/ct2/show/NCT04361500,0,0,0,0,0,0,Germany,0,seraph,NA
NCT04361396,2020-06-16,2021-06-30,Interventional,Assessment of the Presence of the SARS-COV-2 Virus in the Peritoneum of COVID-19 Patients,Recruiting,N/A,Centre Hospitalier RenÃ© Dubos,NA,https://clinicalzeros.gov/ct2/show/NCT04361396,0,0,0,0,5,0,France,0,biological samples,NA
NCT04361214,2020-05-05,2021-02-28,Interventional,Leflunomide in Mild COVID-19 Patients,Recruiting,Phase 1,University of Chicago,NA,https://clinicalzeros.gov/ct2/show/NCT04361214,0,0,0,0,5,1,United States,0,leflunomide,NA
NCT04358614,2020-03-16,2020-04-05,Interventional,Baricitinib Therapy in COVID-19,Completed,Phase 2/Phase 3,Hospital of Prato,NA,https://clinicalzeros.gov/ct2/show/NCT04358614,0,0,0,0,0,0,Italy,0,baricitinib,NA
NCT04361019,2020-04-16,2020-10-20,Observational,Physical Activity in University Students Around COVID-19 Confinement,Recruiting,NA,Basque Country University,NA,https://clinicalzeros.gov/ct2/show/NCT04361019,0,0,0,0,1,0,Spain,0,online survey,NA
NCT04361123,2020-05-06,2021-12-31,Observational,Atrium COVID-19 Syndromic and Serologic Surveillance,Enrolling by invitation,NA,Atrium Health,NA,https://clinicalzeros.gov/ct2/show/NCT04361123,0,0,0,0,2,1,United States,0,daily syndromic surveillance|igm/igg rapid test|igm test,NA
NCT04360954,2020-04-23,2020-07-08,Observational,Evaluation of Antibody Tests for COVID-19,Completed,NA,Washington University School of Medicine,NA,https://clinicalzeros.gov/ct2/show/NCT04360954,0,0,0,0,3,1,United States,0,diagnostic test,NA
NCT04361253,2020-04-30,2021-06-30,Interventional,Evaluation of SARS-CoV-2 (COVID-19) Antibody-containing Plasma thErapy,Recruiting,Phase 3,Brigham and Women's Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04361253,0,0,0,0,2,1,United States,0,convalescent plasma|plasma,NA
NCT04360863,2020-04-24,2021-12-30,Observational,The Impact of COVID-19 Pandemic on the Smoking Behaviour of Young Smokers and the Youth Quitline Service in Hong Kong,Recruiting,NA,The University of Hong Kong,NA,https://clinicalzeros.gov/ct2/show/NCT04360863,0,0,0,0,2,0,Hong Kong,0,questionnaire,NA
NCT04360850,2020-04-24,2025-10-31,Observational,Use of Telehealth Technology by Mental Health Care Professionals in Times of COVID-19 Pandemic,Recruiting,NA,University of Washington,NA,https://clinicalzeros.gov/ct2/show/NCT04360850,0,0,0,0,1,1,United States,0,online survey,NA
NCT04360811,2020-04-17,2021-04-30,Interventional,"Assessment of Obstetric, Fetal and Neonatal Risks and Vertical SARS-CoV-2 Transmission During COVID-19 Pandemic",Recruiting,N/A,"University Hospital, Toulouse",NA,https://clinicalzeros.gov/ct2/show/NCT04360811,0,0,0,0,0,0,France,0,pcr,NA
NCT04360707,2020-04-08,2021-04-08,Observational,Solid Organ Transplant Recipients With SARS-CoV-2 French Registry,Recruiting,NA,"University Hospital, Strasbourg, France",NA,https://clinicalzeros.gov/ct2/show/NCT04360707,0,0,0,0,1,0,France,0,"NA",NA
NCT04360551,2020-07-01,2021-06-30,Interventional,Pilot Clinical Trial of the Safety and Efficacy of Telmisartan for the Mitigation of Pulmonary and Cardiac Complications in COVID-19 Patients,Recruiting,Phase 2,University of Hawaii,NA,https://clinicalzeros.gov/ct2/show/NCT04360551,0,0,0,0,1,1,United States,0,telmisartan|placebo,NA
NCT04359862,2020-04-16,2021-03-31,Interventional,Sedation With Sevoflurane Versus Propofol in Patients With Acute Respiratory Distress Syndrome Caused by COVID19 Infection,Recruiting,Phase 4,FundaciÃ³n para la InvestigaciÃ³n del Hospital ClÃ­nico de Valencia,NA,https://clinicalzeros.gov/ct2/show/NCT04359862,0,0,0,0,3,0,Spain,0,sevoflurane|propofol,NA
NCT04359849,2020-05-31,2022-05-31,Observational,Sequencing and Tracking of Phylogeny in COVID-19 Study,Recruiting,NA,Portsmouth Hospitals NHS Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04359849,0,0,0,0,0,0,United Kingdom,0,"NA",NA
NCT04359797,2020-04-27,2020-12-17,Interventional,COVID-19 Patient Positioning Pragmatic Trial,"Active, not recruiting",N/A,Vanderbilt University Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04359797,0,0,0,0,12,1,United States,0,prone positioning|standard care,NA
NCT04359667,2020-06-16,2021-04-16,Observational,Serum IL-6 and Soluble IL-6 Receptor in Severe COVID-19 Pneumonia Treated With Tocilizumab,Recruiting,NA,"University Hospital for Infectious Diseases, Croatia",NA,https://clinicalzeros.gov/ct2/show/NCT04359667,0,0,0,0,2,0,Croatia,0,tocilizumab|methylprednisolone,NA
NCT04359654,2020-06-16,2021-08-01,Interventional,Nebulised Dornase Alfa for Treatment of COVID-19,Recruiting,Phase 2,"University College, London",NA,https://clinicalzeros.gov/ct2/show/NCT04359654,0,0,0,0,2,0,United Kingdom,0,pulmozyme,NA
NCT04359537,2020-05-01,2020-08-25,Interventional,Efficacy of Various Doses of Hydroxychloroquine in Pre-Exposure Prophylaxis for COVID 19,Recruiting,Phase 2,Shaheed Zulfiqar Ali Bhutto Medical University,NA,https://clinicalzeros.gov/ct2/show/NCT04359537,0,0,0,0,2,0,Pakistan,0,hydroxychloroquine|placebo,NA
NCT04359706,2020-05-08,2020-09-30,Observational,Bacterial and Fungal Microbiota of Patients With Severe Viral Pneumonia With COVID-19,Recruiting,NA,"University Hospital, Lille",NA,https://clinicalzeros.gov/ct2/show/NCT04359706,0,0,0,0,2,0,France,0,"NA",NA
NCT04359693,2020-04-22,2020-07-01,Observational,Impact of COVID-19 Infection on the Incidence of Ventilator-acquired Infections,Completed,NA,"University Hospital, Lille",NA,https://clinicalzeros.gov/ct2/show/NCT04359693,0,0,0,0,3,0,France,0,"NA",NA
NCT04359407,2020-04-27,2020-12-31,Observational,Prone Positioning and Regional Ventilation in Mechanically Ventilated COVID-19 Patients,Recruiting,NA,"University Hospital, Geneva",NA,https://clinicalzeros.gov/ct2/show/NCT04359407,0,0,0,0,1,0,Switzerland,0,prone positioning,NA
NCT04359953,2020-04-25,2021-06-01,Interventional,"Efficacy of Hydroxychloroquine, Telmisartan and Azithromycin on the Survival of Hospitalized Elderly Patients With COVID-19",Recruiting,Phase 3,"University Hospital, Strasbourg, France",NA,https://clinicalzeros.gov/ct2/show/NCT04359953,0,0,0,0,1,0,France,0,hydroxychloroquine|azithromycin|telmisartan,NA
NCT04359927,2020-04-20,2021-08-31,Observational [Patient Registry],Long-term Effects of Coronavirus Disease 2019 on the Cardiovascular System: CV COVID-19 Registry,Recruiting,NA,Hospital Clinic of Barcelona,NA,https://clinicalzeros.gov/ct2/show/NCT04359927,0,0,0,0,2,0,Spain,0,"NA",NA
NCT04359290,2020-07-01,2020-12-31,Interventional,Ruxolitinib for Treatment of Covid-19 Induced Lung Injury ARDS,"Active, not recruiting",Phase 2,Philipps University Marburg Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04359290,0,0,0,0,5,0,Germany,0,ruxolitinib,NA
NCT04359121,2020-04-15,2023-04-15,Observational,COVID-19 and the Developement of Phobic Fears of Disease,Recruiting,NA,Medical University of Graz,NA,https://clinicalzeros.gov/ct2/show/NCT04359121,0,0,0,0,1,0,Austria,0,phobia questionairre,NA
NCT04359264,2020-04-20,2020-05-29,Interventional,Direct Income SupporT and Advice Negating Spread of Epidemic COVID-19: a Randomized Controlled Trial,"Active, not recruiting",N/A,"St. Michael's Hospital, Toronto",NA,https://clinicalzeros.gov/ct2/show/NCT04359264,0,0,0,0,2,0,Canada,0,cash transfer,NA
NCT04359251,2020-03-05,2020-03-25,Interventional,Different PEEP Settings of COVID-19 Induced ARDS,Completed,N/A,"Southeast University, China",NA,https://clinicalzeros.gov/ct2/show/NCT04359251,0,0,0,0,0,0,China,0,gas exchanges at different peep|lung mechanics at different peep|hemodynamics changes at different peep,NA
NCT04358640,2020-04-09,2020-04-27,Observational,Anxiety and Work Resilience Among Tertiary University Hospital Workers During the COVID-19 Outbreak: An Online Survey,Completed,NA,Centre Hospitalier Universitaire de NÄ«mes,NA,https://clinicalzeros.gov/ct2/show/NCT04358640,0,0,0,0,1,0,France,0,"NA",NA
NCT04358809,2020-06-30,2021-02-28,Interventional,"Clinical Trial of Mycobacterium w in COVID-19 Positive Patients, Hospitalized But Not Critically Ill",Recruiting,Phase 3,Cadila Pharnmaceuticals,NA,https://clinicalzeros.gov/ct2/show/NCT04358809,0,0,0,0,1,0,India,0,suspension of heat killed (autoclaved) mycobacterium w|placebo,NA
NCT04358536,2020-04-01,2020-04-17,Observational,Classification of COVID-19 Infection in Posteroanterior Chest X-rays,Completed,NA,Dascena,NA,https://clinicalzeros.gov/ct2/show/NCT04358536,0,0,0,0,0,1,United States,0,covx,NA
NCT04358510,2020-04-01,2020-04-17,Observational,COVID-19 Mortality Prediction Model,Completed,NA,Dascena,NA,https://clinicalzeros.gov/ct2/show/NCT04358510,0,0,0,0,0,1,United States,0,coviage,NA
NCT04357990,2020-09-04,2021-03-31,Interventional,Viruxal Oral and Nasal Spray for Treating the Symptoms of COVID-19,Recruiting,N/A,Kerecis Ltd.,NA,https://clinicalzeros.gov/ct2/show/NCT04357990,0,0,0,0,2,0,Iceland,0,viruxal oral/nasal spray|placebo|viruxal oral|nasal rinse,NA
NCT04357834,2020-05-01,2021-12-31,Observational,WAVE. Wearable-based COVID-19 Markers for Prediction of Clinical Trajectories,Recruiting,NA,"University Hospital Inselspital, Berne",NA,https://clinicalzeros.gov/ct2/show/NCT04357834,0,0,0,0,2,0,Switzerland,0,equipment with smartwatch throughout hospital stay on the general ward,NA
NCT04357782,2020-04-16,2020-10-13,Interventional,Administration of Intravenous Vitamin C in Novel Coronavirus Infection (COVID-19) and Decreased Oxygenation,Completed,Phase 1/Phase 2,Hunter Holmes Mcguire Veteran Affairs Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04357782,0,0,0,0,3,1,United States,0,vitamin c,NA
NCT04357340,2020-04-02,2020-04-30,Interventional,The Effects of Pulmonary Physiotherapy Treatments on Patients With COVID-19,Completed,N/A,Tehran University of Medical Sciences,NA,https://clinicalzeros.gov/ct2/show/NCT04357340,0,0,0,0,1,0,"Iran, Islamic Republic of",0,pulmonary physiotherapy techniques,NA
NCT04358042,2020-04-24,2022-01-01,Observational [Patient Registry],PSYCHIATRIC Disorders and Covid-19,Recruiting,NA,Nantes University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04358042,0,0,0,0,1,0,France,0,"brief psychiatric rating scale|depression, anxiety/stress scale|impact of event scale-revised|connor-davidson resilience scale 10 items (cd-risc 10)|depression, anxiety|stress scale",NA
NCT04357327,2020-04-16,2020-05-31,Interventional,Rapid Salivary Test to Detect SARS-CoV-2 (COVID-19),Completed,N/A,UniversitÃ  degli Studi dell'Insubria,NA,https://clinicalzeros.gov/ct2/show/NCT04357327,0,0,0,0,2,0,Italy,0,rapid salivary test,NA
NCT04357639,2020-05-28,2021-01-31,Observational [Patient Registry],Impact of Long-term Protease Inhibitors in Patients Living With HIV on the Incidence of COVID-19 ( COVIP ),Recruiting,NA,Centre Hospitalier Intercommunal Creteil,NA,https://clinicalzeros.gov/ct2/show/NCT04357639,0,0,0,0,6,0,France,0,no intervention,NA
NCT04357314,2020-03-01,2020-05-31,Observational,Myocardial Infarction Rates Overview During COVID-19 Pandemic In France: MODIF Study,Completed,NA,French Cardiology Society,NA,https://clinicalzeros.gov/ct2/show/NCT04357314,0,0,0,0,2,0,France,0,"NA",NA
NCT04357275,2020-03-13,2021-03-31,Observational [Patient Registry],The RIsk Stratification in COVID-19 Patients in the ICU Registry,Recruiting,NA,University of Zurich,NA,https://clinicalzeros.gov/ct2/show/NCT04357275,0,0,0,0,0,0,Switzerland,0,icu treatment,NA
NCT04356586,2020-05-04,2020-08-21,Observational [Patient Registry],Immune Response to Covid-19 in 300 Health Care Workers With Mild Symptoms,Completed,NA,Sciensano,NA,https://clinicalzeros.gov/ct2/show/NCT04356586,0,0,0,0,1,0,Belgium,0,"NA",NA
NCT04356378,2020-06-02,2021-10-02,Observational,Long Term Physical Functional Limitations in Daily Living in SARS-CoV2 Infected Patients Hospitalized in the Acute Phase Then Requiring Rehabilitation,Recruiting,NA,CHU de Reims,NA,https://clinicalzeros.gov/ct2/show/NCT04356378,0,0,0,0,1,0,France,0,data record,NA
NCT04356365,2020-03-31,2020-04-07,Observational,The Mental Health Status of the General Population During the COVID-19 Pandemic and Its Association With Adherence to Government-initiated Non-pharmacological Epidemiological Interventions (NPI's),Completed,NA,University of Oslo,NA,https://clinicalzeros.gov/ct2/show/NCT04356365,0,0,0,0,1,0,Norway,0,cross-sectional study investigating the association of npis with mental health,NA
NCT04357431,2020-04-22,2020-05-26,Observational,COVID-19 Among Egyptian Health Care Providers,Completed,NA,Assiut University,NA,https://clinicalzeros.gov/ct2/show/NCT04357431,0,0,0,0,2,0,Egypt,0,questionnaire,NA
NCT04357418,2020-04-01,2020-06-30,Observational,Psychological Outcome of COVID-19 Lockdown on Psychiatric Hospital Staff and Close Relatives,Completed,NA,"Centre hospitalier de Ville-Evrard, France",NA,https://clinicalzeros.gov/ct2/show/NCT04357418,0,0,0,0,2,0,France,0,survey,NA
NCT04356950,2020-04-28,2022-04-30,Observational,Analysis of the Coagulopathy Developed by COVID-19 Infected Patients,"Active, not recruiting",NA,Centre Hospitalier Universitaire de NÄ«mes,NA,https://clinicalzeros.gov/ct2/show/NCT04356950,0,0,0,0,5,0,France,0,thrombin|fibrin generation markers assays,NA
NCT04356885,2020-04-01,2020-07-30,Observational,COVID-19 and Psychotic Symptoms in France,Completed,NA,"University Hospital, Montpellier",NA,https://clinicalzeros.gov/ct2/show/NCT04356885,0,0,0,0,2,0,France,0,"NA",NA
NCT04356560,2020-03-23,2020-09-30,Observational,COVID-19 Surveillance of Patients and Healthcare Workers in a Hospital Department,Enrolling by invitation,NA,"Rigshospitalet, Denmark",NA,https://clinicalzeros.gov/ct2/show/NCT04356560,0,0,0,0,1,0,Denmark,0,pcr,NA
NCT04356534,2020-04-19,2020-06-15,Interventional,Convalescent Plasma Trial in COVID -19 Patients,Completed,N/A,Royal College of Surgeons in Ireland - Medical University of Bahrain,NA,https://clinicalzeros.gov/ct2/show/NCT04356534,0,0,0,0,3,0,Bahrain,0,convalescent plasma|standard care,NA
NCT04355143,2020-05-01,2021-04-25,Interventional,Colchicine to Reduce Cardiac Injury in COVID-19 (COLHEART-19),Recruiting,Phase 2,"University of California, Los Angeles",NA,https://clinicalzeros.gov/ct2/show/NCT04355143,0,0,0,0,3,1,United States,0,colchicine|current care per ucla treating physicians,NA
NCT04356443,2020-04-15,2020-12-31,Observational,Non-Invasive Monitoring of Respiratory Function in Spontaneously Breathing Patients With COVID-19 Infection,Recruiting,NA,Massachusetts General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04356443,0,0,0,0,0,1,United States,0,respiratory monitor,NA
NCT04355897,2020-04-28,2020-07-31,Interventional,CoVID-19 Plasma in Treatment of COVID-19 Patients,Recruiting,Early Phase 1,The Christ Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04355897,0,0,0,0,3,1,United States,0,convalescent plasma,NA
NCT04355871,2020-03-18,2020-04-15,Observational,Characteristics and Outcomes of Hospitalized Patients With COVID-19 in Spain,Completed,NA,Fundacion SEIMC-GESIDA,NA,https://clinicalzeros.gov/ct2/show/NCT04355871,0,0,0,0,1,0,Spain,0,"NA",NA
NCT04355351,2020-05-05,2020-10-22,Interventional,Study of Immune Response During SARS-CoV-2 Infection - (COVID-19),Recruiting,N/A,Centre Hospitalier Universitaire de Nice,NA,https://clinicalzeros.gov/ct2/show/NCT04355351,0,0,0,0,2,0,France,0,blood sample|blood,NA
NCT04355338,2020-10-25,2021-05-30,Observational,Assessment of Incidence of SARS-CoV-2 Infection and COVID-19 in Brazil (AVISA),Recruiting,NA,Butantan Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04355338,0,0,0,0,3,0,Brazil,0,"NA",NA
NCT04355247,2020-04-14,2020-07-31,Interventional,Prophylactic Corticosteroid to Prevent COVID-19 Cytokine Storm,Recruiting,Phase 2,Auxilio Mutuo Cancer Center,NA,https://clinicalzeros.gov/ct2/show/NCT04355247,0,0,0,0,0,0,Puerto Rico,0,methylprednisolone,NA
NCT04355741,2020-04-20,2020-07-01,Observational,"Gut Microbiota, ""Spark and Flame"" of COVID-19 Disease",Completed,NA,Universidade Nova de Lisboa,NA,https://clinicalzeros.gov/ct2/show/NCT04355741,0,0,0,0,2,0,Portugal,0,exposure,NA
NCT04591613,2020-12-31,2022-08-31,Interventional,Late Clinical Events Associated With COVID-19 Infection,Recruiting,N/A,Tourcoing Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04591613,0,0,0,0,1,0,France|French Guiana,0,questionnaire|biocollection|follow-up visit,NA
NCT04355715,2019-04-01,2020-10-01,Observational,Combination of Chest Scanography and Nasal Viral Detection Test to Detect COVID-19 Positive Patients Before Surgical Intervention in a University Hospital During Coronavirus Pandemia,Completed,NA,"University Hospital, Montpellier",NA,https://clinicalzeros.gov/ct2/show/NCT04355715,0,0,0,0,2,0,France,0,"NA",NA
NCT04355624,2020-04-15,2020-04-30,Observational,Kidney Involvement in COVID-19 Disease (COVKID),Recruiting,NA,Centre Hospitalier Universitaire de Nice,NA,https://clinicalzeros.gov/ct2/show/NCT04355624,0,0,0,0,1,0,France,0,"NA",NA
NCT04355611,2020-04-20,2022-04-20,Observational,Epidemiological Characteristics of COVID-19 in Patients With MS or NMO,Recruiting,NA,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04355611,0,0,0,0,2,0,France,0,evaluation of the epidemiological characteristics of coronavirus infection (sars-cov-2),NA
NCT04355507,2020-03-01,2020-10-16,Observational,Computed Tomography for COVID-19 Diagnosis,Completed,NA,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04355507,0,0,0,0,2,0,France,0,chest ct|pcr,NA
NCT04355481,2020-04-17,2020-10-17,Observational,Dissemination of SARS-COV-2 (COVID-19) in the Environment of Infected Patients Admitted to Intensive Care Unit,Recruiting,NA,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04355481,0,0,0,0,1,0,France,0,"NA",NA
NCT04355442,2020-04-01,2020-05-01,Observational,Evolution of Facial Trauma During COVID Containment Measures,Completed,NA,"University Hospital, Montpellier",NA,https://clinicalzeros.gov/ct2/show/NCT04355442,0,0,0,0,3,0,France,0,facial fractures reduction/osteosynthesis|facial fractures reduction|osteosynthesis,NA
NCT04355026,2020-04-10,2020-06-30,Interventional,Use of Bromhexine and Hydroxychloroquine for Treatment of COVID-19 Pneumonia,Recruiting,Phase 4,General and Teaching Hospital Celje,NA,https://clinicalzeros.gov/ct2/show/NCT04355026,0,0,0,0,0,0,Slovenia,0,bromhexine oral tablet and/or hydroxychloroquine tablet|bromhexine hydrochloride|hydroxychloroquine,NA
NCT04354870,2020-04-03,2020-09-15,Interventional,COVID-19 PrEP HCW HCQ Study,Completed,Phase 2,NYU Langone Health,NA,https://clinicalzeros.gov/ct2/show/NCT04354870,0,0,0,0,3,1,United States,0,hydroxychloroquine,NA
NCT04354857,2020-03-27,2020-07-31,Observational,Qualitative and Quantitative Evaluation of Anosmia Over Time in Clinically Symptomatic Patients Tested for COVID-19 Infection,Recruiting,NA,Centre Hospitalier Universitaire de NÄ«mes,NA,https://clinicalzeros.gov/ct2/show/NCT04354857,0,0,0,0,0,0,France,0,olfactory/gustatory tests|olfactory|gustatory tests,NA
NCT04354831,2020-05-11,2022-05-01,Interventional,A Study Evaluating the Efficacy and Safety of High-Titer Anti-SARS-CoV-2 Plasma in Hospitalized Patients With COVID-19 Infection,"Active, not recruiting",Phase 2,Medical College of Wisconsin,NA,https://clinicalzeros.gov/ct2/show/NCT04354831,0,0,0,0,4,1,United States,0,convalescent plasma,NA
NCT04354818,2020-05-11,2022-04-27,Observational [Patient Registry],Coronavirus (COVID-19) Outcomes Registries in Immunocompromised Individuals Australia (CORIA),Recruiting,NA,Kirby Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04354818,0,0,0,0,3,0,Australia,0,"NA",NA
NCT04354792,2020-05-01,2020-06-10,Observational,Asymptomatic COVID-19 Infection Among Healthcare Workers,Completed,NA,Kasr El Aini Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04354792,0,0,0,0,4,0,Egypt,0,igg antibody test,NA
NCT04354779,2020-05-11,2020-08-23,Observational,Antibody Seroprevalence and Rate of Asymptomatic Infections With SARS-CoV-2 in Austrian Hospital Personnel.,Completed,NA,AUVA,NA,https://clinicalzeros.gov/ct2/show/NCT04354779,0,0,0,0,4,0,Austria,0,self-administered questionnaire,NA
NCT04354766,2020-04-29,2020-07-31,Observational,COVID-19 : Neutralizing Human Monoclonal Antibodies Against SARS-Cov-2,Recruiting,NA,Hospices Civils de Lyon,NA,https://clinicalzeros.gov/ct2/show/NCT04354766,0,0,0,0,1,0,France,0,blood sample,NA
NCT04354753,2020-03-28,2020-04-14,Observational,AiM COVID for Covid 19 Tracking and Prediction,Completed,NA,Aarogyam UK,NA,https://clinicalzeros.gov/ct2/show/NCT04354753,0,0,0,0,0,0,United Kingdom,0,no intervention,NA
NCT04354610,2020-04-27,2020-12-19,Interventional,Cardiovascular and Renal Biomarkers to Predict Acute Heart or Kidney Injury in Severe Covid-19 Infection,"Active, not recruiting",N/A,"Central Hospital, Nancy, France",NA,https://clinicalzeros.gov/ct2/show/NCT04354610,0,0,0,0,4,0,France,0,biological samples|clinical examination|telephone follow-up,NA
NCT04354558,2020-07-01,2021-07-31,Observational,French Single Centre Experience of Critically Ill Patients With Covid 19,Recruiting,NA,"Centre Hospitalier Universitaire, Amiens",NA,https://clinicalzeros.gov/ct2/show/NCT04354558,0,0,0,0,2,0,France,0,"NA",NA
NCT04354519,2020-03-14,2021-07-14,Observational [Patient Registry],The United Kingdom Multiple Sclerosis Register Covid-19 Substudy,Recruiting,NA,Swansea University,NA,https://clinicalzeros.gov/ct2/show/NCT04354519,0,0,0,0,1,0,United Kingdom,0,"NA",NA
NCT04353518,2020-06-30,2021-03-30,Interventional,Clinical Trial to Evaluate Mycobacterium w in Preventing COVID-19 in Subjects at Risk of Getting Infected With COVID-19,Recruiting,Phase 3,Cadila Pharnmaceuticals,NA,https://clinicalzeros.gov/ct2/show/NCT04353518,0,0,0,0,2,0,India,0,suspension of heat killed (autoclaved) mycobacterium w|placebo,NA
NCT04353206,2020-06-27,2021-05-31,Interventional,Convalescent Plasma in ICU Patients With COVID-19-induced Respiratory Failure,Recruiting,Early Phase 1,Cedars-Sinai Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04353206,0,0,0,0,3,1,United States,0,convalescent plasma,NA
NCT04352933,2020-05-11,2020-10-31,Interventional,PROLIFIC ChemoprophylaxisTrial (COVID-19),Recruiting,Phase 3,Cambridge University Hospitals NHS Foundation Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04352933,0,0,0,0,1,0,United Kingdom,0,hydroxychloroquine|placebo,NA
NCT04353401,2020-08-03,2021-04-30,Observational,WGS Analysis of COVID-19 Positive Patients,Enrolling by invitation,NA,Vanda Pharmaceuticals,NA,https://clinicalzeros.gov/ct2/show/NCT04353401,0,0,0,0,2,1,United States,0,"NA",NA
NCT04353336,2020-03-23,2030-09-23,Interventional,Efficacay of Chloroquine or Hydroxychloroquine in COVID-19 Treatment,Recruiting,Phase 2/Phase 3,Tanta University,NA,https://clinicalzeros.gov/ct2/show/NCT04353336,0,0,0,0,5,0,Egypt,0,chloroquine/hydroxychloroquine|chloroquine|hydroxychloroquine,NA
NCT04353284,2020-06-19,2021-05-31,Interventional,Camostat Mesylate in COVID-19 Outpatients,Recruiting,Phase 2,Yale University,NA,https://clinicalzeros.gov/ct2/show/NCT04353284,0,0,0,0,7,1,United States,0,camostat mesilate|placebo,NA
NCT04353271,2020-04-17,2020-07-08,Interventional,Trial of Hydroxychloroquine In Covid-19 Kinetics,Terminated,Phase 2/Phase 3,University of South Alabama,"FDA recommendations to not use outside of the hospital setting or in a clinical trial due to
    the risk of cardiac arrhythmias",https://clinicalzeros.gov/ct2/show/NCT04353271,0,0,0,0,3,1,United States,0,hydroxychloroquine|placebo,NA
NCT04353141,2020-04-28,2020-05-31,Observational,International Lung UltraSound Analysis (ILUSA) Study,Recruiting,NA,KU Leuven,NA,https://clinicalzeros.gov/ct2/show/NCT04353141,0,0,0,0,1,0,Belgium|Italy|United Kingdom,0,standard care,NA
NCT04352751,2020-05-01,2021-04-30,Interventional,Experimental Use of Convalescent Plasma for Passive Immunization in Current COVID-19 Pandemic in Pakistan in 2020,Recruiting,N/A,Hilton Pharma,NA,https://clinicalzeros.gov/ct2/show/NCT04352751,0,0,0,0,4,0,Pakistan,0,convalescent plasma,NA
NCT04352842,2020-01-21,2020-04-08,Observational,Echocardiographic Manifestation in Patient With COVID-19 ï¼ˆEARLY-MYO COVID-19ï¼‰,Completed,NA,RenJi Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04352842,0,0,0,0,2,0,China,0,echocardiography,NA
NCT04353128,2020-04-20,2020-10-31,Interventional,Efficacy of Melatonin in the Prophylaxis of Coronavirus Disease 2019 (COVID-19) Among Healthcare Workers.,Recruiting,Phase 2/Phase 3,Instituto de InvestigaciÃ³n Hospital Universitario La Paz,NA,https://clinicalzeros.gov/ct2/show/NCT04353128,0,0,0,0,2,0,Spain,0,melatonin|placebo,NA
NCT04352699,2020-03-15,2020-04-17,Observational,Outcomes of Urological Surgery During Periods of Social COVID-19 Containemnt: is it Reasonable to Limit Access to Surgical Care for All?,Completed,NA,Centre Hospitalier Universitaire de Nice,NA,https://clinicalzeros.gov/ct2/show/NCT04352699,0,0,0,0,2,0,France,0,"NA",NA
NCT04353011,2020-04-20,2020-04-27,Observational,Psychological Impact of Quarantine in Chronic Pain Patient During COVID-19 Outbreak,Completed,NA,"University Hospital, Lille",NA,https://clinicalzeros.gov/ct2/show/NCT04353011,0,0,0,0,3,0,France,0,questionnaire,NA
NCT04352582,2020-04-14,2020-04-30,Observational,COVID-19 and Vaccination Attitudes,Completed,NA,"University Hospital, Geneva",NA,https://clinicalzeros.gov/ct2/show/NCT04352582,0,0,0,0,1,0,United Kingdom,0,questionnaire,NA
NCT04352491,2020-04-24,2020-05-31,Observational,An Online Survey to Understand Feelings Related to COVID-19 Among ILBS Patients With Liver Disease,Completed,NA,"Institute of Liver and Biliary Sciences, India",NA,https://clinicalzeros.gov/ct2/show/NCT04352491,0,0,0,0,3,0,India,0,no intervention,NA
NCT04352348,2020-03-31,2021-05-31,Interventional,Cohort of Patients Infected With SARS-CoV2 (COVID-19) or Suspected of Being,Recruiting,N/A,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04352348,0,0,0,0,4,0,France,0,blood sample|fecal sample|sweat samples (covidog ancillary study)|saliva|6 minutes walk test|phone call|urine samples,NA
NCT04351763,2020-04-27,2021-03-02,Interventional,Amiodarone or Verapamil in COVID-19 Hospitalized Patients With Symptoms,Recruiting,Phase 2/Phase 3,Nicolaus Copernicus University,NA,https://clinicalzeros.gov/ct2/show/NCT04351763,0,0,0,0,0,0,Poland,0,amiodarone|verapamil,NA
NCT04351854,2020-04-20,2025-12-31,Observational,Registry for Clinical Presentation and Management of Patients With COVID-19 in the Emergency Room,Recruiting,NA,University of Cologne,NA,https://clinicalzeros.gov/ct2/show/NCT04351854,0,0,0,0,2,0,Germany,0,retrospective data collection,NA
NCT04351659,2020-04-14,2020-08-31,Observational,Novel Adoptive Cellular Therapy With SARS-CoV-2 Specific T Cells in Patients With Severe COVID-19,Recruiting,NA,KK Women's and Children's Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04351659,0,0,0,0,1,0,Singapore,0,convalescent plasma,NA
NCT04351633,2020-04-23,2020-04-30,Observational,Psychological Impact of Quarantine in Osteoporosis Patient During COVID-19 Outbreak,Completed,NA,"University Hospital, Lille",NA,https://clinicalzeros.gov/ct2/show/NCT04351633,0,0,0,0,4,0,France,0,questionnaire,NA
NCT04351620,2020-04-30,2020-06-30,Interventional,High-dose Hydroxychloroquine for the Treatment of Ambulatory Patients With Mild COVID-19,Recruiting,Phase 1,University of Chicago,NA,https://clinicalzeros.gov/ct2/show/NCT04351620,0,0,0,0,0,1,United States,0,hydroxychloroquine,NA
NCT04351581,2020-05-18,2020-12-31,Interventional,Effects of Discontinuing Renin-angiotensin System Inhibitors in Patients With COVID-19,Recruiting,N/A,"University Hospital, Gentofte, Copenhagen",NA,https://clinicalzeros.gov/ct2/show/NCT04351581,0,0,0,0,3,0,Denmark,0,discontinuation of acei/arb|continuation of acei/arb|discontinuation of acei|arb|continuation of acei,NA
NCT04351568,2020-04-01,2020-07-31,Observational,Professional and Ethical Challenges of Social Media Usage in Providing Healthcare Services During the Period of 19 Covid Pandemics;,Recruiting,NA,Assiut University,NA,https://clinicalzeros.gov/ct2/show/NCT04351568,0,0,0,0,1,0,Egypt,0,questionnaire,NA
NCT04351542,2020-03-06,2020-04-06,Interventional,Ayurveda for Flu Like Illness During Covid-19 Outbreak,Completed,N/A,Aarogyam UK,NA,https://clinicalzeros.gov/ct2/show/NCT04351542,0,0,0,0,0,0,United Kingdom,0,ayurveda|standard care,NA
NCT04351529,2020-04-01,2021-12-31,Observational [Patient Registry],Austrian COVID-19 Registry,Recruiting,NA,Arbeitsgemeinschaft medikamentoese Tumortherapie,NA,https://clinicalzeros.gov/ct2/show/NCT04351529,0,0,0,0,2,0,Austria,0,"NA",NA
NCT04351802,2020-05-11,2021-01-20,Observational,CORonavirus (COVID-19) Diagnostic Lung UltraSound Study,Recruiting,NA,University Hospital Plymouth NHS Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04351802,0,0,0,0,1,0,United Kingdom,0,lung ultrasound,NA
NCT04351399,2020-04-27,2020-05-04,Observational,Psychological Impact of Quarantine in Rheumatoid Arthritis Patient During COVID-19 Outbreak,Completed,NA,"University Hospital, Lille",NA,https://clinicalzeros.gov/ct2/show/NCT04351399,0,0,0,0,3,0,France,0,questionnaire,NA
NCT04351789,2020-05-01,2023-04-30,Interventional,Impact of a Minimal Psychoeducational Intervention on Anxiety Among Hospitalized COVID-19 Patients in Denmark,Recruiting,N/A,"Copenhagen University Hospital, Hvidovre",NA,https://clinicalzeros.gov/ct2/show/NCT04351789,0,0,0,0,1,0,Denmark,0,psychoeducational intervention,NA
NCT04351139,2020-05-06,2020-11-30,Observational,Impact of the COVID-19 Pandemic in Gynecological Oncology,Completed,NA,Hospices Civils de Lyon,NA,https://clinicalzeros.gov/ct2/show/NCT04351139,0,0,0,0,5,0,France,0,modification,NA
NCT04350736,2020-04-23,2020-06-24,Interventional,"First in Human SAD and MAD Study of Inhaled TD-0903, a Potential Treatment for ALI Associated With COVID-19",Completed,Phase 1,Theravance Biopharma,NA,https://clinicalzeros.gov/ct2/show/NCT04350736,0,0,0,0,4,0,United Kingdom,0,td-0903|placebo,NA
NCT04350710,2020-03-18,2020-04-20,Observational,Description of Respiratory Mechanics in Patients With SARS-CoV-2 Associated ARDS,Recruiting,NA,"University Hospital, Angers",NA,https://clinicalzeros.gov/ct2/show/NCT04350710,0,0,0,0,0,0,France,0,peep,NA
NCT04350684,2020-04-15,2020-04-22,Interventional,Umifenovir in Hospitalized COVID-19 Patients,Enrolling by invitation,Phase 4,Shahid Beheshti University of Medical Sciences,NA,https://clinicalzeros.gov/ct2/show/NCT04350684,0,0,0,0,1,0,"Iran, Islamic Republic of",0,umifenovir|interferon-î² 1a|lopinavir/ritonavir|hydroxychloroquine|standard care|interferon-î² 1a|lopinavir|ritonavir,NA
NCT04350671,2020-04-15,2020-04-20,Interventional,Interferon Beta 1a in Hospitalized COVID-19 Patients,Enrolling by invitation,Phase 4,Shahid Beheshti University of Medical Sciences,NA,https://clinicalzeros.gov/ct2/show/NCT04350671,0,0,0,0,1,0,"Iran, Islamic Republic of",0,interferon|lopinavir/ritonavir|hydroxychloroquine|lopinavir|ritonavir,NA
NCT04350320,2020-04-30,2020-10-20,Interventional,Trial to Study the Benefit of Colchicine in Patients With COVID-19,Completed,Phase 3,Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia,NA,https://clinicalzeros.gov/ct2/show/NCT04350320,0,0,0,0,3,0,Spain,0,colchicine|standard care,NA
NCT04349098,2020-04-17,2020-10-05,Interventional,Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection,Completed,Phase 2,Karyopharm Therapeutics Inc,NA,https://clinicalzeros.gov/ct2/show/NCT04349098,0,0,0,0,5,1,United States|Austria|France|Israel|Spain|United Kingdom,0,selinexor|placebo,NA
NCT04350281,2020-04-09,2020-07-01,Interventional,Double Therapy With IFN-beta 1b and Hydroxychloroquine,Completed,Phase 2,The University of Hong Kong,NA,https://clinicalzeros.gov/ct2/show/NCT04350281,0,0,0,0,2,0,Hong Kong,0,interferon|hydroxychloroquine,NA
NCT04349540,2020-04-15,2020-10-15,Observational,Role of Immune and Inflammatory Response in Recipients of Allogeneic Haematopoietic Stem Cell Transplantation (SCT) Affected by Severe COVID19,"Active, not recruiting",NA,Great Ormond Street Hospital for Children NHS Foundation Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04349540,0,0,0,0,0,0,United Kingdom,0,no intervention,NA
NCT04498377,2021-01-26,2021-09-30,Interventional,Study of F-652 (IL-22:IgG2 Fusion Protein) in Patients With Moderate to Severe COVID-19,Recruiting,Phase 2,Generon (Shanghai) Corporation Ltd.,NA,https://clinicalzeros.gov/ct2/show/NCT04498377,0,0,0,0,5,1,United States,0,f-652|placebo,NA
NCT04350099,2020-04-15,2021-02-15,Observational,Emotional Burden of Healthcare Professionals and Covid Infection 19,Recruiting,NA,"University Hospital, Limoges",NA,https://clinicalzeros.gov/ct2/show/NCT04350099,0,0,0,0,1,0,France,0,questionnaire,NA
NCT04350073,2020-04-20,2021-10-01,Observational,Longitudinal Energy Expenditure and Metabolic Effects in Patients With COVID-19 (LEEP-COVID),Recruiting,NA,Duke University,NA,https://clinicalzeros.gov/ct2/show/NCT04350073,0,0,0,0,3,1,United States,0,q-nrg metobolic cart device|musclesound ultrasound|multifrequency bioimpedance spectroscopy,NA
NCT04349982,2020-04-08,2022-06-30,Observational [Patient Registry],ICU Trial in Critical Ill COVID-19 Patients,Recruiting,NA,Medical University of Graz,NA,https://clinicalzeros.gov/ct2/show/NCT04349982,0,0,0,0,1,0,Austria,0,"biomarker (tropt, myoglobin, ck, ck-mb, ldh, d-dimer, crp, pct)",NA
NCT04349410,2020-04-11,2020-09-14,Interventional,The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol,Completed,Phase 2/Phase 3,The Camelot Foundation,NA,https://clinicalzeros.gov/ct2/show/NCT04349410,0,0,0,0,8,1,United States,0,hydroxychloroquine / azithromycin|hydroxychloroquine/doxycycline|hydroxychloroquine/clindamycin|hydroxychloroquine/clindamycin/primaquine|remdesivir|tocilizumab|methylprednisolone|interferon|losartan|convalescent plasma,NA
NCT04349241,2020-04-18,2020-06-01,Interventional,Efficacy and Safety of Favipiravir in Management of COVID-19,Completed,Phase 3,Ain Shams University,NA,https://clinicalzeros.gov/ct2/show/NCT04349241,0,0,0,0,2,0,Egypt,0,favipiravir|standard care,NA
NCT04480138,2020-08-11,2021-04-15,Interventional,Pegylated Interferon - Î±2b With SARSCoV- 2 (COVID-19),Recruiting,Phase 2,Cadila Healthcare Limited,NA,https://clinicalzeros.gov/ct2/show/NCT04480138,0,0,0,0,3,0,Mexico,0,pegylated interferon-î±2b|standard care|pegylated interferon-î±2b,NA
NCT04349163,2020-05-10,2020-06-15,Observational,Resilience Evaluation of Caregivers During the SARS-CoV2 Epidemic Period : Prospective Cohort.,Completed,NA,"University Hospital, Angers",NA,https://clinicalzeros.gov/ct2/show/NCT04349163,0,0,0,0,3,0,France,0,questionnaire,NA
NCT04348942,2020-05-29,2021-05-01,Observational [Patient Registry],"A COVID-19 Symptom, Exposure and Immune Response Registry","Active, not recruiting",NA,ObvioHealth,NA,https://clinicalzeros.gov/ct2/show/NCT04348942,0,0,0,0,4,1,United States,0,"NA",NA
NCT04348552,2020-04-28,2020-06-28,Observational,Non-COVID Patient-safety Incidents Reported by Primary Care Professionals in Time of Lockdown: Protocol for a Cross-sectional Descriptive Study,Recruiting,NA,Nantes University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04348552,0,0,0,0,2,0,France,0,"primary care professionals reports of potential patient safety incidents, non-covid-19 related",NA
NCT04348409,2020-05-25,2020-07-31,Interventional,Efficacy and Safety of Nitazoxanide for the Treatment of Hospitalized Patients With Moderate COVID-19,Recruiting,N/A,Azidus Brasil,NA,https://clinicalzeros.gov/ct2/show/NCT04348409,0,0,0,0,2,0,Brazil,0,nitazoxanide|placebo,NA
NCT04348396,2020-04-03,2020-12-31,Observational,Clinical and Biological Predictors of COVID-19 Disease in Older Patients,Recruiting,NA,Istituto Nazionale di Ricovero e Cura per Anziani,NA,https://clinicalzeros.gov/ct2/show/NCT04348396,0,0,0,0,1,0,Italy,0,"NA",NA
NCT04348370,2020-04-20,2021-05-31,Interventional,BCG Vaccine for Health Care Workers as Defense Against COVID 19,Recruiting,Phase 4,Texas A&M University,NA,https://clinicalzeros.gov/ct2/show/NCT04348370,0,0,0,1,5,1,United States,0,bcg|placebo,NA
NCT04347876,2020-04-11,2020-06-16,Observational,Outcome of COVID-19 Cases Based on Tuberculin Test: Can Previous BCG Alter the Prognosis?,Recruiting,NA,Assiut University,NA,https://clinicalzeros.gov/ct2/show/NCT04347876,0,0,0,0,0,0,Egypt,0,tuberculin,NA
NCT04348227,2019-01-01,2020-01-01,Observational [Patient Registry],How COVID-19 Virus Outbreak Affects Antimicrobial Resistance in a Low-middle-income Country's ICU?,"Active, not recruiting",NA,HÃ´pital Universitaire Fattouma Bourguiba,NA,https://clinicalzeros.gov/ct2/show/NCT04348227,0,0,0,0,1,0,Tunisia,0,enhanced hygiene measures,NA
NCT04347850,2020-02-01,2022-12-01,Observational,A Cohort of Patients With Possible or Confirmed SARS-CoV-2 (COVID-19),Recruiting,NA,"University Hospital, Montpellier",NA,https://clinicalzeros.gov/ct2/show/NCT04347850,0,0,0,0,2,0,France,0,blood sample,NA
NCT04347798,2020-09-30,2021-04-30,Observational [Patient Registry],IMPACT: IMPact of Antimalarials on Covid-19 Infections in RAPPORT,Enrolling by invitation,NA,University of Alberta,NA,https://clinicalzeros.gov/ct2/show/NCT04347798,0,0,0,0,2,0,Canada,0,chloroquine/hydroxychloroquine|hydroxychloroquine|chloroquine,NA
NCT04347980,2020-04-30,2020-06-30,Interventional,Dexamethasone Treatment for Severe Acute Respiratory Distress Syndrome Induced by COVID-19,Recruiting,Phase 3,Centre Chirurgical Marie Lannelongue,NA,https://clinicalzeros.gov/ct2/show/NCT04347980,0,0,0,0,1,0,France,0,dexamethasone/hydroxychloroquine|hydroxychloroquine|dexamethasone,NA
NCT04347954,2020-08-15,2020-12-13,Interventional,PVP-I Nasal Sprays and SARS-CoV-2 Nasopharyngeal Titers (for COVID-19),Completed,Phase 1/Phase 2,Stanford University,NA,https://clinicalzeros.gov/ct2/show/NCT04347954,0,0,0,0,6,1,United States,0,povidone/iodine|saline,NA
NCT04347928,2020-04-20,2020-11-06,Observational,Respiratory and Hemodynamic Changes Induced in Mechanically Ventilated Patients for COVID-19,Completed,NA,"University Hospital, Lille",NA,https://clinicalzeros.gov/ct2/show/NCT04347928,0,0,0,0,2,0,France,0,"NA",NA
NCT04347915,2020-05-06,2021-01-30,Interventional,The Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Moderate COVID-19,Recruiting,Phase 2,Bukwang Pharmaceutical,NA,https://clinicalzeros.gov/ct2/show/NCT04347915,0,0,0,0,4,0,"Korea, Republic of",0,clevudine|placebo,NA
NCT04468386,2020-07-07,2021-03-30,Observational,Specimen Collection Study Protocol,"Active, not recruiting",NA,Biomerica,NA,https://clinicalzeros.gov/ct2/show/NCT04468386,0,0,0,0,3,1,United States,0,"NA",NA
NCT04347278,2020-04-22,2020-10-15,Observational [Patient Registry],Observational Study of Follow-up of Hospitalized Patients Diagnosed With COVID-19 to Evaluate the Effectiveness of the Drug Treatment Used to Treat This Disease. COVID-19 Registry,Recruiting,NA,Instituto de InvestigaciÃ³n MarquÃ©s de Valdecilla,NA,https://clinicalzeros.gov/ct2/show/NCT04347278,0,0,0,0,1,0,Spain,0,patients with the treatment agains covid19,NA
NCT04347382,2020-04-30,2020-08-30,Interventional,Honey & Nigella Sativa Trial Against COVID-19,Completed,Phase 3,Sheikh Zayed Federal Postgraduate Medical Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04347382,0,0,0,0,6,0,Pakistan,0,honey|nigella sativa / black cumin|placebo|nigella sativa|cumin,NA
NCT04462627,2020-04-14,2021-12-31,Interventional,Reduction of COVID 19 Transmission to Health Care Professionals,Recruiting,N/A,Brugmann University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04462627,0,0,0,0,1,0,Belgium,0,blood group determination|serology test|probiotic,NA
NCT04459403,2020-06-08,2020-12-30,Observational,Psychiatric Disturbances and COVID-19 Infection,Completed,NA,Cairo University,NA,https://clinicalzeros.gov/ct2/show/NCT04459403,0,0,0,0,2,0,Egypt,0,"NA",NA
NCT04347460,2020-03-27,2020-07-01,Observational,Establishing a COVID-19 Prospective Cohort for Identification of Secondary HLH,Recruiting,NA,Technische UniversitÃ¤t MÃ¼nchen,NA,https://clinicalzeros.gov/ct2/show/NCT04347460,0,0,0,0,0,0,Germany,0,"NA",NA
NCT04347538,2020-05-01,2021-06-30,Interventional,Impact of Nasal Saline Irrigations on Viral Load in Patients With COVID-19,"Active, not recruiting",N/A,Vanderbilt University Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04347538,0,0,0,0,5,1,United States,0,saline|saline with baby shampoo nasal irrigation,NA
NCT04347070,2017-04-01,2020-09-01,Observational,Implementation of Physiotherapy on COVID-19 Patients in ICU,"Active, not recruiting",NA,"University Hospital, Montpellier",NA,https://clinicalzeros.gov/ct2/show/NCT04347070,0,0,0,0,2,0,France,0,phsyiotherapy,NA
NCT04347031,2020-04-08,2020-11-01,Interventional,A Study of the Effectiveness of an Off Label Mefloquine Use for the Treatment of Patients With COVID19,Completed,Phase 2/Phase 3,Burnasyan Federal Medical Biophysical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04347031,0,0,0,0,2,0,Russian Federation,0,mefloquine|hydroxychloroquine|mefloquine/azithromycin/ tocilizumab|hydroxychloroquine/azithromycin/ tocilizumab|azithromycin|NA|- tocilizumab,NA
NCT04347226,2020-04-16,2021-09-30,Interventional,Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19,Recruiting,Phase 2,Columbia University,NA,https://clinicalzeros.gov/ct2/show/NCT04347226,0,0,0,0,3,1,United States,0,bms-986253,NA
NCT04347174,2020-04-30,2020-08-10,Interventional,A Clinical Trial of Mycobacterium w in Critically Ill COVID 19 Patients,Completed,N/A,Cadila Pharnmaceuticals,NA,https://clinicalzeros.gov/ct2/show/NCT04347174,0,0,0,0,6,0,India,0,suspension of heat killed (autoclaved) mycobacterium w|placebo,NA
NCT04347369,2020-01-17,2020-08-30,Observational,A Retrospective Study of Neural Network Model to Dynamically Quantificate the Severity in COVID-19 Disease,Recruiting,NA,Xinqiao Hospital of Chongqing,NA,https://clinicalzeros.gov/ct2/show/NCT04347369,0,0,0,0,1,0,China,0,other,NA
NCT04346446,2020-04-20,2020-05-30,Interventional,Efficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients,Completed,Phase 2,"Institute of Liver and Biliary Sciences, India",NA,https://clinicalzeros.gov/ct2/show/NCT04346446,0,0,0,0,7,0,India,0,convalescent plasma|supportive care|plasma,NA
NCT04346797,2020-04-16,2020-09-30,Interventional,"CORIMUNO19-ECU: Trial Evaluating Efficacy and Safety of Eculizumab (Soliris) in Patients With COVID-19 Infection, Nested in the CORIMUNO-19 Cohort",Recruiting,Phase 2,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04346797,0,0,0,0,1,0,France,0,eculizumab,NA
NCT04346693,2020-04-08,2020-11-01,Interventional,An Open Randomized Study of Dalargin Effectiveness in Patients With Severe and Critical Manifestations of SARS-COVID-19,Completed,Phase 3,Burnasyan Federal Medical Biophysical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04346693,0,0,0,0,2,0,Russian Federation,0,standard care|dalargin,NA
NCT04346589,2020-04-15,2020-08-31,Interventional,Convalescent Antibodies Infusion in Critically Ill COVID 19 Patients,Recruiting,N/A,A.O. Ospedale Papa Giovanni XXIII,NA,https://clinicalzeros.gov/ct2/show/NCT04346589,0,0,0,0,3,0,Italy,0,anti-coronavirus antibodies (immunoglobulins)obtained with dfpp from convalescent patients,NA
NCT04346121,2020-04-28,2020-06-29,Observational,Non-COVID Patient-safety Incidents Reported by General Practitioners in Time of Lockdown: Protocol for a Cross-sectional Descriptive Study.cRisis,Completed,NA,Nantes University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04346121,0,0,0,0,3,0,France,0,"gps reports of potential patient safety incidents, non-covid-19 related",NA
NCT04345640,2020-04-10,2020-12-31,Observational,The Spectrum and Profile of COVID-19 Infection and Its Impact on Liver.,Recruiting,NA,"Institute of Liver and Biliary Sciences, India",NA,https://clinicalzeros.gov/ct2/show/NCT04345640,0,0,0,0,2,0,India,0,no intervention,NA
NCT04346420,2020-04-09,2020-05-01,Interventional,Impact of the Double-Trunk Mask on Oxygenation Titration in COVID-19,Completed,N/A,Cliniques universitaires Saint-Luc- UniversitÃ© Catholique de Louvain,NA,https://clinicalzeros.gov/ct2/show/NCT04346420,0,0,0,0,1,0,Belgium,0,standard interface|mask,NA
NCT04346056,2020-04-14,2020-10-01,Observational,Retrospective Study on Severe Respiratory Illness to Access the Presence of COVID-19,Recruiting,NA,Ain Shams University,NA,https://clinicalzeros.gov/ct2/show/NCT04346056,0,0,0,0,3,0,Egypt,0,"NA",NA
NCT04346212,2020-04-14,2020-12-31,Observational,Oropharyngeal Dysphagia in Patients With COVID-19,Recruiting,NA,Hospital de MatarÃ³,NA,https://clinicalzeros.gov/ct2/show/NCT04346212,0,0,0,0,2,0,Spain,0,swallowing evaluation with the eat-10/the volume-viscosity swallowing test (v-vst)|swallowing evaluation with the eat-10|volume rapid test,NA
NCT04346017,2020-03-20,2020-12-31,Interventional,Evaluation of Interleukine 6 (and Other Cytokines and Inflammatory Markers) in COVID-19 Patients With a Systemic Inflammatory Response Syndrome,Recruiting,N/A,Brugmann University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04346017,0,0,0,0,0,0,Belgium,0,cytokines|complement dosage,NA
NCT04345692,2020-03-26,2020-08-31,Interventional,A Randomized Controlled Clinical Trial: Hydroxychloroquine for the Treatment of COVID-19 in Hospitalized Patients,Terminated,Phase 3,Queen's Medical Centre,RECOVERY Trial results - no efficacy,https://clinicalzeros.gov/ct2/show/NCT04345692,0,0,0,0,2,1,United States,0,hydroxychloroquine,NA
NCT04345315,2020-03-27,2021-03-31,Observational,"Correlative Study on Cancer Patients and Healthcare Professionals Exposed to Infection by Severe Acute Respiratory Syndrome-Corona Virus-2 (SARS-Cov-2), COVID-19 Causative Agent.",Recruiting,NA,Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori,NA,https://clinicalzeros.gov/ct2/show/NCT04345315,0,0,0,0,1,0,Italy,0,serology test|rapid molecular test|next generation sequencing (ngs) analysis|serum test,NA
NCT04345991,2020-04-15,2020-05-15,Interventional,"Efficacy of Convalescent Plasma to Treat COVID-19 Patients, a Nested Trial in the CORIMUNO-19 Cohort",Recruiting,Phase 2,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04345991,0,0,0,0,1,0,France,0,convalescent plasma,NA
NCT04345861,2020-04-11,2020-06-08,Interventional,Hydroxychloroquine Plus Azithromycin Versus Hydroxychloroquine for COVID-19 Pneumonia (COVIDOC Trial),Terminated,Phase 2/Phase 3,"University Hospital, Montpellier",halted prematurely.,https://clinicalzeros.gov/ct2/show/NCT04345861,0,0,0,0,3,0,France,0,hydroxychloroquine/placebo|hydroxychloroquine / azithromycin|hydroxychloroquine|placebo|azithromycin,NA
NCT04345289,2020-05-01,2021-06-15,Interventional,Efficacy and Safety of Novel Treatment Options for Adults With COVID-19 Pneumonia,Recruiting,Phase 3,Hvidovre University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04345289,0,0,0,0,2,0,Denmark,0,convalescent plasma|placebo,NA
NCT04345276,2020-03-18,2020-04-15,Interventional,Efficacy and Safety of Ganovo (Danoprevir) Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection,Completed,Phase 4,Huoshenshan Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04345276,0,0,0,0,1,0,China,0,danoprevir/ritonavir|danoprevir|ritonavir,NA
NCT04345549,2020-02-26,2020-03-30,Interventional,Ayurveda Self-Management for Flu Like Symptoms During the Covid-19 Outbreak,Completed,N/A,Aarogyam UK,NA,https://clinicalzeros.gov/ct2/show/NCT04345549,0,0,0,0,0,0,United Kingdom,0,ayurveda,NA
NCT04345159,2020-04-17,2020-11-30,Observational,Association Between Long-term Hydroxychloroquine Treatment and Outcome of a History of Symptoms Suggestive of COVID-19 Infection During the Epidemic Period in France in Patients With Autoimmune Disease,Completed,NA,Fondation Ophtalmologique Adolphe de Rothschild,NA,https://clinicalzeros.gov/ct2/show/NCT04345159,0,0,0,0,4,0,France,0,questionnaire,NA
NCT04344912,2020-03-20,2020-06-30,Observational [Patient Registry],Impact of COVID19 Outbreak in Cardiac Acute Care,Recruiting,NA,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04344912,0,0,0,0,1,0,France,0,data collection,NA
NCT04344964,2020-04-15,2020-05-29,Observational,Endoscopy-related Phone Consultation During the COVID-19 Outbreak,Completed,NA,Austin Health,NA,https://clinicalzeros.gov/ct2/show/NCT04344964,0,0,0,0,2,0,Australia,0,none - na,NA
NCT04344561,2020-05-25,2021-05-01,Interventional,Incline Positioning in COVID-19 Patients for Improvement in Oxygen Saturation,Recruiting,N/A,Johns Hopkins University,NA,https://clinicalzeros.gov/ct2/show/NCT04344561,0,0,0,0,3,1,United States,0,postural positioning,NA
NCT04344457,2020-04-16,2020-06-20,Interventional,"Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects With Mild Symptoms of COVID-19",Recruiting,Phase 1/Phase 2,"Perseverance Research Center, LLC",NA,https://clinicalzeros.gov/ct2/show/NCT04344457,0,0,0,0,3,1,United States,0,hydroxychloroquine|indomethacin|zithromax,NA
NCT04344444,2020-04-13,2021-04-10,Interventional,Treatment in Patients With Suspected or Confirmed COVID-19 With Early Moderate or Severe Disease,"Active, not recruiting",Phase 3,LCMC Health,NA,https://clinicalzeros.gov/ct2/show/NCT04344444,0,0,0,0,1,1,United States,0,hydroxychloroquine|azithromycin,NA
NCT04344431,2020-04-14,2022-04-30,Interventional,Management by Hyperbaric Oxygen Therapy of Patients With Hypoxaemic Pneumonia With SARS-CoV-2 (COVID-19),Recruiting,Phase 2/Phase 3,Direction Centrale du Service de SantÃ© des ArmÃ©es,NA,https://clinicalzeros.gov/ct2/show/NCT04344431,0,0,0,0,2,0,France,0,hyperbaric oxygen|device),NA
NCT04344288,2020-04-21,2020-08-18,Interventional,Corticosteroids During Covid-19 Viral Pneumonia Related to SARS-Cov-2 Infection,Terminated,Phase 2,Hospices Civils de Lyon,Competent Authority's decision,https://clinicalzeros.gov/ct2/show/NCT04344288,0,0,0,0,4,0,France,0,control|prednisone,NA
NCT04344249,2020-04-10,2020-09-30,Observational [Patient Registry],Cohort of Patients With Inflammatory Bowel Disease During COVID-19 Pandemic,Recruiting,NA,Nantes University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04344249,0,0,0,0,1,0,France,0,"NA",NA
NCT04344106,2020-04-01,2020-04-15,Interventional,Prone Positioning in Spontaneously Breathing Nonintubated Covid-19 Patient: a Pilot Study,Recruiting,N/A,Centre Hospitalier Intercommunal Aix-Pertuis,NA,https://clinicalzeros.gov/ct2/show/NCT04344106,0,0,0,0,0,0,France,0,prone positioning,NA
NCT04344236,2020-04-09,2020-05-01,Interventional,Gargling and Nasal Rinses to Reduce Oro- and Nasopharyngeal Viral Load in Patients With COVID-19,Recruiting,Phase 2,NYU Langone Health,NA,https://clinicalzeros.gov/ct2/show/NCT04344236,0,0,0,0,0,1,United States,0,saline|povidone/iodine|chlorhexidine|nasal rinse|povidone|iodine,NA
NCT04344210,2020-04-17,2020-09-20,Interventional,Impact of Tele-interventions During the COVID-19 Pandemic in Patients With Diabetes Mellitus,Completed,N/A,Federal University of Rio Grande do Sul,NA,https://clinicalzeros.gov/ct2/show/NCT04344210,0,0,0,0,1,0,Brazil,0,tele-interventions related to diabetes management/mental well-being|tele-interventions related to diabetes management|mental well-being,NA
NCT04344015,2020-04-13,2021-04-12,Interventional,COVID-19 Plasma Collection,Recruiting,N/A,Thomas Jefferson University,NA,https://clinicalzeros.gov/ct2/show/NCT04344015,0,0,0,0,2,1,United States,0,plasma,NA
NCT04343989,2020-03-31,2021-01-30,Interventional,A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection,"Active, not recruiting",Phase 2,NYU Langone Health,NA,https://clinicalzeros.gov/ct2/show/NCT04343989,0,0,0,0,4,1,United States,0,clazakizumab|placebo,NA
NCT04344171,2020-03-30,2022-12-31,Observational,CovidDB: The Covid-19 Inpatient Database,Recruiting,NA,ClarData,NA,https://clinicalzeros.gov/ct2/show/NCT04344171,0,0,0,0,1,0,Germany|Romania,0,"NA",NA
NCT04343404,2020-04-01,2020-04-15,Observational,Place of ECMO in the Management of Severe Refractory ARDS Associated With Covid-19,Completed,NA,"University Hospital, Strasbourg, France",NA,https://clinicalzeros.gov/ct2/show/NCT04343404,0,0,0,0,1,0,France,0,"NA",NA
NCT04343794,2020-04-01,2021-12-31,Interventional,Using BiovitalsÂ® Sentinel to Monitor Disease Progression in Subjects Quarantined for Suspected COVID-19,Recruiting,N/A,The University of Hong Kong,NA,https://clinicalzeros.gov/ct2/show/NCT04343794,0,0,0,0,1,0,Hong Kong,0,biovitals,NA
NCT04343755,2020-04-09,2021-04-30,Interventional,Convalescent Plasma as Treatment for Hospitalized Subjects With COVID-19 Infection,"Active, not recruiting",Phase 2,Hackensack Meridian Health,NA,https://clinicalzeros.gov/ct2/show/NCT04343755,0,0,0,0,5,1,United States,0,convalescent plasma,NA
NCT04343742,2020-04-01,2020-04-07,Observational,Determination of the Effectiveness of Oral Chlorine Dioxide in the Treatment of COVID 19,Recruiting,NA,Genesis Foundation,NA,https://clinicalzeros.gov/ct2/show/NCT04343742,0,0,0,0,1,0,Colombia,0,chlorine dioxide,NA
NCT04343651,2020-04-01,2020-07-21,Interventional,Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19,"Active, not recruiting",Phase 2,"CytoDyn, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04343651,0,0,0,0,7,1,United States,0,placebo|lenzilumab,NA
NCT04343339,2020-04-08,2020-07-30,Observational,Evolution of Psychoactive Substances Consumption in Connection With COVID-19 Containment,Completed,NA,"University Hospital, Montpellier",NA,https://clinicalzeros.gov/ct2/show/NCT04343339,0,0,0,0,2,0,France,0,"NA",NA
NCT04343092,2020-04-18,2020-05-31,Interventional,Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management,Completed,Phase 1,University of Baghdad,NA,https://clinicalzeros.gov/ct2/show/NCT04343092,0,0,0,0,4,0,Iraq,1,ivermectin,NA
NCT04342897,2020-04-20,2020-10-12,Interventional,A Study of LY3127804 in Participants With COVID-19,Terminated,Phase 2,Eli Lilly and Company,Trial terminated for futility.,https://clinicalzeros.gov/ct2/show/NCT04342897,0,0,0,0,19,1,United States,0,ly3127804|placebo,NA
NCT04342884,2020-04-08,2021-12-31,Observational,COVID-19 Community Research Partnership,Recruiting,NA,Wake Forest University Health Sciences,NA,https://clinicalzeros.gov/ct2/show/NCT04342884,0,0,0,0,2,1,United States,0,"NA",NA
NCT04342702,2020-03-16,2021-03-31,Observational,A Study on the Prospective Cohort Library of COVID-19 in Southeran,"Active, not recruiting",NA,Second Affiliated Hospital of Wenzhou Medical University,NA,https://clinicalzeros.gov/ct2/show/NCT04342702,0,0,0,0,2,0,China,0,"NA",NA
NCT04342689,2020-06-03,2021-06-01,Interventional,The Role of Resistant Starch in COVID-19 Infection,Recruiting,Phase 2/Phase 3,Yale University,NA,https://clinicalzeros.gov/ct2/show/NCT04342689,0,0,0,0,5,1,United States,0,dietary supplement containing resistant starch|placebo,NA
NCT04342650,2020-04-08,2020-05-14,Interventional,Chloroquine Diphosphate in the Prevention of SARS in Covid-19 Infection,Completed,Phase 2,FundaÃ§Ã£o de Medicina Tropical Dr. Heitor Vieira Dourado,NA,https://clinicalzeros.gov/ct2/show/NCT04342650,0,0,0,0,2,0,Brazil,0,chloroquine|placebo,NA
NCT04342195,2020-03-25,2021-03-31,Observational,Acquiring Convalescent Specimens for COVID-19 Antibodies,Recruiting,NA,Columbia University,NA,https://clinicalzeros.gov/ct2/show/NCT04342195,0,0,0,0,2,1,United States,0,blood sample,NA
NCT04342169,2020-04-04,2021-04-30,Interventional,University of Utah COVID-19 Hydrochloroquine Trial,Recruiting,Phase 2,University of Utah,NA,https://clinicalzeros.gov/ct2/show/NCT04342169,0,0,0,0,3,1,United States,0,hydroxychloroquine|placebo,NA
NCT04341792,2020-04-11,2021-04-30,Observational,Predictive Biomarkers of Secondary Aggravation in Covid-19 Suspect Patient,Recruiting,NA,"University Hospital, Lille",NA,https://clinicalzeros.gov/ct2/show/NCT04341792,0,0,0,0,2,0,France,0,"NA",NA
NCT04341766,2020-03-31,2020-05-27,Observational [Patient Registry],Evolution of Pulmonary Ultrasound in Patients Hospitalized for Covid (Coronavirus Disease) 19,Completed,NA,Centre Hospitalier Intercommunal Creteil,NA,https://clinicalzeros.gov/ct2/show/NCT04341766,0,0,0,0,2,0,France,0,no special intervention,NA
NCT04341714,2020-03-16,2020-05-30,Observational,Efficiency and Satisfaction With Telephone Consultation in Neuro-urology: Experience of the COVID-19 Pandemic,Recruiting,NA,Pierre and Marie Curie University,NA,https://clinicalzeros.gov/ct2/show/NCT04341714,0,0,0,0,1,0,France,0,satisfaction evaluation,NA
NCT04341675,2020-04-24,2020-07-31,Interventional,Sirolimus Treatment in Hospitalized Patients With COVID-19 Pneumonia,Recruiting,Phase 2,University of Cincinnati,NA,https://clinicalzeros.gov/ct2/show/NCT04341675,0,0,0,0,4,1,United States,0,sirolimus|placebo,NA
NCT04341441,2020-04-07,2020-12-15,Interventional,Will Hydroxychloroquine Impede or Prevent COVID-19,Terminated,Phase 3,Henry Ford Health System,"Interim analysis did not reveal any safety concerns by the DSMB, but unblinded data did not
    provide support to continue. Event rate did not meet projected magnitude; given low recruitment
    potential, it is unlikely that a positive result will occur.",https://clinicalzeros.gov/ct2/show/NCT04341441,0,0,0,0,5,1,United States,0,hydroxychloroquine|placebo|monitoring visit|weekly assessment,NA
NCT04341519,2020-04-06,2020-11-30,Observational,"Psychological Burden in ICU Survivors of Severe COVID-19 Pneumonia, Their Relatives and Their Healthcare Providers",Recruiting,NA,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04341519,0,0,0,0,1,0,France,0,ptsd|burnout,NA
NCT04341207,2020-04-03,2022-04-30,Interventional,Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease in French Cancer Patients,Recruiting,Phase 2,"Gustave Roussy, Cancer Campus, Grand Paris",NA,https://clinicalzeros.gov/ct2/show/NCT04341207,0,0,0,0,0,0,France,0,hydroxychloroquine|azithromycin,NA
NCT04341116,2020-04-11,2021-12-31,Interventional,Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19),Recruiting,Phase 2/Phase 3,I-Mab Biopharma Co. Ltd.,NA,https://clinicalzeros.gov/ct2/show/NCT04341116,0,0,0,0,14,1,United States,0,tj003234|placebo,NA
NCT04341506,2020-09-08,2021-07-15,Observational,Non-contact ECG Sensor System for COVID19,Recruiting,NA,Northwestern Medicine,NA,https://clinicalzeros.gov/ct2/show/NCT04341506,0,0,0,0,1,1,United States,0,ecg,NA
NCT04341480,2020-07-01,2020-12-10,Observational,The Safety of Chemotherapy for Patients With Gynecological Malignancy in High-risk Region of COVID-19,"Active, not recruiting",NA,Tongji Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04341480,0,0,0,0,1,0,China,0,chemotherapy,NA
NCT04340557,2020-03-27,2020-10-06,Interventional,Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome With SARS-CoV-2 Infection,Recruiting,Phase 4,Sharp HealthCare,NA,https://clinicalzeros.gov/ct2/show/NCT04340557,0,0,0,0,1,1,United States,0,losartan,NA
NCT04368845,2020-05-11,2021-03-31,Interventional,Telerehabilitation in Patients With COVID-19 After Hospitalization. The ATHLOS Study,Recruiting,N/A,Clinical Exercise Physiology and Rehabilitation Reasearch Laboratory,NA,https://clinicalzeros.gov/ct2/show/NCT04368845,0,0,0,0,2,0,Greece,0,telehealth,NA
NCT04340544,2020-04-22,2020-10-12,Interventional,Hydroxychloroquine for the Treatment of Mild COVID-19 Disease,Terminated,Phase 2,University Hospital Tuebingen,"It appeared to be impossible for the study centres to recruit the targeted number of patients,
    due to reduced incidence and reduced acceptance to IMP",https://clinicalzeros.gov/ct2/show/NCT04340544,0,0,0,0,2,0,Germany,0,hydroxychloroquine|placebo,NA
NCT04340479,2020-07-30,2022-05-31,Observational [Patient Registry],The Use of Ultrasound in Establishing COVID-19 Infection as Part of a Trauma Evaluation,Recruiting,NA,"University of Colorado, Denver",NA,https://clinicalzeros.gov/ct2/show/NCT04340479,0,0,0,0,4,1,United States,0,ultrasound|evaluation,NA
NCT04350593,2020-04-22,2021-04-30,Interventional,Dapagliflozin in Respiratory Failure in Patients With COVID-19,"Active, not recruiting",Phase 3,Saint Luke's Health System,NA,https://clinicalzeros.gov/ct2/show/NCT04350593,0,0,0,0,4,1,United States|Argentina|Brazil|Canada|India|Mexico|United Kingdom,0,dapagliflozin|placebo,NA
NCT04340466,2020-04-03,2020-07-03,Observational [Patient Registry],French Multicentre Observational Study on SARS-Cov-2 Infections (COVID-19) ICU Management Study,Completed,NA,Centre Hospitalier Universitaire de NÄ«mes,NA,https://clinicalzeros.gov/ct2/show/NCT04340466,0,0,0,0,2,0,France,0,no intervention,NA
NCT04340219,2020-03-30,2020-04-10,Observational,"Oncology-patient-reported Anxiety, Mood, and QoL During the COVID-19 Pandemic",Completed,NA,"University Hospital, Ghent",NA,https://clinicalzeros.gov/ct2/show/NCT04340219,0,0,0,0,2,0,Belgium,0,questionnaire,NA
NCT04339712,2020-04-02,2020-12-01,Interventional,Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,Completed,Phase 2,Hellenic Institute for the Study of Sepsis,NA,https://clinicalzeros.gov/ct2/show/NCT04339712,0,0,0,0,5,0,Greece,0,anakinra|tocilizumab,NA
NCT04339686,2020-04-20,2020-09-30,Observational,Multicentric Retrospective Observational Study of Thoracic Scanner Performance in COVID Screening.,Recruiting,NA,Poitiers University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04339686,0,0,0,0,2,0,France,0,thoracic ct,NA
NCT04339660,2020-02-01,2020-06-30,Interventional,Clinical Research of Human Mesenchymal Stem Cells in the Treatment of COVID-19 Pneumonia,Recruiting,Phase 1/Phase 2,Puren Hospital Affiliated to Wuhan University of Science and Technology,NA,https://clinicalzeros.gov/ct2/show/NCT04339660,0,0,0,0,0,0,China,0,mesenchymal stem cells|placebo,NA
NCT04339634,2020-04-07,2020-07-07,Observational,Simulation of Risk of Adverse Drug Events Associated With the Initiation of Drugs Repurposed for the Treatment of COVID-19 in Frail Elderly Adults With Polypharmacy,"Active, not recruiting",NA,Tabula Rasa HealthCare,NA,https://clinicalzeros.gov/ct2/show/NCT04339634,0,0,0,0,1,1,United States,0,simulation of repurposed drugs for covid-19,NA
NCT04339998,2020-04-15,2020-10-31,Observational,Assessment of Exam Findings in Coronavirus Disease 2019 (COVID-19) With Point-of-Care Ultrasonography (POCUS),Recruiting,NA,University of Minnesota,NA,https://clinicalzeros.gov/ct2/show/NCT04339998,0,0,0,0,2,1,United States,0,ultrasonography,NA
NCT04339881,2020-04-17,2020-07-10,Observational [Patient Registry],NOsocomial Dissemination Risk of SARS-Cov2,Completed,NA,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04339881,0,0,0,0,1,0,France,0,"NA",NA
NCT04339491,2020-04-01,2020-05-31,Observational,Physical Activity During Social Isolation,Completed,NA,Istanbul University-Cerrahpasa,NA,https://clinicalzeros.gov/ct2/show/NCT04339491,0,0,0,0,1,0,Turkey,0,"NA",NA
NCT04339426,2020-04-20,2021-07-31,Interventional,Atovaquone and Azithromycin Combination for Confirmed COVID-19 Infection,Recruiting,Phase 2,HonorHealth Research Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04339426,0,0,0,0,5,1,United States,0,atovaquone/azithromycin|atovaquone|azithromycin,NA
NCT04339387,2020-03-01,2020-04-26,Observational,COVID-19 Risk Stratification,Completed,NA,Brigham and Women's Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04339387,0,0,0,0,1,1,United States,0,"NA",NA
NCT04338945,2020-03-15,2020-04-15,Observational,Impact of Pandemic COVID-19 on Surgical Specialities Residents in Italy,Completed,NA,Piazza della Vittoria 14 Studio Medico - Ginecologia e Ostetricia,NA,https://clinicalzeros.gov/ct2/show/NCT04338945,0,0,0,0,3,0,Italy,0,covid-surgres questionaire,NA
NCT04338932,2020-04-17,2020-05-15,Observational,COVID-19 and Deep Venous Thrombosis,Completed,NA,Jessa Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04338932,0,0,0,0,2,0,Belgium,0,"NA",NA
NCT04337190,2020-04-03,2020-10-06,Observational,Impact of Angiotensin II Receptor Blockers Treatment in Patients With COVID 19 (COVID-ARA2),Recruiting,NA,"University Hospital, Angers",NA,https://clinicalzeros.gov/ct2/show/NCT04337190,0,0,0,0,1,0,France,0,blood sample,NA
NCT04337762,2020-04-06,2020-12-31,Observational,Beat COVID-19 - Observational Trial,Recruiting,NA,Beat COVID LLC,NA,https://clinicalzeros.gov/ct2/show/NCT04337762,0,0,0,0,1,1,United States,0,"NA",NA
NCT04337424,2020-04-13,2020-10-07,Observational,Evaluation of Quickly Diagnostic Saliva Tests for SARS-CoV-2,Completed,NA,"University Hospital, Montpellier",NA,https://clinicalzeros.gov/ct2/show/NCT04337424,0,0,0,0,4,0,France,0,salivary,NA
NCT04337346,2020-04-05,2020-04-20,Observational [Patient Registry],Evaluation of Covid 19 Anxiety in Endometriosis Patients,Completed,NA,Kanuni Sultan Suleyman Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04337346,0,0,0,0,2,0,Turkey,0,"NA",NA
NCT04337320,2020-03-15,2020-05-25,Observational,"Maternal And Neonatal Outcome of Pregnant Patients With COVID-19 in Istanbul, Turkey: A Single-Center, Retrospective, Descriptive Study",Completed,NA,Kanuni Sultan Suleyman Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04337320,0,0,0,0,1,0,Turkey,0,newborns,NA
NCT04337502,2019-12-23,2020-01-20,Observational,Clinical and Radiomic Model of COVID-19,Completed,NA,Maastricht University,NA,https://clinicalzeros.gov/ct2/show/NCT04337502,0,0,0,0,0,0,China,0,machine learning model,NA
NCT04337151,2020-04-30,2021-01-31,Observational,Blood Titanium Analysis of Patients With MAGEC Spine Rods in the COVID-19 Environment,Recruiting,NA,Royal National Orthopaedic Hospital NHS Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04337151,0,0,0,0,0,0,United Kingdom,0,magec spine rod|titanium blood test,NA
NCT04337047,2020-03-31,2020-04-30,Observational,Distress in Crisis Situations During COVID-19,Completed,NA,Wefight,NA,https://clinicalzeros.gov/ct2/show/NCT04337047,0,0,0,0,1,0,France,0,questionnaire,NA
NCT04337008,2020-04-03,2020-06-03,Interventional,Renin Angiotensin System - CoronaVirus,Recruiting,N/A,Assistance Publique Hopitaux De Marseille,NA,https://clinicalzeros.gov/ct2/show/NCT04337008,0,0,0,0,1,0,France,0,blood sample,NA
NCT04336657,2020-04-30,2020-05-31,Observational,Corona-Like Illness: Did we Got it Before WHO Announcement of the Disease?,Recruiting,NA,Assiut University,NA,https://clinicalzeros.gov/ct2/show/NCT04336657,0,0,0,0,0,0,Egypt,0,questionnaire|igg,NA
NCT04336956,2020-04-07,2021-06-30,Observational [Patient Registry],Covid-19 Pediatric Observatory,Recruiting,NA,Centre Hospitalier Intercommunal Creteil,NA,https://clinicalzeros.gov/ct2/show/NCT04336956,0,0,0,0,5,0,France,0,hospitalized children with covid19,NA
NCT04336904,2020-03-25,2020-07-31,Interventional,Clinical Study To Evaluate The Performance And Safety Of Favipiravir in COVID-19,"Active, not recruiting",Phase 3,ASST Fatebenefratelli Sacco,NA,https://clinicalzeros.gov/ct2/show/NCT04336904,0,0,0,0,1,0,Italy,0,favipiravir|placebo,NA
NCT04335630,2020-03-30,2021-03-31,Observational,Cardiovascular Manifestations of COVID-19,Recruiting,NA,Memorial Hermann Health System,NA,https://clinicalzeros.gov/ct2/show/NCT04335630,0,0,0,0,1,1,United States,0,"electrocardiogram, telemetry, echocardiogram, laboratory values",NA
NCT04336462,2020-02-15,2020-02-21,Interventional,Hydrogen-Oxygen Generator With Nebulizer in the Improvement of Symptoms in Patients Infected With COVID-19,Recruiting,N/A,Shanghai Asclepius Meditec Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04336462,0,0,0,0,0,0,China,0,oxyhydrogen|oxygen,NA
NCT04335851,2020-04-06,2020-05-15,Interventional,Video-Based Exercises and Well-Being During Social Isolation,Completed,N/A,Biruni University,NA,https://clinicalzeros.gov/ct2/show/NCT04335851,0,0,0,0,1,0,Turkey,0,exercise,NA
NCT04335552,2020-04-17,2020-06-17,Interventional,"Pragmatic Factorial Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection",Terminated,Phase 2,Duke University,"Poor recruitment, strong evidence from larger trials of no therapeutic benefit",https://clinicalzeros.gov/ct2/show/NCT04335552,0,0,0,0,3,1,United States,0,standard care|hydroxychloroquine|azithromycin,NA
NCT04335773,2020-04-03,2030-12-31,Observational [Patient Registry],"COVID-19 in Hospitalised Norwegian Children - Risk Factors, Outcomes and Immunology",Recruiting,NA,"University Hospital, Akershus",NA,https://clinicalzeros.gov/ct2/show/NCT04335773,0,0,0,0,1,0,Norway,0,"NA",NA
NCT04335747,2020-04-23,2021-08-01,Observational,COVID-19 Infection in Vulnerable Patients With Inflammatory Rheumatic Diseases,Recruiting,NA,Aalborg University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04335747,0,0,0,0,2,0,Denmark,0,covid-19 infection,NA
NCT04335188,2020-04-06,2021-07-31,Observational,COVID-19 Registry Rhineland-Palatinate (Germany),Recruiting,NA,IHF GmbH - Institut fÃ¼r Herzinfarktforschung,NA,https://clinicalzeros.gov/ct2/show/NCT04335188,0,0,0,0,2,0,Germany,0,prospective oberservational registry,NA
NCT04335136,2020-04-30,2020-12-26,Interventional,Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19,Completed,Phase 2,Apeiron Biologics,NA,https://clinicalzeros.gov/ct2/show/NCT04335136,0,0,0,0,6,0,Austria|Denmark|Germany|Russian Federation|United Kingdom,0,rhace2|saline,NA
NCT04335097,2020-04-22,2021-04-08,Interventional,Sensor Based Vital Signs Monitoring of Covid 19 Patients During Home Isolation,Recruiting,N/A,Oslo University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04335097,0,0,0,0,3,0,Norway,0,biosensor,NA
NCT04335071,2020-04-26,2020-09-27,Interventional,Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19),Terminated,Phase 2,"University Hospital Inselspital, Berne","1.) Not possible to recruit the planned number of patients during the planned study period; 2.)
    ""Dexamethason"" was included in the standard of care for the study population during the course
    of the study and inclusion criteria could no longer be met.",https://clinicalzeros.gov/ct2/show/NCT04335071,0,0,0,0,4,0,Switzerland,0,tocilizumab|placebo,NA
NCT04334850,2020-04-20,2020-07-31,Interventional,Use of a Respiratory Multiplex PCR and Procalcitonin to Reduce Antibiotics Exposure in Patients With Severe Confirmed COVID-19 Pneumonia,Recruiting,N/A,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04334850,0,0,0,0,1,0,France,0,pcr|usual antibiotic treatment|procalcitonin,NA
NCT04334928,2020-04-15,2020-12-31,Interventional,Randomized Clinical Trial for the Prevention of SARS-CoV-2 Infection (COVID-19) in Healthcare Personnel,Recruiting,Phase 3,Plan Nacional sobre el Sida (PNS),NA,https://clinicalzeros.gov/ct2/show/NCT04334928,0,0,0,0,5,0,Spain,0,emtricitabine/tenofovir disoproxil|hydroxychloroquine|placebo|emtricitabine|tenofovir disoproxil,NA
NCT04335305,2020-04-09,2020-12-31,Interventional,Checkpoint Blockade in COVID-19 Pandemic,Recruiting,Phase 2,MedSIR,NA,https://clinicalzeros.gov/ct2/show/NCT04335305,0,0,0,0,8,0,Spain,0,tocilizumab|pembrolizumab,NA
NCT04334382,2020-04-02,2020-12-31,Interventional,Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19,Recruiting,Phase 3,"Intermountain Health Care, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04334382,0,0,0,0,1,1,United States,0,hydroxychloroquine|azithromycin,NA
NCT04334629,2020-05-26,2021-05-25,Interventional,LIBERATE Trial in COVID-19,Recruiting,Phase 4,King's College London,NA,https://clinicalzeros.gov/ct2/show/NCT04334629,0,0,0,0,4,0,United Kingdom,0,ibuprofen,NA
NCT04334252,2020-04-17,2020-12-20,Observational,Descriptive Study Regarding Ambulant Screening During COVID-19 Pandemia,Completed,NA,Jessa Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04334252,0,0,0,0,4,0,Belgium,0,questionnaire,NA
NCT04333914,2020-04-15,2021-06-30,Interventional,Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection,Recruiting,Phase 2,Centre Leon Berard,NA,https://clinicalzeros.gov/ct2/show/NCT04333914,0,0,0,0,7,0,France,0,avdoralimab|autophagy inhibitor (gns651)|standard care|monalizumab,NA
NCT04333862,2020-03-19,2022-01-31,Observational,Assessment of Covid-19 Infection Rates in Healthcare Workers Using a Desynchronization Strategy,Recruiting,NA,"University Hospital Inselspital, Berne",NA,https://clinicalzeros.gov/ct2/show/NCT04333862,0,0,0,0,1,0,Switzerland,0,"NA",NA
NCT04333407,2020-04-03,2021-03-30,Interventional,Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomised Controlled Trial.,Recruiting,N/A,Imperial College London,NA,https://clinicalzeros.gov/ct2/show/NCT04333407,0,0,0,0,2,0,United Kingdom,0,aspirin|clopidogrel|rivaroxaban|atorvastatin|omeprazole,NA
NCT04333225,2020-04-03,2020-06-30,Interventional,Hydroxychloroquine in the Prevention of COVID-19 Infection in Healthcare Workers,Completed,Phase 2,Baylor Research Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04333225,0,0,0,0,4,1,United States,0,hydroxychloroquine,NA
NCT04333654,2020-04-12,2020-05-26,Interventional,Hydroxychloroquine in Outpatient Adults With COVID-19,Terminated,Phase 1,Sanofi,Rate of enrollment too slow to allow completion in a reasonable timeframe,https://clinicalzeros.gov/ct2/show/NCT04333654,0,0,0,0,7,1,United States|Belgium|France|Netherlands,0,hydroxychloroquine|placebo,NA
NCT04333628,2020-06-01,2020-09-01,Interventional,Chloroquine for Mild Symptomatic and Asymptomatic COVID-19,Terminated,Phase 2/Phase 3,"HaEmek Medical Center, Israel",Teminated due to changes in treatment guidelines .,https://clinicalzeros.gov/ct2/show/NCT04333628,0,0,0,0,3,0,Israel,0,chloroquine|standard care,NA
NCT04333368,2020-04-06,2021-01-30,Interventional,Cell Therapy Using Umbilical Cord-derived Mesenchymal Stromal Cells in SARS-CoV-2-related ARDS,"Active, not recruiting",Phase 1/Phase 2,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04333368,0,0,0,0,4,0,France,0,mesenchymal stem cells|saline,NA
NCT04332913,2020-04-01,2020-12-31,Observational,Efficacy and Safety of Tocilizumab in the Treatment of SARS-Cov-2 Related Pneumonia,Recruiting,NA,University of L'Aquila,NA,https://clinicalzeros.gov/ct2/show/NCT04332913,0,0,0,0,2,0,Italy,0,"NA",NA
NCT04332380,2020-05-01,2020-07-28,Interventional,Convalescent Plasma for Patients With COVID-19: A Pilot Study,Completed,Phase 2,Universidad del Rosario,NA,https://clinicalzeros.gov/ct2/show/NCT04332380,0,0,0,0,2,0,Colombia,0,plasma,NA
NCT04332835,2020-08-08,2020-10-31,Interventional,"Convalescent Plasma for Patients With COVID-19: A Randomized, Single Blinded, Parallel, Controlled Clinical Study",Completed,Phase 2/Phase 3,Universidad del Rosario,NA,https://clinicalzeros.gov/ct2/show/NCT04332835,0,0,0,0,4,0,Colombia,0,plasma|standard care,NA
NCT04332016,2020-04-02,2023-03-31,Observational,COVID-19 Biological Samples Collection,Recruiting,NA,"University Hospital, Bordeaux",NA,https://clinicalzeros.gov/ct2/show/NCT04332016,0,0,0,0,1,0,France,0,biological samples,NA
NCT04332081,2020-04-06,2020-05-29,Interventional,Hyperbaric Oxygen for COVID-19 Patients,Terminated,N/A,NYU Langone Health,"The IRB has determined that the design of this trial should be changed to a randomized
    controlled trial. A new record will be created for the redesigned study.",https://clinicalzeros.gov/ct2/show/NCT04332081,0,0,0,0,5,1,United States,0,hyperbaric oxygen,NA
NCT04331613,2020-01-27,2020-12-31,Interventional,Safety and Efficacy of CAStem for Severe COVID-19 Associated With/Without ARDS,Recruiting,Phase 1/Phase 2,Chinese Academy of Sciences,NA,https://clinicalzeros.gov/ct2/show/NCT04331613,0,0,0,0,0,0,China,0,castem,NA
NCT04331054,2020-04-13,2022-01-13,Interventional,Protective Role of Inhaled Steroids for Covid-19 Infection,Recruiting,Phase 3,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04331054,0,0,0,0,3,0,France,0,usual practice / symbicort rapihaler|standard care|symbicort,NA
NCT04330599,2020-05-01,2025-04-01,Observational,Longitudinal Population-based Observational Study of COVID-19 in the UK Population,Recruiting,NA,Queen Mary University of London,NA,https://clinicalzeros.gov/ct2/show/NCT04330599,0,0,0,0,3,0,United Kingdom,0,"NA",NA
NCT04330521,2020-04-08,2022-05-31,Observational,Impact of the Coronavirus (COVID-19) on Patients With Cancer,Recruiting,NA,Stanford University,NA,https://clinicalzeros.gov/ct2/show/NCT04330521,0,0,0,0,2,1,United States,0,"NA",NA
NCT04329650,2020-04-15,2020-05-20,Interventional,Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID-19 Pneumonia,Recruiting,Phase 2,Fundacion Clinic per a la Recerca BiomÃ©dica,NA,https://clinicalzeros.gov/ct2/show/NCT04329650,0,0,0,0,3,0,Spain,0,siltuximab|methylprednisolone,NA
NCT04329507,2020-03-25,2021-03-25,Observational,Non-invasive Detection of Pneumonia in Context of Covid-19 Using Gas Chromatography - Ion Mobility Spectrometry (GC-IMS),Recruiting,NA,NHS Lothian,NA,https://clinicalzeros.gov/ct2/show/NCT04329507,0,0,0,0,1,0,United Kingdom,0,breath test,NA
NCT04328454,2020-01-30,2020-04-02,Observational,Clinical Characteristics and Prognostic Factors of Patients With COVID-19,Recruiting,NA,Shanghai 10th People's Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04328454,0,0,0,0,0,0,China,0,retrospective,NA
NCT04329611,2020-04-13,2020-07-20,Interventional,ALBERTA HOPE COVID-19 for the Prevention of Severe COVID19 Disease,Terminated,Phase 3,University of Calgary,"Enrolment was suspended on 22may2020, after Mehra et al (Lancet 2020) then stopped due to lack
    of Covid19 cases.",https://clinicalzeros.gov/ct2/show/NCT04329611,0,0,0,0,8,0,Canada,0,hydroxychloroquine,NA
NCT04329546,2020-03-27,2022-01-31,Observational,Understanding COVID-19,Recruiting,NA,"University Hospital, Geneva",NA,https://clinicalzeros.gov/ct2/show/NCT04329546,0,0,0,0,1,0,Switzerland,0,na (no intervention),NA
NCT04328285,2020-04-14,2021-03-30,Interventional,Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers,"Active, not recruiting",Phase 3,Centre Hospitalier Universitaire de Saint Etienne,NA,https://clinicalzeros.gov/ct2/show/NCT04328285,0,0,0,0,7,0,France,0,hydroxychloroquine|placebo|lopinavir/ritonavir|lopinavir|ritonavir|r tablets,NA
NCT04327804,2020-03-25,2020-04-03,Observational,A Longitudinal Study of COVID-19 Positive Patients Testing Nasal Swabs and Collecting Blood Samples for Research,Recruiting,NA,UnitedHealth Group,NA,https://clinicalzeros.gov/ct2/show/NCT04327804,0,0,0,0,1,1,United States,0,odd/even birth year intervention groups|odd|even birth year intervention groups,NA
NCT04328129,2020-03-23,2022-03-23,Interventional,Household Transmission Investigation Study for COVID-19 in Tropical Regions,Recruiting,N/A,Institut Pasteur,NA,https://clinicalzeros.gov/ct2/show/NCT04328129,0,0,0,0,3,0,French Guiana|Guadeloupe|New Caledonia,0,biological samples,NA
NCT04327505,2020-06-03,2021-12-31,Interventional,Safety and Efficacy of Hyperbaric Oxygen for ARDS in Patients With COVID-19,Recruiting,Phase 2/Phase 3,Karolinska Institutet,NA,https://clinicalzeros.gov/ct2/show/NCT04327505,0,0,0,0,5,0,Germany|Romania|Sweden,0,oxygen,NA
NCT04327349,2020-03-28,2020-05-20,Interventional,Investigating Effect of Convalescent Plasma on COVID-19 Patients Outcome: A Clinical Trial,Enrolling by invitation,N/A,Mazandaran University of Medical Sciences,NA,https://clinicalzeros.gov/ct2/show/NCT04327349,0,0,0,0,0,0,"Iran, Islamic Republic of",0,convalescent plasma,NA
NCT04327479,2020-03-26,2026-03-25,Observational [Patient Registry],Characterization of Cardiovascular Diseases and Risk Factors in Patients With Suspected SARS-CoV2/Covid-19 Infection,Recruiting,NA,"University Hospital, Essen",NA,https://clinicalzeros.gov/ct2/show/NCT04327479,0,0,0,0,2,0,Germany,0,assessment of cardiovascular diseases/cardiovascular risk factors|assessment of cardiovascular diseases|cardiovascular risk factors,NA
NCT04327674,2020-03-14,2020-05-15,Observational [Patient Registry],The Use of Focused Lung Ultrasound in Patients Suspected of COVID-19,Recruiting,NA,University of Aarhus,NA,https://clinicalzeros.gov/ct2/show/NCT04327674,0,0,0,0,0,0,Denmark,0,"NA",NA
NCT04326452,2020-03-27,2021-03-27,Interventional,Treating COVID-19 With a Bidirectional Oxygenation Valve,Recruiting,N/A,TMC HealthCare,NA,https://clinicalzeros.gov/ct2/show/NCT04326452,0,0,0,0,2,1,United States,0,bidirectional oxygenation mouthpiece,NA
NCT04326725,2020-03-20,2020-07-01,Observational,Proflaxis Using Hydroxychloroquine Plus Vitamins-Zinc During COVID-19 Pandemia,"Active, not recruiting",NA,Istinye University,NA,https://clinicalzeros.gov/ct2/show/NCT04326725,0,0,0,0,2,0,Turkey,0,hydroxychloroquine,NA
NCT04327180,2020-03-30,2021-09-30,Observational,PREdiction of DIagnosed Covid-19 infecTion in IUC Patients,Recruiting,NA,"University Hospital, Lille",NA,https://clinicalzeros.gov/ct2/show/NCT04327180,0,0,0,0,2,0,France,0,"NA",NA
NCT04326426,2020-04-13,2020-08-01,Interventional,ODYSSEY: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 Infection,Enrolling by invitation,Phase 3,Vanda Pharmaceuticals,NA,https://clinicalzeros.gov/ct2/show/NCT04326426,0,0,0,0,2,1,United States,0,tradipitant|placebo,NA
NCT04326387,2020-04-06,2021-04-07,Observational,Evaluation of Novel Diagnostic Tests for COVID-19,Recruiting,NA,Cambridge University Hospitals NHS Foundation Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04326387,0,0,0,0,2,0,United Kingdom,0,samba ii|public health england gold standard|cambridge validated viral detection|radiological,NA
NCT04325867,2020-03-31,2020-10-01,Interventional,Integrated Distance Management Strategy for Patients With Cardiovascular Diseases in the Context of COVID-19,Recruiting,N/A,Grigore T. Popa University of Medicine and Pharmacy,NA,https://clinicalzeros.gov/ct2/show/NCT04325867,0,0,0,0,1,0,Romania,0,telehealth,NA
NCT04326075,2020-12-01,2021-03-31,Interventional,Early CPAP in COVID-19 Patients With Respiratory Failure.,Recruiting,N/A,Mario Negri Institute for Pharmacological Research,NA,https://clinicalzeros.gov/ct2/show/NCT04326075,0,0,0,0,3,0,Italy,0,cpap,NA
NCT04326036,2020-03-25,2021-11-01,Interventional,Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection,Recruiting,Early Phase 1,"Black Tie Medical, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04326036,0,0,0,0,2,1,United States,0,tsvf|centricyte 1000|csvf|liberase enzyme|saline,NA
NCT04325646,2020-03-13,2021-02-28,Observational,Sero-epidemiological Study of the SARS-CoV-2 Virus Responsible for COVID-19 in France,Recruiting,NA,Institut Pasteur,NA,https://clinicalzeros.gov/ct2/show/NCT04325646,0,0,0,0,5,0,France,0,biological samples,NA
NCT04325919,2020-02-24,2021-02-28,Observational,Coronavirus Disease 2019 (COVID-19) Study of Hospitalized Patients in Hong Kong,Recruiting,NA,Chinese University of Hong Kong,NA,https://clinicalzeros.gov/ct2/show/NCT04325919,0,0,0,0,0,0,Hong Kong,0,no intervention,NA
NCT04325893,2020-04-01,2020-06-18,Interventional,Hydroxychloroquine Versus Placebo in COVID-19 Patients at Risk for Severe Disease,Terminated,Phase 3,"University Hospital, Angers",decrease in number of eligible patients,https://clinicalzeros.gov/ct2/show/NCT04325893,0,0,0,0,4,0,France|Monaco,0,hydroxychloroquine|placebo,NA
NCT04325412,2020-03-23,2021-03-23,Observational [Patient Registry],Cardiac complicAtions in Patients With SARS Corona vIrus 2 (COVID-19) regisTrY,Recruiting,NA,UMC Utrecht,NA,https://clinicalzeros.gov/ct2/show/NCT04325412,0,0,0,0,1,0,Netherlands,0,"NA",NA
NCT04324996,2020-02-21,2022-02-20,Interventional,A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells for Therapy of COVID-19,Recruiting,Phase 1/Phase 2,Chongqing Public Health Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04324996,0,0,0,0,1,0,China,0,nk cells,NA
NCT04324684,2020-03-31,2020-05-07,Observational,Prognostic Factors Keeping Track for COVID-19 Pneumonia,Completed,NA,Catholic University of the Sacred Heart,NA,https://clinicalzeros.gov/ct2/show/NCT04324684,0,0,0,0,6,0,Italy,0,"NA",NA
NCT04324190,2020-04-08,2020-06-30,Interventional,DIgital Online SuPport for COVID-19 StrEss,Recruiting,N/A,International Psychoanalytic University Berlin,NA,https://clinicalzeros.gov/ct2/show/NCT04324190,0,0,0,0,3,0,Germany,0,guided online support program|who recommendations (waiting condition),NA
NCT04324489,2020-03-06,2020-04-16,Interventional,DAS181 for Severe COVID-19: Compassionate Use,Completed,N/A,Renmin Hospital of Wuhan University,NA,https://clinicalzeros.gov/ct2/show/NCT04324489,0,0,0,0,2,0,China,0,das181,NA
NCT04324021,2020-04-02,2020-11-13,Interventional,Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection.,Terminated,Phase 2/Phase 3,Swedish Orphan Biovitrum,"Standard of care evolved during the timeframe of the study and had critical impact on
    recruitment.

    Early termination is not based on safety reasons but because of recruitment issues.

    Patients ongoing will be completed. Planned LPLV 25Jan2021",https://clinicalzeros.gov/ct2/show/NCT04324021,0,0,0,0,7,1,United States|Italy,0,emapalumab|anakinra,NA
NCT04324073,2020-03-27,2021-03-27,Interventional,Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - CORIMUNO-19 - SARI,"Active, not recruiting",Phase 2/Phase 3,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04324073,0,0,0,0,2,0,France,0,sarilumab,NA
NCT04324047,2020-03-27,2021-03-27,Observational,Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients,Recruiting,NA,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04324047,0,0,0,0,1,0,France,0,"NA",NA
NCT04323878,2020-06-01,2021-03-31,Observational,Early CPAP in COVID-19 Patients With Respiratory Failure. A Prospective Cohort Study.,Recruiting,NA,Mario Negri Institute for Pharmacological Research,NA,https://clinicalzeros.gov/ct2/show/NCT04323878,0,0,0,0,3,0,Italy,0,"NA",NA
NCT04322773,2020-04-05,2020-10-08,Interventional,Anti-il6 Treatment of Serious COVID-19 Disease With Threatening Respiratory Failure,Terminated,Phase 2,Frederiksberg University Hospital,The study has been terminated due to changed clinical conditions and too few patients available,https://clinicalzeros.gov/ct2/show/NCT04322773,0,0,0,0,4,0,Denmark,0,roactemra|sarilumab|standard care,NA
NCT04323345,2020-04-15,2020-12-15,Interventional,Efficacy of Natural Honey Treatment in Patients With Novel Coronavirus,Recruiting,Phase 3,Misr University for Science and Technology,NA,https://clinicalzeros.gov/ct2/show/NCT04323345,0,0,0,0,1,0,Egypt,0,honey|standard care,NA
NCT04323228,2020-09-01,2020-12-01,Interventional,Anti-inflammatory/Antioxidant Oral Nutrition Supplementation in COVID-19,Recruiting,Phase 2/Phase 3,King Saud University,NA,https://clinicalzeros.gov/ct2/show/NCT04323228,0,0,0,0,6,0,Saudi Arabia,0,antioxidants|placebo,NA
NCT04322682,2020-03-23,2021-01-21,Interventional,Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA),Completed,Phase 3,Montreal Heart Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04322682,0,0,0,0,12,1,United States|Brazil|Canada|South Africa|Spain,0,colchicine|placebo,NA
NCT04322565,2020-04-20,2020-12-20,Interventional,Colchicine Counteracting Inflammation in COVID-19 Pneumonia,Recruiting,Phase 2,Azienda Ospedaliero-Universitaria di Parma,NA,https://clinicalzeros.gov/ct2/show/NCT04322565,0,0,0,0,3,0,Italy,0,colchicine,NA
NCT04323514,2020-03-13,2021-03-13,Interventional,Use of Ascorbic Acid in Patients With COVID 19,Recruiting,N/A,University of Palermo,NA,https://clinicalzeros.gov/ct2/show/NCT04323514,0,0,0,0,0,0,Italy,0,vitamin c,NA
NCT04322344,2020-03-23,2020-06-30,Interventional,Escin in Patients With Covid-19 Infection,Recruiting,Phase 2/Phase 3,University of Catanzaro,NA,https://clinicalzeros.gov/ct2/show/NCT04322344,0,0,0,0,2,0,Italy,0,escin|standard care,NA
NCT04322188,2020-03-19,2020-05-08,Observational,An Observational Study of the Use of Siltuximab (SYLVANT) in Patients Diagnosed With COVID-19 Infection Who Have Developed Serious Respiratory Complications,Completed,NA,A.O. Ospedale Papa Giovanni XXIII,NA,https://clinicalzeros.gov/ct2/show/NCT04322188,0,0,0,0,3,0,Italy,0,"NA",NA
NCT04322513,2020-03-24,2020-06-30,Observational,Biomarkers for Identification of COVID-19 Infection,Recruiting,NA,University of Catanzaro,NA,https://clinicalzeros.gov/ct2/show/NCT04322513,0,0,0,0,4,0,Italy,0,biomarkers expression,NA
NCT04322487,2020-04-08,2020-12-31,Observational,"Simple, Safe, Same: Lung Ultrasound for COVID-19",Recruiting,NA,Catholic University of the Sacred Heart,NA,https://clinicalzeros.gov/ct2/show/NCT04322487,0,0,0,0,2,0,Italy,0,lung ultrasound,NA
NCT04322279,2020-03-09,2021-03-01,Observational,Factors Associated With a Positive SARS-CoV-2 Serology in Contact Subjects at High/Moderate Risk of Coronavirus SARS-CoV-2 Infection. COVID19.,Recruiting,NA,"Institut National de la SantÃ© Et de la Recherche MÃ©dicale, France",NA,https://clinicalzeros.gov/ct2/show/NCT04322279,0,0,0,0,1,0,France|French Guiana,0,serology test|sequencing,NA
NCT04321993,2020-04-17,2022-02-28,Interventional,Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients,Recruiting,Phase 2,Nova Scotia Health Authority,NA,https://clinicalzeros.gov/ct2/show/NCT04321993,0,0,0,0,6,0,Canada,0,baricitinib,NA
NCT04321616,2020-03-28,2020-08-31,Interventional,The Efficacy of Different Anti-viral Drugs in COVID 19 Infected Patients,Recruiting,Phase 2/Phase 3,Oslo University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04321616,0,0,0,0,2,0,Norway,0,hydroxychloroquine|remdesivir|standard care,NA
NCT04320056,2020-04-20,2021-04-30,Interventional,Closed-Loop Oxygen to Verify That Healthcare Workers Interventions Decrease During SARS-CoV-2 Pneumonia (COVID-19),Recruiting,N/A,Laval University,NA,https://clinicalzeros.gov/ct2/show/NCT04320056,0,0,0,0,2,0,Canada,0,oxygen,NA
NCT04320732,2020-03-27,2022-03-27,Observational,Risk Factors for Community- and Workplace Transmission of COVID-19,Recruiting,NA,Oslo University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04320732,0,0,0,0,3,0,Norway,0,observation|covid-19 infection will be conducted.,NA
NCT04320238,2020-01-21,2020-05-31,Interventional,Experimental Trial of rhIFNÎ± Nasal Drops to Prevent 2019-nCOV in Medical Staff,Recruiting,Phase 3,Shanghai Jiao Tong University School of Medicine,NA,https://clinicalzeros.gov/ct2/show/NCT04320238,0,0,0,0,1,0,China,0,interferon|thymosin,NA
NCT04320017,2020-03-20,2020-05-20,Observational,Joint Use of Electrocardiogram and Transthoracic Echocardiography With Other Clinico-biological Parameters in an Observational Study to Monitor Cardio-vascular Events and Predict Outcomes in Patients Diagnosed With COVID-19,Recruiting,NA,Groupe Hospitalier Pitie-Salpetriere,NA,https://clinicalzeros.gov/ct2/show/NCT04320017,0,0,0,0,1,0,France,0,"electrocardiogram, transthoracic echocardiography/clinico-biological parameters in routine care|electrocardiogram, transthoracic echocardiography|clinico-biological parameters in routine care",NA
NCT04319900,2020-03-05,2020-04-30,Interventional,Clinical Trial of Favipiravir Tablets Combine With Chloroquine Phosphate in the Treatment of Novel Coronavirus Pneumonia,Recruiting,Phase 2/Phase 3,Beijing Chao Yang Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04319900,0,0,0,0,0,0,China,0,favipiravir/chloroquine|favipiravir|placebo|chloroquine,NA
NCT04320472,2020-03-23,2020-09-30,Observational [Patient Registry],Acute Encephalopathy in Critically Ill Patients With COVID-19,"Active, not recruiting",NA,Ictal Group,NA,https://clinicalzeros.gov/ct2/show/NCT04320472,0,0,0,0,13,1,United States|Brazil|Colombia|Egypt|France|Mexico|Spain,0,follow up,NA
NCT04319172,2020-03-12,2021-03-31,Observational,Multicentric Study of Coronavirus Disease 2019 (COVID-2019) in Solid Organ Transplant Recipients,Recruiting,NA,FundaciÃ³n PÃºblica Andaluza para la gestiÃ³n de la InvestigaciÃ³n en Sevilla,NA,https://clinicalzeros.gov/ct2/show/NCT04319172,0,0,0,0,1,0,Spain,0,"NA",NA
NCT04319016,2020-01-01,2020-04-30,Observational [Patient Registry],Clinical Characteristics of Coronavirus Disease 2019 (COVID-19) in Pregnancy,Recruiting,NA,Federico II University,NA,https://clinicalzeros.gov/ct2/show/NCT04319016,0,0,0,0,3,0,Italy,0,pregnant women with laboratory-confirmed 2019-n-cov,NA
NCT04319315,2020-03-11,2020-04-01,Observational,Social Media Effect on Knowledge Dissemination During COVID-19 Virus Outbreak,Recruiting,NA,Assiut University,NA,https://clinicalzeros.gov/ct2/show/NCT04319315,0,0,0,0,1,0,Egypt,0,questionnaire,NA
NCT04318015,2020-04-14,2020-12-31,Interventional,Hydroxychloroquine Chemoprophylaxis in Healthcare Personnel in Contact With COVID-19 Patients (PHYDRA Trial),Recruiting,Phase 3,"National Institute of Respiratory Diseases, Mexico",NA,https://clinicalzeros.gov/ct2/show/NCT04318015,0,0,0,0,1,0,Mexico,0,hydroxychloroquine|placebo,NA
NCT04318418,2020-03-23,2020-05-10,Observational,"ACE Inhibitors, Angiotensin II Type-I Receptor Blockers and Severity of COVID-19",Completed,NA,Neuromed IRCCS,NA,https://clinicalzeros.gov/ct2/show/NCT04318418,0,0,0,0,1,0,Italy,0,"NA",NA
NCT04318301,2020-03-21,2020-03-28,Observational,Hypertension in Patients Hospitalized With COVID-19,Completed,NA,Nanfang Hospital of Southern Medical University,NA,https://clinicalzeros.gov/ct2/show/NCT04318301,0,0,0,0,3,0,China,0,"NA",NA
NCT04315896,2020-04-14,2020-07-01,Interventional,Hydroxychloroquine Treatment for Severe COVID-19 Pulmonary Infection (HYDRA Trial),"Active, not recruiting",Phase 3,"National Institute of Respiratory Diseases, Mexico",NA,https://clinicalzeros.gov/ct2/show/NCT04315896,0,0,0,0,2,0,Mexico,0,hydroxychloroquine|placebo,NA
NCT04316299,2020-02-26,2020-02-28,Observational,Acute Kidney Injury in Patients Hospitalized With COVID-19,Completed,NA,Nanfang Hospital of Southern Medical University,NA,https://clinicalzeros.gov/ct2/show/NCT04316299,0,0,0,0,2,0,China,0,"NA",NA
NCT04315870,2020-01-01,2020-04-20,Observational [Patient Registry],Clinical Characteristics of Coronavirus Disease 2019 (COVID-19) in Pregnancy: The Italian Registry on Coronavirus in Pregnancy.,Recruiting,NA,Federico II University,NA,https://clinicalzeros.gov/ct2/show/NCT04315870,0,0,0,0,0,0,Italy,0,pregnant women with laboratory-confirmed 2019-n-cov,NA
NCT04315298,2020-03-18,2020-07-24,Interventional,Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19,Completed,Phase 2/Phase 3,Regeneron Pharmaceuticals,NA,https://clinicalzeros.gov/ct2/show/NCT04315298,0,0,0,0,7,1,United States,0,sarilumab|placebo,NA
NCT04314271,2020-03-20,2020-05-01,Observational [Patient Registry],The Observational Study of Cardiac and Pulmonary Ultrasound and Evaluation of Treatment of Severe Patients With Novel Coronavirus Pneumonia,Recruiting,NA,Xiangya Hospital of Central South University,NA,https://clinicalzeros.gov/ct2/show/NCT04314271,0,0,0,0,0,0,China,0,"NA",NA
NCT04312100,2020-02-01,2020-10-31,Observational,Sequential Oxygen Therapy Strategy for Patients With COVID-19,Recruiting,NA,Henan Provincial People's Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04312100,0,0,0,0,0,0,China,0,oxygen,NA
NCT04313946,2020-03-18,2020-08-16,Observational,Artificial Intelligence Algorithms for Discriminating Between COVID-19 and Influenza Pneumonitis Using Chest X-Rays,Recruiting,NA,Grigore T. Popa University of Medicine and Pharmacy,NA,https://clinicalzeros.gov/ct2/show/NCT04313946,0,0,0,0,3,0,Italy|Romania|United Kingdom,0,scanning chest x-rays/performing ai algorithms on images|x-ray|performing ai algorithms on images,NA
NCT04313322,2020-03-16,2020-06-30,Interventional,Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells,Recruiting,Phase 1,Stem Cells Arabia,NA,https://clinicalzeros.gov/ct2/show/NCT04313322,0,0,0,0,0,0,Jordan,0,mesenchymal stem cells,NA
NCT04312464,2020-01-01,2020-03-15,Observational,Myocardial Damage in COVID-19,Enrolling by invitation,NA,"Wuhan Union Hospital, China",NA,https://clinicalzeros.gov/ct2/show/NCT04312464,0,0,0,0,0,0,China,0,non,NA
NCT04310228,2020-03-08,2020-05-31,Interventional,Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019,Recruiting,N/A,Peking University First Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04310228,0,0,0,0,1,0,China,0,favipiravir/tocilizumab|favipiravir|tocilizumab,NA
NCT04308317,2020-03-05,2021-03-01,Interventional,Tetrandrine Tablets Used in the Treatment of COVID-19,Enrolling by invitation,Phase 4,Henan Provincial People's Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04308317,0,0,0,0,0,0,China,0,tetrandrine,NA
NCT04306705,2020-02-20,2020-05-30,Observational,Tocilizumab vs CRRT in Management of Cytokine Release Syndrome (CRS) in COVID-19,Recruiting,NA,Tongji Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04306705,0,0,0,0,1,0,China,0,tocilizumab|standard care|continuous renal replacement therapy,NA
NCT04305106,2020-03-17,2020-06-30,Interventional,Bevacizumab in Severe or Critically Severe Patients With COVID-19 Pneumonia-RCT,Recruiting,N/A,Qilu Hospital of Shandong University,NA,https://clinicalzeros.gov/ct2/show/NCT04305106,0,0,0,0,2,0,China,0,bevacizumab,NA
NCT04306497,2020-01-22,2020-04-30,Observational,TCM Differentiation and Treatment Protocol of COVID-19,Completed,NA,"Jiangsu Famous Medical Technology Co., Ltd.",NA,https://clinicalzeros.gov/ct2/show/NCT04306497,0,0,0,0,2,0,China,0,tcm,NA
NCT04306055,2020-03-13,2020-03-13,Interventional,Blood Donor Recruitment During Epidemic of COVID-19,Completed,N/A,Guangzhou Blood Center,NA,https://clinicalzeros.gov/ct2/show/NCT04306055,0,0,0,0,1,0,China,0,questionnaire|experimental: questionnaire without precaution information,NA
NCT04305457,2020-03-21,2021-04-01,Interventional,Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19,"Active, not recruiting",Phase 2,Massachusetts General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04305457,0,0,0,0,12,1,United States,0,nitric oxide,NA
NCT04304690,2020-03-16,2021-05-16,Interventional,"COVID-19 Seroconversion Among Front Line Medical and Paramedical Staff in Emergency, Intensive Care Units and Infectious Disease Departments During the 2020 Epidemic","Active, not recruiting",N/A,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04304690,0,0,0,0,4,0,France,0,blood sample,NA
NCT04302688,2019-12-10,2020-02-10,Observational,Accurate Classification System for Patients With COVID-19 Pneumonitis,Completed,NA,Renmin Hospital of Wuhan University,NA,https://clinicalzeros.gov/ct2/show/NCT04302688,0,0,0,0,0,0,China,0,"NA",NA
NCT04299724,2020-02-15,2023-07-31,Interventional,Safety and Immunity of Covid-19 aAPC Vaccine,Recruiting,Phase 1,Shenzhen Geno-Immune Medical Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04299724,0,0,0,1,0,0,China,0,aapc,NA
NCT04292340,2020-02-01,2020-07-31,Observational,Anti-SARS-CoV-2 Inactivated Convalescent Plasma in the Treatment of COVID-19,Recruiting,NA,Shanghai Public Health Clinical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04292340,0,0,0,0,0,0,China,0,"NA",NA
NCT04292327,2020-01-01,2020-04-30,Observational,Clinical Progressive Characteristics and Treatment Effects of 2019-novel Coronavirus,"Active, not recruiting",NA,Fujian Provincial Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04292327,0,0,0,0,0,0,China,0,"NA",NA
NCT04291729,2020-02-17,2020-03-19,Interventional,Evaluation of Ganovo ï¼ˆDanoprevir ï¼‰ Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection,Completed,Phase 4,The Ninth Hospital of Nanchang,NA,https://clinicalzeros.gov/ct2/show/NCT04291729,0,0,0,0,3,0,China,0,ganovo/ritonavir//-interferon nebulization|ganovo|ritonavir|NA|-interferon nebulization,NA
NCT04285801,2020-02-14,2020-02-25,Observational,Critically Ill Patients With COVID-19 in Hong Kong: a Multicentre Observational Cohort Study,Completed,NA,Chinese University of Hong Kong,NA,https://clinicalzeros.gov/ct2/show/NCT04285801,0,0,0,0,3,0,Hong Kong,0,"NA",NA
NCT04284046,2020-01-31,2020-02-18,Observational,CT Scores Predict Mortality in 2019-nCoV Pneumonia,Completed,NA,"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine",NA,https://clinicalzeros.gov/ct2/show/NCT04284046,0,0,0,0,0,0,China,0,ct-scan,NA
NCT04283396,2020-02-21,2020-05-30,Observational,Study for Novel Coronavirus Pneumonia (NCP),Recruiting,NA,"Wuhan Union Hospital, China",NA,https://clinicalzeros.gov/ct2/show/NCT04283396,0,0,0,0,2,0,China,0,systemic,NA
NCT04276987,2020-02-15,2020-05-31,Interventional,A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia,Completed,Phase 1,Ruijin Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04276987,0,0,0,0,3,0,China,0,mesenchymal stem cells,NA
NCT04279795,2020-01-20,2021-01-31,Observational,Detection of 2019 Novel Coronavirus in Multiple Organ System and Its Relationship With Clinical Manifestations,Recruiting,NA,"Third Affiliated Hospital, Sun Yat-Sen University",NA,https://clinicalzeros.gov/ct2/show/NCT04279795,0,0,0,0,0,0,China,0,"NA",NA
NCT04279197,2020-04-23,2021-12-31,Interventional,Treatment of Pulmonary Fibrosis Due to COVID-19 With Fuzheng Huayu,Recruiting,Phase 2,ShuGuang Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04279197,0,0,0,0,2,0,China,0,fuzheng huayu|vitamin c tablets|placebo|respiratory function rehabilitation training,NA
NCT04276896,2020-03-24,2023-07-31,Interventional,Immunity and Safety of Covid-19 Synthetic Minigene Vaccine,Recruiting,Phase 1/Phase 2,Shenzhen Geno-Immune Medical Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04276896,0,0,0,1,2,0,China,0,lv-smenp-dc vaccine/antigen-specific ctls|injection|lv-smenp-dc vaccine|control,NA
NCT04274322,2020-02-19,2020-04-04,Observational,Identifying Critically-ill Patients With COVID-19 Who Will Benefit Most From Nutrition Support Therapy: Validation of the NUTRIC Nutritional Risk Assessment Tool,"Active, not recruiting",NA,Peking University Third Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04274322,0,0,0,0,1,0,China,0,nutrition,NA
NCT04275947,2020-02-14,2020-04-30,Observational,The COVID-19 Mobile Health Study (CMHS),Recruiting,NA,Chinese Alliance Against Lung Cancer,NA,https://clinicalzeros.gov/ct2/show/NCT04275947,0,0,0,0,0,0,China,0,ncapp,NA
NCT04273763,2020-02-16,2020-05-10,Interventional,Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19),"Active, not recruiting",N/A,Second Affiliated Hospital of Wenzhou Medical University,NA,https://clinicalzeros.gov/ct2/show/NCT04273763,0,0,0,0,4,0,China,0,bromhexine hydrochloride|arbidol|recombinant human interferon î±2b spray|recombinant human interferon î±2b spray,NA
NCT04269525,2020-02-06,2020-12-01,Interventional,Umbilical Cord(UC)-Derived Mesenchymal Stem Cells(MSCs) Treatment for the 2019-novel Coronavirus(nCOV) Pneumonia,Recruiting,Phase 2,Zhongnan Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04269525,0,0,0,0,3,0,China,0,mesenchymal stem cells,NA
NCT04263402,2020-02-01,2020-06-01,Interventional,The Efficacy of Different Hormone Doses in 2019-nCoV Severe Pneumonia,Recruiting,Phase 4,Tongji Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04263402,0,0,0,0,3,0,China,0,methylprednisolone,NA
NCT04261270,2020-02-01,2020-05-01,Interventional,"A Randomized,Open,Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV Pneumonia",Recruiting,Phase 3,Tongji Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04261270,0,0,0,0,2,0,China,0,asc09f/oseltamivir|ritonavir/oseltamivir|oseltamivir|asc09|ritonavir,NA
NCT04259892,2020-02-04,2020-10-04,Observational,Viral Excretion in Contact Subjects at High/Moderate Risk of Coronavirus 2019-nCoV Infection. COVID-19.,Recruiting,NA,"Institut National de la SantÃ© Et de la Recherche MÃ©dicale, France",NA,https://clinicalzeros.gov/ct2/show/NCT04259892,0,0,0,0,4,0,France|French Guiana,0,pcr,NA
NCT04260308,2020-02-03,2020-04-15,Observational,A Survey of Psychological Status of Medical Workers and Residents in the Context of 2019 Novel Coronavirus Pneumonia,Recruiting,NA,Huazhong University of Science and Technology,NA,https://clinicalzeros.gov/ct2/show/NCT04260308,0,0,0,0,0,0,China,0,"NA",NA
NCT04255940,2020-01-20,2020-04-30,Observational,2019-nCoV Outbreak and Cardiovascular Diseases,Recruiting,NA,Qilu Hospital of Shandong University,NA,https://clinicalzeros.gov/ct2/show/NCT04255940,0,0,0,0,0,0,China,0,"NA",NA
NCT04256395,2020-02-01,2020-07-01,Observational,Efficacy of a Self-test and Self-alert Mobile Applet in Detecting Susceptible Infection of COVID-19,Completed,NA,Beijing Tsinghua Chang Gung Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04256395,0,0,0,0,4,0,China,0,mobile internet survey on self-test,NA
NCT04255017,2020-02-01,2020-06-01,Interventional,"A Prospective/Retrospective,Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia",Recruiting,Phase 4,Tongji Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04255017,0,0,0,0,3,0,China,0,arbidol|oseltamivir|lopinavir/ritonavir|lopinavir|ritonavir,NA
NCT04254874,2020-02-01,2020-06-01,Interventional,"A Prospective/Retrospective,Randomized Controlled Clinical Study of Interferon Atomization in the 2019-nCoV Pneumonia",Recruiting,Phase 4,Tongji Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04254874,0,0,0,0,3,0,China,0,arbidol|arbidol hydrochloride/interferon atomization|interferon,NA
NCT04252118,2020-01-27,2020-12-31,Interventional,Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With COVID-19,Recruiting,Phase 1,Beijing 302 Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04252118,0,0,0,0,4,0,China,0,mesenchymal stem cells,NA
NCT04245631,2020-01-01,2020-12-31,Observational,"Development of a Simple, Fast and Portable Recombinase Aided Amplification Assay for 2019-nCoV",Recruiting,NA,Beijing Ditan Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04245631,0,0,0,0,1,0,China,0,recombinase,NA
NCT04766983,2021-01-22,2022-01-31,Observational,Incidence of VAP in Patients With Severe COVID-19,Recruiting,NA,"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico",NA,https://clinicalzeros.gov/ct2/show/NCT04766983,0,0,0,0,0,0,Italy,0,bronchoalveolar lavage,NA
NCT04767087,2021-02-05,2021-06-15,Interventional,Honey and Nigella Sativa in COVID-19 Prophylaxis,Recruiting,Phase 2/Phase 3,Sheikh Zayed Federal Postgraduate Medical Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04767087,0,0,0,0,0,0,Pakistan,0,honey|nigella sativa seed|placebo,NA
NCT04701710,2020-10-15,2020-12-18,Interventional,Prophylaxis Covid-19 in Healthcare Agents by Intensive Treatment With Ivermectin and Iota-carrageenan,Completed,Phase 1/Phase 2,"Ministry of Public Health, Argentina",NA,https://clinicalzeros.gov/ct2/show/NCT04701710,0,0,0,0,2,0,Argentina,0,ivermectin / iota-carrageenan|ivermectin|iota-carrageenan,NA
NCT04766788,2020-09-03,2021-05-31,Observational,Studying Students at Risk for COVID-19,"Active, not recruiting",NA,University of Michigan,NA,https://clinicalzeros.gov/ct2/show/NCT04766788,0,0,0,0,0,1,United States,0,"wearable devices, saliva samples, survey measures",NA
NCT04765839,2021-02-12,2021-03-22,Interventional,Community-Engaged Bidirectional Pandemic Crisis and Emergency Risk Communication With COVID-19 Vaccine Messages to Minority Populations,"Active, not recruiting",N/A,Mayo Clinic,NA,https://clinicalzeros.gov/ct2/show/NCT04765839,0,0,0,1,0,1,United States,0,"educational, culturally appropriate covid-19 messages",NA
NCT04448704,2020-06-22,2020-10-11,Observational,Understanding the Mental Health of Migrant Workers During the COVID-19 Outbreak,Completed,NA,Yale-NUS College,NA,https://clinicalzeros.gov/ct2/show/NCT04448704,0,0,0,0,4,0,Singapore,0,"NA",NA
NCT04432922,2020-11-01,2020-11-15,Observational,"Perceptions, Representations and Experiences of Septic Isolation of Hospitalized Patients for COVID-19 Infection",Completed,NA,Centre Hospitalier Intercommunal Creteil,NA,https://clinicalzeros.gov/ct2/show/NCT04432922,0,0,0,0,5,0,France,0,hospitalized patients for covid-19 infection,NA
NCT04527575,2020-07-27,2021-05-31,Interventional,"Study of the Safety, Reactogenicity and Immunogenicity of ""EpiVacCorona"" Vaccine for the Prevention of COVID-19","Active, not recruiting",Phase 1/Phase 2,"Federal Budgetary Research Institution State Research Center of Virology and Biotechnology ""Vector""",NA,https://clinicalzeros.gov/ct2/show/NCT04527575,0,0,0,1,3,0,Russian Federation,0,epivaccorona (epivaccorona vaccine based on peptide antigens for the prevention of covid-19)|placebo,NA
NCT04429555,2021-01-11,2021-06-30,Interventional,"Efficacy, Safety, Tolerability, and Biomarkers of MN-166 (Ibudilast) in Patients Hospitalized With COVID-19 and at Risk for ARDS",Recruiting,Phase 2,MediciNova,NA,https://clinicalzeros.gov/ct2/show/NCT04429555,0,0,0,0,5,1,United States,0,ibudilast|placebo,NA
NCT04507893,2020-03-15,2020-09-30,Observational,Comparison Between Positive and Negative COVID-19 Pneumonia,Recruiting,NA,University of Palermo,NA,https://clinicalzeros.gov/ct2/show/NCT04507893,0,0,0,0,2,0,Italy,0,"clinical, laboratory/imaging characteristics of pneumonia|clinical, laboratory|imaging characteristics of pneumonia",NA
NCT04365595,2020-06-03,2021-02-17,Observational,SARS-CoV-2 Associated Respiratory Failure Recovery (COVID-19 CAir),Completed,NA,University of Zurich,NA,https://clinicalzeros.gov/ct2/show/NCT04365595,0,0,0,0,3,0,Switzerland,0,questionnaire,NA
NCT04384445,2020-09-08,2021-06-30,Interventional,Zofin (Organicell Flow) for Patients With COVID-19,Recruiting,Phase 1/Phase 2,Organicell Regenerative Medicine,NA,https://clinicalzeros.gov/ct2/show/NCT04384445,0,0,0,0,7,1,United States,0,zofin|placebo,NA
NCT04371354,2020-04-27,2021-06-14,Observational,Outcomes of Covid-19 Protective Measures in Endoscopy,"Active, not recruiting",NA,Fundacion Miguel Servet,NA,https://clinicalzeros.gov/ct2/show/NCT04371354,0,0,0,0,2,0,Spain,0,"NA",NA
NCT04358783,2020-04-27,2021-05-01,Interventional,Convalescent Plasma Compared to the Best Available Therapy for the Treatment of SARS-CoV-2 Pneumonia,"Active, not recruiting",Phase 2,Hospital Universitario Dr. Jose E. Gonzalez,NA,https://clinicalzeros.gov/ct2/show/NCT04358783,0,0,0,0,2,0,Mexico,0,plasma|best available therapy,NA
NCT04358003,2020-05-20,2021-08-01,Interventional,Plasma Adsorption in Patients With Confirmed COVID-19,Recruiting,N/A,Marker Therapeutics AG,NA,https://clinicalzeros.gov/ct2/show/NCT04358003,0,0,0,0,8,1,United States,0,marker therapeutics d2000 cartridge (d2000) for use with the spectra optiaâ® apheresis system (optia spd protocol)|marker therapeutics d2000 cartridge (d2000) for use with the spectra optiaâ® apheresis system (optia spd protocol),NA
NCT04355962,2020-04-23,2022-03-31,Interventional,Sevoflurane in COVID-19 ARDS (SevCov),Recruiting,Phase 3,University of Zurich,NA,https://clinicalzeros.gov/ct2/show/NCT04355962,0,0,0,0,6,0,Switzerland,0,sevoflurane|intravenous drug,NA
NCT04334460,2020-05-04,2020-11-11,Interventional,Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects,"Active, not recruiting",Phase 2,Blade Therapeutics,NA,https://clinicalzeros.gov/ct2/show/NCT04334460,0,0,0,0,10,1,United States|Brazil,0,bld-2660,NA
NCT04731116,2021-01-10,2021-12-31,Interventional,Cannabidiol Treatment for Severe and Critical Coronavirus (COVID-19) Pulmonary Infection,Recruiting,Phase 1/Phase 2,Rabin Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04731116,0,0,0,0,0,0,Israel,0,cannabidiol,NA
NCT04730284,2020-08-25,2021-09-30,Interventional,Evaluation of a Synbiotic Formula in Patient With COVID-19,Recruiting,N/A,Chinese University of Hong Kong,NA,https://clinicalzeros.gov/ct2/show/NCT04730284,0,0,0,0,0,0,Hong Kong,0,health supplements,NA
NCT04730427,2021-01-31,2021-05-31,Interventional,Safety and Preliminary Efficacy Study of GX-I7 in Patients With COVID-19,Recruiting,Phase 1,"Genexine, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04730427,0,0,0,0,0,0,"Korea, Republic of",0,gx-i7|gx-i7 vehicle,NA
NCT04696679,2020-06-19,2020-11-30,Observational,Quality of Life of Very Preterm Children With Dysexecutive Disorders at Elementary School Age During the Confinement-deconfinement Period of Covid-19 Pandemic,Completed,NA,Assistance Publique Hopitaux De Marseille,NA,https://clinicalzeros.gov/ct2/show/NCT04696679,0,0,0,0,2,0,France,0,patient quality of life assessment|control group quality of life assessment,NA
NCT04723524,2020-09-22,2021-06-30,Interventional,Jinhua Qinggan Granules in the Treatment of COVID-19,Recruiting,Phase 2,University of Karachi,NA,https://clinicalzeros.gov/ct2/show/NCT04723524,0,0,0,0,2,0,Pakistan,0,"jinhua qinggan (jhqg) granules, traditional chinese medicine|placebo",NA
NCT04695301,2020-07-01,2021-07-01,Interventional,Functional Outcomes in COVID-19 Survivors and Use of a Digital Platform for Rehabilitation,Recruiting,N/A,Hospital Israelita Albert Einstein,NA,https://clinicalzeros.gov/ct2/show/NCT04695301,0,0,0,0,2,0,Brazil,0,rehabilitation protocol through a digital platform,NA
NCT04538456,2020-10-15,2021-04-30,Observational,Impact of COVID-19 on Lung Cancer Patients,Recruiting,NA,The Christie NHS Foundation Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04538456,0,0,0,0,2,0,United Kingdom,0,questionnaire/optional interview|questionnaire|optional interview,NA
NCT04647682,2020-11-01,2021-06-30,Observational,Physical Activity Program Implementation in Hospitalized Positive Covid-19 Older Adults,Recruiting,NA,"University Hospital, Toulouse",NA,https://clinicalzeros.gov/ct2/show/NCT04647682,0,0,0,0,2,0,France,0,physical activity program,NA
NCT04640233,2020-11-30,2021-08-31,Interventional,Clinical Trial to Assess Safety and Immunogenicity of Gam-COVID-Vac Combined Vector Vaccine for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Ð¡ov-2) Infection,Recruiting,Phase 2/Phase 3,Dr. Reddy's Laboratories Limited,NA,https://clinicalzeros.gov/ct2/show/NCT04640233,0,0,0,1,1,0,India,0,gam-covid-vac|placebo,NA
NCT04637295,2021-01-27,2021-06-30,Observational,"Perceptions, Experiences, and Activity in CancEr Survivors During COVID-19",Recruiting,NA,University of Nebraska,NA,https://clinicalzeros.gov/ct2/show/NCT04637295,0,0,0,0,1,1,United States,0,"NA",NA
NCT04590352,2020-03-26,2020-05-13,Observational,Mucosal Immunity Against SARS-CoV-2 Infection in COVID-19 Patients,Completed,NA,Radboud University,NA,https://clinicalzeros.gov/ct2/show/NCT04590352,0,0,0,0,1,0,Netherlands,0,nasopharyngeal/throat swab|collection of mucosal lining fluid|blood sample|nasopharyngeal|throat swab,NA
NCT04584450,2020-09-02,2020-12-31,Observational,Investigation of Validity and Reliability of Post-COVID-19 Functional Status Scale,Completed,NA,Hacettepe University,NA,https://clinicalzeros.gov/ct2/show/NCT04584450,0,0,0,0,1,0,Turkey,0,questionnaire,NA
NCT04582331,2020-09-10,2021-04-30,Observational,Improving Real-time COVID-19 Monitoring Through Smartphone Voice Analysis,Recruiting,NA,Sonde Health,NA,https://clinicalzeros.gov/ct2/show/NCT04582331,0,0,0,0,1,1,United States|India,0,smartphone-based voice/self-reported symptom collection|smartphone-based voice|self-reported symptom collection,NA
NCT04464395,2020-07-01,2021-03-31,Interventional,Study of CPI-006 as Immunotherapy for Hospitalized COVID-19 Patients,Recruiting,Phase 1,"Corvus Pharmaceuticals, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04464395,0,0,0,0,4,1,United States,0,cpi-006|standard care,NA
NCT04459962,2020-06-29,2021-01-07,Interventional,Covid-19 Breath Test,Completed,N/A,Ancon Technologies Ltd,NA,https://clinicalzeros.gov/ct2/show/NCT04459962,0,0,0,0,1,0,United Kingdom,0,breath test/cheek swab|breath test|cheek swab,NA
NCT04412668,2020-06-12,2020-12-21,Interventional,Study to Evaluate the Safety and Efficacy of ATYR1923 In Patients With Severe Pneumonia Related to COVID-19,Completed,Phase 2,"aTyr Pharma, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04412668,0,0,0,0,9,1,United States|Puerto Rico,0,atyr1923|placebo|kg,NA
NCT04366934,2020-05-04,2020-10-29,Observational,Study of the Pathogenesis of Olfactory Disorders in COVID-19,Completed,NA,Institut Pasteur,NA,https://clinicalzeros.gov/ct2/show/NCT04366934,0,0,0,0,2,0,France,0,nasal|taste/olfactory function evaluation|taste|olfactory function evaluation,NA
NCT04769349,2021-01-29,2021-12-15,Observational,Effectiveness of Supportive Housing on COVID-19 Related Outcomes for People Experiencing Homelessness,Recruiting,NA,University of Southern California,NA,https://clinicalzeros.gov/ct2/show/NCT04769349,0,0,0,0,0,1,United States,0,"NA",NA
NCT04769284,2021-02-12,2021-02-20,Observational,Psychological State of Students of Health Sciences During COVID-19,Completed,NA,Instituto de InvestigaciÃ³n Sanitaria AragÃ³n,NA,https://clinicalzeros.gov/ct2/show/NCT04769284,0,0,0,0,0,0,Spain,0,mental health student,NA
NCT04769245,2021-02-18,2021-04-01,Observational,The Effectiveness of ACB-IP 1.0 Convalescent Plasma in COVID-19 Infection,Recruiting,NA,Acibadem University,NA,https://clinicalzeros.gov/ct2/show/NCT04769245,0,0,0,0,0,0,Turkey,0,"NA",NA
NCT04769700,2021-01-01,2021-06-01,Observational,"Post-partum Depression, Breastfeeding Adherence and Fear in COVID-19",Recruiting,NA,Instituto Mexicano del Seguro Social,NA,https://clinicalzeros.gov/ct2/show/NCT04769700,0,0,0,0,0,0,Mexico,0,edinburgh postnatal depression scale|breast feeding adherence|fear of covid-19 scale,NA
NCT04769297,2020-04-15,2021-04-30,Interventional,"Micro-Dose, Macro-Impact: Leveraging Psychedelics in Frontline Healthcare Workers During the COVID-19 Pandemic","Active, not recruiting",Phase 4,Limbic Medical,NA,https://clinicalzeros.gov/ct2/show/NCT04769297,0,0,0,0,0,1,United States,0,sublingual micro-dose ketamine,NA
NCT04700462,2021-02-05,2021-10-30,Interventional,COVID-19 Preventive Behavior in African Americans,Recruiting,N/A,Johns Hopkins University,NA,https://clinicalzeros.gov/ct2/show/NCT04700462,0,0,0,0,2,1,United States,0,sm-ema,NA
NCT04768153,2020-06-29,2021-06-29,Observational,Prioritising Prevention of COVID-19 in Persons With Cancer in the French West Indies,Recruiting,NA,University Hospital Center of Martinique,NA,https://clinicalzeros.gov/ct2/show/NCT04768153,0,0,0,0,0,0,Martinique,0,serology test,NA
NCT04768413,2020-06-01,2021-04-30,Observational [Patient Registry],Evaluation of a Non-face to Face Multidisciplinary Health Care Model in a Population With Rheumatoid Arthritis,Recruiting,NA,FundaciÃ³n Universitaria de Ciencias de la Salud,NA,https://clinicalzeros.gov/ct2/show/NCT04768413,0,0,0,0,0,0,Colombia,0,teleconsultation either by phone/by computer consultation. quantitative/qualitative approaches to analysis|care modalities. quantitative/qualitative approaches to analysis|teleconsultation either by phone|by computer consultation. quantitative|qualitative approaches to analysis|care modalities. quantitative,NA
NCT04762628,2020-10-27,2021-11-01,Interventional,"Trial Efficacy of Saisei Pharma Dietary Supplements MAF Capsules, 148 mg and M Capsules, 148 mg in Hospitalized COVID-19 Patients","Active, not recruiting",N/A,Saisei Pharma,NA,https://clinicalzeros.gov/ct2/show/NCT04762628,0,0,0,0,1,0,Ukraine,0,maf capsules 148 mg|m capsules 148 mg|standard care,NA
NCT04727372,2021-01-23,2021-02-23,Observational [Patient Registry],Social Acceptability of COVID-19 Vaccines in Pakistan,Completed,NA,Islamia University of Bahawalpur,NA,https://clinicalzeros.gov/ct2/show/NCT04727372,0,0,0,0,1,0,Pakistan,0,questionnaire,NA
NCT04723563,2021-02-22,2021-05-01,Interventional,Nebulized Heparin for the Treatment of COVID-19,Enrolling by invitation,Phase 4,Frederick Health,NA,https://clinicalzeros.gov/ct2/show/NCT04723563,0,0,0,0,1,1,United States,0,heparin|saline,NA
NCT04695197,2021-01-08,2022-11-01,Interventional,Malaria as a Risk Factor for COVID-19 in Western Kenya and Burkina Faso,Recruiting,Phase 3,Liverpool School of Tropical Medicine,NA,https://clinicalzeros.gov/ct2/show/NCT04695197,0,0,0,0,1,0,Burkina Faso|Kenya,0,artemether-lumefantrine (al)|pyronaridine-artesunate (pa),NA
NCT04659707,2021-02-22,2021-12-31,Interventional,Hyperpolarized 129Xe MRI of Survivors of COVID-19,Recruiting,Phase 1,University of Kansas Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04659707,0,0,0,0,2,1,United States,0,hyperpolarized xe129,NA
NCT04681053,2021-02-25,2021-04-30,Interventional,Inhaled Ivermectin and COVID-19,Recruiting,Phase 3,Mansoura University,NA,https://clinicalzeros.gov/ct2/show/NCT04681053,0,0,0,0,2,0,Egypt,0,ivermectin powder,NA
NCT04679909,2021-02-28,2022-02-28,Interventional,Safety and Immunogenicity of AdCOVID in Healthy Adults (COVID-19 Vaccine Study),Recruiting,Phase 1,"Altimmune, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04679909,0,0,0,1,3,1,United States,0,adcovid|placebo,NA
NCT04618835,2021-01-11,2021-11-03,Observational,Physical Activity a Vital Sign? 40 Steps to Safety Test for Patients With COVID-19,Recruiting,NA,Betsi Cadwaladr University Health Board,NA,https://clinicalzeros.gov/ct2/show/NCT04618835,0,0,0,0,1,0,United Kingdom,0,40-steps-test,NA
NCT04494646,2020-09-08,2021-01-08,Interventional,BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19),Completed,Phase 2,NYU Langone Health,NA,https://clinicalzeros.gov/ct2/show/NCT04494646,0,0,0,0,5,1,United States,0,bardoxolone methyl|placebo,NA
NCT04610515,2020-12-15,2022-11-14,Observational [Patient Registry],Innovative Support for Patients With SARS-COV2 Infections (COVID-19) Registry (INSPIRE),Recruiting,NA,Rush University Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04610515,0,0,0,0,2,1,United States,0,"NA",NA
NCT04535869,2020-12-28,2021-04-01,Interventional,Efficacy and Safety of Direct Anti HCV Drugs in the Treatment of SARS-COV-2 (COVID-19),Recruiting,Phase 3,Mansoura University,NA,https://clinicalzeros.gov/ct2/show/NCT04535869,0,0,0,0,3,0,Egypt,0,sofosbuvir 400 mg/daclatasvir 200mg|sofosbuvir 400 mg|daclatasvir 200mg,NA
NCT04532411,2020-03-01,2020-09-30,Observational,COVID-19 Testing Sample Acquisition Throughput and Efficiency,Completed,NA,Massachusetts General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04532411,0,0,0,0,1,1,United States,0,personal protective testing booth,NA
NCT04390269,2020-09-10,2021-10-10,Observational,Immunogenetics Predictors With COVID-19,Recruiting,NA,Mansoura University,NA,https://clinicalzeros.gov/ct2/show/NCT04390269,0,0,0,0,3,0,Egypt,0,"NA",NA
NCT04415151,2020-07-29,2021-03-31,Interventional,Tofacitinib for Treatment of Moderate COVID-19,Recruiting,Phase 2,Yale University,NA,https://clinicalzeros.gov/ct2/show/NCT04415151,0,0,0,0,4,1,United States,0,tofacitinib|placebo,NA
NCT04384471,2020-04-29,2020-07-01,Observational,Covid-19 Pandemic: Patients' Experience in T1D,Completed,NA,McGill University,NA,https://clinicalzeros.gov/ct2/show/NCT04384471,0,0,0,0,1,0,Canada,0,online survey,NA
NCT04365699,2020-04-08,2021-01-31,Interventional,Cardiovascular Effects of COVID-19,Completed,Phase 2,NYU Langone Health,NA,https://clinicalzeros.gov/ct2/show/NCT04365699,0,0,0,0,1,1,United States,0,at-001,NA
NCT04370249,2020-04-09,2020-08-31,Observational,Construction of a Composite Clinical-echo Score Predictive of a Risk of Short-term Aggravation of Respiratory Impairment in Patients Suspected of Covid-19,Completed,NA,Nantes University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04370249,0,0,0,0,2,0,France,0,ultrasound,NA
NCT04366141,2020-05-01,2021-02-01,Interventional,COVID-19 (Coronavirus Disease 2019) Intubation Barrier Box,Completed,N/A,University of British Columbia,NA,https://clinicalzeros.gov/ct2/show/NCT04366141,0,0,0,0,3,0,Canada,0,covid-19 barrier box,NA
NCT04394013,2020-08-26,2020-12-31,Interventional,A Web-Based Gentle Body Stretching to Alleviate Loneliness and Improve Mental Fitness During COVID-19 Isolation Period,Completed,N/A,Monash University Malaysia,NA,https://clinicalzeros.gov/ct2/show/NCT04394013,0,0,0,0,2,0,Malaysia,0,mindfulness|non-mindfulness intervention,NA
NCT04329559,2020-03-30,2021-02-10,Observational [Patient Registry],COVID-19 in Patients With Pre-existing Cirrhosis (COVID-Cirrhosis-CHESS2002): A Multicentre Observational Study,Completed,NA,Hepatopancreatobiliary Surgery Institute of Gansu Province,NA,https://clinicalzeros.gov/ct2/show/NCT04329559,0,0,0,0,1,0,China,0,"NA",NA
NCT04734912,2021-01-13,2021-06-15,Interventional,Evaluation of Transnasal Endoscopy During COVID-19 Pandemic,Recruiting,N/A,Johannes Gutenberg University Mainz,NA,https://clinicalzeros.gov/ct2/show/NCT04734912,0,0,0,0,0,0,Germany,0,gastroscopy in transnasal techique,NA
NCT04734717,2021-01-12,2021-04-12,Interventional,Coordination and Locomotor Problems in Patients With Covid-19 Virus,Enrolling by invitation,N/A,Somogy Megyei Kaposi MÃ³r Teaching Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04734717,0,0,0,0,0,0,Hungary,0,neurology test,NA
NCT04734678,2020-12-01,2021-03-01,Observational,Comparison of Tocilizumab Versus Tocilizumab/Infliximab in Patients With COVID-19-associated Cytokine Storm Syndrome,Recruiting,NA,Ain Shams University,NA,https://clinicalzeros.gov/ct2/show/NCT04734678,0,0,0,0,0,0,Egypt,0,tocilizumab|infliximab,NA
NCT04734886,2020-11-27,2021-08-30,Interventional,The Effect of Probiotic Supplementation on SARS-CoV-2 Antibody Response After COVID-19,Recruiting,N/A,"Ã–rebro University, Sweden",NA,https://clinicalzeros.gov/ct2/show/NCT04734886,0,0,0,0,0,0,Sweden,0,l. reuteri dsm 17938 / vitamin d|placebo / vitamin d|l. reuteri dsm 17938|vitamin d|placebo,NA
NCT04733833,2021-01-26,2022-06-30,Interventional,A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With COVID-19,Recruiting,Phase 2,Vascular Biogenics Ltd. operating as VBL Therapeutics,NA,https://clinicalzeros.gov/ct2/show/NCT04733833,0,0,0,0,0,0,Israel,0,vb-201 / standard of care|standard care|vb-201,NA
NCT04734171,2020-04-02,2020-04-16,Interventional,"Social Activity, Loneliness and Stigma During COVID-19 Outbreak",Completed,N/A,Columbia University,NA,https://clinicalzeros.gov/ct2/show/NCT04734171,0,0,0,0,0,1,United States,0,digital social activity video intervention|informational sheet|stigma awareness video intervention,NA
NCT04733625,2020-09-15,2020-12-17,Interventional,The Effect of Vitamin D Therapy on Morbidity and Moratlity in Patients With SARS-CoV 2 Infection,Completed,N/A,Kasr El Aini Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04733625,0,0,0,0,0,0,Egypt,0,cholecalciferol|placebo,NA
NCT04728594,2021-01-15,2021-01-17,Interventional,Emails Promoting COVID-19 Vaccination Among Healthcare Workers,Completed,N/A,Geisinger Clinic,NA,https://clinicalzeros.gov/ct2/show/NCT04728594,0,0,0,1,1,1,United States,0,social proof|reframing|scarcity message,NA
NCT04692129,2020-05-29,2021-12-31,Observational,Prone Positioning Short-term Effects on Tissue Oxygen Saturation in Critical COVID-19 Patients,Recruiting,NA,Corporacion Parc Tauli,NA,https://clinicalzeros.gov/ct2/show/NCT04692129,0,0,0,0,1,0,Brazil|Mexico|Spain,0,"NA",NA
NCT04724434,2020-12-04,2021-06-30,Observational,Follow-up Study of COVID-19 Patients in the District Konstanz,Enrolling by invitation,NA,Hegau-Bodensee-Klinikum Singen,NA,https://clinicalzeros.gov/ct2/show/NCT04724434,0,0,0,0,2,0,Germany,0,"NA",NA
NCT04726163,2021-01-29,2021-06-14,Interventional,Tele-expertise in Patients With Diabetes Hospitalized for Covid-19 Infection,Recruiting,N/A,"University Hospital, Strasbourg, France",NA,https://clinicalzeros.gov/ct2/show/NCT04726163,0,0,0,0,1,0,France,0,continuous blind glucose measurement device (free style pro),NA
NCT04713488,2021-01-15,2021-07-20,Interventional,"An Open Study on the Safety, Tolerability, and Immunogenicity of ""Sputnik Light"" Vaccine","Active, not recruiting",Phase 1/Phase 2,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",NA,https://clinicalzeros.gov/ct2/show/NCT04713488,0,0,0,1,2,0,Russian Federation,0,sputnik light,NA
NCT04704466,2021-01-07,2021-06-30,Observational,Impact of Covid-19 Pandemic on Management of Head and Neck Cancers,Recruiting,NA,"Centre Hospitalier Universitaire, Amiens",NA,https://clinicalzeros.gov/ct2/show/NCT04704466,0,0,0,0,1,0,France,0,"NA",NA
NCT04674644,2020-10-16,2020-10-23,Interventional,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Completed,N/A,Suleyman Demirel University,NA,https://clinicalzeros.gov/ct2/show/NCT04674644,0,0,0,0,2,0,Turkey,1,the psychosocial effects of covid-19 pandemic on dental professionals,NA
NCT04639375,2020-11-15,2021-04-18,Interventional,Polio Vaccine (IPV) for SARS-CoV-2 and Prevention of Coronavirus Disease (COVID-19),Recruiting,Phase 4,E-MO Biology Inc,NA,https://clinicalzeros.gov/ct2/show/NCT04639375,0,0,0,1,4,1,United States,0,vaccinated with polio vaccine (ipv),NA
NCT04661657,2020-12-28,2021-12-31,Observational [Patient Registry],COvid-19 LongitUdinal Multiethnic BioImaging Assessment of CARDiovascular Sequelae Registry,Recruiting,NA,Columbia University,NA,https://clinicalzeros.gov/ct2/show/NCT04661657,0,0,0,0,1,1,United States,0,transthoracic echocardiogram (tte)|cardiovascular magnetic resonance (cmr) imaging,NA
NCT04669912,2021-01-15,2021-01-22,Observational,COVID-19 Pandemic Lockdown Effect in Adolescents and Young Adults With Type 1 Diabetes: Positive Results of an Unpreceded Challenge for Telemedicine and Patient Self-management,Completed,NA,Centre Hospitalier Sud Francilien,NA,https://clinicalzeros.gov/ct2/show/NCT04669912,0,0,0,0,2,0,France,0,glucose control/sensor usage|glucose control|sensor usage,NA
NCT04635605,2020-11-05,2021-12-31,Interventional,Methylene Blue Treatment of COVID-19,Recruiting,Phase 2,Fondazione Epatocentro Ticino,NA,https://clinicalzeros.gov/ct2/show/NCT04635605,0,0,0,0,1,0,Switzerland,0,methylene blue|control test,NA
NCT04646603,2021-01-28,2021-04-01,Interventional,MRG-001 as an Immunoregulatory and Regenerative Therapy for COVID-19 Patients,Recruiting,Phase 1/Phase 2,MedRegen LLC,NA,https://clinicalzeros.gov/ct2/show/NCT04646603,0,0,0,0,5,1,United States,0,mrg-001|placebo,NA
NCT04548934,2020-09-13,2020-10-31,Interventional,Effect of Wearing Personal Protective Equipment (PPE) on CPR Quality in Times of the COVID-19-pandemic,Completed,N/A,Institute of Mountain Emergency Medicine,NA,https://clinicalzeros.gov/ct2/show/NCT04548934,0,0,0,0,1,0,Italy,0,personal protective equipment (ppe)|no personal protective equipment (ppe),NA
NCT04623021,2020-09-25,2020-12-12,Interventional,A Study Evaluating the Efficacy and Safety of CKD-314 (Nafabelltan) in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia,Completed,Phase 2,Chong Kun Dang Pharmaceutical,NA,https://clinicalzeros.gov/ct2/show/NCT04623021,0,0,0,0,1,0,Russian Federation,0,nafamostat mesilate,NA
NCT04474457,2020-06-11,2020-12-31,Observational,Efficacy and Safety of Favipiravir in the Treatment of COVID-19 Patients Over 15 Years of Age,"Active, not recruiting",NA,"Ministry of Health, Turkey",NA,https://clinicalzeros.gov/ct2/show/NCT04474457,0,0,0,0,2,0,Turkey,0,favipiravir,NA
NCT04528667,2021-01-06,2021-05-31,Interventional,Study of the Safety and Efficacy of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized Due to COVID-19,Recruiting,Phase 2,"Sorrento Therapeutics, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04528667,0,0,0,0,2,0,Brazil,0,sti-5656|placebo,NA
NCT04528368,2020-12-11,2021-04-30,Interventional,Convalescent Plasma for Treating Patients With COVID-19 Pneumonia Without Indication of Ventilatory Support,Recruiting,Phase 2,D'Or Institute for Research and Education,NA,https://clinicalzeros.gov/ct2/show/NCT04528368,0,0,0,0,1,0,Brazil,0,convalescent plasma,NA
NCT04519411,2020-05-21,2021-12-31,Interventional,Transpulmonary Pressure Measurements in Intubated Children With Covid-19 Respiratory Failure,Recruiting,N/A,Mayo Clinic,NA,https://clinicalzeros.gov/ct2/show/NCT04519411,0,0,0,0,1,1,United States,0,transpulmonary pressure measurements,NA
NCT04498442,2020-05-22,2020-10-22,Interventional,"A Study on Prevalence, Protection and Recovery From COVID-19 in Seasoned Yoga Practitioners in Comparison to Age and Gender Matched Controls",Completed,N/A,Beth Israel Deaconess Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04498442,0,0,0,0,3,1,United States,0,simha kriya|reading a book,NA
NCT04488575,2020-08-26,2021-07-06,Interventional,Safety and Efficacy of EDP1815 in the Treatment of Patients Hospitalized With COVID-19 Infection,Recruiting,Phase 2,"Evelo Biosciences, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04488575,0,0,0,0,4,1,United States,0,edp1815|placebo,NA
NCT04486001,2020-12-15,2022-01-15,Interventional,Study of Intravenous Administration of Allogeneic Adipose Stem Cells for COVID-19,Recruiting,Phase 1,"Sorrento Therapeutics, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04486001,0,0,0,0,4,1,United States,0,psc-04,NA
NCT04469114,2020-09-16,2021-03-01,Interventional,Tofacitinib in Hospitalized Patients With COVID-19 Pneumonia,"Active, not recruiting",Phase 2,Hospital Israelita Albert Einstein,NA,https://clinicalzeros.gov/ct2/show/NCT04469114,0,0,0,0,5,0,Brazil,0,tofacitinib|placebo,NA
NCT04431284,2020-06-16,2020-12-16,Observational,Impact of COVID-19 Lockdown on Obesity and Eating Behaviors,Completed,NA,Hospices Civils de Lyon,NA,https://clinicalzeros.gov/ct2/show/NCT04431284,0,0,0,0,3,0,France,0,questionnaire,NA
NCT04452669,2020-09-15,2021-05-01,Interventional,VentaProst in Subjects With COVID-19 Requiring Mechanical Ventilation,Recruiting,Phase 2,Aerogen Pharma Limited,NA,https://clinicalzeros.gov/ct2/show/NCT04452669,0,0,0,0,3,1,United States,0,ventaprost (inhaled epoprostenol delivered via a dedicated delivery system),NA
NCT04407143,2020-04-15,2021-09-30,Observational,Study of the Immunity of Patients With Lung Cancer and COVID-19 Infection,Recruiting,NA,FundaciÃ³n GECP,NA,https://clinicalzeros.gov/ct2/show/NCT04407143,0,0,0,0,3,0,Spain,0,igg antibody test,NA
NCT04435379,2020-06-18,2021-09-30,Interventional,Study to Assess VPM1002 in Reducing Hospital Admissions and/or Severe Respiratory Infectious Diseases in Elderly in COVID-19 Pandemic,"Active, not recruiting",Phase 3,Vakzine Projekt Management GmbH,NA,https://clinicalzeros.gov/ct2/show/NCT04435379,0,0,0,0,11,0,Germany,0,vpm1002|placebo,NA
NCT04434118,2020-03-20,2021-12-30,Observational,Anti-rheumatic Drug Use and Risk of COVID-19 Infection in Rheumatoid Arthritis Patients,Enrolling by invitation,NA,Sadat City University,NA,https://clinicalzeros.gov/ct2/show/NCT04434118,0,0,0,0,4,0,Egypt,0,antirheumatic drugs,NA
NCT04430049,2020-06-22,2021-10-22,Observational,"Impact of Covid-19 Restrictive Measure on Anxiety, Depression and PTSD for Relatives of ICU Patients",Recruiting,NA,"University Hospital, Clermont-Ferrand",NA,https://clinicalzeros.gov/ct2/show/NCT04430049,0,0,0,0,3,0,France,0,covid icu containment measures,NA
NCT04411433,2020-05-08,2020-12-31,Interventional,Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19,"Active, not recruiting",Phase 3,"Ministry of Health, Turkey",NA,https://clinicalzeros.gov/ct2/show/NCT04411433,0,0,0,0,1,0,Turkey,0,favipiravir|favipiravir/hydroxychloroquine|favipiravir/azithromycin|hydroxychloroquine|hydroxychloroquine / azithromycin|1200 mg)|1600 mg)|azithromycin,NA
NCT04376658,2020-07-15,2022-04-15,Observational,Quality of Life and Long-term Outcomes After Hospitalization for COVID-19,Recruiting,NA,Hospital Moinhos de Vento,NA,https://clinicalzeros.gov/ct2/show/NCT04376658,0,0,0,0,4,0,Brazil,0,covid-19,NA
NCT04363346,2020-05-14,2022-01-31,Interventional,Study of FT516 for the Treatment of COVID-19 in Hospitalized Patients With Hypoxia,"Active, not recruiting",Phase 1,"Masonic Cancer Center, University of Minnesota",NA,https://clinicalzeros.gov/ct2/show/NCT04363346,0,0,0,0,3,1,United States,0,nk cells,NA
NCT04403932,2020-04-17,2020-06-01,Observational,Increased Risk of Severe Coronavirus Disease 2019 in Patients With Vitamin D Deficiency,Completed,NA,"Hospital San Carlos, Madrid",NA,https://clinicalzeros.gov/ct2/show/NCT04403932,0,0,0,0,2,0,Spain,0,"NA",NA
NCT04388683,2020-05-12,2021-04-30,Interventional,Inhaled Nitric Oxide for Preventing Progression in COVID-19,"Active, not recruiting",Phase 2,Tufts Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04388683,0,0,0,0,2,1,United States,0,nitric oxide,NA
NCT04334044,2020-09-01,2021-03-01,Interventional,Treatment of SARS Caused by COVID-19 With Ruxolitinib,Recruiting,Phase 1/Phase 2,Grupo Cooperativo de HemopatÃ­as Malignas,NA,https://clinicalzeros.gov/ct2/show/NCT04334044,0,0,0,0,2,0,Mexico,0,ruxolitinib,NA
NCT04771052,2020-09-01,2021-04-30,Observational,Minimizing the Effects of COVID-19 Hospitalization With the COVID Rehabilitation Program for the Elderly,Enrolling by invitation,NA,UniversitÃ© de Sherbrooke,NA,https://clinicalzeros.gov/ct2/show/NCT04771052,0,0,0,0,0,0,Canada,0,covid rehabilitation program for the elderly (core),NA
NCT04771624,2020-10-30,2021-04-30,Observational,Assessment of Executive Functions After Covid-19,Recruiting,NA,Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04771624,0,0,0,0,0,0,Turkey,0,"NA",NA
NCT04771585,2021-03-15,2022-01-31,Interventional,Quantification of Exhaled Particles to Identify Airborne Transmission Risks of COVID-19,Recruiting,N/A,Fraunhofer-Institute of Toxicology and Experimental Medicine,NA,https://clinicalzeros.gov/ct2/show/NCT04771585,0,0,0,0,0,0,Germany,0,community mask|surgical mask|ffp2 respirator|ffp3 respirator,NA
NCT04346199,2020-06-12,2020-11-17,Interventional,Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.,Completed,Phase 2,AstraZeneca,NA,https://clinicalzeros.gov/ct2/show/NCT04346199,0,0,0,0,5,0,Argentina|Brazil|Chile|France|Germany|India|Italy|Japan|Mexico|Peru|Russian Federation|South Africa|Turkey,0,acalabrutinib,NA
NCT04344002,2020-04-21,2021-06-30,Observational [Patient Registry],LunG and Melanoma canceR pAtients coVId19 Disease (GRAVID),Recruiting,NA,Spanish Lung Cancer Group,NA,https://clinicalzeros.gov/ct2/show/NCT04344002,0,0,0,0,5,0,Spain,0,"NA",NA
NCT04341584,2020-04-08,2020-05-10,Interventional,CORIMUNO-ANA: Trial Evaluating Efficacy Of Anakinra In Patients With Covid-19 Infection,Completed,Phase 2,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04341584,0,0,0,0,2,0,France,0,anakinra,NA
NCT04336384,2020-03-01,2020-12-01,Observational,Impact of Covid-19 in Congenital Heart Disease,Completed,NA,"University Hospital, Montpellier",NA,https://clinicalzeros.gov/ct2/show/NCT04336384,0,0,0,0,2,0,France,0,"NA",NA
NCT04568707,2020-10-23,2022-10-15,Interventional,Evaluation of Biological Response to SARS-COV2 (COVID-19) in Patients With Pre-existing Neurological Disease or Newly Neurological Symptoms (BIO-COCO-NEUROSCIENCES),Recruiting,N/A,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04568707,0,0,0,0,1,0,France,0,blood sample,NA
NCT04706156,2021-01-27,2021-02-28,Observational,Oral Side Effects of COVID-19 Vaccine,Recruiting,NA,Masaryk University,NA,https://clinicalzeros.gov/ct2/show/NCT04706156,0,0,0,0,1,0,Czechia|Germany|Slovakia,0,covid-19 vaccine,NA
NCT04614844,2021-01-06,2022-09-15,Interventional,COVID-19 Responsive Intervention: Systems Improvement Simulations (CRI:SIS),Recruiting,N/A,Yale University,NA,https://clinicalzeros.gov/ct2/show/NCT04614844,0,0,0,0,3,1,United States,0,simulation intervention|control,NA
NCT04769999,2020-06-04,2020-10-16,Interventional,Computer Assisted Lessening of Intrusive Memories in the Emergency Department,Completed,N/A,University of Oxford,NA,https://clinicalzeros.gov/ct2/show/NCT04769999,0,0,0,0,0,0,United Kingdom,0,simple cognitive task,NA
NCT04768244,2020-04-01,2021-12-31,Observational,Impact of Maternal COVID-19 Disease on Breast Milk and Infant Health,Recruiting,NA,"Institute of Agrochemistry and Food Technology, National Research Council",NA,https://clinicalzeros.gov/ct2/show/NCT04768244,0,0,0,0,1,0,Spain,0,maternal sars-cov-2 infection,NA
NCT04757857,2020-09-29,2021-02-28,Interventional,COVID-19 Antithrombotic Rivaroxaban Evaluation,Recruiting,Phase 4,Hospital AlemÃ£o Oswaldo Cruz,NA,https://clinicalzeros.gov/ct2/show/NCT04757857,0,0,0,0,1,0,Brazil,0,rivaroxaban 10 mg,NA
NCT04677660,2021-01-21,2022-03-03,Interventional,A Study of TAK-919 in Healthy Japanese Adults (COVID-19),"Active, not recruiting",Phase 1/Phase 2,Takeda,NA,https://clinicalzeros.gov/ct2/show/NCT04677660,0,0,0,0,4,0,Japan,0,tak-919|placebo,NA
NCT04557358,2020-10-01,2022-12-31,Observational,Impact in the Medical Care Among the Rheumatic Diseases Patients in a Tertiary Hospital in MÃ©xico During the COVID-19 Pandemic,Enrolling by invitation,NA,"National Institute of Medical Sciences and Nutrition, Salvador Zubiran",NA,https://clinicalzeros.gov/ct2/show/NCT04557358,0,0,0,0,1,0,Mexico,0,covid-19 survey|rapid-3|whoqol-bref|dass-21 instrument (depression/anxiety)|ier-r (posttraumatic stress)|dass-21 instrument (depression|anxiety),NA
NCT04541979,2020-06-04,2021-05-01,Interventional,Aerosoliserat DNase for Treatment of Respiratory Failure in Severe COVID-19,Recruiting,Phase 2,Region Skane,NA,https://clinicalzeros.gov/ct2/show/NCT04541979,0,0,0,0,1,0,Sweden,0,aerosolized dnase|sodium,NA
NCT04736524,2021-01-15,2022-03-31,Observational,Immune Response Following COVID-19 Vaccination,Recruiting,NA,Texas Cardiac Arrhythmia Research Foundation,NA,https://clinicalzeros.gov/ct2/show/NCT04736524,0,0,0,0,0,1,United States,0,rapid antibody test,NA
NCT04408170,2020-06-19,2021-06-30,Observational,Facilitating AcceLerated Clinical Validation Of Novel Diagnostics for COVID-19 (FALCON-C19),Recruiting,NA,Manchester University NHS Foundation Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04408170,0,0,0,0,2,0,United Kingdom,0,point-of-care test for sars-cov-2,NA
NCT04736732,2021-01-01,2023-01-01,Observational,The IRCM POST-COVID-19 (IPCO) Clinic,Recruiting,NA,Institut de Recherches Cliniques de Montreal,NA,https://clinicalzeros.gov/ct2/show/NCT04736732,0,0,0,0,0,0,Canada,0,medical follow-up,NA
NCT04412317,2020-06-03,2021-05-30,Observational [Patient Registry],Use of PCR-Sars-CoV-2 in Children,Recruiting,NA,Centre Hospitalier Intercommunal Creteil,NA,https://clinicalzeros.gov/ct2/show/NCT04412317,0,0,0,0,2,0,France,0,"NA",NA
NCT04410549,2020-06-01,2021-12-31,Interventional,Pulmonary Optical Coherence Tomography in COVID-19 Patients,Recruiting,N/A,IRCCS San Raffaele,NA,https://clinicalzeros.gov/ct2/show/NCT04410549,0,0,0,0,2,0,Brazil|Italy,0,optical coherence tomography (oct),NA
NCT04397575,2020-04-03,2021-12-01,Observational [Patient Registry],The GCO-002 CACOVID-19 Cohort: a French Nationwide Multicenter Study of COVID-19 Infected Cancer Patients,"Active, not recruiting",NA,Federation Francophone de Cancerologie Digestive,NA,https://clinicalzeros.gov/ct2/show/NCT04397575,0,0,0,0,4,0,France,0,"NA",NA
NCT04678700,2021-03-01,2021-06-01,Interventional,Implementation of a Respiratory Physiotherapy Program in Post COVID-19 Patients Through Tele-assistance,Recruiting,N/A,European University of Madrid,NA,https://clinicalzeros.gov/ct2/show/NCT04678700,0,0,0,0,1,0,Spain,0,chest physiotherapy post-covid19,NA
NCT04390165,2020-06-06,2020-11-30,Observational,Malaysian COVID-19 Anosmia Study (Phase 1) - A Nationwide Multicentre Cross-Sectional Study,Completed,NA,Hospital Sultanah Bahiyah,NA,https://clinicalzeros.gov/ct2/show/NCT04390165,0,0,0,0,1,0,Malaysia,0,patient-reported online questionnaire on olfactory/taste disturbances|patient-reported online questionnaire on olfactory|taste disturbances,NA
NCT04682912,2021-01-30,2021-02-28,Observational,Blood Types in Children With COVID-19,Recruiting,NA,Mersin Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04682912,0,0,0,0,1,0,Turkey,0,"NA",NA
NCT04345679,2020-04-14,2021-06-01,Interventional,Anti COVID-19 Convalescent Plasma Therapy,Recruiting,Early Phase 1,Orthosera Kft.,NA,https://clinicalzeros.gov/ct2/show/NCT04345679,0,0,0,0,3,0,Hungary,0,convalescent plasma,NA
NCT04384042,2020-06-06,2021-03-31,Observational,Malaysian COVID-19 Anosmia Study (Phase 2) - A Nationwide Multicentre Case-Control Study,Recruiting,NA,Hospital Sultanah Bahiyah,NA,https://clinicalzeros.gov/ct2/show/NCT04384042,0,0,0,0,2,0,Malaysia,0,patient-reported online questionnaire on olfactory/taste disturbances|patient-reported online questionnaire on olfactory|taste disturbances,NA
NCT04377763,2020-07-15,2021-03-31,Observational,Developement and Evaluation of Serological Assays for COVID-19,Recruiting,NA,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04377763,0,0,0,0,3,0,France,0,"NA",NA
NCT04686578,2020-12-01,2021-02-15,Observational,The Effects of Covid-19 Pandemic on The Patients With Fibromyalgia,Recruiting,NA,Diskapi Yildirim Beyazit Education and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04686578,0,0,0,0,1,0,Turkey,0,"NA",NA
NCT04686565,2020-02-15,2021-02-28,Observational,Covid-19 Pandemic and Cerebral Palsy,Recruiting,NA,Diskapi Yildirim Beyazit Education and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04686565,0,0,0,0,1,0,Turkey,0,"NA",NA
NCT04678687,2021-01-01,2021-06-01,Interventional,COVID-19 and Tissue Damage in Vital Organs,"Active, not recruiting",N/A,Dokuz Eylul University,NA,https://clinicalzeros.gov/ct2/show/NCT04678687,0,0,0,0,1,0,Turkey,0,"liver, lung, heart/kidney biopsy|liver, lung, heart|kidney biopsy",NA
NCT04325633,2020-04-24,2020-12-15,Interventional,Efficacy of Addition of Naproxen in the Treatment of Critically Ill Patients Hospitalized for COVID-19 Infection,Terminated,Phase 3,Assistance Publique - HÃ´pitaux de Paris,Stop inclusions for insufficient recruitment,https://clinicalzeros.gov/ct2/show/NCT04325633,0,0,0,0,2,0,France,0,naproxen|standard care,NA
NCT04325048,2020-04-23,2021-06-30,Observational [Patient Registry],Clinical Evaluation of Cordio Application in Adult COVID-19 Virus Positive Patients,Recruiting,NA,Cordio Medical,NA,https://clinicalzeros.gov/ct2/show/NCT04325048,0,0,0,0,2,0,Israel,0,cordio app,NA
NCT04498416,2020-04-27,2021-07-31,Observational,CoCo-20: a Longitudinal Follow-up Study of the French Paediatric Population During and After the Coronavirus Pandemic COVID-19,Recruiting,NA,Fondation Lenval,NA,https://clinicalzeros.gov/ct2/show/NCT04498416,0,0,0,0,3,0,France,0,quantitative/qualitative assessments of mental health|quantitative|qualitative assessments of mental health,NA
NCT04653727,2021-01-06,2021-05-31,Observational,Effects of Integrative Medicine on Infectious Respiratory Diseases Including COVID-19,Recruiting,NA,"Charite University, Berlin, Germany",NA,https://clinicalzeros.gov/ct2/show/NCT04653727,0,0,0,0,2,0,Germany,0,cross-sectional survey,NA
NCT04581200,2021-01-25,2021-07-31,Interventional,Lift Mobile Mindfulness for COVID-19 Distress Symptoms,Recruiting,N/A,Duke University,NA,https://clinicalzeros.gov/ct2/show/NCT04581200,0,0,0,0,4,1,United States,0,lift,NA
NCT04529499,2020-08-20,2021-03-31,Interventional,Clinical Trial Evaluating the Efficacy and Safety of Favipiravir in Moderate to Severe COVID-19 Patients,"Active, not recruiting",Phase 3,Dr. Reddy's Laboratories Limited,NA,https://clinicalzeros.gov/ct2/show/NCT04529499,0,0,0,0,2,0,Kuwait,0,avigan|placebo,NA
NCT04525417,2020-04-25,2020-09-25,Interventional,Rapid Screening Test for Covid-19 Antibodies in Healthcare Workers,Completed,N/A,Groupe d'Etude sur le Risque d'Exposition des Soignants aux Agents Infectieux,NA,https://clinicalzeros.gov/ct2/show/NCT04525417,0,0,0,0,1,0,France,0,aaz covid-19 rapid test,NA
NCT04585945,2020-08-04,2021-03-31,Observational,COVID-19 on Placental Gene Expression and Pathology,Recruiting,NA,Prisma Health-Upstate,NA,https://clinicalzeros.gov/ct2/show/NCT04585945,0,0,0,0,1,1,United States,0,positive for sars-cov-2 infection,NA
NCT04511949,2020-07-12,2020-09-30,Interventional,COVID-19: Epidemiological Study of the Spread of SARS-CoV-2 in the Household of a Person Who Has Had a COVID-19 Disease,Completed,N/A,Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida,NA,https://clinicalzeros.gov/ct2/show/NCT04511949,0,0,0,0,2,0,France,0,igm/igg rapid test|igg|igm antibodytest,NA
NCT04409821,2020-05-29,2022-02-28,Interventional,Tele-based Psychological Emotional Support for Informal CARegivers of COVID-19 Patients in Intensive Care,Recruiting,N/A,"Rigshospitalet, Denmark",NA,https://clinicalzeros.gov/ct2/show/NCT04409821,0,0,0,0,1,0,Denmark,0,tele-delivered psychological intervention,NA
NCT04446429,2020-09-15,2020-12-24,Interventional,Anti-Androgen Treatment for COVID-19,Completed,N/A,"Applied Biology, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04446429,0,0,0,0,7,0,Brazil,1,proxalutamide|standard care,NA
NCT04445272,2020-05-22,2020-12-23,Interventional,Clinical Trial to Evaluate the Effectiveness and Safety of Tocilizumab for Treating Patients With COVID-19 Pneumonia,Completed,Phase 2,Fundacion SEIMC-GESIDA,NA,https://clinicalzeros.gov/ct2/show/NCT04445272,0,0,0,0,1,0,Spain,0,tocilizumab,NA
NCT04441502,2020-03-30,2021-09-30,Observational,Identification of Predictors for the Evolution of COVID-19 Related Pneumonia by Transcriptomic and Seroproteomic,Recruiting,NA,IRCCS Policlinico S. Donato,NA,https://clinicalzeros.gov/ct2/show/NCT04441502,0,0,0,0,1,0,Italy,0,"NA",NA
NCT04438863,2020-08-08,2021-09-01,Observational,Daily Home Spirometry for Early Detection of Pulmonary Complications in Patients With COVID19,Recruiting,NA,Sheba Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04438863,0,0,0,0,2,0,Israel,0,home spirometry,NA
NCT04406038,2020-05-27,2021-10-28,Observational,"Study of the Spread of COVID-19 in Saint Petersburg, Russia","Active, not recruiting",NA,European University at St. Petersburg,NA,https://clinicalzeros.gov/ct2/show/NCT04406038,0,0,0,0,5,0,Russian Federation,0,"NA",NA
NCT04402905,2020-06-15,2020-07-15,Observational,"Observational Study in Diagnosed Patients COVID-19, Supported on an Outpatient Basis. (COVID-PSL)",Completed,NA,Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida,NA,https://clinicalzeros.gov/ct2/show/NCT04402905,0,0,0,0,2,0,France,0,"NA",NA
NCT04384731,2020-05-29,2021-05-29,Interventional,CurosurfÂ® in Adult Acute Respiratory Distress Syndrome Due to COVID-19,Recruiting,Phase 2,Versailles Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04384731,0,0,0,0,2,0,France,0,poractant alfa,NA
NCT04374513,2020-04-02,2020-06-01,Observational,Community Pharmacists Behaviour During Covid-19,Completed,NA,Damanhour University,NA,https://clinicalzeros.gov/ct2/show/NCT04374513,0,0,0,0,3,0,Egypt,0,"NA",NA
NCT04369066,2020-04-28,2021-04-28,Interventional,"COVID-19 Study of the Serological Response Against the Severe Acute Respiratory Syndrome (SARS) Coronavirus 2 (CoV-2) Virus in 2 Types of Employees, Hospital and Non-hospital, at Institute Curie and Institute Pasteur",Recruiting,N/A,Institut Curie,NA,https://clinicalzeros.gov/ct2/show/NCT04369066,0,0,0,0,5,0,France,0,blood sample|nasopharyngeal swabs,NA
NCT04358926,2020-04-30,2020-10-15,Interventional,Hyperbaric Oxygen Therapy Effect in COVID-19 RCT (HBOTCOVID19),Completed,N/A,Assaf-Harofeh Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04358926,0,0,0,0,5,0,Israel,0,oxygen,NA
NCT04778033,2021-02-09,2021-04-10,Observational,Semen Analysis Parameters Following Pfizer's COVID-19 Vaccine,Recruiting,NA,Sheba Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04778033,0,0,0,0,0,0,Israel,0,sperm collection,NA
NCT04357769,2020-04-10,2020-04-20,Observational,COVID-19 Pandemic Burden in Severe Mental Disease Patients,Completed,NA,Federico II University,NA,https://clinicalzeros.gov/ct2/show/NCT04357769,0,0,0,0,1,0,Italy,0,pss|gad-7 (7-item generalized anxiety disorder)|phq|speq (specific psychotic experiences questionnaire) - paranoia/grandiosity subscales|zaritt burden interview|speq (specific psychotic experiences questionnaire) - paranoia|grandiosity subscales,NA
NCT04334434,2020-07-30,2020-09-15,Interventional,Telerehabilitation in Individuals Over 65 Years of Age Having Social Isolation Due to Coronavirus (Covid-19),Completed,N/A,Istanbul University-Cerrahpasa,NA,https://clinicalzeros.gov/ct2/show/NCT04334434,0,0,0,0,4,0,Turkey,0,telehealth,NA
NCT04776941,2020-08-07,2021-12-31,Interventional,Expressive Writing for the Management of Stress in Cancer Survivors,Recruiting,N/A,M.D. Anderson Cancer Center,NA,https://clinicalzeros.gov/ct2/show/NCT04776941,0,0,0,0,0,1,United States,0,behavioral intervention|quality-of-life assessment|questionnaire,NA
NCT04739410,2020-05-01,2020-06-30,Interventional,Effectiveness of Ivermectin in SARS-CoV-2/COVID-19 Patients,Completed,Phase 4,FMH College of Medicine and Dentistry,NA,https://clinicalzeros.gov/ct2/show/NCT04739410,0,0,0,0,0,0,Pakistan,0,ivermectin,NA
NCT04739345,2020-12-01,2021-04-01,Observational,New Immune-inflammation Index for Predicting Prognosis of Coronavirus Disease 2019 (COVID- 19) Infection,Recruiting,NA,Ain Shams University,NA,https://clinicalzeros.gov/ct2/show/NCT04739345,0,0,0,0,0,0,Egypt,0,"NA",NA
NCT04738331,2021-02-01,2022-05-20,Observational,Analysing the French COVID-19 Epidemic Using a National SARS-CoV-2 RT-PCR Database,Recruiting,NA,"University Hospital, Montpellier",NA,https://clinicalzeros.gov/ct2/show/NCT04738331,0,0,0,0,0,0,France,0,"NA",NA
NCT04775563,2021-02-01,2021-08-30,Observational,COVID-19 Vaccine Hesitancy Among Rheumatic Diseases Patients,Recruiting,NA,"National Institute of Medical Sciences and Nutrition, Salvador Zubiran",NA,https://clinicalzeros.gov/ct2/show/NCT04775563,0,0,0,0,0,0,Mexico,0,covid-19 vaccine hesitancy scale in rheumatic diseases|covid-19 vaccine hesitancy associated factors,NA
NCT04736901,2020-12-01,2021-04-01,Observational,Effect of Prophylactic and Therapeutic Anticoagulants in Egyptian Patients With COVID-19,Recruiting,NA,Ain Shams University,NA,https://clinicalzeros.gov/ct2/show/NCT04736901,0,0,0,0,1,0,Egypt,0,enoxaparin|rivaroxaban|apixaban,NA
NCT04738032,2020-08-26,2021-01-07,Observational,Stories for Change: Digital Storytelling Intervention for Diabetes Self-Management in the COVID-19 Pandemic,Completed,NA,Mayo Clinic,NA,https://clinicalzeros.gov/ct2/show/NCT04738032,0,0,0,0,0,1,United States,0,digital storytelling intervention,NA
NCT04726176,2021-01-30,2021-07-01,Observational,COVID-19 and the Brain,Recruiting,NA,Vrije Universiteit Brussel,NA,https://clinicalzeros.gov/ct2/show/NCT04726176,0,0,0,0,1,0,Belgium,0,exposure to covid-19,NA
NCT04732702,2020-10-29,2021-01-31,Observational,Effects of Contact Restrictions During the COVID-19 Pandemic on Newborns and Their Parents,Recruiting,NA,University of Cologne,NA,https://clinicalzeros.gov/ct2/show/NCT04732702,0,0,0,0,1,0,Germany,0,no intervention,NA
NCT04775017,2021-01-01,2021-12-31,Observational,Delirium in Covid-19: Germany-wide Covid-19 Intensive Register,Recruiting,NA,"Charite University, Berlin, Germany",NA,https://clinicalzeros.gov/ct2/show/NCT04775017,0,0,0,0,0,0,Germany,0,"NA",NA
NCT04734223,2020-04-01,2020-12-31,Observational,Neuroimaging Findings in Patients With COVID-19,Completed,NA,Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04734223,0,0,0,0,1,0,Turkey,0,neuroimaging findings in patients with covid-19,NA
NCT04703036,2021-01-11,2021-12-31,Interventional,"Glutathione, Oxidative Stress and Mitochondrial Function in COVID-19",Recruiting,Early Phase 1,Baylor College of Medicine,NA,https://clinicalzeros.gov/ct2/show/NCT04703036,0,0,0,0,2,1,United States,0,glycine|n-acetylcysteine|alanine,NA
NCT04668911,2020-12-13,2021-12-12,Observational,"Oral Health, Microbial Burden and COVID-19",Recruiting,NA,Eastman Dental Insitute and Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04668911,0,0,0,0,1,0,United Kingdom,0,swab,NA
NCT04685629,2020-05-07,2022-05-22,Observational,Covid-19 Long-term Revalidation Follow-up,Recruiting,NA,"University Hospital, Antwerp",NA,https://clinicalzeros.gov/ct2/show/NCT04685629,0,0,0,0,2,0,Belgium,0,25 post icu-patients|25 post non-icu patients,NA
NCT04613817,2020-12-03,2021-06-30,Observational [Patient Registry],Sero-prevalence COVID-19 Among Belgian Children,Recruiting,NA,Sciensano,NA,https://clinicalzeros.gov/ct2/show/NCT04613817,0,0,0,0,1,0,Belgium,0,"NA",NA
NCT04647747,2020-11-30,2021-03-30,Interventional,Silent Hypoxia and Awake Proning in COVID-19 Patients,Recruiting,N/A,Ostfold Hospital Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04647747,0,0,0,0,2,0,Norway,0,self measurement with pulse oximeter,NA
NCT04609774,2020-10-08,2020-11-20,Observational,Aerosol Transmission of Severe Acute Respiratory Syndrome Coronavirus of Coronavirus Disease 2019,Completed,NA,Hospital Italiano de Buenos Aires,NA,https://clinicalzeros.gov/ct2/show/NCT04609774,0,0,0,0,2,0,Argentina,0,severe acute respiratory syndrome coronavirus 2 detection,NA
NCT04772833,2020-06-05,2021-12-31,Observational,"Spanish Study to Analyze the Histopathological, Ultrastructural and Microbiological Findings Obtained in Autopsies of Patients Who Died Due to COVID-19",Recruiting,NA,MaimÃ³nides Biomedical Research Institute of CÃ³rdoba,NA,https://clinicalzeros.gov/ct2/show/NCT04772833,0,0,0,0,0,0,Spain,0,autopsy,NA
NCT04772703,2020-11-23,2021-02-28,Observational,DNA Damage in Critically Ill COVID-19 Patients,Recruiting,NA,University Hospital Hradec Kralove,NA,https://clinicalzeros.gov/ct2/show/NCT04772703,0,0,0,0,0,0,Czechia,0,comet assay,NA
NCT04772586,2020-09-01,2022-03-01,Observational,Sarcopenia and Mechanical Ventilation in Older Patients Admitted Due to COVID-19,Recruiting,NA,Brugmann University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04772586,0,0,0,0,0,0,Belgium,0,"NA",NA
NCT04760990,2021-02-01,2023-12-31,Observational,A Study to Assess the Potential Impact of Disease Modifying Therapies on COVID-19 Outcomes and the Antibody Response Following an Infection With SARS-CoV-2 in Patients With Multiple Sclerosis Within the Swiss Multiple Sclerosis Cohort.,Recruiting,NA,"University Hospital, Basel, Switzerland",NA,https://clinicalzeros.gov/ct2/show/NCT04760990,0,0,0,0,2,0,Switzerland,0,data collection|analysis of blood samples,NA
NCT04771117,2020-05-01,2020-08-01,Observational,Defiances to Face COVID-19 Pandemic in Mexico,Completed,NA,Instituto Mexicano del Seguro Social,NA,https://clinicalzeros.gov/ct2/show/NCT04771117,0,0,0,0,1,0,Mexico,0,fear of covid-19 scale,NA
NCT04465552,2020-07-10,2021-06-30,Observational,Arrhythmic Manifestations and Management in Hospitalized COVID-19 Patients,Recruiting,NA,Kansas City Heart Rhythm Research Foundation,NA,https://clinicalzeros.gov/ct2/show/NCT04465552,0,0,0,0,3,1,United States,0,patients received standard of care treatment during hospitalization,NA
NCT04466241,2020-11-27,2021-03-26,Interventional,Combination Therapies to Reduce Carriage of SARS-Cov-2 and Improve Outcome of COVID-19 in Ivory Coast: a Phase Randomized IIb Trial,Recruiting,Phase 2/Phase 3,French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS),NA,https://clinicalzeros.gov/ct2/show/NCT04466241,0,0,0,0,3,0,CÃ´te D'Ivoire,0,lopinavir/ritonavir 200 mg-50 mg oral tablet|telmisartan 40mg oral tablet|atorvastatin 20 mg oral tablet|lopinavir|ritonavir 200 mg-50 mg oral tablet,NA
NCT04766294,2020-04-25,2021-03-15,Observational,Macrophage Activation Markers in COVID-19 Patients,Recruiting,NA,Sohag University,NA,https://clinicalzeros.gov/ct2/show/NCT04766294,0,0,0,0,1,0,Egypt,0,"NA",NA
NCT04760132,2021-02-08,2024-12-31,Interventional,National Cohort Study of Effectiveness and Safety of SARS-CoV-2/COVID-19 Vaccines (ENFORCE),Recruiting,Phase 4,"Rigshospitalet, Denmark",NA,https://clinicalzeros.gov/ct2/show/NCT04760132,0,0,0,1,1,0,Denmark,0,comirnaty - biontech manufacturing gmbh|covid-19 vaccine moderna dispersion for injection - moderna biotech|covid-19 vaccine astrazeneca suspension for injection,NA
NCT04435522,2020-10-01,2020-12-31,Interventional,Maraviroc in Patients With Moderate and Severe COVID-19,Completed,Phase 1,Rhode Island Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04435522,0,0,0,0,3,1,United States,0,maraviroc,NA
NCT04435457,2020-09-01,2021-06-30,Observational [Patient Registry],Cardiovascular Implications of COVID-19,Recruiting,NA,University of Texas Southwestern Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04435457,0,0,0,0,3,1,United States,0,"NA",NA
NCT04409847,2020-06-01,2021-04-30,Observational,COVID-19 Blood Pressure Endothelium Interaction Study (OBELIX),Recruiting,NA,NHS Greater Glasgow and Clyde,NA,https://clinicalzeros.gov/ct2/show/NCT04409847,0,0,0,0,3,0,United Kingdom,0,abpm|ecg|fmd|pwv|rarefaction,NA
NCT04361344,2020-05-19,2020-10-25,Interventional,Neurodegeneration Markers and Neurological Course in Severe Covid-19 Infection,Terminated,N/A,Centre Hospitalier de PAU,objective of the study demonstrated by other research teams,https://clinicalzeros.gov/ct2/show/NCT04361344,0,0,0,0,2,0,France,0,blood sample,NA
NCT04407130,2020-06-16,2020-10-30,Interventional,Efficacy and Safety of Ivermectin and Doxycycline in Combination or IVE Alone in Patients With COVID-19 Infection.,Completed,Phase 2,"International Centre for Diarrhoeal Disease Research, Bangladesh",NA,https://clinicalzeros.gov/ct2/show/NCT04407130,0,0,0,0,5,0,Bangladesh,0,ivermectin / doxycycline / placebo|ivermectin / placebo|placebo|ivermectin|doxycycline,NA
NCT04747158,2020-08-10,2020-12-10,Interventional,COVID-19 Convalescent Plasma Therapy,Completed,Phase 2/Phase 3,Universidad Nacional de AsunciÃ³n,NA,https://clinicalzeros.gov/ct2/show/NCT04747158,0,0,0,0,1,0,Paraguay,0,convalescent plasma,NA
NCT04681079,2021-02-28,2021-04-30,Observational,Comparison of Viral Particle Dispersion Following Administration of an MDI or Nebulizer in Subjects With COVID-19,Recruiting,NA,Theravance Biopharma,NA,https://clinicalzeros.gov/ct2/show/NCT04681079,0,0,0,0,1,1,United States,0,albuterol sulfate (mdi)|albuterol sulfate (nebulizer),NA
NCT04730934,2021-01-01,2021-02-25,Observational [Patient Registry],Effects of the COVID-19 Pandemic on Fibromyalgia Patients,Completed,NA,Kars State Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04730934,0,0,0,0,2,0,Turkey,0,"perceived stress scale|fibromyalgia impact questionnaire|the drugs used before/during the pandemic, the patient's job status, physical activity conditions, pain status|the drugs used before|during the pandemic, the patient's job status, physical activity conditions, pain status",NA
NCT04701502,2020-11-09,2021-02-15,Interventional,Efficacy and Safety of Viusid and Asbrip in Hospitalized Patients With Mild and Moderate COVID-19,Completed,Phase 2,Catalysis SL,NA,https://clinicalzeros.gov/ct2/show/NCT04701502,0,0,0,0,2,0,Bulgaria,0,viusid|asbrip|standard care,NA
NCT04679272,2020-12-01,2021-01-30,Observational,Prognostic Evaluation of COVID-19 in Rheumatoid Arthritis Patients,Completed,NA,"University Hospital, Montpellier",NA,https://clinicalzeros.gov/ct2/show/NCT04679272,0,0,0,0,3,0,France,0,"NA",NA
NCT04652102,2020-12-14,2021-03-05,Interventional,A Study to Determine the Safety and Efficacy of SARS-CoV-2 mRNA Vaccine CVnCoV in Adults for COVID-19,Recruiting,Phase 2/Phase 3,CureVac AG,NA,https://clinicalzeros.gov/ct2/show/NCT04652102,0,0,0,1,5,0,Belgium|Germany|Mexico|Netherlands|Peru|Spain,0,cvncov|placebo,NA
NCT04651790,2020-11-27,2022-01-31,Interventional,"Efficacy, Safety, and Immunogenicity of Two Vaccination Schedules of an Inactivated Vaccine Against COVID-19 in Adults",Recruiting,Phase 3,Pontificia Universidad Catolica de Chile,NA,https://clinicalzeros.gov/ct2/show/NCT04651790,0,0,0,1,2,0,Chile,0,sars-cov-2 inactivated vaccine,NA
NCT04644341,2021-01-15,2021-08-31,Observational,Tele-monitoring of COVID-19 Survivors for Long-Term Impacts,Recruiting,NA,University of Manitoba,NA,https://clinicalzeros.gov/ct2/show/NCT04644341,0,0,0,0,1,0,Canada,0,cardiovascular/respiratory systems monitoring|cardiovascular|respiratory systems monitoring,NA
NCT04627584,2020-12-29,2021-05-31,Interventional,A Phase 2 Clinical Trial of MW33 Injection in Patients With COVID-19,Recruiting,Phase 2,"Mabwell (Shanghai) Bioscience Co., Ltd.",NA,https://clinicalzeros.gov/ct2/show/NCT04627584,0,0,0,0,3,0,China,0,mw33 injection|mw33 injection placebo,NA
NCT04625036,2020-05-30,2021-04-30,Observational [Patient Registry],NO-mediated Vascular Function in Covid-19 Patient,Recruiting,NA,Istituti Clinici Scientifici Maugeri SpA,NA,https://clinicalzeros.gov/ct2/show/NCT04625036,0,0,0,0,1,0,Italy,0,single passive leg movement,NA
NCT04608383,2020-11-19,2022-01-01,Observational,Laparoscopy and COVID-19 Contamination,Recruiting,NA,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04608383,0,0,0,0,1,0,France,0,additional/minimal collection of products of the human body carried out during a sample for standard of care|additional|minimal collection of products of the human body carried out during a sample for standard of care,NA
NCT04615208,2020-12-19,2021-10-30,Observational,Screening for COVID-19,Recruiting,NA,University of Manitoba,NA,https://clinicalzeros.gov/ct2/show/NCT04615208,0,0,0,0,1,0,Canada,0,suspected of covid-19 infection,NA
NCT04613739,2020-12-08,2021-09-01,Interventional,Asthma in Families Facing Out-of-pocket Requirements Due to COVID-19,Recruiting,N/A,Harvard Pilgrim Health Care,NA,https://clinicalzeros.gov/ct2/show/NCT04613739,0,0,0,0,2,1,United States,0,insurance navigation,NA
NCT04604145,2021-02-03,2021-06-30,Interventional,Self-Collected Saliva Samples Without Viral Transport Media for COVID-19 Testing Via RT-PCR,Recruiting,N/A,David Grant U.S. Air Force Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04604145,0,0,0,0,1,1,United States,0,sars-cov-2 testing on the eppendorf thermal cycler pcr system using self-collected saliva as the specimen,NA
NCT04603781,2020-12-04,2021-12-31,Interventional,CBD Oil for Reducing Emotional Impact of COVID-19,Recruiting,Phase 2/Phase 3,University of Texas at Austin,NA,https://clinicalzeros.gov/ct2/show/NCT04603781,0,0,0,0,4,1,United States,0,cbd isolate|full spectrum cbd oil|broad-spectrum cbd oil|placebo oil,NA
NCT04588415,2021-01-03,2021-12-01,Interventional,Supporting Family Members With Severe Grief Reaction During the COVID-19 Pandemic,Enrolling by invitation,N/A,Ottawa Hospital Research Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04588415,0,0,0,0,1,0,Canada,0,bereavement virtual support group,NA
NCT04535674,2020-10-09,2021-02-28,Interventional,Asunercept in Patients With Severe COVID-19,Recruiting,Phase 2,Apogenix AG,NA,https://clinicalzeros.gov/ct2/show/NCT04535674,0,0,0,0,5,0,Russian Federation|Spain,0,asunercept,NA
NCT04542850,2020-11-15,2021-06-15,Interventional,"Pilot Study to Evaluate the Safety, Tolerability, and Efficacy of 5-ALA-Phosphate + SFC in Subjects With COVID-19",Recruiting,N/A,Royal College of Surgeons in Ireland - Medical University of Bahrain,NA,https://clinicalzeros.gov/ct2/show/NCT04542850,0,0,0,0,3,0,Bahrain,0,5-ala-phosphate / sfc (5-ala / sfc)|5-ala-phosphate|sfc (5-ala|sfc),NA
NCT04541680,2020-10-29,2021-03-31,Interventional,Nintedanib for the Treatment of SARS-Cov-2 Induced Pulmonary Fibrosis,Recruiting,Phase 3,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04541680,0,0,0,0,2,0,France,0,nintedanib 150 mg [ofev]|placebo,NA
NCT04456413,2020-11-06,2021-11-30,Interventional,Convalescent Plasma as Treatment for Subjects With Early COVID-19 Infection,Recruiting,Phase 2,Hackensack Meridian Health,NA,https://clinicalzeros.gov/ct2/show/NCT04456413,0,0,0,0,3,1,United States,0,convalescent plasma|best supportive care,NA
NCT04475913,2018-07-11,2020-07-11,Interventional,Digital vs Analog Impression in Cases of All-on-4 - Prosthesis,Completed,N/A,October University for Modern Sciences and Arts,NA,https://clinicalzeros.gov/ct2/show/NCT04475913,0,0,0,0,1,0,Egypt,0,dig axial|dig tilted|cig axial|cig tilted,NA
NCT04525443,2020-06-03,2020-11-11,Observational,Endothelial Function and COVID-19,Completed,NA,"Hospital San Carlos, Madrid",NA,https://clinicalzeros.gov/ct2/show/NCT04525443,0,0,0,0,1,1,United States|Spain,0,"NA",NA
NCT04505774,2020-09-04,2021-09-30,Interventional,Anti-thrombotics for Adults Hospitalized With COVID-19 (ACTIV-4),Recruiting,Phase 4,University of Pittsburgh,NA,https://clinicalzeros.gov/ct2/show/NCT04505774,0,0,0,0,5,1,United States|Spain,0,theraputic heparin|heparin|p2y12,NA
NCT04472611,2020-10-30,2021-10-30,Interventional,Colchicine/Statins for the Prevention of COVID-19 Complications (COLSTAT) Trial,Recruiting,Phase 3,Yale University,NA,https://clinicalzeros.gov/ct2/show/NCT04472611,0,0,0,0,2,1,United States,0,standard of care (soc)/colchicine/rosuvastatin|standard care|colchicine|rosuvastatin,NA
NCT04441372,2020-10-01,2021-05-01,Observational [Patient Registry],Prognostication of Oxygen Requirement in Non-severe SARS-CoV-2 Infection,Recruiting,NA,"Medecins Sans Frontieres, Spain",NA,https://clinicalzeros.gov/ct2/show/NCT04441372,0,0,0,0,5,0,India,0,"NA",NA
NCT04427254,2020-06-26,2023-01-31,Interventional,Study of the Sars-Cov2 Neuroinvasiveness - COVID19,Recruiting,N/A,Fondation Ophtalmologique Adolphe de Rothschild,NA,https://clinicalzeros.gov/ct2/show/NCT04427254,0,0,0,0,2,0,France,0,"cerebrospinal fluid sampling, meningeal/brain parenchyma biopsies|cerebrospinal fluid sampling, meningeal|brain parenchyma biopsies",NA
NCT04417270,2020-06-12,2020-11-30,Interventional,Reliability of the Freestyle Libre CGM in the Inpatient Setting During the COVID-19 Surge,Completed,N/A,Northwell Health,NA,https://clinicalzeros.gov/ct2/show/NCT04417270,0,0,0,0,4,1,United States,0,freestyle libre 14 day cgm system|accuchek inform ii platform,NA
NCT04411680,2020-08-18,2021-03-31,Interventional,Study of Sargramostim in Patients With COVID-19,"Active, not recruiting",Phase 2,"Partner Therapeutics, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04411680,0,0,0,0,13,1,United States,0,sargramostim|standard care,NA
NCT04411602,2020-04-07,2021-05-03,Interventional,Intermediate IND Severe Illness COVID-19 CP,Recruiting,Phase 1,Ascension South East Michigan,NA,https://clinicalzeros.gov/ct2/show/NCT04411602,0,0,0,0,1,1,United States,0,plasma,NA
NCT04408196,2020-05-26,2021-02-15,Observational,QoL and the Emotional-affective Sphere o in Rehabilitation Setting During COVID-19 Quarantine,Completed,NA,Fondazione Don Carlo Gnocchi Onlus,NA,https://clinicalzeros.gov/ct2/show/NCT04408196,0,0,0,0,3,0,Italy,0,"NA",NA
NCT04355728,2020-04-25,2020-10-31,Interventional,Use of UC-MSCs for COVID-19 Patients,Completed,Phase 1/Phase 2,University of Miami,NA,https://clinicalzeros.gov/ct2/show/NCT04355728,0,0,0,0,6,1,United States,0,mesenchymalÂ stem cells/heparin|vehicle / heparin along with best supportive care|mesenchymal stem cells|heparin|vehicle,NA
NCT04382495,2020-06-15,2021-06-01,Observational,The Impact of COVID-19 Pandemic on Cancer Care,Recruiting,NA,El Zaitoun Specialized Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04382495,0,0,0,0,9,0,Egypt,0,questionnaire,NA
NCT04363749,2020-04-27,2021-04-27,Interventional,COVID-19 Infection: Exploration of Respiratory Control Center Abnormalities,Recruiting,N/A,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04363749,0,0,0,0,1,0,France,0,"hypoxia : 14.3/12.7% fio2, hypercapnia 7% co2, inspiratory mechanical constraint|hypoxia : 14.3|12.7% fio2, hypercapnia 7% co2, inspiratory mechanical constraint",NA
NCT04397523,2020-04-30,2021-04-29,Interventional,Efficacy and Safety of COVID-19 Convalescent Plasma,Recruiting,N/A,Institute for Transfusion Medicine of RNM,NA,https://clinicalzeros.gov/ct2/show/NCT04397523,0,0,0,0,2,0,North Macedonia,0,convalescent plasma,NA
NCT04355702,2020-03-01,2020-12-01,Observational,Covid-19 in Lupus Patients,Completed,NA,"University Hospital, Montpellier",NA,https://clinicalzeros.gov/ct2/show/NCT04355702,0,0,0,0,3,0,France,0,"NA",NA
NCT04351724,2020-04-16,2021-12-01,Interventional,Austrian CoronaVirus Adaptive Clinical Trial (COVID-19),Recruiting,Phase 2/Phase 3,Medical University of Vienna,NA,https://clinicalzeros.gov/ct2/show/NCT04351724,0,0,0,0,3,0,Austria,0,chloroquine/hydroxychloroquine|lopinavir/ritonavir|standard care|rivaroxaban|thromboprophylaxis|candesartan|antihypertensives|remdesivir|asunercept 400mg|asunercept 100mg|asunercept 25mg|pentaglobin|chloroquine|hydroxychloroquine|lopinavir|ritonavir,NA
NCT04354272,2020-04-21,2020-04-29,Observational,Evaluation of Dental Emergency Treatments During COVID19 Crisis,Completed,NA,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04354272,0,0,0,0,1,0,France,0,questionnaire,NA
NCT04353596,2020-04-20,2021-02-16,Interventional,Stopping ACE-inhibitors in COVID-19,Completed,Phase 4,Medical University Innsbruck,NA,https://clinicalzeros.gov/ct2/show/NCT04353596,0,0,0,0,3,0,Austria|Germany,0,"ace inhibitor, angiotensin receptor blocker",NA
NCT04311697,2020-05-15,2021-02-22,Interventional,Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure,Completed,Phase 2/Phase 3,"NeuroRx, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04311697,0,0,0,0,20,1,United States,0,aviptadil/standard care|saline/standard care|aviptadil|standard care|saline,NA
NCT04344925,2020-04-18,2020-11-27,Observational,Non Invasive Positive Pressure Ventilation to Minimize Aerosolization for COVID 19,Terminated,NA,Lawson Health Research Institute,Device demonstrated to be less effective than the control mask in reducing leak,https://clinicalzeros.gov/ct2/show/NCT04344925,0,0,0,0,5,0,Canada,0,mask,NA
NCT04721444,2021-03-01,2022-08-01,Observational,Optimising Cancer Therapy And Identifying Causes of Pneumonitis USing Artificial Intelligence (COVID-19),Recruiting,NA,Royal Marsden NHS Foundation Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04721444,0,0,0,0,1,0,United Kingdom,0,machine learning classification of parenchymal lung change cause|machine learning classification of recurrence/non-recurrence|machine learning classification of recurrence|non-recurrence,NA
NCT04740372,2020-11-20,2021-06-30,Observational,"Development of an International COVID-19 Specific Quality of Life Questionnaire, Phase III. The OSLO COVID-19 QLQ",Recruiting,NA,Oslo University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04740372,0,0,0,0,0,0,Norway,0,no intervention. method study. psychometric testing,NA
NCT04729374,2021-01-27,2023-12-31,Observational,COVID-19 Vaccine Induced Adaptive Immune Responses,Recruiting,NA,The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School,NA,https://clinicalzeros.gov/ct2/show/NCT04729374,0,0,0,0,2,0,China,0,"NA",NA
NCT04740125,2020-05-01,2020-07-31,Observational,SURVEY ABOUT STRESS-COVID IN HEALTH CARE WORKERS IN NORTH AFRICA COUNTRY,Completed,NA,"General Administration of Military Health, Tunisia",NA,https://clinicalzeros.gov/ct2/show/NCT04740125,0,0,0,0,0,0,Tunisia,0,"NA",NA
NCT04738760,2020-12-01,2021-04-01,Observational,Clinical Outcomes of High Dose Vitamin D Versus Standard Dose in COVID-19 Egyptian Patients,Recruiting,NA,Ain Shams University,NA,https://clinicalzeros.gov/ct2/show/NCT04738760,0,0,0,0,1,0,Egypt,0,"NA",NA
NCT04663945,2020-12-11,2021-06-01,Interventional,Predictors of Recovery and the App-Facilitated Tele-Rehabilitation (AFTER) Program for COVID-19 Survivors,Recruiting,N/A,"University of Colorado, Denver",NA,https://clinicalzeros.gov/ct2/show/NCT04663945,0,0,0,0,3,1,United States,0,biobehavioral tele-rehabilitation sessions,NA
NCT04584567,2020-11-20,2021-02-01,Interventional,"OD-doxy-PNV-COVID-19 Old Drug "" DOXY "" for Prevention of New Virus "" COVID-19 """,Recruiting,Phase 3,"General Administration of Military Health, Tunisia",NA,https://clinicalzeros.gov/ct2/show/NCT04584567,0,0,0,0,3,0,Tunisia,0,doxycyclin,NA
NCT04519255,2020-07-01,2022-12-31,Observational,Study for Quantitative Analysis of the Recovered COVID-19 Patients by 18F-FDG-PET/CT,"Active, not recruiting",NA,"Fifth Affiliated Hospital, Sun Yat-Sen University",NA,https://clinicalzeros.gov/ct2/show/NCT04519255,0,0,0,0,1,0,China,0,"NA",NA
NCT04451993,2020-06-25,2020-09-01,Observational,Physical Activity Level in Patients With OSAS During Covid-19 Pandemic,Completed,NA,Ahi Evren Chest and Cardiovascular Surgery Education and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04451993,0,0,0,0,2,0,Turkey,0,"NA",NA
NCT04373889,2020-04-22,2021-04-30,Observational,COVID-19 Among Healthcare Workers in Belgian Hospitals,"Active, not recruiting",NA,Sciensano,NA,https://clinicalzeros.gov/ct2/show/NCT04373889,0,0,0,0,2,0,Belgium,0,"NA",NA
NCT04370236,2020-10-21,2021-02-28,Interventional,INB03 for the Treatment of Pulmonary Complications From COVID-19,Recruiting,Phase 2/Phase 3,"Inmune Bio, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04370236,0,0,0,0,3,1,United States,0,inb03|placebo,NA
NCT04404426,2020-11-02,2021-09-15,Interventional,CACOLAC : Citrulline Administration in the Hospital Patient in Intensive Care for COVID-19 Acute Respiratory Distress Syndrome,Recruiting,N/A,Rennes University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04404426,0,0,0,0,3,0,France,0,l-citrulline|placebo,NA
NCT04358549,2020-04-17,2020-11-01,Interventional,Study of the Use of Favipiravir in Hospitalized Subjects With COVID-19,"Active, not recruiting",Phase 2,"Fujifilm Pharmaceuticals U.S.A., Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04358549,0,0,0,0,9,1,United States,0,favipiravir / standard care|standard care|favipiravir,NA
NCT04780698,2021-03-31,2021-10-31,Interventional,DCI COVID-19 Surveillance Project,Recruiting,N/A,Temple University,NA,https://clinicalzeros.gov/ct2/show/NCT04780698,0,0,0,0,0,1,United States,0,sars-cov-2 rt-pcr assay for detection of covid-19 infection,NA
NCT04780685,2021-03-20,2021-08-31,Interventional,A Phase II Study in Patients With Moderate to Severe ARDS Due to COVID-19,Recruiting,Phase 2,"Stemedica Cell Technologies, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04780685,0,0,0,0,0,1,United States,0,hmsc,NA
NCT04780659,2021-02-23,2022-12-31,Interventional,COVID-19 Vaccination of Immunodeficient Persons (COVAXID),Recruiting,Phase 4,Karolinska University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04780659,0,0,0,1,0,0,Sweden,0,"comirnaty (covid-19, mrna vaccine)",NA
NCT04780594,2020-02-13,2020-05-15,Observational,Impact of the COVID-19 Pandemic on the Surgical Activity of Bellvitge University Hospital,Completed,NA,Hospital Universitari de Bellvitge,NA,https://clinicalzeros.gov/ct2/show/NCT04780594,0,0,0,0,0,0,Spain,0,"the study evaluates all surgical patients operated, both elective scheduled/emergent cases|the study evaluates all surgical patients operated, both elective scheduled|emergent cases",NA
NCT04780581,2021-02-01,2021-12-01,Interventional,Glucocorticoid Therapy in Coronavirus Disease COVID-19 Patients,Recruiting,Phase 4,FundaciÃ³n Instituto de Estudios de Ciencias de la Salud de Castilla y LeÃ³n,NA,https://clinicalzeros.gov/ct2/show/NCT04780581,0,0,0,0,0,0,Spain,0,dexamethasone|methylprednisolone,NA
NCT04780295,2020-04-15,2021-12-31,Observational,COvid-19 REgistry on THROMBOSIS Complications,Recruiting,NA,Johannes Gutenberg University Mainz,NA,https://clinicalzeros.gov/ct2/show/NCT04780295,0,0,0,0,0,0,Brazil|Denmark|Germany|Ireland|Italy|Mexico|Spain|Turkey,0,"NA",NA
NCT04775966,2021-01-15,2021-02-15,Observational,CPAP Observance During the COVID-19 (SARS-CoV-2) Pandemic,Completed,NA,"University Hospital, Montpellier",NA,https://clinicalzeros.gov/ct2/show/NCT04775966,0,0,0,0,1,0,France,0,"NA",NA
NCT04779879,2021-02-18,2021-04-30,Interventional,"Safety, Tolerability and Pharmacokinetics of Second Generation VIR-7831 Material in Non-hospitalized Participants With Mild to Moderate COVID-19",Recruiting,Phase 2,"Vir Biotechnology, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04779879,0,0,0,0,0,1,United States,0,vir-7831 (gen1)|vir-7831 (gen2),NA
NCT04779021,2020-02-15,2021-12-31,Observational,Caracterisation of COVID-19 Patients Hospitalized in Infectious Disease Department,Recruiting,NA,Centre Hospitalier Universitaire de Nice,NA,https://clinicalzeros.gov/ct2/show/NCT04779021,0,0,0,0,0,0,France,0,hospitalisation for sars-cov2 infection,NA
NCT04780035,2020-11-18,2021-08-31,Interventional,"Study of the Tolerability, Safety, Immunogenicity and Preventive Efficacy of the EpiVacCorona Vaccine for the Prevention of COVID-19","Active, not recruiting",Phase 3,"Federal Budgetary Research Institution State Research Center of Virology and Biotechnology ""Vector""",NA,https://clinicalzeros.gov/ct2/show/NCT04780035,0,0,0,1,0,0,Russian Federation,0,"epivaccorona (epivaccorona vaccine based on peptide antigens for the prevention of covid-19)|placebo (sodium chloride, a 0.9% solution for the preparation of dosage forms for injections)",NA
NCT04779996,2021-02-16,2021-08-31,Observational,Antibodies Production After Covid-19 Vaccination Among Patients With Medical History of Cancer and Anti-CD-20 Treatment,Recruiting,NA,Auxilio Mutuo Cancer Center,NA,https://clinicalzeros.gov/ct2/show/NCT04779996,0,0,0,0,0,0,Puerto Rico,0,laboratory samples,NA
NCT04779450,2021-03-31,2021-08-31,Interventional,"Effect of Telemonitoring on Upper Limb Function, Quality of Life and Risk of Lymphedema During and After Pandemic COVID-19 in Women Submitted to Treatment for Breast Cancer",Recruiting,N/A,University of the State of Santa Catarina,NA,https://clinicalzeros.gov/ct2/show/NCT04779450,0,0,0,0,0,0,Brazil,0,kinesiotherapy protocol|usual orientations,NA
NCT04779424,2020-11-15,2021-12-31,Observational,Prevalence and Incidence of Antibodies Against SARS-CoV-2 Among Primary Healthcare Providers in Belgium (COVID-19),"Active, not recruiting",NA,Universiteit Antwerpen,NA,https://clinicalzeros.gov/ct2/show/NCT04779424,0,0,0,0,0,0,Belgium,0,poct,NA
NCT04779268,2020-05-01,2020-08-26,Observational [Patient Registry],Large Scale ICU Data Sharing for 1000 Critically Ill Patients With Severe Acute Respiratory Distress Syndrome coronavirus2(SARS.COV2) in Three Distinct Isoltion Centers,Completed,NA,Minia University,NA,https://clinicalzeros.gov/ct2/show/NCT04779268,0,0,0,0,0,0,Egypt,0,"NA",NA
NCT04775407,2021-01-18,2022-03-01,Observational,COVID-19 Serological Testing of Patients With a Mental Disorder From the Catchment Area of the Capital Region of Denmark,Recruiting,NA,Psychiatric Centre Rigshospitalet,NA,https://clinicalzeros.gov/ct2/show/NCT04775407,0,0,0,0,1,0,Denmark,0,blood sample,NA
NCT04775784,2020-12-17,2022-09-20,Observational,Determination of COVID-19 Related Virus in Central Nervous System,Recruiting,NA,IRCCS San Raffaele,NA,https://clinicalzeros.gov/ct2/show/NCT04775784,0,0,0,0,1,0,Italy,0,determination of sars-cov2 presence in cns,NA
NCT04699058,2020-07-17,2021-01-31,Observational,COVID-19 Sero-prevalence Health Care Workers Kinshasa,"Active, not recruiting",NA,"Institute of Tropical Medicine, Belgium",NA,https://clinicalzeros.gov/ct2/show/NCT04699058,0,0,0,0,1,0,"Congo, The Democratic Republic of the",0,covid-antibody test,NA
NCT04770740,2021-02-22,2021-06-01,Interventional,Randomized Controlled Clinical Trial to Investigate Effects of Vitamin K2 in COVID-19,Recruiting,Phase 2,Canisius-Wilhelmina Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04770740,0,0,0,0,1,0,Netherlands,0,vitamin k2 in the form of menaquinone-7 (mk-7)|placebo,NA
NCT04732949,2021-01-12,2021-06-01,Interventional,Study to Assess Efficacy and Safety of Inhaled Interferon-Î² Therapy for COVID-19,Recruiting,Phase 3,Synairgen Research Ltd.,NA,https://clinicalzeros.gov/ct2/show/NCT04732949,0,0,0,0,1,1,United States|United Kingdom,0,sng001|placebo,NA
NCT04690413,2020-09-01,2020-12-31,Interventional,NOWDx Test for the Detection of Antibodies to COVID-19,Completed,N/A,"NOWDiagnostics, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04690413,0,0,0,0,1,1,United States,0,nowdx covid-19 test,NA
NCT04713176,2021-02-02,2021-06-30,Interventional,Efficacy and Safety of DWJ1248 With Remdesivir in Severe COVID-19 Patients,Recruiting,Phase 3,Daewoong Pharmaceutical Co. LTD.,NA,https://clinicalzeros.gov/ct2/show/NCT04713176,0,0,0,0,2,0,"Korea, Republic of",0,dwj1248 with remdesivir|placebo with remdesivir,NA
NCT04649424,2020-12-22,2021-04-30,Interventional,COVID-19 Nasal Swab Trial,Recruiting,N/A,Orthopaedic Innovation Centre,NA,https://clinicalzeros.gov/ct2/show/NCT04649424,0,0,0,0,1,0,Canada,0,canswab,NA
NCT04668950,2020-12-22,2021-07-31,Interventional,Fluvoxamine for Early Treatment of Covid-19 (Stop Covid 2),Recruiting,Phase 3,Washington University School of Medicine,NA,https://clinicalzeros.gov/ct2/show/NCT04668950,0,0,0,0,6,1,United States|Canada,0,fluvoxamine|placebo,NA
NCT04576351,2020-09-01,2023-12-31,Observational,The Norwegian Study of Nervous System Manifestations and Sequelae After COVID-19,Recruiting,NA,Oslo University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04576351,0,0,0,0,1,0,Norway,0,observation,NA
NCT04659772,2020-12-03,2021-02-01,Interventional,A Study to Evaluate Clazakizumab in Patients With Life-threatening COVID-19 Infection,Completed,Phase 2,Mayo Clinic,NA,https://clinicalzeros.gov/ct2/show/NCT04659772,0,0,0,0,1,1,United States,0,clazakizumab|placebo,NA
NCT04617262,2021-01-05,2021-08-31,Interventional,Pilot Feasibility Study of Remote Problem Management Plus for Adults Affected by COVID-19,Recruiting,N/A,The New School,NA,https://clinicalzeros.gov/ct2/show/NCT04617262,0,0,0,0,2,1,United States,0,remote problem management plus,NA
NCT04604704,2021-01-28,2021-08-31,Interventional,Pilot Study Into LDN and NAD+ for Treatment of Patients With Post-COVID-19 Syndrome,Recruiting,Phase 2,AgelessRx,NA,https://clinicalzeros.gov/ct2/show/NCT04604704,0,0,0,0,4,1,United States,0,naltrexone|nad/|placebo|nad|NA,NA
NCT04632043,2020-11-18,2021-05-01,Interventional,Early Versus Delayed Intubation of Patients With COVID-19,Recruiting,N/A,Evangelismos Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04632043,0,0,0,0,1,0,Greece,0,endotracheal intubation,NA
NCT04619706,2020-12-14,2021-08-14,Interventional,Ultramicronized Palmitoylethanolamide (PEA) Treatment in Hospitalized Participants With COVID-19,Recruiting,Phase 2,"FSD Pharma, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04619706,0,0,0,0,3,1,United States,0,fsd201|placebo,NA
NCT04596579,2020-10-09,2021-10-09,Observational,SARS-CoV-2 (COVID-19) Immune Surveillance Among a Population Based Sample of Adults in Florida,Enrolling by invitation,NA,H. Lee Moffitt Cancer Center and Research Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04596579,0,0,0,0,2,1,United States,0,sars-cov-2 antibody analysis|weck-cel swab collection|web based questionnaire,NA
NCT04547127,2020-04-29,2021-02-04,Interventional,A Study to Evaluate Safety and Efficacy of Convalescent Methylene Blue Treated (MBT) Plasma From Donors Recovered From Coronavirus Disease 2019 (COVID-19),Completed,Phase 2,Grifols Therapeutics LLC,NA,https://clinicalzeros.gov/ct2/show/NCT04547127,0,0,0,0,3,0,Spain,0,convalescent plasma|standard care,NA
NCT04522310,2020-05-20,2021-03-03,Observational,ProAdrenomedullin Assessment of Multi-Organ Failure in COvid-19 Sepsis,Recruiting,NA,Centre Hospitalier de Lens,NA,https://clinicalzeros.gov/ct2/show/NCT04522310,0,0,0,0,3,0,France,0,mr-pro-adm,NA
NCT04542993,2020-09-08,2021-02-05,Interventional,Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy,"Active, not recruiting",Phase 2,Swedish Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04542993,0,0,0,0,2,1,United States,0,zinc picolinate|resveratrol|placebo,NA
NCT04559542,2020-09-10,2021-05-30,Observational,"Body Weight Regulation, Disordered Eating Behaviour, and Experiences of Sexual Harassment in Female Martial Art Athletes",Recruiting,NA,Norwegian School of Sport Sciences,NA,https://clinicalzeros.gov/ct2/show/NCT04559542,0,0,0,0,1,0,Norway,0,"NA",NA
NCT04555213,2020-09-30,2021-05-31,Interventional,A Dose Escalation and Dose Expansion Study of NOX66 in the Treatment of COVID-19,Recruiting,Phase 1,Noxopharm Limited,NA,https://clinicalzeros.gov/ct2/show/NCT04555213,0,0,0,0,3,0,"Moldova, Republic of",0,nox66,NA
NCT04490200,2021-03-01,2021-12-30,Interventional,Effectiveness of a Novel Respirator With Chitosan Nanoparticles,Recruiting,N/A,University of Brasilia,NA,https://clinicalzeros.gov/ct2/show/NCT04490200,0,0,0,0,2,0,Brazil,0,vesta respirator|conventional n95 respirator,NA
NCT04443075,2020-06-24,2020-12-04,Observational,Alterations of Gut Microbiome in the Frontline Medical Staff Under the Stress,Completed,NA,First Affiliated Hospital Xi'an Jiaotong University,NA,https://clinicalzeros.gov/ct2/show/NCT04443075,0,0,0,0,3,0,China,0,fecal,NA
NCT04382040,2020-05-08,2020-11-05,Interventional,"A Phase II, Controlled Clinical Study Designed to Evaluate the Effect of ArtemiC in Patients Diagnosed With COVID-19",Completed,Phase 2,MGC Pharmaceuticals d.o.o,NA,https://clinicalzeros.gov/ct2/show/NCT04382040,0,0,0,0,6,0,India|Israel,0,artemic|placebo,NA
NCT04358952,2020-04-04,2021-04-04,Observational,Myocardial Involvement of Severe Acute Respiratory Syndrome-Cov-2 (Covid19) Infected Patients,Recruiting,NA,"University Hospital, Toulouse",NA,https://clinicalzeros.gov/ct2/show/NCT04358952,0,0,0,0,1,0,France,0,global longitudinal strain,NA
NCT04420273,2020-07-02,2021-03-01,Interventional,Targeted Melanoma Detection With Skin Self-Examination During COVID-19 Restricted Physician Access,Completed,N/A,Northwestern University,NA,https://clinicalzeros.gov/ct2/show/NCT04420273,0,0,0,0,3,1,United States,0,sse educational intervention|home sample collection of concerning mole with physician supervision|active control:healthy living,NA
NCT04782700,2021-03-15,2025-03-03,Interventional,P-Co-Li (Pulmonary Covid-19 Study),Recruiting,N/A,Northwell Health,NA,https://clinicalzeros.gov/ct2/show/NCT04782700,0,0,0,0,1,1,United States,0,steroid taper (prednisone),NA
NCT04782336,2020-12-12,2022-03-31,Interventional,"Sample Collection Study to Aid Evaluation of an Influenza A/B, Respiratory Syncytial Virus & COVID-19 Virus POC Test",Recruiting,N/A,LumiraDx UK Limited,NA,https://clinicalzeros.gov/ct2/show/NCT04782336,0,0,0,0,0,0,United Kingdom,0,group a (sample collection)|group b (sample collection)|on-site testing (lumiradx),NA
NCT04753242,2020-12-08,2021-07-31,Observational,Psychosocial Care During the COVID-19 Pandemic in Acute Hospitals,Recruiting,NA,"University Hospital, Basel, Switzerland",NA,https://clinicalzeros.gov/ct2/show/NCT04753242,0,0,0,0,2,0,Austria|Germany|Switzerland,0,"NA",NA
NCT04747574,2020-09-25,2021-02-25,Interventional,Evaluation of the Safety of CD24-Exosomes in Patients With COVID-19 Infection,Recruiting,Phase 1,Tel-Aviv Sourasky Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04747574,0,0,0,0,1,0,Israel,0,exo-cd24,NA
NCT04569786,2020-10-29,2021-02-18,Interventional,Dose Ranging Trial to Assess Safety and Immunogenicity of V590 (COVID-19 Vaccine) in Healthy Adults (V590-001),Terminated,Phase 1,Merck Sharp & Dohme Corp.,The study was terminated based on an interim assessment of immunogenicity.,https://clinicalzeros.gov/ct2/show/NCT04569786,0,0,0,1,10,1,United States,0,v590|placebo,NA
NCT04551898,2020-12-02,2021-01-25,Interventional,Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19),Completed,Phase 2,BeiGene,NA,https://clinicalzeros.gov/ct2/show/NCT04551898,0,0,0,0,1,1,United States|Australia|Brazil|Mexico|South Africa,0,bgb-dxp593|placebo,NA
NCT04469491,2020-09-20,2021-09-30,Interventional,Treatment of COVID-19 by Nebulization of Inteferon Beta 1b Efficiency and Safety Study,Recruiting,Phase 2,"Centre Hospitalier Universitaire, Amiens",NA,https://clinicalzeros.gov/ct2/show/NCT04469491,0,0,0,0,5,0,France,0,inhaled type i interferon|wfi water nebulization,NA
NCT04469179,2020-08-20,2021-03-31,Interventional,"Safety, Tolerability, and Pharmacokinetics of SAB-185 in Ambulatory Participants With COVID-19","Active, not recruiting",Phase 1,"SAb Biotherapeutics, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04469179,0,0,0,0,2,1,United States,0,sab-185|saline,NA
NCT04409496,2020-06-02,2021-01-22,Interventional,Chat-based Support for Preventing Smoking Relapse,Completed,N/A,The University of Hong Kong,NA,https://clinicalzeros.gov/ct2/show/NCT04409496,0,0,0,0,4,0,Hong Kong,0,chat-based instant messaging support|sms message support|self-help booklet,NA
NCT04407546,2020-05-27,2022-05-28,Observational,Role of Children in Transmission of COVID-19 to Immunocompromised Patients,Recruiting,NA,Jonsson Comprehensive Cancer Center,NA,https://clinicalzeros.gov/ct2/show/NCT04407546,0,0,0,0,4,1,United States,0,"NA",NA
NCT04379089,2020-04-29,2021-12-31,Observational,Neurologic Manifestations of COVID 19 in Children,Recruiting,NA,University of Pittsburgh,NA,https://clinicalzeros.gov/ct2/show/NCT04379089,0,0,0,0,1,1,United States,0,no intervention,NA
NCT04372680,2020-04-22,2021-10-22,Interventional,WeanINg From Mechanical Ventilation for ARDS CovId-19 Patients Guided by Combined Thoracic UltraSound,Recruiting,N/A,"University Hospital, Toulouse",NA,https://clinicalzeros.gov/ct2/show/NCT04372680,0,0,0,0,1,0,France,0,ctus examination,NA
NCT04345601,2021-02-12,2022-10-31,Interventional,Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease),Recruiting,Phase 1/Phase 2,Baylor College of Medicine,NA,https://clinicalzeros.gov/ct2/show/NCT04345601,0,0,0,0,8,1,United States,0,mesenchymal stem cells|supportive care,NA
NCT04334980,2020-11-02,2022-02-08,Interventional,"Evaluating the Safety, Tolerability and Immunogenicity of bacTRL-Spike Vaccine for Prevention of COVID-19","Active, not recruiting",Phase 1,Symvivo Corporation,NA,https://clinicalzeros.gov/ct2/show/NCT04334980,0,0,0,1,8,0,Australia,0,bactrl-spike,NA
NCT04720378,2021-03-31,2021-08-31,Interventional,Safety and Tolerability Study of IV ST266 in COVID-19 Subjects,Recruiting,Phase 1,"Noveome Biotherapeutics, formerly Stemnion",NA,https://clinicalzeros.gov/ct2/show/NCT04720378,0,0,0,0,2,1,United States,0,st266,NA
NCT04784546,2021-03-01,2021-10-31,Observational,"Evaluation of Muscle Strength, Functional Independence, Myalgia, Fatigue and Dyspnea in COVID-19 Infection",Recruiting,NA,Gazi University,NA,https://clinicalzeros.gov/ct2/show/NCT04784546,0,0,0,0,0,0,Turkey,0,"NA",NA
NCT04779749,2020-12-08,2021-12-31,Observational,Pregnancy Outcomes According to the Gestational Age of Acquiring COVID-19,Recruiting,NA,Brugmann University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04779749,0,0,0,0,1,0,Belgium|France|Italy,0,data extraction from medical files,NA
NCT04717089,2020-02-10,2021-02-28,Observational,Extended Post Anaesthetic Care in PACU During COVID-19: Multi-perspective Value-based Analysis,Recruiting,NA,Tuen Mun Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04717089,0,0,0,0,3,0,Hong Kong,0,overnight intensive recovery / extended post anaesthetic care in pacu|overnight intensive recovery|extended post anaesthetic care in pacu,NA
NCT04716556,2020-07-16,2021-05-31,Interventional,TranSfUsion of coNvalescent plAsma for the Early Treatment of pneuMonIa in COVID-19 Patients,"Active, not recruiting",N/A,Istituto Superiore di SanitÃ ,NA,https://clinicalzeros.gov/ct2/show/NCT04716556,0,0,0,0,1,0,Italy,0,convalescent plasma,NA
NCT04784403,2020-12-14,2021-02-24,Observational,SCREENING AND SEROEPIDEMIOLOGY OF SARS-CoV-2 INFECTION AT THE UNIVERSITY OF BARCELONA: A CROSS-SECTIONAL STUDY,Completed,NA,University of Barcelona,NA,https://clinicalzeros.gov/ct2/show/NCT04784403,0,0,0,0,0,0,Spain,0,sars-cov-2 pcr/serology tests|pcr|serology tests,NA
NCT04782427,2021-01-01,2021-04-13,Observational,COVID-19 Infections and Mortality in Long-term Care Facilities During the First Wave,"Active, not recruiting",NA,Centre integre universitaire de sante et de services sociaux du Centre-Sud-de-l'ÃŽle-de-MontrÃ©al,NA,https://clinicalzeros.gov/ct2/show/NCT04782427,0,0,0,0,1,0,Canada,0,covid-19 infection,NA
NCT04756466,2021-01-01,2021-04-30,Interventional,Effect of the Consumption of a Lactobacillus Strain on the Incidence of Covid-19 in the Elderly,"Active, not recruiting",N/A,Biosearch S.A.,NA,https://clinicalzeros.gov/ct2/show/NCT04756466,0,0,0,0,2,0,Spain,0,placebo|lactobacillus,NA
NCT04659759,2020-11-17,2021-12-31,Observational,"COVID-19 Pregnancy Related Immunological, Clinical and Epidemiological Factors and Perinatal Outcomes",Recruiting,NA,Thomas Jefferson University,NA,https://clinicalzeros.gov/ct2/show/NCT04659759,0,0,0,0,2,1,United States,0,exposure|covid-19 vaccine,NA
NCT04787536,2020-06-10,2022-12-31,Observational,Perioperative Cognitive Trajectories in Deferred Surgery (CoTELE-SURGE),Recruiting,NA,McMaster University,NA,https://clinicalzeros.gov/ct2/show/NCT04787536,0,0,0,0,0,0,Canada,0,non-cardiac surgery,NA
NCT04465604,2021-02-01,2021-11-01,Interventional,Hypertonic Saline for COVID-19 Symptoms,Recruiting,N/A,King Faisal Specialist Hospital & Research Center,NA,https://clinicalzeros.gov/ct2/show/NCT04465604,0,0,0,0,1,0,Saudi Arabia,0,wearing surgical face mask sprayed with hypertonic saline,NA
NCT04463823,2020-07-06,2022-05-31,Observational,"""NORPLASMA"" Covid-19 Convalescent Plasma Treatment Monitoring Study",Recruiting,NA,Oslo University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04463823,0,0,0,0,1,0,Norway,0,"NA",NA
NCT04371848,2020-04-16,2020-05-07,Observational,Impact of the COVID-19 Pandemic on Diet Quality and Food Insecurity: a NutriQuÃ©bec Sub-study,Completed,NA,Laval University,NA,https://clinicalzeros.gov/ct2/show/NCT04371848,0,0,0,0,1,0,Canada,0,"NA",NA
NCT04363463,2020-08-28,2022-08-28,Interventional,Impact of Prone Position in Patients Under Spontaneous Breathing on Intubation or Non-invasive Ventilation or Death Incidence During COVID-19 Acute Respiratory Distress,Recruiting,N/A,Centre Hospitalier RÃ©gional d'OrlÃ©ans,NA,https://clinicalzeros.gov/ct2/show/NCT04363463,0,0,0,0,3,0,France|Monaco,0,prone positioning,NA
NCT04344977,2020-06-01,2020-11-20,Observational,Collection of Anti-SARS-CoV-2 Immune Plasma,Completed,NA,National Institutes of Health Clinical Center (CC),NA,https://clinicalzeros.gov/ct2/show/NCT04344977,0,0,0,0,15,1,United States,0,"NA",NA
NCT04787614,2020-11-01,2021-06-30,Observational,2019 NSECE COVID-19 Follow-up,Enrolling by invitation,NA,National Opinion Research Center,NA,https://clinicalzeros.gov/ct2/show/NCT04787614,0,0,0,0,0,1,United States,0,no intervention,NA
NCT04787588,2021-02-14,2021-12-01,Observational,COVID-19 Infection and Epithelial Cell Markers,Recruiting,NA,McMaster University,NA,https://clinicalzeros.gov/ct2/show/NCT04787588,0,0,0,0,0,0,Canada,0,"NA",NA
NCT04649151,2020-12-09,2022-06-30,Interventional,"A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19","Active, not recruiting",Phase 2/Phase 3,"ModernaTX, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04649151,0,0,0,1,7,1,United States,0,mrna-1273|placebo,NA
NCT04590430,2020-10-20,2021-04-30,Interventional,"Study to Assess the Safety, Tolerability, and Pharmacokinetics of HFB30132A Against COVID-19 in Healthy Adults","Active, not recruiting",Phase 1,HiFiBiO Therapeutics,NA,https://clinicalzeros.gov/ct2/show/NCT04590430,0,0,0,0,3,1,United States,0,hfb30132a|placebo,NA
NCT04416919,2020-05-20,2020-06-01,Interventional,Assessment of N-95 Facemask for Use in COVID-19 Pandemic in Case of Shortage of Personal Protective Equipment,"Active, not recruiting",N/A,University of Oklahoma,NA,https://clinicalzeros.gov/ct2/show/NCT04416919,0,0,0,0,2,1,United States,0,assembled mask,NA
NCT04403555,2020-06-01,2030-12-01,Interventional,Ivermectin as a Novel Therapy in COVID-19 Treatment,Recruiting,Phase 2/Phase 3,Tanta University,NA,https://clinicalzeros.gov/ct2/show/NCT04403555,0,0,0,0,5,0,Egypt,0,ivermectin,NA
NCT04403386,2020-06-01,2022-05-31,Observational,"Prospective Natural History Study of Smoking, Immune Cell Profiles, Epigenetics and COVID-19",Recruiting,NA,National Institutes of Health Clinical Center (CC),NA,https://clinicalzeros.gov/ct2/show/NCT04403386,0,0,0,0,16,1,United States,0,"NA",NA
NCT04402918,2020-05-17,2020-05-19,Interventional,Study of Viral Load and Maternal-fetal Serology in the Interpretation of the Vertical Transmission of SARS Cov-2 (COVID-19) During Pregnancy,Recruiting,N/A,Centre Hospitalier Universitaire de Besancon,NA,https://clinicalzeros.gov/ct2/show/NCT04402918,0,0,0,0,1,0,France,0,biological samples,NA
NCT04787510,2020-12-23,2021-05-23,Observational [Patient Registry],COVID-19 Disease and Coagulopathy: Assessment of Clotting Factor Levels in Patients With SARS-CoV-2 Infection,Recruiting,NA,"University Hospital, Ioannina",NA,https://clinicalzeros.gov/ct2/show/NCT04787510,0,0,0,0,0,0,Greece,0,low molecular weight heparin as standard of care treatment,NA
NCT04730401,2021-01-27,2021-08-31,Interventional,Convalescent Plasma in the Treatment of Covid-19,Recruiting,Phase 2,Helsinki University Central Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04730401,0,0,0,0,1,0,Finland,0,convalescent plasma|placebo,NA
NCT04786483,2020-11-01,2021-01-30,Interventional,The Effect of Laughter Therapy on Students in the COVID-19 Pandemic,"Active, not recruiting",N/A,Zonguldak Bulent Ecevit University,NA,https://clinicalzeros.gov/ct2/show/NCT04786483,0,0,0,0,0,0,Turkey,0,laughter theraphy,NA
NCT04785898,2020-11-09,2020-12-22,Interventional,Diagnostic Performance of the ID Nowâ„¢ COVID-19 Screening Test Versus Simplexaâ„¢ COVID-19 Direct Assay,"Active, not recruiting",N/A,Groupe Hospitalier Paris Saint Joseph,NA,https://clinicalzeros.gov/ct2/show/NCT04785898,0,0,0,0,0,0,France,0,id nowâ„¢ covid-19 screening test|id nowâ„¢ covid-19 screening test,NA
NCT04780152,2021-03-31,2022-08-31,Interventional,TDCS in Pediatric and Teenage Patients With Major Depressive Disorder During COVID-19 Pandemic,Recruiting,Phase 2/Phase 3,El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez,NA,https://clinicalzeros.gov/ct2/show/NCT04780152,0,0,0,0,1,0,Mexico,0,transcranial direct current stimulation|placebo-simulation of transcranial direct current stimulation|fluoxetine tablets,NA
NCT04706403,2021-01-04,2021-06-01,Interventional,Views on COVID-19 and Vaccination,"Active, not recruiting",N/A,"University of Massachusetts, Worcester",NA,https://clinicalzeros.gov/ct2/show/NCT04706403,0,0,0,1,1,1,United States,0,healthcare providers' communication about the covid-19 vaccine,NA
NCT04786041,2020-03-01,2020-05-30,Observational,the Impact of COVID-19 Pandemic on the Incidence and Outcome of Complicated Appendicitis,Completed,NA,Meir Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04786041,0,0,0,0,0,0,Israel,0,laparoscopic appendectomy,NA
NCT04703205,2020-09-16,2021-09-30,Interventional,Study in COvid-19 Patients With iveRmectin (CORVETTE-01),Recruiting,Phase 2,Kitasato University,NA,https://clinicalzeros.gov/ct2/show/NCT04703205,0,0,0,0,2,0,Japan,0,ivermectin 3 mg|placebo,NA
NCT04486521,2020-07-22,2021-07-22,Observational,Anti-IL6 and Corticosteroid Monotherapy vs Combination in COVID-19,Recruiting,NA,King Faisal Specialist Hospital & Research Center,NA,https://clinicalzeros.gov/ct2/show/NCT04486521,0,0,0,0,1,0,Saudi Arabia,0,interleukin|corticosteroid alone|corticosteroids,NA
NCT04531254,2020-08-10,2020-08-31,Observational,Back to School COVID-19 Simulation Study,Completed,NA,The Hospital for Sick Children,NA,https://clinicalzeros.gov/ct2/show/NCT04531254,0,0,0,0,2,0,Canada,0,behavior,NA
NCT04530435,2020-10-06,2021-04-30,Interventional,PEP Flute-selfcare in COVID-19,"Active, not recruiting",N/A,Bispebjerg Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04530435,0,0,0,0,3,0,Denmark,0,pep flute,NA
NCT04517396,2020-08-18,2021-10-31,Interventional,FEnofibRate as a Metabolic INtervention for COVID-19,Enrolling by invitation,Phase 2,University of Pennsylvania,NA,https://clinicalzeros.gov/ct2/show/NCT04517396,0,0,0,0,6,1,United States,0,fenofibrate/fenofibric acid|placebo|standard care|fenofibrate|fenofibric acid,NA
NCT04473547,2020-07-10,2020-08-20,Observational,COVID 19 Preventive Measures Among Mansoura Nursing Students,Completed,NA,Mansoura University,NA,https://clinicalzeros.gov/ct2/show/NCT04473547,0,0,0,0,1,0,Egypt,0,"NA",NA
NCT04471766,2020-07-20,2021-06-30,Interventional,Locally Produced Cloth Face Mask and COVID-19 Like Illness Prevention,"Active, not recruiting",N/A,Bandim Health Project,NA,https://clinicalzeros.gov/ct2/show/NCT04471766,0,0,0,0,4,0,Guinea-Bissau,0,certified cloth face mask/preventive information|preventive information|certified cloth face mask,NA
NCT04359901,2020-04-10,2022-04-30,Interventional,Sarilumab for Patients With Moderate COVID-19 Disease,"Active, not recruiting",Phase 2,VA Boston Healthcare System,NA,https://clinicalzeros.gov/ct2/show/NCT04359901,0,0,0,0,6,1,United States,0,sarilumab,NA
NCT04397718,2020-07-06,2021-07-06,Interventional,Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization,Recruiting,Phase 2,VA Office of Research and Development,NA,https://clinicalzeros.gov/ct2/show/NCT04397718,0,0,0,0,11,1,United States,0,degarelix|saline,NA
NCT04390503,2021-03-31,2022-04-30,Interventional,Convalescent Plasma for Early Treatment of COVID-19,Recruiting,Phase 2,Columbia University,NA,https://clinicalzeros.gov/ct2/show/NCT04390503,0,0,0,0,1,0,Brazil,0,convalescent plasma|control,NA
NCT04434261,2020-05-11,2020-12-31,Observational,Oncological Surgery in Times of COVID-19: Effectiveness of Preoperative Screening for Sars-Cov-2,Recruiting,NA,Instituto Brasileiro de Controle do Cancer,NA,https://clinicalzeros.gov/ct2/show/NCT04434261,0,0,0,0,3,0,Brazil,0,pcr,NA
NCT04789447,2021-03-04,2021-03-28,Observational,"Evaluation of Prognosis of COVID-19 Patients With Only CT Findings, Only RT-PCR Positivity and Both of Them Positive",Recruiting,NA,"Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey",NA,https://clinicalzeros.gov/ct2/show/NCT04789447,0,0,0,0,0,0,Turkey,0,"NA",NA
NCT04789395,2020-09-02,2021-09-20,Observational,Evaluation of Post-covid 19 Patients Who Receive Ozonetheraphy With Thorax CT,Recruiting,NA,Gaziosmanpasa Taksim Research and Education Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04789395,0,0,0,0,0,0,Turkey,0,"NA",NA
NCT04603755,2020-10-26,2022-04-30,Observational,Electrical Impedance Tomography: Collapse in Dependent Areas as a Predictor of Response to Prone Position Ventilation in COVID-19 Acute Respiratory Distress Syndrome,Recruiting,NA,Direction Centrale du Service de SantÃ© des ArmÃ©es,NA,https://clinicalzeros.gov/ct2/show/NCT04603755,0,0,0,0,2,0,France,0,electrical impedance tomography,NA
NCT04788433,2021-03-04,2022-03-31,Observational,Registry of Coronavirus Complications - CORRELATION WITH GLYCOMIC PROFILE,Recruiting,NA,Papa Giovanni XXIII Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04788433,0,0,0,0,0,0,Italy,0,glycomic analysis|phone interview,NA
NCT04671017,2020-12-16,2021-02-26,Interventional,"Dose Finding Study to Evaluate Safety, Tolerability and Immunogenicity of an Inactiviated Adjuvanted Sars-Cov-2 Virus Vaccine Candidate Against Covid-19 in Healthy Adults","Active, not recruiting",Phase 1/Phase 2,Valneva Austria GmbH,NA,https://clinicalzeros.gov/ct2/show/NCT04671017,0,0,0,1,4,0,United Kingdom,0,vla2001,NA
NCT04629989,2020-11-13,2021-03-05,Interventional,Comparison of the Surgical Facemask With the Double-trunk Mask on Oxygenation in COVID-19,Completed,N/A,Cliniques universitaires Saint-Luc- UniversitÃ© Catholique de Louvain,NA,https://clinicalzeros.gov/ct2/show/NCT04629989,0,0,0,0,3,0,Belgium,0,standard oxygen delivery system|mask|surgical mask,NA
NCT04788355,2020-07-01,2020-11-15,Interventional,Prevention of Complications (SARS-CoV-2): Clinical Study,Completed,Phase 3,Universidade do Vale do Sapucai,NA,https://clinicalzeros.gov/ct2/show/NCT04788355,0,0,0,0,0,0,Brazil,0,control group (standard hospital treatment)|group hydroxychloroquine|group hydroxychloroquine/apixaban|group apixaban|apixaban,NA
NCT04786808,2021-01-15,2021-12-31,Observational,Risk Factors for COVID-19 Mortality,Recruiting,NA,Azienda UnitÃ  Sanitaria Locale di Piacenza,NA,https://clinicalzeros.gov/ct2/show/NCT04786808,0,0,0,0,1,0,Italy,0,"NA",NA
NCT04784468,2020-11-19,2021-03-31,Observational,DNA Damage and Oxidative Stress in Hospitalized COVID-19 Patients,Recruiting,NA,University of Vienna,NA,https://clinicalzeros.gov/ct2/show/NCT04784468,0,0,0,0,1,0,Austria,0,no intervention,NA
NCT04752085,2020-11-01,2021-03-01,Observational,Prognosis and Course of COVID-19 Infection in Hospitalised Patients,"Active, not recruiting",NA,I.M. Sechenov First Moscow State Medical University,NA,https://clinicalzeros.gov/ct2/show/NCT04752085,0,0,0,0,2,0,Russian Federation,0,chitotriosidase activity,NA
NCT04667962,2020-12-23,2021-09-30,Observational,Impact of the Change in Hospital Service of Caregivers During COVID-19 Health Crisis on Operational Strain,Recruiting,NA,Direction Centrale du Service de SantÃ© des ArmÃ©es,NA,https://clinicalzeros.gov/ct2/show/NCT04667962,0,0,0,0,2,0,France,0,online survey,NA
NCT04666779,2020-12-18,2021-02-21,Observational [Patient Registry],Access to Chiropractic Care During the COVID-19 Pandemic,"Active, not recruiting",NA,Real Centro Universitario Maria Cristina,NA,https://clinicalzeros.gov/ct2/show/NCT04666779,0,0,0,0,3,0,Spain,0,chiropractic care,NA
NCT04590794,2020-10-11,2021-03-31,Observational,SuPAR in Adult Patients With Covid-19,"Active, not recruiting",NA,University of Thessaly,NA,https://clinicalzeros.gov/ct2/show/NCT04590794,0,0,0,0,5,0,Greece,0,soluble urokinase plasminogen activator receptor,NA
NCT04517136,2020-09-14,2021-03-14,Observational,Impact of Perceived Control on Operational Strain: a Study of COVID-19 Pandemic Caregivers and Military Personnel on Operational Missions,Recruiting,NA,Direction Centrale du Service de SantÃ© des ArmÃ©es,NA,https://clinicalzeros.gov/ct2/show/NCT04517136,0,0,0,0,4,0,France,0,assessment of work-related stress|saliva|cardiac/electrodermal recordings|emotional stimulation|cardiac|electrodermal recordings,NA
NCT04514874,2020-09-01,2020-10-05,Observational,Assessment of the Prevalence and the Impact of the COVID-19 Epidemic in the French Flight Crew in 2020,Completed,NA,Direction Centrale du Service de SantÃ© des ArmÃ©es,NA,https://clinicalzeros.gov/ct2/show/NCT04514874,0,0,0,0,2,0,France,0,questionnaire,NA
NCT04581577,2020-09-11,2020-12-31,Observational,Perceptions of the Clinical and Psychosocial Impact of Covid-19 in Patients With Neuromuscular and Neurological Disorders,Recruiting,NA,Royal Brompton & Harefield NHS Foundation Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04581577,0,0,0,0,1,0,United Kingdom,0,semi-structured telephone questionnaire,NA
NCT04548505,2020-10-05,2023-04-05,Observational,Recovery of Exertion Ability Following COVID-19 Infection in Military Staff,Recruiting,NA,Direction Centrale du Service de SantÃ© des ArmÃ©es,NA,https://clinicalzeros.gov/ct2/show/NCT04548505,0,0,0,0,2,0,France,0,"NA",NA
NCT04516928,2020-09-21,2020-09-25,Observational,Study of SARS-CoV2 Virus (COVID-19) Seroprevalence Among Lyon-Bron Military Health Schools Personnel,Completed,NA,Direction Centrale du Service de SantÃ© des ArmÃ©es,NA,https://clinicalzeros.gov/ct2/show/NCT04516928,0,0,0,0,2,0,France,0,serology test|questionnaire,NA
NCT04424017,2020-06-07,2020-10-30,Observational,Sero-prevalence of Coronavirus Disease 2019 (COVID-19) in Healthcare Workers,Completed,NA,Egyptian Center for Research and Regenerative Medicine,NA,https://clinicalzeros.gov/ct2/show/NCT04424017,0,0,0,0,6,0,Egypt,0,specific anti-sars-cov-2 antibodies,NA
NCT04460638,2020-07-23,2022-07-31,Observational,SARS-CoV2 (COVID-19) Diagnosis in Human Saliva by MALDI-TOF MS Profiling,Recruiting,NA,Direction Centrale du Service de SantÃ© des ArmÃ©es,NA,https://clinicalzeros.gov/ct2/show/NCT04460638,0,0,0,0,3,0,France,0,saliva|clinical assessment,NA
NCT04447469,2020-07-27,2021-12-31,Interventional,Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation,Recruiting,Phase 2/Phase 3,"Kiniksa Pharmaceuticals, Ltd.",NA,https://clinicalzeros.gov/ct2/show/NCT04447469,0,0,0,0,6,1,United States|Brazil|Chile|Peru|South Africa,0,mavrilimumab|placebo,NA
NCT04494386,2020-07-23,2021-10-30,Interventional,Umbilical Cord Lining Stem Cells (ULSC) in Patients With COVID-19 ARDS,Recruiting,Phase 1/Phase 2,"Restem, LLC.",NA,https://clinicalzeros.gov/ct2/show/NCT04494386,0,0,0,0,3,1,United States,0,mesenchymal stem cells|placebo,NA
NCT04470622,2020-07-20,2021-06-30,Interventional,Aprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1),Recruiting,Phase 2,Heron Therapeutics,NA,https://clinicalzeros.gov/ct2/show/NCT04470622,0,0,0,0,7,1,United States|Puerto Rico,0,aprepitant injectable emulsion|placebo,NA
NCT04400890,2020-09-12,2021-01-11,Interventional,"Randomized Proof-of-Concept Trial to Evaluate the Safety and Explore the Effectiveness of Resveratrol, a Plant Polyphenol, for COVID-19","Active, not recruiting",Phase 2,Mount Carmel Health System,NA,https://clinicalzeros.gov/ct2/show/NCT04400890,0,0,0,0,6,1,United States,0,resveratrol|vitamin d,NA
NCT04365335,2020-04-25,2020-06-12,Observational,Stress Biomarkers Leading to Professional Burnout Among People Involved in a Mobile Intensive Care Unit During the COVID-19 Pandemic,Completed,NA,Direction Centrale du Service de SantÃ© des ArmÃ©es,NA,https://clinicalzeros.gov/ct2/show/NCT04365335,0,0,0,0,4,0,France,0,assessment of work-related stress|saliva|cardiac/electrodermal recordings|emotional stimulation|cardiac|electrodermal recordings,NA
NCT04387838,2020-05-14,2020-08-15,Observational,Study of the SARS-COV-2 (COVID-19) Serological Profile of an Army Training Hospital Staff,Completed,NA,Direction Centrale du Service de SantÃ© des ArmÃ©es,NA,https://clinicalzeros.gov/ct2/show/NCT04387838,0,0,0,0,2,0,France,0,serology test|questionnaire,NA
NCT04387760,2020-08-11,2021-04-14,Interventional,Favipiravir vs Hydroxychloroquine vs Control in COVID -19,Recruiting,Phase 2,Royal College of Surgeons in Ireland - Medical University of Bahrain,NA,https://clinicalzeros.gov/ct2/show/NCT04387760,0,0,0,0,4,0,Bahrain,0,hydroxychloroquine|favipiravir|standard care,NA
NCT04377165,2020-05-06,2020-08-26,Interventional,Innovative Tool to Limit Spread of COVID 19 in Residential Aged Care Facilities,Terminated,N/A,The University of Queensland,"Engagement issues, poor recruitment to study",https://clinicalzeros.gov/ct2/show/NCT04377165,0,0,0,0,3,0,NA,0,gamification|news,NA
NCT04408001,2020-06-04,2021-06-04,Observational,Study of Kinetics and Efficacy of the Immune Response Against COVID-19 Among Hospital Staff,"Active, not recruiting",NA,Direction Centrale du Service de SantÃ© des ArmÃ©es,NA,https://clinicalzeros.gov/ct2/show/NCT04408001,0,0,0,0,2,0,France,0,clinical interview|blood sample|saliva,NA
NCT04406545,2020-05-15,2021-12-31,Observational,Microvascular Flow and Reactivity in Patients Presenting in the Acute Phase of COVID-19.,Recruiting,NA,"National Institute of Cardiology, Laranjeiras, Brazil",NA,https://clinicalzeros.gov/ct2/show/NCT04406545,0,0,0,0,2,0,Brazil,0,evaluation of skin microvascular flow/reactivity|evaluation of skin microvascular flow|reactivity,NA
NCT04404270,2020-05-26,2021-03-31,Observational,Study of SARS-CoV2 Virus (COVID-19) Seroprevalence in the Population of Creil Air Force Base (BA110),"Active, not recruiting",NA,Direction Centrale du Service de SantÃ© des ArmÃ©es,NA,https://clinicalzeros.gov/ct2/show/NCT04404270,0,0,0,0,2,0,France,0,serology test|questionnaire|anti-sars-cov2 serological controls/serum neutralization|anti-sars-cov2 serological controls|serum neutralization,NA
NCT04402866,2020-06-24,2021-04-30,Interventional,TD-0903 for ALI Associated With COVID-19,Recruiting,Phase 2,Theravance Biopharma,NA,https://clinicalzeros.gov/ct2/show/NCT04402866,0,0,0,0,10,1,"United States|Brazil|Finland|Moldova, Republic of|Romania|Ukraine|United Kingdom",0,td-0903|placebo,NA
NCT04365166,2020-04-21,2022-04-21,Observational,Study of Clinical and Immune Severity Profiles of Patients Infected With SARS-Cov2 (COVID-19),Recruiting,NA,Direction Centrale du Service de SantÃ© des ArmÃ©es,NA,https://clinicalzeros.gov/ct2/show/NCT04365166,0,0,0,0,3,0,France,0,"NA",NA
NCT04348305,2020-04-17,2020-09-10,Interventional,Hydrocortisone for COVID-19 and Severe Hypoxia,"Active, not recruiting",Phase 3,Scandinavian Critical Care Trials Group,NA,https://clinicalzeros.gov/ct2/show/NCT04348305,0,0,0,0,13,0,Denmark,0,hydrocortisone|saline|methylprednisolone,NA
NCT04746443,2020-12-08,2021-03-08,Observational,Effect of Covid-19 Affliction on Psychological and Mental Health Among College Going Students: Cross-Sectional Survey,Recruiting,NA,King Khalid University,NA,https://clinicalzeros.gov/ct2/show/NCT04746443,0,0,0,0,0,0,Saudi Arabia,0,not applicable (na),NA
NCT04746365,2020-12-06,2021-01-31,Interventional,Ivermectin Role in Covid-19 Clinical Trial,Completed,Phase 4,Elaraby Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04746365,0,0,0,0,0,0,Egypt,0,ivermectin|hydroxychloroquine|placebo,NA
NCT04746092,2021-01-06,2022-05-24,Observational,The Capability of Haemato-oncology Patients to Generate Antibodies Against COVID-19,Recruiting,NA,Tel-Aviv Sourasky Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04746092,0,0,0,0,0,0,Israel,0,"NA",NA
NCT04745923,2021-01-20,2021-02-28,Observational,Physical Activity Level in Patients With Chronic Kidney Disease During COVID-19 Pandemic,Recruiting,NA,Hacettepe University,NA,https://clinicalzeros.gov/ct2/show/NCT04745923,0,0,0,0,0,0,Turkey,0,"NA",NA
NCT04745442,2020-04-27,2020-12-20,Interventional,Pilot Study of Antithrombin as Prophylaxis of Acute Respiratory Distress Syndrome in Patients With COVID-19,Completed,Phase 2,MaimÃ³nides Biomedical Research Institute of CÃ³rdoba,NA,https://clinicalzeros.gov/ct2/show/NCT04745442,0,0,0,0,0,0,Spain,0,antithrombin / best available treatment|best available therapy|antithrombin,NA
NCT04745416,2020-01-01,2020-12-31,Observational,Clinical Characteristics of Patients With Leukemia and COVID-19,Completed,NA,Hospital General de Mexico,NA,https://clinicalzeros.gov/ct2/show/NCT04745416,0,0,0,0,0,0,Mexico,0,"NA",NA
NCT04745377,2021-01-12,2021-08-30,Observational,Responses to COVID-19 Vaccination in Patients With Cancer,Recruiting,NA,Hellenic Cooperative Oncology Group,NA,https://clinicalzeros.gov/ct2/show/NCT04745377,0,0,0,0,0,0,Greece,0,igg neutralising antibody titers to s1/s2 proteins of sars-cov-2 virus|igg neutralising antibody titers to s1|s2 proteins of sars-cov-2 virus,NA
NCT04743349,2021-01-26,2021-10-31,Interventional,Steam Inhalations in COVID-19 Patients,Recruiting,N/A,Meyer Children's Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04743349,0,0,0,0,0,0,Italy,0,steam inhalations,NA
NCT04742595,2020-12-18,2022-03-31,Interventional,SARS-CoV-2 Specific Cytotoxic T Lymphocytes for the Treatment of COVID-19 in Patients With Cancer,Recruiting,Early Phase 1,M.D. Anderson Cancer Center,NA,https://clinicalzeros.gov/ct2/show/NCT04742595,0,0,0,0,0,1,United States,0,sars-cov-2 antigen-specific cytotoxic t-lymphocytes,NA
NCT04742569,2020-12-21,2021-06-30,Observational,Wearable Diagnostic for Detection of COVID-19 Infection,Recruiting,NA,"ClinOne, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04742569,0,0,0,0,0,1,United States,0,"NA",NA
NCT04739462,2021-02-03,2022-02-28,Interventional,SMS Maama Project COVID-19,Recruiting,N/A,University of Minnesota,NA,https://clinicalzeros.gov/ct2/show/NCT04739462,0,0,0,0,1,1,United States|Uganda,0,mhealth platform,NA
NCT04745611,2020-12-12,2021-09-30,Observational [Patient Registry],Neurological and Neuropsychological Sequelae of COVID-19 Infection,Recruiting,NA,Maastricht University,NA,https://clinicalzeros.gov/ct2/show/NCT04745611,0,0,0,0,0,0,Netherlands,0,mri|neuropsychological assessment|questionnaires patient|questionnaires family,NA
NCT04744415,2020-11-09,2021-02-09,Observational [Patient Registry],Hospitalizations During Pandemia in the Italian Coronary Care Unit Network,Recruiting,NA,Heart Care Foundation,NA,https://clinicalzeros.gov/ct2/show/NCT04744415,0,0,0,0,0,0,Italy,0,epidemiology of admissions,NA
NCT04742712,2020-10-27,2021-11-01,Observational,A Feasibility Study Using the CoronaCheck Device to Identify Incident Cases of SARS CoV-2 Covid-19,Recruiting,NA,Portsmouth Hospitals NHS Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04742712,0,0,0,0,0,0,United Kingdom,0,coronacheck device,NA
NCT04732858,2020-03-01,2020-08-31,Observational,"Educational Interventions for Surgeons During COVID-19 Pandemic: Cross-sectional, E-survey","Active, not recruiting",NA,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04732858,0,0,0,0,1,0,France,0,cross sectional e-survey on surgeons exposed to any educational intervention,NA
NCT04730661,2020-12-21,2021-12-21,Interventional,Efficacy of the Sit to Stand Test in the Decision to Hospitalize a Patient Consulting the Emergency Dept for COVID 19,Recruiting,N/A,"University Hospital, Rouen",NA,https://clinicalzeros.gov/ct2/show/NCT04730661,0,0,0,0,1,0,France,0,sit to stand test,NA
NCT04710771,2020-11-23,2021-01-15,Observational,Effect of Prone Positioning in Patients With COVID-19,Completed,NA,Sialkott College of Physical Therapy,NA,https://clinicalzeros.gov/ct2/show/NCT04710771,0,0,0,0,2,0,Pakistan,0,prone lying position|alternate nostril breathing,NA
NCT04668625,2020-11-30,2020-12-20,Interventional,"Risk of Infection of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), COVID-19, in a Massive Musical Show With Transmission Prevention Measures",Completed,N/A,"FundaciÃ³n FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la PromociÃ³n de la Salud y la Ciencia",NA,https://clinicalzeros.gov/ct2/show/NCT04668625,0,0,0,0,4,0,Spain,0,participate in a massive musical event,NA
NCT04629183,2020-11-01,2021-04-30,Observational,Risk Stratification of COVID-19 Patients Discharged From the Emergency Department,Recruiting,NA,Azienda Ospedaliera CittÃ  della Salute e della Scienza di Torino,NA,https://clinicalzeros.gov/ct2/show/NCT04629183,0,0,0,0,2,0,Italy,0,integrated clinical evaluation,NA
NCT04658121,2021-02-04,2021-05-30,Observational,SARS-CoV-2/COVID-19 Prevalence Study,Enrolling by invitation,NA,COVID-19 Prevention Network,NA,https://clinicalzeros.gov/ct2/show/NCT04658121,0,0,0,0,1,1,United States|Puerto Rico,0,"NA",NA
NCT04584710,2020-10-13,2021-02-28,Interventional,A Phase 2 Study of RTB101 as COVID-19 Post-Exposure Prophylaxis in Older Adults,"Active, not recruiting",Phase 2,Restorbio Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04584710,0,0,0,0,3,1,United States,0,rtb101|placebo,NA
NCT04534790,2020-07-24,2020-12-12,Interventional,Anti-inflammatory Effect of Low-Dose Whole-Lung Radiation for COVID-19 Pneumonia,Completed,N/A,Instituto Mexicano del Seguro Social,NA,https://clinicalzeros.gov/ct2/show/NCT04534790,0,0,0,0,1,0,Mexico,0,radiotherapy,NA
NCT04568850,2020-07-01,2021-02-28,Observational,Waxing and Waning of Serum SARS CoV-2-IgG Level in COVID-19 Exposed Population,Recruiting,NA,Lahore General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04568850,0,0,0,0,2,0,Pakistan,0,plasma igg levels,NA
NCT04476914,2020-06-29,2021-12-31,Observational,Stress Related Disorders in Family Members of COVID-19 Patients Admitted to the ICU,Recruiting,NA,"University of Colorado, Denver",NA,https://clinicalzeros.gov/ct2/show/NCT04476914,0,0,0,0,3,1,United States,0,"NA",NA
NCT04517630,2020-06-01,2021-09-30,Observational [Patient Registry],Renal Biomarkers in AKI and COVID-19,Recruiting,NA,Instituto Nacional de Enfermedades Respiratorias,NA,https://clinicalzeros.gov/ct2/show/NCT04517630,0,0,0,0,2,0,Mexico,0,"urinary ngal, timp-2, igfbp7, il-6, viral load/metabolomic|urinary ngal, timp-2, igfbp7, il-6, viral load|metabolomic",NA
NCT04510454,2020-11-02,2021-05-31,Interventional,Evaluation of a ddPCR Technology for the SARS-CoV-2 Detection in Symptomatic Patients With Suspicion of COVID-19,Recruiting,N/A,Centre Leon Berard,NA,https://clinicalzeros.gov/ct2/show/NCT04510454,0,0,0,0,1,0,France,0,nasopharyngeal/throat/oropharyngeal swabs analyses by rt-pcr/ddpcr|nasopharyngeal|throat|oropharyngeal swabs analyses by rt-pcr|ddpcr,NA
NCT04509752,2020-10-08,2021-02-15,Observational,Dysphagia Management During COVID-19 Pandemic,Recruiting,NA,Hacettepe University,NA,https://clinicalzeros.gov/ct2/show/NCT04509752,0,0,0,0,1,0,Turkey,0,questionnaire,NA
NCT04547660,2020-07-16,2021-01-07,Interventional,Convalescent Plasma for Severe COVID-19 Patients,Completed,Phase 3,Hospital de Clinicas de Porto Alegre,NA,https://clinicalzeros.gov/ct2/show/NCT04547660,0,0,0,0,1,0,Brazil,0,convalescent plasma|best supportive care,NA
NCT04542200,2021-01-01,2022-12-31,Observational,Workforce Serosurveillance to Track Long-term Modifications to COVID-19 Exposure Due to Factors in the Built Environment,Enrolling by invitation,NA,Northwell Health,NA,https://clinicalzeros.gov/ct2/show/NCT04542200,0,0,0,0,2,1,United States,0,serology test,NA
NCT04536376,2021-01-15,2021-08-02,Interventional,First Responder Resiliency Program During COVID-19,Recruiting,N/A,Mayo Clinic,NA,https://clinicalzeros.gov/ct2/show/NCT04536376,0,0,0,0,3,1,United States,0,resilience program,NA
NCT04453657,2021-02-04,2021-09-30,Interventional,"Tele-Wellness Supported App for Family Child Care Home Providers and Families to Promote Health, Family Engagement, and School Readiness Amid COVID-19",Enrolling by invitation,N/A,Johns Hopkins University,NA,https://clinicalzeros.gov/ct2/show/NCT04453657,0,0,0,0,8,1,United States,0,familychildcare (provisional name of app),NA
NCT04494776,2020-05-21,2021-11-03,Observational,SARS-COV-2 Infection in Kidney Transplant Recipients: a Brazilian Multicenter Study,Recruiting,NA,Hospital do Rim e HipertensÃ£o,NA,https://clinicalzeros.gov/ct2/show/NCT04494776,0,0,0,0,1,0,Brazil,0,"NA",NA
NCT04394403,2020-05-14,2021-12-31,Interventional,Pilot Internet-based Self-Help Program for Managing Corona (COVID-19) Stress,Recruiting,N/A,Hebrew University of Jerusalem,NA,https://clinicalzeros.gov/ct2/show/NCT04394403,0,0,0,0,2,0,Israel,0,internet-based guided self-help based on cbt principles,NA
NCT04391920,2020-08-28,2022-08-31,Observational [Patient Registry],Registry of CytoSorb Therapy in COVID-19 ICU Patients,Recruiting,NA,"CytoSorbents, Inc",NA,https://clinicalzeros.gov/ct2/show/NCT04391920,0,0,0,0,3,1,United States,0,cytosorb,NA
NCT04386564,2020-05-15,2020-08-01,Observational,Kidney Injury Severity and COVID-19,Completed,NA,I.M. Sechenov First Moscow State Medical University,NA,https://clinicalzeros.gov/ct2/show/NCT04386564,0,0,0,0,2,0,Russian Federation,0,mrna in urine test,NA
NCT04385901,2020-05-19,2020-09-19,Interventional,Long Term Functional Outcomes of COVID-19 Patients Treated by Rehabilitation Services viaTelehealth,Completed,N/A,University of Missouri-Columbia,NA,https://clinicalzeros.gov/ct2/show/NCT04385901,0,0,0,0,3,1,United States,0,therapy intervention,NA
NCT04408027,2020-06-01,2021-06-01,Interventional,Mental Health Support for SickKids Children and Families During COVID-19 Using Established eHealth Interventions,Recruiting,N/A,The Hospital for Sick Children,NA,https://clinicalzeros.gov/ct2/show/NCT04408027,0,0,0,0,1,0,Canada,0,virtual-care cognitive behavioural therapy,NA
NCT04362956,2020-07-10,2020-10-01,Observational,Clinical and Immunologic Impact of Perinatal SARS-CoV-2 (COVID-19) Infection,Completed,NA,Fundacion Infant,NA,https://clinicalzeros.gov/ct2/show/NCT04362956,0,0,0,0,3,0,Argentina,0,"NA",NA
NCT04359680,2020-05-13,2021-03-29,Interventional,Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection,"Active, not recruiting",Phase 3,Romark Laboratories L.C.,NA,https://clinicalzeros.gov/ct2/show/NCT04359680,0,0,0,0,5,1,United States,0,nitazoxanide|placebo|vitamin super b-complex,NA
NCT04335084,2020-06-22,2021-12-31,Interventional,"A Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection",Recruiting,Phase 2,ProgenaBiome,NA,https://clinicalzeros.gov/ct2/show/NCT04335084,0,0,0,0,6,1,United States,0,hydroxychloroquine|vitamin c|vitamin d|zinc,NA
NCT04747678,2021-02-03,2021-02-28,Observational [Patient Registry],Adverse Effects of Ivermectin Used in Egypt During COVID-19,Enrolling by invitation,NA,Menoufia University,NA,https://clinicalzeros.gov/ct2/show/NCT04747678,0,0,0,0,0,0,Egypt,0,ivermectin,NA
NCT04344184,2020-12-18,2021-05-31,Interventional,SAFEty Study of Early Infusion of Vitamin C for Treatment of Novel Coronavirus Acute Lung Injury (SAFE EVICT CORONA-ALI),Recruiting,Phase 2,Virginia Commonwealth University,NA,https://clinicalzeros.gov/ct2/show/NCT04344184,0,0,0,0,7,1,United States,0,vitamin c|placebo,NA
NCT04348383,2020-04-08,2021-04-15,Interventional,Defibrotide as Prevention and Treatment of Respiratory Distress and Cytokine Release Syndrome of Covid 19.,Recruiting,Phase 2,Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia,NA,https://clinicalzeros.gov/ct2/show/NCT04348383,0,0,0,0,4,0,Spain,0,defibrotide 25 mg/kg 24 hours continuous infusion for 15 days|placebo|defibrotide|kg 24 hours continuous infusion for 15 days,NA
NCT04344730,2020-04-10,2021-12-31,Interventional,Dexamethasone and Oxygen Support Strategies in ICU Patients With Covid-19 Pneumonia,"Active, not recruiting",N/A,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04344730,0,0,0,0,2,0,France,0,dexamethasone|placebo|oxygen|cpap|mechanical ventilation,NA
NCT04748185,2021-01-18,2023-01-30,Observational,Immunogenicity and Safety of Commercially Available Vaccines Against SARS-CoV-2 (COVID-19) in Patients With Hematologic Malignancies,Recruiting,NA,Mayo Clinic,NA,https://clinicalzeros.gov/ct2/show/NCT04748185,0,0,0,0,0,1,United States,0,"NA",NA
NCT04748120,2020-12-28,2021-06-28,Interventional,Operative vs Non-Operative Management of Acute Appendicitis and Acute Cholecystitis in COVID-19 Positive Patients,Enrolling by invitation,N/A,The Cleveland Clinic,NA,https://clinicalzeros.gov/ct2/show/NCT04748120,0,0,0,0,0,1,United States,0,operative management|non-operative management,NA
NCT04717011,2021-02-28,2021-07-31,Observational,Case Series Study to Detect SARS-CoV-2 in Semen of COVID-19 Patients,Recruiting,NA,Igenomix,NA,https://clinicalzeros.gov/ct2/show/NCT04717011,0,0,0,0,2,0,Spain,0,pcr test,NA
NCT04747366,2020-11-06,2025-11-01,Observational [Patient Registry],"Analysis of the Pathophysiology and Pathology of Coronavirus Disease 2019 (COVID-19), Including Chronic Morbidity",Recruiting,NA,"Charite University, Berlin, Germany",NA,https://clinicalzeros.gov/ct2/show/NCT04747366,0,0,0,0,0,0,Germany,0,"NA",NA
NCT04747132,2020-07-20,2020-10-20,Interventional,Effectiveness of a Telegeriatric Intervention in Older Adults During the Covid-19 Contingency,Completed,N/A,"Universidad Iberoamericana A.C., Mexico",NA,https://clinicalzeros.gov/ct2/show/NCT04747132,0,0,0,0,0,0,Mexico,0,telegeriatric intervention,NA
NCT04746521,2021-03-31,2022-01-31,Observational,Cellular-Mediated Immunity in COVID-19,Recruiting,NA,"University of Campania ""Luigi Vanvitelli""",NA,https://clinicalzeros.gov/ct2/show/NCT04746521,0,0,0,0,1,0,Italy,0,multitest 6 color tbnk/bd lyotubes|multitest 6 color tbnk|bd lyotubes,NA
NCT04746066,2020-03-31,2030-12-31,Observational,Observational Study for Patients With Hemoglobinopathies and Rare Inherited Anemia and Covid 19,"Active, not recruiting",NA,SocietÃ  Italiana Talassemie ed Emoglobinopatie,NA,https://clinicalzeros.gov/ct2/show/NCT04746066,0,0,0,0,1,0,Italy,0,"NA",NA
NCT04743947,2020-12-21,2024-12-31,Observational,Vaccination Against COVID-19 in Chronic Kidney Disease,Recruiting,NA,"Heinrich-Heine University, Duesseldorf",NA,https://clinicalzeros.gov/ct2/show/NCT04743947,0,0,0,0,1,0,Germany,0,no intervention; observational study,NA
NCT04743232,2021-03-01,2021-12-31,Interventional,COVID-19 Resuscitation Plans and Decisions on Escalation and Limitation of Treatment,Recruiting,N/A,Erasmus Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04743232,0,0,0,0,1,0,Netherlands,0,decision tool for clinicians,NA
NCT04747522,2021-01-22,2021-06-30,Observational,Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) Immune Kidney Transplant Study (COVID-19),Recruiting,NA,Oslo University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04747522,0,0,0,0,0,0,Norway,0,sars-cov-2 vaccine,NA
NCT04741178,2020-03-20,2021-01-02,Observational,PAtterns and Extension in COVID-19 Related Interstitial Pneumonia: CT Analysis,Recruiting,NA,Morgagni Pierantoni Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04741178,0,0,0,0,1,0,Italy,0,"NA",NA
NCT04739020,2021-01-18,2021-06-30,Interventional,Respiratory Aerosols in Patients With COVID-19 and Healthy Controls,Recruiting,N/A,Johann Wolfgang Goethe University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04739020,0,0,0,0,1,0,Germany,0,resp-aer-meter|spirometry|qualitative/quantitative virus pcr of respiratory secretions in patients with high aerosol concentrations|qualitative|quantitative virus pcr of respiratory secretions in patients with high aerosol concentrations,NA
NCT04631497,2020-07-01,2021-12-31,Observational,"Assessment of Stress, Depression and Anxiety in Healthcare Caring for Patients With COVID-19",Recruiting,NA,Jagiellonian University,NA,https://clinicalzeros.gov/ct2/show/NCT04631497,0,0,0,0,1,0,Poland,0,test,NA
NCT04659239,2021-01-28,2021-09-30,Interventional,"The Efficacy, Safety and Immunogenicity Study of Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19",Enrolling by invitation,Phase 3,Chinese Academy of Medical Sciences,NA,https://clinicalzeros.gov/ct2/show/NCT04659239,0,0,0,1,2,0,Brazil|Malaysia,0,inactivated sars-cov-2 vaccine|placebo,NA
NCT04487197,2020-07-15,2021-01-15,Observational,"SARS-CoV2 (COVID-19) Seroepidemiological Transplanted Subjects (Kidney, Kidney-pancreas, Pancreas, Langerhans Islets)",Completed,NA,IRCCS San Raffaele,NA,https://clinicalzeros.gov/ct2/show/NCT04487197,0,0,0,0,3,0,Italy,0,blood sample,NA
NCT04643678,2020-10-30,2021-04-30,Interventional,Anakinra in the Management of COVID-19 Infection,Recruiting,Phase 2/Phase 3,Hamad Medical Corporation,NA,https://clinicalzeros.gov/ct2/show/NCT04643678,0,0,0,0,2,0,Qatar,0,anakinra|standard care,NA
NCT04642950,2020-12-17,2021-10-31,Interventional,A Phase II/III Study of Sargramostim,Recruiting,Phase 2/Phase 3,Nobelpharma,NA,https://clinicalzeros.gov/ct2/show/NCT04642950,0,0,0,0,2,0,Japan,0,sargramostim|placebo,NA
NCT04582201,2020-09-21,2021-04-24,Interventional,An Experiment to Evaluate the Safety of agenT-797 in COVID-19 Patients With Severe Difficulty Breathing.,Recruiting,Phase 1,Agenus Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04582201,0,0,0,0,2,1,United States,0,agent-797,NA
NCT04568889,2020-09-28,2020-10-26,Interventional,Minnesota COVID-19 Testing Project,"Active, not recruiting",N/A,Harvard University,NA,https://clinicalzeros.gov/ct2/show/NCT04568889,0,0,0,0,1,1,United States,0,a $10 survey incentive|a $20 survey incentive|emphasis of government involvement|emphasis of academic researchers involvement|cost-benefit frame|duty frame|racial/ethnic frame|no messaging|racial|ethnic frame,NA
NCT04568811,2020-09-26,2020-10-25,Interventional,The Phase I Clinical Trial of Booster Vaccination of Adenovirus Type-5 Vectored COVID-19 Vaccine,"Active, not recruiting",Phase 1,Jiangsu Province Centers for Disease Control and Prevention,NA,https://clinicalzeros.gov/ct2/show/NCT04568811,0,0,0,1,1,0,China,0,adenovirus type-5 vectored covid-19 vaccine,NA
NCT04462367,2020-07-01,2022-06-30,Observational,Northeast COVID-19 and Pregnancy Study Group,Recruiting,NA,Instituto Materno Infantil Prof. Fernando Figueira,NA,https://clinicalzeros.gov/ct2/show/NCT04462367,0,0,0,0,1,0,Brazil,0,"NA",NA
NCT04661839,2020-12-24,2021-09-30,Interventional,A COVID-19 Study to Evaluate Safety and Pharmacokinetics of COVID-HIGIV Administered in Healthy Adults,Recruiting,Phase 1,Emergent BioSolutions,NA,https://clinicalzeros.gov/ct2/show/NCT04661839,0,0,0,0,1,1,United States,0,covid-higiv|placebo (saline),NA
NCT04511923,2020-12-23,2021-12-31,Interventional,Nebulised Heparin to Reduce COVID-19 Induced Acute Lung Injury,Recruiting,Phase 1/Phase 2,University College Hospital Galway,NA,https://clinicalzeros.gov/ct2/show/NCT04511923,0,0,0,0,2,0,Ireland,0,nebulised heparin,NA
NCT04368143,2020-04-01,2021-12-30,Observational [Patient Registry],COVID-19 Immune Repertoire Sequencing,Recruiting,NA,"Institute of Tropical Medicine, Belgium",NA,https://clinicalzeros.gov/ct2/show/NCT04368143,0,0,0,0,2,0,Belgium,0,"NA",NA
NCT04368026,2020-03-30,2020-12-01,Observational,SARS-CoV-2 (COVID-19) and Surgery,Completed,NA,Jagiellonian University,NA,https://clinicalzeros.gov/ct2/show/NCT04368026,0,0,0,0,2,0,Poland,0,no intervention (survey study for medical doctors).,NA
NCT04349371,2020-04-21,2021-01-07,Interventional,Saved From COVID-19,Terminated,Phase 2,Columbia University,Low enrollment.,https://clinicalzeros.gov/ct2/show/NCT04349371,0,0,0,0,2,1,United States,0,chloroquine|placebo,NA
NCT04398264,2020-07-22,2021-03-31,Observational [Patient Registry],Characteristics of COVID-19 Infection Among PREGnant Women,Recruiting,NA,Inova Health System,NA,https://clinicalzeros.gov/ct2/show/NCT04398264,0,0,0,0,2,1,United States,0,covid-19 positive via testing,NA
NCT04394026,2020-04-16,2021-06-30,Observational,Imaging Feature of SARS-CoV2 Infection,Recruiting,NA,IRCCS San Raffaele,NA,https://clinicalzeros.gov/ct2/show/NCT04394026,0,0,0,0,1,0,Italy,0,"NA",NA
NCT04392531,2020-04-16,2021-03-31,Interventional,Clinical Trial to Assess Efficacy of cYclosporine Plus Standard of Care in Hospitalized Patients With COVID19,Recruiting,Phase 4,Instituto de InvestigaciÃ³n Sanitaria de la FundaciÃ³n JimÃ©nez DÃ­az,NA,https://clinicalzeros.gov/ct2/show/NCT04392531,0,0,0,0,2,0,Spain,0,cyclosporine|standard care,NA
NCT04372602,2020-10-12,2021-11-30,Interventional,Duvelisib to Combat COVID-19,Recruiting,Phase 2,Washington University School of Medicine,NA,https://clinicalzeros.gov/ct2/show/NCT04372602,0,0,0,0,5,1,United States,0,duvelisib|blood draw|placebo,NA
NCT04409327,2020-07-11,2020-12-27,Interventional,Phase 2 Study to Determine if RTB101 Reduces the Severity of COVID-19 in Older Adults Residing in Nursing Homes,Terminated,Phase 2,Restorbio Inc.,Insufficient accrual rate,https://clinicalzeros.gov/ct2/show/NCT04409327,0,0,0,0,5,1,United States,0,rtb101|placebo,NA
NCT04346147,2020-05-07,2021-06-30,Interventional,Clinical Trial to Evaluate Efficacy of 3 Types of Treatment in Patients With Pneumonia by COVID-19,Recruiting,Phase 2,Hospital Universitario de Fuenlabrada,NA,https://clinicalzeros.gov/ct2/show/NCT04346147,0,0,0,0,4,0,Spain,0,imatinib|baricitinib|supportive tratment,NA
NCT04333355,2020-05-08,2020-08-20,Interventional,Safety in Convalescent Plasma Transfusion to COVID-19,Terminated,Phase 1,Hospital San Jose Tec de Monterrey,"Other clinical trails probed that the use of convalescent plasma for patients with COVID-19 is
    safe .",https://clinicalzeros.gov/ct2/show/NCT04333355,0,0,0,0,3,0,Mexico,0,convalescent plasma,NA
NCT04321811,2020-03-21,2021-02-09,Observational [Patient Registry],"Behavior, Environment And Treatments for Covid-19","Active, not recruiting",NA,xCures,NA,https://clinicalzeros.gov/ct2/show/NCT04321811,0,0,0,0,3,1,United States,0,observation|at risk for covid-19 infection,NA
NCT04337918,2020-05-08,2021-01-31,Interventional,Nitric Oxide Releasing Solutions to Prevent and Treat Mild/Moderate COVID-19 Infection,Completed,Phase 2,Sanotize Research and Development corp.,NA,https://clinicalzeros.gov/ct2/show/NCT04337918,0,0,0,0,7,0,Canada,0,nitric oxide,NA
NCT04336215,2020-04-07,2021-05-01,Observational,Rutgers COVID-19 Cohort Study,Recruiting,NA,"Rutgers, The State University of New Jersey",NA,https://clinicalzeros.gov/ct2/show/NCT04336215,0,0,0,0,2,1,United States,0,non-interventional,NA
NCT04751604,2021-02-01,2021-09-30,Interventional,Improvement of the Nutritional Status Regarding Nicotinamide (Vitamin B3) and the Disease Course of COVID-19,Recruiting,N/A,University Hospital Schleswig-Holstein,NA,https://clinicalzeros.gov/ct2/show/NCT04751604,0,0,0,0,0,0,Germany,0,nicotinamide|placebo,NA
NCT04751617,2021-01-01,2021-01-31,Interventional,Pulmonary Rehabilitation of Patients With a History of COVID-19,Enrolling by invitation,N/A,University of Rzeszow,NA,https://clinicalzeros.gov/ct2/show/NCT04751617,0,0,0,0,0,0,Poland,0,pulmonary rehabilitation,NA
NCT04751227,2020-11-22,2021-01-30,Observational,Modafinil for Wakefulness in the Critical Care Units,Completed,NA,King Faisal Specialist Hospital & Research Center,NA,https://clinicalzeros.gov/ct2/show/NCT04751227,0,0,0,0,0,0,Saudi Arabia,0,modafinil,NA
NCT04750369,2020-04-01,2021-03-31,Observational,Enhanced Triage for COVID-19,Recruiting,NA,"University Health Network, Toronto",NA,https://clinicalzeros.gov/ct2/show/NCT04750369,0,0,0,0,0,0,Canada,0,"NA",NA
NCT04750356,2021-01-27,2024-12-31,Observational,"SARS-CoV-2 (COVID-19) Longitudinal Study: Understanding Susceptibility, Transmission and Disease Severity (Legacy Study)",Recruiting,NA,"University College, London",NA,https://clinicalzeros.gov/ct2/show/NCT04750356,0,0,0,0,0,0,United Kingdom,0,"NA",NA
NCT04709068,2021-02-08,2021-03-19,Observational,Risk Stratification and Early Alerting Regarding COVID-19 Hospitalization,Recruiting,NA,Current Health,NA,https://clinicalzeros.gov/ct2/show/NCT04709068,0,0,0,0,1,1,United States,0,current health,NA
NCT04749121,2020-04-01,2021-02-05,Interventional,Ultraviolet Germicidal Irradiation on the New Silicone Half-Piece Elastometric Respirators,Completed,N/A,Bangkok Metropolitan Administration Medical College and Vajira Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04749121,0,0,0,0,0,0,Thailand,0,uvc irradiation|fit test|tensile strength,NA
NCT04743388,2021-01-04,2021-11-30,Observational [Patient Registry],Study of the Kinetics of Antibodies Against COVID-19 (SARS-CoV-2) and of Cellular Subpopulations of the Immune System,Recruiting,NA,National and Kapodistrian University of Athens,NA,https://clinicalzeros.gov/ct2/show/NCT04743388,0,0,0,0,1,0,Greece,0,bnt162b2|other vaccine against sars-cov-2,NA
NCT04740320,2020-12-15,2021-05-31,Observational [Patient Registry],COVID-19 SARS-CoV-2 Screening Protocol,Recruiting,NA,Imperial College London,NA,https://clinicalzeros.gov/ct2/show/NCT04740320,0,0,0,0,1,0,United Kingdom,0,"NA",NA
NCT04662671,2020-11-18,2020-12-09,Interventional,"Phase I/II Randomized, Dose Escalation Study to Evaluate the Safety and Antiviral Activity of the RD-X19 Device in SARS-CoV-2 Infected Individuals With Uncomplicated COVID-19",Completed,Phase 1/Phase 2,KNOWBio Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04662671,0,0,0,0,1,1,United States,0,rd-x19,NA
NCT04695158,2021-01-06,2021-02-28,Observational,Blood Sample Measurements and Physical Activity Levels in Type II Diabetes and/or COVID-19,Recruiting,NA,Izmir Bakircay University,NA,https://clinicalzeros.gov/ct2/show/NCT04695158,0,0,0,0,3,0,Turkey,0,covid-19 group (group i)|type ii diabetes mellitus/covid-19 group (group ii)|type ii diabetes mellitus|covid-19 group (group ii),NA
NCT04694716,2021-01-06,2021-02-28,Observational,Determination of Serum Trace Element and Physical Activity Levels in COVID-19,Recruiting,NA,Izmir Bakircay University,NA,https://clinicalzeros.gov/ct2/show/NCT04694716,0,0,0,0,3,0,Turkey,0,no intervention,NA
NCT04694703,2021-01-06,2021-02-28,Observational,"Changing of Trace Element, Homocysteine, Oxidative Stress Parameters and Physical Activity Levels in Covid-19",Recruiting,NA,Izmir Bakircay University,NA,https://clinicalzeros.gov/ct2/show/NCT04694703,0,0,0,0,3,0,Turkey,0,covid-19 group,NA
NCT04652765,2021-02-03,2023-01-31,Interventional,Camostat With Bicalutamide for COVID-19,Recruiting,Phase 1,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,NA,https://clinicalzeros.gov/ct2/show/NCT04652765,0,0,0,0,2,1,United States,0,camostat mesilate|bicalutamide 150 mg,NA
NCT04652596,2021-02-08,2022-06-30,Interventional,Reducing Food Insecurity During COVID-19,Enrolling by invitation,N/A,Boston Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04652596,0,0,0,0,1,1,United States,0,produce prescription program|grocery store gift cards,NA
NCT04621461,2020-12-20,2021-02-08,Interventional,Placebo Controlled Trial to Evaluate Zinc for the Treatment of COVID-19 in the Outpatient Setting,Completed,Phase 4,"St. Francis Hospital, New York",NA,https://clinicalzeros.gov/ct2/show/NCT04621461,0,0,0,0,2,1,United States,0,zinc sulfate 220 mg|placebo,NA
NCT04535778,2020-11-16,2021-06-01,Interventional,COMPASS Study: an Online Cognitive-behavioural Therapy (CBT) Program Treating Anxiety and Low Mood in Long-term Conditions During the COVID-19 Pandemic,Recruiting,N/A,King's College London,NA,https://clinicalzeros.gov/ct2/show/NCT04535778,0,0,0,0,1,0,United Kingdom,0,compass|standard charity resources,NA
NCT04559100,2020-11-15,2021-10-01,Observational,Long-term Characterization of Patients With Severe/Critical Infection by COVID-19 Virus,Enrolling by invitation,NA,Fundacion Clinica Valle del Lili,NA,https://clinicalzeros.gov/ct2/show/NCT04559100,0,0,0,0,3,0,Colombia,0,chest radiography|thoracic computed tomography scan|spirometry|diffusing capacity of carbon monoxide|6 minute walk test|saint george respiratory questionnaire,NA
NCT04581863,2020-11-30,2021-02-05,Interventional,COVID-19 Watch + COVID-19 Pulse,"Active, not recruiting",N/A,University of Pennsylvania,NA,https://clinicalzeros.gov/ct2/show/NCT04581863,0,0,0,0,6,1,United States,0,pulse oximeter|covid watch,NA
NCT04530656,2020-08-28,2020-10-28,Interventional,Phase I Trial of a Recombinant SARS-CoV-2 Vaccine (Sf9 Cell),"Active, not recruiting",Phase 1,Jiangsu Province Centers for Disease Control and Prevention,NA,https://clinicalzeros.gov/ct2/show/NCT04530656,0,0,0,1,2,0,China,0,"two doses of middle-dose recombinant sars-cov-2 vaccine (sf9 cell) at the schedule of day 0, 28|two doses of high-dose recombinant sars-cov-2 vaccine (sf9 cell) at the schedule of day 0, 28|three doses of high-dose recombinant sars-cov-2 vaccine (sf9 cell) at the schedule of day 0, 14, 28|two doses of placebo at the schedule of day 0, 28ï¼ˆmiddle-dose groupï¼‰|two doses of placebo at the schedule of day 0, 28ï¼ˆhigh-dose groupï¼‰|three doses of placebo at the schedule of day 0, 14, 28ï¼ˆhigh-dose groupï¼‰|two doses of placebo at the schedule of day 0, 28ï¼ˆmiddle-dose groupï¼‰|two doses of placebo at the schedule of day 0, 28ï¼ˆhigh-dose groupï¼‰|three doses of placebo at the schedule of day 0, 14, 28ï¼ˆhigh-dose groupï¼‰",NA
NCT04544176,2020-01-01,2020-06-30,Observational,COVID-19 Risk From Attending Outpatient Radiology Appointments,Completed,NA,Nottingham University Hospitals NHS Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04544176,0,0,0,0,2,0,United Kingdom,0,observational,NA
NCT04512079,2020-09-08,2021-12-31,Interventional,FREEDOM COVID-19 Anticoagulation Strategy,Recruiting,Phase 4,Icahn School of Medicine at Mount Sinai,NA,https://clinicalzeros.gov/ct2/show/NCT04512079,0,0,0,0,3,1,United States|Brazil|Colombia|India|Mexico,0,enoxaparin|apixaban,NA
NCT04490824,2020-10-01,2021-03-30,Interventional,Inhalation of KELEA Excellerated Water in Covid-19 Infected Individuals,Recruiting,N/A,Institute of Progressive Medicine,NA,https://clinicalzeros.gov/ct2/show/NCT04490824,0,0,0,0,4,1,United States,0,kelea water|water without an elevated level of kelea,NA
NCT04397705,2020-10-12,2021-04-30,Interventional,Remote Monitoring of Cancer Patients With Suspected Covid-19,Recruiting,Phase 1,The Christie NHS Foundation Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04397705,0,0,0,0,1,0,United Kingdom,0,patient status engine,NA
NCT04491214,2020-07-24,2021-01-21,Observational,Post ICU Follow up in Patients With Severe SARS-CoV-2 Infection (Covid-19),Completed,NA,"University Hospital, Strasbourg, France",NA,https://clinicalzeros.gov/ct2/show/NCT04491214,0,0,0,0,2,0,France,0,quality of live assessment,NA
NCT04456595,2020-07-21,2020-12-17,Interventional,Clinical Trial of Efficacy and Safety of Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine in Healthcare Professionals,"Active, not recruiting",Phase 3,Butantan Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04456595,0,0,0,1,4,0,Brazil,0,adsorbed covid-19 (inactivated) vaccine|placebo,NA
NCT04449588,2020-07-23,2021-08-07,Interventional,Efficacy and Safety Study of BDB-001 in Severe COVID-19 With ALI/ARDS,Recruiting,Phase 2/Phase 3,"Staidson (Beijing) Biopharmaceuticals Co., Ltd",NA,https://clinicalzeros.gov/ct2/show/NCT04449588,0,0,0,0,2,0,Bangladesh|China|India|Indonesia|Spain,0,"bdb-001 injection|conventional medicines (oxygen therapy, alfa interferon via aerosol inhalation,/lopinavir/ritonavir)/traditional chinese medicines (tcms) granules",NA
NCT04442165,2020-12-15,2021-07-14,Observational,Characterising Transmission of SARS-CoV-2 in a Peri-urban Population in Mozambique,Recruiting,NA,"Institute of Tropical Medicine, Belgium",NA,https://clinicalzeros.gov/ct2/show/NCT04442165,0,0,0,0,2,0,Mozambique,0,"NA",NA
NCT04393155,2020-04-16,2021-01-20,Observational,COVID Cohort Study,Terminated,NA,University of Vermont,Grant application to fund this work was not funded. We won't be posting data for this study.,https://clinicalzeros.gov/ct2/show/NCT04393155,0,0,0,0,3,1,United States,0,covid-19/ observational|covid-19|observational,NA
NCT04389294,2020-05-05,2020-06-16,Interventional,HSS Covid-19 Antibody Serology Among Surgeons & Anesthesiologists,Completed,N/A,"Hospital for Special Surgery, New York",NA,https://clinicalzeros.gov/ct2/show/NCT04389294,0,0,0,0,1,1,United States,0,antibody test,NA
NCT04383730,2020-06-26,2021-04-30,Observational,Inhaled Sedation in COVID-19-related Acute Respiratory Distress Syndrome (ISCA): an International Research Data Study in the Recent Context of Widespread Disease Resulting From the 2019 (SARS-CoV2) Coronavirus Pandemics (COVID-19),Recruiting,NA,"University Hospital, Clermont-Ferrand",NA,https://clinicalzeros.gov/ct2/show/NCT04383730,0,0,0,0,4,1,United States|France|Germany|Spain|Switzerland,0,sedation,NA
NCT04382586,2020-07-06,2021-02-02,Interventional,Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants,"Active, not recruiting",Phase 2,BeiGene,NA,https://clinicalzeros.gov/ct2/show/NCT04382586,0,0,0,0,8,1,United States,0,zanubrutinib|supportive care|placebo,NA
NCT04379258,2021-02-08,2021-02-08,Observational [Patient Registry],Analysis of Mortality of Critically Ill Patients With COVID-19,Completed,NA,Hospital Universitario Getafe,NA,https://clinicalzeros.gov/ct2/show/NCT04379258,0,0,0,0,2,0,Spain,0,"NA",NA
NCT04371289,2020-04-08,2020-07-10,Observational,Predictors of Cardiovascular Risk in Covid-19 Patients During Acute Disease and at Short Term Follow-up,"Active, not recruiting",NA,Istituto Auxologico Italiano,NA,https://clinicalzeros.gov/ct2/show/NCT04371289,0,0,0,0,1,0,Italy,0,"NA",NA
NCT04336332,2020-04-01,2021-04-30,Interventional,Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19,"Active, not recruiting",Phase 2,"Rutgers, The State University of New Jersey",NA,https://clinicalzeros.gov/ct2/show/NCT04336332,0,0,0,0,4,1,United States,0,hydroxychloroquine / azithromycin|hydroxychloroquine|azithromycin,NA
NCT04331600,2020-04-16,2020-12-17,Interventional,Chloroquine as Antiviral Treatment in Coronavirus Infection 2020,Completed,Phase 4,Wroclaw Medical University,NA,https://clinicalzeros.gov/ct2/show/NCT04331600,0,0,0,0,2,0,Poland,0,chloroquine|telehealth,NA
NCT04723394,2021-01-28,2021-06-30,Interventional,Phase III Study of AZD7442 for Treatment of COVID-19 in Outpatient Adults,Recruiting,Phase 3,AstraZeneca,NA,https://clinicalzeros.gov/ct2/show/NCT04723394,0,0,0,0,1,1,United States|Germany|Hungary|Mexico|United Kingdom,0,azd7442|placebo,NA
NCT04495764,2020-07-20,2021-02-12,Observational,Registry of Sustained Immunity to COVID-19 Among ESKD Patients,Completed,NA,Davita Clinical Research,NA,https://clinicalzeros.gov/ct2/show/NCT04495764,0,0,0,0,6,1,United States,0,"NA",NA
NCT04754633,2020-07-01,2020-07-20,Observational,Comparison of Chest CT Findings Related to COVID-19 With RSNA and BSTI Guidelines,Completed,NA,Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04754633,0,0,0,0,0,0,Turkey,0,"NA",NA
NCT04753645,2020-09-19,2021-05-31,Interventional,BRAC Institute of Governance and Development-Hygiene Behavioural Change and Coalition,"Active, not recruiting",N/A,BRAC University,NA,https://clinicalzeros.gov/ct2/show/NCT04753645,0,0,0,0,0,0,Bangladesh,0,handwashing stations at the public places|no activities of the hbcc project,NA
NCT04750317,2020-05-11,2020-08-01,Interventional,Efficacy and Safety of Tofacitinib in Patients With COVID-19 Pneumonia,Completed,Phase 2,I.M. Sechenov First Moscow State Medical University,NA,https://clinicalzeros.gov/ct2/show/NCT04750317,0,0,0,0,1,0,Russian Federation,0,tofacitinib,NA
NCT04703140,2021-02-11,2022-08-11,Interventional,COVIDISC: Rapid Diagnostic Tests on Nasopharyngeal Swabs for the Detection of COVID-19,Recruiting,N/A,CMC Ambroise ParÃ©,NA,https://clinicalzeros.gov/ct2/show/NCT04703140,0,0,0,0,2,0,France,0,rapid diagnostic test vs pcr,NA
NCT04710329,2021-01-16,2021-01-25,Observational,High-Dose Vitamin C Treatment in Critically Ill COVID-19 Patients,Completed,NA,Sisli Hamidiye Etfal Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04710329,0,0,0,0,4,0,Turkey,0,vitamin c,NA
NCT04649021,2020-12-04,2021-12-31,Interventional,Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy Population,"Active, not recruiting",Phase 2,BioNTech SE,NA,https://clinicalzeros.gov/ct2/show/NCT04649021,0,0,0,1,2,0,China,0,bnt162b2|placebo,NA
NCT04638634,2021-02-02,2021-05-31,Interventional,"Pharmacokinetics, Safety, and Tolerability of CSL760, an Intravenous Anti-SARS-CoV-2 Hyperimmune Globulin, in Healthy Adult Subjects",Recruiting,Phase 1,CSL Behring,NA,https://clinicalzeros.gov/ct2/show/NCT04638634,0,0,0,0,3,0,Australia,0,csl760,NA
NCT04561102,2020-09-11,2021-02-28,Observational,Evaluation of the COVIDSeq Test in Nasal Swab and Saliva From a COVID-19 Asymptomatic Population,Enrolling by invitation,NA,"Illumina, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04561102,0,0,0,0,1,1,United States,0,diagnostic test for detection of sars-cov-2,NA
NCT04591210,2021-01-27,2021-12-31,Interventional,The COVID-RASi Trial (COVID-19),Recruiting,Phase 3,Ottawa Heart Institute Research Corporation,NA,https://clinicalzeros.gov/ct2/show/NCT04591210,0,0,0,0,1,0,Canada,0,ace inhibitor|angiotensin ii receptor blockers,NA
NCT04414293,2020-10-01,2021-07-31,Interventional,Low Dose Pulmonary Irradiation in Patients With COVID-19 Infection of Bad Prognosis,Recruiting,N/A,Hospital Provincial de Castellon,NA,https://clinicalzeros.gov/ct2/show/NCT04414293,0,0,0,0,3,0,Spain,0,lung low dose radiation,NA
NCT04392453,2020-10-26,2021-12-31,Interventional,Upper Limb Robotic Rehabilitation During COVID-19 Outbreak,Recruiting,N/A,Fondazione Don Carlo Gnocchi Onlus,NA,https://clinicalzeros.gov/ct2/show/NCT04392453,0,0,0,0,1,0,Italy,0,robotic therapy,NA
NCT04385160,2020-05-13,2022-02-15,Observational,Myeloproliferative Neoplasms (MPN) and COVID-19,Recruiting,NA,Fondazione per la Ricerca Ospedale Maggiore,NA,https://clinicalzeros.gov/ct2/show/NCT04385160,0,0,0,0,3,1,United States|France|Germany|Italy|Poland|Spain|United Kingdom,0,"NA",NA
NCT04384965,2020-05-12,2022-05-01,Interventional,Accelerated iTBS for Depressed Patients During the COVID-19 Pandemic,Recruiting,N/A,Centre for Addiction and Mental Health,NA,https://clinicalzeros.gov/ct2/show/NCT04384965,0,0,0,0,2,0,Canada,0,"magpro x100 stimulator, b70 fluid-cooled coil",NA
NCT04375761,2020-05-01,2021-01-24,Observational,COVID-19: Human Epidemiology and Response to SARS-CoV-2,Completed,NA,National Institute of Allergy and Infectious Diseases (NIAID),NA,https://clinicalzeros.gov/ct2/show/NCT04375761,0,0,0,0,10,1,United States,0,biological samples|symptom/exposure surveys|symptom|exposure surveys,NA
NCT04366908,2020-05-07,2021-06-30,Interventional,Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory Syndrome,Recruiting,Phase 2,MaimÃ³nides Biomedical Research Institute of CÃ³rdoba,NA,https://clinicalzeros.gov/ct2/show/NCT04366908,0,0,0,0,2,0,Spain,0,bat / calcifediol|bat|calcifediol,NA
NCT04361448,2020-04-20,2020-06-30,Interventional,Performance of 3 Sampling Methods for the Detection of SARS-CoV-2 (COVID-19) With Real-time Reverse Transcriptase PCR,Terminated,N/A,Jessa Hospital,Insufficient sample number,https://clinicalzeros.gov/ct2/show/NCT04361448,0,0,0,0,1,0,Belgium,0,sampling of oropharynx/nasopharynx|sampling of oropharynx|nasopharynx,NA
NCT04353154,2020-04-15,2021-01-31,Observational,The RAPID COVID TRIAGE Algorithm,"Active, not recruiting",NA,Ottawa Heart Institute Research Corporation,NA,https://clinicalzeros.gov/ct2/show/NCT04353154,0,0,0,0,1,0,Canada,0,cube rapid test,NA
NCT04756817,2021-02-13,2021-08-30,Observational,Immunogenicity of the BNT162b2 Covid-19 Vaccine in Elderly People Aged 85 and Older in Greece,Recruiting,NA,G.Gennimatas General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04756817,0,0,0,0,0,0,Greece,0,"NA",NA
NCT04756193,2021-04-01,2022-12-31,Observational,Evaluate Long Term Cardiovascular and Pulmonary Complications After COVID-19 With Point of Care Ultrasound,Recruiting,NA,University of Louisville,NA,https://clinicalzeros.gov/ct2/show/NCT04756193,0,0,0,0,0,1,United States,0,"point of care ultrasound including echocardiography, lung ultrasound, vascular ultrasound",NA
NCT04349618,2020-04-15,2023-04-15,Interventional,Ultraprotective Ventilation Without Extracorporeal Circulation During COVID 19 Pneumonia,Recruiting,N/A,Hospices Civils de Lyon,NA,https://clinicalzeros.gov/ct2/show/NCT04349618,0,0,0,0,2,0,France,0,protective ventilation|ultraprotective ventilation,NA
NCT04348422,2020-05-01,2021-12-01,Observational,Evaluating the Immune Response for COVID-19,Recruiting,NA,Assaf-Harofeh Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04348422,0,0,0,0,3,0,Israel,0,pcr|serology test|symptoms,NA
NCT04756479,2020-03-01,2020-06-30,Observational,Mortality Due to COVID-19 in the COVID-AGEBRU Study,Completed,NA,Brugmann University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04756479,0,0,0,0,0,0,Belgium,0,"NA",NA
NCT04756518,2020-07-06,2021-07-01,Observational,COVID-19 Infection and Machine Learning Using Artificial Intelligence (AI),Recruiting,NA,East Suffolk and North Essex NHS Foundation Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04756518,0,0,0,0,0,0,United Kingdom,0,"NA",NA
NCT04755972,2021-01-29,2021-07-29,Interventional,Mucolytics in Patients on Invasive Mechanical Ventilation Due to Severe Acute Respiratory Syndrome Coronavirus 2,Recruiting,N/A,"Clinical Hospital Center, Split",NA,https://clinicalzeros.gov/ct2/show/NCT04755972,0,0,0,0,0,0,Croatia,0,"inhalation of n-acetylcysteine|inhalation of 5% sodium chloride|inhalation of 8,4% sodium bicarbonate",NA
NCT04749173,2020-11-21,2021-03-28,Interventional,"To Assess the Safety, Tolerability and Pharmacokinetic Properties of Niclosamide Injectable (DWRX2003) Which is the Treatment of COVID-19 in Healthy Volunteers.",Recruiting,Phase 1,Daewoong Pharmaceutical Co. LTD.,NA,https://clinicalzeros.gov/ct2/show/NCT04749173,0,0,0,0,1,0,"Korea, Republic of",0,dwrx2003,NA
NCT04646590,2020-12-16,2022-04-30,Interventional,A Phase III Clinical Trial to Determine the Safety and Efficacy of ZF2001 for Prevention of COVID-19,Recruiting,Phase 3,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",NA,https://clinicalzeros.gov/ct2/show/NCT04646590,0,0,0,1,4,0,China|Ecuador|Indonesia|Pakistan|Uzbekistan,0,recombinant new coronavirus vaccine (cho cell) group|placebo,NA
NCT04751734,2021-01-16,2021-12-31,Observational,Impact of Maternal COVID-19 Vaccines on Breast Milk,Enrolling by invitation,NA,"Institute of Agrochemistry and Food Technology, National Research Council",NA,https://clinicalzeros.gov/ct2/show/NCT04751734,0,0,0,0,1,0,Spain,0,covid vaccines,NA
NCT04691921,2021-01-04,2021-01-18,Observational,Current Pharmacological Practices in Severe COVID-19,Completed,NA,NMC Specialty Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04691921,0,0,0,0,4,0,India,0,current clinical practices of participating physicians,NA
NCT04643444,2021-02-09,2022-01-31,Observational,Police COVID-19 Serosurvey,Enrolling by invitation,NA,University of Bern,NA,https://clinicalzeros.gov/ct2/show/NCT04643444,0,0,0,0,3,0,Switzerland,0,blood sample|online survey,NA
NCT04558203,2020-09-22,2021-05-25,Observational [Patient Registry],"The Relationship Between COVID-19 and Autoimmune Diseases, Lessons From Practice",Recruiting,NA,ClinAmygate,NA,https://clinicalzeros.gov/ct2/show/NCT04558203,0,0,0,0,2,0,Egypt,0,"NA",NA
NCT04540419,2020-09-11,2021-05-30,Interventional,Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Against COVID-19,"Active, not recruiting",Phase 3,NPO Petrovax,NA,https://clinicalzeros.gov/ct2/show/NCT04540419,0,0,0,1,3,0,Russian Federation,0,adenovirus type 5 vector|placebo,NA
NCT04530539,2020-10-05,2021-09-01,Interventional,The Effect of Melatonin and Vitamin C on COVID-19,Recruiting,N/A,Lancaster General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04530539,0,0,0,0,2,1,United States,0,vitamin c|melatonin|placebo|symptom survey,NA
NCT04530409,2020-08-26,2021-04-01,Interventional,Timing of Corticosteroids in COVID-19,Recruiting,Phase 4,ClinAmygate,NA,https://clinicalzeros.gov/ct2/show/NCT04530409,0,0,0,0,3,0,Egypt,0,early-dexamethasone|dexamethasone,NA
NCT04581928,2020-10-10,2021-04-10,Observational,Patients Reactions Towards Their Diagnosis as Having COVID-19,Recruiting,NA,ClinAmygate,NA,https://clinicalzeros.gov/ct2/show/NCT04581928,0,0,0,0,2,0,Egypt,0,"NA",NA
NCT04561089,2020-02-13,2021-02-28,Observational,Evaluation of the COVIDSeq Test in Saliva Specimens From COVID-19 Asymptomatic Illumina Personnel,Enrolling by invitation,NA,"Illumina, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04561089,0,0,0,0,1,1,United States,0,covidseq test,NA
NCT04501458,2020-08-10,2021-06-10,Interventional,Western Kenya Integrated COVID-19 Response,"Active, not recruiting",N/A,Surgical Systems Research Group,NA,https://clinicalzeros.gov/ct2/show/NCT04501458,0,0,0,0,3,0,Kenya,0,"training of youth, community health assistants/community health workers.|training clinicians in basic critical care/the management of severe covid-19 cases|training of youth, community health assistants|community health workers.|training clinicians in basic critical care|the management of severe covid-19 cases",NA
NCT04492410,2020-07-21,2021-05-31,Interventional,COVID-19 Infection Screening in Cancer Patients (NEOSCREENCOVID),"Active, not recruiting",N/A,Centre Antoine Lacassagne,NA,https://clinicalzeros.gov/ct2/show/NCT04492410,0,0,0,0,1,0,France,0,serology test,NA
NCT04419025,2020-09-23,2021-03-31,Interventional,Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease,Recruiting,Phase 2,Cambridge Health Alliance,NA,https://clinicalzeros.gov/ct2/show/NCT04419025,0,0,0,0,4,1,United States,0,n-acetylcysteine,NA
NCT04338074,2020-06-01,2021-12-15,Interventional,TXA and Corona Virus 2019 (COVID19) in Outpatients,Recruiting,Phase 2,University of Alabama at Birmingham,NA,https://clinicalzeros.gov/ct2/show/NCT04338074,0,0,0,0,6,1,United States,0,placebo|tranexamic acid,NA
NCT04381377,2020-04-29,2021-04-30,Interventional,Efficacy and Safety of PolyoxidoniumÂ® in Hospitalized Patients With Coronavirus Disease COVID-19,"Active, not recruiting",Phase 2/Phase 3,NPO Petrovax,NA,https://clinicalzeros.gov/ct2/show/NCT04381377,0,0,0,0,2,0,Russian Federation|Slovakia,0,azoximer bromide|placebo,NA
NCT04378920,2020-04-14,2021-06-30,Interventional,"A Study of Liposomal Trans Crocetin, LEAF-4L6715, in Patients With Acute Respiratory Distress Syndrome Due to COVID-19, Sepsis or Other Causes",Recruiting,Phase 1/Phase 2,Institut de cancÃ©rologie Strasbourg Europe,NA,https://clinicalzeros.gov/ct2/show/NCT04378920,0,0,0,0,6,0,France,0,leaf-4l6715,NA
NCT04373733,2020-05-01,2021-03-31,Interventional,Early Intervention in COVID-19: Favipiravir Verses Standard Care,Recruiting,Phase 3,Chelsea and Westminster NHS Foundation Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04373733,0,0,0,0,3,0,United Kingdom,0,favipiravir|standard care,NA
NCT04426201,2020-12-20,2021-04-30,Interventional,InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic Patients With COVID-19 Infection ( ILIAD-7-US-O ),Recruiting,Phase 2,Revimmune,NA,https://clinicalzeros.gov/ct2/show/NCT04426201,0,0,0,0,3,1,United States,0,cyt107|placebo,NA
NCT04363502,2020-05-07,2021-06-30,Interventional,Use of the Interleukin-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection,Recruiting,Phase 2,Johns Hopkins University,NA,https://clinicalzeros.gov/ct2/show/NCT04363502,0,0,0,0,6,1,United States,0,clazakizumab|placebo,NA
NCT04328012,2020-04-06,2021-06-01,Interventional,COVID MED Trial - Comparison Of Therapeutics for Hospitalized Patients Infected With COVID-19,Recruiting,Phase 2/Phase 3,Bassett Healthcare,NA,https://clinicalzeros.gov/ct2/show/NCT04328012,0,0,0,0,3,1,United States,0,losartan|placebo,NA
NCT04335201,2020-05-20,2021-06-20,Interventional,Defibrotide in COVID-19 Pneumonia,Recruiting,Phase 2,IRCCS San Raffaele,NA,https://clinicalzeros.gov/ct2/show/NCT04335201,0,0,0,0,1,0,Italy,0,defibrotide,NA
NCT04348864,2020-04-16,2021-04-30,Interventional,COVID-19 Diagnostic Self-testing Using Virtual Point-of-care,Recruiting,N/A,Neuroganics LLC,NA,https://clinicalzeros.gov/ct2/show/NCT04348864,0,0,0,0,10,1,United States,0,"covid-19 antigen/antibody rapid testing, mobile device image capture/telemedicine support|telehealth|covid-19 antigen|rapid test",NA
NCT04757285,2020-05-10,2020-10-30,Observational [Patient Registry],Copeptin and Psychological Stress of Medic During COVID-19 Pandemic,Completed,NA,Alexandria University,NA,https://clinicalzeros.gov/ct2/show/NCT04757285,0,0,0,0,0,0,Egypt,0,"NA",NA
NCT04342104,2020-04-01,2021-07-31,Observational,NIV and CPAP Failure Predictors in COVID-19 Associated Respiratory Failure,Recruiting,NA,Hospital General Universitario Morales Meseguer,NA,https://clinicalzeros.gov/ct2/show/NCT04342104,0,0,0,0,3,0,Spain,0,monitoring for aggravation|evaluate hacor score effectivity in this patients,NA
NCT04338828,2020-04-18,2021-04-30,Interventional,Nitric Oxide Inhalation Therapy for COVID-19 Infections in the ED,"Active, not recruiting",Phase 2,Massachusetts General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04338828,0,0,0,0,2,1,United States,0,nitric oxide|oxygen,NA
NCT04758286,2020-07-01,2021-02-01,Interventional,Anesthetic & Surgical Protocol for Emergency Surgeries During the Era of COVID-19,Completed,N/A,Benha University,NA,https://clinicalzeros.gov/ct2/show/NCT04758286,0,0,0,0,0,0,Egypt,0,emergency surgical procedures,NA
NCT04758273,2020-10-07,2021-06-30,Interventional,A Safety and Immunogenicity Study of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above(COVID-19),"Active, not recruiting",Phase 1,"Beijing Minhai Biotechnology Co., Ltd",NA,https://clinicalzeros.gov/ct2/show/NCT04758273,0,0,0,1,0,0,China,0,medium dosage inactivated sars-cov-2 vaccine|high dosage inactivated sars-cov-2 vaccine|placebo,NA
NCT04757792,2020-06-06,2021-02-01,Observational,Back to the Traditional: Anti-COX Drugs Can Improve the Outcome of COVID-19 Patients Admitted to ICU,Completed,NA,Benha University,NA,https://clinicalzeros.gov/ct2/show/NCT04757792,0,0,0,0,0,0,Egypt,0,file inquiry,NA
NCT04758962,2021-02-15,2021-06-11,Interventional,A Study of the Safety of and Immune Response to Varying Doses of a Vaccine Against COVID-19 in Healthy Adults,Recruiting,Phase 1,GlaxoSmithKline,NA,https://clinicalzeros.gov/ct2/show/NCT04758962,0,0,0,1,0,1,United States,0,1 âµg cov2 sam (lnp)|3 âµg cov2 sam (lnp)|10 âµg cov2 sam (lnp)|30 âµg cov2 sam (lnp)|1 âµg cov2 sam (lnp)|3 âµg cov2 sam (lnp)|10 âµg cov2 sam (lnp)|30 âµg cov2 sam (lnp),NA
NCT04757818,2021-02-04,2021-03-25,Interventional,"Double-blind, Randomized, Parallel, Placebo-controlled Clinical Study to Evaluate the Viral Load of SARS-CoV-2 in the Oral Cavity of SARS-CoV-2 Positive Subjects After the Use of a Mouthwash Containing Cetylpyridinium Chloride 0,07%.",Recruiting,N/A,Dentaid SL,NA,https://clinicalzeros.gov/ct2/show/NCT04757818,0,0,0,0,0,0,Spain,0,0.07% cetylpyridinium chloride (cpc) in mouthwash|distilled water with the same colorant as the experimental product,NA
NCT04756323,2020-10-27,2021-06-30,Interventional,A Study to Evaluate Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above(COVID-19),"Active, not recruiting",Phase 2,"Beijing Minhai Biotechnology Co., Ltd",NA,https://clinicalzeros.gov/ct2/show/NCT04756323,0,0,0,1,1,0,China,0,medium dosage inactivated sars-cov-2 vaccine|high dosage inactivated sars-cov-2 vaccine|placebo,NA
NCT04710836,2020-12-03,2032-08-31,Observational,NoRCoRP Assessment Clinic,Recruiting,NA,Nottingham University Hospitals NHS Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04710836,0,0,0,0,1,0,United Kingdom,0,"NA",NA
NCT04753619,2021-01-03,2021-05-03,Interventional,Effectiveness of Niclosamide as Add-on Therapy to the Standard of Care Measures in COVID-19 Management,Recruiting,Phase 2,University of Baghdad,NA,https://clinicalzeros.gov/ct2/show/NCT04753619,0,0,0,0,1,0,Iraq,0,niclosamide oral tablet,NA
NCT04583410,2020-10-22,2021-12-31,Interventional,Efficacy of Nicotine in Preventing COVID-19 Infection,Recruiting,Phase 3,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04583410,0,0,0,0,4,0,France,0,nicotine patch|placebo patch,NA
NCT04472585,2020-11-14,2021-08-15,Interventional,Efficacy of Subcutaneous Ivermectin With or Without Zinc in COVID-19 Patients,Recruiting,Phase 1/Phase 2,Sheikh Zayed Federal Postgraduate Medical Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04472585,0,0,0,0,2,0,Pakistan,0,ivermectin|injectable placebo|zinc|placebo empty capsule|oral ivermectin,NA
NCT04463849,2020-06-30,2021-06-30,Interventional,Effects of COVID-19 Infection on Beta-cell Function in Euglycemic Patients,Recruiting,N/A,University of Milan,NA,https://clinicalzeros.gov/ct2/show/NCT04463849,0,0,0,0,1,0,Italy,0,stimulation test with arginine infusion in order to verify the possible existence of damage to the beta cell function induced by covid-19 infection,NA
NCT04733807,2021-01-28,2021-07-31,Observational,Antibodies Response to mRNA Vaccine Against Covid-19,Recruiting,NA,University of Roma La Sapienza,NA,https://clinicalzeros.gov/ct2/show/NCT04733807,0,0,0,0,1,0,Italy,0,bnt162b2 mrna covid-19 vaccine,NA
NCT04644198,2021-04-01,2021-12-01,Interventional,Convalescent Plasma Transfusion in Severe COVID-19 Patients in Jamaica,Recruiting,Phase 2,The University of The West Indies,NA,https://clinicalzeros.gov/ct2/show/NCT04644198,0,0,0,0,3,0,Jamaica,0,convalescent plasma infusion,NA
NCT04364828,2020-10-21,2022-04-30,Interventional,NGS Diagnostic in COVID-19 Hosts - Genetic Cause Relating to the Course of Disease Progression,Recruiting,N/A,University Hospital Tuebingen,NA,https://clinicalzeros.gov/ct2/show/NCT04364828,0,0,0,0,3,0,Germany,0,dalargin|t-cell receptor|sars-cov-2 viral composition,NA
NCT04386616,2020-06-02,2021-01-02,Interventional,A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia,Completed,Phase 2,"Genentech, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04386616,0,0,0,0,18,1,United States|Brazil|Mexico|Spain,0,mstt1041a|placebo|uttr1147a,NA
NCT04379076,2020-05-14,2021-10-30,Interventional,InterLeukin-7 (CYT107) to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection UK Cohort,Recruiting,Phase 2,Revimmune,NA,https://clinicalzeros.gov/ct2/show/NCT04379076,0,0,0,0,4,0,United Kingdom,0,interleukin|placebo,NA
NCT04346615,2020-04-25,2021-07-31,Interventional,Safety and Efficacy Trial of Zavegepant* Intranasal for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen,Recruiting,Phase 2/Phase 3,"Biohaven Pharmaceuticals, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04346615,0,0,0,0,13,1,United States,0,zavegepant (bhv-3500)|placebo,NA
NCT04760639,2020-12-16,2021-03-16,Observational,COVID Breath Test - Ancon,Recruiting,NA,Medical University of South Carolina,NA,https://clinicalzeros.gov/ct2/show/NCT04760639,0,0,0,0,0,1,United States,0,breath test,NA
NCT04760795,2020-11-15,2021-06-30,Observational,"Stress, Personality, Attachment and Coping During the Covid Crisis.",Recruiting,NA,Centre Hospitalier Universitaire de Saint Etienne,NA,https://clinicalzeros.gov/ct2/show/NCT04760795,0,0,0,0,0,0,France,0,ptsd check list (pcl) scale|brief cope scale|gad-7 (generalized anxiety disorder) scale (during containment)|analog scale|gad-7 (generalized anxiety disorder) scale (post containment)|big five inventory (bfi) scale|relationship scales questionnaire (rsq),NA
NCT04760743,2020-12-17,2021-04-30,Interventional,Safety and Immunogenicity of a SARS-CoV-2 Vaccine (NBP2001) in Healthy Adults (COVID-19),"Active, not recruiting",Phase 1,"SK Chemicals Co., Ltd.",NA,https://clinicalzeros.gov/ct2/show/NCT04760743,0,0,0,1,0,0,"Korea, Republic of",0,nbp2001 adjuvanted with alum (rbd 30î¼g/dose)|nbp2001 adjuvanted with alum (rbd 50î¼g/dose)|saline|nbp2001 adjuvanted with alum (rbd 30î¼g|dose)|nbp2001 adjuvanted with alum (rbd 50î¼g,NA
NCT04703608,2021-01-22,2022-03-31,Interventional,Prevention and Treatment for COVID -19 (Severe Acute Respiratory Syndrome Coronavirus 2 SARS-CoV-2) Associated Severe Pneumonia in the Gambia,Recruiting,Phase 3,London School of Hygiene and Tropical Medicine,NA,https://clinicalzeros.gov/ct2/show/NCT04703608,0,0,0,0,3,0,Gambia,0,ivermectin|asp|placebo,NA
NCT04750759,2021-02-03,2021-06-30,Interventional,Safety and Preliminary Efficacy of the Combination of Niclosamide and Camostat,Recruiting,Phase 2,CharitÃ© Research Organisation GmbH,NA,https://clinicalzeros.gov/ct2/show/NCT04750759,0,0,0,0,2,0,Germany,0,niclosamide / camostat|placebo|niclosamide|camostat,NA
NCT04758039,2020-03-13,2020-07-10,Observational [Patient Registry],Clinical Characteristics and In-hospital Death of a Chilean COVID-19 Prospective Cohort,Completed,NA,University of Chile,NA,https://clinicalzeros.gov/ct2/show/NCT04758039,0,0,0,0,1,0,Chile,0,"NA",NA
NCT04757298,2021-02-12,2022-01-30,Interventional,COVID-19 Treatment Cascade Optimization Study,Recruiting,N/A,University of Illinois at Urbana-Champaign,NA,https://clinicalzeros.gov/ct2/show/NCT04757298,0,0,0,0,1,1,United States,0,navigation services|critical dialogue|brief counseling|referral/digital brochure|referral|digital brochure,NA
NCT04756128,2021-01-25,2021-12-31,Interventional,Impact of Colchicine and Low-dose Naltrexone on COVID-19,Enrolling by invitation,Phase 2,HealthPartners Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04756128,0,0,0,0,1,1,United States,0,colchicine 0.6 mg|naltrexone,NA
NCT04698798,2021-01-02,2021-05-31,Interventional,Skeletal Muscle Wasting in SARS-CoV-2,Recruiting,N/A,Hasselt University,NA,https://clinicalzeros.gov/ct2/show/NCT04698798,0,0,0,0,2,0,Belgium,0,muscle biopsy,NA
NCT04692779,2021-01-31,2021-10-30,Observational,A Prospective Clinical Study to Explore Response to Prone Positioning in ARDS Patients,Recruiting,NA,Rush University Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04692779,0,0,0,0,2,1,United States,0,lung ultrasound (lus),NA
NCT04673292,2021-02-08,2021-08-31,Interventional,Community Collaboration to Combat COVID-19 (C-FORWARD),Enrolling by invitation,N/A,Johns Hopkins University,NA,https://clinicalzeros.gov/ct2/show/NCT04673292,0,0,0,0,2,1,United States,0,"fixed site standard of care testing|community-based, mobile van testing|self-collected, home-based testing",NA
NCT04498546,2020-07-20,2021-03-30,Observational [Patient Registry],Mask Usage and Exercise During the COVÄ°D-19 Pandemic,Recruiting,NA,KTO Karatay University,NA,https://clinicalzeros.gov/ct2/show/NCT04498546,0,0,0,0,2,0,Turkey,0,"NA",NA
NCT04649918,2020-11-25,2021-01-16,Observational,Short and Medium-term Effects of Pulmonary Rehabilitation in Mild to Critical Post-acute COVID-19,"Active, not recruiting",NA,SchÃ¶n Klinik Berchtesgadener Land,NA,https://clinicalzeros.gov/ct2/show/NCT04649918,0,0,0,0,1,0,Germany,0,pulmonary rehabilitation,NA
NCT04563247,2020-07-01,2021-02-08,Observational,Seroprevalence of SARS-CoV-2 in Asymptomatic Frontline COVID-19 HCWs,Completed,NA,Lahore General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04563247,0,0,0,0,2,0,Pakistan,0,igg sars cov 2 antibodies,NA
NCT04476953,2020-08-03,2021-07-31,Interventional,COVID-FISETIN: Pilot in SARS-CoV-2 of Fisetin to Alleviate Dysfunction and Inflammation,Enrolling by invitation,Phase 2,Mayo Clinic,NA,https://clinicalzeros.gov/ct2/show/NCT04476953,0,0,0,0,2,1,United States,0,placebo|fisetin,NA
NCT04473898,2020-06-19,2020-10-19,Interventional,Telerehabilitation After Coronavirus,Completed,N/A,KTO Karatay University,NA,https://clinicalzeros.gov/ct2/show/NCT04473898,0,0,0,0,2,0,Turkey,0,exercise|education,NA
NCT04477668,2021-02-08,2021-12-31,Interventional,Helmet Non-Invasive Ventilation for COVID-19 Patients,Recruiting,N/A,King Abdullah International Medical Research Center,NA,https://clinicalzeros.gov/ct2/show/NCT04477668,0,0,0,0,2,0,Saudi Arabia,0,helmet non-invasive ventilation,NA
NCT04425538,2020-06-01,2021-01-22,Interventional,A Phase 2 Trial of Infliximab in Coronavirus Disease 2019 (COVID-19).,Completed,Phase 2,Tufts Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04425538,0,0,0,0,2,1,United States,0,infliximab,NA
NCT04393142,2020-05-05,2021-02-16,Observational [Patient Registry],Serologic Testing of Household Contacts of Confirmed Cases of COVID-19,Completed,NA,Hospital Universitario Dr. Jose E. Gonzalez,NA,https://clinicalzeros.gov/ct2/show/NCT04393142,0,0,0,0,2,0,Mexico,0,"NA",NA
NCT04377789,2020-03-20,2020-07-31,Interventional,Effect of Quercetin on Prophylaxis and Treatment of COVID-19,Completed,N/A,Kanuni Sultan Suleyman Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04377789,0,0,0,0,5,0,Turkey,0,quercetin,NA
NCT04373811,2020-04-16,2021-07-13,Observational,One-Year Quality of Life and Functional Prognosis of COVID-19 Patients in Post-ICU Setting,"Active, not recruiting",NA,Groupe Hospitalier Paris Saint Joseph,NA,https://clinicalzeros.gov/ct2/show/NCT04373811,0,0,0,0,3,0,France,0,lung ultrasound|muscle,NA
NCT04412291,2020-06-11,2021-03-31,Interventional,"A Study in Patients With COVID-19 and Respiratory Distress Not Requiring Mechanical Ventilation, to Compare Standard-of-care With Anakinra and Tocilizumab Treatment The Immunomodulation-CoV Assessment (ImmCoVA) Study",Recruiting,Phase 2,Karolinska University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04412291,0,0,0,0,3,0,Sweden,0,anakinra|tocilizumab|standard care,NA
NCT04354584,2020-04-06,2021-04-06,Observational,Compartmental Inflammation in Mechanically Ventilated Patients With COVID-19,Recruiting,NA,Hvidovre University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04354584,0,0,0,0,1,0,Denmark,0,"NA",NA
NCT04331366,2020-04-08,2020-08-31,Interventional,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Completed,N/A,Emory University,NA,https://clinicalzeros.gov/ct2/show/NCT04331366,0,0,0,0,5,1,United States,1,go2 peep mouthpiece,NA
NCT04765436,2021-01-14,2021-04-30,Interventional,"PTX-COVID19-B, an mRNA Humoral Vaccine, is Intended for Prevention of COVID-19 in a General Population. This Study is Designed to Evaluate Safety, Tolerability, and Immunogenicity of PTX-COVID19-B Vaccine in Healthy Seronegative Adults Aged 18-64",Recruiting,Phase 1,Providence Therapeutics Holdings Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04765436,0,0,0,1,0,0,Canada,0,ptx-covid19-b|placebo,NA
NCT04765254,2021-02-20,2021-03-20,Observational,COVID-19 Infection in Diabetic Patients,Recruiting,NA,Cairo University,NA,https://clinicalzeros.gov/ct2/show/NCT04765254,0,0,0,0,0,0,Egypt,0,no intervention as it is an observational study,NA
NCT04764773,2020-05-01,2021-02-28,Observational,Persistence of Symptoms After Improvement of Acute COVID-19,Recruiting,NA,Sohag University,NA,https://clinicalzeros.gov/ct2/show/NCT04764773,0,0,0,0,0,0,Egypt,0,no intervention,NA
NCT04764981,2021-05-31,2022-05-31,Interventional,Olfactory Training for Olfactory Dysfunction After Coronavirus Disease - 19 (COVID-19),Enrolling by invitation,N/A,Universidade do Estado do ParÃ¡,NA,https://clinicalzeros.gov/ct2/show/NCT04764981,0,0,0,0,0,0,Brazil,0,essence oils,NA
NCT04764747,2020-11-01,2021-04-30,Observational,Effectiveness of Convalescent Plasma in Hospitalized Patients With COVID-19,Recruiting,NA,Kufa University,NA,https://clinicalzeros.gov/ct2/show/NCT04764747,0,0,0,0,0,0,Iraq,0,"NA",NA
NCT04763681,2021-01-01,2021-08-31,Interventional,Couple HOPES (Helping Overcome PTSD and Enhance Satisfaction),Recruiting,N/A,York University,NA,https://clinicalzeros.gov/ct2/show/NCT04763681,0,0,0,0,0,0,Canada,0,"couple hopes guided, internet-delivered, self-help intervention",NA
NCT04764032,2020-09-02,2021-03-31,Observational,Right Ventricular Dysfunction in Ventilated Patients With COVID-19,Recruiting,NA,University of Glasgow,NA,https://clinicalzeros.gov/ct2/show/NCT04764032,0,0,0,0,0,0,United Kingdom,0,echocardiography,NA
NCT04657809,2020-10-01,2021-02-18,Interventional,Clinical Assessment of Insulin Fast Dissolving Film in Treatment of Post Infection Anosmia,"Active, not recruiting",Phase 2,Deraya University,NA,https://clinicalzeros.gov/ct2/show/NCT04657809,0,0,0,0,2,0,Egypt,0,insulin film|fast dissolving film,NA
NCT04760821,2020-12-10,2021-04-30,Interventional,Prevention of Acute Myocardial Injury by Trimetazidine in Patients Hospitalized for COVID-19,Recruiting,Phase 2,"Ministry of Health, Brazil",NA,https://clinicalzeros.gov/ct2/show/NCT04760821,0,0,0,0,1,0,Brazil,0,trimetazidine,NA
NCT04763395,2021-01-29,2021-02-20,Observational,Liver Function Test Abnormalities in COVID-19,Recruiting,NA,Sohag University,NA,https://clinicalzeros.gov/ct2/show/NCT04763395,0,0,0,0,0,0,Egypt,0,no intervention,NA
NCT04756271,2021-02-11,2021-08-31,Interventional,Safety and Immunogenicity of Inactivated Vaccine Against COVID-19 Infection,Recruiting,Phase 3,Zagazig University,NA,https://clinicalzeros.gov/ct2/show/NCT04756271,0,0,0,1,1,0,Egypt,0,sars-cov-2 neutralizing antibody titer,NA
NCT04606732,2020-09-20,2021-12-31,Observational [Patient Registry],CardioVascular Disease Progression and Prognosis in COVID-19,Recruiting,NA,University of Bologna,NA,https://clinicalzeros.gov/ct2/show/NCT04606732,0,0,0,0,1,0,Italy,0,"NA",NA
NCT04600141,2020-11-10,2021-10-20,Interventional,Clinical Efficacy of Heparin and Tocilizumab in Patients With Severe COVID-19 Infection,Recruiting,Phase 3,University of Sao Paulo,NA,https://clinicalzeros.gov/ct2/show/NCT04600141,0,0,0,0,1,0,Brazil,0,tocilizumab|heparin - therapeutic dosage|heparin - prophylactic dosage,NA
NCT04483635,2021-02-08,2021-09-30,Interventional,PRevention of COVID-19 With Oral Vitamin D Supplemental Therapy in Essential healthCare Teams,Recruiting,Phase 3,St. Justine's Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04483635,0,0,0,0,2,0,Canada,0,placebo|vitamin d,NA
NCT04533347,2021-02-19,2021-06-08,Interventional,Tafenoquine in Patients With Mild to Moderate COVID-19,Recruiting,Phase 2,60 Degrees Pharmaceuticals LLC,NA,https://clinicalzeros.gov/ct2/show/NCT04533347,0,0,0,0,2,1,United States,0,tafenoquine oral tablet|placebo,NA
NCT04456153,2020-07-22,2021-01-31,Interventional,Atovaquone for Treatment of COVID-19,Completed,Phase 2,University of Texas Southwestern Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04456153,0,0,0,0,5,1,United States,0,experimental group|placebo,NA
NCT04426071,2020-06-01,2021-12-31,Observational,The Impact of a Societal Lockdown on Those With Spinal Cord and Brain Injuries,Recruiting,NA,Lawson Health Research Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04426071,0,0,0,0,1,0,Canada,0,"NA",NA
NCT04424212,2020-06-10,2021-06-30,Interventional,ICBT for Mental Health Problems Related to the Coronavirus Pandemic,"Active, not recruiting",N/A,Linkoeping University,NA,https://clinicalzeros.gov/ct2/show/NCT04424212,0,0,0,0,2,0,Sweden,0,intervention group coronacope,NA
NCT04395430,2020-09-18,2021-06-30,Interventional,A Novel School-clinic-community Online Model of Child Obesity Treatment in Singapore During COVID-19,Recruiting,N/A,KK Women's and Children's Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04395430,0,0,0,0,2,0,Singapore,0,standard care|online kkh sports singapore program with usual care,NA
NCT04411147,2020-06-17,2027-12-31,Observational,A Longitudinal Study of COVID-19 Sequelae and Immunity,Recruiting,NA,National Institutes of Health Clinical Center (CC),NA,https://clinicalzeros.gov/ct2/show/NCT04411147,0,0,0,0,15,1,United States,0,"NA",NA
NCT04408287,2020-09-15,2021-02-28,Interventional,Improving Activity Engagement Among Persons With SCI During COVID-19,Recruiting,N/A,Lawson Health Research Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04408287,0,0,0,0,2,0,Canada,0,webex physical activity program,NA
NCT04408040,2020-07-14,2024-07-31,Interventional,Use of Convalescent Plasma for COVID-19,Recruiting,Phase 2,"Northside Hospital, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04408040,0,0,0,0,2,1,United States,0,convalescent plasma,NA
NCT04367636,2020-04-30,2021-09-30,Interventional,The Effects of Attention Training on Emotion Regulation and Stress Related Complaints During COVID-19,Recruiting,N/A,University Ghent,NA,https://clinicalzeros.gov/ct2/show/NCT04367636,0,0,0,0,1,0,Belgium,0,ocat|psycho-education video,NA
NCT04361838,2020-05-21,2021-06-30,Interventional,The COVID-19 ICU PRAYER Study,Recruiting,N/A,Kansas City Heart Rhythm Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04361838,0,0,0,0,2,1,United States,0,prayer,NA
NCT04803370,2020-07-08,2021-09-01,Interventional,Efficacy of Reinforcing Standard Therapy in COVID-19 Patients With Repeated Transfusion of Convalescent Plasma,Recruiting,N/A,Hospital Son Llatzer,NA,https://clinicalzeros.gov/ct2/show/NCT04803370,0,0,0,0,0,0,Spain,0,convalescent plasma with antibody against sars-cov-2.|standard care,NA
NCT04803227,2021-03-11,2021-04-30,Interventional,Safety and Tolerability of Emricasan in Symptomatic Outpatients Diagnosed With Mild-COVID-19,Recruiting,Phase 1,Histogen,NA,https://clinicalzeros.gov/ct2/show/NCT04803227,0,0,0,0,0,1,United States,0,emricasan|placebo,NA
NCT04802187,2020-12-01,2022-08-31,Interventional,Implementation of SARS-CoV Testing Strategies in Community Health Centers,Recruiting,N/A,Massachusetts General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04802187,0,0,0,0,0,1,United States,0,radx chcs testing intervention strategy|usual care control,NA
NCT04802642,2021-01-01,2021-03-01,Observational,"Evaluation of COVID-19 Fear, Anxiety and Their Effects in Physiotherapy Technician Students",Completed,NA,Ufuk University,NA,https://clinicalzeros.gov/ct2/show/NCT04802642,0,0,0,0,0,0,Turkey,0,questionnaire,NA
NCT04801836,2020-11-19,2021-06-30,Interventional,Estetrol (E4) for the Treatment of Patients With Confirmed SARS-COV-2 Infection,Recruiting,Phase 2,NEURALIS s.a.,NA,https://clinicalzeros.gov/ct2/show/NCT04801836,0,0,0,0,0,0,Belgium|Hungary|Poland|Russian Federation,0,estetrol monohydrate 15 mg|placebo,NA
NCT04802044,2020-12-08,2022-02-28,Observational,"COVID-19, Aging, and Cardiometabolic Risk Factors Study",Recruiting,NA,Indonesia University,NA,https://clinicalzeros.gov/ct2/show/NCT04802044,0,0,0,0,0,0,Indonesia,0,"NA",NA
NCT04800770,2021-03-03,2021-06-15,Observational [Patient Registry],The Effect of COVID-19 Patients' Serum Phosphate Level on Mortality in ICU,Recruiting,NA,Ankara City Hospital Bilkent,NA,https://clinicalzeros.gov/ct2/show/NCT04800770,0,0,0,0,0,0,Turkey,0,4c mortality score,NA
NCT04797624,2021-01-15,2021-02-15,Observational,Does Coronavirus Disease 2019 (COVID-19) Pandemic Cause a Delay in the Diagnosis of Gastric Cancer Patients?,Completed,NA,Adana City Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04797624,0,0,0,0,0,0,Turkey,0,gastric cancer surgery,NA
NCT04800146,2021-02-25,2022-06-30,Observational,A Study on the Immune-response to COVID-19 Vaccination in Cancer Patients - the IOSI-COVID-19-001 Study,Recruiting,NA,Oncology Institute of Southern Switzerland,NA,https://clinicalzeros.gov/ct2/show/NCT04800146,0,0,0,0,0,0,Switzerland,0,blood sample,NA
NCT04800120,2021-02-15,2021-12-31,Interventional,Use of Hyperbaric Oxygen Therapy to Treat COVID-19 Patients With Respiratory Distress,Recruiting,N/A,"Steward St. Elizabeth's Medical Center of Boston, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04800120,0,0,0,0,0,1,United States,0,oxygen,NA
NCT04799704,2020-09-11,2020-12-13,Observational,Tear Film SARS-nCoV-2 Detection in Symptomatic and Pauci-symptomatic Patients.,Completed,NA,Universitaire Ziekenhuizen Leuven,NA,https://clinicalzeros.gov/ct2/show/NCT04799704,0,0,0,0,0,0,Belgium,0,swabbing of conjunctiva,NA
NCT04799652,2021-01-15,2021-04-30,Observational,Are Surgeons Ready to Get the COVID-19 Vaccine?,Recruiting,NA,Brugmann University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04799652,0,0,0,0,0,0,Belgium,0,questionnaire,NA
NCT04797936,2020-05-01,2020-12-19,Interventional,BNO 1030 Extract (Imupret) in the Treatment of Mild Forms of COVID-19,Completed,Phase 4,Ivano-Frankivsk National Medical University,NA,https://clinicalzeros.gov/ct2/show/NCT04797936,0,0,0,0,0,0,Ukraine,0,bno 1030|standard care,NA
NCT04797871,2021-03-08,2022-03-15,Interventional,Resistance Training and Clinical Status in Patients With Post Discharge Symptoms After Covid-19,Enrolling by invitation,N/A,Universidad PÃºblica de Navarra,NA,https://clinicalzeros.gov/ct2/show/NCT04797871,0,0,0,0,0,0,Spain,0,resistance training|standard care,NA
NCT04828460,2021-02-09,2021-06-30,Observational,Monitoring of COVID-19 Vaccine Response in Organ Transplant Patients,Recruiting,NA,"University Hospital, Strasbourg, France",NA,https://clinicalzeros.gov/ct2/show/NCT04828460,0,0,0,0,0,0,France,0,"NA",NA
NCT04799873,2020-04-08,2020-12-01,Observational,Alpha-1-Antitrypsin-Deficiency in COVID-19,Completed,NA,UniversitÃ¤t des Saarlandes,NA,https://clinicalzeros.gov/ct2/show/NCT04799873,0,0,0,0,0,0,Germany,0,aat( alpha 1 antitrypsin),NA
NCT04799834,2020-11-30,2021-10-31,Observational,Genotype and Susceptibility to COVID-19,Recruiting,NA,Mario Negri Institute for Pharmacological Research,NA,https://clinicalzeros.gov/ct2/show/NCT04799834,0,0,0,0,0,0,Italy,0,"questionnaire administration,blood sampling/genetic analyses.|questionnaire administration,blood sampling|genetic analyses.",NA
NCT04799808,2021-01-15,2022-07-15,Observational,"Saxon SARS-CoV-2 Infection and Vaccination Study in Dialysis Patients, Solid Organ Recipients and Staff",Recruiting,NA,Technische UniversitÃ¤t Dresden,NA,https://clinicalzeros.gov/ct2/show/NCT04799808,0,0,0,0,0,0,Germany,0,"NA",NA
NCT04799444,2020-10-01,2022-06-30,Observational [Patient Registry],LATE-COVID/LATE-COVID-Kids - Observational Study in Children and Adults,Recruiting,NA,Polish Mother Memorial Hospital Research Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04799444,0,0,0,0,0,0,Poland,0,"NA",NA
NCT04799132,2020-03-11,2021-03-01,Observational,Association Between Body Mass Index and HFNC Therapy Success,Completed,NA,ClÃ­nica del country,NA,https://clinicalzeros.gov/ct2/show/NCT04799132,0,0,0,0,0,0,Colombia,0,"NA",NA
NCT04798625,2021-02-15,2026-02-15,Observational,Vaccine Response to COVID-19 Vaccines in Patients Using Immunosuppressive Medication,Recruiting,NA,Diakonhjemmet Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04798625,0,0,0,0,0,0,Norway,0,"NA",NA
NCT04798599,2020-12-01,2021-06-30,Interventional,Information and Communication Technologies (ICTS) in Dentistry for SUS,Recruiting,N/A,University of Sao Paulo,NA,https://clinicalzeros.gov/ct2/show/NCT04798599,0,0,0,0,0,0,Brazil,0,telemonitoring/teleorientation|control group - waiting list|telemonitoring|teleorientation,NA
NCT04796064,2020-03-30,2020-11-05,Interventional,Low Versus High-Intensity Aerobic Training in Community-dwelling Older Men With Post-COVID 19 (SARS-CoV-2) Sarcopenia,Completed,N/A,Cairo University,NA,https://clinicalzeros.gov/ct2/show/NCT04796064,0,0,0,0,0,0,Egypt,0,low-intensity aerobic training,NA
NCT04794998,2021-02-08,2021-03-30,Observational,A Simple Approach to Treat COVID-19 Patients at Home.,Recruiting,NA,Mario Negri Institute for Pharmacological Research,NA,https://clinicalzeros.gov/ct2/show/NCT04794998,0,0,0,0,0,0,Italy,0,recommended treatment schedule|control treatment schedule,NA
NCT04793984,2021-03-08,2021-06-30,Interventional,Efficacy and Safety Evaluation of Inhaleen Inhalation in Hospitalized COVID-19 Patients,Recruiting,N/A,Marinomed Biotech AG,NA,https://clinicalzeros.gov/ct2/show/NCT04793984,0,0,0,0,0,0,Austria,0,carragelose|sodium,NA
NCT04794803,2020-05-05,2020-11-30,Interventional,Reparixin in COVID-19 Pneumonia - Efficacy and Safety,Terminated,Phase 2/Phase 3,DompÃ© Farmaceutici S.p.A,"The sponsor has decided to start with a separate protocol for phase 3 and therefore this study
    was terminated with only phase 2.",https://clinicalzeros.gov/ct2/show/NCT04794803,0,0,0,0,1,0,Brazil|Italy,0,reparixin|standard care,NA
NCT04794920,2020-07-10,2020-10-03,Observational,Post-Covid-19 Emotional Aspects of Hospital Staff,"Active, not recruiting",NA,Groupe Hospitalier Paris Saint Joseph,NA,https://clinicalzeros.gov/ct2/show/NCT04794920,0,0,0,0,0,0,France,0,"NA",NA
NCT04794387,2021-02-23,2031-02-23,Observational [Patient Registry],The Lymphoma and Leukemia Society COVID-19 Registry,Recruiting,NA,Lymphoma and Leukemia Society,NA,https://clinicalzeros.gov/ct2/show/NCT04794387,0,0,0,0,0,1,United States,0,observational study: this registry data will provide more specific information about how people with blood cancer respond to covid-19 virus and/or a covid-19 vaccination.|observational study: this registry data will provide more specific information about how people with blood cancer respond to covid-19 virus and|or a covid-19 vaccination.,NA
NCT04794374,2020-11-16,2022-01-16,Interventional,Effects of Telerehabilitation After Discharge in COVID-19 Survivors,Recruiting,N/A,Hacettepe University,NA,https://clinicalzeros.gov/ct2/show/NCT04794374,0,0,0,0,1,0,Turkey,0,telehealth,NA
NCT04794361,2020-03-05,2020-05-05,Observational,Management of Patients Suspected of COVID 19 With Ultra Low Dose Thoracic Scanner,Completed,NA,Centre Hospitalier Universitaire de NÄ«mes,NA,https://clinicalzeros.gov/ct2/show/NCT04794361,0,0,0,0,0,0,France,0,"NA",NA
NCT04791085,2021-02-08,2021-05-08,Observational,Investigation of Stress Levels and Lifestyle of a Sample of Greek General Surgeons in Covid-19,Recruiting,NA,National and Kapodistrian University of Athens,NA,https://clinicalzeros.gov/ct2/show/NCT04791085,0,0,0,0,0,0,Greece,0,"NA",NA
NCT04792021,2021-03-09,2021-06-30,Interventional,Effect of N-acetylcysteine on Oxidative Stress in COVID-19 Patients,Recruiting,Phase 3,Ain Shams University,NA,https://clinicalzeros.gov/ct2/show/NCT04792021,0,0,0,0,0,0,Egypt,0,n-acetylcysteine,NA
NCT04791241,2021-03-03,2021-05-03,Interventional,A Check-list Including Lung Ultrasound for ED Patients With ARF,Recruiting,N/A,Centre Hospitalier Metropole Savoie,NA,https://clinicalzeros.gov/ct2/show/NCT04791241,0,0,0,0,0,0,France,0,check-list including lung ultrasound,NA
NCT04794062,2020-09-16,2021-03-31,Observational,Myocardial Injury and Quality of Life After COVID-19,Recruiting,NA,Voronezh Regional Clinical Consultative and Diagnostic Center,NA,https://clinicalzeros.gov/ct2/show/NCT04794062,0,0,0,0,0,0,Russian Federation,0,"NA",NA
NCT04793997,2021-02-01,2022-02-01,Interventional,Microbiome Therapy in Covid-19 Primary Care Support,Recruiting,N/A,"University Hospital, Antwerp",NA,https://clinicalzeros.gov/ct2/show/NCT04793997,0,0,0,0,0,0,Belgium,0,microbiome spray|placebo spray,NA
NCT04793269,2021-02-23,2023-12-31,Observational,Characteristics of Long COVID-19 Syndrome,Recruiting,NA,University of Zurich,NA,https://clinicalzeros.gov/ct2/show/NCT04793269,0,0,0,0,0,0,Switzerland,0,no intervention,NA
NCT04793243,2020-08-17,2020-10-10,Interventional,Vitamin D3 Levels in COVID-19 Outpatients From Western Mexico,Completed,N/A,University of Guadalajara,NA,https://clinicalzeros.gov/ct2/show/NCT04793243,0,0,0,0,0,0,Mexico,0,vitamin d,NA
NCT04792086,2021-02-18,2023-11-01,Observational,Disease Containment Measures Among Older Adults During the Covid-19 Pandemia,Recruiting,NA,Norwegian Centre for Ageing and Health,NA,https://clinicalzeros.gov/ct2/show/NCT04792086,0,0,0,0,0,0,Norway,0,"NA",NA
NCT04790851,2021-02-23,2021-10-31,Interventional,Evaluation of Immunogenicity and Safety of Combined Immunization of COVIV and PPV23 / IIV4,Recruiting,Phase 4,China National Biotec Group Company Limited,NA,https://clinicalzeros.gov/ct2/show/NCT04790851,0,0,0,1,1,0,China,0,coviv/iiv4; coviv/ppv23|coviv only (1st/2nd dose)|iiv4 for the 1st dose/ppv23 for the 2nd dose|coviv|iiv4; coviv|ppv23|coviv only (1st|2nd dose)|iiv4 for the 1st dose|ppv23 for the 2nd dose,NA
NCT04790994,2020-07-24,2020-10-16,Observational,COVID-19 Prevalence in UNIVI Geriatric Institutions: Epidemiological Study of Immunological Status With Rapid Serological Tests,"Active, not recruiting",NA,Centre MÃ©dical Porte Verte,NA,https://clinicalzeros.gov/ct2/show/NCT04790994,0,0,0,0,0,0,France,0,"NA",NA
NCT04790240,2021-02-01,2022-12-31,Interventional,Medical Herbs Inhibit Inflammation Directing T Cells to Kill the COVID-19 Virus (COVID),Recruiting,Phase 1/Phase 2,"All Natural Medicine Clinic, LLC",NA,https://clinicalzeros.gov/ct2/show/NCT04790240,0,0,0,0,0,1,United States,0,inflammation (i)|inflammation (ii)|inflammation (iii)|standard care,NA
NCT04776044,2021-03-31,2021-12-31,Interventional,Clinical Trial to Evaluate the Safety and Efficacy of ATR-002 in Adult Hospitalized Patients With COVID-19,Recruiting,Phase 2,Atriva Therapeutics GmbH,NA,https://clinicalzeros.gov/ct2/show/NCT04776044,0,0,0,0,2,0,Germany|India|Netherlands|South Africa|Spain,0,atr-002|placebo,NA
NCT04789525,2020-03-10,2020-10-01,Interventional,Physical Training and Diet for Childhood Obesity,Completed,N/A,Cairo University,NA,https://clinicalzeros.gov/ct2/show/NCT04789525,0,0,0,0,1,0,Egypt,0,high-intensity aerobic training with high protein diet,NA
NCT04788459,2021-02-25,2021-09-30,Interventional,"Safety and Immunogenicity of COVID-eVax, a Candidate Plasmid DNA Vaccine for COVID-19, in Healthy Adult Volunteers",Recruiting,Phase 1/Phase 2,Takis,NA,https://clinicalzeros.gov/ct2/show/NCT04788459,0,0,0,1,1,0,Italy,0,covid-evax|cliniporatorâ®/epsgun|cliniporatorâ®|epsgun,NA
NCT04788407,2020-12-01,2021-04-30,Interventional,Efficacy and Safety of Nitazoxanide for Post Exposure Prophylaxis of COVID-19 in Household Contacts,Recruiting,Phase 4,FundaciÃ³n HuÃ©sped,NA,https://clinicalzeros.gov/ct2/show/NCT04788407,0,0,0,0,1,0,Argentina,0,nitazoxanide|placebo,NA
NCT04788394,2021-03-01,2021-12-31,Observational,Renal Involvement in Hospitalized Children With COVID-19,Recruiting,NA,Hamad Medical Corporation,NA,https://clinicalzeros.gov/ct2/show/NCT04788394,0,0,0,0,1,0,Qatar,0,to determine the prevalence of renal dysfunction in hospitalized children with covid19 in qatar.,NA
NCT04786301,2020-04-30,2022-01-31,Observational,Severe Acute Respiratory Infection - Preparedness (COVID-19 and Influenza),Recruiting,NA,University of Washington,NA,https://clinicalzeros.gov/ct2/show/NCT04786301,0,0,0,0,1,1,United States,0,"NA",NA
NCT04786249,2021-02-24,2021-02-26,Observational,Impact of Rapid Screening for COVID-19 in Delocalized Biology in the Emergency Department,Recruiting,NA,Groupe Hospitalier Paris Saint Joseph,NA,https://clinicalzeros.gov/ct2/show/NCT04786249,0,0,0,0,1,0,France,0,"NA",NA
NCT04786197,2020-12-17,2021-06-16,Observational,Detection of SARS-CoV-2 (COVID-19) by SERS Spectroscopy Combined With Artificial Intelligence,Recruiting,NA,Groupe Hospitalier Paris Saint Joseph,NA,https://clinicalzeros.gov/ct2/show/NCT04786197,0,0,0,0,1,0,France,0,"NA",NA
NCT04779047,2020-10-01,2021-03-10,Interventional,Comparative Therapeutic Efficacy and Safety of Different Antiviral and Anti Inflammatory Drugs in COVID-19 Patients.,Recruiting,Phase 4,October 6 University,NA,https://clinicalzeros.gov/ct2/show/NCT04779047,0,0,0,0,2,0,Egypt,0,remdesivir|hydroxychloroquine|tocilizumab|lopinavir/ ritonavir|ivermectin|lopinavir|ritonavir,NA
NCT04780672,2021-03-09,2021-08-19,Interventional,Clinical Study in the Treatment of Patients With COVID-19,Recruiting,Phase 3,Pharma VAM,NA,https://clinicalzeros.gov/ct2/show/NCT04780672,0,0,0,0,1,0,Russian Federation,0,molixan|placebo,NA
NCT04775134,2021-01-31,2022-01-31,Observational,Residual SARS-CoV-2 Presence in the Respiratory Tract and Lung Parenchyma (After SARS-CoV-2 Infection or COVID-19),Recruiting,NA,Universitaire Ziekenhuizen Leuven,NA,https://clinicalzeros.gov/ct2/show/NCT04775134,0,0,0,0,1,0,Belgium,0,lung biopsy,NA
NCT04780425,2021-01-26,2021-05-22,Interventional,"Structured Diabetes Self-Management Education and Care Outcomes in Adults liVIng With Type 2 Diabetes in Accra, Ghana","Active, not recruiting",N/A,"Korle-Bu Teaching Hospital, Accra, Ghana",NA,https://clinicalzeros.gov/ct2/show/NCT04780425,0,0,0,0,1,0,Ghana,0,desmond|standard care,NA
NCT04750720,2020-08-27,2023-12-31,Interventional,Study of the Kinetics of COVID-19 Antibodies for 24 Months in Patients With Confirmed SARS-CoV-2 Infection,Recruiting,N/A,Centre Hospitalier RÃ©gional d'OrlÃ©ans,NA,https://clinicalzeros.gov/ct2/show/NCT04750720,0,0,0,0,3,0,France,0,sampling by venipuncture (and eventually by nasopharyngeal swab),NA
NCT04757272,2020-05-01,2021-03-30,Observational,Does Hepatitis C Management Protect Egyptian Population Against Severe Corona Virus Disease-2019?,Recruiting,NA,Zagazig University,NA,https://clinicalzeros.gov/ct2/show/NCT04757272,0,0,0,0,1,0,Egypt,0,"NA",NA
NCT04746339,2021-03-04,2021-08-31,Interventional,Apixaban for PrOphyLaxis of thromboemboLic Outcomes in COVID-19,Recruiting,Phase 4,Brazilian Clinical Research Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04746339,0,0,0,0,1,0,Brazil,0,apixaban 2.5 mg|placebo,NA
NCT04733105,2020-11-19,2021-11-20,Observational,Pronostic Value of Type I ANTi-Interferon Antibodies in Patients With COVID-19 Acute Respiratory Failure,Recruiting,NA,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04733105,0,0,0,0,1,0,France,0,"NA",NA
NCT04738045,2020-11-01,2021-03-28,Interventional,Comparison of Remdesivir Versus Lopinavir/ Ritonavir and Remdesivir Combination in COVID-19 Patients,Recruiting,Phase 4,October 6 University,NA,https://clinicalzeros.gov/ct2/show/NCT04738045,0,0,0,0,2,0,Egypt,0,remdesivir|lopinavir/ ritonavir/remdesivir combination|lopinavir|ritonavir|remdesivir combination,NA
NCT04732663,2021-03-04,2023-02-28,Observational,Understanding Exertional Dyspnea and Exercise Intolerance in COVID-19,Recruiting,NA,University of Alberta,NA,https://clinicalzeros.gov/ct2/show/NCT04732663,0,0,0,0,1,0,Canada,0,no intervention,NA
NCT04698993,2021-02-12,2021-03-31,Interventional,DrÃ¤ger COVID-19 Antigen Test Clinical Performance Study,Recruiting,N/A,DrÃ¤gerwerk AG & Co. KGaA,NA,https://clinicalzeros.gov/ct2/show/NCT04698993,0,0,0,0,1,0,Germany,0,drã¤ger antigen test sars-cov-2|drã¤ger antigen test sars-cov-2,NA
NCT04723459,2021-01-23,2021-02-19,Interventional,Efficacy of Nano-Ivermectin Impregnated Masks in Prevention of Covid-19 Among Healthy Contacts and Medical Staff,Recruiting,N/A,South Valley University,NA,https://clinicalzeros.gov/ct2/show/NCT04723459,0,0,0,0,3,0,Egypt,0,ivermectin impregnated mask,NA
NCT04713111,2020-05-04,2020-11-30,Interventional,Stress and Recovery in Frontline COVID-19 Workers,Completed,N/A,4YouandMe,NA,https://clinicalzeros.gov/ct2/show/NCT04713111,0,0,0,0,1,1,United States,0,lifestyle (meditation)|lifestyle (exercise),NA
NCT04727775,2020-11-25,2021-01-25,Interventional,Antiviral Drugs on the Treatment of SARS-CoV-2,Recruiting,Phase 1,Astana Medical University,NA,https://clinicalzeros.gov/ct2/show/NCT04727775,0,0,0,0,1,0,Kazakhstan,0,favipiravir|remdesivir,NA
NCT04716569,2021-01-20,2021-02-20,Interventional,Evaluation of Ivermectin Mucoadhesive Nanosuspension as Nasal Spray in Management of Early Covid-19,Recruiting,Phase 2/Phase 3,South Valley University,NA,https://clinicalzeros.gov/ct2/show/NCT04716569,0,0,0,0,7,0,Egypt,0,intranasal ivermectin spray,NA
NCT04715932,2021-02-18,2021-05-31,Interventional,Study of Hesperidin Therapy on COVID-19 Symptoms (HESPERIDIN),Recruiting,Phase 2,Montreal Heart Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04715932,0,0,0,0,3,0,Canada,0,hesperidin|placebo,NA
NCT04710303,2021-03-02,2022-04-30,Interventional,COVID-19 Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenoviral Platform in Healthy South African Adults,Recruiting,Phase 1,"ImmunityBio, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04710303,0,0,0,1,4,0,South Africa,0,had5-s-fusion/n-etsd vaccine|had5-s-fusion|n-etsd vaccine,NA
NCT04686721,2020-12-20,2021-09-30,Observational [Patient Registry],Observational Study for the Evaluation of Tracheal Stenosis in COVID-19 Patients,Recruiting,NA,Istituto Clinico Humanitas,NA,https://clinicalzeros.gov/ct2/show/NCT04686721,0,0,0,0,2,0,Italy,0,chest ct scan / baseline spirometry|chest ct|baseline spirometry,NA
NCT04689464,2020-12-01,2021-05-28,Observational,COVID 19 and Psychological Health: a Cross Sectional Study to Evaluate Anxiety and Depression in Covid-19 Patients,Recruiting,NA,AlFayhaa General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04689464,0,0,0,0,1,0,Iraq,0,"NA",NA
NCT04684433,2020-04-14,2021-03-15,Observational,Surgery in the Time of COVID-19 Pandemic,Completed,NA,Brugmann University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04684433,0,0,0,0,2,0,Belgium,0,data extraction from medical files,NA
NCT04659252,2021-03-04,2021-12-01,Observational,CORONADO (Circulating tumOur pROtein quaNtification cApillary blooD cOvid-19),Recruiting,NA,"Institute of Cancer Research, United Kingdom",NA,https://clinicalzeros.gov/ct2/show/NCT04659252,0,0,0,0,1,0,United Kingdom,0,n/a - samples collected along routine care samples only|n|a - samples collected along routine care samples only,NA
NCT04663737,2020-12-03,2021-05-31,Interventional,"Evaluating Safety, Pharmacokinetics and Clinical Benefit of Silmitasertib (CX-4945) in Subjects With Moderate COVID-19",Recruiting,Phase 2,"Senhwa Biosciences, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04663737,0,0,0,0,3,1,United States,0,silmitasertib|standard care,NA
NCT04661540,2021-03-02,2021-05-31,Interventional,A Study of Auxora in Patients With Critical COVID-19 Pneumonia,Recruiting,Phase 2,"CalciMedica, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04661540,0,0,0,0,2,1,United States,0,cm4620-ie (injectable emulsion)|placebo,NA
NCT04681040,2020-12-19,2022-03-31,Observational,Risk Stratification of COVID-19 Using Urine Biomarkers,Recruiting,NA,"National Center for Global Health and Medicine, Japan",NA,https://clinicalzeros.gov/ct2/show/NCT04681040,0,0,0,0,2,1,United States|Brazil|Denmark|Japan|Philippines,0,"NA",NA
NCT04667247,2020-12-03,2021-06-01,Interventional,Mushroom-based Product for COVID-19,Recruiting,Phase 1/Phase 2,"University of California, San Diego",NA,https://clinicalzeros.gov/ct2/show/NCT04667247,0,0,0,0,1,1,United States,0,fotv,NA
NCT04666441,2020-12-15,2021-03-04,Interventional,COVID-19 Study Assessing the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Adult Outpatients With SARS-CoV-2 Infection,"Active, not recruiting",Phase 2,Regeneron Pharmaceuticals,NA,https://clinicalzeros.gov/ct2/show/NCT04666441,0,0,0,0,2,1,United States,0,regn10933/regn10987 combination therapy|placebo|regn10933|regn10987,NA
NCT04657471,2020-12-08,2021-03-08,Interventional,Hospitalization or Outpatient ManagEment of Patients With SRAS-CoV-2 Infection - Revised HOME-CoV Score Study,Completed,N/A,"University Hospital, Angers",NA,https://clinicalzeros.gov/ct2/show/NCT04657471,0,0,0,0,3,0,France,0,revised home-cov score,NA
NCT04657497,2020-11-09,2021-05-31,Interventional,A Study of FOY-305 in Patients With SARS-Cov-2 Infection (COVID-19),Recruiting,Phase 3,Ono Pharmaceutical Co. Ltd,NA,https://clinicalzeros.gov/ct2/show/NCT04657497,0,0,0,0,1,0,Japan,0,foy-305|placebo,NA
NCT04627675,2020-12-30,2021-05-31,Interventional,CORVax12: SARS-CoV-2 Spike (S) Protein Plasmid DNA Vaccine Trial for COVID-19 (SARS-CoV-2),"Active, not recruiting",Phase 1,Providence Health & Services,NA,https://clinicalzeros.gov/ct2/show/NCT04627675,0,0,0,1,2,1,United States,0,corvax|il-12 plasmid|cliniporator,NA
NCT04644120,2020-12-10,2021-09-05,Interventional,Study to Assess Adverse Events and How Intravenous (IV) ABBV-47D11 and IV ABBV-2B04 Given Alone and in Combination Moves Through the Body of Adult Participants With Coronavirus Disease 2019 (COVID-19),Recruiting,Phase 1,AbbVie,NA,https://clinicalzeros.gov/ct2/show/NCT04644120,0,0,0,0,4,1,United States|Hungary|Israel|Netherlands|Puerto Rico,0,abbv-47d11|placebo for abbv-47d11|abbv-2b04|placebo for abbv-2b04,NA
NCT04637906,2020-11-18,2021-04-18,Interventional,Short and Long-term Effects of Adding Oral L-arginine to Standard Therapy in Patients With COVID-19 (SARS-CoV-2),Recruiting,N/A,"University of Campania ""Luigi Vanvitelli""",NA,https://clinicalzeros.gov/ct2/show/NCT04637906,0,0,0,0,3,0,Italy,0,bioargininaâ®|bioargininaâ®,NA
NCT04619719,2021-03-15,2021-06-15,Interventional,Hyperbaric Oxygen for COVID-19 Patients With Moderate to Severe Hypoxemia,Recruiting,N/A,Legacy Health System,NA,https://clinicalzeros.gov/ct2/show/NCT04619719,0,0,0,0,6,1,United States,0,hyperbaric oxygen,NA
NCT04578132,2020-11-24,2021-06-30,Observational,Description of the Population With Genitourinary Tumors and COVID-19,Recruiting,NA,Spanish Oncology Genito-Urinary Group,NA,https://clinicalzeros.gov/ct2/show/NCT04578132,0,0,0,0,9,0,Spain,0,"NA",NA
NCT04621123,2020-10-30,2021-06-15,Interventional,Plasma for Early Treatment in Non-hospitalised Mild or Moderate COVID-19 Patients,Recruiting,Phase 2,"FundaciÃ³n FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la PromociÃ³n de la Salud y la Ciencia",NA,https://clinicalzeros.gov/ct2/show/NCT04621123,0,0,0,0,1,0,Spain,0,convalescent plasma|control,NA
NCT04604223,2021-01-18,2021-06-29,Interventional,Effect of Pioglitazone on T2DM Patients With COVID-19,Recruiting,Phase 4,Dasman Diabetes Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04604223,0,0,0,0,1,0,Kuwait|Qatar,0,pioglitazone 45 mg,NA
NCT04545008,2020-10-20,2021-09-30,Interventional,Trial of Famotidine & N-Acetyl Cysteine for Outpatients With COVID-19,Recruiting,Phase 1,Prisma Health-Upstate,NA,https://clinicalzeros.gov/ct2/show/NCT04545008,0,0,0,0,1,1,United States,0,famotidine|n-acetyl cysteine,NA
NCT04568044,2020-09-16,2022-12-31,Observational,Evaluation of Humoral Immunity Following COVID-19 in Pregnancy,Recruiting,NA,Imperial College London,NA,https://clinicalzeros.gov/ct2/show/NCT04568044,0,0,0,0,1,0,United Kingdom,0,blood sample,NA
NCT04575038,2020-11-19,2021-04-28,Interventional,CRISIS2: A Phase 2 Study of the Safety and Antiviral Activity of Brequinar in Non-hospitalized Pts With COVID-19,"Active, not recruiting",Phase 2,"Clear Creek Bio, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04575038,0,0,0,0,9,1,United States,0,brequinar|placebo,NA
NCT04568031,2020-08-23,2021-11-15,Interventional,Study of AZD1222 for the Prevention of COVID-19 in Japan,"Active, not recruiting",Phase 1/Phase 2,AstraZeneca,NA,https://clinicalzeros.gov/ct2/show/NCT04568031,0,0,0,1,4,0,Japan,0,azd1222|0.9% (w/v) saline|0.9% (w|v) saline,NA
NCT04565379,2020-09-25,2021-04-30,Interventional,Clinical Trial to Investigate the Efficacy and Safety of NuSepinÂ® in COVID-19 Pneumonia Patients,Recruiting,Phase 2,Shaperon,NA,https://clinicalzeros.gov/ct2/show/NCT04565379,0,0,0,0,3,0,Romania,0,nusepinâ® 0.1 mg|nusepinâ® 0.2 mg|placebo|nusepinâ® 0.1 mg|nusepinâ® 0.2 mg,NA
NCT04550390,2020-09-15,2020-10-19,Observational,Study of the Analytical Performance of Different Salivary Self-collection Methods for the Detection of COVID-19,Completed,NA,Direction Centrale du Service de SantÃ© des ArmÃ©es,NA,https://clinicalzeros.gov/ct2/show/NCT04550390,0,0,0,0,3,0,France,0,saliva,NA
NCT04525820,2020-12-15,2021-05-31,Interventional,"High Dose Vitamin-D Substitution in Patients With COVID-19: a Randomized Controlled, Multi Center Study",Recruiting,N/A,"Cantonal Hosptal, Baselland",NA,https://clinicalzeros.gov/ct2/show/NCT04525820,0,0,0,0,3,0,Switzerland,0,single high dose vitamin d|placebo|treatment as usual vitamin d,NA
NCT04539626,2020-10-01,2021-07-31,Interventional,Estrogen Therapy in Non-severe COVID-19 Patients,Recruiting,N/A,"CMN ""20 de Noviembre""",NA,https://clinicalzeros.gov/ct2/show/NCT04539626,0,0,0,0,2,0,Mexico,0,estrogen therapy,NA
NCT04536935,2020-11-30,2021-04-30,Interventional,Mobile Mental Health Apps for Suicide Prevention,Enrolling by invitation,N/A,University of Washington,NA,https://clinicalzeros.gov/ct2/show/NCT04536935,0,0,0,0,3,1,United States,0,mobile mental health app - 1|mobile mental health app - 2|mobile mental health app - 3|mobile mental health app - 4,NA
NCT04508075,2020-08-10,2021-01-09,Interventional,"Efficacy, Safety and Immunogenicity Study of SARS-CoV-2 Inactivated Vaccine","Active, not recruiting",Phase 3,PT Bio Farma,NA,https://clinicalzeros.gov/ct2/show/NCT04508075,0,0,0,1,2,0,Indonesia,0,inactivated vaccine|placebo,NA
NCT04507230,2020-08-07,2020-10-31,Observational,COVID-19 Associated Coagulopathy in Egypt,Completed,NA,Assiut University,NA,https://clinicalzeros.gov/ct2/show/NCT04507230,0,0,0,0,3,0,Egypt,0,"NA",NA
NCT04506268,2020-09-09,2020-10-30,Interventional,COVID-19 SAFE Enrollment,Completed,N/A,University of Pennsylvania,NA,https://clinicalzeros.gov/ct2/show/NCT04506268,0,0,0,0,6,1,United States,0,opt-out recruitment email|opt-in recruitment email,NA
NCT04504240,2020-08-01,2021-04-10,Interventional,Role of Famotidine in the Clinical Improvement of COVID-19 Patients.,"Active, not recruiting",Phase 3,Chattogram General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04504240,0,0,0,0,2,0,Bangladesh,0,famotidine,NA
NCT04490174,2020-01-08,2022-06-01,Observational,Serological Surveillance for COVID-19 in Central North Carolina,Recruiting,NA,National Institutes of Health Clinical Center (CC),NA,https://clinicalzeros.gov/ct2/show/NCT04490174,0,0,0,0,38,1,United States,0,"NA",NA
NCT04513561,2020-07-21,2020-08-27,Observational,Evaluation of the Impact of Lock Down and End of Lock Down on the Management of Patients With Inflammatory and Dysimmune Diseases Followed in the Context of IMMINeNT FHU and COVID-19,Completed,NA,"University Hospital, Lille",NA,https://clinicalzeros.gov/ct2/show/NCT04513561,0,0,0,0,2,0,France,0,"NA",NA
NCT04498247,2020-08-27,2021-03-05,Interventional,"A Study to Assess Safety, Tolerability, and Immunogenicity of V591 (COVID-19 Vaccine) in Healthy Participants (V591-001)",Terminated,Phase 1/Phase 2,Merck Sharp & Dohme Corp.,The study was terminated based on an interim assessment of immunogenicity,https://clinicalzeros.gov/ct2/show/NCT04498247,0,0,0,1,11,1,United States|Austria|Belgium,0,v591|placebo,NA
NCT04495803,2020-09-01,2022-08-01,Interventional,Augmented CBGT for Perinatal Anxiety During a Global Pandemic (COVID-19),Recruiting,N/A,St. Joseph's Healthcare Hamilton,NA,https://clinicalzeros.gov/ct2/show/NCT04495803,0,0,0,0,1,0,Canada,0,cognitive behavioural group therapy for perinatal anxiety,NA
NCT04439825,2020-07-20,2020-09-03,Interventional,Impact of Botox Treatment Into the Upper One Third of the Face an Area on Mood and Self -Appearance Satisfaction,Completed,Phase 1,DeNova Research,NA,https://clinicalzeros.gov/ct2/show/NCT04439825,0,0,0,0,3,1,United States,0,botulinum neurotoxin|placebo,NA
NCT04445220,2020-11-19,2021-06-30,Interventional,A Study of Cell Therapy in COVID-19 Subjects With Acute Kidney Injury Who Are Receiving Renal Replacement Therapy,Recruiting,Phase 1/Phase 2,"Sentien Biotechnologies, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04445220,0,0,0,0,5,1,United States,0,sbi-101,NA
NCT04487691,2020-12-08,2021-06-01,Interventional,Nebulized PL for Post-COVID-19 Syndrome,"Active, not recruiting",N/A,"Regenexx, LLC",NA,https://clinicalzeros.gov/ct2/show/NCT04487691,0,0,0,0,3,1,United States,0,nebulized platelet lysate|nebulized sterile saline,NA
NCT04470999,2020-04-15,2021-09-30,Interventional,Changes in Cellular Immune Profile During COVID-19 Infection,Recruiting,N/A,Seraph Research Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04470999,0,0,0,0,3,1,United States,0,leukapheresis,NA
NCT04466683,2020-08-28,2021-12-31,Interventional,Low-Dose Radiotherapy For Patients With SARS-COV-2 (COVID-19) Pneumonia,Recruiting,Phase 2,Ohio State University Comprehensive Cancer Center,NA,https://clinicalzeros.gov/ct2/show/NCT04466683,0,0,0,0,2,1,United States|Colombia,0,radiotherapy|high dose radiation 100 cgy,NA
NCT04432350,2020-06-15,2021-12-31,Observational,Assessment of Mortality Rates in COVID-19 Infected Populations Treated With Repurposed Medications,"Active, not recruiting",NA,Tabula Rasa HealthCare,NA,https://clinicalzeros.gov/ct2/show/NCT04432350,0,0,0,0,1,1,United States,0,"NA",NA
NCT04432324,2020-06-02,2021-03-03,Interventional,Study to Evaluate the Safety and Efficacy of High Dose IVIG in Hospitalized Participants With Coronavirus Disease (COVID-19),Completed,Phase 2,Grifols Therapeutics LLC,NA,https://clinicalzeros.gov/ct2/show/NCT04432324,0,0,0,0,4,0,Spain,0,immune globulin|standard care,NA
NCT04427566,2020-07-23,2021-12-31,Interventional,Low Dose Whole Lung Radiation Therapy for Patients With COVID-19 and Respiratory Compromise,Recruiting,Phase 2,Ohio State University Comprehensive Cancer Center,NA,https://clinicalzeros.gov/ct2/show/NCT04427566,0,0,0,0,6,1,United States,0,radiotherapy,NA
NCT04420637,2020-06-15,2021-09-30,Observational,Impact of the Covid-19 Pandemic on Gastrointestinal and Liver Diseases,Enrolling by invitation,NA,Medical University of Graz,NA,https://clinicalzeros.gov/ct2/show/NCT04420637,0,0,0,0,2,0,Austria,0,"NA",NA
NCT04418284,2020-06-05,2020-11-05,Observational,Online Learning of Veterinary Anatomy During COVID-19 Pandemic,Completed,NA,South Valley University,NA,https://clinicalzeros.gov/ct2/show/NCT04418284,0,0,0,0,4,0,Egypt,0,questionnaire,NA
NCT04411511,2020-05-06,2021-11-06,Observational,"COVID-19, Obesity and Lifestyle in Children",Recruiting,NA,Maastricht University Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04411511,0,0,0,0,1,0,Netherlands,0,exposure to the dutch measures due to the covid-19 pandemic.,NA
NCT04379154,2020-04-14,2021-04-30,Interventional,Analysis of Volatile Organic Compounds by Electronic Noses in Hospitalised Patients for an Infection by SARS-COV-2 (COVID-19),Recruiting,N/A,Hopital Foch,NA,https://clinicalzeros.gov/ct2/show/NCT04379154,0,0,0,0,3,0,France,0,volatile organic compounds analysis,NA
NCT04409262,2020-06-16,2021-02-01,Interventional,A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia,Completed,Phase 3,Hoffmann-La Roche,NA,https://clinicalzeros.gov/ct2/show/NCT04409262,0,0,0,0,9,1,United States|Brazil|Russian Federation|Spain,0,remdesivir|tocilizumab|placebo,NA
NCT04407533,2020-05-25,2022-08-31,Observational,Dietary Intake and Eating Habits During the COVID-19 Pandemic,"Active, not recruiting",NA,McGill University,NA,https://clinicalzeros.gov/ct2/show/NCT04407533,0,0,0,0,2,0,Canada,0,survey|diet tracking|questionnaire,NA
NCT04400058,2020-06-01,2021-01-07,Interventional,Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression,Completed,Phase 3,Octapharma,NA,https://clinicalzeros.gov/ct2/show/NCT04400058,0,0,0,0,16,1,United States|Russian Federation|Ukraine,0,octagam|placebo,NA
NCT04399356,2020-10-01,2021-04-30,Interventional,Niclosamide for Mild to Moderate COVID-19,Recruiting,Phase 2,Tufts Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04399356,0,0,0,0,4,1,United States,0,niclosamide|placebo|telehealth monitoring,NA
NCT04397796,2020-08-03,2021-06-30,Interventional,Study of the Safety of Therapeutic Tx With Immunomodulatory MSC in Adults With COVID-19 Infection Requiring Mechanical Ventilation,Recruiting,Phase 1,"ImmunityBio, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04397796,0,0,0,0,4,1,United States,0,mesenchymal stem cells|placebo,NA
NCT04382417,2020-03-26,2020-11-12,Observational,Prospective Observational Cohort Study of Critically Ill Patients With Covid-19 in Sweden,Completed,NA,Region VÃ¤stmanland,NA,https://clinicalzeros.gov/ct2/show/NCT04382417,0,0,0,0,3,0,Sweden,0,observational,NA
NCT04382391,2020-05-08,2021-09-01,Interventional,Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms,Recruiting,N/A,Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute),NA,https://clinicalzeros.gov/ct2/show/NCT04382391,0,0,0,0,3,1,United States,0,gammacoreâ® sapphire (non-invasive vagus nerve stimulator)|standard care|gammacoreâ® sapphire (non-invasive vagus nerve stimulator),NA
NCT04382378,2021-02-01,2021-09-30,Interventional,Effects of NMES in Critically Ill Patients,Recruiting,N/A,Escola Superior de Ciencias da Saude,NA,https://clinicalzeros.gov/ct2/show/NCT04382378,0,0,0,0,4,0,Brazil,0,neuromuscular electrical stimulation,NA
NCT04408157,2020-05-20,2021-08-22,Interventional,A Research Study to Evaluate the Benefits of a Self-management Booklet to Promote Wellbeing During the COVID-19 Pandemic,"Active, not recruiting",N/A,King's College London,NA,https://clinicalzeros.gov/ct2/show/NCT04408157,0,0,0,0,4,0,United Kingdom,0,self-management booklet (switch: stay well during covid-19),NA
NCT04414618,2020-07-02,2020-11-26,Interventional,A Study of Opaganib in Coronavirus Disease 2019 Pneumonia,Completed,Phase 2,RedHill Biopharma Limited,NA,https://clinicalzeros.gov/ct2/show/NCT04414618,0,0,0,0,17,1,United States|Israel,0,opaganib|placebo,NA
NCT04390191,2020-05-07,2022-04-30,Interventional,Early CPAP in COVID-19 Confirmed or Suspected Patients,Recruiting,N/A,Icahn School of Medicine at Mount Sinai,NA,https://clinicalzeros.gov/ct2/show/NCT04390191,0,0,0,0,1,1,United States,0,continuous positive airway pressure,NA
NCT04388826,2020-06-18,2020-12-18,Interventional,COVID-19 Treatment of Severe Acute Respiratory Syndrome With Veru-111,"Active, not recruiting",Phase 2,Veru Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04388826,0,0,0,0,17,1,United States,0,veru-111,NA
NCT04388618,2020-06-15,2021-08-31,Observational,Investigating Anosmia and Ageusia in COVID-19 Adult Patients in Saudi Arabia,Recruiting,NA,Princess Nourah Bint Abdulrahman University,NA,https://clinicalzeros.gov/ct2/show/NCT04388618,0,0,0,0,6,0,Saudi Arabia,0,nhanes smell/taste tests|nhanes smell|taste,NA
NCT04374461,2020-05-01,2023-05-31,Interventional,A Study of N-acetylcysteine in Patients With COVID-19 Infection,Recruiting,Phase 2,Memorial Sloan Kettering Cancer Center,NA,https://clinicalzeros.gov/ct2/show/NCT04374461,0,0,0,0,9,1,United States,0,n-acetylcysteine|blood,NA
NCT04373200,2020-05-25,2021-05-25,Interventional,Human Ab Response & immunoMONItoring of COVID-19 Patients,Recruiting,N/A,Rennes University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04373200,0,0,0,0,4,0,France,0,blood sample|saliva,NA
NCT04371978,2020-10-01,2021-06-30,Interventional,Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19,Recruiting,Phase 3,Rabin Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04371978,0,0,0,0,3,0,Israel,0,linagliptin 5 mg,NA
NCT04358406,2020-07-30,2021-05-01,Interventional,Rhu-pGSN for Severe Covid-19 Pneumonia,"Active, not recruiting",Phase 2,BioAegis Therapeutics Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04358406,0,0,0,0,4,0,Romania|Spain,0,recombinant human plasma gelsolin (rhu-pgsn)|placebo,NA
NCT04377620,2020-05-24,2021-02-26,Interventional,Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT),Terminated,Phase 3,Incyte Corporation,Study terminated by sponsor,https://clinicalzeros.gov/ct2/show/NCT04377620,0,0,0,0,7,1,United States|Russian Federation,0,placebo|ruxolitinib,NA
NCT04351191,2020-04-15,2020-08-23,Interventional,PRophylaxis of Exposed COVID-19 Individuals With Mild Symptoms Using choloroquinE Compounds,Terminated,Phase 4,"Government of Punjab, Specialized Healthcare and Medical Education Department",Poor accrual,https://clinicalzeros.gov/ct2/show/NCT04351191,0,0,0,0,2,0,Pakistan,0,hydroxychloroquine|chloroquine|placebo,NA
NCT04353037,2020-04-07,2020-07-11,Interventional,PATCH 2&3:Prevention & Treatment of COVID-19 (Severe Acute Respiratory Syndrome Coronavirus 2) With Hydroxychloroquine,Terminated,Phase 2,UnitedHealth Group,"As enrollment began external studies called into question the safety and efficacy of
    hydroxychloroquine as a treatment which resulted in controversy. The timing of the controversy
    significantly impacted our ability to enroll and retain participants.",https://clinicalzeros.gov/ct2/show/NCT04353037,0,0,0,0,2,1,United States,0,hydroxychloroquine|control,NA
NCT04351347,2020-06-16,2030-12-01,Interventional,The Efficacy of Ivermectin in Larger Doses in COVID-19 Treatment,Recruiting,Phase 2/Phase 3,Tanta University,NA,https://clinicalzeros.gov/ct2/show/NCT04351347,0,0,0,0,5,0,Egypt,0,ivermectin,NA
NCT04347408,2020-05-06,2020-12-13,Observational,Seroprevalence of SARS-Cov-2 Antibodies in Children,Completed,NA,"Queen's University, Belfast",NA,https://clinicalzeros.gov/ct2/show/NCT04347408,0,0,0,0,6,0,United Kingdom,0,igm/igg rapid test|igm,NA
NCT04346667,2020-04-14,2020-08-23,Interventional,Post-Exposure Prophylaxis for Asymptomatic SARS-CoV-2 COVID-19 Patients With choloroquinE Compounds,Terminated,Phase 4,"Government of Punjab, Specialized Healthcare and Medical Education Department",Poor accrual.,https://clinicalzeros.gov/ct2/show/NCT04346667,0,0,0,0,2,0,Pakistan,0,hydroxychloroquine|chloroquine|placebo,NA
NCT04345653,2020-04-14,2020-06-05,Interventional,Hydroxychloroquine as Chemoprevention for COVID-19 for High Risk Healthcare Workers,"Active, not recruiting",Phase 2,Hackensack Meridian Health,NA,https://clinicalzeros.gov/ct2/show/NCT04345653,0,0,0,0,5,1,United States,0,hydroxychloroquine,NA
NCT04345510,2020-04-20,2021-09-30,Observational,Testing for COVID-19 Infection in Asymptomatic Persons,Recruiting,NA,German Cancer Research Center,NA,https://clinicalzeros.gov/ct2/show/NCT04345510,0,0,0,0,1,0,Germany,0,"NA",NA
NCT04345419,2020-06-16,2029-12-31,Interventional,Remdesivir Efficacy in Coronavirus Disease,Recruiting,Phase 2/Phase 3,Tanta University,NA,https://clinicalzeros.gov/ct2/show/NCT04345419,0,0,0,0,5,0,Egypt,0,remdesivir|standard care,NA
NCT04324528,2020-03-27,2021-01-27,Interventional,Cytokine Adsorption in Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation,Completed,N/A,University Hospital Freiburg,NA,https://clinicalzeros.gov/ct2/show/NCT04324528,0,0,0,0,3,0,Germany,0,vv-ecmo / cytokine adsorption|vv-ecmo|cytokine adsorption,NA
NCT04336761,2020-04-15,2021-01-01,Observational,Prevalence of Covid-19 in Children Admitted to Paediatric Emergency Departments During the Pandemic Period in France,Completed,NA,"University Hospital, Lille",NA,https://clinicalzeros.gov/ct2/show/NCT04336761,0,0,0,0,3,0,France,0,nasopharyngeal swab,NA
NCT04807699,2020-07-25,2021-10-25,Observational [Patient Registry],Collaborative Network for Generating Scientific Evidence in COVID-19 For the Unified Health System in Brazil - RECOVER SUS-BRASIL,Enrolling by invitation,NA,Evandro Chagas National Institute of Infectious Disease,NA,https://clinicalzeros.gov/ct2/show/NCT04807699,0,0,0,0,0,0,Brazil,0,data collection,NA
NCT04303299,2020-08-19,2021-12-31,Interventional,Fight COVID-19 Trial,Recruiting,Phase 3,Rajavithi Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04303299,0,0,0,0,7,0,Thailand,0,oral,NA
NCT04805684,2021-01-01,2021-03-05,Interventional,Different Lung Ultrasound Imaging Protocols in COVID-19 Pneumonia,Completed,N/A,Bursa YÃ¼ksek Ä°htisas Education and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04805684,0,0,0,0,0,0,Turkey,0,lus twelve area|lus fourteen area,NA
NCT04805203,2020-12-16,2022-12-31,Interventional,Analysis of the Immune Parameters of COVID-19 Infection in Patients With Multiple Myeloma,Recruiting,N/A,Intergroupe Francophone du Myelome,NA,https://clinicalzeros.gov/ct2/show/NCT04805203,0,0,0,0,0,0,France,0,blood sample analyses,NA
NCT04805086,2021-03-08,2022-06-01,Interventional,The MONACO Cell Therapy Study: Monocytes as an Anti-fibrotic Treatment After COVID-19,Recruiting,Phase 1/Phase 2,Guy's and St Thomas' NHS Foundation Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04805086,0,0,0,0,0,0,United Kingdom,0,mon002,NA
NCT04799977,2020-10-01,2021-02-01,Observational,COVID-19: Post-covid Olfactory Disorders Assessment,Recruiting,NA,Centre Hospitalier Universitaire de Nice,NA,https://clinicalzeros.gov/ct2/show/NCT04799977,0,0,0,0,1,0,France,0,"NA",NA
NCT04779541,2021-02-08,2021-04-08,Observational,National Survey Concerning Vaccination Against COVID-19 in Nursing Homes and Long-Term Care Units,Recruiting,NA,"University Hospital, Angers",NA,https://clinicalzeros.gov/ct2/show/NCT04779541,0,0,0,0,1,0,France,0,observation,NA
NCT04738695,2021-02-01,2022-03-31,Observational,SARS-CoV-2 Seroprevalence Among Nursing Home Staff and Residents (COVID-19),Recruiting,NA,Sciensano,NA,https://clinicalzeros.gov/ct2/show/NCT04738695,0,0,0,0,1,0,Belgium,0,point-of-care rapid anti-sars-cov-2 antibody test (orient gene biotech)/dry blood spot collection (euroimmun)|point-of-care rapid anti-sars-cov-2 antibody test (orient gene biotech)|dry blood spot collection (euroimmun),NA
NCT04735757,2021-02-03,2023-01-19,Observational,"Effects of COVID-19 Infection and Critical Illness on Diaphragm Tissue Characteristics and Movement, Visualized With MRI",Recruiting,NA,VU University Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04735757,0,0,0,0,2,0,Netherlands,0,contrast-enhanced mri|measurement of respiratory muscle force,NA
NCT04728802,2021-02-02,2021-03-22,Interventional,Proxalutamide Treatment for Hospitalized COVID-19 Patients,"Active, not recruiting",Phase 3,"Applied Biology, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04728802,0,0,0,0,2,0,Brazil,0,proxalutamide|standard care,NA
NCT04705766,2021-03-01,2022-03-31,Observational [Patient Registry],KIDney Injury in Times of COVID-19 (KIDCOV),Recruiting,NA,"University of California, San Francisco",NA,https://clinicalzeros.gov/ct2/show/NCT04705766,0,0,0,0,2,1,United States,0,urine collection,NA
NCT04633915,2020-11-26,2021-08-31,Observational,Antibody Response in Hemodialysis and Non-dialysis Patients Diagnosed With COVID-19.,"Active, not recruiting",NA,"Saint Petersburg State University, Russia",NA,https://clinicalzeros.gov/ct2/show/NCT04633915,0,0,0,0,2,0,Russian Federation,0,"NA",NA
NCT04610502,2020-09-06,2020-10-06,Interventional,Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients,Completed,Phase 2,Caja Costarricense de Seguro Social,NA,https://clinicalzeros.gov/ct2/show/NCT04610502,0,0,0,0,2,0,Costa Rica,0,administration of equine immunoglobulin anti sars-cov-2,NA
NCT04568863,2020-06-20,2020-11-30,Interventional,Efficacy of Intravenous Melatonin on Mortality in Adult Patients Admitted to the Intensive Care Unit With COVID-19,Completed,Phase 2,Pharmamel S.L.,NA,https://clinicalzeros.gov/ct2/show/NCT04568863,0,0,0,0,1,0,Spain,0,melatonin intravenous|placebo,NA
NCT04522986,2020-08-21,2021-02-02,Interventional,An Exploratory Study of ADR-001 in Patients With Severe Pneumonia Caused by SARS-CoV-2 Infection,Completed,Phase 1,"Rohto Pharmaceutical Co., Ltd.",NA,https://clinicalzeros.gov/ct2/show/NCT04522986,0,0,0,0,2,0,Japan,0,mesenchymalÂ stem cells,NA
NCT04497324,2020-09-21,2021-04-30,Interventional,PERUCONPLASMA: Evaluating the Use of Convalescent Plasma as Management of COVID-19,Recruiting,Phase 2,Universidad Peruana Cayetano Heredia,NA,https://clinicalzeros.gov/ct2/show/NCT04497324,0,0,0,0,3,0,Peru,0,convalescent plasma,NA
NCT04380402,2020-06-25,2021-12-31,Interventional,Atorvastatin as Adjunctive Therapy in COVID-19,Recruiting,Phase 2,Mount Auburn Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04380402,0,0,0,0,2,1,United States,0,atorvastatin,NA
NCT04364984,2020-04-01,2021-05-01,Observational [Patient Registry],"ARB, ACEi, DRi in COVID-19",Recruiting,NA,Medical Practice Prof D. Ivanov,NA,https://clinicalzeros.gov/ct2/show/NCT04364984,0,0,0,0,2,0,Ukraine,0,ace inhibitor,NA
NCT04363489,2020-08-20,2021-05-30,Observational,The CEDiD Study (COVID-19 Early Diagnosis in Doctors and Healthcare Workers),Recruiting,NA,King's College London,NA,https://clinicalzeros.gov/ct2/show/NCT04363489,0,0,0,0,3,0,United Kingdom,0,wearable medical device (empatica e4)|covid-19 pcr swab|pulse oximeter,NA
NCT04823234,2021-03-10,2021-06-30,Observational,Lung Ultrasound Signs and Patterns in COVID-19 Pregnant Women,Recruiting,NA,Azienda Sanitaria-Universitaria Integrata di Udine,NA,https://clinicalzeros.gov/ct2/show/NCT04823234,0,0,0,0,0,0,Italy,0,lung ultrasound,NA
NCT04822012,2021-03-01,2021-04-30,Observational,Anti COVID-19 Antibodies in Follicular Fluid and Spermatic Fluid,Recruiting,NA,Meir Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04822012,0,0,0,0,0,0,Israel,0,anti covid19 igg antibodies,NA
NCT04821934,2021-03-26,2021-06-30,Interventional,Tele-rehabilitation Program After Hospitalization for COVID-19,Recruiting,N/A,Istituti Clinici Scientifici Maugeri SpA,NA,https://clinicalzeros.gov/ct2/show/NCT04821934,0,0,0,0,0,0,Italy,0,tr|tsu,NA
NCT04820803,2021-02-03,2021-04-23,Interventional,Assessment of the Impact of Oral Intervention With Cetylpyridinium Chloride to Decrease SARS-CoV-2 Viral Load in Patients With COVID-19,Recruiting,N/A,Instituto de InvestigaciÃ³n Sanitaria AragÃ³n,NA,https://clinicalzeros.gov/ct2/show/NCT04820803,0,0,0,0,0,0,Spain,0,oral intervention with cetylpyridinium chloride|placebo,NA
NCT04313023,2020-06-09,2021-05-31,Interventional,The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2,Recruiting,Phase 2,"Pulmotect, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04313023,0,0,0,0,11,1,United States,0,pul-042|placebo,NA
NCT04312997,2020-06-16,2021-04-30,Interventional,The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection,Recruiting,Phase 2,"Pulmotect, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04312997,0,0,0,0,14,1,United States,0,pul-042|placebo,NA
NCT04664296,2020-12-21,2021-03-23,Observational,COVID-19 - SARS-CoV-2 Community Contamination in Children and Adults (Dyn3CEA_Nosocor),Completed,NA,Hospices Civils de Lyon,NA,https://clinicalzeros.gov/ct2/show/NCT04664296,0,0,0,0,2,0,France,0,review of medical patient file|phone call interview,NA
NCT04806880,2021-02-01,2021-08-01,Observational [Patient Registry],Study Evaluating the Olfactory Recovery of Anosmia Post COVID-19 by Olfactory Rehabilitation Assisted by Web-application,Recruiting,NA,Weprom,NA,https://clinicalzeros.gov/ct2/show/NCT04806880,0,0,0,0,0,0,France,0,web-application,NA
NCT04805931,2021-03-15,2021-05-01,Interventional,VEText Message Framing and Covid-19 Vaccine Uptake Among at Risk Veterans,Recruiting,N/A,VA Puget Sound Health Care System,NA,https://clinicalzeros.gov/ct2/show/NCT04805931,0,0,0,1,0,1,United States,0,behavioral economics,NA
NCT04805892,2021-03-17,2021-04-27,Interventional,"Open Label, Single-Center Study Utilizing BIOZEK COVID-19 Antigen Rapid Test as Compared to Standard Testing Technique. Test Performed by a Professional Versus Self-collection and Standard of Care",Recruiting,N/A,Mach-E B.V.,NA,https://clinicalzeros.gov/ct2/show/NCT04805892,0,0,0,0,0,1,United States,0,biozek covid-19 antigen rapid test,NA
NCT04805840,2021-02-19,2021-05-28,Observational,Sensitivity of Frequent SARS-CoV-2 (COVID-19) Rapid Antigen Testing Regimen,Recruiting,NA,Columbia University,NA,https://clinicalzeros.gov/ct2/show/NCT04805840,0,0,0,0,0,1,United States,0,cov-scan rapid covid-19 antigen test,NA
NCT04803812,2021-01-26,2021-05-04,Interventional,Supporting the Wellness of Ontario Physicians During COVID-19,Recruiting,N/A,Ontario Medical Association,NA,https://clinicalzeros.gov/ct2/show/NCT04803812,0,0,0,0,0,0,Canada,0,"remote sms (short message service, also known as ""text message"") delivery",NA
NCT04797091,2020-04-20,2025-12-31,Observational,Kidney in Coronavirus Disease 2019 Registry,Recruiting,NA,University of Cologne,NA,https://clinicalzeros.gov/ct2/show/NCT04797091,0,0,0,0,1,0,Germany,0,retrospective data collection,NA
NCT04795414,2021-01-14,2022-04-30,Observational,Safety and Immunogenicity of an Inactivated Vaccine Against COVID-19 in Medical Workers,Recruiting,NA,Ruijin Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04795414,0,0,0,0,1,0,China,0,"sars-cov-2 vaccine(vero cell), inactivated",NA
NCT04750265,2021-01-21,2021-11-30,Interventional,Robotic Assisted Early Mobilization in Ventilated ICU Patients With COVID-19,Recruiting,N/A,"Charite University, Berlin, Germany",NA,https://clinicalzeros.gov/ct2/show/NCT04750265,0,0,0,0,2,0,Germany,0,robotic assisted early mobilization,NA
NCT04649086,2020-06-05,2021-10-05,Interventional,Muscular Rehabilitation by Eccentric Exercise After Severe COVID-19 Infection,Recruiting,N/A,"University Hospital, Clermont-Ferrand",NA,https://clinicalzeros.gov/ct2/show/NCT04649086,0,0,0,0,2,0,France,0,rehabilitation by concentric exercises|rehabilitation by eccentric exercises,NA
NCT04641481,2020-11-16,2021-01-08,Interventional,An Efficacy and Safety Clinical Trial of an Investigational COVID-19 Vaccine (BBV152) in Adult Volunteers,"Active, not recruiting",Phase 3,Bharat Biotech International Limited,NA,https://clinicalzeros.gov/ct2/show/NCT04641481,0,0,0,1,3,0,India,0,bbv152|placebo,NA
NCT04611399,2021-03-05,2022-03-05,Interventional,MIND-VR: Virtual Reality for COVID-19 Operators' Psychological Support,Recruiting,N/A,Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta,NA,https://clinicalzeros.gov/ct2/show/NCT04611399,0,0,0,0,2,0,Italy,0,vr for psychoeducation/relaxation|text material for psychoeducation/audio for relaxation techniques|vr for psychoeducation|relaxation|text material for psychoeducation|audio for relaxation techniques,NA
NCT04551339,2020-09-28,2021-06-14,Interventional,Zinc Versus Multivitamin Micronutrient Supplementation in the Setting of COVID-19,"Active, not recruiting",N/A,Mayo Clinic,NA,https://clinicalzeros.gov/ct2/show/NCT04551339,0,0,0,0,3,1,United States,0,preservision areds formulation soft gels/tablets|multivitamin with 11mg of zinc|preservision areds formulation soft gels|tablets,NA
NCT04391179,2020-05-31,2021-02-22,Interventional,Dipyridamole to Prevent Coronavirus Exacerbation of Respiratory Status (DICER) in COVID-19,Completed,Phase 2,University of Michigan,NA,https://clinicalzeros.gov/ct2/show/NCT04391179,0,0,0,0,7,1,United States,0,dipyridamole|placebo,NA
NCT04383613,2020-05-15,2021-06-01,Interventional,Prone Positioning for Patients on General Medical Wards With COVID19,Recruiting,N/A,Unity Health Toronto,NA,https://clinicalzeros.gov/ct2/show/NCT04383613,0,0,0,0,5,0,Canada,0,prone positioning,NA
NCT04351711,2020-04-09,2023-04-30,Observational,Immunological Profiling of Patients With COVID-19 in Respiratory Distress,Recruiting,NA,Centre Hospitalier Universitaire de NÄ«mes,NA,https://clinicalzeros.gov/ct2/show/NCT04351711,0,0,0,0,5,0,France,0,immunological,NA
NCT04344834,2020-06-15,2021-03-30,Observational,Short and Long-term Psychological Impact of Covid-19 on The Egyptians,Recruiting,NA,Assiut University,NA,https://clinicalzeros.gov/ct2/show/NCT04344834,0,0,0,0,2,0,Egypt,0,a questionnaire/scales|a questionnaire|scales,NA
NCT04332107,2020-05-22,2021-09-30,Interventional,Azithromycin for COVID-19 Treatment in Outpatients Nationwide,"Active, not recruiting",Phase 3,"University of California, San Francisco",NA,https://clinicalzeros.gov/ct2/show/NCT04332107,0,0,0,0,9,1,United States,0,azithromycin|placebo,NA
NCT04822285,2020-01-22,2020-04-22,Interventional,Effect Psychological Triaging Intervention on Students' Psychological Distress and Resilience Capacity,Completed,N/A,Alexandria University,NA,https://clinicalzeros.gov/ct2/show/NCT04822285,0,0,0,0,0,0,Egypt,0,psychological triaging intervention|routine psychological support,NA
NCT04821973,2020-09-22,2021-05-15,Interventional,Respiratory Tele Monitoring COVID 19 (TMR COVID-19),Recruiting,N/A,Assistance Publique Hopitaux De Marseille,NA,https://clinicalzeros.gov/ct2/show/NCT04821973,0,0,0,0,0,0,France,0,radius ppg tetherless pulse oximetry (masimo)|usual monitoring,NA
NCT04821570,2021-02-23,2022-03-28,Observational,To Assess Immunogenicity of Coronavirus Disease 2019 (COVID-19) Vaccine in Cancer Patients Receiving Cancer Treatment,Recruiting,NA,University of Kansas Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04821570,0,0,0,0,0,1,United States,0,covid-19 vaccine,NA
NCT04818489,2021-03-25,2021-05-25,Interventional,Colchicine and Post-COVID-19 Pulmonary Fibrosis,Recruiting,Phase 4,ClinAmygate,NA,https://clinicalzeros.gov/ct2/show/NCT04818489,0,0,0,0,1,0,Egypt,0,colchicine 0.5 mg|the standard protocol only,NA
NCT04818697,2020-06-24,2021-03-19,Observational,"Effect of Social Isolation on Physical Activity Level, and Kinesophobia in Heart Rhythm Disorders During Pandemic",Completed,NA,Hacettepe University,NA,https://clinicalzeros.gov/ct2/show/NCT04818697,0,0,0,0,1,0,Turkey,0,"NA",NA
NCT04817553,2021-03-24,2021-07-31,Observational,Impact of COVID-19 on the Clinical Outcomes and Management of IgG4 Related Disease Patients,Recruiting,NA,Chinese University of Hong Kong,NA,https://clinicalzeros.gov/ct2/show/NCT04817553,0,0,0,0,0,0,Hong Kong,0,exposure to covid19,NA
NCT04817371,2021-03-01,2022-03-31,Interventional,Analysis of Volatile Organic Compounds in Exhaled Air and Sweat: Interest in Rapid Screening for COVID-19 Infection.,Recruiting,N/A,Hopital Foch,NA,https://clinicalzeros.gov/ct2/show/NCT04817371,0,0,0,0,1,0,France,0,volatile organic compounds analysis (e-noses)|canine odor detection of volatile organic compounds|volatile organic compounds analysis (mass spectrometry)|volatile organic compounds analysis in sweat (mass spectrometry),NA
NCT04815850,2021-03-01,2021-10-01,Observational,Phenotyping Seroconversion Following Vaccination Against COVID-19 in Patients on Haemodialysis Study,Recruiting,NA,University of Leicester,NA,https://clinicalzeros.gov/ct2/show/NCT04815850,0,0,0,0,0,0,United Kingdom,0,"NA",NA
NCT04817332,2020-06-05,2021-02-28,Interventional,STOP-COVID19: Superiority Trial Of Protease Inhibition in COVID-19,Completed,Phase 3,University of Dundee,NA,https://clinicalzeros.gov/ct2/show/NCT04817332,0,0,0,0,0,0,United Kingdom,0,brensocatib|placebo,NA
NCT04816760,2020-03-25,2021-06-30,Observational,Immune Cells Phenotypes During COVID-19,Recruiting,NA,Institut Hospitalo-Universitaire MÃ©diterranÃ©e Infection,NA,https://clinicalzeros.gov/ct2/show/NCT04816760,0,0,0,0,0,0,France,0,peripheral blood samples,NA
NCT04816682,2021-03-17,2021-06-30,Interventional,Silymarin in COVID-19 Patients Admitted to Hospital With Elevated Liver Enzymes,Recruiting,Phase 4,F.D. Roosevelt Teaching Hospital with Policlinic Banska Bystrica,NA,https://clinicalzeros.gov/ct2/show/NCT04816682,0,0,0,0,0,0,Slovakia,0,silymarin,NA
NCT04816656,2020-08-03,2021-02-01,Interventional,An Integrated Digital PROM-platform for Cancer Patients During the COVID-19 Pandemic,Completed,N/A,Jessa Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04816656,0,0,0,0,1,0,Belgium,0,eproms assessment,NA
NCT04816630,2020-12-21,2021-03-31,Observational,Feasibility Study of Hematology Parameters in COVID-19 Disease,Recruiting,NA,"Beckman Coulter, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04816630,0,0,0,0,1,1,United States,0,cbc-diff monocyte volume width distribution,NA
NCT04816084,2020-11-05,2020-12-01,Interventional,SERUR: COVID-19 Serological Survey of Staff From the University Reims-Champagne Ardennes,Completed,N/A,UniversitÃ© de Reims Champagne-Ardenne,NA,https://clinicalzeros.gov/ct2/show/NCT04816084,0,0,0,0,0,0,France,0,serology test,NA
NCT04816942,2020-04-23,2020-07-21,Interventional,Clinical Efficacy of Early Administration of Convalescent Plasma Among COVID-19 Cases in Egypt,Completed,Phase 3,"Ministry of Health and Population, Egypt",NA,https://clinicalzeros.gov/ct2/show/NCT04816942,0,0,0,0,0,0,Egypt,0,convalescent plasma,NA
NCT04816786,2021-01-01,2021-06-01,Observational,COVID-19 Patients Admitted to the ICU,Recruiting,NA,"Ministry of Health, Kuwait",NA,https://clinicalzeros.gov/ct2/show/NCT04816786,0,0,0,0,0,0,Kuwait,0,"no intervention will be administered, this is a retrospective observational study.",NA
NCT04815759,2021-03-01,2021-04-27,Observational,Dental Anxiety Among Children Pre and Post COVID 19 Pandemic,Recruiting,NA,Alexandria University,NA,https://clinicalzeros.gov/ct2/show/NCT04815759,0,0,0,0,0,0,Egypt,0,routine dental restorative procedures,NA
NCT04815304,2020-03-13,2021-06-28,Observational,Clinical Features of COVID-19 Patients,Recruiting,NA,San Salvatore Hospital of L'Aquila,NA,https://clinicalzeros.gov/ct2/show/NCT04815304,0,0,0,0,0,0,Italy,0,peripheral lymphocytes subsets,NA
NCT04813939,2021-03-22,2021-12-31,Observational,Is Bio-adrenomedullin (Bio-ADM) a Prognostic Factor in Patients With COVID-19 Treated in the ICU?,Recruiting,NA,Medical University of Warsaw,NA,https://clinicalzeros.gov/ct2/show/NCT04813939,0,0,0,0,0,0,Poland,0,"ib10 sphingotestâ® bio-admâ® apparatus (sphingotec gmbh, hennigsdorf, germany)|ib10 sphingotestâ® bio-admâ® apparatus (sphingotec gmbh, hennigsdorf, germany)",NA
NCT04815135,2019-03-01,2020-05-31,Observational,Effect of Covid-19 Pandemic on Emergency Surgery Practice,Completed,NA,University of Jordan,NA,https://clinicalzeros.gov/ct2/show/NCT04815135,0,0,0,0,0,0,Jordan,0,observational,NA
NCT04815096,2021-04-15,2023-03-01,Interventional,Imaging Immune Activation in COVID-19,Recruiting,Early Phase 1,"CellSight Technologies, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04815096,0,0,0,0,2,1,United States,0,[18f]f-arag (2'-deoxy-2'-fluoro-9-î²-d-arabinofuranosylguanine)|[18f]f-arag (2'-deoxy-2'-fluoro-9-î²-d-arabinofuranosylguanine),NA
NCT04815018,2020-10-07,2021-04-30,Observational,Shifts in the Respiratory Microbiome and Clinical Outcomes of SARS-CoV-2,Recruiting,NA,Pathnostics,NA,https://clinicalzeros.gov/ct2/show/NCT04815018,0,0,0,0,0,1,United States,0,"NA",NA
NCT04814914,2021-03-31,2021-04-30,Observational,"An Observational Clinical Study to Evaluate COVID-19 Symptoms in ""Long Hauler"" Patients Who Participated in K031-120 or K032-120",Recruiting,NA,Kaleido Biosciences,NA,https://clinicalzeros.gov/ct2/show/NCT04814914,0,0,0,0,0,1,United States,0,kb109 / self supportive care|self supportive care (ssc) alone|kb109|self supportive care,NA
NCT04813796,2021-03-11,2022-04-13,Interventional,"A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines in Healthy Adults Between 18 Years and 55 Years of Age",Recruiting,Phase 1,"ModernaTX, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04813796,0,0,0,1,0,1,United States,0,mrna-1283|mrna-1273|placebo,NA
NCT04813575,2021-04-01,2022-04-01,Interventional,COVID-19 Pathophysiology of Long Term Implications,Enrolling by invitation,N/A,King Faisal Specialist Hospital & Research Center,NA,https://clinicalzeros.gov/ct2/show/NCT04813575,0,0,0,0,0,0,Saudi Arabia,0,cryo lung biopsies,NA
NCT04813562,2021-03-23,2021-07-30,Interventional,Immunogenicity and Safety of Recombinant COVID-19 Vaccine (CHO Cells),Recruiting,Phase 2,Jiangsu Province Centers for Disease Control and Prevention,NA,https://clinicalzeros.gov/ct2/show/NCT04813562,0,0,0,1,0,0,China,0,"a middle-dose recombinant covid-19 vaccine (cho cell) (18-59 years) at the schedule of day 0, 28, 56|a high-dose recombinant covid-19 vaccine (cho cell) (18-59 years) at the schedule of day 0, 28, 56|a middle-dose recombinant covid-19 vaccine (cho cell) (60-85 years) at the schedule of day 0, 28, 56|a high-dose recombinant covid-19 vaccine (cho cell) (60-85 years) at the schedule of day 0, 28, 56|a middle-dose placebo (18-59 years) at the schedule of day 0, 28, 56|a high-dose placebo (18-59 years) at the schedule of day 0, 28, 56|a middle-dose placebo (60-85 years) at the schedule of day 0, 28, 56|a high-dose placebo (60-85 years) at the schedule of day 0, 28, 56",NA
NCT04813497,2021-02-05,2021-05-30,Interventional,Monitoring of COVID-19 Seroprevalence Among GHdC Staff Members,Recruiting,N/A,Grand HÃ´pital de Charleroi,NA,https://clinicalzeros.gov/ct2/show/NCT04813497,0,0,0,0,0,0,Belgium,0,serology to determine sars-cov-2 infection,NA
NCT04813471,2021-01-20,2021-03-20,Interventional,Managing Endothelial Dysfunction in Critically Ill COVID-19 Patients at LAUMCRH,Recruiting,Phase 3,Lebanese American University Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04813471,0,0,0,0,0,0,Lebanon,0,endothelial protocol,NA
NCT04813731,2020-12-12,2021-12-31,Observational,COVID-19 And Lingering Symptoms In Primary Care Patients,Recruiting,NA,Region JÃ¶nkÃ¶ping County,NA,https://clinicalzeros.gov/ct2/show/NCT04813731,0,0,0,0,0,0,Australia|Belgium|Brazil|Denmark|France|Georgia|Germany|Ireland|Italy|Netherlands|Poland|Romania|Sweden|Ukraine|United Kingdom,0,"NA",NA
NCT04813692,2021-03-01,2021-05-31,Observational,Mechanical Complications of Acute Myocardial Infarction During COVID-19 Pandemics,Recruiting,NA,Maastricht University Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04813692,0,0,0,0,1,0,Netherlands,0,surgical repair|percutaneous treatment|mitral valve surgery,NA
NCT04812496,2020-03-01,2020-05-30,Observational,Tenofovir-DF Versus Hydroxychloroquine in the Treatment of Hospitalized Patients With COVID-19 (TEDHICOV),Completed,NA,Hospital Nacional Carlos Alberto Seguin Escobedo - EsSalud,NA,https://clinicalzeros.gov/ct2/show/NCT04812496,0,0,0,0,1,0,Peru,0,"NA",NA
NCT04810949,2020-08-05,2021-03-01,Interventional,Vitamine D3 Supplementation in Patients With Serum Values +/- 20ng/ml,Terminated,N/A,Hospital Clinica Nova,patients enrolled got vaccinated vs COVID-19 and Influenza,https://clinicalzeros.gov/ct2/show/NCT04810949,0,0,0,0,0,0,Mexico,0,vitamine d3 supplementation|diet/sun exposure|diet|sun exposure,NA
NCT04812041,2021-01-21,2021-05-15,Observational [Patient Registry],Relationship Between Delirium Severity by CAM-ICU 7 and 4C Mortality Score of the COVID-19 Patients in ICU,Recruiting,NA,Ankara City Hospital Bilkent,NA,https://clinicalzeros.gov/ct2/show/NCT04812041,0,0,0,0,0,0,Turkey,0,cam-icu 7 score|4c mortality score,NA
NCT04811456,2020-05-25,2025-05-25,Observational [Patient Registry],MultiOrgan Inflammatory Syndromes COVID-19 Related Study,Recruiting,NA,Medical University of Warsaw,NA,https://clinicalzeros.gov/ct2/show/NCT04811456,0,0,0,0,1,0,Poland,0,multisystem inflammatory syndrome in children (mis-c),NA
NCT04811391,2021-02-19,2022-05-20,Observational,COVID-19 Vaccine Effectiveness in Albanian Health Workers,Recruiting,NA,"Institute of Public Health, Albania",NA,https://clinicalzeros.gov/ct2/show/NCT04811391,0,0,0,0,1,0,Albania,0,covid-19 vaccine,NA
NCT04811885,2019-10-14,2021-10-14,Observational,The Effects of Covid-19 Pandemic on the Cardiovascular Heath of Children With Autism Spectrum Disorder,"Active, not recruiting",NA,"Institute of Technology, Carlow",NA,https://clinicalzeros.gov/ct2/show/NCT04811885,0,0,0,0,1,0,Ireland,0,the effects of covid 19 pandemic on the cardiovascular heath of children with autism spectrum disorder,NA
NCT04811859,2021-01-10,2022-01-10,Interventional,The Effect of Inspiratory Muscle Training in Post COVID-19 Patients,Recruiting,N/A,Istinye University,NA,https://clinicalzeros.gov/ct2/show/NCT04811859,0,0,0,0,0,0,Turkey,0,inspiratory muscle training,NA
NCT04811781,2020-06-04,2021-06-04,Observational,Epidemiological Features and Clinical Course of SARS-CoV-2 Infection in Cancer Patients: The Rovid Study,Recruiting,NA,Istituto Oncologico Veneto IRCCS,NA,https://clinicalzeros.gov/ct2/show/NCT04811781,0,0,0,0,0,0,Italy,0,"NA",NA
NCT04811352,2021-03-01,2021-05-01,Observational,Drug Abuse During the COVID-19 Pandemic.,Recruiting,NA,Instituto Mexicano del Seguro Social,NA,https://clinicalzeros.gov/ct2/show/NCT04811352,0,0,0,0,0,0,Mexico,0,"NA",NA
NCT04811339,2020-09-02,2023-08-31,Interventional,Studies of COVID-19 Patients Treated With Oral Bismuth Subsalicylate (Pepto-Bismol),Recruiting,Phase 4,University of Louisville,NA,https://clinicalzeros.gov/ct2/show/NCT04811339,0,0,0,0,1,1,United States,0,open label bss (pepto bismol),NA
NCT04810689,2021-03-01,2022-03-01,Interventional,"Pilot Trial of XFBD, a TCM, in Persons With COVID-19",Recruiting,Phase 2,University of Southern California,NA,https://clinicalzeros.gov/ct2/show/NCT04810689,0,0,0,0,0,1,United States,0,xuanfei baidu granules|placebo,NA
NCT04794946,2021-03-19,2022-03-19,Interventional,"Safety and Efficacy of a Non-replicating ChAdOx1 Vector Vaccine AZD1222 (COVISHIELD), for Prevention of COVID-19 in Patients With Liver Cirrhosis",Recruiting,N/A,"Institute of Liver and Biliary Sciences, India",NA,https://clinicalzeros.gov/ct2/show/NCT04794946,0,0,0,1,1,0,India,0,covishield,NA
NCT04809480,2017-01-01,2020-12-31,Observational,COVID-19 and Acute Invasive Fungal Rhinosinusitis,Completed,NA,Al-Azhar University,NA,https://clinicalzeros.gov/ct2/show/NCT04809480,0,0,0,0,0,0,NA,0,fungal rhinosinusitis,NA
NCT04805632,2021-03-23,2021-09-30,Observational,Immune Response in Dialysis Patients Vaccinated Against SARS-CoV-2,Recruiting,NA,"Saint Petersburg State University, Russia",NA,https://clinicalzeros.gov/ct2/show/NCT04805632,0,0,0,0,1,0,Russian Federation,0,"NA",NA
NCT04799691,2021-02-01,2021-12-31,Observational,Comparison of 2 Ventilatory Support Strategies During Coronavirus Disease 2019 (Covid-19) Pneumonia,Recruiting,NA,Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer,NA,https://clinicalzeros.gov/ct2/show/NCT04799691,0,0,0,0,1,0,France,0,invasive ventilation strategy|non-invasive ventilation strategies,NA
NCT04810637,2020-11-01,2021-06-30,Interventional,A Study to Evaluate the Safety and Efficacy of GX-I7 in Elderly Patients With Asymptomatic or Mild Symptoms of COVID-19,Recruiting,Phase 2,PT Kalbe Genexine Biologics,NA,https://clinicalzeros.gov/ct2/show/NCT04810637,0,0,0,0,1,0,Indonesia,0,gx-i7,NA
NCT04809272,2021-03-08,2021-07-01,Interventional,ePLH Pilot Study: Online Support Parent Groups - ParentChat,Recruiting,N/A,University of Oxford,NA,https://clinicalzeros.gov/ct2/show/NCT04809272,0,0,0,0,0,0,United Kingdom,0,parentchat for parents of children ages 2-17,NA
NCT04600895,2020-11-30,2021-08-31,Interventional,The Prevent Severe COVID-19 (PRESECO) Study,Recruiting,Phase 3,Appili Therapeutics Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04600895,0,0,0,0,4,1,United States,0,favipiravir|placebo,NA
NCT04806074,2020-08-14,2020-12-06,Interventional,FOODLIT-PRO: Improving Food Literacy and Food Sustainability Amidst the COVID-19 Pandemic,"Active, not recruiting",N/A,"ISPA - Instituto Universitario de Ciencias Psicologicas, Sociais e da Vida",NA,https://clinicalzeros.gov/ct2/show/NCT04806074,0,0,0,0,1,0,Portugal,0,experimental group|comparison group,NA
NCT04802018,2021-03-09,2021-06-30,Interventional,Clinical Decision Support System Based on Non-invasive Tele-monitoring of COVID-19 Patients,"Active, not recruiting",N/A,Increase-Tech,NA,https://clinicalzeros.gov/ct2/show/NCT04802018,0,0,0,0,1,0,Spain,0,clinical decision support system based on non-invasive multimodal monitoring,NA
NCT04801524,2021-02-07,2021-12-31,Interventional,Text-based Reminders to Promote COVID-19 Vaccinations,Enrolling by invitation,N/A,"University of California, Los Angeles",NA,https://clinicalzeros.gov/ct2/show/NCT04801524,0,0,0,1,1,1,United States,0,self-benefit|prosocial-benefit|early access|fresh start,NA
NCT04800965,2021-01-31,2021-12-31,Interventional,Text-based Interventions to Promote COVID-19 Vaccinations,Enrolling by invitation,N/A,"University of California, Los Angeles",NA,https://clinicalzeros.gov/ct2/show/NCT04800965,0,0,0,1,1,1,United States,0,patient mychart scheduling link|patient educational video|enhanced follow through message,NA
NCT04794088,2021-03-14,2021-12-31,Interventional,Intravenous Imatinib in Mechanically Ventilated COVID-19 Patients,Recruiting,Phase 2,VU University Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04794088,0,0,0,0,1,0,Netherlands,0,imatinib mesylate intravenous solution|placebo,NA
NCT04789356,2021-03-18,2021-06-30,Interventional,Effectiveness of the Adsorbed Vaccine COVID-19 (Coronavac) Among Education and Public Safety Workers With Risk Factors for Severity,Recruiting,Phase 4,FundaÃ§Ã£o de Medicina Tropical Dr. Heitor Vieira Dourado,NA,https://clinicalzeros.gov/ct2/show/NCT04789356,0,0,0,1,2,0,Brazil,0,adsorbed sars-cov-2 (inactivated) vaccine,NA
NCT04765475,2021-03-08,2022-02-28,Interventional,Protecting Native Families From COVID-19,Recruiting,N/A,Johns Hopkins Bloomberg School of Public Health,NA,https://clinicalzeros.gov/ct2/show/NCT04765475,0,0,0,0,1,1,United States,0,motivational interviewing|covid-19 symptom monitoring system|motivational interviewing/covid-19 symptom monitoring system|supportive services,NA
NCT04779346,2020-12-21,2021-12-31,Observational [Patient Registry],Immunity Against Severe Acute Respiratory Syndrome Coronavirus 2 Disease (COVID-19) in the Oncology Outpatient Setting,Recruiting,NA,UniversitÃ¤tsklinikum Hamburg-Eppendorf,NA,https://clinicalzeros.gov/ct2/show/NCT04779346,0,0,0,0,1,0,Germany,0,"NA",NA
NCT04767958,2021-03-19,2022-02-28,Interventional,The RAPID COVID Study - Application of Point-of-Care COVID-19 Testing,Recruiting,N/A,Ottawa Heart Institute Research Corporation,NA,https://clinicalzeros.gov/ct2/show/NCT04767958,0,0,0,0,1,0,Canada,0,spartan covid-19 platform,NA
NCT04784689,2021-02-24,2023-02-28,Observational,Host Immune Response to Novel RNA COVID-19 Vaccination,Recruiting,NA,The University of Texas Health Science Center at San Antonio,NA,https://clinicalzeros.gov/ct2/show/NCT04784689,0,0,0,0,1,1,United States,0,covid-19 vaccine,NA
NCT04772404,2021-03-07,2021-05-15,Observational,"Repercussion of the COVID-19 Pandemic on Physical Activity, Psychological State and Sleep",Recruiting,NA,Universidad de Granada,NA,https://clinicalzeros.gov/ct2/show/NCT04772404,0,0,0,0,1,0,Spain,0,"NA",NA
NCT04754698,2021-02-09,2021-12-31,Interventional,COVID-19 CoronaVac in Patients With Autoimmune Rheumatic Diseases and HIV/AIDS,Recruiting,Phase 4,University of Sao Paulo General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04754698,0,0,0,0,3,0,Brazil,0,coronavac,NA
NCT04760704,2021-02-19,2023-05-31,Observational,Covid-19 Vaccine Response in Elderly Subjects,Recruiting,NA,"University Hospital, Lille",NA,https://clinicalzeros.gov/ct2/show/NCT04760704,0,0,0,0,1,0,France,0,specific antibody/cellular immune response after anti-sars-cov-2 vaccine administration|specific antibody|cellular immune response after anti-sars-cov-2 vaccine administration,NA
NCT04756141,2021-03-03,2022-01-28,Interventional,CGM Use in COVID19 Patients (Infection With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)),Recruiting,N/A,Mayo Clinic,NA,https://clinicalzeros.gov/ct2/show/NCT04756141,0,0,0,0,2,1,United States,0,continuous glucose monitor (cgm),NA
NCT04751682,2021-03-01,2021-03-25,Interventional,Safety and Immunogenicity of an Intranasal SARS-CoV-2 Vaccine (BBV154) for COVID-19,"Active, not recruiting",Phase 1,Bharat Biotech International Limited,NA,https://clinicalzeros.gov/ct2/show/NCT04751682,0,0,0,1,2,0,India,0,bbv154 vaccine,NA
NCT04753632,2021-03-09,2021-05-15,Observational,Status of People With Cerebral Palsy and Their Caregivers During COVID-19 Pandemic,Recruiting,NA,Universidad de Granada,NA,https://clinicalzeros.gov/ct2/show/NCT04753632,0,0,0,0,2,0,Spain,0,"NA",NA
NCT04748172,2021-02-01,2022-02-28,Observational,COVID-19 Vaccine and Ovarian Reserve,Recruiting,NA,Sheba Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04748172,0,0,0,0,1,0,Israel,0,sars-cov-2 virus vaccines|amh sampling,NA
NCT04741386,2021-02-17,2022-04-05,Observational [Patient Registry],The REnal Patients COVID-19 VACcination Immune Response (RECOVAC IR) Study,"Active, not recruiting",NA,University Medical Center Groningen,NA,https://clinicalzeros.gov/ct2/show/NCT04741386,0,0,0,0,1,0,Netherlands,0,sars-cov-2 vaccination,NA
NCT04743609,2021-02-08,2021-07-11,Observational,RSV Burden in Outpatient Settings,Recruiting,NA,Association Clinique ThÃ©rapeutique Infantile du val de Marne,NA,https://clinicalzeros.gov/ct2/show/NCT04743609,0,0,0,0,1,0,France,0,nasopharyngeal samples,NA
NCT04705597,2021-03-18,2021-05-31,Interventional,"Study to Evaluate the Safety, Tolerability, and Efficacy of BGE-175 in Participants â‰¥ 60 Years of Age and Hospitalized With Coronavirus Disease 2019 (COVID-19) That Are Not in Respiratory Failure",Recruiting,Phase 2,"BioAge Labs, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04705597,0,0,0,0,3,1,United States,0,bge-175|placebo,NA
NCT04727424,2021-01-19,2022-02-01,Interventional,Repurposed Approved Therapies for Outpatient Treatment of Patients With Early-Onset COVID-19 and Mild Symptoms,Recruiting,Phase 3,Cardresearch,NA,https://clinicalzeros.gov/ct2/show/NCT04727424,0,0,0,0,1,0,Brazil,0,fluvoxamine maleate 100 mg [luvox]|metformin extended release oral tablet|ivermectin oral tablets/sublingual waffles|placebo|ivermectin oral tablets|sublingual waffles,NA
NCT04707703,2021-03-16,2022-01-31,Interventional,Isavuconazole for the Prevention of COVID-19-associated Pulmonary Aspergillosis,Recruiting,Phase 3,"University of California, San Diego",NA,https://clinicalzeros.gov/ct2/show/NCT04707703,0,0,0,0,1,1,United States,0,isavuconazonium injection [cresemba]|placebo,NA
NCT04723706,2021-03-19,2022-03-01,Observational,Response to SARS-CoV-2 Vaccine in Stem Cell Transplant and Cellular Therapy Patients,Recruiting,NA,Henry Ford Health System,NA,https://clinicalzeros.gov/ct2/show/NCT04723706,0,0,0,0,2,1,United States,0,covid-19 serology igg,NA
NCT04723290,2020-06-20,2020-10-31,Interventional,COVID-19 Seroconversion Study Among GHdC Staff Members - Summer 2020,Completed,N/A,Grand HÃ´pital de Charleroi,NA,https://clinicalzeros.gov/ct2/show/NCT04723290,0,0,0,0,3,0,Belgium,0,serological tests for sars cov-2,NA
NCT04713553,2021-02-15,2021-05-11,Interventional,"A Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Production Lots and Dose Levels of BNT162b2 Against COVID-19 in Healthy Participants",Recruiting,Phase 3,BioNTech SE,NA,https://clinicalzeros.gov/ct2/show/NCT04713553,0,0,0,1,3,1,United States,0,bnt162b2,NA
NCT04708912,2020-12-15,2021-03-30,Observational,Nasopharynx Microbiota Component and in Vitro Cytokines Production in Coronavirus Disease (COVID-19),Recruiting,NA,Basaksehir Cam & Sakura Åžehir Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04708912,0,0,0,0,2,0,Turkey,0,observation,NA
NCT04701606,2021-03-29,2021-10-15,Interventional,The Safety and Efficacy of Pyronaridine-artesunate (PyramaxÂ® or ArtecomÂ®)in COVID-19 Patients,Recruiting,Phase 2/Phase 3,Shin Poong Pharmaceutical Co. Ltd.,NA,https://clinicalzeros.gov/ct2/show/NCT04701606,0,0,0,0,2,0,Philippines,0,artecomâ® (pyronaridine-artesunate)|placebo|artecomâ® (pyronaridine-artesunate),NA
NCT04700163,2021-01-11,2021-06-15,Interventional,RU Anti-SARS-CoV-2 (COVID-19) mAbs in Healthy Volunteers,"Active, not recruiting",Phase 1,Rockefeller University,NA,https://clinicalzeros.gov/ct2/show/NCT04700163,0,0,0,0,3,1,United States,0,c144-ls/c-135-ls|c144-ls|c-135-ls,NA
NCT04689399,2020-12-26,2021-03-25,Interventional,Sensitivity and Specificity of SARS-CoV-2 Rapid Antigen Test Compared to RT-PCR Test,Completed,N/A,"Rigshospitalet, Denmark",NA,https://clinicalzeros.gov/ct2/show/NCT04689399,0,0,0,0,3,0,Denmark,0,"standard q covid-19 ag - test, produced by sd biosensor inc.",NA
NCT04706533,2020-03-23,2021-06-30,Observational,"Michigan Medicine COVID-19 Cohort: Clinical Characteristics, Inflammatory Markers and Outcomes of Patients Hospitalized for COVID-19",Recruiting,NA,University of Michigan,NA,https://clinicalzeros.gov/ct2/show/NCT04706533,0,0,0,0,1,1,United States,0,biomarkers of inflammation,NA
NCT04695652,2020-12-30,2021-06-30,Interventional,A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Adult,"Active, not recruiting",Phase 2,Medigen Vaccine Biologics Corp.,NA,https://clinicalzeros.gov/ct2/show/NCT04695652,0,0,0,1,6,0,Taiwan|Vietnam,0,mvc-cov1901(s protein with adjuvant)|mvc-cov1901(saline),NA
NCT04668339,2021-01-07,2022-04-30,Interventional,A Trial Evaluating the Safety and Effects of an RNA Vaccine ARCT-021 in Healthy Adults,"Active, not recruiting",Phase 2,"Arcturus Therapeutics, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04668339,0,0,0,1,3,1,United States|Singapore,0,"arct-021 single dose priming|arct-021 two lower dose priming|arct-021 two higher dose priming|placebo (two doses), priming|randomized booster|placebo booster",NA
NCT04666012,2020-12-29,2021-03-31,Interventional,Safety and Immunogenicity Study of AdCLD-CoV19: A COVID-19 Preventive Vaccine in Healthy Volunteers,Recruiting,Phase 1/Phase 2,"Cellid Co., Ltd.",NA,https://clinicalzeros.gov/ct2/show/NCT04666012,0,0,0,1,2,0,"Korea, Republic of",0,adcld-cov19,NA
NCT04661813,2021-03-01,2022-12-31,Interventional,Assess and Adapt to the Impact of COVID-19 on CVD Self-Management and Prevention Care in Adults Living With HIV,Recruiting,N/A,Case Western Reserve University,NA,https://clinicalzeros.gov/ct2/show/NCT04661813,0,0,0,0,1,1,United States,0,extra-cvd virtual care,NA
NCT04637477,2020-08-01,2020-12-31,Interventional,Virtual Enhanced Lifestyle for Metabolic Syndrome (ELM) Proof-of-Concept Study,"Active, not recruiting",N/A,Rush University Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04637477,0,0,0,0,1,1,United States,0,virtual elm,NA
NCT04659356,2020-09-01,2021-07-01,Observational,NOSOcomial COVID-19 in ICU (NOSOCOVID),Recruiting,NA,Nantes University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04659356,0,0,0,0,1,0,France,0,patients admitted in intensive care units,NA
NCT04642638,2020-11-30,2022-09-30,Interventional,"Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Healthy Seronegative Adults at High Risk of SARS-CoV-2 Exposure","Active, not recruiting",Phase 2/Phase 3,Inovio Pharmaceuticals,NA,https://clinicalzeros.gov/ct2/show/NCT04642638,0,0,0,1,6,1,United States,0,ino-4800|cellectraâ® 2000|placebo|cellectraâ® 2000,NA
NCT04591717,2020-10-19,2021-11-19,Interventional,COVID-19 Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenoviral-COVID-19 in Normal Healthy Volunteers,Recruiting,Phase 1,"ImmunityBio, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04591717,0,0,0,1,7,1,United States,0,had5-s-fusion/n-etsd vaccine|had5-s-fusion|n-etsd vaccine,NA
NCT04640402,2020-11-17,2021-02-18,Interventional,A Phase â…¡ Clinical Trial of Recombinant Corona Virus Disease-19 (COVID-19) Vaccine (Sf9 Cells),Recruiting,Phase 2,Jiangsu Province Centers for Disease Control and Prevention,NA,https://clinicalzeros.gov/ct2/show/NCT04640402,0,0,0,1,1,0,China,0,low-dose recombinant covid-19 vaccine (sf9 cells) (18-59 years)/two dose regimen|low-dose recombinant covid-19 vaccine (sf9 cells) (18-59 years)/three dose regimen|high-dose recombinant covid-19 vaccine (sf9 cells) (18-59 years)/two dose regimen|high-dose recombinant covid-19 vaccine (sf9 cells) (18-59 years)/three dose regimen|low-dose recombinant covid-19 vaccine (sf9 cells) (60-85 years)/two dose regimen|low-dose recombinant covid-19 vaccine (sf9 cells) (60-85 years)/three dose regimen|high-dose recombinant covid-19 vaccine (sf9 cells) (60-85 years)/two dose regimen|high-dose recombinant covid-19 vaccine (sf9 cells) (60-85 years)/three dose regimen|low-dose placebo (18-59 years)/two dose regimen|low-dose placebo (18-59 years)/three dose regimen|high-dose placebo (18-59 years)/two dose regimen|high-dose placebo (18-59 years)/three dose regimen|low-dose placebo (60-85 years)/two dose regimen|low-dose placebo (60-85 years)/three dose regimen|high-dose placebo (60-85 years)/two dose regimen|high-dose placebo (60-85 years)/three dose regimen|low-dose recombinant covid-19 vaccine (sf9 cells) (18-59 years)|two dose regimen|three dose regimen|high-dose recombinant covid-19 vaccine (sf9 cells) (18-59 years)|low-dose recombinant covid-19 vaccine (sf9 cells) (60-85 years)|high-dose recombinant covid-19 vaccine (sf9 cells) (60-85 years)|low-dose placebo (18-59 years)|high-dose placebo (18-59 years)|low-dose placebo (60-85 years)|high-dose placebo (60-85 years),NA
NCT04631536,2021-01-10,2021-05-31,Interventional,Managing Endothelial Dysfunction in COVID-19 : A Randomized Controlled Trial at LAUMC,Recruiting,Phase 3,Lebanese American University Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04631536,0,0,0,0,2,0,Lebanon,0,atorvastatin / l-arginine / folic acid / nicorandil / nebivolol|placebo|atorvastatin|l-arginine|folic acid|nicorandil|nebivolol,NA
NCT04606784,2020-10-28,2021-03-18,Interventional,Study of Nebulized Ampion for the Treatment of Adult COVID-19 Patients With Respiratory Distress,"Active, not recruiting",Phase 1,Ampio Pharmaceuticals. Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04606784,0,0,0,0,2,1,United States,0,ampion|standard care,NA
NCT04631705,2020-12-14,2021-07-31,Interventional,SARS-CoV-2-Neutralizing Monoclonal COVID-19 Antibody DZIF-10c by Inhalation,Recruiting,Phase 1/Phase 2,University of Cologne,NA,https://clinicalzeros.gov/ct2/show/NCT04631705,0,0,0,0,1,0,Germany,0,dzif-10c|placebo,NA
NCT04631666,2020-12-08,2021-07-31,Interventional,SARS-CoV-2-Neutralizing Monoclonal COVID-19 Antibody DZIF-10c by Infusion,Recruiting,Phase 1/Phase 2,University of Cologne,NA,https://clinicalzeros.gov/ct2/show/NCT04631666,0,0,0,0,1,0,Germany,0,dzif-10c|placebo,NA
NCT04523246,2020-09-01,2021-07-01,Interventional,Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents,Recruiting,Early Phase 1,University of Oklahoma,NA,https://clinicalzeros.gov/ct2/show/NCT04523246,0,0,0,1,3,1,United States,0,"shingrix (zoster vaccine recombinant, adjuvanted)|saline",NA
NCT04565249,2020-10-22,2021-08-31,Interventional,"Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Acute Respiratory Distress Syndrome (ARDS) Associated With at Least Severe COVID-19",Recruiting,Phase 2,"Pliant Therapeutics, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04565249,0,0,0,0,5,1,United States,0,pln-74809|placebo,NA
NCT04545060,2020-08-27,2021-03-31,Interventional,VIR-7831 for the Early Treatment of COVID-19 in Outpatients,"Active, not recruiting",Phase 2/Phase 3,"Vir Biotechnology, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04545060,0,0,0,0,14,1,United States|Austria|Brazil|Canada|Peru|Spain|United Kingdom,0,vir-7831|placebo,NA
NCT04544033,2020-09-15,2021-04-30,Observational,IL- 6 Gene (174G/C) Single Nucleotide Polymorphism as an Indicator of COVID-19 Severity in Egyptian Patients,Recruiting,NA,Tanta University,NA,https://clinicalzeros.gov/ct2/show/NCT04544033,0,0,0,0,2,0,Egypt,0,interleuken 6,NA
NCT04542213,2020-08-01,2021-02-28,Interventional,Dipeptidyl Peptidase-4 Inhibitor (DPP4i) for the Control of Hyperglycemia in Patients With COVID-19,Completed,Phase 3,Hospital Regional de Alta Especialidad del Bajio,NA,https://clinicalzeros.gov/ct2/show/NCT04542213,0,0,0,0,1,0,Mexico,0,linagliptin|insulin,NA
NCT04528329,2020-08-30,2021-04-01,Interventional,Anosmia and / or Ageusia and Early Corticosteroid Use,Recruiting,Phase 4,ClinAmygate,NA,https://clinicalzeros.gov/ct2/show/NCT04528329,0,0,0,0,3,0,Egypt,0,early-dexamethasone|late dexamethazone,NA
NCT04595773,2021-01-22,2023-12-31,Interventional,"COVID-19, Chronic Adaptation and Response to Exercise (COVID-CARE)",Recruiting,Phase 1/Phase 2,National Institutes of Health Clinical Center (CC),NA,https://clinicalzeros.gov/ct2/show/NCT04595773,0,0,0,0,65,1,United States,0,exercise|education,NA
NCT04582266,2021-02-12,2022-01-15,Observational,PK and Safety of Remdesivir for Treatment of COVID-19 in Pregnant and Non-Pregnant Women in the US,Recruiting,NA,National Institute of Allergy and Infectious Diseases (NIAID),NA,https://clinicalzeros.gov/ct2/show/NCT04582266,0,0,0,0,1,1,United States|Puerto Rico,0,remdesivir,NA
NCT04578509,2020-10-19,2021-04-30,Observational,Evaluation of a Screening Program for SARS-CoV-2 Infection in the General Population Based on the Use of New Detection Approaches or for Diagnostic Orientation on Saliva,Recruiting,NA,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04578509,0,0,0,0,3,0,France,0,nasopharyngeal swab|saliva|axillary sweat sample|data collection,NA
NCT04570202,2020-11-20,2021-08-20,Interventional,Health cAre woRkers exposeD to COVID-19,Recruiting,N/A,"University Hospital, Tours",NA,https://clinicalzeros.gov/ct2/show/NCT04570202,0,0,0,0,3,0,France,0,emdr,NA
NCT04487210,2020-10-07,2021-06-30,Interventional,A Study to Evaluate the Safety and Immunogenicity of MVC-COV1901 Against COVID-19,"Active, not recruiting",Phase 1,Medigen Vaccine Biologics Corp.,NA,https://clinicalzeros.gov/ct2/show/NCT04487210,0,0,0,0,4,0,Taiwan,0,mvc-cov1901,NA
NCT04514016,2020-08-12,2021-03-17,Observational,Cross Sectional CFAR HIV/COVID-19 Study,Completed,NA,University of Miami,NA,https://clinicalzeros.gov/ct2/show/NCT04514016,0,0,0,0,3,1,United States,0,"NA",NA
NCT04497636,2020-07-03,2021-04-30,Observational,Mental Health Impact of the COVID-19 Pandemic Among Migrants in Chile,Recruiting,NA,Pontificia Universidad Catolica de Chile,NA,https://clinicalzeros.gov/ct2/show/NCT04497636,0,0,0,0,1,0,Chile,0,"NA",NA
NCT04483375,2020-07-24,2020-11-17,Interventional,"Safety, Tolerability and Pharmacokinetics of SCTA01, an Anti-SARS-CoV-2 Monoclonal Antibody, in Healthy Chinese Subjects",Completed,Phase 1,Sinocelltech Ltd.,NA,https://clinicalzeros.gov/ct2/show/NCT04483375,0,0,0,0,4,0,China,0,scta01|placebo,NA
NCT04482023,2021-03-23,2021-04-30,Observational,Emotional Support and Stress Management in Patients Diagnosed With COVID-19,Recruiting,NA,Corporacion Parc Tauli,NA,https://clinicalzeros.gov/ct2/show/NCT04482023,0,0,0,0,1,0,Spain,0,"training video on anxiety, fear/loneliness in the covid-19 environment.|training video on anxiety, fear|loneliness in the covid-19 environment.",NA
NCT04481620,2020-08-31,2021-05-31,Observational,"Development and Validation of a Prediction Model for the Transition From Mild to Moderate Form of COVID-19, Using Data From Chest CT",Recruiting,NA,"University Hospital, Bordeaux",NA,https://clinicalzeros.gov/ct2/show/NCT04481620,0,0,0,0,2,0,France,0,"NA",NA
NCT04481477,2020-11-27,2021-04-15,Observational,Results of Emotional Support Activities During Hospital Admission With a Diagnosis of COVID19,Recruiting,NA,Corporacion Parc Tauli,NA,https://clinicalzeros.gov/ct2/show/NCT04481477,0,0,0,0,1,0,Spain,0,"nursing care to reduce anxiety, fear/loneliness|nursing care to reduce anxiety, fear|loneliness",NA
NCT04476680,2020-09-01,2021-04-28,Interventional,Influence of Military Preventive Policy for reCruit Training on COVID-19 Seroconversion,Recruiting,N/A,Royal Centre for Defence Medicine,NA,https://clinicalzeros.gov/ct2/show/NCT04476680,0,0,0,0,1,0,United Kingdom,0,vitamin d,NA
NCT04467112,2020-07-30,2020-12-19,Observational,Non Inferiority Trial for Detection of nCOVID-19 Through Analysis of Exhaled Breath Aerosols,Completed,NA,Owlstone Ltd,NA,https://clinicalzeros.gov/ct2/show/NCT04467112,0,0,0,0,4,0,United Kingdom,0,breath biopsy face masks with removable filters/fitted pva strip|breath biopsy face masks with removable filters|fitted pva strip,NA
NCT04466839,2020-07-02,2020-12-18,Observational,Evaluation of the Containment Impact Linked to the Covid-19 Pandemic in a Population of Parkinson Patients,Completed,NA,"University Hospital, Toulouse",NA,https://clinicalzeros.gov/ct2/show/NCT04466839,0,0,0,0,3,0,France,0,questionnaire/interview|questionnaire|interview,NA
NCT04466098,2020-07-30,2021-12-01,Interventional,Multiple Dosing of Mesenchymal Stromal Cells in Patients With ARDS (COVID-19),"Active, not recruiting",Phase 2,"Masonic Cancer Center, University of Minnesota",NA,https://clinicalzeros.gov/ct2/show/NCT04466098,0,0,0,0,3,1,United States,0,mesenchymal stem cells|placebo,NA
NCT04447404,2020-09-21,2021-03-04,Interventional,"DUR-928 in Subjects With SARS-CoV-2 With Acute Lung, Liver or Kidney Injury",Terminated,Phase 2,Durect,low enrollment,https://clinicalzeros.gov/ct2/show/NCT04447404,0,0,0,0,3,1,United States,0,dur-928|placebo,NA
NCT04410718,2020-04-20,2021-05-30,Observational,Glycaemia and Cardiac Function in Patients With COVID-19,Recruiting,NA,Steno Diabetes Center Copenhagen,NA,https://clinicalzeros.gov/ct2/show/NCT04410718,0,0,0,0,1,0,Denmark,0,glycaemic levels,NA
NCT04441996,2020-07-17,2021-03-18,Interventional,Therapeutic Plasma Exchange for COVID-19-associated Hyperviscosity,Completed,Phase 4,Emory University,NA,https://clinicalzeros.gov/ct2/show/NCT04441996,0,0,0,0,3,1,United States,0,therapeutic plasma exchange (tpe)|standard care,NA
NCT04441476,2020-04-21,2020-12-21,Observational,Ethical and Psychological Support for Health Care Professions in Intensive Care Units in the COVID19 Pandemic Context: Adequacy With Needs and Psychological Impact Crisis and Post-crisis,Completed,NA,Centre Hospitalier Universitaire Dijon,NA,https://clinicalzeros.gov/ct2/show/NCT04441476,0,0,0,0,2,0,France,0,questionnaire|psychological/sociological interviews|psychological|interview,NA
NCT04439045,2020-06-24,2021-09-02,Interventional,Efficacy and Safety of VPM1002 in Reducing SARS-CoV-2 (COVID-19) Infection Rate and Severity,"Active, not recruiting",Phase 3,"University Health Network, Toronto",NA,https://clinicalzeros.gov/ct2/show/NCT04439045,0,0,0,0,4,0,Canada,0,vpm1002|placebo,NA
NCT04420468,2020-06-10,2020-06-30,Observational,Descriptive and Retrospective Analysis of Acute Myocarditis Associated With Pandemic COVID-19 in Children,Completed,NA,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04420468,0,0,0,0,1,0,France,0,"NA",NA
NCT04418505,2020-09-02,2021-06-01,Interventional,Vielight RX Plus for the Treatment of COVID-19 Respiratory Symptoms,Recruiting,N/A,Vielight Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04418505,0,0,0,0,5,1,United States|Canada,0,vielight rx plus,NA
NCT04416464,2020-06-15,2022-07-31,Observational,Quality of Life and Patient-centered Outcomes After ICU Admission for COVID-19,Recruiting,NA,Universidade do Porto,NA,https://clinicalzeros.gov/ct2/show/NCT04416464,0,0,0,0,2,0,Portugal,0,covid-19 pneumonia,NA
NCT04400305,2020-05-20,2021-07-31,Interventional,"""Increasing Physical Activity in Canadian Adults Affected by COVID-19 Social Distancing Restrictions: A Feasibility Trial of an Online Intervention""",Recruiting,N/A,University of Victoria,NA,https://clinicalzeros.gov/ct2/show/NCT04400305,0,0,0,0,5,0,Canada,0,digital health online platform,NA
NCT04408183,2020-06-01,2021-08-31,Interventional,GLS-1200 Topical Nasal Spray to Prevent SARS-CoV-2 Infection (COVID-19) in Health Care Personnel,Recruiting,Phase 2,"GeneOne Life Science, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04408183,0,0,0,0,3,1,United States,0,gls-1200|placebo,NA
NCT04399603,2020-06-01,2021-11-17,Observational,Mechanisms of Multi-organ Failure in COVID-19,Recruiting,NA,Imperial College London,NA,https://clinicalzeros.gov/ct2/show/NCT04399603,0,0,0,0,2,0,United Kingdom,0,no intervention-mechanistic study,NA
NCT04397614,2020-07-22,2021-12-31,Interventional,Mobile Health Study and Enhanced Symptom Monitoring in COVID-19 Cancer Patients,Recruiting,Phase 2,University of Oklahoma,NA,https://clinicalzeros.gov/ct2/show/NCT04397614,0,0,0,0,5,1,United States,0,mhealth assessments,NA
NCT04395911,2020-09-10,2021-06-30,Interventional,Safety and Efficacy of SCD in AKI or ARDS Patients Associated With COVID-19 Infections,Recruiting,N/A,SeaStar Medical,NA,https://clinicalzeros.gov/ct2/show/NCT04395911,0,0,0,0,4,1,United States,0,scd,NA
NCT04406246,2020-05-21,2020-12-31,Interventional,Prevention of Coronavirus Disease (COVID-19) Outbreaks With Nitazoxanide,Completed,Phase 4,Materno-Perinatal Hospital of the State of Mexico,NA,https://clinicalzeros.gov/ct2/show/NCT04406246,0,0,0,0,1,0,Mexico,0,nitazoxanide,NA
NCT04391738,2020-02-01,2020-05-15,Observational,Association Between BMI and COVID-19,Completed,NA,"University Hospital, Lille",NA,https://clinicalzeros.gov/ct2/show/NCT04391738,0,0,0,0,3,0,France,0,patients admitted to intensive care unit with sars-cov2,NA
NCT04391166,2020-05-20,2020-07-10,Observational,Validity of at Home Visual Acuity Measurements for Telemedicine During Corona Virus (COVID-19) Pandemic,Completed,NA,Vanderbilt University Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04391166,0,0,0,0,6,1,United States,0,non invasive visual acuity testing,NA
NCT04401150,2020-08-14,2021-11-30,Interventional,Lessening Organ Dysfunction With VITamin C - COVID-19,Recruiting,Phase 3,UniversitÃ© de Sherbrooke,NA,https://clinicalzeros.gov/ct2/show/NCT04401150,0,0,0,0,4,0,Canada,0,vitamin c|control,NA
NCT04383483,2020-06-15,2022-01-31,Observational,"CoV-ICU Score, Intensive Care Unit, SARS-CoV-2",Recruiting,NA,Bursa YÃ¼ksek Ä°htisas Education and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04383483,0,0,0,0,3,0,Turkey,0,covicu,NA
NCT04383444,2020-07-07,2023-08-01,Observational,Surveillance of Individuals Following SARS-CoV-2 Exposure,Recruiting,NA,National Institutes of Health Clinical Center (CC),NA,https://clinicalzeros.gov/ct2/show/NCT04383444,0,0,0,0,44,1,United States,0,"NA",NA
NCT04357886,2020-05-15,2020-06-01,Observational,Awareness of COVID-19 in Turkey,Completed,NA,Istanbul University-Cerrahpasa,NA,https://clinicalzeros.gov/ct2/show/NCT04357886,0,0,0,0,2,0,Turkey,0,"NA",NA
NCT04389671,2020-11-02,2021-05-31,Interventional,The Safety and Preliminary Tolerability of Lyophilized Lucinactant in Adults With Coronavirus Disease 2019 (COVID-19),Recruiting,Phase 2,Windtree Therapeutics,NA,https://clinicalzeros.gov/ct2/show/NCT04389671,0,0,0,0,3,1,United States,0,lucinactant,NA
NCT04368221,2020-05-04,2021-02-23,Observational,Characterization of Fungal Infections in COVID-19 Infected and Mechanically Ventilated Patients in ICU,Completed,NA,Rennes University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04368221,0,0,0,0,4,0,France,0,"NA",NA
NCT04367740,2020-04-28,2021-12-31,Observational,"ScreenNC, a Study to Determine the Number of Asymptomatic Individuals Who Have Antibodies to the Virus That Causes COVID-19",Enrolling by invitation,NA,"University of North Carolina, Chapel Hill",NA,https://clinicalzeros.gov/ct2/show/NCT04367740,0,0,0,0,2,1,United States,0,igg antibody test,NA
NCT04365439,2020-07-20,2020-12-20,Interventional,Convalescent Plasma for COVID-19,"Active, not recruiting",N/A,"Ente Ospedaliero Cantonale, Bellinzona",NA,https://clinicalzeros.gov/ct2/show/NCT04365439,0,0,0,0,1,0,Switzerland,0,plasma,NA
NCT04349631,2020-04-22,2020-11-24,Interventional,A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19,"Active, not recruiting",Phase 2,Hope Biosciences,NA,https://clinicalzeros.gov/ct2/show/NCT04349631,0,0,0,0,7,1,United States,0,mesenchymal stem cells,NA
NCT04364737,2020-04-17,2021-03-29,Interventional,CONTAIN COVID-19: Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients,"Active, not recruiting",Phase 2,NYU Langone Health,NA,https://clinicalzeros.gov/ct2/show/NCT04364737,0,0,0,0,11,1,United States,0,convalescent plasma|saline,NA
NCT04371432,2020-05-05,2025-06-01,Observational,Genetics of COVID-19 Susceptibility and Manifestations,Recruiting,NA,National Institutes of Health Clinical Center (CC),NA,https://clinicalzeros.gov/ct2/show/NCT04371432,0,0,0,0,193,1,United States,0,"NA",NA
NCT04362189,2020-06-30,2021-10-31,Interventional,Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19,"Active, not recruiting",Phase 2,Hope Biosciences,NA,https://clinicalzeros.gov/ct2/show/NCT04362189,0,0,0,0,7,1,United States,0,mesenchymal stem cells|placebo,NA
NCT04357457,2020-09-03,2021-07-31,Interventional,Efficacy of Intravenous Almitrine in Reducing the Need for Mechanical Ventilation in Patients With Hypoxemic Acute Respiratory Failure Due to Covid-19-related Pneumonia,Recruiting,Phase 3,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04357457,0,0,0,0,3,0,France,0,almitrine|placebo,NA
NCT04827160,2020-03-02,2020-08-11,Observational,Prediction of Thrombosis Using D-dimer Trends in COVID-19,Completed,NA,"Central Hospital, Nancy, France",NA,https://clinicalzeros.gov/ct2/show/NCT04827160,0,0,0,0,0,0,France,0,"NA",NA
NCT04355533,2020-07-29,2022-07-31,Interventional,Immunity Against SARS-CoV2 in Children and Their Parents / COVID-19,Recruiting,N/A,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04355533,0,0,0,0,6,0,France,0,serology test|nasopharyngeal swab|rectal swab|saliva,NA
NCT04348435,2020-05-14,2021-05-30,Interventional,"A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Allogeneic Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19","Active, not recruiting",Phase 2,Hope Biosciences,NA,https://clinicalzeros.gov/ct2/show/NCT04348435,0,0,0,0,7,1,United States,0,mesenchymal stem cells|placebo,NA
NCT04346927,2020-08-10,2020-10-10,Interventional,Telerehabilitation for Patients Diagnosed With Coronavirus,Completed,N/A,Istinye University,NA,https://clinicalzeros.gov/ct2/show/NCT04346927,0,0,0,0,2,0,Turkey,0,telehealth|exercise,NA
NCT04333472,2021-01-06,2022-03-06,Interventional,Piclidenoson for Treatment of COVID-19,Recruiting,Phase 2,Can-Fite BioPharma,NA,https://clinicalzeros.gov/ct2/show/NCT04333472,0,0,0,0,9,0,Israel,0,piclidenoson|placebo,NA
NCT04317040,2020-04-24,2020-10-20,Interventional,CD24Fc as a Non-antiviral Immunomodulator in COVID-19 Treatment,Completed,Phase 3,"OncoImmune, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04317040,0,0,0,0,12,1,United States,0,cd24fc|placebo,NA
NCT04826822,2021-02-24,2021-07-08,Interventional,Spironolactone and Dexamethasone in Patients Hospitalized With COVID-19,Recruiting,Phase 3,Chita State Regional Clinical Hospital Number 1,NA,https://clinicalzeros.gov/ct2/show/NCT04826822,0,0,0,0,0,0,Russian Federation,0,spironolactone / dexamethasone|standard-of-care sars-cov-2 treatment|spironolactone|dexamethasone,NA
NCT04826770,2021-01-06,2021-10-31,Observational,Adaptive Immune Response Against Corona Virus Vaccination,Recruiting,NA,University Medicine Greifswald,NA,https://clinicalzeros.gov/ct2/show/NCT04826770,0,0,0,0,0,0,Germany,0,anti-sars-cov-2 antibody testing,NA
NCT04824677,2020-05-18,2021-12-31,Observational [Patient Registry],Risk Factors and Prognoses in Patients Hospitalized for COVID-19,Recruiting,NA,Sociedad EspaÃ±ola de NeumologÃ­a y CirugÃ­a TorÃ¡cica,NA,https://clinicalzeros.gov/ct2/show/NCT04824677,0,0,0,0,0,0,Spain,0,hospital treatment of covid disease,NA
NCT04824638,2021-03-08,2021-08-08,Interventional,BNT162b2 Vaccination With Two Doses in COVID-19 Negative Adult Volunteers and With a Single Dose in COVID-19 Positive Adult Volunteers,Recruiting,Phase 2,"ANRS, Emerging Infectious Diseases",NA,https://clinicalzeros.gov/ct2/show/NCT04824638,0,0,0,1,0,0,France,0,two doses of bnt162b2 vaccine|one dose of bnt162b2 vaccine,NA
NCT04821674,2021-03-15,2022-07-31,Interventional,Study of DS-5670a (COVID-19 Vaccine) in Japanese Healthy Adults and Elderly Subjects,Recruiting,Phase 1/Phase 2,"Daiichi Sankyo, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04821674,0,0,0,1,1,0,Japan,0,ds-5670a|placebo,NA
NCT04823182,2021-02-16,2021-06-16,Observational [Patient Registry],Study of HEarT DiseAse and ImmuNiTy After COVID-19 in Ireland,Recruiting,NA,Cardiovascular Research Institute Dublin,NA,https://clinicalzeros.gov/ct2/show/NCT04823182,0,0,0,0,1,0,Ireland,0,cardiovascular magnetic resonance imaging,NA
NCT04824391,2021-02-10,2021-04-30,Interventional,"Efficacy, Immunogenicity and Safety of Inactivated ERUCOV-VAC Compared With Placebo in COVID-19",Recruiting,Phase 2,Health Institutes of Turkey,NA,https://clinicalzeros.gov/ct2/show/NCT04824391,0,0,0,1,0,0,Turkey,0,erucov-vac 3 âµg/0.5 ml vaccine|erucov-vac 6 âµg/0.5 ml vaccine|placebo|erucov-vac 3 âµg|0.5 ml vaccine|erucov-vac 6 âµg,NA
NCT04824313,2020-03-01,2020-07-31,Observational [Patient Registry],Vascular Abnormalities Detected With Chest CT in COVID-19,"Active, not recruiting",NA,University of Lausanne,NA,https://clinicalzeros.gov/ct2/show/NCT04824313,0,0,0,0,0,0,Switzerland,0,chest ct|chest cta,NA
NCT04793464,2021-02-04,2021-08-31,Interventional,COVID-19: Healthy Oregon (Oregon Saludable): Together We Can (Juntos Podemos),Recruiting,N/A,University of Oregon,NA,https://clinicalzeros.gov/ct2/show/NCT04793464,0,0,0,0,2,1,United States,0,promotores de salud|services as usual,NA
NCT04819802,2021-03-28,2022-04-30,Observational,MIcrovascular Dysfunction in CRitically Ill cOVID-19 Patients,Recruiting,NA,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04819802,0,0,0,0,1,0,France,0,measurement of sublingual microcirculation|plasma sampling,NA
NCT04819282,2020-09-10,2020-12-30,Observational [Patient Registry],Mask Usage and Physical Performance During COVID-19 Pandemic in Geriatrics,Completed,NA,KTO Karatay University,NA,https://clinicalzeros.gov/ct2/show/NCT04819282,0,0,0,0,1,0,Turkey,0,senior fitness test,NA
NCT04806867,2020-05-01,2020-07-01,Observational,Selection of Patients With Chronic Inflammatory Rheumatism Requiring Management During the COVID-19 Pandemia,Completed,NA,"University Hospital, Limoges",NA,https://clinicalzeros.gov/ct2/show/NCT04806867,0,0,0,0,1,0,France,0,separic-covid19 cohort,NA
NCT04789512,2021-03-01,2021-03-26,Observational,Respiratory Muscle Strength in Volleyball Players Suffered From COVID-19,Completed,NA,Gazi University,NA,https://clinicalzeros.gov/ct2/show/NCT04789512,0,0,0,0,1,0,Turkey,0,respiratory functions,NA
NCT04845880,2020-10-01,2021-03-01,Interventional,SARS Cov_2 Incidence of Healthy Health Workers,Completed,N/A,Baskent University,NA,https://clinicalzeros.gov/ct2/show/NCT04845880,0,0,0,0,0,0,Turkey,0,spike protein (s)/the nucleocapsid (n) of sars-cov-2|spike protein (s)|the nucleocapsid (n) of sars-cov-2,NA
NCT04704388,2020-06-01,2020-10-01,Observational,Study Project Comparing the Sequelae of COVID-19 Infection in Patients Who Have and Have Not Received Ventilatory Support in Critical Care,Completed,NA,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04704388,0,0,0,0,1,0,France,0,"NA",NA
NCT04727762,2021-02-04,2021-03-01,Observational,Use of the Mask and Current Pandemic,Completed,NA,University of Valencia,NA,https://clinicalzeros.gov/ct2/show/NCT04727762,0,0,0,0,3,0,Spain,0,"NA",NA
NCT04729140,2020-12-28,2021-12-28,Interventional,An Outpatient Clinical Trial Using Ivermectin and Doxycycline in COVID-19 Positive Patients at High Risk to Prevent COVID-19 Related Hospitalization,Recruiting,Phase 4,"Max Health, Subsero Health",NA,https://clinicalzeros.gov/ct2/show/NCT04729140,0,0,0,0,2,1,United States,0,ivermectin|doxycycline tablets|placebo,NA
NCT04720118,2021-03-01,2021-04-30,Observational [Patient Registry],Parkinson's Disease and Experiences Throughout the COVID-19 Pandemic,Recruiting,NA,Towson University,NA,https://clinicalzeros.gov/ct2/show/NCT04720118,0,0,0,0,2,1,United States,0,no intervention,NA
NCT04666233,2021-03-16,2021-03-23,Interventional,Personal Protective Equipment for the Prevention of SARS-Cov-2 During Neonatal Resuscitation,Completed,N/A,University Hospital Padova,NA,https://clinicalzeros.gov/ct2/show/NCT04666233,0,0,0,0,2,0,Italy,0,neonatal resuscitation with ppe for the prevention of sars-cov-2 infection|neonatal resuscitation without ppe for the prevention of sars-cov-2 infection,NA
NCT04664309,2021-03-26,2023-01-31,Observational,Understanding Immunity to the COVID-19 Vaccines,Recruiting,NA,Stanford University,NA,https://clinicalzeros.gov/ct2/show/NCT04664309,0,0,0,0,3,1,United States,0,no intervention,NA
NCT04619680,2020-11-18,2024-04-30,Interventional,The Study Will Evaluate the Use of Nintedanib in Slowing Lung Fibrosis in Patients With Pulmonary Infiltrates Related to COVID-19,Recruiting,Phase 4,Icahn School of Medicine at Mount Sinai,NA,https://clinicalzeros.gov/ct2/show/NCT04619680,0,0,0,0,3,1,United States,0,nintedanib|placebo,NA
NCT04551378,2020-07-13,2021-12-31,Observational,The Effect of COVID-19 Pandemic on Adolescent and Young Adult Cancer Patients and Survivors,Recruiting,NA,M.D. Anderson Cancer Center,NA,https://clinicalzeros.gov/ct2/show/NCT04551378,0,0,0,0,1,1,United States,0,quality-of-life assessment|questionnaire,NA
NCT04629703,2021-02-22,2021-08-31,Interventional,"Double-Blind, Randomized, Placebo-Controlled, Adaptive Design, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects",Recruiting,Phase 3,Rigel Pharmaceuticals,NA,https://clinicalzeros.gov/ct2/show/NCT04629703,0,0,0,0,3,1,Peru|United States|Argentina|Brazil|Mexico,0,fostamatinib|placebo,NA
NCT04558385,2020-07-01,2021-03-31,Observational,Seroconversion in COVID-19 Recovered Population,Completed,NA,Lahore General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04558385,0,0,0,0,3,0,Pakistan,0,igg sars cov2,NA
NCT04640428,2020-07-10,2021-10-31,Observational,COVID-19 Stroke Apical Lung Examination Study,Recruiting,NA,King's College Hospital NHS Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04640428,0,0,0,0,4,0,United Kingdom,0,"NA",NA
NCT04609462,2020-08-11,2021-01-13,Interventional,High-Flow Nasal Cannula in Severe COVID-19 With Acute Hypoxemic Respiratory Failure.,Completed,N/A,Fundacion Clinica Valle del Lili,NA,https://clinicalzeros.gov/ct2/show/NCT04609462,0,0,0,0,4,0,Colombia,0,conventional oxygen therapy|high flow nasal cannula,NA
NCT04539821,2020-10-01,2021-04-30,Interventional,Virtual Pain Care Management (COVID-19),Recruiting,N/A,VA Office of Research and Development,NA,https://clinicalzeros.gov/ct2/show/NCT04539821,0,0,0,0,2,1,United States,0,vcpm,NA
NCT04508556,2020-09-30,2020-12-19,Observational,Performance Assessment of SARS-CoV-2 Detection Breath Biopsy - SARS-CoV-2 Study,Completed,NA,Owlstone Ltd,NA,https://clinicalzeros.gov/ct2/show/NCT04508556,0,0,0,0,2,0,Netherlands,0,breath biopsy face masks with removable filters/fitted pva strip|nasopharyngeal swab|oropharyngeal swabs|breath biopsy face masks with removable filters|fitted pva strip,NA
NCT04496245,2020-08-24,2021-06-30,Interventional,Reducing Acute Severe Respiratory Events in Health Care Workers During the Covid-19 Pandemic With OM85,"Active, not recruiting",Phase 3,The University of Queensland,NA,https://clinicalzeros.gov/ct2/show/NCT04496245,0,0,0,0,2,0,Australia,0,broncho-vaxomâ®|broncho-vaxomâ®,NA
NCT04523090,2020-08-27,2021-12-31,Interventional,Catalysing the Containment of COVID-19,Recruiting,Phase 2/Phase 3,University of Cape Town,NA,https://clinicalzeros.gov/ct2/show/NCT04523090,0,0,0,0,3,0,South Africa,0,nitazoxanide|placebo,NA
NCT04466800,2020-07-30,2021-08-30,Interventional,Functional and Respiratory Rehabilitation and Nutritional Care of COVID-19 Patients (RECOVER-19),Recruiting,N/A,Rennes University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04466800,0,0,0,0,5,0,France,0,intervention group_rehabilitation program,NA
NCT04486313,2020-08-13,2021-02-08,Interventional,Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild or Moderate COVID-19,Completed,Phase 3,Romark Laboratories L.C.,NA,https://clinicalzeros.gov/ct2/show/NCT04486313,0,0,0,0,5,1,United States,0,nitazoxanide|placebo|vitamin super b-complex,NA
NCT04401410,2020-11-04,2021-08-15,Interventional,Anti-SARS Cov-2 T Cell Infusions for COVID 19,Recruiting,Phase 1,Baylor College of Medicine,NA,https://clinicalzeros.gov/ct2/show/NCT04401410,0,0,0,0,4,1,United States,0,dose finding phase (mtd)|partially hla-matched sars-covsts|routine care (no sars-covsts),NA
NCT04446169,2020-06-27,2020-09-01,Observational,COVID-19 (SARS-CoV-2) in Urine and Semen,"Active, not recruiting",NA,University of Florence,NA,https://clinicalzeros.gov/ct2/show/NCT04446169,0,0,0,0,5,0,Italy,0,pcr|semen qualitative analysis|questionnaire|interleukin,NA
NCT04445870,2020-05-01,2021-12-31,Observational,Oncology Care Pathway's Modifications Impact During COVID-19 Pandemic : the ONCOCARE-COV Study,Recruiting,NA,CHU de Reims,NA,https://clinicalzeros.gov/ct2/show/NCT04445870,0,0,0,0,2,0,France,0,data record,NA
NCT04382560,2020-05-02,2020-05-31,Interventional,Coping Strategies and Responsiveness to a Brief Online Intervention During COVID-19 Pandemic,Completed,N/A,University of Parma,NA,https://clinicalzeros.gov/ct2/show/NCT04382560,0,0,0,0,2,0,Italy,0,deep breathing training|compassion focused intervention,NA
NCT04381364,2020-05-29,2021-12-01,Interventional,Inhalation of Ciclesonide for Patients With COVID-19: A Randomised Open Treatment Study (HALT COVID-19),Recruiting,Phase 2,St Goran's Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04381364,0,0,0,0,3,0,Sweden,0,ciclesonide,NA
NCT04409743,2020-06-07,2021-10-31,Interventional,Brief Telehealth CBT-I Intervention in the Context of the COVID-19 Pandemic,Recruiting,N/A,Stanford University,NA,https://clinicalzeros.gov/ct2/show/NCT04409743,0,0,0,0,4,1,United States,0,remote cognitive behavioral therapy for insomnia,NA
NCT04360096,2021-02-15,2021-08-15,Interventional,Inhaled ZYESAMIâ„¢ (Aviptadil Acetate) for the Treatment of Moderate and Severe COVID-19,Recruiting,Phase 2/Phase 3,"NeuroRx, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04360096,0,0,0,0,7,1,United States,0,zyesamiâ„¢ (aviptadil acetate)|placebo|nebulized administration of zyesamiâ„¢/placebo|zyesamiâ„¢ (aviptadil acetate)|nebulized administration of zyesamiâ„¢,NA
NCT04397939,2020-05-08,2022-03-31,Observational,Myocardial Injury and Major Adverse Outcomes in Patients With COVID-19,Recruiting,NA,Icahn School of Medicine at Mount Sinai,NA,https://clinicalzeros.gov/ct2/show/NCT04397939,0,0,0,0,2,1,United States,0,"NA",NA
NCT04394195,2020-04-03,2020-05-01,Observational,sFlt1: a Biomarker of Organ Dysfunction in Critically-ill Patients With COVID-19?,Completed,NA,CHU de Reims,NA,https://clinicalzeros.gov/ct2/show/NCT04394195,0,0,0,0,1,0,France,0,measurement of circulating sflt1 concentration,NA
NCT04370119,2020-04-27,2021-05-31,Observational,Screening for COVID-19 and Monitoring of Serological Responses to SARS-CoV-2 in Healthcare Workers,Recruiting,NA,University Medicine Greifswald,NA,https://clinicalzeros.gov/ct2/show/NCT04370119,0,0,0,0,2,0,Germany,0,nasal|serum test,NA
NCT04365764,2020-03-14,2022-12-31,Observational,Effect of Treatments in Patients Hospitalized for Severe COVID-19 Pneumonia: a Multicenter Cohort Study,Recruiting,NA,Groupe Hospitalier Pitie-Salpetriere,NA,https://clinicalzeros.gov/ct2/show/NCT04365764,0,0,0,0,3,0,France,0,"NA",NA
NCT04360278,2020-04-21,2030-04-06,Observational,Plasma Collection From Convalescent and/or Immunized Donors for the Treatment of COVID-19,Recruiting,NA,National Institutes of Health Clinical Center (CC),NA,https://clinicalzeros.gov/ct2/show/NCT04360278,0,0,0,0,17,1,United States,0,"NA",NA
NCT04352634,2020-04-26,2021-12-31,Observational,The Covid-19 HEalth caRe wOrkErS (HEROES) Study,Recruiting,NA,University of Chile,NA,https://clinicalzeros.gov/ct2/show/NCT04352634,0,0,0,0,9,1,United States|Argentina|Armenia|Australia|Bolivia|Chile|Costa Rica|Czechia|Germany|Guatemala|Italy|Lebanon|Mexico|Netherlands|Nigeria|Puerto Rico|Saudi Arabia|Spain|Tunisia|Turkey|Venezuela,0,exposure|its,NA
NCT04388813,2020-05-28,2021-09-30,Observational,Predictors of Severe COVID-19 Outcomes,Recruiting,NA,Verily Life Sciences LLC,NA,https://clinicalzeros.gov/ct2/show/NCT04388813,0,0,0,0,8,1,United States,0,"NA",NA
NCT04383002,2020-09-02,2021-08-31,Interventional,High Dose Inhaled Nitric Oxide for COVID-19 (ICU Patients),Recruiting,Phase 1,"University Health Network, Toronto",NA,https://clinicalzeros.gov/ct2/show/NCT04383002,0,0,0,0,4,0,Canada,0,nitric oxide,NA
NCT04343248,2020-05-12,2021-06-30,Interventional,Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF),"Active, not recruiting",Phase 3,Romark Laboratories L.C.,NA,https://clinicalzeros.gov/ct2/show/NCT04343248,0,0,0,0,6,1,United States,0,nitazoxanide|placebo|vitamin super b-complex,NA
NCT04828915,2021-02-01,2021-07-31,Observational [Patient Registry],Early Detection of Clinical Deterioration in Patients With COVID-19 Using Machine Learning,Recruiting,NA,University Hospital Tuebingen,NA,https://clinicalzeros.gov/ct2/show/NCT04828915,0,0,0,0,0,0,Germany,0,machine learning|machine based evaluation,NA
NCT04830020,2021-02-26,2021-08-31,Interventional,Use of Inhaled High-molecular Weight Hyaluronan in Patients With Severe COVID19: Feasibility and Outcomes,Recruiting,Phase 2,Campus Bio-Medico University,NA,https://clinicalzeros.gov/ct2/show/NCT04830020,0,0,0,0,0,0,Italy,0,hmw-ha,NA
NCT04829552,2020-03-10,2020-04-15,Observational,Prophylactic Versus Therapeutic Dose Anticoagulation In COVID-19 Infection at the Time of Admission To Critical Care Units,Completed,NA,William Beaumont Hospitals,NA,https://clinicalzeros.gov/ct2/show/NCT04829552,0,0,0,0,0,1,United States,0,"NA",NA
NCT04766931,2021-03-27,2021-08-31,Interventional,The Safety and Efficacy of FB2001 in Healthy Subjects and Patients With COVID-19 Infection,Recruiting,Phase 1,Frontier Biotechnologies Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04766931,0,0,0,0,1,1,United States,0,fb2001|fb2001 placebo,NA
NCT04828538,2021-03-01,2021-07-31,Interventional,"Vitamin D, Omega-3, and Combination Vitamins B, C and Zinc Supplementation for the Treatment and Prevention of COVID-19",Recruiting,N/A,Hospital de la Soledad,NA,https://clinicalzeros.gov/ct2/show/NCT04828538,0,0,0,0,0,0,Mexico,0,"vitamin d|omega dha / epa|vitamin c, vitamin b complex/zinc acetate|omega dha|epa|vitamin c, vitamin b complex|zinc acetate",NA
NCT04826367,2021-01-20,2021-12-31,Interventional,Relaxation Training by Tele-Rehabilitation in Patients With Breast Cancer,Recruiting,N/A,Hacettepe University,NA,https://clinicalzeros.gov/ct2/show/NCT04826367,0,0,0,0,1,0,Turkey,0,telerehabilitation-based relaxation exercise group (eg),NA
NCT04828629,2020-12-23,2021-12-01,Observational,Complications and the Influence of COVID-19 on Myocardial Function and Exercise Capacity,Recruiting,NA,Polish Mother Memorial Hospital Research Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04828629,0,0,0,0,0,0,Poland,0,diagnostic tests,NA
NCT04828772,2020-08-17,2021-01-31,Observational,A Study of Anticoagulation Treatment Patterns and Outcomes of Participants Hospitalized With Coronavirus Disease 2019 (COVID-19) in Japan,"Active, not recruiting",NA,Bristol-Myers Squibb,NA,https://clinicalzeros.gov/ct2/show/NCT04828772,0,0,0,0,0,0,Japan,0,"NA",NA
NCT04678739,2020-08-15,2021-01-30,Interventional,Efficacy and Safety of Remdesivir and Tociluzumab for the Management of Severe COVID-19: A Randomized Controlled Trial,Completed,Phase 3,M Abdur Rahim Medical College and Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04678739,0,0,0,0,3,0,Bangladesh,0,remdesivir|tocilizumab,NA
NCT04665752,2021-02-02,2023-06-30,Observational,Ocular Findings and Viral Persistence in Ocular Fluids in COVID-19 Survivors,Recruiting,NA,National Institutes of Health Clinical Center (CC),NA,https://clinicalzeros.gov/ct2/show/NCT04665752,0,0,0,0,40,1,United States,0,"NA",NA
NCT04401423,2021-02-10,2021-06-30,Interventional,TXA127 for the Treatment of Severe COVID-19,Recruiting,Phase 2,Columbia University,NA,https://clinicalzeros.gov/ct2/show/NCT04401423,0,0,0,0,2,1,United States,0,txa127|placebo,NA
NCT04458298,2020-08-11,2021-05-14,Interventional,A Study to Evaluate OP-101 (Dendrimer N-acetyl-cysteine) in Severe Coronavirus Disease 2019 (COVID-19) Patients,"Active, not recruiting",Phase 2,"Orpheris, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04458298,0,0,0,0,5,1,United States,0,op-101|placebo,NA
NCT04646642,2020-12-14,2021-02-01,Observational,"Psychological Health, Coping Strategies and Preferences of Military COVID-19 Deployers",Completed,NA,David Grant U.S. Air Force Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04646642,0,0,0,0,2,1,United States,0,"NA",NA
NCT04640181,2020-12-01,2021-06-30,Interventional,Factor Xa Inhibitor Versus Standard of Care Heparin in Hospitalized Patients With COVID-19 (XACT),Recruiting,Phase 2,St. David's HealthCare,NA,https://clinicalzeros.gov/ct2/show/NCT04640181,0,0,0,0,1,1,United States,0,enoxaparin|rivaroxaban,NA
NCT04583592,2020-11-09,2021-03-31,Interventional,Camostat Efficacy vs. Placebo for Outpatient Treatment of COVID-19 (CAMELOT),Completed,Phase 2,Sagent Pharmaceuticals Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04583592,0,0,0,0,17,1,United States,0,camostat mesilate|placebo,NA
NCT04367870,2020-05-23,2021-05-31,Observational,COVID-19 Detection Test in Oncology,Recruiting,NA,UNICANCER,NA,https://clinicalzeros.gov/ct2/show/NCT04367870,0,0,0,0,2,0,France,0,"NA",NA
NCT04358081,2020-05-01,2020-07-27,Interventional,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Completed,Phase 3,Novartis,NA,https://clinicalzeros.gov/ct2/show/NCT04358081,0,0,0,0,8,1,United States,1,hydroxychloroquine|hydroxychloroquine / azithromycin|placebo|zidovudine,NA
NCT04357574,2020-04-14,2021-04-30,Observational,Assessing the System for High-Intensity Evaluation During Radiotherapy During Changes in Response to COVID-19,Enrolling by invitation,NA,Duke University,NA,https://clinicalzeros.gov/ct2/show/NCT04357574,0,0,0,0,1,1,United States,0,telehealth,NA
NCT04432298,2020-06-20,2021-03-22,Interventional,"Study of the Efficacy and Safety of Intravenous Pamrevlumab, in Hospitalized Participants With Acute COVID-19 Disease",Terminated,Phase 2,FibroGen,The study was terminated by Sponsor due to low enrollment.,https://clinicalzeros.gov/ct2/show/NCT04432298,0,0,0,0,3,1,United States,0,pamrevlumab|placebo,NA
NCT04378777,2020-05-01,2021-03-19,Observational,Immunophenotyping Assessment in a COVID-19 Cohort,"Active, not recruiting",NA,National Institute of Allergy and Infectious Diseases (NIAID),NA,https://clinicalzeros.gov/ct2/show/NCT04378777,0,0,0,0,10,1,United States,0,biological samples|data collection: clinical care assessments,NA
NCT04830800,2021-03-10,2022-05-30,Interventional,A Phase 1/2 Safety and Immunogenicity Trial of COVID-19 Vaccine COVIVAC,Recruiting,Phase 1/Phase 2,"Institute of Vaccines and Medical Biologicals, Vietnam",NA,https://clinicalzeros.gov/ct2/show/NCT04830800,0,0,0,1,0,0,Vietnam,0,covivac|phosphate-buffered saline,NA
NCT04830943,2020-08-01,2021-02-28,Interventional,Cerebrolycin for Treatment of Covid-related Anosmia and Ageusia,Completed,Phase 4,Assiut University,NA,https://clinicalzeros.gov/ct2/show/NCT04830943,0,0,0,0,0,0,Egypt,0,cerebrolysin,NA
NCT04828148,2021-03-01,2021-05-30,Observational,Incidence of Infection and Mortality by COVID-19 in Specialists,Recruiting,NA,Instituto Mexicano del Seguro Social,NA,https://clinicalzeros.gov/ct2/show/NCT04828148,0,0,0,0,1,0,Mexico,0,questionnaire,NA
NCT04799392,2021-04-01,2021-04-30,Interventional,NOWDx Test for the Detection of Antibodies to COVID-19 in Lay Persons,Recruiting,N/A,"NOWDiagnostics, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04799392,0,0,0,0,1,1,United States,0,nowdx covid-19 test,NA
NCT04712110,2021-02-24,2022-04-04,Interventional,A Study of TAK-019 in Healthy Japanese Adults (COVID-19),"Active, not recruiting",Phase 1/Phase 2,Takeda,NA,https://clinicalzeros.gov/ct2/show/NCT04712110,0,0,0,0,4,0,Japan,0,tak-019|placebo,NA
NCT04762680,2021-02-24,2022-04-30,Interventional,Study of Recombinant Protein Vaccine With Adjuvant Against COVID-19 in Adults 18 Years of Age and Older,"Active, not recruiting",Phase 2,Sanofi,NA,https://clinicalzeros.gov/ct2/show/NCT04762680,0,0,0,1,4,1,United States|Honduras,0,sars-cov-2 recombinant protein vaccine formulation 1|sars-cov-2 recombinant protein vaccine formulation 2|sars-cov-2 recombinant protein vaccine formulation 3,NA
NCT04690387,2020-12-07,2021-01-13,Interventional,"Dendritic Cell Vaccine, AV-COVID-19, to Prevent COVID-19 Infection",Completed,Phase 1,"Aivita Biomedical, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04690387,0,0,0,1,2,0,Indonesia,0,av-covid-19|gm-csf,NA
NCT04680949,2020-12-23,2021-03-31,Interventional,suPAR-Guided Anakinra Treatment for Management of Severe Respiratory Failure by COVID-19,"Active, not recruiting",Phase 3,Hellenic Institute for the Study of Sepsis,NA,https://clinicalzeros.gov/ct2/show/NCT04680949,0,0,0,0,4,0,Greece|Italy,0,anakinra|placebo,NA
NCT04746430,2021-02-16,2022-02-28,Interventional,COVID-19 Primary Care Platform for Early Treatment and Recovery (COPPER) Study,Recruiting,Phase 4,General Practitioners Research Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04746430,0,0,0,0,1,0,Netherlands,0,dexamethasone,NA
NCT04710394,2021-01-11,2022-03-11,Interventional,Visual-OLfactory Training in Participants With COVID-19 Resultant Loss of Smell,"Active, not recruiting",N/A,Washington University School of Medicine,NA,https://clinicalzeros.gov/ct2/show/NCT04710394,0,0,0,0,4,1,United States,0,smell training,NA
NCT04655586,2020-12-10,2021-04-30,Interventional,"Assessing Safety, Hospitalization and Efficacy of rNAPc2 in COVID-19",Recruiting,Phase 2/Phase 3,"ARCA Biopharma, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04655586,0,0,0,0,6,1,United States,0,rnapc2|heparin,NA
NCT04608266,2020-12-03,2022-01-31,Interventional,CAMOVID : Evaluation of Efficacy and Safety of Camostat Mesylate for the Treatment of SARS-CoV-2 Infection - COVID-19 in Ambulatory Adult Patients,Recruiting,Phase 3,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04608266,0,0,0,0,3,0,France,0,camostat mesylate|placebo,NA
NCT04527354,2020-09-01,2021-02-10,Interventional,Pilot Study to Assess Efficacy and Safety of Treamid in the Rehabilitation of Patients After COVID-19 Pneumonia,Completed,Phase 2,PHARMENTERPRISES LLC,NA,https://clinicalzeros.gov/ct2/show/NCT04527354,0,0,0,0,3,0,Russian Federation,0,treamid|placebo,NA
NCT04510207,2020-07-16,2021-06-16,Interventional,"A Study to Evaluate The Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and Above",Recruiting,Phase 3,China National Biotec Group Company Limited,NA,https://clinicalzeros.gov/ct2/show/NCT04510207,0,0,0,1,7,0,Bahrain|Egypt|Jordan|United Arab Emirates,0,inactivated sars-cov-2 vaccine|placebo,NA
NCT04511819,2020-08-28,2021-06-30,Interventional,Losmapimod Safety and Efficacy in COVID-19,"Active, not recruiting",Phase 3,Fulcrum Therapeutics,NA,https://clinicalzeros.gov/ct2/show/NCT04511819,0,0,0,0,17,1,United States|Brazil|Mexico|Peru,0,losmapimod|placebo,NA
NCT04488081,2020-07-31,2022-07-24,Interventional,I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients,Recruiting,Phase 2,QuantumLeap Healthcare Collaborative,NA,https://clinicalzeros.gov/ct2/show/NCT04488081,0,0,0,0,4,1,United States,0,remdesivir|cenicriviroc|icatibant|pulmozyme|ic14|celecoxib famotidine|narsoplimab,NA
NCT04351243,2020-04-12,2020-12-01,Interventional,A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE),Completed,Phase 2,Kinevant Sciences GmbH,NA,https://clinicalzeros.gov/ct2/show/NCT04351243,0,0,0,0,12,1,United States,0,gimsilumab|placebo,NA
NCT04481685,2020-07-20,2021-02-25,Interventional,"A Trial of Aclaris Therapeutics, Inc. (ATI)-450 in Patients With Moderate-severe Novel Coronavirus Disease 2019 (COVID-19)","Active, not recruiting",Phase 2,University of Kansas Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04481685,0,0,0,0,3,1,United States,0,ati-450|placebo,NA
NCT04474496,2020-07-27,2020-11-30,Observational,Impact of COVID-19 on Marshallese Communities in the U.S.,Completed,NA,University of Arkansas,NA,https://clinicalzeros.gov/ct2/show/NCT04474496,0,0,0,0,5,1,United States,1,assessing the impact of covid-19,NA
NCT04834115,2020-11-17,2021-04-30,Interventional,Efficacy of Ivermectin in Outpatients With Non-severe COVID-19,Recruiting,Phase 3,Universidad Nacional de AsunciÃ³n,NA,https://clinicalzeros.gov/ct2/show/NCT04834115,0,0,0,0,0,0,Paraguay,0,ivermectin|placebo,NA
NCT04832828,2020-06-01,2020-11-28,Observational,Sensitivity and Specificity of the Roth Test in Patients With COVID-19 Positive,Completed,NA,Universidad Autonoma de Madrid,NA,https://clinicalzeros.gov/ct2/show/NCT04832828,0,0,0,0,0,0,Spain,0,rothâ´s test|rothâ´s test,NA
NCT04371393,2020-04-30,2021-01-14,Interventional,MSCs in COVID-19 ARDS,"Active, not recruiting",Phase 3,Icahn School of Medicine at Mount Sinai,NA,https://clinicalzeros.gov/ct2/show/NCT04371393,0,0,0,0,18,1,United States,0,remestemcel-l|placebo,NA
NCT04355234,2020-05-04,2021-08-31,Interventional,"Prevalence and Impact of COVID-19 Infection in Pregnant Women, Fetuses and Newborns","Active, not recruiting",N/A,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04355234,0,0,0,0,3,0,France,0,serology test|biological samples,NA
NCT04832867,2021-01-01,2021-04-01,Observational,Pulmonary Rehabilitation in COVID-19 Patients,Recruiting,NA,Bakirkoy Dr. Sadi Konuk Research and Training Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04832867,0,0,0,0,0,0,Turkey,0,"NA",NA
NCT04832841,2021-03-18,2021-09-30,Observational,IgG Antibodies After SARS-CoV-2 mRNA Vaccine in Kidney Transplantation (TASMANIA),Recruiting,NA,Institute for Clinical and Experimental Medicine,NA,https://clinicalzeros.gov/ct2/show/NCT04832841,0,0,0,0,0,0,Czechia,0,anti-spike sars-cov-2 igg,NA
NCT04828668,2021-04-02,2021-10-31,Interventional,Study to Evaluate Benefits & Safety of Endourage Formula Câ„¢ Oral Drops in People With Post-Acute COVID-19 Syndrome.,Recruiting,N/A,"Endourage, LLC",NA,https://clinicalzeros.gov/ct2/show/NCT04828668,0,0,0,0,2,1,United States,0,targeted wellness formula câ„¢ sublingual drops - 1200mg - 30 ml (formula c)|targeted wellness formula câ„¢ sublingual drops - 1200mg - 30 ml (formula c),NA
NCT04826731,2021-04-01,2021-06-30,Observational,Effect of Respiratory Exerciser on Pulmonary Functions of COVID-19 Patients,Recruiting,NA,Diskapi Yildirim Beyazit Education and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04826731,0,0,0,0,1,0,Turkey,0,incentive spirometer/respiratory exerciser|incentive spirometer|respiratory exerciser,NA
NCT04824495,2021-01-07,2021-08-31,Observational,Evaluation of Inflammatory Cytokines During COVID-19,Recruiting,NA,University of Vienna,NA,https://clinicalzeros.gov/ct2/show/NCT04824495,0,0,0,0,1,0,Austria,0,blood sample,NA
NCT04710199,2021-02-08,2021-08-31,Interventional,Trial to Evaluate the Safety and Efficacy of Maraviroc in Patients Hospitalized for Coronavirus Disease 2019 (COVID-19),Recruiting,Phase 2,FundaciÃ³n PÃºblica Andaluza para la gestiÃ³n de la InvestigaciÃ³n en Sevilla,NA,https://clinicalzeros.gov/ct2/show/NCT04710199,0,0,0,0,1,0,Spain,0,maraviroc experimental group|standard care,NA
NCT04818320,2021-02-16,2021-08-31,Interventional,Favipiravir in High-risk COVID-19 Patients,Recruiting,Phase 3,"Penang Hospital, Malaysia",NA,https://clinicalzeros.gov/ct2/show/NCT04818320,0,0,0,0,2,0,Malaysia,0,favipiravir,NA
NCT04806620,2020-05-01,2025-05-01,Observational [Patient Registry],Comparison of ME/CFS and Long COVID-19 Patients,Recruiting,NA,Solve ME/CFS Initiative,NA,https://clinicalzeros.gov/ct2/show/NCT04806620,0,0,0,0,1,1,United States,0,"NA",NA
NCT04679493,2020-12-24,2021-04-30,Interventional,"Study to Assess Safety, Tolerability and Pharmacokinetics of XC7 (Which is Planned Use in the Treatment of COVID-19) in Healthy Volunteers","Active, not recruiting",Phase 1,NP Therapeutics,NA,https://clinicalzeros.gov/ct2/show/NCT04679493,0,0,0,0,1,0,Russian Federation,0,xc7 100 mg single|xc7 200 mg single|placebo single|xc7 200 mg multiple|placebo multiple,NA
NCT04668209,2021-01-01,2021-09-30,Interventional,Silmitasertib (CX-4945) in Patients With Severe Coronavirus Disease 2019 (COVID-19),Recruiting,Phase 2,University of Arizona,NA,https://clinicalzeros.gov/ct2/show/NCT04668209,0,0,0,0,2,1,United States,0,silmitasertib,NA
NCT04688372,2020-10-01,2021-02-15,Observational,Hospital COVID-19 Surge and Associated Mortality Risk,Completed,NA,National Institutes of Health Clinical Center (CC),NA,https://clinicalzeros.gov/ct2/show/NCT04688372,0,0,0,0,2,1,United States,0,surge index,NA
NCT04537806,2020-12-18,2021-10-31,Interventional,A Study of Brexanolone for Acute Respiratory Distress Syndrome Due to COVID-19,Recruiting,Phase 3,Sage Therapeutics,NA,https://clinicalzeros.gov/ct2/show/NCT04537806,0,0,0,0,3,1,United States,0,brexanolone|placebo,NA
NCT04505761,2020-08-01,2021-02-01,Interventional,"The Usability, Feasibility, and Tolerability of Virtual Reality for Rehabilitation From COVID-19",Completed,N/A,Radboud University,NA,https://clinicalzeros.gov/ct2/show/NCT04505761,0,0,0,0,2,0,Netherlands,0,virtual reality,NA
NCT04568499,2020-11-27,2021-06-30,Observational,"Presenting Nutrition Characteristics, Comorbidities and Outcomes of COVID-19 in African Humanitarian Settings",Recruiting,NA,Johns Hopkins Bloomberg School of Public Health,NA,https://clinicalzeros.gov/ct2/show/NCT04568499,0,0,0,0,1,0,"Congo, The Democratic Republic of the|South Sudan",0,"NA",NA
NCT04494893,2020-04-24,2021-03-23,Observational,ImmuneRACE - Immune Response Action to COVID-19 Events,"Active, not recruiting",NA,Adaptive Biotechnologies,NA,https://clinicalzeros.gov/ct2/show/NCT04494893,0,0,0,0,1,1,United States,0,"NA",NA
NCT04536298,2020-12-28,2021-06-30,Interventional,Vitamin D and COVID-19 Trial,Recruiting,Phase 3,Brigham and Women's Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04536298,0,0,0,0,3,1,United States,0,vitamin d|placebo,NA
NCT04836351,2021-03-01,2023-12-30,Interventional,Rehabilitation for Patients With Persistent Symptoms Post COVID-19,Recruiting,N/A,Western Norway University of Applied Sciences,NA,https://clinicalzeros.gov/ct2/show/NCT04836351,0,0,0,0,0,0,Norway,0,concentrated rehabilitation for patients with persistent symptoms post covid-19,NA
NCT04428021,2020-06-15,2021-03-31,Interventional,Standard or Convalescent Plasma in Patients With Recent Onset of COVID-19 Respiratory Failure,"Active, not recruiting",Phase 2,Azienda Ospedaliera CittÃ  della Salute e della Scienza di Torino,NA,https://clinicalzeros.gov/ct2/show/NCT04428021,0,0,0,0,2,0,Italy,0,standard therapy protocol (stp)|stp / standard plasma (sp)|stp / covid-19 convalescent plasma (cp)|stp|plasma|covid-19 convalescent plasma (cp),NA
NCT04426695,2020-06-11,2021-04-16,Interventional,"Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19",Recruiting,Phase 1/Phase 2,Regeneron Pharmaceuticals,NA,https://clinicalzeros.gov/ct2/show/NCT04426695,0,0,0,0,19,1,"United States|Brazil|Chile|Mexico|Moldova, Republic of|Romania",0,regn10933/regn10987 combination therapy|placebo|regn10933|regn10987,NA
NCT04356833,2020-04-22,2021-04-30,Interventional,Nebulised Rt-PA for ARDS Due to COVID-19,Recruiting,Phase 2,"University College, London",NA,https://clinicalzeros.gov/ct2/show/NCT04356833,0,0,0,0,2,0,United Kingdom,0,nebulised recombinant tissue-plasminogen activator (rt-pa) - cohort 1|nebulised recombinant tissue-plasminogen activator (rt-pa) - cohort 2 imv|nebulised recombinant tissue-plasminogen activator (rt-pa) - cohort 2 niv,NA
NCT04838106,2020-08-01,2021-11-01,Observational,Outcomes of Patients Who Survived Treatment on an Intensive Care Unit for COVID-19 in England and Wales,"Active, not recruiting",NA,University of Oxford,NA,https://clinicalzeros.gov/ct2/show/NCT04838106,0,0,0,0,0,0,United Kingdom,0,not applicable as observational study,NA
NCT04838093,2020-03-01,2020-12-01,Observational,COVID-19 Testing in Patients With Vascular Disorders,Completed,NA,Medical University of Vienna,NA,https://clinicalzeros.gov/ct2/show/NCT04838093,0,0,0,0,0,0,Austria,0,pcr,NA
NCT04836065,2020-07-01,2020-09-30,Observational,ESICM UNITE COVID-19 Project (UNITE-COVID),Completed,NA,"University Hospital, Ghent",NA,https://clinicalzeros.gov/ct2/show/NCT04836065,0,0,0,0,0,0,Belgium,0,"NA",NA
NCT04476992,2020-07-24,2021-07-17,Interventional,Nitric Oxide Therapy for COVID-19 Patients With Oxygen Requirement,"Active, not recruiting",Phase 1/Phase 2,Tomsk National Research Medical Center of the Russian Academy of Sciences,NA,https://clinicalzeros.gov/ct2/show/NCT04476992,0,0,0,0,4,0,Russian Federation,0,nitric oxide|sessions,NA
NCT04836260,2021-04-08,2021-12-31,Interventional,Preemptive Use of Convalescent Plasma for High-risk Patients With COVID-19,Recruiting,Phase 3,"University Hospital, Geneva",NA,https://clinicalzeros.gov/ct2/show/NCT04836260,0,0,0,0,0,0,Switzerland,0,convalescent plasma,NA
NCT04839913,2020-09-01,2020-12-10,Observational,"Seroprevalence of SARS-CoV-2 in Unselected Surgical Patients: an Unicentric, Regional Study",Completed,NA,University of Cagliari,NA,https://clinicalzeros.gov/ct2/show/NCT04839913,0,0,0,0,0,0,Italy,0,antibodies testing,NA
NCT04839094,2020-12-10,2021-02-01,Observational,Dry Versus Wet Nasopharyngeal Rapid Test for the Detection of COVID-19.,Completed,NA,Centre Hospitalier Universitaire Vaudois,NA,https://clinicalzeros.gov/ct2/show/NCT04839094,0,0,0,0,0,0,Switzerland,0,rapid antigen testing versus rt-pcr,NA
NCT04838834,2020-05-15,2024-12-31,Observational,Monitoring Serologic Response to Severe Acute Respiratory Syndrome-2 (SARS-COV-2)/COVID-19 in Children,"Active, not recruiting",NA,Connecticut Children's Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04838834,0,0,0,0,0,1,United States,0,"NA",NA
NCT04839315,2021-02-15,2021-12-31,Interventional,COVID-19 Vaccination in Rheumatic Disease Patients,Recruiting,Early Phase 1,Mayo Clinic,NA,https://clinicalzeros.gov/ct2/show/NCT04839315,0,0,0,1,0,1,United States,0,mrna covd19 vaccine,NA
NCT04836052,2020-12-24,2021-08-24,Interventional,Omega-3 Oil Use in COVID-19 Patients in Qatar,Recruiting,Phase 3,Hamad Medical Corporation,NA,https://clinicalzeros.gov/ct2/show/NCT04836052,0,0,0,0,0,0,Qatar,0,omega 3 fatty acid,NA
NCT04836039,2021-01-27,2021-02-27,Observational,Rehabilitation Experiences of Physiotherapists in Covid-19 Outbreak,Completed,NA,Medipol University,NA,https://clinicalzeros.gov/ct2/show/NCT04836039,0,0,0,0,0,0,Turkey,0,a questionnaire/scales.|a questionnaire|scales.,NA
NCT04834739,2021-01-04,2021-03-28,Interventional,Comparison of Functional Capacities of Healthcare Workers With and Without Covid-19,Recruiting,N/A,Gaziosmanpasa Research and Education Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04834739,0,0,0,0,0,0,Turkey,0,6 minute walk test|1 minute sit to stand test|fatigue severity scale|medical research council (mrc) dyspnea scale|sf-12|beck depression inventory|beck anxiety inventory|5 times sit to stand test|6 point likert scale,NA
NCT04834934,2020-02-16,2020-09-30,Observational,Artificial Intelligence - SARS-CoV-2 Risk Evaluation,Recruiting,NA,IRCCS San Raffaele,NA,https://clinicalzeros.gov/ct2/show/NCT04834934,0,0,0,0,0,0,Italy,0,"NA",NA
NCT04834882,2021-01-20,2021-05-20,Observational,"Burnout, Stress and Coping Strategies: Impact of the Covid-19 Epidemic",Recruiting,NA,CHU de Reims,NA,https://clinicalzeros.gov/ct2/show/NCT04834882,0,0,0,0,0,0,France,0,data collection (,NA
NCT04834856,2021-04-01,2021-10-31,Interventional,"Viral Clearance, PK and Tolerability of Ensovibep in COVID-19 Patients",Recruiting,Phase 2,Molecular Partners AG,NA,https://clinicalzeros.gov/ct2/show/NCT04834856,0,0,0,0,0,0,Netherlands,0,ensovibep,NA
NCT04834401,2021-03-22,2023-02-15,Observational,Effect of Disease Modifying Therapy on Antibody Response to COVID19 Vaccination in Multiple Sclerosis,Recruiting,NA,St. Barnabas Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04834401,0,0,0,0,0,1,United States,0,"NA",NA
NCT04808921,2021-01-09,2021-01-18,Interventional,Performance Evaluation of SARS-COV-2 (Covid-19) Antigen Rapid Test,Completed,N/A,"Sky Medical Supplies & Equipments, LLC",NA,https://clinicalzeros.gov/ct2/show/NCT04808921,0,0,0,0,2,1,United States,0,"xiamen wiz biotech co., ltd. sars-cov-2 antigen rapid test",NA
NCT04824443,2021-03-29,2023-03-29,Interventional,Exercise Therapy in Cancer Patients Who Are Recovering From COVID-19,Recruiting,Phase 1,Memorial Sloan Kettering Cancer Center,NA,https://clinicalzeros.gov/ct2/show/NCT04824443,0,0,0,0,1,1,United States,0,aerobic exercise therapy,NA
NCT04805970,2021-04-30,2022-01-31,Observational,REsearching Covid-19 Outcomes in Diabetes (RECODE),Recruiting,NA,"Translational Research Institute for Metabolism and Diabetes, Florida",NA,https://clinicalzeros.gov/ct2/show/NCT04805970,0,0,0,0,1,1,United States,0,"NA",NA
NCT04830683,2020-04-27,2021-03-25,Observational [Patient Registry],Endothelial Dysfunction in Covid-19,Recruiting,NA,Cliniques universitaires Saint-Luc- UniversitÃ© Catholique de Louvain,NA,https://clinicalzeros.gov/ct2/show/NCT04830683,0,0,0,0,1,0,Belgium,0,"NA",NA
NCT04818853,2021-03-09,2023-03-01,Observational,COVID-19 Associated Pulmonary Aspergillosis (CAPA) and Other Invasive Fungal Infections (IFI),Recruiting,NA,University of Alabama at Birmingham,NA,https://clinicalzeros.gov/ct2/show/NCT04818853,0,0,0,0,1,1,United States,0,observation to monitor patients for these infections,NA
NCT04818281,2021-03-27,2022-01-31,Interventional,Study of a Severe Acute Respiratory Syndrome CoV-2 (SARS-CoV-2) Virus-like Particle (VLP) Vaccine in Healthy Adults,Recruiting,Phase 1,The Scientific and Technological Research Council of Turkey,NA,https://clinicalzeros.gov/ct2/show/NCT04818281,0,0,0,1,2,0,Turkey,0,sars-cov-2 vlp vaccine|placebo,NA
NCT04818164,2020-09-01,2020-12-31,Observational,Prone Position Improves End-Expiratory Lung Volumes in COVID-19 Acute Respiratory Distress Syndrome,Completed,NA,Istanbul University-Cerrahpasa,NA,https://clinicalzeros.gov/ct2/show/NCT04818164,0,0,0,0,1,0,Turkey,0,"NA",NA
NCT04817397,2021-03-20,2021-06-30,Observational,The Lymphocyte/Neutrophil Ratio as a Prognostic Index for Short Term Outcome in the ICU Admitted COVID-19 Adult Patients,Recruiting,NA,Assiut University,NA,https://clinicalzeros.gov/ct2/show/NCT04817397,0,0,0,0,1,0,Egypt,0,"NA",NA
NCT04817280,2020-12-01,2021-01-17,Observational,COVID-19 in Polish Ice Swimmers.,Completed,NA,Wroclaw Medical University,NA,https://clinicalzeros.gov/ct2/show/NCT04817280,0,0,0,0,1,0,Poland,0,ice swimming,NA
NCT04798053,2021-04-08,2022-10-31,Interventional,Impact of COVID-19 Pandemic and Social Distancing on Mental Health of Chronic Inflammatory Rheumatism Affected Patients,Recruiting,N/A,"University Hospital, Bordeaux",NA,https://clinicalzeros.gov/ct2/show/NCT04798053,0,0,0,0,1,0,France,0,questionnaire|blood sample/salivary sample|blood sample|salivary sample,NA
NCT04789499,2021-03-15,2021-07-31,Interventional,Smell in Covid-19 and Efficacy of Nasal Theophylline,Recruiting,Phase 2,Washington University School of Medicine,NA,https://clinicalzeros.gov/ct2/show/NCT04789499,0,0,0,0,1,1,United States,0,theophylline powder,NA
NCT04796402,2021-03-17,2021-06-30,Interventional,A Study to Assess if a Medicine Called Bamlanivimab is Safe and Effective in Reducing Hospitalization Due to COVID-19,Recruiting,Phase 4,Fraser Health,NA,https://clinicalzeros.gov/ct2/show/NCT04796402,0,0,0,0,2,0,Canada,0,bamlanivimab|standard care,NA
NCT04800939,2021-04-05,2021-06-22,Interventional,The Effect of Acupressure on the Sleep Quality and Daytime Sleepiness,Recruiting,N/A,Mersin University,NA,https://clinicalzeros.gov/ct2/show/NCT04800939,0,0,0,0,2,0,Turkey,0,acupressure|plasebo acupressure,NA
NCT04747821,2021-02-07,2021-05-31,Interventional,An Effectiveness Study of the Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine,"Active, not recruiting",Phase 4,Butantan Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04747821,0,0,0,1,1,0,Brazil,0,adsorbed covid-19 (inactivated) vaccine,NA
NCT04761107,2021-02-18,2023-02-28,Observational,Impact of COVID-19 on GU Disease,Recruiting,NA,Icahn School of Medicine at Mount Sinai,NA,https://clinicalzeros.gov/ct2/show/NCT04761107,0,0,0,0,1,1,United States,0,"NA",NA
NCT04716426,2021-01-28,2021-03-25,Interventional,APTâ„¢ T3X on the COVID-19 Contamination Rate,Completed,N/A,University of Nove de Julho,NA,https://clinicalzeros.gov/ct2/show/NCT04716426,0,0,0,0,4,0,Brazil,1,tetracycline hydrochloride 3%|placebo,NA
NCT04734561,2021-02-08,2022-07-30,Interventional,Effects of Respiratory Muscle Training in People Who Have Had COVID-19 Disease,Recruiting,N/A,Universidad Complutense de Madrid,NA,https://clinicalzeros.gov/ct2/show/NCT04734561,0,0,0,0,1,0,Spain,0,inspiratory muscle training group|inspiratory muscle training placebo group|inspiratory / expiratory muscle training group|inspiratory / expiratory muscle training placebo group|inspiratory|expiratory muscle training group|expiratory muscle training placebo group,NA
NCT04709835,2021-02-03,2021-06-03,Interventional,Study to Evaluate the Effects of AT-527 in Non-Hospitalized Adult Patients With Mild or Moderate COVID-19,Recruiting,Phase 2,Hoffmann-La Roche,NA,https://clinicalzeros.gov/ct2/show/NCT04709835,0,0,0,0,3,1,United States|Bulgaria|Canada|Greece|Ireland|Latvia|Poland|Spain|United Kingdom,0,at-527|placebo,NA
NCT04718220,2021-03-01,2022-11-30,Interventional,"Safety, Testing/Transmission, and Outcomes in Pregnancies With COVID-19",Recruiting,N/A,Washington University School of Medicine,NA,https://clinicalzeros.gov/ct2/show/NCT04718220,0,0,0,0,1,1,United States,0,antibody testing for sars-cov-2 igg|testing for sars-cov-2 rna|testing for sars-cov-2 igm/igg|testing for sars-cov-2 igm|igg,NA
NCT04686734,2021-01-06,2021-05-30,Observational,Long-term Effects of COVID-19 in Adolescents,Recruiting,NA,"University Hospital, Akershus",NA,https://clinicalzeros.gov/ct2/show/NCT04686734,0,0,0,0,2,0,Norway,0,no active intervention (observational only),NA
NCT04669925,2020-09-01,2021-07-31,Observational,COVID-19 Impact on the Lombardy Region's Emergency System,"Active, not recruiting",NA,Mario Negri Institute for Pharmacological Research,NA,https://clinicalzeros.gov/ct2/show/NCT04669925,0,0,0,0,1,0,Italy,0,"NA",NA
NCT04667923,2020-10-01,2021-06-30,Observational,Noninvasive Ventilation in Moderate-to-severe COVID-19-associated Acute Respiratory Distress-syndrome,Recruiting,NA,I.M. Sechenov First Moscow State Medical University,NA,https://clinicalzeros.gov/ct2/show/NCT04667923,0,0,0,0,2,0,Russian Federation,0,respiratory monitoring|respiratory muscles ultrasound|electro impedance tomography|capnography|arterial blood gas|quasistatic pressure-volume curve,NA
NCT04665960,2021-03-29,2021-04-25,Observational,Infection Control for Severe Acute Respiratory Syndrome Coronavirus 2,Enrolling by invitation,NA,NMC Specialty Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04665960,0,0,0,0,7,0,United Arab Emirates,0,"NA",NA
NCT04672564,2021-03-30,2021-06-30,Interventional,Study to Evaluate Safety and Efficacy of Carrimycin for Treatment of Severe Coronavirus Disease 2019 (COVID-19) in Hospitalized Patients,Recruiting,Phase 3,"Shenyang Tonglian Group CO., Ltd",NA,https://clinicalzeros.gov/ct2/show/NCT04672564,0,0,0,0,3,1,United States|Argentina|Brazil|Colombia|India|Mexico|Peru|Philippines|Ukraine,0,carrimycin|placebo,NA
NCT04655625,2020-11-23,2021-04-02,Interventional,Phase II / III Study of COVID-19 DNA Vaccine (AG0302-COVID19),"Active, not recruiting",Phase 2/Phase 3,"AnGes, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04655625,0,0,0,1,2,0,Japan,0,group a (ag0302-covid19)|group a (placebo)|group b (ag0302-covid19)|group b (placebo),NA
NCT04625725,2020-11-21,2021-04-21,Interventional,"Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult.","Active, not recruiting",Phase 3,AstraZeneca,NA,https://clinicalzeros.gov/ct2/show/NCT04625725,0,0,0,0,4,1,United States|Belgium|France|Spain|United Kingdom,0,azd7442|placebo,NA
NCT04625985,2020-07-14,2021-03-08,Interventional,"Metformin Glycinate, Treatment of Patients With COVID-19 and Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2.",Completed,Phase 2,Laboratorios Silanes S.A. de C.V.,NA,https://clinicalzeros.gov/ct2/show/NCT04625985,0,0,0,0,1,0,Mexico,0,metformin glycinate|placebo,NA
NCT04621071,2021-01-12,2021-06-30,Interventional,Efficacy of Probiotics in Reducing Duration and Symptoms of COVID-19,Recruiting,N/A,Centre de recherche du Centre hospitalier universitaire de Sherbrooke,NA,https://clinicalzeros.gov/ct2/show/NCT04621071,0,0,0,0,4,0,Canada,0,probiotics (2 strains 10x10^9 ufc)|placebo (potato starch/magnesium stearate)|placebo (potato starch|magnesium stearate),NA
NCT04606498,2020-12-18,2021-12-31,Observational,Blood Purification With Seraph 100 Microbind Affinity Blood Filter for Treatment of Severe COVID19 Observational Study,Recruiting,NA,Henry M. Jackson Foundation for the Advancement of Military Medicine,NA,https://clinicalzeros.gov/ct2/show/NCT04606498,0,0,0,0,9,1,United States,0,observational,NA
NCT04602351,2021-03-22,2021-04-07,Observational,Communication in ICU During COVID-19,Enrolling by invitation,NA,NMC Specialty Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04602351,0,0,0,0,4,0,United Arab Emirates,0,communication,NA
NCT04594343,2020-11-20,2021-07-20,Interventional,Clinical Study to Evaluate the Effects of Disulfiram in Patients With Moderate COVID-19,Recruiting,Phase 2,ETICA,NA,https://clinicalzeros.gov/ct2/show/NCT04594343,0,0,0,0,3,0,Brazil,0,disulfiram|placebo,NA
NCT04598594,2020-11-06,2021-04-30,Interventional,Evaluation of the Efficacy of Nicotine Patches in SARS-CoV2 (COVID-19) Infection in Intensive Care Unit Patients,"Active, not recruiting",Phase 3,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04598594,0,0,0,0,7,0,France,0,"patch, nicotine|patch, placebo",NA
NCT04588363,2020-11-19,2021-11-30,Observational,COVID-19: Pediatric Research Immune Network on SARS-CoV-2 and MIS-C,Recruiting,NA,National Institute of Allergy and Infectious Diseases (NIAID),NA,https://clinicalzeros.gov/ct2/show/NCT04588363,0,0,0,0,21,1,United States,0,sars-cov-2 and/or mis-c exposure|sars-cov-2 and|or mis-c exposure,NA
NCT04590547,2021-04-30,2021-10-31,Interventional,GLS-1027 for the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection (COVID-19),Recruiting,Phase 2,"GeneOne Life Science, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04590547,0,0,0,0,3,1,United States,0,gls-1027|placebo,NA
NCT04583345,2020-06-01,2021-07-01,Observational,Physical Activity Levels of Hypertensive and Healthy Individuals Under Social Isolation During the COVID-19 Pandemic,Recruiting,NA,Hacettepe University,NA,https://clinicalzeros.gov/ct2/show/NCT04583345,0,0,0,0,3,0,Turkey,0,questionnaire,NA
NCT04558125,2020-09-08,2021-12-31,Interventional,Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism,Recruiting,Phase 4,Cedars-Sinai Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04558125,0,0,0,0,2,1,United States,0,tnkase,NA
NCT04563702,2020-09-21,2021-05-10,Interventional,Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults,"Active, not recruiting",Phase 1,Vaxart,NA,https://clinicalzeros.gov/ct2/show/NCT04563702,0,0,0,1,3,1,United States,0,vxa-cov2-1,NA
NCT04556513,2020-09-18,2021-12-31,Observational,Functional Recovery From Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19: Influence of Socio-Economic Status,Recruiting,NA,Centre Hospitalier Universitaire Dijon,NA,https://clinicalzeros.gov/ct2/show/NCT04556513,0,0,0,0,3,0,France,0,paraclinical examination|clinical examination|semi-directive interview|quality of life questionnaires,NA
NCT04496128,2020-04-13,2021-03-31,Observational,COVID19 Neurological Manifestation,"Active, not recruiting",NA,University of Pittsburgh,NA,https://clinicalzeros.gov/ct2/show/NCT04496128,0,0,0,0,3,1,United States,0,"NA",NA
NCT04539262,2020-09-14,2021-02-26,Interventional,"Study in Participants With Early Stage Coronavirus Disease 2019 (COVID-19) to Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered by Inhalation",Completed,Phase 1/Phase 2,Gilead Sciences,NA,https://clinicalzeros.gov/ct2/show/NCT04539262,0,0,0,0,9,1,United States,0,remdesivir|placebo,NA
NCT04508777,2020-09-09,2020-12-08,Observational,COVID SAFE: COVID-19 Screening Assessment for Exposure,Enrolling by invitation,NA,University of Pennsylvania,NA,https://clinicalzeros.gov/ct2/show/NCT04508777,0,0,0,0,4,1,United States,0,saliva,NA
NCT04507256,2020-08-18,2021-10-25,Interventional,AZD7442 - a Potential Combination Therapy for the Prevention and Treatment of COVID-19,"Active, not recruiting",Phase 1,AstraZeneca,NA,https://clinicalzeros.gov/ct2/show/NCT04507256,0,0,0,0,5,0,United Kingdom,0,azd7442|placebo,NA
NCT04496076,2020-04-02,2021-03-31,Observational,COVID-19 Brain Injury,"Active, not recruiting",NA,University of Pittsburgh,NA,https://clinicalzeros.gov/ct2/show/NCT04496076,0,0,0,0,3,1,United States,0,"NA",NA
NCT04488796,2020-09-07,2020-12-16,Interventional,STAND UP to SARS-CoV-2 (COVID-19): Using Behavioural Economics to Reduce Sedentary Behaviour in At-home Office Workers,Completed,N/A,"Western University, Canada",NA,https://clinicalzeros.gov/ct2/show/NCT04488796,0,0,0,0,5,0,Canada,0,assigned strategies: opt-in|assigned strategies: active choice|assigned strategies: enhanced active choice|choice of assignment: opt-in|choice of assignment: active choice|choice of assignment: enhanced active choice,NA
NCT04479488,2020-07-27,2021-03-30,Observational [Patient Registry],Brazilian Registry for Clinical Presentation of Individuals With COVID-19 (SARS-Brazil),"Active, not recruiting",NA,Hospital Israelita Albert Einstein,NA,https://clinicalzeros.gov/ct2/show/NCT04479488,0,0,0,0,4,0,Brazil,0,hospital admission|non-hospitalization procedures,NA
NCT04478019,2020-07-07,2022-04-30,Interventional,SHIELD Study: Using Naso-oropharyngeal Antiseptic Decolonization to Reduce COVID-19 Viral Shedding,Recruiting,Early Phase 1,"University of Wisconsin, Madison",NA,https://clinicalzeros.gov/ct2/show/NCT04478019,0,0,0,0,3,1,United States,0,povidone-iodine|0.12% chg oral rinse,NA
NCT04477993,2020-08-14,2021-03-29,Interventional,Ruxolitinib for Acute Respiratory Disorder Syndrome Due to COVID-19,Terminated,Phase 2/Phase 3,University of Sao Paulo General Hospital,Low accrual,https://clinicalzeros.gov/ct2/show/NCT04477993,0,0,0,0,1,0,Brazil,0,ruxolitinib|placebo,NA
NCT04429529,2020-06-09,2020-11-19,Interventional,"Safety of TY027, a Treatment for COVID-19, in Humans",Completed,Phase 1,Tychan Pte Ltd.,NA,https://clinicalzeros.gov/ct2/show/NCT04429529,0,0,0,0,2,0,Singapore,0,ty027|saline,NA
NCT04439071,2020-07-09,2021-07-31,Interventional,A Study to Evaluate Efficacy and Safety of PTC299 in Hospitalized Participants With Coronavirus (COVID-19),Recruiting,Phase 2/Phase 3,PTC Therapeutics,NA,https://clinicalzeros.gov/ct2/show/NCT04439071,0,0,0,0,5,1,United States|Australia|Belgium|Brazil|Mexico|Portugal|Spain,0,ptc299|standard care|placebo,NA
NCT04280224,2020-02-15,2021-12-30,Interventional,NK Cells Treatment for COVID-19,Recruiting,Phase 1,Xinxiang medical university,NA,https://clinicalzeros.gov/ct2/show/NCT04280224,0,0,0,0,2,0,China,0,nk cells,NA
NCT04378452,2020-03-31,2021-03-22,Observational [Patient Registry],Assessment of the Psycho-social Impact of COVID-19 Outbreak,Completed,NA,FundaciÃ³ Institut Germans Trias i Pujol,NA,https://clinicalzeros.gov/ct2/show/NCT04378452,0,0,0,0,4,0,Spain,0,survey,NA
NCT04405986,2020-05-19,2021-03-10,Interventional,Exploring Brain Damages After COVID-19 Infection,Completed,N/A,"University Hospital, Bordeaux",NA,https://clinicalzeros.gov/ct2/show/NCT04405986,0,0,0,0,3,0,France,0,auditory evoked potentials (aep)|blink/masseter inhibitory reflex|blink|masseter inhibitory reflex,NA
NCT04402944,2020-07-05,2021-05-31,Interventional,Pulmozyme to Improve COVID-19 ARDS Outcomes,Recruiting,Phase 2,Boston Children's Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04402944,0,0,0,0,3,1,United States,0,pulmozyme|placebo,NA
NCT04373460,2020-06-03,2022-12-21,Interventional,Convalescent Plasma to Limit SARS-CoV-2 Associated Complications,Recruiting,Phase 2,Johns Hopkins University,NA,https://clinicalzeros.gov/ct2/show/NCT04373460,0,0,0,0,23,1,United States,0,convalescent plasma|plasma,NA
NCT04390139,2020-05-13,2021-10-31,Interventional,Efficacy and Safety Evaluation of Mesenchymal Stem Cells for the Treatment of Patients With Respiratory Distress Due to COVID-19,Recruiting,Phase 1/Phase 2,Banc de Sang i Teixits,NA,https://clinicalzeros.gov/ct2/show/NCT04390139,0,0,0,0,1,0,Spain,0,xcel-umc-beta|placebo,NA
NCT04373148,2020-04-08,2022-04-30,Observational,"Understanding Immunity to SARS-CoV-2, the Coronavirus Causing COVID-19",Recruiting,NA,Stanford University,NA,https://clinicalzeros.gov/ct2/show/NCT04373148,0,0,0,0,7,1,United States,0,no intervention,NA
NCT04371835,2020-08-12,2021-12-31,Observational,COHIVE: Coronavirus (COVID-19) Outcomes in HIV Evaluation in Resource Limited Settings,Recruiting,NA,Kirby Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04371835,0,0,0,0,2,0,Argentina|Brazil|Cameroon|India|Malaysia|Nigeria|South Africa|Thailand|Uganda|Zimbabwe,0,"NA",NA
NCT04357444,2020-10-23,2020-11-02,Interventional,Low Dose of IL-2 In Acute Respiratory DistrEss Syndrome Related to COVID-19,"Active, not recruiting",Phase 2,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04357444,0,0,0,0,3,0,France,0,human recombinant interleukin 2|placebo,NA
NCT04331886,2020-04-13,2022-03-31,Observational,An Observational Study of Patients With Coronavirus Disease 2019,Recruiting,NA,"Target PharmaSolutions, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04331886,0,0,0,0,5,1,United States,0,"NA",NA
NCT04329195,2020-04-09,2020-12-09,Interventional,ACE Inhibitors or ARBs Discontinuation in Context of COVID-19 Pandemic,Terminated,Phase 3,Assistance Publique - HÃ´pitaux de Paris,insufficient recrutment,https://clinicalzeros.gov/ct2/show/NCT04329195,0,0,0,0,4,0,France,0,discontinuation of ras blocker|continuation of ras blocker,NA
NCT04334512,2020-06-22,2021-06-30,Interventional,A Study of Quintuple Therapy to Treat COVID-19 Infection,Recruiting,Phase 2,ProgenaBiome,NA,https://clinicalzeros.gov/ct2/show/NCT04334512,0,0,0,0,5,1,United States,0,hydroxychloroquine|azithromycin|vitamin c|vitamin d|zinc,NA
NCT04323800,2020-06-10,2022-12-31,Interventional,Convalescent Plasma to Stem Coronavirus (CSSC-001),"Active, not recruiting",Phase 2,Johns Hopkins University,NA,https://clinicalzeros.gov/ct2/show/NCT04323800,0,0,0,0,21,1,United States,0,convalescent plasma|plasma,NA
NCT04841759,2021-04-01,2021-09-30,Interventional,The Effects of a Multi-factorial Rehabilitation Program for Healthcare Workers Suffering From Post-COVID-19 Fatigue Syndrome,Recruiting,N/A,Medical University of Vienna,NA,https://clinicalzeros.gov/ct2/show/NCT04841759,0,0,0,0,0,0,Austria,0,exercise,NA
NCT04275245,2020-02-03,2020-03-09,Interventional,Clinical Study of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia,Completed,Phase 1/Phase 2,Tang-Du Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04275245,0,0,0,0,1,0,China,0,meplazumab,NA
NCT04800133,2021-04-30,2025-03-31,Interventional,Covid-19 Vaccination in Adolescents,Recruiting,Phase 2,The University of Hong Kong,NA,https://clinicalzeros.gov/ct2/show/NCT04800133,0,0,0,1,1,0,China,0,tozinameran|oxford-astrazeneca covid-19 vaccine|coronavac,NA
NCT04830761,2021-03-26,2022-04-01,Interventional,Behavior Change in Context to Contain the Spread of COVID-19,Recruiting,N/A,University of Bern,NA,https://clinicalzeros.gov/ct2/show/NCT04830761,0,0,0,0,1,0,Switzerland,0,motivation|habit|social,NA
NCT04840953,2020-12-01,2021-01-01,Observational [Patient Registry],"Negative Pressure Therapy, Minimally Invasive and Accessible Technique in the Treatment of Massive Subcutaneous Emphysema in COVID-19 or Non Infected Critical Patients",Completed,NA,FundaciÃ³n para el Fomento de la InvestigaciÃ³n Sanitaria y BiomÃ©dica de la Comunitat Valenciana,NA,https://clinicalzeros.gov/ct2/show/NCT04840953,0,0,0,0,0,0,Spain,0,vã§ac|vã§ac,NA
NCT04840459,2020-11-20,2021-12-31,Interventional,Use of Monoclonal Antibodies for the Treatment of Mild to Moderate COVID-19 in Non-Hospitalized Setting,Recruiting,Phase 2,DHR Health Institute for Research and Development,NA,https://clinicalzeros.gov/ct2/show/NCT04840459,0,0,0,0,0,1,United States,0,bamlanivimab|casirivimab|imdevimab,NA
NCT04816669,2021-04-01,2021-05-30,Interventional,"Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Lyophilized Formulation of BNT162b2 Against COVID-19 in Healthy Adults",Recruiting,Phase 3,BioNTech SE,NA,https://clinicalzeros.gov/ct2/show/NCT04816669,0,0,0,1,1,1,United States,0,bnt162b2,NA
NCT04794036,2021-04-05,2021-06-30,Interventional,Efficacy of an Asynchronous Telerehabilitation Programme in Post-COVID-19 Patient,Recruiting,N/A,Universidad San Jorge,NA,https://clinicalzeros.gov/ct2/show/NCT04794036,0,0,0,0,2,0,Spain,0,asynchronous telerehabilitation programme|rehabilitation programme,NA
NCT04581915,2020-09-08,2021-12-31,Interventional,PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19,Recruiting,Phase 2/Phase 3,Wits Health Consortium (Pty) Ltd,NA,https://clinicalzeros.gov/ct2/show/NCT04581915,0,0,0,0,2,0,South Africa,0,triazavirin (riamilovir)|placebo,NA
NCT04732468,2021-02-24,2022-04-30,Interventional,COVID-19 Oral and Subcutaneous Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenovirus Platform in Healthy Volunteers in USA,Recruiting,Phase 1,"ImmunityBio, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04732468,0,0,0,1,2,1,United States,0,had5-s-fusion/n-etsd (suspension for injection)|had5-sfusion/ n-etsd (oral capsule)|had5-s-fusion|n-etsd (suspension for injection)|had5-sfusion|n-etsd (oral capsule),NA
NCT04720235,2020-12-09,2021-03-09,Interventional,A Follow On Community Testing Study To Evaluate The Performance of the Lucira COVID-19 All-In-One Test Kit,Completed,N/A,Lucira Health Inc,NA,https://clinicalzeros.gov/ct2/show/NCT04720235,0,0,0,0,1,1,United States,0,lucira covid-19 all-in-one test kit,NA
NCT04644185,2021-03-27,2021-06-27,Interventional,The Efficacy and Safety of SCTA01 in Hospitalized Patients With Severe COVID-19,Recruiting,Phase 2/Phase 3,Sinocelltech Ltd.,NA,https://clinicalzeros.gov/ct2/show/NCT04644185,0,0,0,0,4,1,United States|Argentina|Brazil|Chile|Colombia|Mexico|Peru,0,scta01|placebo,NA
NCT04771351,2021-04-30,2021-08-31,Interventional,Study to Evaluate a Single Dose of STI-2020 (COVI-AMGâ„¢) in Hospitalized Adults With COVID-19,Recruiting,Phase 2,"Sorrento Therapeutics, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04771351,0,0,0,0,1,1,United States,0,covi-amg|placebo,NA
NCT04748783,2021-03-26,2021-04-07,Interventional,Antiviral Efficacy and Acceptability of Mouth Rinses for Inactivation of COVID-19,Terminated,Phase 2,"University of North Carolina, Chapel Hill",Funding withdrawn,https://clinicalzeros.gov/ct2/show/NCT04748783,0,0,0,0,2,1,United States,0,water|peroxyl|periogard|colgate total zero,NA
NCT04482699,2020-12-30,2021-12-30,Interventional,RAPA-501-Allo Therapy of COVID-19-ARDS,Recruiting,Phase 1/Phase 2,Rapa Therapeutics LLC,NA,https://clinicalzeros.gov/ct2/show/NCT04482699,0,0,0,0,9,1,United States,0,rapa-501-allo off-the-shelf therapy of covid-19|placebo,NA
NCT04448145,2020-03-26,2022-05-01,Observational,Determinants of SARS-COV2 (COVID-19) Persistence After Convalescence,Recruiting,NA,Columbia University,NA,https://clinicalzeros.gov/ct2/show/NCT04448145,0,0,0,0,2,1,United States,0,"NA",NA
NCT04440007,2020-10-09,2021-05-05,Interventional,Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized With COVID-19,"Active, not recruiting",Phase 2,"Sorrento Therapeutics, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04440007,0,0,0,0,7,1,United States,0,abivertinib|standard care,NA
NCT04359875,2020-04-30,2020-06-30,Interventional,A Phone-call With a Student/General Practitioner Team to Impact Morbidity of Chronic Patients During COVID-19 Containment,Completed,N/A,"University Hospital, Tours",NA,https://clinicalzeros.gov/ct2/show/NCT04359875,0,0,0,0,1,0,France,0,phone-call screening/management by a medical student/general practitioner tandem|phone-call screening|management by a medical student|general practitioner tandem,NA
NCT04842734,2021-03-27,2021-06-27,Interventional,Comparison of the Effect of Online Physical Exercise and Computerized Cognitive Stimulation in Patients With Alzheimer's Disease During the Covid-19 Pandemic,"Active, not recruiting",N/A,Yeditepe University,NA,https://clinicalzeros.gov/ct2/show/NCT04842734,0,0,0,0,0,0,Turkey,0,exercise|physical exercise/computerized cognitive training|computerized cognitive training,NA
NCT04397757,2020-05-13,2021-02-05,Interventional,COVID-19 Convalescent Plasma for the Treatment of Hospitalized Patients With Pneumonia Caused by SARS-CoV-2.,"Active, not recruiting",Phase 1,University of Pennsylvania,NA,https://clinicalzeros.gov/ct2/show/NCT04397757,0,0,0,0,7,1,United States,0,convalescent plasma,NA
NCT04842708,2020-12-24,2021-10-24,Interventional,Evaluation of Anti-COVID 19 Pfizer Vaccination Effect on COVID 19 Detection Using Breath Analysis,Recruiting,N/A,Scentech Medical Technologies Ltd,NA,https://clinicalzeros.gov/ct2/show/NCT04842708,0,0,0,1,0,0,Israel,0,vaccination against covid19,NA
NCT04842331,2021-04-30,2022-01-31,Interventional,PREvent Viral Exposure aNd Transmission Study: a SARS-CoV-2 PEP Study (PREVENT),Recruiting,Phase 2/Phase 3,Thirty Respiratory Limited,NA,https://clinicalzeros.gov/ct2/show/NCT04842331,0,0,0,0,0,0,United Kingdom,0,"resp301, a nitric oxide generating solution",NA
NCT04842292,2021-04-12,2022-02-28,Interventional,Nebulized Heparin for COVID19-associated Acute Respiratory Failure,Recruiting,Phase 2,University of Kentucky,NA,https://clinicalzeros.gov/ct2/show/NCT04842292,0,0,0,0,0,1,United States,0,heparin|placebo,NA
NCT04818463,2021-04-01,2021-12-31,Observational,Characterization and Verification of the Intensive Care Standard Operating Procedure (SOP) Adherence of the Treated COVID-19 Patients,Recruiting,NA,"Charite University, Berlin, Germany",NA,https://clinicalzeros.gov/ct2/show/NCT04818463,0,0,0,0,2,0,Germany,0,"NA",NA
NCT04573764,2021-02-01,2021-10-01,Interventional,Acute Effects of Oral Ketone Ester on Cardiac Function in Patients With COVID-19,Recruiting,N/A,Steno Diabetes Center Copenhagen,NA,https://clinicalzeros.gov/ct2/show/NCT04573764,0,0,0,0,3,0,Denmark,0,"d-beta-hydroxybutyrate-(r)-1,3 butanediol monoester|placebo",NA
NCT04838080,2021-03-19,2021-06-01,Interventional,Safety and Immunogenicity of the Inactivated KoÃ§ak-19 Inaktif AdjuvanlÄ± COVID-19 Vaccine Compared to Placebo,Recruiting,Phase 1,Kocak Farma,NA,https://clinicalzeros.gov/ct2/show/NCT04838080,0,0,0,1,1,0,Turkey,0,koã§ak-19 inaktif adjuvanlä± covid-19 vaccine 4 âµg/0.5 ml vaccine|koã§ak-19 inaktif adjuvanlä± covid-19 vaccine 6 âµg/0.5 ml vaccine|placebo|koã§ak-19 inaktif adjuvanlä± covid-19 vaccine 4 âµg|0.5 ml vaccine|koã§ak-19 inaktif adjuvanlä± covid-19 vaccine 6 âµg,NA
NCT04832945,2020-06-29,2020-09-20,Observational,SARS-CoV-2 Pre-exposure Prophylaxis With Ivermectin Retrospective Cohort Study,Completed,NA,Grupo Rescue S.A.S RepÃºblica Dominicana,NA,https://clinicalzeros.gov/ct2/show/NCT04832945,0,0,0,0,1,0,Dominican Republic,0,ivermectin 6 mg oral tablet,NA
NCT04816019,2021-04-01,2021-10-31,Interventional,A Study of Intranasal ChAdOx1 nCOV-19,Enrolling by invitation,Phase 1,University of Oxford,NA,https://clinicalzeros.gov/ct2/show/NCT04816019,0,0,0,1,2,0,United Kingdom,0,chadox1,NA
NCT04662086,2021-04-30,2022-03-31,Interventional,COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Master Protocol,Enrolling by invitation,Phase 2,Stanford University,NA,https://clinicalzeros.gov/ct2/show/NCT04662086,0,0,0,0,3,1,United States,0,acebilustat|camostat,NA
NCT04746183,2020-07-03,2021-11-18,Interventional,AGILE (Early Phase Platform Trial for COVID-19),Recruiting,Phase 1/Phase 2,University of Liverpool,NA,https://clinicalzeros.gov/ct2/show/NCT04746183,0,0,0,0,1,0,United Kingdom,0,cst-2: eidd-2801|cst-2: placebo|nitazoxanide|vir-7832|vir-7831|cst-5: placebo,NA
NCT04734860,2021-04-30,2021-09-30,Interventional,Study to Evaluate a Single Dose of STI-2020 (COVI-AMGâ„¢) in Adults With Mild COVID-19 Symptoms,Recruiting,Phase 2,"Sorrento Therapeutics, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04734860,0,0,0,0,1,1,United States,0,covi-amg|placebo,NA
NCT04685447,2020-03-16,2020-04-20,Interventional,Effects of Different Dialysis Strategies on Inflammation in COVID-19 Maintenance Hemodialysis Patients,Recruiting,N/A,Universita degli Studi di Genova,NA,https://clinicalzeros.gov/ct2/show/NCT04685447,0,0,0,0,2,0,Italy,0,expanded hemodialysis for covid19 maintenance hemodialysis patients|hemodialysis by protein-leaking dialyzer for covid19 maintenance hemodialysis patients,NA
NCT04682548,2021-01-05,2021-12-31,Observational,Estimating Prevalence of COVID-19 Infection and SARS-CoV-2 Antibodies in MS Patients,Recruiting,NA,NYU Langone Health,NA,https://clinicalzeros.gov/ct2/show/NCT04682548,0,0,0,0,2,1,United States,0,"NA",NA
NCT04668196,2020-05-22,2021-01-25,Observational,Noninvasive Respiratory Support in COVID-19 (CATCOVID-AIR),Completed,NA,Hospital Universitari Vall d'Hebron Research Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04668196,0,0,0,0,1,0,Spain,0,high-flow nasal cannula treatment|continuous positive airway pressure (cpap) treatment|noninvasive ventilation treatment,NA
NCT04662073,2021-04-30,2022-03-31,Interventional,COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Camostat Sub-Protocol,Enrolling by invitation,Phase 2,Stanford University,NA,https://clinicalzeros.gov/ct2/show/NCT04662073,0,0,0,0,2,1,United States,0,placebo|camostat,NA
NCT04662060,2021-04-30,2022-03-31,Interventional,COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Acebilustat Sub-Protocol,Enrolling by invitation,Phase 2,Stanford University,NA,https://clinicalzeros.gov/ct2/show/NCT04662060,0,0,0,0,2,1,United States,0,acebilustat|placebo,NA
NCT04602871,2020-07-03,2021-01-30,Interventional,Early Detection of COVID-19 Using Breath Analysis - Feasibility Study,Completed,N/A,Scentech Medical Technologies Ltd,NA,https://clinicalzeros.gov/ct2/show/NCT04602871,0,0,0,0,1,0,Israel,0,breath biopsy,NA
NCT04522830,2020-07-30,2021-02-28,Interventional,A Study in Adults to Test the Effects of Low Dose Thimerosal on Symptoms of COVID-19,Completed,Phase 2,"Beech Tree Labs, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04522830,0,0,0,0,9,1,United States,0,btl-tml-covid|placebo,NA
NCT04473690,2020-12-30,2021-05-06,Interventional,KBP-201 COVID-19 Vaccine Trial in Healthy Volunteers,Recruiting,Phase 1/Phase 2,"Kentucky BioProcessing, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04473690,0,0,0,1,14,1,United States,0,low dose of kbp-covid-19|high dose of kbp-covid-19|placebo,NA
NCT04516746,2020-08-28,2021-03-05,Interventional,"Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults","Active, not recruiting",Phase 3,AstraZeneca,NA,https://clinicalzeros.gov/ct2/show/NCT04516746,0,0,0,1,7,1,United States|Argentina|Chile|Colombia|France|Peru,0,azd1222|placebo,NA
NCT04498273,2020-09-07,2021-09-30,Interventional,COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80,Recruiting,Phase 3,University of Pittsburgh,NA,https://clinicalzeros.gov/ct2/show/NCT04498273,0,0,0,0,3,1,United States,0,apixaban 2.5 mg|apixaban 5mg|aspirin|placebo,NA
NCT04497298,2020-08-10,2021-06-30,Interventional,Clinical Trial to Evaluate the Safety and Immunogenicity of the COVID-19 Vaccine,"Active, not recruiting",Phase 1,Institut Pasteur,NA,https://clinicalzeros.gov/ct2/show/NCT04497298,0,0,0,1,6,0,Belgium|France,0,two covid-19 vaccine candidate (tmv-083) administrations - low dose|two covid-19 vaccine candidate (tmv-083) administrations - high dose|one covid-19 vaccine candidate (tmv-083) administration - high dose|placebo,NA
NCT04400461,2020-05-15,2021-02-25,Observational,Short-term Physical Function Outcomes in Severe COVID-19 Patients Admitted to ICU for Invasive Mechanical Ventilation,Completed,NA,Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal,NA,https://clinicalzeros.gov/ct2/show/NCT04400461,0,0,0,0,2,0,Spain,0,data collection/clinical testing of subjects|data collection|clinical testing of subjects,NA
NCT04442048,2020-06-25,2021-12-31,Interventional,Immunization With IMM-101 vs Observation for Prevention of Respiratory and Severe COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure,Recruiting,Phase 3,Canadian Cancer Trials Group,NA,https://clinicalzeros.gov/ct2/show/NCT04442048,0,0,0,0,11,0,Canada,0,imm-101|observation,NA
NCT04320511,2020-06-24,2021-06-30,Observational,Beaumont Quantitative Lung Function Imaging to Characterize Patients With SARS-COV 2,Recruiting,NA,William Beaumont Hospitals,NA,https://clinicalzeros.gov/ct2/show/NCT04320511,0,0,0,0,5,1,United States,0,ct-scan,NA
NCT04367077,2020-04-28,2023-01-31,Interventional,MultiStem Administration for COVID-19 Induced ARDS (MACoVIA),Recruiting,Phase 2/Phase 3,"Athersys, Inc",NA,https://clinicalzeros.gov/ct2/show/NCT04367077,0,0,0,0,6,1,United States,0,multistem|placebo,NA
NCT04341415,2020-04-09,2020-11-20,Interventional,Impact of Auricular Vagus Nerve Neuromodulation on COVID-19 Positive Inpatients Outcome,Terminated,N/A,Fondation Ophtalmologique Adolphe de Rothschild,Inclusion stopped at 50% after interim analysis: primary efficacy endpoint not significant,https://clinicalzeros.gov/ct2/show/NCT04341415,0,0,0,0,3,0,France,0,auricular neuromodulation|control,NA
NCT04844710,2020-09-01,2020-11-15,Interventional,The Effects of Acupuncture in Overcoming Inflammatory Response to COVID-19 Mild-moderate Symptoms,Completed,N/A,Indonesia University,NA,https://clinicalzeros.gov/ct2/show/NCT04844710,0,0,0,0,0,0,Indonesia,0,acupuncture/standard care|standard care|acupuncture,NA
NCT04844658,2021-02-17,2021-09-01,Interventional,"Covid-19, Hospitalized, PatIents, Nasafytol",Recruiting,N/A,Tilman S.A.,NA,https://clinicalzeros.gov/ct2/show/NCT04844658,0,0,0,0,0,0,Belgium,0,nasafytolâ®|fultiumâ® -d3 800|nasafytolâ®|fultiumâ® -d3 800,NA
NCT04844632,2021-02-11,2022-04-01,Observational,"COVID19 Vaccination: Clinical, Laboratory and Cellular Monitoring",Recruiting,NA,University of Roma La Sapienza,NA,https://clinicalzeros.gov/ct2/show/NCT04844632,0,0,0,0,0,0,Italy,0,vaccine anti-covid19,NA
NCT04844567,2020-11-26,2021-12-31,Interventional,Virtual Reality Intervention to Alleviate Breathlessness (COVID-19),Recruiting,N/A,Ecole Polytechnique FÃ©dÃ©rale de Lausanne,NA,https://clinicalzeros.gov/ct2/show/NCT04844567,0,0,0,0,0,0,Switzerland,0,covvr,NA
NCT04843878,2021-01-05,2021-03-12,Observational,COVID-19 Testing Pilot Study,Completed,NA,University of Pennsylvania,NA,https://clinicalzeros.gov/ct2/show/NCT04843878,0,0,0,0,0,1,United States,0,covid detect,NA
NCT04841707,2021-04-22,2022-02-22,Interventional,Total-Body Parametric 18F-FDG PET of COVID-19,Recruiting,N/A,"University of California, Davis",NA,https://clinicalzeros.gov/ct2/show/NCT04841707,0,0,0,0,1,1,United States,0,uexplorer/mct|uexplorer|mct,NA
NCT04825301,2020-07-21,2021-07-21,Observational,Prognostic Prediction of COVID-19 Clinical Course Through the Development of a Convolutional Neural Network,Recruiting,NA,University of L'Aquila,NA,https://clinicalzeros.gov/ct2/show/NCT04825301,0,0,0,0,2,0,Italy,0,"NA",NA
NCT04800224,2021-04-12,2021-06-30,Interventional,Brazilian Green Propolis Extract (EPP-AF) as an Adjunct Treatment for Hospitalized COVID-19 Patients (BeeCovid2),Recruiting,Phase 2/Phase 3,D'Or Institute for Research and Education,NA,https://clinicalzeros.gov/ct2/show/NCT04800224,0,0,0,0,2,0,Brazil,0,standardized brazilian green propolis extract|placebo,NA
NCT04798001,2021-04-12,2022-10-31,Interventional,Safety and Immunogenicity of an Intranasal RSV Vaccine Expressing SARS-CoV-2 Spike Protein (COVID-19 Vaccine) in Adults,Recruiting,Phase 1,"Meissa Vaccines, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04798001,0,0,0,1,1,1,United States,0,"investigational vaccine against sars-cov-2 [mv-014-212] dosage 1, single dose, intranasal drops|investigational vaccine against sars-cov-2 [mv-014-212] dosage 2, single dose, intranasal drops|investigational vaccine against sars-cov-2 [mv-014-212] dosage 3, single dose, intranasal drops|investigational vaccine against sars-cov-2 [mv-014-212] dosage 3, two doses, intranasal drops|investigational vaccine against sars-cov-2 [mv-014-212] dosage 3, single dose, intranasal spray",NA
NCT04815057,2020-11-02,2020-11-23,Interventional,The Effects of Wellness Training Given to Fifth Grade Students During the Covid-19 Epidemic Period,Completed,N/A,Saglik Bilimleri Universitesi,NA,https://clinicalzeros.gov/ct2/show/NCT04815057,0,0,0,0,3,0,Turkey,0,wellness education,NA
NCT04791423,2021-03-15,2021-05-30,Interventional,Study of GRAd-COV2 for the Prevention of COVID-19 in Adults,"Active, not recruiting",Phase 2/Phase 3,ReiThera Srl,NA,https://clinicalzeros.gov/ct2/show/NCT04791423,0,0,0,1,2,0,Italy,0,grad-cov2|placebo,NA
NCT04810065,2021-03-29,2021-07-31,Interventional,SingStrong: Strong Lungs Through Song - Long COVID-19 Study,Recruiting,N/A,University of Limerick,NA,https://clinicalzeros.gov/ct2/show/NCT04810065,0,0,0,0,1,0,Ireland,0,singstrong: strong lungs through song,NA
NCT04678830,2021-03-01,2021-06-23,Interventional,COVID-19 Long-Haulers Study,"Active, not recruiting",Phase 2,"CytoDyn, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04678830,0,0,0,0,6,1,United States,0,placebo|lenzilumab,NA
NCT04762173,2020-11-06,2021-06-03,Interventional,Self-Help for Stress Related to COVID-19,"Active, not recruiting",N/A,Penn State University,NA,https://clinicalzeros.gov/ct2/show/NCT04762173,0,0,0,0,2,1,United States,0,online self-help intervention,NA
NCT04754594,2021-02-16,2022-06-27,Interventional,"Study to Evaluate the Safety, Tolerability, and Immunogenicity of SARS CoV-2 RNA Vaccine Candidate (BNT162b2) Against COVID-19 in Healthy Pregnant Women 18 Years of Age and Older",Recruiting,Phase 2/Phase 3,BioNTech SE,NA,https://clinicalzeros.gov/ct2/show/NCT04754594,0,0,0,1,3,1,United States,0,bnt162b2|placebo,NA
NCT04611425,2020-11-30,2021-05-01,Interventional,"REmimazolam Infusion in the Context of Hypnotic Shortage in the Critical Care Unit During the Pandemic of COVID-19, the REHSCU Study",Recruiting,Phase 2,Nantes University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04611425,0,0,0,0,1,0,France,0,remimazolam,NA
NCT04651400,2020-10-19,2021-06-30,Observational,"Observational, Retrospective Study to Evaluate Coagulation Changes and the Influence of Antithrombin III Treatment in Patients With Severe COVID-19 Infection",Recruiting,NA,Octapharma,NA,https://clinicalzeros.gov/ct2/show/NCT04651400,0,0,0,0,3,0,Austria|France|Germany,0,antithrombin iii,NA
NCT04602949,2020-11-12,2021-07-28,Interventional,Detection of COVID-19 Using Breath Analysis - Validation Study,Recruiting,N/A,Scentech Medical Technologies Ltd,NA,https://clinicalzeros.gov/ct2/show/NCT04602949,0,0,0,0,1,0,Israel,0,breath biopsy analysis,NA
NCT04431414,2020-07-20,2021-09-30,Observational,A Study of Immune Responses to the Virus That Causes COVID-19,Recruiting,NA,COVID-19 Prevention Network,NA,https://clinicalzeros.gov/ct2/show/NCT04431414,0,0,0,0,14,1,United States|Argentina|Botswana|Brazil|Kenya|Malawi|Mexico|Mozambique|Peru|South Africa|Tanzania|Zambia|Zimbabwe,0,sample collection,NA
NCT04537650,2021-01-01,2021-08-31,Observational,Swallowing Impairment After COVID-19 Infection,Enrolling by invitation,NA,"University Health Network, Toronto",NA,https://clinicalzeros.gov/ct2/show/NCT04537650,0,0,0,0,4,1,United States|Canada,0,videofluoroscopic swallowing study (vfss),NA
NCT04509947,2020-08-11,2021-02-22,Interventional,A Study of Ad26.COV2.S in Adults (COVID-19),"Active, not recruiting",Phase 1,Janssen Pharmaceutical K.K.,NA,https://clinicalzeros.gov/ct2/show/NCT04509947,0,0,0,0,5,0,Japan,0,ad26.cov2.s|placebo,NA
NCT04501952,2020-09-18,2021-05-31,Interventional,Study to Evaluate the Efficacy and Safety of Remdesivir (GS-5734â„¢) Treatment of Coronavirus Disease 2019 (COVID-19) in an Outpatient Setting,"Active, not recruiting",Phase 3,Gilead Sciences,NA,https://clinicalzeros.gov/ct2/show/NCT04501952,0,0,0,0,12,1,United States|Denmark|Portugal|Spain|United Kingdom,0,rdv|placebo,NA
NCT04471636,2020-09-18,2021-11-30,Interventional,Telemedicine in Outpatient Covid-19 Patients,Recruiting,N/A,Ludwig-Maximilians - University of Munich,NA,https://clinicalzeros.gov/ct2/show/NCT04471636,0,0,0,0,2,0,Germany,0,withings scanwatch,NA
NCT04415060,2020-06-15,2023-06-15,Interventional,SedAting With Volatile Anesthetics Critically Ill COVID-19 Patients in ICU: Effects On Ventilatory Parameters And Survival,Recruiting,Phase 3,Sunnybrook Health Sciences Centre,NA,https://clinicalzeros.gov/ct2/show/NCT04415060,0,0,0,0,5,0,Canada,0,isoflurane inhalant product|sevoflurane,NA
NCT04622332,2020-12-18,2021-12-15,Interventional,A Pilot Study to Assess Safety and Efficacy of SIR1-365 in Patients With Severe COVID-19,Recruiting,Phase 1,"Sironax USA, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04622332,0,0,0,0,1,1,United States,0,sir1-365|placebo,NA
NCT04619407,2020-11-04,2021-03-26,Observational,"Screening for COVID-19 in Teachers, Childcare Educators, Pupils and Preschoolers",Completed,NA,University Medicine Greifswald,NA,https://clinicalzeros.gov/ct2/show/NCT04619407,0,0,0,0,1,0,Germany,0,nasopharyngeal swab|serum test,NA
NCT04570384,2020-10-15,2021-07-28,Interventional,Intravenous L-Citrulline to Delay and Potentially Prevent the Need for Invasive Mechanical Ventilation for Acute Hypoxemic Respiratory Failure in Patients With COVID-19 (SARS-CoV-2) Illness,Recruiting,Phase 2,"Asklepion Pharmaceuticals, LLC",NA,https://clinicalzeros.gov/ct2/show/NCT04570384,0,0,0,0,3,1,United States,0,l-citrulline|placebo,NA
NCT04556318,2020-09-23,2021-04-30,Observational,Identification of Differences in Breath Components Detected With IMS in Patients Tested on SARS-CoV-2 (COVID-19),Recruiting,NA,B. Braun Melsungen AG,NA,https://clinicalzeros.gov/ct2/show/NCT04556318,0,0,0,0,5,0,Germany,0,ion mobility spectrometry (ims),NA
NCT04416308,2020-05-29,2020-07-10,Interventional,COVID 19 : Seroprevalence Study of Anti SRAS-CoV-2 Antibodies in GHT Employees in Haute Bretagne (AntiCoV-HB),Completed,N/A,Rennes University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04416308,0,0,0,0,2,0,France,0,ng test|blood test|self-questionnary,NA
NCT04388527,2020-04-30,2020-12-29,Interventional,COVID-19 Convalescent Plasma for Mechanically Ventilated Population,"Active, not recruiting",Phase 1,University of Pennsylvania,NA,https://clinicalzeros.gov/ct2/show/NCT04388527,0,0,0,0,5,1,United States,0,convalescent plasma,NA
NCT04403880,2020-05-13,2021-08-31,Observational,Characterizing SARS-CoV-2-specific Immunity in Individuals Who Have Recovered From COVID-19,"Active, not recruiting",NA,HIV Vaccine Trials Network,NA,https://clinicalzeros.gov/ct2/show/NCT04403880,0,0,0,0,10,1,United States|Malawi|Peru|South Africa|Zambia|Zimbabwe,0,sample collection,NA
NCT04402970,2020-06-19,2020-12-31,Interventional,Dornase Alfa for ARDS in Patients With Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2),Completed,Phase 3,University of Missouri-Columbia,NA,https://clinicalzeros.gov/ct2/show/NCT04402970,0,0,0,0,6,1,United States,1,dornase alfa,NA
NCT04397900,2020-04-09,2021-04-12,Observational,Blood Collection Study From COVID-19 Convalescents Previously Hospitalized to Identify Immunogenic Viral Epitopes,Completed,NA,"TScan Therapeutics, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04397900,0,0,0,0,2,1,United States,0,"NA",NA
NCT04380961,2020-04-24,2021-04-09,Interventional,A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19,Recruiting,Phase 2,"Janssen Pharmaceutica N.V., Belgium",NA,https://clinicalzeros.gov/ct2/show/NCT04380961,0,0,0,0,13,1,United States,0,sirukumab|placebo|standard care,NA
NCT04314817,2020-03-17,2023-01-01,Observational,Adverse Events Related to Treatments Used Against Coronavirus Disease 2019,Recruiting,NA,Groupe Hospitalier Pitie-Salpetriere,NA,https://clinicalzeros.gov/ct2/show/NCT04314817,0,0,0,0,2,0,France,0,any drug used to treat covid-19,NA
NCT04347239,2020-04-15,2021-06-15,Interventional,Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19),Recruiting,Phase 2,"CytoDyn, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04347239,0,0,0,0,13,1,United States,0,placebo|lenzilumab,NA
NCT04344080,2020-04-01,2021-05-01,Interventional,Effect of CytoSorb Adsorber on Hemodynamic and Immunological Parameters in Critical Ill Patients With COVID-19,"Active, not recruiting",N/A,UniversitÃ¤tsklinikum Hamburg-Eppendorf,NA,https://clinicalzeros.gov/ct2/show/NCT04344080,0,0,0,0,1,0,Germany,0,cytosorb,NA
NCT04333732,2020-09-04,2021-08-31,Interventional,CROWN CORONATION: COVID-19 Research Outcomes Worldwide Network for CORONAvirus prevenTION,Recruiting,Phase 3,Washington University School of Medicine,NA,https://clinicalzeros.gov/ct2/show/NCT04333732,0,0,0,0,13,1,United States|Ghana|South Africa|United Kingdom|Zambia,0,mr/m-m-r ii â® vaccine|placebo|mr|m-m-r ii â® vaccine,NA
NCT04846907,2020-07-01,2021-09-30,Observational,Mental Health of Professionals Working in Pediatric Intensive Care Units During the COVID-19 Pandemic,"Active, not recruiting",NA,D'Or Institute for Research and Education,NA,https://clinicalzeros.gov/ct2/show/NCT04846907,0,0,0,0,0,0,Brazil,0,web-based survey,NA
NCT04846790,2021-06-01,2022-12-01,Interventional,The Effect of a Combined Nature-based and Virtual Mindfulness Intervention on Perceived Stress in Healthcare Workers,Enrolling by invitation,N/A,National Institutes of Health Clinical Center (CC),NA,https://clinicalzeros.gov/ct2/show/NCT04846790,0,0,0,0,0,1,United States,0,nature only|nature/mindfulness|nature|mindfulness,NA
NCT04817293,2021-04-06,2021-09-30,Observational,Prolonged Symptoms and Reasons for Consultation in Town Medicine Associated With COVID-19 Infection in the Hauts de France Region,Recruiting,NA,Tourcoing Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04817293,0,0,0,0,1,0,France,0,questionnaire|medical consultation,NA
NCT04845984,2020-09-01,2021-01-15,Observational,Evaluation of the Prevalence of SARS-CoV-2 Infection in the Healthcare Workers (HCWs) in Four Hospital of the Alpine Region,Completed,NA,Centre Hospitalier Annecy Genevois,NA,https://clinicalzeros.gov/ct2/show/NCT04845984,0,0,0,0,0,0,France,0,"NA",NA
NCT04843917,2021-04-09,2022-06-09,Observational,Immunity Against COVID-19 Vaccine in Healthcare Workers in Argentine,Recruiting,NA,Hospital Italiano de Buenos Aires,NA,https://clinicalzeros.gov/ct2/show/NCT04843917,0,0,0,0,1,0,Argentina,0,immunoglobulin g detection,NA
NCT04843722,2021-04-30,2021-09-30,Interventional,COVID-19 Supplemental Vaccine Boost to Enhance T Cell Protection in Those Who Have Already Received EUA S-Based Vaccines,Recruiting,Phase 1/Phase 2,"ImmunityBio, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04843722,0,0,0,1,1,1,United States,0,had5-s-fusion/n-etsd vaccine|had5-s-fusion|n-etsd vaccine,NA
NCT04840966,2020-05-05,2021-01-15,Observational,A Simplified Test to Assess Flavor in COVID-19 Patients,Completed,NA,Federico II University,NA,https://clinicalzeros.gov/ct2/show/NCT04840966,0,0,0,0,1,0,Italy,0,flavor test|self-assesment questionnaire,NA
NCT04501796,2020-11-27,2021-10-31,Interventional,A Trial of NT-I7 in COVID-19 (SPESELPIS),Recruiting,Phase 1,NeoImmuneTech,NA,https://clinicalzeros.gov/ct2/show/NCT04501796,0,0,0,0,2,1,United States,0,double-blind nt-i7|placebo,NA
NCT04723537,2021-02-16,2021-09-30,Interventional,"Upamostat, a Serine Protease Inhibitor, or Placebo for Treatment of COVID-19 Disease",Recruiting,Phase 2/Phase 3,RedHill Biopharma Limited,NA,https://clinicalzeros.gov/ct2/show/NCT04723537,0,0,0,0,9,1,United States,0,part a: upamostat 200 mg|part a: upamostat 400 mg|part a/b: placebo|part b: upamostat 200/400 mg|part a|b: placebo|part b: upamostat 200|400 mg,NA
NCT04530682,2021-03-05,2023-07-20,Observational,COVID-19 in Rheumatic Inflammatory Diseases Under Immuno-suppressive Drugs,Recruiting,NA,"University Hospital, Montpellier",NA,https://clinicalzeros.gov/ct2/show/NCT04530682,0,0,0,0,3,0,France,0,biological samples,NA
NCT04780555,2021-03-01,2021-05-01,Observational,Evaluation of Musculoskeletal System Symptoms and Biochemical Parameters in COVID-19,Recruiting,NA,Abant Izzet Baysal University,NA,https://clinicalzeros.gov/ct2/show/NCT04780555,0,0,0,0,1,0,Turkey,0,"NA",NA
NCT04584684,2020-12-18,2022-09-30,Interventional,Mouth Rinses for Inactivation of COVID-19,Recruiting,Phase 2,"University of North Carolina, Chapel Hill",NA,https://clinicalzeros.gov/ct2/show/NCT04584684,0,0,0,0,3,1,United States,0,1.5% w/v hydrogen peroxide|0.12% chlorhexidine gluconate|27% ethanol/essential oils|0.5% w/v povidone-iodide|0.075% cetylpyridinium chloride|saline|1.5% w|v hydrogen peroxide|27% ethanol|essential oils|0.5% w|v povidone-iodide,NA
NCT04459676,2020-07-31,2021-04-30,Interventional,Study to Assess Efficacy and Safety Relative to Standard of Care in Patients With COVID-19 Pneumonia,"Active, not recruiting",Phase 2,Angion Biomedica Corp,NA,https://clinicalzeros.gov/ct2/show/NCT04459676,0,0,0,0,4,0,Brazil,0,standard care|ang-3777|placebo,NA
NCT04375397,2020-06-06,2021-05-10,Interventional,Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Pulmonary Injury,"Active, not recruiting",Phase 2,AbbVie,NA,https://clinicalzeros.gov/ct2/show/NCT04375397,0,0,0,0,11,1,United States,0,ibrutinib|placebo,NA
NCT04849598,2021-04-13,2021-09-01,Interventional,Automatic Oxygen Titration in Patients After SARS-CoV-2 Infection,Recruiting,N/A,SchÃ¶n Klinik Berchtesgadener Land,NA,https://clinicalzeros.gov/ct2/show/NCT04849598,0,0,0,0,0,0,Germany,0,oxygen,NA
NCT04849585,2021-04-30,2021-08-31,Observational,Evaluation of the Impact of Hospitalization in Intensive Care for COVID-19 Infection,Recruiting,NA,Tourcoing Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04849585,0,0,0,0,0,0,France,0,semi-directed entretien,NA
NCT04849546,2020-07-01,2020-08-31,Observational,Staff Physical and Mental Health Assessment in the Aftermath of the First Peak of the Covid-19 Outbreak,Completed,NA,"University Hospital, Brest",NA,https://clinicalzeros.gov/ct2/show/NCT04849546,0,0,0,0,0,0,France,0,"NA",NA
NCT04365153,2020-04-24,2021-02-02,Interventional,Canakinumab in Covid-19 Cardiac Injury (The Three C Study),Completed,Phase 2,The Cleveland Clinic,NA,https://clinicalzeros.gov/ct2/show/NCT04365153,0,0,0,0,9,1,United States,1,canakinumab|placebo,NA
NCT04849624,2021-03-05,2021-10-01,Observational,Body Composition Study in Critically Ill Patients-Extended to COVID-19,Recruiting,NA,University of Malaya,NA,https://clinicalzeros.gov/ct2/show/NCT04849624,0,0,0,0,0,0,Malaysia,0,no intervention,NA
NCT04849793,2021-04-13,2021-06-13,Interventional,The Effect of Acupressure on the Anxiety Level,Recruiting,N/A,Mersin University,NA,https://clinicalzeros.gov/ct2/show/NCT04849793,0,0,0,0,0,0,Turkey,0,acupressure,NA
NCT04849637,2020-10-22,2021-06-30,Interventional,Virgin Coconut Oil as Adjunctive Therapy for Hospitalized COVID-19 Patients,Recruiting,Phase 2,University of the Philippines,NA,https://clinicalzeros.gov/ct2/show/NCT04849637,0,0,0,0,0,0,Philippines,0,virgin coconut oil,NA
NCT04848610,2020-10-18,2020-11-18,Observational,The Factors That Affect the Infection of COVID-19,Completed,NA,Istanbul University-Cerrahpasa,NA,https://clinicalzeros.gov/ct2/show/NCT04848610,0,0,0,0,0,0,Turkey,0,"NA",NA
NCT04847817,2020-08-01,2021-12-31,Observational,Important Data on COVID-19 Profile in Africa,Recruiting,NA,Centre de Recherche MÃ©dicale de LambarÃ©nÃ©,NA,https://clinicalzeros.gov/ct2/show/NCT04847817,0,0,0,0,0,0,Gabon,0,"NA",NA
NCT04847791,2021-01-14,2022-01-31,Interventional,Lactoferrin in Covid-19 Hospitalized Patients,Recruiting,N/A,Paolo Manzoni,NA,https://clinicalzeros.gov/ct2/show/NCT04847791,0,0,0,0,0,0,Italy,0,bovine lactoferrin|placebo,NA
NCT04847362,2021-04-11,2021-05-30,Interventional,The Effect of Tele-Health Education Provided in the Postpartum Period in the Covid 19 Pandemic,Recruiting,N/A,Saglik Bilimleri Universitesi,NA,https://clinicalzeros.gov/ct2/show/NCT04847362,0,0,0,0,1,0,Turkey,0,experimental,NA
NCT04847544,2021-03-31,2021-12-31,Interventional,"A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacodynamics for the Treatment of COVID-19.",Recruiting,Phase 2,"Aldeyra Therapeutics, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04847544,0,0,0,0,0,1,United States,0,adx-629|placebo,NA
NCT04847687,2021-03-01,2021-04-01,Observational,Investigation of Hospitalisation Times and Mortality According to Drug Dose in Patients Given Systemic Methylprednisolone With a Pre-diagnosis of Covid-19 Pneumonia; Retrospective Study,Completed,NA,Bursa YÃ¼ksek Ä°htisas Education and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04847687,0,0,0,0,0,0,Turkey,0,methylprednisolone,NA
NCT04847661,2021-03-28,2021-07-30,Interventional,"Efficacy of Mefloquine as Prophylaxis Against COVID-19: A Placebo-control, Randomized Clinical Trial",Recruiting,Phase 2/Phase 3,Helwan University,NA,https://clinicalzeros.gov/ct2/show/NCT04847661,0,0,0,0,0,0,Egypt,0,mefloquine as a prophylaxis against sars-cov-2 infection in household contacts of covid 19 confirmed cases,NA
NCT04847622,2021-02-01,2021-06-30,Observational,Study to Evaluate the Clinical Outcomes in Adults With Covid-19 Who Have Been Treated With Remdesivir.,Recruiting,NA,NEAT ID Foundation,NA,https://clinicalzeros.gov/ct2/show/NCT04847622,0,0,0,0,0,0,France|Israel|Netherlands|Spain|United Kingdom,0,remdesivir,NA
NCT04845971,2020-11-05,2021-04-30,Interventional,Efficacy and Safety of Oral Immunotherapy With GcMAF in Hospitalized Patients With COVID-19 Pneumonia,Recruiting,Phase 2,Ospedale del Mare,NA,https://clinicalzeros.gov/ct2/show/NCT04845971,0,0,0,0,1,0,Italy,0,saisei maf capsules,NA
NCT04844242,2020-12-23,2021-06-22,Observational,Pediatric COVID Study,Recruiting,NA,"Tuberculosis Research Centre, India",NA,https://clinicalzeros.gov/ct2/show/NCT04844242,0,0,0,0,1,0,India,0,"NA",NA
NCT04832022,2021-04-07,2023-04-30,Observational,Longitudinal Follow-up of Patients With Chronic Inflammatory Rheumatisms (CIRs) Vaccinated Against COVID-19 Compared to Patients Refusing Vaccination,Recruiting,NA,"University Hospital, Montpellier",NA,https://clinicalzeros.gov/ct2/show/NCT04832022,0,0,0,0,1,0,France,0,biological samples,NA
NCT04839146,2021-03-11,2021-12-20,Interventional,Safety and Tolerability of COVID-19 Vaccine (ABNCoV2),Recruiting,Phase 1,Radboud University,NA,https://clinicalzeros.gov/ct2/show/NCT04839146,0,0,0,1,1,0,Netherlands,0,abncov2 vaccine,NA
NCT04838795,2021-02-18,2022-03-31,Interventional,Sisonke (Together): OPEN LABEL TRIAL COVID-19,Recruiting,Phase 3,Wits Health Consortium (Pty) Ltd,NA,https://clinicalzeros.gov/ct2/show/NCT04838795,0,0,0,1,1,0,South Africa,0,to monitor the effectiveness of the single dose ad26.cov2.s covid-19 vaccine,NA
NCT04824625,2021-03-27,2021-03-27,Observational,Incidence of Infection Reported by COVID-19 in Attendees of a Commercial Music Concert,Completed,NA,"FundaciÃ³n FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la PromociÃ³n de la Salud y la Ciencia",NA,https://clinicalzeros.gov/ct2/show/NCT04824625,0,0,0,0,1,0,Spain,0,"NA",NA
NCT04821999,2021-04-10,2021-05-20,Interventional,Diode Laser 940 nm in Management of Loss of Taste Sensation,Recruiting,N/A,Fayoum University,NA,https://clinicalzeros.gov/ct2/show/NCT04821999,0,0,0,0,2,0,Egypt,0,a 940-nm diode laser,NA
NCT04821986,2021-04-01,2021-05-30,Observational,Oral Manifestation in Patients With SARS-CoV2 Infection.,Recruiting,NA,Fayoum University,NA,https://clinicalzeros.gov/ct2/show/NCT04821986,0,0,0,0,2,0,Egypt,0,"NA",NA
NCT04771000,2021-02-08,2021-07-31,Interventional,A Study of Micro Dose Ambrisentan in Hospitalized Patients With Respiratory Insufficiency Due to COVID-19,Recruiting,Phase 2,Noorik Biopharmaceuticals AG,NA,https://clinicalzeros.gov/ct2/show/NCT04771000,0,0,0,0,5,0,Spain,0,ambrisentan|placebo,NA
NCT04716907,2021-03-19,2023-03-19,Observational,Thymic Function in Patients With COVID-19,Recruiting,NA,CMC Ambroise ParÃ©,NA,https://clinicalzeros.gov/ct2/show/NCT04716907,0,0,0,0,3,0,France,0,single-nucleotide polymorphisms (snp) within the tcra/d region|blood sample|ct scan|bronchial fibroscopy|single-nucleotide polymorphisms (snp) within the tcra|d region,NA
NCT04699916,2021-01-04,2021-06-30,Interventional,EEG-based Sedation Protocol for Patients on Mechanical Ventilation Due to SARS-CoV-2 Pneumonia,Recruiting,N/A,University of Chile,NA,https://clinicalzeros.gov/ct2/show/NCT04699916,0,0,0,0,3,0,Chile,0,eeg based protocol for deep sedation,NA
NCT04476979,2020-07-16,2021-06-30,Interventional,Comparison of Tocilizumab Plus Dexamethasone vs. Dexamethasone for Patients With Covid-19,Recruiting,Phase 2,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04476979,0,0,0,0,2,0,French Guiana,0,tocilizumab|dexamethasone,NA
NCT04614948,2020-11-16,2022-05-10,Interventional,A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults,"Active, not recruiting",Phase 3,Janssen Vaccines & Prevention B.V.,NA,https://clinicalzeros.gov/ct2/show/NCT04614948,0,0,0,0,11,1,United States|Belgium|Brazil|Colombia|France|Germany|Philippines|South Africa|Spain|United Kingdom,0,ad26.cov2.s|placebo,NA
NCT04667286,2021-01-16,2021-06-01,Interventional,Awake Pronation for Covid-19 Treatment,Recruiting,N/A,IRCCS Azienda Ospedaliero-Universitaria di Bologna,NA,https://clinicalzeros.gov/ct2/show/NCT04667286,0,0,0,0,1,0,Italy,0,prone position (pp),NA
NCT04625972,2020-12-02,2021-04-07,Interventional,"Phase III Double-blind, Placebo-controlled Study of AZD7442 for Post- Exposure Prophylaxis of COVID-19 in Adults","Active, not recruiting",Phase 3,AstraZeneca,NA,https://clinicalzeros.gov/ct2/show/NCT04625972,0,0,0,0,3,1,United States|United Kingdom,0,azd7442|placebo,NA
NCT04591015,2021-02-01,2021-07-31,Interventional,Dulce Digital-COVID Aware (DD-CA) Discharge Texting Platform for US/Mexico Border Hispanics With Diabetes + COVID-19,Recruiting,Phase 3,Scripps Whittier Diabetes Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04591015,0,0,0,0,4,1,United States,0,hospital: dd-ca|hospital: usual care (uc),NA
NCT04685655,2020-01-07,2021-12-31,Interventional,RescuE pLAsma eXchange in Severe COVID-19,Recruiting,N/A,Heidelberg University,NA,https://clinicalzeros.gov/ct2/show/NCT04685655,0,0,0,0,4,0,Germany,0,therapeutic plasma exchange (tpe),NA
NCT04595097,2021-03-01,2021-11-30,Interventional,Inspiratory Muscle Training in COVID-19 Patients,Recruiting,N/A,Escola Superior de Ciencias da Saude,NA,https://clinicalzeros.gov/ct2/show/NCT04595097,0,0,0,0,2,0,Brazil,0,inspiratory muscle traiing,NA
NCT04549922,2020-10-22,2022-02-28,Interventional,Antisense Therapy to Block the Kallikrein-kinin Pathway in COVID-19,"Active, not recruiting",Phase 2,Hospital do Coracao,NA,https://clinicalzeros.gov/ct2/show/NCT04549922,0,0,0,0,3,0,Brazil,0,isis 721744|saline,NA
NCT04583969,2020-10-19,2021-12-31,Interventional,ACTIV-5 / Big Effect Trial (BET-B) for the Treatment of COVID-19,Recruiting,Phase 2,National Institute of Allergy and Infectious Diseases (NIAID),NA,https://clinicalzeros.gov/ct2/show/NCT04583969,0,0,0,0,24,1,United States,0,lenzilumab|placebo|remdesivir,NA
NCT04575597,2020-10-19,2021-06-23,Interventional,Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adult Participants With COVID-19 (MK-4482-002),Recruiting,Phase 2/Phase 3,Merck Sharp & Dohme Corp.,NA,https://clinicalzeros.gov/ct2/show/NCT04575597,0,0,0,0,25,1,United States|Brazil|Canada|Chile|Colombia|France|Germany|Israel|Italy|Mexico|Philippines|Russian Federation|South Africa|Spain|Ukraine|United Kingdom,0,molnupiravir|placebo,NA
NCT04524598,2020-07-20,2021-09-01,Interventional,A CBT-based Mobile Intervention as First Line Treatment for Adolescent Depression During COVID-19,Recruiting,N/A,"Limbix Health, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04524598,0,0,0,0,2,1,United States,0,limbix spark|psychoeducation,NA
NCT04504032,2020-09-02,2021-03-10,Interventional,A Trial to Evaluate Safety and Efficacy of Rivaroxaban (COVID-19),Terminated,Phase 2,Bill & Melinda Gates Medical Research Institute,"Based on Data Monitoring Committee's recommendation on February 3, 2021, the study was stopped
    due to futility.",https://clinicalzeros.gov/ct2/show/NCT04504032,0,0,0,0,9,1,United States|United Kingdom,0,rivaroxaban|placebo,NA
NCT04500626,2021-04-15,2022-08-31,Interventional,Hyperbaric Versus Normobaric Oxygen Therapy for COVID-19 Patients,Recruiting,Phase 2/Phase 3,Ottawa Hospital Research Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04500626,0,0,0,0,4,0,Canada,0,oxygen,NA
NCT04341012,2019-09-10,2021-12-31,Observational,Breath Analysis Based Disease Biomarkers of COVID-19 and Other Diseases,Recruiting,NA,Mayo Clinic,NA,https://clinicalzeros.gov/ct2/show/NCT04341012,0,0,0,0,2,1,United States,0,collection of breath sample,NA
NCT04417257,2020-06-29,2021-05-15,Interventional,Study of LAU-7b for the Treatment of COVID-19 Disease in Adults,Recruiting,Phase 2,Laurent Pharmaceuticals Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04417257,0,0,0,0,14,1,United States|Canada,0,lau-7b|placebo,NA
NCT04357041,2020-04-17,2021-04-30,Observational,"COVID-19 Survey Study on Dietary Intake, Physical Activity and Overall Well-being","Active, not recruiting",NA,"Clinical Nutrition Research Center, Illinois Institute of Technology",NA,https://clinicalzeros.gov/ct2/show/NCT04357041,0,0,0,0,4,1,United States,0,"NA",NA
NCT04530448,2020-10-05,2021-12-31,Interventional,Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization,Recruiting,Phase 4,West Virginia University,NA,https://clinicalzeros.gov/ct2/show/NCT04530448,0,0,0,0,3,1,United States,0,sodium bicarbonate|standard care,NA
NCT04492254,2020-09-15,2021-07-31,Interventional,Early Prophylactic Low-molecular-weight Heparin (LMWH) in Symptomatic COVID-19 Positive Patients,Recruiting,Phase 3,Thrombosis Research Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04492254,0,0,0,0,1,0,Australia|Belgium|South Africa,0,enoxaparin,NA
NCT04431453,2020-07-21,2022-02-28,Interventional,"Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734â„¢) in Participants From Birth to < 18 Years of Age With Coronavirus Disease 2019 (COVID-19)",Recruiting,Phase 2/Phase 3,Gilead Sciences,NA,https://clinicalzeros.gov/ct2/show/NCT04431453,0,0,0,0,24,1,United States|Italy|Spain|United Kingdom,0,remdesivir,NA
NCT04365725,2020-05-05,2020-06-12,Observational,"Multicenter, Retrospective Study of the Effects of Remdesivir in the Treatment of Severe Covid-19 Infections",Completed,NA,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04365725,0,0,0,0,2,0,France,0,remdesivir,NA
NCT04362995,2020-04-23,2022-04-30,Observational,St. Jude Tracking of Viral and Host Factors Associated With COVID-19,Recruiting,NA,St. Jude Children's Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04362995,0,0,0,0,5,1,United States,0,"NA",NA
NCT04851821,2021-01-04,2021-02-28,Interventional,PHYTOTHERAPY IN SEVERE ACUTE RESPIRATORYSYNDROME CORONAVIRUS 2,Recruiting,Phase 1,HÃ´pital Universitaire Sahloul,NA,https://clinicalzeros.gov/ct2/show/NCT04851821,0,0,0,0,0,0,Tunisia,0,quercetin,NA
NCT04851561,2021-03-02,2021-09-02,Observational,Post-coronavirus Disease-2019 Fatigue,Recruiting,NA,Rabin Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04851561,0,0,0,0,0,0,Israel,0,cardiopulmonary stress test (cpet),NA
NCT04837651,2021-03-08,2022-03-08,Observational,Comparing the Antibody Response to COVID-19 Vaccination in Multiple Sclerosis Patients Treated With Ocrelizumab or Natalizumab,Recruiting,NA,"Dragonfly Research, LLC",NA,https://clinicalzeros.gov/ct2/show/NCT04837651,0,0,0,0,1,1,United States,0,t-detect covid t-cell blood test|elecsys semi-quantitative anti-sars-cov-2 antibody test,NA
NCT04846010,2021-03-01,2022-05-01,Interventional,Recovering Damaged Cells for Sequelae Caused by SARS-CoV-2,Recruiting,Phase 1/Phase 2,"All Natural Medicine Clinic, LLC",NA,https://clinicalzeros.gov/ct2/show/NCT04846010,0,0,0,0,1,1,United States,0,furwat|furfat|purapo|purphl|purclo|purinf|smoliv,NA
NCT04849611,2020-11-12,2021-03-30,Observational,Covid-19 Fear and Compliance With Protective Measures of Students,"Active, not recruiting",NA,T.C. ORDU ÃœNÄ°VERSÄ°TESÄ°,NA,https://clinicalzeros.gov/ct2/show/NCT04849611,0,0,0,0,1,0,Turkey,0,"NA",NA
NCT04847349,2021-04-13,2021-10-13,Interventional,Live Microbials to Boost Anti-Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Immunity Clinical Trial,Recruiting,N/A,"Rutgers, The State University of New Jersey",NA,https://clinicalzeros.gov/ct2/show/NCT04847349,0,0,0,0,1,1,United States,0,"ol-1, standard dose|ol-1, high dose|placebo",NA
NCT04834908,2021-05-31,2022-03-31,Interventional,Evaluation of Equine Antibody Treatment in Patients With COVID 19 Infection,Recruiting,Phase 1/Phase 2,Bharat Serums and Vaccines Limited,NA,https://clinicalzeros.gov/ct2/show/NCT04834908,0,0,0,0,1,0,India,0,equine covid-19 antiserum|standard care,NA
NCT04844346,2021-04-19,2021-08-31,Interventional,Plant Stanol Esters and COVID-19 Vaccination Response,Recruiting,N/A,Maastricht University Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04844346,0,0,0,1,1,0,Netherlands,0,plant stanol mini drinks|placebo mini drinks|covid-19 vaccine,NA
NCT04784897,2021-02-22,2021-07-31,Interventional,A Study to Evaluate the Efficacy and Safety of Brilacidin in Hospitalized Participants With COVID-19,Recruiting,Phase 2,"Innovation Pharmaceuticals, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04784897,0,0,0,0,4,1,United States|Russian Federation,0,brilacidin|placebo|standard care,NA
NCT04810728,2020-06-20,2020-12-04,Interventional,Efficacy of Psidii Guava's Extract For COVID-19,Completed,Phase 3,Faculty of Medicine Baiturrahmah University,NA,https://clinicalzeros.gov/ct2/show/NCT04810728,0,0,0,0,1,0,Indonesia,0,extract psidii guava|standard therapy for covid-19 patient,NA
NCT04784767,2021-04-05,2022-10-30,Interventional,SARS-COV-2-Spike-Ferritin-Nanoparticle (SpFN) Vaccine With ALFQ Adjuvant for Prevention of COVID-19 in Healthy Adults,Recruiting,Phase 1,U.S. Army Medical Research and Development Command,NA,https://clinicalzeros.gov/ct2/show/NCT04784767,0,0,0,1,2,1,United States,0,"25 âµg spfn_1b-06-pl / alfq (qs21 adjuvant)|sodium chloride, usp, for injection (0.9% nacl)|50 âµg spfn_1b-06-pl / alfq (qs21 adjuvant)|25 âµg spfn_1b-06-pl|alfq (qs21 adjuvant)|50 âµg spfn_1b-06-pl",NA
NCT04675281,2020-04-24,2021-02-26,Observational,Pathological Findings of Fatal COVID-19,Recruiting,NA,Nantes University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04675281,0,0,0,0,1,0,France,0,2 post-mortem transcutaneous lung biopsies (1 anterior ; 1 posterior) using anatomical landmarks,NA
NCT04751474,2021-02-01,2021-03-01,Interventional,"The Effect of Motivational Messages on Optimism, Hopelessness and Life Satisfaction",Completed,N/A,Saglik Bilimleri Universitesi,NA,https://clinicalzeros.gov/ct2/show/NCT04751474,0,0,0,0,1,0,Turkey,0,motivational messages,NA
NCT04655638,2021-02-10,2022-01-10,Interventional,HFNT vs. COT in COVID-19,Recruiting,N/A,Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo,NA,https://clinicalzeros.gov/ct2/show/NCT04655638,0,0,0,0,3,0,Italy,0,high flow nasal therapy|conventional oxygen therapy,NA
NCT04708236,2021-04-30,2021-05-31,Interventional,A Study of ORTD-1 in Patients Hospitalized With COVID-19 Related Pneumonia,Recruiting,Phase 1/Phase 2,"Oryn Therapeutics, LLC",NA,https://clinicalzeros.gov/ct2/show/NCT04708236,0,0,0,0,2,1,United States,0,ortd-1 low dose|ortd-1 mid dose|ortd-1 high dose|vehicle control,NA
NCT04648709,2021-03-09,2021-06-30,Observational,Evaluation and Longitudinal Follow-up of Biomarkers Predictive of Severe Forms of COVID-19,Recruiting,NA,Centre Hospitalier Universitaire de Saint Etienne,NA,https://clinicalzeros.gov/ct2/show/NCT04648709,0,0,0,0,4,0,France,0,elispot|quantiferon,NA
NCT04516759,2020-08-12,2021-04-30,Interventional,AZD1656 in Diabetic Patients Hospitalised With Suspected or Confirmed COVID-19,"Active, not recruiting",Phase 2,St George Street Capital,NA,https://clinicalzeros.gov/ct2/show/NCT04516759,0,0,0,0,13,0,Czechia|Romania|United Kingdom,0,azd1656|placebo,NA
NCT04570488,2020-05-15,2021-12-30,Interventional,Predicting Favorable Outcomes in Hospitalized Covid-19 Patients,Recruiting,N/A,NYU Langone Health,NA,https://clinicalzeros.gov/ct2/show/NCT04570488,0,0,0,0,2,1,United States,0,epic risk score display,NA
NCT04565665,2020-07-29,2021-04-30,Interventional,Cord Blood-Derived Mesenchymal Stem Cells for the Treatment of COVID-19 Related Acute Respiratory Distress Syndrome,Recruiting,Phase 1/Phase 2,M.D. Anderson Cancer Center,NA,https://clinicalzeros.gov/ct2/show/NCT04565665,0,0,0,0,4,1,United States,0,best available therapy|mesenchymalÂ stem cells,NA
NCT04604184,2020-11-03,2021-03-24,Interventional,ACTION ON COVID-19: A Study to Test Whether BI 764198 Helps Lung Health of People Hospitalised With COVID-19,Terminated,Phase 2,Boehringer Ingelheim,Company decision,https://clinicalzeros.gov/ct2/show/NCT04604184,0,0,0,0,10,1,United States|Brazil|Chile|Mexico|Puerto Rico|Spain,0,bi 764198|placebo,NA
NCT04527471,2020-09-04,2021-02-15,Interventional,Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19,"Active, not recruiting",Phase 2,Verona Pharma plc,NA,https://clinicalzeros.gov/ct2/show/NCT04527471,0,0,0,0,4,1,United States,0,ensifentrine|placebo,NA
NCT04523181,2020-10-08,2021-04-30,Interventional,Double-blind Study to Evaluate the Safety and Efficacy of Antroquinonol in Mild-Moderate COVID-19 Hospitalized Patients,Recruiting,Phase 2,Golden Biotechnology Corporation,NA,https://clinicalzeros.gov/ct2/show/NCT04523181,0,0,0,0,5,1,United States|Argentina|Peru,0,antroquinonol|placebo,NA
NCT04497987,2020-08-02,2021-01-16,Interventional,A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff,"Active, not recruiting",Phase 3,Eli Lilly and Company,NA,https://clinicalzeros.gov/ct2/show/NCT04497987,0,0,0,0,17,1,United States,0,ly3819253|placebo|ly3832479,NA
NCT04492384,2020-06-11,2021-01-14,Observational,Analysis of Chronic Non-infectious Diseases Dynamics After COVID-19 Infection in Adult Patients,Completed,NA,Eurasian Association of Therapists,NA,https://clinicalzeros.gov/ct2/show/NCT04492384,0,0,0,0,4,0,Russian Federation,0,non-interventional,NA
NCT04470258,2020-06-25,2020-08-30,Interventional,Elmo Respiratory Support Project - COVID-19,Completed,N/A,Escola de SaÃºde PÃºblica do CearÃ¡,NA,https://clinicalzeros.gov/ct2/show/NCT04470258,0,0,0,0,2,0,Brazil,0,elmo project at covid-19: study in humans|elmo project at covid-19: proof of concept/usability|elmo project at covid-19: proof of concept|usability,NA
NCT04392141,2020-04-01,2020-11-01,Interventional,Colchicine Plus Phenolic Monoterpenes to Treat COVID-19,Completed,Phase 1/Phase 2,Kermanshah University of Medical Sciences,NA,https://clinicalzeros.gov/ct2/show/NCT04392141,0,0,0,0,3,0,"Iran, Islamic Republic of",1,standard care|colchicine/herbal phenolic monoterpene fractions|colchicine|herbal phenolic monoterpene,NA
NCT04368065,2020-04-02,2022-12-31,Observational [Patient Registry],COVID-19 Active Research Experience (CARE),Recruiting,NA,Iqvia Pty Ltd,NA,https://clinicalzeros.gov/ct2/show/NCT04368065,0,0,0,0,6,1,United States|United Kingdom,0,"NA",NA
NCT04363606,2020-05-27,2022-04-30,Interventional,Chronic Fatigue Etiology and Recovery in Covid-19 Patients: the Role of Fatigability,Recruiting,N/A,Centre Hospitalier Universitaire de Saint Etienne,NA,https://clinicalzeros.gov/ct2/show/NCT04363606,0,0,0,0,5,0,France,0,actigraphy|blood test|questionnaire|maximal effort test|neuromuscular|stool analysis|food diary,NA
NCT04348240,2020-04-16,2022-02-28,Observational,Transmissibility and Viral Load of SARS-CoV-2 in Oral Secretions,Recruiting,NA,National Institutes of Health Clinical Center (CC),NA,https://clinicalzeros.gov/ct2/show/NCT04348240,0,0,0,0,19,1,United States,0,"NA",NA
NCT04346628,2020-07-12,2021-04-16,Interventional,Oral Favipiravir Compared to Placebo in Subjects With Mild COVID-19,Completed,Phase 2,Stanford University,NA,https://clinicalzeros.gov/ct2/show/NCT04346628,0,0,0,0,7,1,United States,0,favipiravir|placebo|standard care,NA
NCT04853316,2020-11-16,2021-06-30,Observational,Asymptomatic SARS-CoV-2 Detection in Children,Recruiting,NA,University of Calgary,NA,https://clinicalzeros.gov/ct2/show/NCT04853316,0,0,0,0,0,1,United States|Canada,0,"NA",NA
NCT04853134,2020-11-01,2021-05-01,Interventional,Proxalutamide Treatment for COVID-19 Female Outpatients,"Active, not recruiting",Phase 3,"Applied Biology, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04853134,0,0,0,0,0,0,Brazil,0,proxalutamide|standard care,NA
NCT04853004,2021-04-30,2023-03-31,Observational,Current and Past SARS-CoV-2 Infection and COVID-19 in Healthcare With Regard to Vaccinations,Recruiting,NA,Karolinska Institutet,NA,https://clinicalzeros.gov/ct2/show/NCT04853004,0,0,0,0,0,0,Sweden,0,sars-cov2 antibody measurement,NA
NCT04852796,2021-04-01,2022-04-01,Observational [Patient Registry],Efficacy and Safety of the Anti- COVID-19 Vaccin in Clinical Hematology Patients,Recruiting,NA,Centre Hospitalier de Cornouaille,NA,https://clinicalzeros.gov/ct2/show/NCT04852796,0,0,0,0,0,0,France,0,patients with hemopathy,NA
NCT04852770,2021-04-23,2021-09-30,Interventional,"Efficacy of TBCT, MBHP and PPT for PTSD During the Covid-19 Pandemics",Recruiting,N/A,FundaÃ§Ã£o Bahiana de Infectologia,NA,https://clinicalzeros.gov/ct2/show/NCT04852770,0,0,0,0,0,0,Brazil,0,trial-based cognitive therapy|mindfulness-based health promotion|positive psychotherapy,NA
NCT04852718,2021-04-13,2021-04-13,Observational,Rehabilitation Program for the Sequelae of COVID 19 Infection,Recruiting,NA,FundaciÃ³ Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau,NA,https://clinicalzeros.gov/ct2/show/NCT04852718,0,0,0,0,0,0,Spain,0,"NA",NA
NCT04842435,2021-04-12,2021-09-30,Interventional,Clinical Study in the Treatment of Patients With Moderate Course of COVID-19,Recruiting,Phase 2/Phase 3,Microgen,NA,https://clinicalzeros.gov/ct2/show/NCT04842435,0,0,0,0,1,0,Russian Federation,0,covid-globulin|placebo,NA
NCT04773665,2021-03-15,2022-06-30,Interventional,"Safety, Tolerability, and Immunogenicity of the COVID-19 Vaccine Candidate (VBI-2902a)","Active, not recruiting",Phase 1/Phase 2,VBI Vaccines Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04773665,0,0,0,1,1,0,Canada,0,vbi-2902a|placebo,NA
NCT04847336,2020-09-02,2021-03-15,Observational,Improving MAternal Newborn carE In the in the WHO European Region During COVID-19 Pandemic,Enrolling by invitation,NA,"WHO Collaborating Centre for Maternal and Child Health, Trieste",NA,https://clinicalzeros.gov/ct2/show/NCT04847336,0,0,0,0,1,0,Italy,0,no intervention is planned,NA
NCT04834869,2021-04-01,2021-12-31,Observational,COVID-19 Vaccines Safety Tracking (CoVaST),Recruiting,NA,Masaryk University,NA,https://clinicalzeros.gov/ct2/show/NCT04834869,0,0,0,0,2,1,"United States|Canada|Croatia|Czechia|Estonia|Ethiopia|Germany|Ghana|Iran, Islamic Republic of|Mexico|Poland|Portugal|Romania|Slovenia|Spain",0,bnt162b2|mrna-1273|azd1222|coronavac|sinopharm|gam-covid-vac|jnj-78436735|cvncov|nvx-cov2373|bbv152,NA
NCT04772859,2021-02-01,2021-07-31,Interventional,Evaluation of an Online Lifestyle Intervention in Mexican School Children During COVID-19 Pandemic,"Active, not recruiting",N/A,Universidad de Sonora,NA,https://clinicalzeros.gov/ct2/show/NCT04772859,0,0,0,0,2,0,Mexico,0,online lifestyle intervention|control,NA
NCT04649775,2021-04-09,2021-07-31,Interventional,AirFLO2 Treatment for Hypoxia and/or Tachypnea in Patients With COVID-19,Recruiting,N/A,Duke University,NA,https://clinicalzeros.gov/ct2/show/NCT04649775,0,0,0,0,2,1,United States,0,airflo2,NA
NCT04682132,2020-05-26,2021-06-30,Observational,Polk COVID-19 and Flu Response,"Active, not recruiting",NA,Polk County Fire Rescue,NA,https://clinicalzeros.gov/ct2/show/NCT04682132,0,0,0,0,1,1,United States,0,"covid-19 antigen/antibody tests,/influenza rapid test|covid-19 antigen|antibody tests,|influenza rapid test",NA
NCT04567836,2020-07-09,2021-06-01,Observational,Screening of Health-care Workers in an University Hospital for SARS-CoV-2,Recruiting,NA,University of Milano Bicocca,NA,https://clinicalzeros.gov/ct2/show/NCT04567836,0,0,0,0,3,0,Italy,0,investigation of the prevalence of test positivity,NA
NCT04751643,2021-04-19,2022-12-31,Interventional,Therapeutic Plasma Exchange to Alleviate Hyperinflammatory Condition During Severe Covid-19 Infections,Recruiting,N/A,Hospices Civils de Lyon,NA,https://clinicalzeros.gov/ct2/show/NCT04751643,0,0,0,0,1,0,France,0,therapeutic plasma exchange : 3 sessions in 3 consecutive days (day 1 to day 3)|usual treatments in intensive care unit according to the current state of knowledge,NA
NCT04475107,2020-07-09,2021-03-25,Interventional,The Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients,Completed,Phase 2,Shin Poong Pharmaceutical Co. Ltd.,NA,https://clinicalzeros.gov/ct2/show/NCT04475107,0,0,0,0,6,0,"Korea, Republic of",0,pyronaridine-artesunate|placebo,NA
NCT04526912,2020-08-28,2021-07-31,Interventional,Treatment and Prevention of Acute Lung Injury (ALI) in Patients With COVID-19 Infection,Recruiting,Phase 1,Viela Bio,NA,https://clinicalzeros.gov/ct2/show/NCT04526912,0,0,0,0,4,1,United States,0,vib7734|placebo,NA
NCT04588792,2021-04-16,2022-01-01,Interventional,Furosemide as Supportive Therapy for COVID-19 Respiratory Failure,Recruiting,Phase 2/Phase 3,Queen's University,NA,https://clinicalzeros.gov/ct2/show/NCT04588792,0,0,0,0,5,0,Canada,0,nebulized furosemide|nebulized saline,NA
NCT04491071,2020-10-22,2021-12-31,Observational,Stress Induced by the COVID-19 Pandemic and Nonconfinement: Study of Anxiety Factors and Potential Effects on Immunity.,Recruiting,NA,Centre Hospitalier Universitaire de Saint Etienne,NA,https://clinicalzeros.gov/ct2/show/NCT04491071,0,0,0,0,3,0,France|United Kingdom,0,generalized anxiety disorder-7 (gad 7)|background questionnaire|impact of covid-19 questionnaire|confinement/communication during the covid-19 pandemic|mental health questionnaire|patient health questionnaire (phq-9)|post traumatic stress disorder questionnaire (ptsd-8)|experiences in close relationship scale questionnaire (ecr-s)|confinement|communication during the covid-19 pandemic,NA
NCT04473365,2020-07-20,2021-06-30,Observational,Rapid Diagnostic Profiling of SARS-CoV-2 (COVID-19),Recruiting,NA,Mekelle University,NA,https://clinicalzeros.gov/ct2/show/NCT04473365,0,0,0,0,3,0,Ethiopia,0,intestinal parasite,NA
NCT04367142,2020-08-24,2022-06-30,Observational,Rapid Detection of COVID-19 by Portable and Connected Biosensor,Recruiting,NA,"University Hospital, Lille",NA,https://clinicalzeros.gov/ct2/show/NCT04367142,0,0,0,0,2,0,France,0,pcr|biosensor,NA
NCT04451291,2020-09-25,2021-09-25,Interventional,Study of Decidual Stromal Cells to Treat COVID-19 Respiratory Failure,Recruiting,N/A,"University Health Network, Toronto",NA,https://clinicalzeros.gov/ct2/show/NCT04451291,0,0,0,0,3,0,Canada,0,decidual stromal cells (dsc),NA
NCT04412265,2020-04-16,2021-06-30,Observational,Frailty in Elderly Patients With COVID-19,Recruiting,NA,University of Milano Bicocca,NA,https://clinicalzeros.gov/ct2/show/NCT04412265,0,0,0,0,4,0,Italy,0,relation between frailty/clinical outcomes in elderly patients with covid-19.|relation between frailty|clinical outcomes in elderly patients with covid-19.,NA
NCT04855539,2020-03-01,2021-05-01,Observational,Coronavirus: Ventilator Outcomes Using Artificial Intelligence Chest Radiographs & Other Evidence-based Co-variates,Recruiting,NA,King's College Hospital NHS Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04855539,0,0,0,0,0,0,United Kingdom,0,"NA",NA
NCT04854941,2020-12-10,2021-03-10,Interventional,Efficacy of Probiotics in the Treatment of Hospitalised Patients With Novel Coronavirus Infection,Completed,N/A,I.M. Sechenov First Moscow State Medical University,NA,https://clinicalzeros.gov/ct2/show/NCT04854941,0,0,0,0,0,0,Russian Federation,0,probiotics,NA
NCT04854837,2021-04-12,2021-10-31,Observational,Safety of Remdesivir Treatment in COVID-19 Patients Requiring Hemodialysis,Recruiting,NA,Semmelweis University,NA,https://clinicalzeros.gov/ct2/show/NCT04854837,0,0,0,0,0,0,Hungary,0,remdesivir,NA
NCT04854785,2021-05-31,2023-04-30,Observational,Neuroinflammation in COVID-19 and Depression,Recruiting,NA,Centre for Addiction and Mental Health,NA,https://clinicalzeros.gov/ct2/show/NCT04854785,0,0,0,0,0,0,Canada,0,[18f]feppa pet scan|[11c]sl25.1188 pet scan,NA
NCT04348500,2020-04-24,2020-12-31,Interventional,Clazakizumab (Anti-IL- 6 Monoclonal) Compared to Placebo for COVID19 Disease,"Active, not recruiting",Phase 2,Cedars-Sinai Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04348500,0,0,0,0,4,1,United States,0,clazakizumab,NA
NCT04333953,2020-04-01,2020-07-01,Observational [Patient Registry],COVID-19 in Patients With HIV,Recruiting,NA,University of Missouri-Columbia,NA,https://clinicalzeros.gov/ct2/show/NCT04333953,0,0,0,0,2,1,United States,0,no intervention,NA
NCT04853966,2021-04-17,2022-04-17,Interventional,The Effects of Physical Activity Counseling on Physical Activity and Quality of Life in Covid-19 Patients,Recruiting,N/A,Gazi University,NA,https://clinicalzeros.gov/ct2/show/NCT04853966,0,0,0,0,0,0,Turkey,0,physical activity counseling,NA
NCT04853901,2020-07-27,2021-01-01,Interventional,Remdesivir Efficacy In Management Of COVID-19 Patients,Completed,Phase 3,Ain Shams University,NA,https://clinicalzeros.gov/ct2/show/NCT04853901,0,0,0,0,0,0,Egypt,0,remdesivir|standard of care_1|standard of care_2,NA
NCT04780321,2020-10-30,2021-10-01,Interventional,JS016 (Anti-SARS-CoV-2 Monoclonal Antibody)With Mild and Moderate COVID-19 or SARS-CoV-2 Asymptomatic Infection Subects,Recruiting,Phase 1/Phase 2,"Shanghai Junshi Bioscience Co., Ltd.",NA,https://clinicalzeros.gov/ct2/show/NCT04780321,0,0,0,0,1,0,China,0,recombinant human anti-sars-cov-2 monoclonal antibody(25mg/kg;50mg/kg;100mg/kg)|placebo|recombinant human anti-sars-cov-2 monoclonal antibody(25mg|kg;50mg|kg;100mg|kg),NA
NCT04848493,2021-04-19,2021-07-20,Observational,"National Project on Vaccines, COVID-19 and Frail Patients",Recruiting,NA,Azienda UnitÃ  Sanitaria Locale Reggio Emilia,NA,https://clinicalzeros.gov/ct2/show/NCT04848493,0,0,0,0,1,0,Italy,0,covid-19 vaccines,NA
NCT04803409,2021-03-22,2021-09-22,Interventional,UNITE Study (UCSD-SW) for COVID-19,Recruiting,N/A,"University of California, San Diego",NA,https://clinicalzeros.gov/ct2/show/NCT04803409,0,0,0,0,3,1,United States,0,splenic ultrasound,NA
NCT04818892,2021-03-26,2021-10-31,Observational,Immunogenicity of COVID-19 Vaccine in Patients With Inflammatory Bowel Disease,Recruiting,NA,"University of Wisconsin, Madison",NA,https://clinicalzeros.gov/ct2/show/NCT04818892,0,0,0,0,3,1,United States,0,serological assay for sars-cov-2,NA
NCT04811664,2021-03-24,2021-12-22,Interventional,A Study of SARS CoV-2 Infection and Potential Transmission in University Students Immunized With Moderna COVID-19 Vaccine,Recruiting,Phase 3,National Institute of Allergy and Infectious Diseases (NIAID),NA,https://clinicalzeros.gov/ct2/show/NCT04811664,0,0,0,1,2,1,United States,0,moderna covid-19 vaccine,NA
NCT04670094,2020-12-30,2021-12-31,Observational,Comorbidities and Risk Score in COVID-19 Patients,"Active, not recruiting",NA,University of Milano Bicocca,NA,https://clinicalzeros.gov/ct2/show/NCT04670094,0,0,0,0,2,0,Italy,0,"NA",NA
NCT04806815,2021-03-25,2021-04-30,Observational,"Menstrual Cycle-induced Pain, Fatigue and Anxiety in Women Suffered From COVID-19",Enrolling by invitation,NA,Biruni University,NA,https://clinicalzeros.gov/ct2/show/NCT04806815,0,0,0,0,2,0,Turkey,0,a survey of 60 questions was created through the internet-based 'google forms surveys' site.,NA
NCT04806113,2021-03-11,2022-03-11,Interventional,COVID-19 Vaccine in Immunosuppressed Adults With Autoimmune Diseases,"Active, not recruiting",Phase 3,McGill University Health Centre/Research Institute of the McGill University Health Centre,NA,https://clinicalzeros.gov/ct2/show/NCT04806113,0,0,0,1,1,0,Canada,0,moderna covid-19 vaccine,NA
NCT04765371,2021-03-03,2021-10-31,Interventional,"Comparison Between Prednisolone and Dexamethasone on Mortality in Patients on Oxygen Therapy, With CoViD-19",Recruiting,Phase 3,Centre Hospitalier RenÃ© Dubos,NA,https://clinicalzeros.gov/ct2/show/NCT04765371,0,0,0,0,2,0,France,0,dexamethasone|prednisolone,NA
NCT04761874,2019-12-01,2020-06-29,Interventional,Telestroke at Comprehensive Stroke Center During the COVID-19 Pandemic,Completed,N/A,University of Minnesota,NA,https://clinicalzeros.gov/ct2/show/NCT04761874,0,0,0,0,1,1,United States,0,telestroke,NA
NCT04708340,2021-03-25,2022-10-31,Interventional,Tolerability and Efficacy of RJX in Patients With COVID-19,Recruiting,Phase 1/Phase 2,"Reven Pharmaceuticals, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04708340,0,0,0,0,4,1,United States,0,rejuveinix (rjx) active comparator|placebo,NA
NCT04701489,2021-01-14,2021-03-15,Interventional,UNITE Study (UMN-GE) for COVID-19,Completed,N/A,University of Minnesota,NA,https://clinicalzeros.gov/ct2/show/NCT04701489,0,0,0,0,4,1,United States,0,splenic ultrasound,NA
NCT04640168,2020-11-24,2021-05-22,Interventional,Adaptive COVID-19 Treatment Trial 4 (ACTT-4),"Active, not recruiting",Phase 3,National Institute of Allergy and Infectious Diseases (NIAID),NA,https://clinicalzeros.gov/ct2/show/NCT04640168,0,0,0,0,24,1,"United States|Japan|Korea, Republic of|Mexico|Singapore",0,baricitinib|dexamethasone|placebo|remdesivir,NA
NCT04741412,2020-06-03,2021-05-31,Observational [Patient Registry],"Pediatric SARS-CoV-2 Infections: Course of COVID-19, Immune Responses, Complications and Long-term Consequences",Recruiting,NA,University Hospital Erlangen,NA,https://clinicalzeros.gov/ct2/show/NCT04741412,0,0,0,0,1,0,Germany,0,"NA",NA
NCT04690816,2021-02-11,2024-12-31,Observational,Natural History of Coronavirus Disease (COVID-19) in Systemic Autoimmune Diseases,Recruiting,NA,National Institutes of Health Clinical Center (CC),NA,https://clinicalzeros.gov/ct2/show/NCT04690816,0,0,0,0,33,1,United States,0,"NA",NA
NCT04542031,2020-12-14,2021-10-31,Interventional,COVID-19 in a Single Large UK Rheumatology Centre and Impact on QOL,Recruiting,N/A,The Royal Wolverhampton Hospitals NHS Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04542031,0,0,0,0,2,0,United Kingdom,0,questionnaire,NA
NCT04575584,2020-10-19,2021-06-27,Interventional,Efficacy and Safety of Molnupiravir (MK-4482) in Hospitalized Adult Participants With COVID-19 (MK-4482-001),Recruiting,Phase 2/Phase 3,Merck Sharp & Dohme Corp.,NA,https://clinicalzeros.gov/ct2/show/NCT04575584,0,0,0,0,29,1,"United States|Brazil|Canada|Chile|Colombia|France|Israel|Italy|Korea, Republic of|Mexico|Philippines|Poland|Russian Federation|South Africa|Spain|Ukraine|United Kingdom",0,molnupiravir|placebo,NA
NCT04358068,2020-05-13,2020-07-08,Interventional,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Terminated,Phase 2,National Institute of Allergy and Infectious Diseases (NIAID),Slow enrollment and lack of community enthusiasm,https://clinicalzeros.gov/ct2/show/NCT04358068,0,0,0,0,17,1,United States,1,hydroxychloroquine|azithromycin|placebo,NA
NCT04832061,2021-04-01,2021-04-20,Observational,Respiratory Supports and COVID-19 Mortality,Completed,NA,Yale University,NA,https://clinicalzeros.gov/ct2/show/NCT04832061,0,0,0,0,1,1,United States,0,respiratory supports,NA
NCT04854408,2021-03-18,2021-04-19,Observational,Evaluation of the Effect of Coronavac Vaccine (Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2 Vaccine) on Healthcare Workers' Menstrual Patterns,"Active, not recruiting",NA,Kanuni Sultan Suleyman Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04854408,0,0,0,0,1,0,Turkey,0,healthcare workers with the coronavac vaccine,NA
NCT04756856,2021-04-21,2021-12-01,Interventional,Muscle-targeted Nutritional Therapy for the Recovery From COVID-19,Recruiting,N/A,IRCCS Policlinico S. Matteo,NA,https://clinicalzeros.gov/ct2/show/NCT04756856,0,0,0,0,1,0,Italy,0,muscle-target oral nutritional supplementation,NA
NCT04805125,2021-04-19,2022-07-31,Interventional,Immunocompromised Swiss Cohorts Based Trial Platform,Recruiting,Phase 3,"University Hospital, Basel, Switzerland",NA,https://clinicalzeros.gov/ct2/show/NCT04805125,0,0,0,1,2,0,Switzerland,0,"moderna covid-19 vaccine, mrna-1273 (100 î¼g)|pfizer-biontech covid-19 vaccine bnt162b2 (30 âµg)( comirnatyâ®)|moderna covid-19 vaccine, mrna-1273 (100 î¼g)|pfizer-biontech covid-19 vaccine bnt162b2 (30 âµg)( comirnatyâ®)",NA
NCT04583956,2020-10-14,2021-12-31,Interventional,ACTIV-5 / Big Effect Trial (BET-A) for the Treatment of COVID-19,Recruiting,Phase 2,National Institute of Allergy and Infectious Diseases (NIAID),NA,https://clinicalzeros.gov/ct2/show/NCT04583956,0,0,0,0,24,1,United States,0,placebo|remdesivir|risankizumab,NA
NCT04681092,2021-04-12,2021-06-30,Interventional,Anti-COVID19 AKS-452 - ACT Study,Enrolling by invitation,Phase 1/Phase 2,University Medical Center Groningen,NA,https://clinicalzeros.gov/ct2/show/NCT04681092,0,0,0,1,2,0,Netherlands,0,aks-452,NA
NCT04676867,2021-01-11,2021-05-31,Interventional,Effect of Dalcetrapib in Patients With Confirmed Mild to Moderate COVID-19,"Active, not recruiting",Phase 2,DalCor Pharmaceuticals,NA,https://clinicalzeros.gov/ct2/show/NCT04676867,0,0,0,0,3,0,Canada,0,dalcetrapib|placebo,NA
NCT04723446,2021-04-20,2021-07-01,Interventional,Efficacy of Mouthwashes in Reducing Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Load in the Saliva,Recruiting,N/A,Queen Mary University of London,NA,https://clinicalzeros.gov/ct2/show/NCT04723446,0,0,0,0,1,0,United Kingdom,0,corsodylâ® alcohol free -0.2 % chlorhexidine digluconate|colgate peroxylâ® -1.5% hydrogen peroxide|oral-bâ® gum/enamel care -cetylpyridinium chloride|no rinsing|corsodylâ® alcohol free -0.2 % chlorhexidine digluconate|colgate peroxylâ® -1.5% hydrogen peroxide|oral-bâ® gum|enamel care -cetylpyridinium chloride,NA
NCT04463602,2020-07-25,2021-01-25,Interventional,Desidustat in the Management of COVID-19 Patients,Completed,Phase 2,Cadila Healthcare Limited,NA,https://clinicalzeros.gov/ct2/show/NCT04463602,0,0,0,0,7,0,Mexico,0,desidustat|standard care,NA
NCT04428008,2021-01-12,2021-08-31,Interventional,Thymosin Alpha 1 to Prevent COVID-19 Infection in Renal Dialysis Patients,Recruiting,Phase 2,Inova Health System,NA,https://clinicalzeros.gov/ct2/show/NCT04428008,0,0,0,0,6,1,United States,0,thymalfasin,NA
NCT04412356,2020-06-04,2021-06-01,Interventional,Timing of Tracheotomy in Covid-19 Patients,"Active, not recruiting",N/A,"Sahlgrenska University Hospital, Sweden",NA,https://clinicalzeros.gov/ct2/show/NCT04412356,0,0,0,0,5,0,Sweden,0,tracheotomy,NA
NCT04404361,2020-05-22,2021-07-31,Interventional,PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer,"Active, not recruiting",Phase 3,CTI BioPharma,NA,https://clinicalzeros.gov/ct2/show/NCT04404361,0,0,0,0,8,1,United States,0,pacritinib|placebo,NA
NCT04325906,2020-04-02,2021-01-26,Interventional,Early PP With HFNC Versus HFNC in COVID-19 Induced Moderate to Severe ARDS,Completed,N/A,Rush University Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04325906,0,0,0,0,6,1,United States,0,high flow nasal cannula (hfnc)|prone positioning,NA
NCT04376684,2020-05-28,2021-07-20,Interventional,Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease,Recruiting,Phase 2,GlaxoSmithKline,NA,https://clinicalzeros.gov/ct2/show/NCT04376684,0,0,0,0,23,1,United States|Argentina|Belgium|Brazil|Canada|Chile|France|India|Japan|Mexico|Netherlands|Peru|Poland|Russian Federation|South Africa|Spain|United Kingdom,0,otilimab|placebo 1|placebo 2|standard care,NA
NCT04371692,2020-06-15,2020-07-09,Observational,Prevalence of COVID-19 Infection Among HCW in a French University Hospital,Completed,NA,"University Hospital, Lille",NA,https://clinicalzeros.gov/ct2/show/NCT04371692,0,0,0,0,1,0,France,0,questionnaire|sars-cov2 testing,NA
NCT04860284,2020-09-18,2021-02-09,Interventional,Hydroxychloroquine for Treatment of Non-Severe COVID-19,"Active, not recruiting",Phase 2,Makerere University,NA,https://clinicalzeros.gov/ct2/show/NCT04860284,0,0,0,0,0,0,Uganda,0,hydroxychloroquine tablets,NA
NCT04860206,2021-01-05,2021-06-30,Observational,Post COVID19 Functional and Cognitive Assessments,Recruiting,NA,Science and Research Centre Koper,NA,https://clinicalzeros.gov/ct2/show/NCT04860206,0,0,0,0,0,0,Slovenia,0,"NA",NA
NCT04860271,2021-03-09,2021-04-30,Interventional,Manual Acupuncture Using Acupuncture Needle vs Press Needle for COVID-19 Healthcare Anxiety,Recruiting,N/A,Indonesia University,NA,https://clinicalzeros.gov/ct2/show/NCT04860271,0,0,0,0,0,0,Indonesia,0,manual acupuncture,NA
NCT04860245,2020-07-01,2021-06-30,Observational,Risks and Outcomes Among COVID-19 Patients Admitted to Assiut University Hospitals.,Recruiting,NA,Assiut University,NA,https://clinicalzeros.gov/ct2/show/NCT04860245,0,0,0,0,0,0,Egypt,0,"NA",NA
NCT04858633,2021-03-22,2021-06-30,Interventional,Hydroxychloroquine (HCQ) as Post Exposure Prophylaxis (PEP) for Prevention of COVID-19,Recruiting,Phase 3,Postgraduate Institute of Medical Education and Research,NA,https://clinicalzeros.gov/ct2/show/NCT04858633,0,0,0,0,0,0,India,0,hydroxychloroquine|standard care|placebo,NA
NCT04859881,2020-04-01,2021-01-31,Observational,Risk Factors for Barotrauma in COVID-19,Completed,NA,Hospital General Ajusco Medio,NA,https://clinicalzeros.gov/ct2/show/NCT04859881,0,0,0,0,0,0,Mexico,0,no intervention,NA
NCT04858620,2020-08-30,2021-08-30,Interventional,A Study to Evaluate the Efficacy of Xlear vs. Placebo for Acute COVID-19 Infection,Recruiting,Phase 3,Larkin Community Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04858620,0,0,0,0,0,1,United States,0,xlear nasal spray|placebo,NA
NCT04858542,2021-02-26,2021-05-31,Interventional,Evaluating the Impact of Vocal Health Education on Mask-wearing Workers During COVID-19,Recruiting,N/A,University of Cincinnati,NA,https://clinicalzeros.gov/ct2/show/NCT04858542,0,0,0,0,0,1,United States,0,educational vocal health modules,NA
NCT04784481,2020-09-20,2020-12-20,Interventional,Ivermectin Reproposing for Mild Stage COVID-19 Outpatients,Completed,Phase 1/Phase 2,"Ministry of Public Health, Argentina",NA,https://clinicalzeros.gov/ct2/show/NCT04784481,0,0,0,0,2,0,Argentina,0,ivermectin,NA
NCT04854382,2021-04-14,2021-11-30,Interventional,Tailored Information About the Coronavirus in Chronic Kidney Disease Patients,Recruiting,N/A,"University Hospital, Akershus",NA,https://clinicalzeros.gov/ct2/show/NCT04854382,0,0,0,0,1,0,Norway,0,tailored information,NA
NCT04853927,2021-02-08,2021-10-30,Interventional,Proxalutamide Treatment for COVID-19 Patients in Intensive Care Unit,Recruiting,Phase 3,"Applied Biology, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04853927,0,0,0,0,1,0,Brazil,0,proxalutamide|placebo,NA
NCT04852822,2021-03-18,2022-08-08,Observational,Immune Response to SARS-CoV-2 (COVID-19) Vaccines in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma,Recruiting,NA,University of Washington,NA,https://clinicalzeros.gov/ct2/show/NCT04852822,0,0,0,0,2,1,United States,0,biospecimen collection|biospeciman collection|electronic health record review,NA
NCT04858412,2021-04-01,2022-03-31,Interventional,Study of HMB-enriched Amino Acid Supplementation in Patients With Alcoholic Liver Disease and COVID-19,Recruiting,N/A,The Cleveland Clinic,NA,https://clinicalzeros.gov/ct2/show/NCT04858412,0,0,0,0,0,1,United States,0,balanced amino acid|î²-hydroxy î²-methyl butyrate (hmb) enriched amino acid|î²-hydroxy î²-methyl butyrate (hmb) enriched amino acid,NA
NCT04783311,2021-02-23,2022-03-31,Interventional,"Safety, Tolerance and Immunogenicity of EuCorVac-19 for the Prevention of COVID-19 in Healthy Adults",Recruiting,Phase 1/Phase 2,"EuBiologics Co.,Ltd",NA,https://clinicalzeros.gov/ct2/show/NCT04783311,0,0,0,1,1,0,"Korea, Republic of",0,eucorvac-19|saline,NA
NCT04685213,2020-08-18,2021-08-18,Interventional,Electrical Stimulation for Critically Ill Covid-19 Patients,Recruiting,Phase 1,Baylor College of Medicine,NA,https://clinicalzeros.gov/ct2/show/NCT04685213,0,0,0,0,1,1,United States,0,electrical stimulation|electrical stimulation - sham,NA
NCT04748536,2021-01-29,2021-04-05,Interventional,Safety and PK of Repeated Doses of IRL201104 in Healthy Volunteers,Completed,Phase 1,Revolo Biotherapeutics,NA,https://clinicalzeros.gov/ct2/show/NCT04748536,0,0,0,0,2,0,United Kingdom,0,irl201104|placebo,NA
NCT04576728,2020-10-06,2021-05-31,Interventional,Efficacy and Safety of Trimodulin in Subjects With Severe COVID-19,Recruiting,Phase 2,Biotest,NA,https://clinicalzeros.gov/ct2/show/NCT04576728,0,0,0,0,4,0,Brazil|France|Russian Federation|Spain,0,trimodulin|placebo,NA
NCT04636203,2020-01-15,2021-09-15,Observational,Burden of COVID-19 Infection in Populations With High or Low Risk of Infection,Recruiting,NA,Neuromed IRCCS,NA,https://clinicalzeros.gov/ct2/show/NCT04636203,0,0,0,0,2,0,Italy,0,"NA",NA
NCT04368234,2020-04-18,2025-04-30,Observational [Patient Registry],Duke COVID-19 Shared Data and Specimen Repository,Recruiting,NA,Duke University,NA,https://clinicalzeros.gov/ct2/show/NCT04368234,0,0,0,0,2,1,United States,0,"NA",NA
NCT04537949,2020-09-09,2021-03-12,Interventional,A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults,"Active, not recruiting",Phase 1/Phase 2,BioNTech SE,NA,https://clinicalzeros.gov/ct2/show/NCT04537949,0,0,0,1,4,0,Germany,0,bnt162b3,NA
NCT04525911,2020-08-26,2021-08-31,Observational,Assessment of Long-term Impact Post COVID-19 for Patients and Health Care Professionals of the European Hospital,Recruiting,NA,HÃ´pital EuropÃ©en Marseille,NA,https://clinicalzeros.gov/ct2/show/NCT04525911,0,0,0,0,2,0,France,0,serology test,NA
NCT04400032,2020-05-15,2021-04-22,Interventional,Cellular Immuno-Therapy for COVID-19 Acute Respiratory Distress Syndrome,Completed,Phase 1/Phase 2,Ottawa Hospital Research Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04400032,0,0,0,0,3,0,Canada,0,mesenchymal stem cells,NA
NCT04381988,2020-05-07,2021-04-21,Interventional,A Study of Hydroxychloroquine vs Placebo to Prevent COVID-19 Infection in Patients Receiving Radiotherapy,Terminated,Phase 2,Memorial Sloan Kettering Cancer Center,The study was terminated based results of other studies and use of the new vaccine.,https://clinicalzeros.gov/ct2/show/NCT04381988,0,0,0,0,2,1,United States,0,hydroxychloroquine|placebo|radiotherapy,NA
NCT04355767,2020-08-11,2021-03-29,Interventional,Convalescent Plasma in Outpatients With COVID-19,Completed,Phase 3,Stanford University,NA,https://clinicalzeros.gov/ct2/show/NCT04355767,0,0,0,0,11,1,United States,0,convalescent plasma|saline,NA
NCT04379271,2020-06-11,2021-01-12,Interventional,"A Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19 (COVID-19)",Completed,Phase 2/Phase 3,Immunic AG,NA,https://clinicalzeros.gov/ct2/show/NCT04379271,0,0,0,0,3,0,Bulgaria|Germany,0,imu-838|placebo,NA
NCT04860908,2021-04-26,2022-01-01,Observational,COVID 19 ANTOBODIES IN PREGNANT WOMEN AND THEIR CONNECTION TO BETA CELL FUNCTION IN THE FETUS,Recruiting,NA,Maaynei Hayesha Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04860908,0,0,0,0,0,0,Israel,0,"no intervention, observation only",NA
NCT04860869,2021-05-01,2022-05-01,Observational,"Endocrine, Metabolic and Microbiome Influence on the Post COVID-19 Syndrome",Recruiting,NA,"The University of Texas Medical Branch, Galveston",NA,https://clinicalzeros.gov/ct2/show/NCT04860869,0,0,0,0,0,1,United States,0,"NA",NA
NCT04861272,2021-04-15,2021-05-05,Observational,Risk Perception Associated With Covid-19 Among Anesthetists,Recruiting,NA,King Saud University,NA,https://clinicalzeros.gov/ct2/show/NCT04861272,0,0,0,0,0,0,Saudi Arabia,0,questionnaire,NA
NCT04860219,2020-07-08,2020-09-18,Interventional,Lactoferrin Use in (SARS-CoV-2) Management,Recruiting,N/A,Zagazig University,NA,https://clinicalzeros.gov/ct2/show/NCT04860219,0,0,0,0,1,0,Egypt,0,lactoferrin,NA
NCT04681859,2021-04-17,2021-07-31,Interventional,Evaluation of a Low-cost CPAP Device on Hospitalized COVID-19 Patients,Recruiting,N/A,Bangladesh University of Engineering and Technology,NA,https://clinicalzeros.gov/ct2/show/NCT04681859,0,0,0,0,3,0,Bangladesh,0,high flow nasal oxygen (hfno) treatment|continuous positive airway pressure (cpap) therapy using oxyjet,NA
NCT04844580,2021-03-10,2022-09-30,Interventional,A Clinical Study Evaluating Inhaled Aviptadil on COVID-19,Recruiting,Phase 2,Centurion Pharma,NA,https://clinicalzeros.gov/ct2/show/NCT04844580,0,0,0,0,2,0,Turkey,0,inhaled aviptadil|placebo,NA
NCT04843774,2021-04-20,2022-06-30,Observational,Covid19 Multiple Sclerosis Vaccine Biospecimen Study,Recruiting,NA,NYU Langone Health,NA,https://clinicalzeros.gov/ct2/show/NCT04843774,0,0,0,0,1,1,United States,0,sars-cov-2 mrna vaccine,NA
NCT04748757,2021-04-20,2022-03-31,Interventional,Annexin A5 in Patients With Severe COVID-19 Disease,Recruiting,Phase 2,Lawson Health Research Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04748757,0,0,0,0,1,0,Canada,0,recombinant human annexin a5|placebo,NA
NCT04647305,2021-01-16,2021-03-04,Interventional,Effectiveness and Adherence to Closed Face Shields to Prevent COVID-19 Transmission,Completed,N/A,"University of Los Andes, Columbia",NA,https://clinicalzeros.gov/ct2/show/NCT04647305,0,0,0,0,2,0,Colombia,0,closed face shield with surgical face mask use|surgical face mask use only,NA
NCT04643860,2021-01-15,2021-08-31,Observational,Differential Leucocyte Count and Covid-19 Diagnosis,"Active, not recruiting",NA,Neuromed IRCCS,NA,https://clinicalzeros.gov/ct2/show/NCT04643860,0,0,0,0,2,0,Italy,0,differential leucocyte count (cldc) device/algorithm|differential leucocyte count (cldc) device|algorithm,NA
NCT04641195,2021-04-22,2021-11-30,Interventional,Vitamin D and Zinc Supplementation for Improving Treatment Outcomes Among COVID-19 Patients in India,Recruiting,Phase 3,Harvard School of Public Health,NA,https://clinicalzeros.gov/ct2/show/NCT04641195,0,0,0,0,2,0,India,0,vitamin d3 (cholecalciferol)|zinc (zinc gluconate)|zinc (zinc gluconate)/vitamin d (cholecalciferol)|placebo|vitamin d (cholecalciferol),NA
NCT04854759,2021-03-15,2022-03-31,Interventional,The Use of Amantadine in the Prevention of Progression and Treatment of COVID-19 Symptoms,Recruiting,Phase 3,Independent Public Clinical Hospital No. 4 in Lublin,NA,https://clinicalzeros.gov/ct2/show/NCT04854759,0,0,0,0,1,0,Poland,0,amantadine hydrochloride|placebo,NA
NCT04833101,2021-04-07,2021-06-15,Interventional,Study on Sequential Immunization of Recombinant COVID-19 Vaccine (Ad5 Vector) and RBD-based Protein Subunit Vaccine,"Active, not recruiting",Phase 4,Jiangsu Province Centers for Disease Control and Prevention,NA,https://clinicalzeros.gov/ct2/show/NCT04833101,0,0,0,1,3,0,China,0,recombinant ad5 vectored covid-19 vaccine|rbd-based protein subunit vaccine (zf2001) against covid-19|trivalent split influenza vaccine,NA
NCT04796896,2021-03-15,2023-06-10,Interventional,A Study to Evaluate Safety and Effectiveness of mRNA-1273 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of Age,Recruiting,Phase 2/Phase 3,"ModernaTX, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04796896,0,0,0,1,5,1,United States,0,placebo|mrna-1273,NA
NCT04789603,2021-03-09,2021-03-30,Interventional,Effects of Using Mask During the 6-minute Walking Test in Times of COVID-19,Completed,N/A,Universitat Internacional de Catalunya,NA,https://clinicalzeros.gov/ct2/show/NCT04789603,0,0,0,0,1,0,Spain,0,6-min-walk surgical mask|6-min-walk fpp2|6-min-walk without mask,NA
NCT04648410,2021-02-16,2021-07-30,Observational,Corticosteroids in Severe COVID-19(ASAP-C Study),Recruiting,NA,Brno University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04648410,0,0,0,0,3,0,Czechia,0,questionnaire,NA
NCT04659109,2020-12-16,2021-07-31,Interventional,Glenzocimab in SARS-Cov-2 Acute Respiratory DistrEss syNdrome Related to COVID-19,Recruiting,Phase 2,Acticor Biotech,NA,https://clinicalzeros.gov/ct2/show/NCT04659109,0,0,0,0,1,0,France,0,glenzocimab|placebo,NA
NCT04623671,2020-11-15,2021-06-30,Interventional,Intravenous Infusion of CAP-1002 in Patients With COVID-19,Recruiting,Phase 2,Capricor Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04623671,0,0,0,0,5,1,United States,0,cap-1002|placebo,NA
NCT04608305,2020-10-28,2021-05-01,Interventional,"Evaluate the Safety, Immunogenicity and Potential Efficacy of an rVSV-SARS-CoV-2-S Vaccine",Recruiting,Phase 1/Phase 2,Israel Institute for Biological Research (IIBR),NA,https://clinicalzeros.gov/ct2/show/NCT04608305,0,0,0,1,3,0,Israel,0,"iibr-100, low dose (prime)|iibr-100 medium dose (prime)|iibr-100 high-dose (prime)|iibr-100 low-dose (prime-boost)|saline placebo (single)|saline placebo (double)|iibr-100 medium-dose (prime-boost)|iibr-100 high-dose (prime-boost)|iibr-100 top-dose (prime-boost)",NA
NCT04596943,2020-10-15,2021-02-01,Observational,RGD PET/CT Imaging in COVID-19 Patients,Completed,NA,Radboud University,NA,https://clinicalzeros.gov/ct2/show/NCT04596943,0,0,0,0,1,0,Netherlands,0,[68ga]ga-dota-(rgd)2 pet/ct|[68ga]ga-dota-(rgd)2 pet|ct-scan,NA
NCT04591184,2021-04-07,2021-08-31,Interventional,A Clinical Trial of a Prophylactic Plasmid DNA Vaccine for COVID-19 [Covigenix VAX-001] in Adults,Recruiting,Phase 1,Entos Pharmaceuticals Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04591184,0,0,0,1,4,0,Canada,0,covigenix vax-001 placebo|covigenix vax-001,NA
NCT04568551,2020-10-30,2021-03-31,Observational,"COVID-19-associated Anxiety of Pregnant Women for Anomalies, Stillbirth and Preterm Labor",Recruiting,NA,Martin-Luther-UniversitÃ¤t Halle-Wittenberg,NA,https://clinicalzeros.gov/ct2/show/NCT04568551,0,0,0,0,1,0,Germany,0,"NA",NA
NCT04568122,2020-11-20,2021-06-30,Interventional,"Rapid Turnaround, Home-based Saliva Testing for COVID-19",Recruiting,N/A,Stanford University,NA,https://clinicalzeros.gov/ct2/show/NCT04568122,0,0,0,0,7,1,United States,0,saliva test kit,NA
NCT04513964,2020-11-01,2021-12-31,Observational,Impact of COVID-19 on the Benefit of Cardiac Rehabilitation,Recruiting,NA,Groupe Hospitalier Paris Saint Joseph,NA,https://clinicalzeros.gov/ct2/show/NCT04513964,0,0,0,0,3,0,France,0,"NA",NA
NCT04465513,2020-08-31,2021-08-31,Interventional,Investigation of the Efficacy of CARDIO Softgels PLUS Best-standard-of-care in the Recovery of Patients With COVID-19,Recruiting,N/A,Hofseth Biocare ASA,NA,https://clinicalzeros.gov/ct2/show/NCT04465513,0,0,0,0,1,0,Canada,0,best standard of care / cardio|standard care|cardio,NA
NCT04456036,2020-07-01,2020-12-31,Observational [Patient Registry],Rehabilitation Needs and Functional Recovery in Covid-19 Acute and Post-acute Care,Recruiting,NA,UniversitÃ  Politecnica delle Marche,NA,https://clinicalzeros.gov/ct2/show/NCT04456036,0,0,0,0,3,0,Italy,0,"NA",NA
NCT04375137,2020-04-20,2022-04-01,Observational,Correlation Between Oxidative Stress Status and COVID-19 Severity,Recruiting,NA,Shahid Beheshti University of Medical Sciences,NA,https://clinicalzeros.gov/ct2/show/NCT04375137,0,0,0,0,4,0,"Iran, Islamic Republic of",0,oxidative stress elisa kit,NA
NCT04328480,2020-04-17,2021-04-25,Interventional,The ECLA PHRI COLCOVID Trial. Effects of Colchicine on Moderate/High-risk Hospitalized COVID-19 Patients.,Completed,Phase 3,Estudios ClÃ­nicos Latino AmÃ©rica,NA,https://clinicalzeros.gov/ct2/show/NCT04328480,0,0,0,0,6,0,Argentina,0,colchicine|standard care,NA
NCT04863586,2021-04-01,2021-10-31,Observational,COVID-19 and Multiple Sclerosis Disease Modifying Therapies,Enrolling by invitation,NA,Nottingham University Hospitals NHS Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04863586,0,0,0,0,0,0,United Kingdom,0,"NA",NA
NCT04863547,2021-03-11,2021-04-30,Observational [Patient Registry],Severity of the New UK SARS-Cov2 Variant in COVID-19 Infection,Recruiting,NA,"ANRS, Emerging Infectious Diseases",NA,https://clinicalzeros.gov/ct2/show/NCT04863547,0,0,0,0,0,0,France|Martinique,0,data collection,NA
NCT04863534,2020-04-01,2021-02-21,Observational,Ultrasound Grayscale Analysis in ARDS covid19,Completed,NA,University of Milan,NA,https://clinicalzeros.gov/ct2/show/NCT04863534,0,0,0,0,0,0,Italy,0,ultrasound,NA
NCT04856111,2021-03-17,2021-12-31,Interventional,Pirfenidone vs. Nintedanib for Fibrotic Lung Disease After Coronavirus Disease-19 Pneumonia,Recruiting,Phase 4,Postgraduate Institute of Medical Education and Research,NA,https://clinicalzeros.gov/ct2/show/NCT04856111,0,0,0,0,1,0,India,0,pirfenidone|nintedanib,NA
NCT04854928,2021-04-30,2021-05-31,Interventional,Study to Evaluate a Single Dose of LTX-109 in Subjects With COVID-19 (Coronavirus Disease 2019) Infection.,Recruiting,Phase 2,Pharma Holdings AS,NA,https://clinicalzeros.gov/ct2/show/NCT04854928,0,0,0,0,2,0,Sweden,0,"ltx-109 gel, 3%|placebo gel",NA
NCT04858607,2021-04-19,2024-05-31,Observational,Humoral and Cellular Immune Response to COVID-19 Vaccines in Immunocompromised and Healthy Individuals,Recruiting,NA,Medical University of Graz,NA,https://clinicalzeros.gov/ct2/show/NCT04858607,0,0,0,0,1,0,Austria,0,blood sample|saliva,NA
NCT04854486,2020-11-16,2021-05-16,Interventional,Impact of GSE and Xylitol (Xlear) on COVID-19 Symptoms and Time to PCR Negativisation in COVID-19 Patients,Recruiting,Phase 3,Larkin Community Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04854486,0,0,0,0,1,1,United States,0,gse/xylitol|gse|xylitol,NA
NCT04822701,2021-04-21,2021-05-22,Interventional,A Study to Test BI 767551 in People With Mild to Moderate Symptoms of COVID-19,Recruiting,Phase 2/Phase 3,Boehringer Ingelheim,NA,https://clinicalzeros.gov/ct2/show/NCT04822701,0,0,0,0,4,1,United States|Netherlands,0,bi 767551 intravenous|bi 767551 inhaled|placebo|placebo inhaled,NA
NCT04821921,2021-04-09,2022-03-31,Observational,The Impact of the COVID-19 Pandemic on Diabetes Management,Recruiting,NA,UniversitÃ¤tsklinikum Hamburg-Eppendorf,NA,https://clinicalzeros.gov/ct2/show/NCT04821921,0,0,0,0,2,0,Germany,0,no intervention,NA
NCT04758299,2021-03-13,2021-04-15,Interventional,Understanding Communications Included With COVID-19 (Corona Virus Disease of 2019) Home Testing Kits,"Active, not recruiting",N/A,Carnegie Mellon University,NA,https://clinicalzeros.gov/ct2/show/NCT04758299,0,0,0,0,2,1,United States,0,decision science-based design,NA
NCT04805216,2021-03-15,2021-11-15,Observational,Covid-19 Vaccine Response in Immunocompromised Haematology Patients,Recruiting,NA,University Hospitals of North Midlands NHS Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04805216,0,0,0,0,1,0,United Kingdom,0,blood test,NA
NCT04715438,2021-01-08,2021-07-31,Interventional,Vaccination Against COVID-19 in Cancer,Recruiting,N/A,University Medical Center Groningen,NA,https://clinicalzeros.gov/ct2/show/NCT04715438,0,0,0,1,2,0,Netherlands,0,mrna-1273 sars-cov-2 vaccine from moderna,NA
NCT04674410,2020-03-01,2021-07-31,Observational,Utility of Empiric Antibiotics for Non-intubated Novel Coronavirus Diseases 2019 Patients,"Active, not recruiting",NA,National Institutes of Health Clinical Center (CC),NA,https://clinicalzeros.gov/ct2/show/NCT04674410,0,0,0,0,2,1,United States,0,antibiotic,NA
NCT04701658,2021-02-01,2021-06-07,Interventional,A Real World Study of Bamlanivimab in Participants With Mild-to-moderate Coronavirus Disease 2019 (COVID-19),"Active, not recruiting",Phase 2,Eli Lilly and Company,NA,https://clinicalzeros.gov/ct2/show/NCT04701658,0,0,0,0,5,1,United States,0,bamlanivimab,NA
NCT04698837,2021-02-02,2021-06-30,Observational,Understanding Potential Airborne Transmission and the Protective Value of Type II Surgical Masks in SARS-CoV-2,Recruiting,NA,"University Hospital Inselspital, Berne",NA,https://clinicalzeros.gov/ct2/show/NCT04698837,0,0,0,0,2,0,Switzerland,0,"NA",NA
NCT04698382,2020-08-01,2021-07-01,Observational,"Impact of COVID-19 on the Incidence, Characteristics, Management and Outcome of Sepsis","Active, not recruiting",NA,National Institutes of Health Clinical Center (CC),NA,https://clinicalzeros.gov/ct2/show/NCT04698382,0,0,0,0,1,1,United States,0,"NA",NA
NCT04673318,2021-02-26,2024-12-31,Interventional,Physical Rehabilitation of COVID-19 Survivors by Heat Therapy,Recruiting,N/A,"University of Massachusetts, Amherst",NA,https://clinicalzeros.gov/ct2/show/NCT04673318,0,0,0,0,1,1,United States,0,heat therapy|exercise training,NA
NCT04636086,2020-11-12,2022-01-31,Interventional,Effect of Vitamin D on Hospitalized Adults With COVID-19 Infection,Recruiting,Phase 4,University of Liege,NA,https://clinicalzeros.gov/ct2/show/NCT04636086,0,0,0,0,1,0,Belgium,0,cholecalciferol|placebo,NA
NCT04657484,2020-12-08,2021-12-07,Interventional,Comparison of Two Corticosteroid Regimens for Post COVID-19 Diffuse Lung Disease,Recruiting,N/A,Postgraduate Institute of Medical Education and Research,NA,https://clinicalzeros.gov/ct2/show/NCT04657484,0,0,0,0,2,0,India,0,medium dose prednisolone|low dose prednisolone,NA
NCT04447209,2020-06-06,2021-05-31,Observational,Dietary Diversity of Young Children During CoVID-19 Outbreak: A Longitudinal Study,"Active, not recruiting",NA,University of Malaya,NA,https://clinicalzeros.gov/ct2/show/NCT04447209,0,0,0,0,1,0,Malaysia,0,"dietary counselling on food groups according to iyc feeding practices, who",NA
NCT04590365,2020-12-17,2021-11-01,Interventional,Carrageenan Nasal Spray for COVID-19 Prophylaxis,Recruiting,N/A,Swansea University,NA,https://clinicalzeros.gov/ct2/show/NCT04590365,0,0,0,0,2,0,United Kingdom,0,carrageenan nasal/throat spray|saline nasal/throat spray|carrageenan nasal|throat spray|saline nasal,NA
NCT04625257,2020-10-24,2021-12-31,Observational,"COVID-19 in Baselland: Validation of Simple and Accurate Tests for COVID-19 Detection, Monitoring and Tracing (ACCURATE-BL-COVID-19)",Recruiting,NA,"University Hospital, Basel, Switzerland",NA,https://clinicalzeros.gov/ct2/show/NCT04625257,0,0,0,0,3,0,Switzerland,0,saliva based assay: crude rna extraction|validation of the ngs method|validation of the lamp assays|validation of the poct antigen/antibody tests|validation of the poct antigen|antibody tests,NA
NCT04563065,2020-08-01,2020-11-30,Interventional,Active Pregnancy Against COVID-19,Recruiting,N/A,Universidad Politecnica de Madrid,NA,https://clinicalzeros.gov/ct2/show/NCT04563065,0,0,0,0,2,0,Spain,0,exercise program|healthy lifestyle advise,NA
NCT04489446,2020-08-19,2021-04-30,Interventional,Sildenafil in COVID-19,"Active, not recruiting",Phase 1/Phase 2,Universidad Nacional Andres Bello,NA,https://clinicalzeros.gov/ct2/show/NCT04489446,0,0,0,0,4,0,Chile,0,sildenafil|placebo,NA
NCT04460027,2020-06-22,2020-11-30,Interventional,W-SUDs for COVID-19,Completed,Phase 1,"Woebot Labs, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04460027,0,0,0,0,3,1,United States,0,woebot substance use disorder,NA
NCT04442789,2020-05-20,2021-12-31,Observational,Sequelae of Sars-CoV-2 Infections,Recruiting,NA,University of Giessen,NA,https://clinicalzeros.gov/ct2/show/NCT04442789,0,0,0,0,2,0,Germany,0,"NA",NA
NCT04424901,2020-05-03,2021-05-01,Interventional,Trial of Open Label Dipyridamole- In Hospitalized Patients With COVID-19,Recruiting,Phase 2,UConn Health,NA,https://clinicalzeros.gov/ct2/show/NCT04424901,0,0,0,0,1,1,United States,0,dipyridamole,NA
NCT04864938,2020-08-01,2024-07-25,Observational,Recovery After Critical Covid-19 Infection,Enrolling by invitation,NA,University of Helsinki,NA,https://clinicalzeros.gov/ct2/show/NCT04864938,0,0,0,0,0,0,Finland,0,"NA",NA
NCT04422873,2020-06-10,2020-07-15,Observational,The Impact of COVID-19 on Dialysis Users,Completed,NA,University of Portsmouth,NA,https://clinicalzeros.gov/ct2/show/NCT04422873,0,0,0,0,3,0,United Kingdom,0,"NA",NA
NCT04421508,2020-07-12,2020-12-28,Interventional,A Study to Assess Pulsed Inhaled Nitric Oxide vs Placebo in Subjects With Mild or Moderate COVID-19,Terminated,Phase 3,Bellerophon,Futility,https://clinicalzeros.gov/ct2/show/NCT04421508,0,0,0,0,12,1,United States,0,inopulse|placebo,NA
NCT04421027,2020-06-12,2021-02-12,Interventional,A Study of Baricitinib (LY3009104) in Participants With COVID-19,"Active, not recruiting",Phase 3,Eli Lilly and Company,NA,https://clinicalzeros.gov/ct2/show/NCT04421027,0,0,0,0,21,1,"United States|Argentina|Brazil|Germany|India|Italy|Japan|Korea, Republic of|Mexico|Puerto Rico|Russian Federation|Spain|United Kingdom",0,baricitinib|placebo,NA
NCT04381273,2020-05-15,2020-08-08,Observational,Oral Health and Psychosocial Factors During the Covid-19 Pandemic,Completed,NA,Heidelberg University,NA,https://clinicalzeros.gov/ct2/show/NCT04381273,0,0,0,0,1,0,Germany,0,no intervention,NA
NCT04370808,2020-08-01,2021-01-01,Observational,VITACOV: Vitamin D Polymorphisms and Severity of COVID-19 Infection,Completed,NA,University of Lisbon,NA,https://clinicalzeros.gov/ct2/show/NCT04370808,0,0,0,0,3,0,Portugal,0,exposure,NA
NCT04327570,2020-03-27,2023-03-30,Observational [Patient Registry],In-depth Immunological Investigation of COVID-19.,Recruiting,NA,Universitaire Ziekenhuizen Leuven,NA,https://clinicalzeros.gov/ct2/show/NCT04327570,0,0,0,0,2,0,Belgium,0,patient sampling,NA
NCT04865913,2021-01-13,2022-05-31,Observational,Venous Thrombosis Virtual Surveillance in COVID,Recruiting,NA,Ottawa Hospital Research Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04865913,0,0,0,0,0,0,Canada,0,observational,NA
NCT04865900,2021-03-09,2022-04-30,Observational [Patient Registry],Prevalence of Perimyocarditis After Covid-19 Vaccine,Recruiting,NA,Hillel Yaffe Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04865900,0,0,0,0,0,0,Israel,0,laboratory blood tests|ecg|pcr|antibody test|echocardiography|mri,NA
NCT04359914,2020-04-15,2021-06-30,Observational,Neurocognitive Impairment in Patients With COVID-19,Recruiting,NA,University of Rostock,NA,https://clinicalzeros.gov/ct2/show/NCT04359914,0,0,0,0,2,0,Germany,0,"NA",NA
NCT04357847,2020-04-09,2021-07-31,Observational,Assessment of Endothelial and Haemostatic Changes During Severe SARS-CoV-2 Infection,Recruiting,NA,"University Hospital, Rouen",NA,https://clinicalzeros.gov/ct2/show/NCT04357847,0,0,0,0,2,0,France,0,"NA",NA
NCT04347824,2020-04-27,2020-12-31,Observational,Predict Adverse Events by Covid-19 Nephritis,Completed,NA,University Hospital Goettingen,NA,https://clinicalzeros.gov/ct2/show/NCT04347824,0,0,0,0,4,0,Germany,0,"NA",NA
NCT04865237,2021-03-06,2022-06-03,Interventional,SARS-CoV-2 Human Challenge Characterisation Study,Enrolling by invitation,N/A,Imperial College London,NA,https://clinicalzeros.gov/ct2/show/NCT04865237,0,0,0,0,0,0,United Kingdom,0,sars-cov-2 virus|remdesivir,NA
NCT04865133,2021-03-31,2021-12-31,Observational,Efficacy and Safety of COVID-19 Vaccine in Cancer Patients,Recruiting,NA,Mayo Clinic,NA,https://clinicalzeros.gov/ct2/show/NCT04865133,0,0,0,0,0,1,United States,0,biospecimen collection|biospeciman collection|electronic health record review,NA
NCT04864899,2021-06-01,2023-03-30,Interventional,Clinical Significance of Subclinical Myocardial Involvement in Recovered COVID-19 Patients Using Cardiovascular Magnetic Resonance (R-COVID-CMR),Recruiting,N/A,The University of Hong Kong,NA,https://clinicalzeros.gov/ct2/show/NCT04864899,0,0,0,0,0,0,Hong Kong,0,cardiac magnetic resonance imaging (cmr)|blood test|6-minute walk test,NA
NCT04615741,2020-11-09,2021-01-22,Interventional,Finding Wellness in the Pandemic,Completed,N/A,University of Lethbridge,NA,https://clinicalzeros.gov/ct2/show/NCT04615741,0,0,0,0,4,0,Canada,0,trauma informed yoga|trauma informed psychotherapy,NA
NCT04859244,2021-01-01,2021-05-01,Interventional,First-in-Human Study of Orally Administered GS-441524 for COVID-19,"Active, not recruiting",Phase 1,Copycat Sciences LLC,NA,https://clinicalzeros.gov/ct2/show/NCT04859244,0,0,0,0,2,1,United States,0,gs-441524,NA
NCT04852835,2021-04-30,2022-04-08,Observational,COVID-19 Vaccine Response,Recruiting,NA,"University Hospital, Strasbourg, France",NA,https://clinicalzeros.gov/ct2/show/NCT04852835,0,0,0,0,2,0,France,0,"NA",NA
NCT04805671,2021-03-22,2021-12-31,Interventional,Evaluation of ADG20 for the Treatment of Mild or Moderate COVID-19,"Active, not recruiting",Phase 2/Phase 3,"Adagio Therapeutics, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04805671,0,0,0,0,5,1,United States,0,adg20|saline,NA
NCT04773067,2021-01-30,2021-06-30,Interventional,"A Study to Evaluate UB-612 COVID-19 Vaccine in Adolescent, Younger and Elderly Adult Volunteers","Active, not recruiting",Phase 2,"United Biomedical Inc., Asia",NA,https://clinicalzeros.gov/ct2/show/NCT04773067,0,0,0,1,1,0,Taiwan,0,ub-612|placebo,NA
NCT04730856,2021-02-01,2021-06-01,Interventional,Standard vs High Prophylactic Doses or Anticoagulation in Patients With High Risk of Thrombosis Admitted With COVID-19 Pneumonia (PROTHROMCOVID),Recruiting,Phase 3,Hospital Universitario Infanta Leonor,NA,https://clinicalzeros.gov/ct2/show/NCT04730856,0,0,0,0,1,0,Spain,0,tinzaparin,NA
NCT04712448,2020-12-30,2021-06-30,Observational,Serum Prevalence of Sars-Cov-2 Antibodies in Pre-pandemic Blood Samples (SPARE),"Active, not recruiting",NA,IRCCS San Raffaele,NA,https://clinicalzeros.gov/ct2/show/NCT04712448,0,0,0,0,1,0,Italy,0,anti-covid test,NA
NCT04656691,2021-01-04,2021-04-18,Interventional,At-Home Infusion Using Bamlanivimab in Participants With Mild to Moderate COVID-19,Completed,Phase 4,UnitedHealth Group,NA,https://clinicalzeros.gov/ct2/show/NCT04656691,0,0,0,0,3,1,United States,0,bamlanivimab,NA
NCT04652518,2020-12-11,2021-08-31,Interventional,LYT-100 in Post-acute COVID-19 Respiratory Disease,Recruiting,Phase 2,PureTech,NA,https://clinicalzeros.gov/ct2/show/NCT04652518,0,0,0,0,7,1,United States|Philippines|Romania|United Kingdom,0,lyt-100|placebo,NA
NCT04650087,2021-02-15,2021-08-31,Interventional,COVID-19 Thrombosis Prevention Trials: Post-hospital Thromboprophylaxis,Recruiting,Phase 3,Duke University,NA,https://clinicalzeros.gov/ct2/show/NCT04650087,0,0,0,0,8,1,United States,0,apixaban 2.5 mg|placebo,NA
NCT04646044,2020-11-13,2021-05-31,Interventional,A Placebo Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) With Standard of Care in Patients With Mild COVID-19,Recruiting,Phase 1,Nektar Therapeutics,NA,https://clinicalzeros.gov/ct2/show/NCT04646044,0,0,0,0,1,1,United States,0,bempegaldesleukin|standard care|placebo,NA
NCT04861298,2021-01-11,2021-07-10,Interventional,Study to Investigate the Clinical Benefits of Dietary Supplement Quercetin for Managing Early COVID-19 Symptoms at Home,Recruiting,N/A,King Edward Medical University,NA,https://clinicalzeros.gov/ct2/show/NCT04861298,0,0,0,0,1,0,Pakistan,0,standard of care for covid-19 as per the hospital guidelines|quercetin phytosome (qp),NA
NCT04860297,2021-04-16,2021-08-26,Interventional,A Study to Evaluate Safety and Immunogenicity of mRNA-1273 Vaccine to Prevent COVID-19 in Adult Organ Transplant Recipients and in Healthy Adult Participants,Recruiting,Phase 3,"ModernaTX, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04860297,0,0,0,1,1,1,United States,0,mrna-1273,NA
NCT04824365,2021-04-12,2022-05-31,Interventional,Sodium Pyruvate Nasal Spray Treatment of COVID-19 and Influenza Infections,Recruiting,Phase 2/Phase 3,"Cellular Sciences, inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04824365,0,0,0,0,3,1,United States,0,sodium pyruvate|saline,NA
NCT04780373,2020-04-01,2020-12-01,Observational,Prognostic Score in Covid-19,Completed,NA,University of L'Aquila,NA,https://clinicalzeros.gov/ct2/show/NCT04780373,0,0,0,0,1,0,Italy,0,data collection,NA
NCT04689724,2020-08-10,2021-05-31,Observational,Covid-19 Airway Management,Recruiting,NA,"University Health Network, Toronto",NA,https://clinicalzeros.gov/ct2/show/NCT04689724,0,0,0,0,1,0,Canada,0,"NA",NA
NCT04678778,2019-03-19,2021-02-19,Interventional,Virtual Reality Study - COVID-19 Protocol,Completed,N/A,University of Southern California,NA,https://clinicalzeros.gov/ct2/show/NCT04678778,0,0,0,0,2,1,United States,0,physical/cognitive activity|physical|cognitive activity,NA
NCT04590586,2020-11-24,2022-04-14,Interventional,Study of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients,Recruiting,Phase 3,Amgen,NA,https://clinicalzeros.gov/ct2/show/NCT04590586,0,0,0,0,11,1,United States|Argentina|Brazil|Chile|Mexico|South Africa|Ukraine,0,standard care|apremilast|apremilast placebo|lanadelumab|lanadelumab placebo|zilucoplan|zilucoplan placebo,NA
NCT04634409,2020-10-29,2021-08-25,Interventional,A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness,Recruiting,Phase 2,Eli Lilly and Company,NA,https://clinicalzeros.gov/ct2/show/NCT04634409,0,0,0,0,11,1,United States|Puerto Rico,0,ly3819253|ly3832479|placebo|vir-7831|ly3853113,NA
NCT04867213,2021-02-15,2021-12-31,Observational,Breath Analysis of Patients Diagnosed With COVID-19 Using Infrared Spectroscopy,Recruiting,NA,McMaster University,NA,https://clinicalzeros.gov/ct2/show/NCT04867213,0,0,0,0,0,0,Canada,0,"NA",NA
NCT04448418,2020-05-20,2020-06-20,Observational,The Impact of COVID-19 Outbreak on Trans-population's Health in Italy,Completed,NA,Unita Complessa di Ostetricia e Ginecologia,NA,https://clinicalzeros.gov/ct2/show/NCT04448418,0,0,0,0,2,0,Italy,0,survey,NA
NCT04374942,2020-04-30,2021-03-31,Interventional,Does Hydroxychloroquine Before & During Patient Exposure Protect Healthcare Workers From Coronavirus?,Terminated,Phase 3,"University Health Network, Toronto","Due to unproven issues associated with hydroxychloroquine use and safety, further complicated
    by media and political misinformation which in effect rendered all global studies on HCQ to
    stop enrolling participants.",https://clinicalzeros.gov/ct2/show/NCT04374942,0,0,0,0,2,0,Canada,0,hydroxychloroquine|placebo,NA
NCT04360538,2020-04-08,2022-07-01,Observational,Long Term Outcomes of Patients With COVID-19,Recruiting,NA,University of Chicago,NA,https://clinicalzeros.gov/ct2/show/NCT04360538,0,0,0,0,1,1,United States,0,quality of life|impact event score|hospital anxiety/depression scale|hospital anxiety|depression scale,NA
NCT04356690,2020-05-08,2021-12-31,Interventional,Etoposide in Patients With COVID-19 Infection,"Active, not recruiting",Phase 2,Boston Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04356690,0,0,0,0,6,1,United States,0,etoposide,NA
NCT04545749,2020-09-25,2021-01-18,Interventional,"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 COVID-19 Vaccine","Active, not recruiting",Phase 1,"United Biomedical Inc., Asia",NA,https://clinicalzeros.gov/ct2/show/NCT04545749,0,0,0,1,3,0,Taiwan,0,ub-612,NA
NCT04540406,2021-05-27,2021-10-01,Interventional,NBT-NM108 as an Early Treatment for Suspected or Confirmed Symptomatic COVID-19 Patients,Recruiting,Phase 2,Notitia Biotechnologies Company,NA,https://clinicalzeros.gov/ct2/show/NCT04540406,0,0,0,0,7,1,United States,0,nbt-nm108|usual care only,NA
NCT04540120,2020-09-25,2021-06-30,Interventional,Safety and Efficacy of Dapansutrile for Treatment of Moderate COVID-19 Symptoms and Evidence of Early Cytokine Release Syndrome,Recruiting,Phase 2,Olatec Therapeutics LLC,NA,https://clinicalzeros.gov/ct2/show/NCT04540120,0,0,0,0,14,1,United States|Netherlands|Switzerland,0,dapansutrile capsules|placebo,NA
NCT04539795,2021-01-25,2021-09-30,Interventional,COVID-19 Study of Safety and Tolerability of Alvelestat,Recruiting,Phase 1/Phase 2,University of Alabama at Birmingham,NA,https://clinicalzeros.gov/ct2/show/NCT04539795,0,0,0,0,2,1,United States,0,alvelestat|placebo,NA
NCT04535167,2020-09-09,2021-06-07,Interventional,"First-In-Human Study To Evaluate Safety, Tolerability, And Pharmacokinetics Following Single Ascending And Multiple Ascending Doses of PF-07304814 In Hospitalized Participants With COVID-19.",Recruiting,Phase 1,Pfizer,NA,https://clinicalzeros.gov/ct2/show/NCT04535167,0,0,0,0,5,1,United States|Belgium|Brazil|Spain,0,placebo|pf-07304814,NA
NCT04534595,2019-04-30,2022-03-31,Observational,Data Collection on the Model Schools Pediatric Health Initiative at 5 SBHC Sites: COVID-19 Questionnaire,Recruiting,NA,Unity Health Toronto,NA,https://clinicalzeros.gov/ct2/show/NCT04534595,0,0,0,0,1,0,Canada,0,covid-19,NA
NCT04508023,2020-08-13,2022-02-22,Interventional,"A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic Coronavirus Disease 2019 (COVID-19) Infection",Recruiting,Phase 3,"Janssen Research & Development, LLC",NA,https://clinicalzeros.gov/ct2/show/NCT04508023,0,0,0,0,8,1,United States,0,rivaroxaban|placebo|standard care,NA
NCT04414410,2020-05-12,2021-09-30,Observational,Echocardiography in Critically-ill Patients With COVID-19 Pneumonia,Enrolling by invitation,NA,Hospital Ambroise ParÃ© Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04414410,0,0,0,0,1,0,France,0,"NA",NA
NCT04867161,2020-12-21,2021-12-31,Observational,Superinfection and Hyperinflammatory Phenotype in COVID-19 (Coronavirus Disease 2019) Pneumonia Patients,Recruiting,NA,Brno University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04867161,0,0,0,0,0,0,Czechia,0,inflammatory markers sampling,NA
NCT04828434,2021-04-01,2023-04-01,Interventional,Virtual Individual Cognitive Stimulation Therapy: a Proof of Concept Study,Recruiting,N/A,"University College, London",NA,https://clinicalzeros.gov/ct2/show/NCT04828434,0,0,0,0,1,0,United Kingdom,0,virtual individual cognitive simulation therapy,NA
NCT04816643,2021-03-24,2022-03-04,Interventional,"Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children <12 Years of Age",Recruiting,Phase 1,BioNTech SE,NA,https://clinicalzeros.gov/ct2/show/NCT04816643,0,0,0,1,2,1,United States,0,biological/vaccine: bnt162b2 10mcg|bnt162b2 20mcg|bnt162b2 30mcg|biological|vaccine: bnt162b2 10mcg,NA
NCT04852276,2021-04-20,2025-06-30,Observational,Analysis of the Immune Response to COVID-19 Vaccination and Outcomes in Individuals With and Without Immune Deficiencies and Dysregulations,Recruiting,NA,National Institutes of Health Clinical Center (CC),NA,https://clinicalzeros.gov/ct2/show/NCT04852276,0,0,0,0,5,1,United States,0,"NA",NA
NCT04767477,2021-03-28,2021-06-30,Interventional,Telerehabilitation and Face-to-face Rehabilitation on COVID-19 Survivors,Recruiting,N/A,Universidade Federal de Pernambuco,NA,https://clinicalzeros.gov/ct2/show/NCT04767477,0,0,0,0,1,0,Brazil,0,face-to-face rehabilitation|telehealth,NA
NCT04830033,2021-04-28,2021-12-31,Interventional,ENO Breathe vs Usual Care in COVID-19 Recovery,Recruiting,N/A,Imperial College London,NA,https://clinicalzeros.gov/ct2/show/NCT04830033,0,0,0,0,2,0,United Kingdom,0,eno breathe group,NA
NCT04863131,2021-04-28,2023-01-31,Interventional,Safety and Immunogenicity of EXG-5003,Recruiting,Phase 1/Phase 2,Fujita Health University,NA,https://clinicalzeros.gov/ct2/show/NCT04863131,0,0,0,1,1,0,Japan,0,exg-5003|placebo,NA
NCT04785144,2021-03-29,2022-08-31,Interventional,Safety and Immunogenicity Study of a SARS-CoV-2 (COVID-19) Variant Vaccine (mRNA-1273.351) in NaÃ¯ve and Previously Vaccinated Adults,Recruiting,Phase 1,National Institute of Allergy and Infectious Diseases (NIAID),NA,https://clinicalzeros.gov/ct2/show/NCT04785144,0,0,0,1,9,1,United States,0,mrna-1273|mrna-1273.351,NA
NCT04581031,2020-07-11,2021-12-01,Interventional,COntinuous Signs Monitoring In Covid-19 Patients,Recruiting,N/A,The Christie NHS Foundation Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04581031,0,0,0,0,1,0,United Kingdom,0,continuous vital sign monitoring - isansys patient status engine|machine learning/ai algorithm|machine learning|ai algorithm,NA
NCT04782739,2021-03-15,2022-04-19,Observational,Evaluation of the Impact of the COVID-19 Pandemic on Provision and Uptake of Services for the Prevention of Mother-to-child Transmission of HIV and Syphilis in Zimbabwe,Recruiting,NA,University of Zimbabwe,NA,https://clinicalzeros.gov/ct2/show/NCT04782739,0,0,0,0,1,0,Zimbabwe,0,none - descriptive study,NA
NCT04776317,2021-03-25,2022-09-19,Interventional,Chimpanzee Adenovirus and Self-Amplifying mRNA Prime-Boost Prophylactic Vaccines Against SARS-CoV-2 in Healthy Adults,Recruiting,Phase 1,National Institute of Allergy and Infectious Diseases (NIAID),NA,https://clinicalzeros.gov/ct2/show/NCT04776317,0,0,0,1,9,1,United States,0,"chadv68-s|chadv68-s-tce|sam-lnp-s|sam-lnp-s-tce|sodium chloride, 0.9%",NA
NCT04612972,2020-09-09,2021-02-19,Interventional,"Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru","Active, not recruiting",Phase 3,Universidad Peruana Cayetano Heredia,NA,https://clinicalzeros.gov/ct2/show/NCT04612972,0,0,0,1,1,0,Peru,0,inactivated sars cov 2 vaccine (vero cell) wuhan/beijing/placebo|inactivated sars cov 2 vaccine (vero cell) wuhan|beijing|placebo,NA
NCT04608097,2020-10-28,2021-03-12,Interventional,Understanding Reactions to Emotional Material in the Media During COVID-19,Completed,N/A,Uppsala University,NA,https://clinicalzeros.gov/ct2/show/NCT04608097,0,0,0,0,3,0,Sweden,0,simple cognitive task intervention|placebo,NA
NCT04547140,2021-01-29,2021-11-30,Interventional,Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) in Hospitalized Participants With Coronavirus Disease (COVID-19),Recruiting,Phase 2,Grifols Therapeutics LLC,NA,https://clinicalzeros.gov/ct2/show/NCT04547140,0,0,0,0,6,1,United States|Brazil|Chile,0,liquid alpha1-proteinase inhibitor (human)|placebo|standard care,NA
NCT04588480,2020-10-21,2021-11-30,Interventional,"Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Japanese Adults","Active, not recruiting",Phase 1/Phase 2,BioNTech SE,NA,https://clinicalzeros.gov/ct2/show/NCT04588480,0,0,0,1,4,0,Japan,0,bnt162b2|placebo,NA
NCT04514900,2020-09-23,2021-03-08,Interventional,Exploring Optimal Treatment Components for Contactless Online Group-based Behavioral Weight Loss Program,Completed,N/A,University of South Carolina,NA,https://clinicalzeros.gov/ct2/show/NCT04514900,0,0,0,0,4,1,United States,0,video chat /personalized feedback|video chat / basic feedback|discussion board for social support /basic feedback|discussion board for social support/personalized feedback|video chat|personalized feedback|basic feedback|discussion board for social support,NA
NCT04453982,2020-06-21,2021-09-30,Observational,Is COVID-19 Transmitted Through Human Milk? Implications for Breastfeeding and Human Milk Banking-Study 1b,Recruiting,NA,The Hospital for Sick Children,NA,https://clinicalzeros.gov/ct2/show/NCT04453982,0,0,0,0,2,0,Canada,0,human milk donors,NA
NCT04498286,2020-07-31,2021-11-01,Observational,COVID-19 and SARS-CoV-2 Antibodies in Multiple Sclerosis Patients,"Active, not recruiting",NA,VU University Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04498286,0,0,0,0,1,0,Netherlands,0,serology test,NA
NCT04462757,2020-05-28,2020-08-31,Interventional,SCIL-1Ra in COVID-19 Feasibility & PK/PD,Terminated,Phase 2,University of Manchester,Lack of patients in the trial population from which to recruit and lack of funding,https://clinicalzeros.gov/ct2/show/NCT04462757,0,0,0,0,4,0,United Kingdom,0,anakinra|0.67ml inj syringe,NA
NCT04453969,2020-05-24,2021-09-30,Observational,Is COVID-19 Transmitted Through Human Milk? Implications for Breastfeeding and Human Milk Banking-Study 1a,Recruiting,NA,The Hospital for Sick Children,NA,https://clinicalzeros.gov/ct2/show/NCT04453969,0,0,0,0,2,0,Canada,0,covid-19,NA
NCT04453566,2020-05-27,2020-08-15,Observational,"Effect of COVID-19 Pandemic on Perceived Stress, Anxiety, Mood, and Training Quality in Elite Athletes.",Completed,NA,Uskudar University,NA,https://clinicalzeros.gov/ct2/show/NCT04453566,0,0,0,0,2,0,Turkey,0,online survey,NA
NCT04419610,2020-10-09,2021-07-31,Interventional,RAS and Coagulopathy in COVID19,Recruiting,Early Phase 1,Imperial College London,NA,https://clinicalzeros.gov/ct2/show/NCT04419610,0,0,0,0,9,0,United Kingdom,0,trv027|saline,NA
NCT04452435,2020-07-21,2020-10-13,Interventional,Safety and Efficacy of C21 in Subjects With COVID-19,Completed,Phase 2,Vicore Pharma AB,NA,https://clinicalzeros.gov/ct2/show/NCT04452435,0,0,0,0,7,0,India|United Kingdom,1,c21|placebo,NA
NCT04410107,2020-05-15,2021-12-31,Observational,"Lung Function, Exercise Capacity and Health-Related Quality of Life After Severe COVID-19",Recruiting,NA,Federal University of Rio Grande do Sul,NA,https://clinicalzeros.gov/ct2/show/NCT04410107,0,0,0,0,1,0,Brazil,0,"lung function tests|exercise|health-related quality of life|respiratory symptoms, symptoms of anxiety/depression,/post-traumatic stress screening|respiratory symptoms, symptoms of anxiety|depression,|post-traumatic stress screening",NA
NCT04330690,2020-03-18,2022-03-18,Interventional,Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,Recruiting,Phase 2,Sunnybrook Health Sciences Centre,NA,https://clinicalzeros.gov/ct2/show/NCT04330690,0,0,0,0,34,0,Canada,0,interferon|remdesivir,NA
NCT04870593,2021-04-17,2021-06-12,Interventional,What Works to Get the Elderly Vaccinated Against COVID-19? Experimental Evidence From India,"Active, not recruiting",N/A,"National Bureau of Economic Research, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04870593,0,0,0,1,0,0,India,0,information|buddy|gossip intervention|information assigned in community|buddy assigned in community,NA
NCT04870723,2021-03-01,2021-08-31,Interventional,#SafeHandsSafeHearts: An eHealth Intervention for COVID-19 Prevention and Support,Recruiting,N/A,University of Toronto,NA,https://clinicalzeros.gov/ct2/show/NCT04870723,0,0,0,0,0,0,Canada|India|Thailand,0,ehealth for covid-19 prevention/support|ehealth for covid-19 prevention|support,NA
NCT04869202,2020-12-01,2021-11-30,Observational,Covid-19 Infection in Pregnancy,Recruiting,NA,University of Jordan,NA,https://clinicalzeros.gov/ct2/show/NCT04869202,0,0,0,0,0,0,Jordan,0,covid-19 test,NA
NCT04870385,2021-04-11,2021-06-20,Interventional,An Islamic Psychospiritual-Acceptance and Commitment-based Prevention Program for At-risk Young Adults in the COVID-19 Pandemic,"Active, not recruiting",N/A,International Islamic University Malaysia,NA,https://clinicalzeros.gov/ct2/show/NCT04870385,0,0,0,0,0,0,Malaysia,0,5-week prevention program|control,NA
NCT04870333,2021-02-19,2021-12-31,Interventional,PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -V,Recruiting,Phase 2/Phase 3,Cambridge University Hospitals NHS Foundation Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04870333,0,0,0,0,0,0,United Kingdom,0,niclosamide|placebo,NA
NCT04869072,2020-04-29,2020-11-30,Interventional,Convalescent Plasma Therapy - Zurich Protocol,Completed,Phase 1,University of Zurich,NA,https://clinicalzeros.gov/ct2/show/NCT04869072,0,0,0,0,0,0,Switzerland,0,convalescent plasma,NA
NCT04868903,2020-11-30,2022-06-30,Interventional,Low vs. Moderate to High Dose Vitamin D for Prevention of COVID-19,Recruiting,N/A,University of Chicago,NA,https://clinicalzeros.gov/ct2/show/NCT04868903,0,0,0,0,0,1,United States,0,vitamin d,NA
NCT04868890,2021-04-30,2021-10-31,Interventional,A Study of Inhaled Ampion in Adults With Respiratory Distress Due to COVID-19,Recruiting,Phase 2,Ampio Pharmaceuticals. Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04868890,0,0,0,0,0,1,United States,0,ampion|placebo,NA
NCT04839965,2021-04-30,2021-10-31,Interventional,Study of Intravenous Ampion in Adult COVID-19 Patients Requiring Supplemental Oxygen,Recruiting,Phase 2,Ampio Pharmaceuticals. Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04839965,0,0,0,0,2,1,United States,0,ampion|saline,NA
NCT04868448,2021-03-20,2022-08-01,Observational,COVID-19 Vaccine Effectiveness Among Health Workers in Georgia,Recruiting,NA,National Center for Disease control and Public Health,NA,https://clinicalzeros.gov/ct2/show/NCT04868448,0,0,0,0,0,0,Georgia,0,covid-19 vaccines,NA
NCT04868435,2020-11-03,2021-06-30,Observational,Triggers for Post-Viral Parosmia After Covid and Non-Covid Infections,Recruiting,NA,University of Reading,NA,https://clinicalzeros.gov/ct2/show/NCT04868435,0,0,0,0,0,0,United Kingdom,0,"NA",NA
NCT04864015,2021-03-17,2021-05-15,Interventional,COVID-19 Aerosol in EGD Using a Droplet Reduction Mouthpiece,"Active, not recruiting",N/A,Universitaire Ziekenhuizen Leuven,NA,https://clinicalzeros.gov/ct2/show/NCT04864015,0,0,0,0,1,0,Belgium,0,"mouthpiece b1(mouthpiece mpc-st gmdn:62534 generic name: endoscopic bite block, basic, reusable",NA
NCT04838119,2021-04-01,2021-05-31,Observational,Preop COVID Testing Patterns,Recruiting,NA,Wake Forest University Health Sciences,NA,https://clinicalzeros.gov/ct2/show/NCT04838119,0,0,0,0,1,1,United States,0,"NA",NA
NCT04809389,2021-03-29,2022-09-30,Interventional,A Study to Evaluate Safety and Immunogenicity of DelNS1-nCoV-RBD LAIV for COVID-19,Recruiting,Phase 1,The University of Hong Kong,NA,https://clinicalzeros.gov/ct2/show/NCT04809389,0,0,0,0,2,0,Hong Kong,0,delns1-ncov-rbd laiv|placebo,NA
NCT04771013,2021-02-10,2021-05-31,Interventional,Safety and Efficacy of Thymic Peptides in the Treatment of Hospitalized COVID-19 Patients in Honduras,Recruiting,Phase 2,Universidad CatÃ³lica de Honduras,NA,https://clinicalzeros.gov/ct2/show/NCT04771013,0,0,0,0,1,0,Honduras,0,thymic peptides,NA
NCT04748588,2021-02-12,2023-01-31,Interventional,Treatment of Nosocomial COVID-19,Recruiting,Phase 4,University of Calgary,NA,https://clinicalzeros.gov/ct2/show/NCT04748588,0,0,0,0,1,0,Canada,0,bamlanivimab,NA
NCT04750278,2021-04-06,2022-02-28,Interventional,"A Phase 2/3, Randomized, Double Blind, Placebo Controlled, Multicenter Study to Evaluate the Efficacy and Safety of FP-025 in Patients With Severe to Critical COVID 19 With Associated Acute Respiratory Distress Syndrome (ARDS)",Recruiting,Phase 2/Phase 3,"Foresee Pharmaceuticals Co., Ltd.",NA,https://clinicalzeros.gov/ct2/show/NCT04750278,0,0,0,0,1,1,United States,0,fp-025 100 mg|fp-025 300 mg|placebo,NA
NCT04732819,2021-01-04,2021-03-30,Interventional,Improving COVID-19 Vaccine Uptake in Nursing Homes,Completed,N/A,Brown University,NA,https://clinicalzeros.gov/ct2/show/NCT04732819,0,0,0,1,1,1,United States,0,high touch multi-pronged behavioral intervention,NA
NCT04703790,2021-04-07,2022-08-31,Observational,Acceptability of a COVID-19 Vaccine Among US Adults Over Two Time Periods,Enrolling by invitation,NA,Columbia University,NA,https://clinicalzeros.gov/ct2/show/NCT04703790,0,0,0,0,2,1,United States,0,"NA",NA
NCT04644328,2020-11-14,2021-01-14,Interventional,The Doctors for Coronavirus Prevention Project Thanksgiving / Christmas Messaging Campaign,"Active, not recruiting",N/A,"National Bureau of Economic Research, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04644328,0,0,0,0,2,1,United States,0,facebook ads on the importance of staying safe during the thanksgiving / christmas holiday|facebook ads on the importance of staying safe during the thanksgiving|christmas holiday,NA
NCT04700137,2021-01-18,2022-01-17,Interventional,"Mental Health Among Patients, Providers, and Staff During the COVID-19 Era",Enrolling by invitation,N/A,"St. Luke's Health System, Boise, Idaho",NA,https://clinicalzeros.gov/ct2/show/NCT04700137,0,0,0,0,3,1,United States,0,caring contacts/introductory phone call (cc/)|caring contacts without an introductory phone call (cc)|caring contacts|introductory phone call (cc|),NA
NCT04636697,2020-11-19,2021-12-31,Interventional,Study of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults,Recruiting,Phase 2/Phase 3,Medicago,NA,https://clinicalzeros.gov/ct2/show/NCT04636697,0,0,0,1,11,1,United States|Canada|United Kingdom,0,intramuscular injection|intramuscular vaccine,NA
NCT04649931,2020-12-14,2021-04-25,Observational,Differences in Exhaled Breath by Using Ion Mobility Spectrometry (IMS) in Subjects Tested for SARS-CoV-2 Infection (COVID-19 Disease),Completed,NA,B. Braun Melsungen AG,NA,https://clinicalzeros.gov/ct2/show/NCT04649931,0,0,0,0,4,0,Germany,0,ion mobility spectrometry (ims),NA
NCT04500639,2020-07-23,2021-12-31,Observational,Over-the-counter Medications & COVID-19,Recruiting,NA,University of Alberta,NA,https://clinicalzeros.gov/ct2/show/NCT04500639,0,0,0,0,2,0,Canada,0,"NA",NA
NCT04495101,2020-07-29,2021-04-26,Interventional,Study to Evaluate the Safety and Efficacy of Prolastin in Hospitalized Subjects With COVID-19,"Active, not recruiting",Phase 2,Grifols Therapeutics LLC,NA,https://clinicalzeros.gov/ct2/show/NCT04495101,0,0,0,0,5,0,Spain,0,prolastin|standard care,NA
NCT04445428,2020-07-15,2021-09-30,Interventional,OPV as Potential Protection Against COVID-19,"Active, not recruiting",Phase 4,Bandim Health Project,NA,https://clinicalzeros.gov/ct2/show/NCT04445428,0,0,0,1,4,0,Guinea-Bissau,0,oral polio vaccine / information|information|oral polio vaccine,NA
NCT04615949,2021-04-30,2021-11-30,Interventional,Cannabidiol in Patients With COVID-19 and Cardiovascular Disease or Risk Factors,Recruiting,Phase 2/Phase 3,Cardiol Therapeutics Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04615949,0,0,0,0,2,1,United States,0,"cannabidiol, pharmaceutically produced with < 5 ppm thc|placebo",NA
NCT04584541,2020-06-11,2023-07-31,Interventional,SarS-Cov-2 Viral Infection (COVID-19) in Patients With Chronic Inflammatory Rheumatism,Recruiting,N/A,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04584541,0,0,0,0,1,0,France,0,blood test|nasopharyngeal swabs|stools,NA
NCT04524663,2020-12-19,2021-06-30,Interventional,Oral Camostat Compared With Standard Supportive Care in Mild-Moderate COVID-19 Patients,"Active, not recruiting",Phase 2,Stanford University,NA,https://clinicalzeros.gov/ct2/show/NCT04524663,0,0,0,0,5,1,United States,0,camostat mesilate|placebo|standard care,NA
NCT04480424,2020-09-17,2021-07-31,Interventional,Study to Evaluate the Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Participants in Intensive Care Unit (ICU) With Coronavirus Disease (COVID-19),Recruiting,Phase 2,Grifols Therapeutics LLC,NA,https://clinicalzeros.gov/ct2/show/NCT04480424,0,0,0,0,7,1,United States,0,gamunex-c|standard care,NA
NCT04362865,2020-04-27,2023-12-01,Observational,Investigation of the B- and T-cell Repertoire and Immune Response in Patients With Acute and Resolved COVID-19 Infection,Recruiting,NA,National Institutes of Health Clinical Center (CC),NA,https://clinicalzeros.gov/ct2/show/NCT04362865,0,0,0,0,27,1,United States,0,"NA",NA
NCT04401475,2020-11-25,2021-04-30,Interventional,"A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EB05 + SOC vs. Placebo + SOC in Adult Hospitalized Patients With COVID-19",Recruiting,Phase 2,Edesa Biotech Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04401475,0,0,0,0,5,1,United States|Canada|Colombia,0,soc/15mg/kg eb05 iv|soc/placebo iv|standard care|15mg|kg eb05 iv|placebo iv,NA
NCT04342221,2020-03-29,2021-02-26,Interventional,Hydroxychloroquine for COVID-19,Terminated,Phase 3,University Hospital Tuebingen,Reduced acceptance of IMP,https://clinicalzeros.gov/ct2/show/NCT04342221,0,0,0,0,3,0,Germany,0,hydroxychloroquine|placebo,NA
NCT04593940,2020-10-15,2021-08-31,Interventional,Immune Modulators for Treating COVID-19,Recruiting,Phase 3,Duke University,NA,https://clinicalzeros.gov/ct2/show/NCT04593940,0,0,0,0,17,1,United States|Argentina|Brazil|Peru,0,infliximab|abatacept|remdesivir|cenicriviroc,NA
NCT04872764,2020-03-20,2020-11-20,Observational,Acute Kidney Injury in Patients With CoVID-19,Completed,NA,UÅŸak University,NA,https://clinicalzeros.gov/ct2/show/NCT04872764,0,0,0,0,0,0,Turkey,0,"duration of hospitalization, mortality rate",NA
NCT04872751,2021-04-27,2022-04-30,Observational,Immune Response of Haemodialysis Patients Post Covid-19 Vaccination,Recruiting,NA,"Penang Hospital, Malaysia",NA,https://clinicalzeros.gov/ct2/show/NCT04872751,0,0,0,0,1,0,Malaysia,0,"NA",NA
NCT04872725,2020-03-01,2020-06-30,Observational [Patient Registry],The Effect of Covid-19 Process,Completed,NA,Istanbul Medipol University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04872725,0,0,0,0,0,0,Turkey,0,time management/participation/the leisure time activity|time management|participation|the leisure time activity,NA
NCT04872699,2021-04-22,2021-05-31,Observational,Prevalence of COVID-19 in a French Dependent Care Facility for the Elderly and in a French Long-term Care Unit: Observational Study,Recruiting,NA,Centre Hospitalier Sud Essonne,NA,https://clinicalzeros.gov/ct2/show/NCT04872699,0,0,0,0,0,0,France,0,"serology testing, rt pcr",NA
NCT04872686,2020-05-23,2021-05-31,Interventional,Virucidal Effect of PVP-I on COVID-19 and as Well as Safety of Its Application on Nasopharynx & Oropharynx,Enrolling by invitation,Phase 3,Bangladesh Reference Institute of Chemical Measurements (BRICM),NA,https://clinicalzeros.gov/ct2/show/NCT04872686,0,0,0,0,0,0,Bangladesh,0,0.6% pvp-i oral/nasal spray to moderately ill covid-19 positive patient|0.6% pvp-i oral/nasal spray to asymptomatic to mild covid-19 patient having multiple comorbidity|0.6% pvp-i oral/nasal spray to healthy volunteer|oral/nasal spray by distilled water to control group|0.6% pvp-i oral|nasal spray to moderately ill covid-19 positive patient|nasal spray to asymptomatic to mild covid-19 patient having multiple comorbidity|nasal spray to healthy volunteer|oral|nasal spray by distilled water to control group,NA
NCT04872049,2021-04-27,2021-10-27,Observational,Assessment of SARS-CoV-2 Effect on Post-traumatic Stress of Patients Hospitalized in Intensive Care Unit,"Active, not recruiting",NA,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04872049,0,0,0,0,0,0,France,0,"NA",NA
NCT04871867,2020-09-01,2021-06-01,Observational [Patient Registry],Cardiac and Lung Assessment of Professional Soccer Players Following COVID-19 Disease,Recruiting,NA,American Hospital of Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04871867,0,0,0,0,0,0,France,0,"NA",NA
NCT04871854,2021-04-26,2021-07-26,Interventional,Evaluating Tocilizumab for Sever COVID-19 Infection in Breast Cancer vs. Non Cancer Pateints,Recruiting,Phase 2,Beni-Suef University,NA,https://clinicalzeros.gov/ct2/show/NCT04871854,0,0,0,0,0,0,Egypt,0,tocilizumab,NA
NCT04871841,2021-04-05,2021-08-05,Observational,Study of Sputnik V COVID-19 Vaccination in Adults in Kazakhstan,Recruiting,NA,Karaganda Medical University,NA,https://clinicalzeros.gov/ct2/show/NCT04871841,0,0,0,0,0,0,Kazakhstan,0,sputnik v,NA
NCT04871828,2021-02-28,2021-09-30,Interventional,The Efficacy of Leukotriene Inhibitor in Adult Patients With Moderate SARS-COV-2 Symptoms (COVID19),Recruiting,Phase 3,King Abdullah International Medical Research Center,NA,https://clinicalzeros.gov/ct2/show/NCT04871828,0,0,0,0,0,0,Saudi Arabia,0,leukotriene receptor antagonist|placebo,NA
NCT04871815,2021-04-27,2022-05-31,Interventional,Effects of Sodium Pyruvate Nasal Spray in COVID-19 Long Haulers.,Recruiting,Phase 2/Phase 3,"Cellular Sciences, inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04871815,0,0,0,0,0,1,United States,0,sodium pyruvate nasal spray,NA
NCT04871789,2021-01-20,2021-05-15,Observational,Optimization of Patients Long-term Management After the Coronavirus Infection COVID-19,Recruiting,NA,Pirogov Russian National Research Medical University,NA,https://clinicalzeros.gov/ct2/show/NCT04871789,0,0,0,0,0,0,Russian Federation,0,laboratory/instrumental examination|laboratory|instrumental examination,NA
NCT04871958,2021-03-19,2021-08-31,Interventional,"Individualized, Technological Interventions for Diabetes Care in the COVID-19 Ward",Enrolling by invitation,N/A,Federico II University,NA,https://clinicalzeros.gov/ct2/show/NCT04871958,0,0,0,0,0,0,Italy,0,"continuous glucose monitoring (cgm, dexcom g6)",NA
NCT04871945,2021-04-20,2021-09-30,Observational,Protective Antibody Level After COVID-19 Vaccination Among Patients Under Hemodialysis,Recruiting,NA,Hanyang University Seoul Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04871945,0,0,0,0,0,0,"Korea, Republic of",0,"elecsys anti-sars-cov-2 s (roche diagnostics gmbh, mannheim, germany), 2) access sars-cov-2 igg ii (beckman coulter, inc. usa)",NA
NCT04871932,2021-02-01,2026-11-03,Observational,COVID-2019 Vaccine Immune Response Base on Single Cell Multi-Omics,Recruiting,NA,RenJi Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04871932,0,0,0,0,0,0,China,0,recently vaccination,NA
NCT04867265,2021-05-03,2021-06-30,Interventional,Mouth-to-mouth Ventilation Efficiency Through Breathable Self-sterilizing Respirator During BLS in COVID-19 Pandemic,Recruiting,N/A,Brno University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04867265,0,0,0,0,1,0,Czechia,0,mout-to-mouth ventilation with quantitative analysis|mout-to-mouth ventilation,NA
NCT04871685,2020-10-18,2021-04-24,Observational,"The ECOVITA Study - Validation of LUS Score in SARS-CoV-2 Disease, i.e COVID-19","Active, not recruiting",NA,"University of Campania ""Luigi Vanvitelli""",NA,https://clinicalzeros.gov/ct2/show/NCT04871685,0,0,0,0,0,0,Italy,0,lung ultrasound,NA
NCT04871633,2020-08-01,2020-11-15,Interventional,Effectiveness of Remedesvir in COVID-19 Patients Presenting at Mayo Hospital Lahore,Completed,N/A,King Edward Medical University,NA,https://clinicalzeros.gov/ct2/show/NCT04871633,0,0,0,0,0,0,Pakistan,0,remdesivir|conventional,NA
NCT04871165,2021-03-24,2024-03-01,Observational,"Analysis of Immunogenicity, Safety and Efficacy of COVID-19 Vaccines in Immunosuppressed Individuals",Recruiting,NA,Vilnius University,NA,https://clinicalzeros.gov/ct2/show/NCT04871165,0,0,0,0,0,0,Lithuania,0,"s-binding igg, rbd-binding igg/n-binding igg immunoassays/sars-cov-2 serum neutralization assay, quantitative serum immunoglobulin tests|assessment of proinflammatory cytokine production/immunophenotypic analysis after stimulation with overlapping s-peptides in peripheral blood mononuclear cells (pbmc)|s-binding igg, rbd-binding igg|n-binding igg immunoassays|sars-cov-2 serum neutralization assay, quantitative serum immunoglobulin tests|assessment of proinflammatory cytokine production|immunophenotypic analysis after stimulation with overlapping s-peptides in peripheral blood mononuclear cells (pbmc)",NA
NCT04860739,2021-04-24,2021-05-20,Interventional,Vaccination With COMIRNATY in Subjects With a VAXZEVRIA First Dose,"Active, not recruiting",Phase 2,Spanish Clinical Research Network - SCReN,NA,https://clinicalzeros.gov/ct2/show/NCT04860739,0,0,0,1,3,0,Spain,0,comirnaty,NA
NCT04858425,2021-04-30,2021-12-31,Interventional,Safety and Efficacy of Niclosamide in Patients With COVID-19 With Gastrointestinal Infection,Recruiting,Phase 2,"AzurRx BioPharma, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04858425,0,0,0,0,2,1,United States,0,niclosamide|placebo,NA
NCT04703114,2021-02-05,2021-11-30,Interventional,Study of the Immunological and Virological Response of Patients With COVID-19 and Presenting an Asymptomatic or Pauci-symptomatic Form (AMBUCOV),Recruiting,N/A,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04703114,0,0,0,0,1,0,France,0,blood count|blood sample|nasopharyngeal swab|saliva|faeces samples|genetic blood collection|data collection,NA
NCT04844489,2021-04-16,2022-09-30,Interventional,Study of the Humoral Response to SARS-CoV-2 Variants and of the Cellular Response After Vaccination Against COVID-19 in Immunocompromised People,Recruiting,N/A,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04844489,0,0,0,1,1,0,France,0,blood samples for the study of the humoral response to sars-cov-2 variants/of the cellular response after vaccination against covid-19|blood samples for the study of the humoral response to sars-cov-2 variants|of the cellular response after vaccination against covid-19,NA
NCT04843761,2021-04-20,2022-10-31,Interventional,ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19,Recruiting,Phase 3,National Institute of Allergy and Infectious Diseases (NIAID),NA,https://clinicalzeros.gov/ct2/show/NCT04843761,0,0,0,0,5,1,United States,0,remdesivir|placebo|aviptadil|aviptadil placebo|corticosteroid,NA
NCT04792567,2021-04-19,2022-01-17,Interventional,Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC),Recruiting,Phase 4,Novartis,NA,https://clinicalzeros.gov/ct2/show/NCT04792567,0,0,0,1,2,0,Germany,0,baf312|baseline disease modifying therapies (dmts),NA
NCT04745351,2021-03-31,2022-01-31,Interventional,Study to Evaluate the Efficacy and Safety of Remdesivir in Participants With Severely Reduced Kidney Function Who Are Hospitalized for Coronavirus Disease 2019 (COVID-19),Recruiting,Phase 3,Gilead Sciences,NA,https://clinicalzeros.gov/ct2/show/NCT04745351,0,0,0,0,4,1,United States,0,remdesivir|rdv placebo|standard care,NA
NCT04734873,2021-02-25,2021-12-30,Interventional,CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to Moderately Symptomatic Hospitalized Covid-19 Patients,Recruiting,Phase 3,"Corvus Pharmaceuticals, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04734873,0,0,0,0,8,1,United States|Argentina|Brazil|Canada|Colombia|France|Germany|Israel|Italy|Mexico|Peru|South Africa|Spain|Ukraine,0,cpi-006 2 mg/kg / soc|cpi-006 1 mg/kg / soc|placebo / soc|cpi-006 2 mg|kg|standard care|cpi-006 1 mg|placebo,NA
NCT04847050,2021-04-28,2022-01-01,Interventional,"A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy",Recruiting,Phase 2,National Institutes of Health Clinical Center (CC),NA,https://clinicalzeros.gov/ct2/show/NCT04847050,0,0,0,1,13,1,United States,0,mrna-1273,NA
NCT04761822,2021-04-07,2021-06-30,Interventional,COVID-19: SARS Vaccination,Recruiting,Phase 2,National Institute of Allergy and Infectious Diseases (NIAID),NA,https://clinicalzeros.gov/ct2/show/NCT04761822,0,0,0,1,14,1,United States,0,moderna covid-19 vaccine|pfizer-biontech covid-19 vaccine|placebo,NA
NCT04724720,2021-01-19,2021-05-03,Interventional,Famotidine vs Placebo for the Treatment of Non-Hospitalized Adults With COVID-19,"Active, not recruiting",Phase 2,Northwell Health,NA,https://clinicalzeros.gov/ct2/show/NCT04724720,0,0,0,0,2,1,United States,0,famotidine|placebo,NA
NCT04685681,2021-01-07,2021-04-06,Interventional,The Get Outside Study,Completed,N/A,State University of New York at Buffalo,NA,https://clinicalzeros.gov/ct2/show/NCT04685681,0,0,0,0,2,1,United States,0,hiking challenge|activity list,NA
NCT04665193,2020-11-23,2021-02-28,Interventional,An Approach to Screening for COVID-19 at Vancouver Airport,Completed,N/A,University of British Columbia,NA,https://clinicalzeros.gov/ct2/show/NCT04665193,0,0,0,0,1,0,Canada,0,rapid antigen test,NA
NCT04681430,2021-01-08,2021-11-30,Interventional,Reconvalescent Plasma/Camostat Mesylate Early in SARS-CoV-2 Q-PCR (COVID-19) Positive High-risk Individuals,Recruiting,Phase 2,"Heinrich-Heine University, Duesseldorf",NA,https://clinicalzeros.gov/ct2/show/NCT04681430,0,0,0,0,4,0,Germany,0,convalescent plasma|camostat mesilate|placebo for camostat mesilate|standard care,NA
NCT04691908,2020-12-25,2021-07-20,Interventional,"Immunogenicity, Efficacy and Safety of QazCovid-inÂ® COVID-19 Vaccine","Active, not recruiting",Phase 3,Research Institute for Biological Safety Problems,NA,https://clinicalzeros.gov/ct2/show/NCT04691908,0,0,0,1,2,0,Kazakhstan,0,qazcovid-inâ®-vaccine against covid-19|placebo|qazcovid-inâ®-vaccine against covid-19,NA
NCT04592055,2020-03-20,2020-10-15,Observational,The Effect of COVID-19 on Diabetes Mellitus,Recruiting,NA,UÅŸak University,NA,https://clinicalzeros.gov/ct2/show/NCT04592055,0,0,0,0,1,0,Turkey,0,"NA",NA
NCT04640194,2020-12-16,2022-05-29,Interventional,A Study to Test Whether Different Doses of Alteplase Help People With Severe Breathing Problems Because of COVID-19,Recruiting,Phase 2/Phase 3,Boehringer Ingelheim,NA,https://clinicalzeros.gov/ct2/show/NCT04640194,0,0,0,0,13,0,Austria|Belgium|Brazil|Denmark|France|Germany|Italy|Netherlands|Portugal|Russian Federation|Spain,0,alteplase|standard care,NA
NCT04627519,2020-12-09,2021-10-31,Interventional,Effectiveness and Safety of Rhea Health ToneÂ® as add-on Therapy for COVID-19 in Hospitalized Adults in Indonesia,Recruiting,N/A,Universitas Padjadjaran,NA,https://clinicalzeros.gov/ct2/show/NCT04627519,0,0,0,0,3,0,Indonesia,0,rhea health toneâ®|rhea health toneâ®,NA
NCT04591704,2020-03-20,2020-10-15,Observational,The Effect of Diabetes Mellitus on the Prognosis of Patients With COVID-19,Recruiting,NA,UÅŸak University,NA,https://clinicalzeros.gov/ct2/show/NCT04591704,0,0,0,0,1,0,Turkey,0,"hospitalisation, necessity of icu, mortality rate, lung involvement",NA
NCT04603924,2020-10-07,2021-06-30,Interventional,Study of Niclosamide in Moderate and Severe Hospitalized Coronavirus-19 (COVID-19) Patients,Recruiting,Phase 2/Phase 3,NeuroBo Pharmaceuticals Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04603924,0,0,0,0,6,1,United States,0,niclosamide|placebo,NA
NCT04590378,2020-03-01,2021-06-01,Observational,Pulmonary Embolism and COVID-19,Recruiting,NA,UÅŸak University,NA,https://clinicalzeros.gov/ct2/show/NCT04590378,0,0,0,0,1,0,Turkey,0,intensive care unit admission ratio,NA
NCT04452318,2020-07-13,2021-09-25,Interventional,COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay,"Active, not recruiting",Phase 3,Regeneron Pharmaceuticals,NA,https://clinicalzeros.gov/ct2/show/NCT04452318,0,0,0,0,16,1,"United States|Moldova, Republic of|Romania",0,regn10933 / regn10987|placebo|regn10933|regn10987,NA
NCT04530357,2020-09-19,2020-11-25,Interventional,"Reactogenicity, Safety and Immunogenicity of QazCovid-inÂ® COVID-19 Vaccine",Completed,Phase 1/Phase 2,Research Institute for Biological Safety Problems,NA,https://clinicalzeros.gov/ct2/show/NCT04530357,0,0,0,1,10,0,Kazakhstan,0,qazcovid-inâ® - covid-19 inactivated vaccine|placebo|qazcovid-inâ® - covid-19 inactivated vaccine,NA
NCT04467840,2020-08-21,2021-06-30,Interventional,"Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia",Recruiting,Phase 2/Phase 3,RedHill Biopharma Limited,NA,https://clinicalzeros.gov/ct2/show/NCT04467840,0,0,0,0,40,0,Brazil|Colombia|Israel|Italy|Mexico|Peru|Poland|Russian Federation|United Kingdom,0,opaganib|placebo,NA
NCT04401436,2020-05-22,2022-06-30,Observational,COVID-19 Associated Lymphopenia Pathogenesis Study in Blood,Recruiting,NA,National Institutes of Health Clinical Center (CC),NA,https://clinicalzeros.gov/ct2/show/NCT04401436,0,0,0,0,16,1,United States,0,"NA",NA
NCT04391309,2021-04-12,2021-11-30,Interventional,COVID-19 and Anti-CD14 Treatment Trial,Recruiting,Phase 2,National Institute of Allergy and Infectious Diseases (NIAID),NA,https://clinicalzeros.gov/ct2/show/NCT04391309,0,0,0,0,11,1,United States,0,anti-cd14|placebo|remdesivir,NA
NCT04404062,2020-03-16,2021-12-31,Observational,Serological and PCR Testing for COVID-19,Recruiting,NA,Richmond Pharmacology Limited,NA,https://clinicalzeros.gov/ct2/show/NCT04404062,0,0,0,0,2,0,United Kingdom,0,membrane-based immunoassay kit|quantitative antibody tests|pcr test,NA
NCT04382651,2020-06-07,2021-01-06,Interventional,Study of Efficacy and Safety of MAS825 in Patients With COVID-19,Completed,Phase 2,Novartis,NA,https://clinicalzeros.gov/ct2/show/NCT04382651,0,0,0,0,13,1,United States,0,mas825|placebo,NA
NCT04382053,2020-05-27,2020-12-10,Interventional,Study of Efficacy and Safety of DV890 in Patients With COVID-19 Pneumonia,Completed,Phase 2,Novartis,NA,https://clinicalzeros.gov/ct2/show/NCT04382053,0,0,0,0,29,0,Argentina|Brazil|Denmark|Germany|Hungary|India|Mexico|Netherlands|Peru|Russian Federation|South Africa|Spain,0,dfv890|standard care,NA
NCT04380870,2020-05-11,2021-05-11,Observational,Describing Chinese Herbal Medicine Telehealth Care for Symptoms Related to Infectious Diseases Such as COVID-19,Recruiting,NA,Center for Integrated Care,NA,https://clinicalzeros.gov/ct2/show/NCT04380870,0,0,0,0,1,1,United States,0,traditional chinese medicine,NA
NCT04362813,2019-12-03,2020-09-16,Interventional,Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia,Completed,Phase 3,Novartis,NA,https://clinicalzeros.gov/ct2/show/NCT04362813,0,0,0,0,12,1,United States|France|Italy|Russian Federation|Spain|United Kingdom,0,canakinumab|placebo,NA
NCT04372628,2020-06-01,2022-04-01,Interventional,Trial of Early Therapies During Non-hospitalized Outpatient Window for COVID-19,Recruiting,Phase 2,Vanderbilt University Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04372628,0,0,0,0,7,1,United States,0,lopinavir/ritonavir|placebo|lopinavir|ritonavir|100 mg,NA
NCT04372056,2020-05-06,2021-06-30,Observational,The COVID-ICU Healthcare Professional Study,Recruiting,NA,Oslo University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04372056,0,0,0,0,3,0,Norway,0,views|experiences of health care professionals working in intensive care units during the covid-19 pandemic,NA
NCT04365101,2020-05-13,2021-12-30,Interventional,Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19,Recruiting,Phase 1/Phase 2,Celularity Incorporated,NA,https://clinicalzeros.gov/ct2/show/NCT04365101,0,0,0,0,17,1,United States,0,nk cells,NA
NCT04344535,2020-04-08,2021-01-01,Interventional,Convalescent Plasma vs. Standard Plasma for COVID-19,Terminated,Phase 1/Phase 2,Stony Brook University,Insufficient eligible and consenting patients,https://clinicalzeros.gov/ct2/show/NCT04344535,0,0,0,0,2,1,United States,0,convalescent plasma|plasma,NA
NCT04865107,2021-04-27,2022-04-30,Interventional,Cellular Immuno-Therapy for COVID-19 ARDS Randomized Clinical Trial,Recruiting,Phase 2,Ottawa Hospital Research Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04865107,0,0,0,0,1,0,Canada,0,mesenchymal stem cells|placebo,NA
NCT04874363,2020-03-15,2020-05-15,Observational,The Effects of Smoking on Mortality in Patients With Acute Respiratory Syndrome Coronavirus 2 Infection,Completed,NA,Sisli Hamidiye Etfal Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04874363,0,0,0,0,0,0,Turkey,0,no intervention,NA
NCT04873414,2020-12-01,2021-10-30,Interventional,Convalescent Plasma as Adjunct Therapy for COVID-19,Recruiting,Phase 2/Phase 3,"National Institute of Health Research and Development, Ministry of Health Republic of Indonesia",NA,https://clinicalzeros.gov/ct2/show/NCT04873414,0,0,0,0,1,0,Indonesia,0,convalescent plasma treatment,NA
NCT04873388,2020-03-01,2021-05-01,Observational,Early Predictors of Prognostic Course in Patients With COVID-19 in Critical or Semi-intensive Area.,Enrolling by invitation,NA,"University of Turin, Italy",NA,https://clinicalzeros.gov/ct2/show/NCT04873388,0,0,0,0,0,0,Italy,0,"NA",NA
NCT04873336,2021-04-01,2021-09-15,Observational [Patient Registry],Closed Loop Ventilation in Patients With COVID-19,Recruiting,NA,Izmir Dr Suat Seren Chest Diseases and Surgery Education and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04873336,0,0,0,0,0,0,Turkey,0,intellivent asv,NA
NCT04324463,2020-04-21,2021-11-30,Interventional,Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial,Recruiting,Phase 3,Population Health Research Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04324463,0,0,0,0,6,0,Brazil|Canada|Colombia|Ecuador|Egypt|India|Pakistan|Philippines|Russian Federation|Saudi Arabia|United Arab Emirates,0,colchicine|interferon|aspirin|rivaroxaban,NA
NCT04873141,2020-04-28,2020-06-22,Observational [Patient Registry],Tocilizumab and Cytokine Release Syndrome (CRS) In Covid-19 Pneumonia,Completed,NA,Shaheed Zulfiqar Ali Bhutto Medical University,NA,https://clinicalzeros.gov/ct2/show/NCT04873141,0,0,0,0,0,0,Pakistan,0,tocilizumab 200 mg/10 ml (20 mg/ml) intraven vial (ml)|tocilizumab 200 mg|10 ml (20 mg|ml) intraven vial (ml),NA
NCT04866303,2021-04-26,2021-08-31,Interventional,Protecting Our Community: COVID-19 Testing,Recruiting,N/A,Montana State University,NA,https://clinicalzeros.gov/ct2/show/NCT04866303,0,0,0,0,1,1,United States,0,home-based sars-cov-2 test kit,NA
NCT04858568,2021-03-11,2022-10-31,Observational,Immune Responses to COVID-19 Vaccination in Lymphoma Patients,Recruiting,NA,University Hospital Southampton NHS Foundation Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04858568,0,0,0,0,1,0,United Kingdom,0,"NA",NA
NCT04790786,2021-03-10,2022-02-28,Interventional,"UPMC OPTIMISE-C19 Trial, a COVID-19 Study",Recruiting,Phase 3,University of Pittsburgh,NA,https://clinicalzeros.gov/ct2/show/NCT04790786,0,0,0,0,2,1,United States,0,lilly bamlanivimab|regeneron casirivimab / imdevimab|lilly bamlanivimab / etesevimab|regeneron casirivimab|imdevimab|etesevimab,NA
NCT04738721,2021-02-05,2021-04-04,Observational [Patient Registry],Physical Activity and Physical Fitness Parameters in COVID-19 Lockdown,Completed,NA,Medipol University,NA,https://clinicalzeros.gov/ct2/show/NCT04738721,0,0,0,0,5,0,Turkey,0,evaluation,NA
NCT04668235,2021-04-23,2021-11-30,Interventional,Study on Safety and Clinical Efficacy of AZVUDINE in COVID-19 Patients (SARS-CoV-2 Infected),Recruiting,Phase 3,HRH Holdngs Limited,NA,https://clinicalzeros.gov/ct2/show/NCT04668235,0,0,0,0,2,0,Brazil,0,azvudine|azvudine placebo,NA
NCT04666285,2021-02-15,2021-06-30,Observational,Southampton Women's Survey COVID-19 Study,Recruiting,NA,University of Southampton,NA,https://clinicalzeros.gov/ct2/show/NCT04666285,0,0,0,0,1,0,United Kingdom,0,experience of pandemic,NA
NCT04636671,2021-04-14,2021-08-01,Interventional,Methylprednisolone vs. Dexamethasone in COVID-19 Pneumonia (MEDEAS RCT),Recruiting,Phase 3,University of Trieste,NA,https://clinicalzeros.gov/ct2/show/NCT04636671,0,0,0,0,1,0,Italy,0,methylprednisolone|dexamethasone,NA
NCT04654442,2021-03-04,2021-05-05,Observational,Feasibility and Analytic Performance of TestNPass (IVDMD) for CoViD-19 Diagnosis on Saliva Sample,Recruiting,NA,"University Hospital, Grenoble",NA,https://clinicalzeros.gov/ct2/show/NCT04654442,0,0,0,0,4,0,France,0,testnpass,NA
NCT04520191,2021-01-04,2021-08-01,Observational,Home-based Kidney Care in Native Americans of New Mexico (HBKC) - Enhancement,Recruiting,NA,University of New Mexico,NA,https://clinicalzeros.gov/ct2/show/NCT04520191,0,0,0,0,2,1,United States,0,"NA",NA
NCT04551768,2021-02-10,2021-07-31,Interventional,Study to Evaluate the Safety and Efficacy of VIRAZOLEÂ® in Hospitalized Adult Participants With Respiratory Distress Due to COVID-19,Recruiting,Phase 1,"Bausch Health Americas, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04551768,0,0,0,0,4,0,Greece|Mexico,0,50 mg/ml virazole|100 mg/ml virazole|50 mg|virazole|100 mg,NA
NCT04569227,2021-04-30,2021-09-30,Interventional,Prevention of COVID-19 Infection to Severe Pneumonia or ARDS,Recruiting,Phase 2,Enzychem Lifesciences Corporation,NA,https://clinicalzeros.gov/ct2/show/NCT04569227,0,0,0,0,2,1,United States,0,ec-18|placebo,NA
NCT04391816,2020-06-03,2022-12-31,Observational,COVID-19 Pandemic Impact on Alcohol (PIA) - A Natural History Study,Recruiting,NA,National Institutes of Health Clinical Center (CC),NA,https://clinicalzeros.gov/ct2/show/NCT04391816,0,0,0,0,228,1,United States,0,"NA",NA
NCT04551911,2020-10-26,2021-08-31,Interventional,Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19,Recruiting,Phase 2,"OPKO Health, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04551911,0,0,0,0,5,1,United States,0,rayaldee 30mcg extended-release (er) capsule|placebo,NA
NCT04504734,2020-11-27,2021-05-01,Interventional,Bucillamine in Treatment of Patients With COVID-19,Enrolling by invitation,Phase 3,"Revive Therapeutics, Ltd.",NA,https://clinicalzeros.gov/ct2/show/NCT04504734,0,0,0,0,21,1,United States,0,bucillamine|placebo,NA
NCT04448756,2020-07-29,2021-06-06,Interventional,Study of M5049 in Participants With COVID-19 Pneumonia (ANEMONE),Recruiting,Phase 2,EMD Serono,NA,https://clinicalzeros.gov/ct2/show/NCT04448756,0,0,0,0,10,1,United States|Brazil|Philippines,0,m5049|placebo,NA
NCT04442087,2020-06-19,2021-09-30,Interventional,Study of Seroprevalence of Anti-SARS-CoV2 Among Children of Hospital Workers in AP-HP,Recruiting,N/A,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04442087,0,0,0,0,3,0,France,0,serology test|data collection,NA
NCT04422509,2020-10-30,2021-02-25,Interventional,Lanadelumab for Treatment of COVID-19 Disease,Completed,Phase 1/Phase 2,Radboud University,NA,https://clinicalzeros.gov/ct2/show/NCT04422509,0,0,0,0,3,0,Netherlands,0,lanadelumab|regular care,NA
NCT04421625,2020-06-15,2022-06-15,Interventional,Patients and Health Staff of Cancer Centres During the Covid-19 Pandemic,Recruiting,N/A,Institut Cancerologie de l'Ouest,NA,https://clinicalzeros.gov/ct2/show/NCT04421625,0,0,0,0,2,0,France,0,diagnostic test for sars-cov2 for patients/health staff|diagnostic test for sars-cov2 for patients|health staff,NA
NCT04421404,2020-06-09,2021-04-30,Interventional,Effects of COVID-19 Convalescent Plasma (CCP) on Coronavirus-associated Complications in Hospitalized Patients,Completed,Phase 2,"University of California, San Francisco",NA,https://clinicalzeros.gov/ct2/show/NCT04421404,0,0,0,0,5,1,United States,0,convalescent plasma|placebo,NA
NCT04360733,2020-04-20,2022-04-30,Observational,Precision Immunology to Determine the Immune Response in Patients With COVID-19,Recruiting,NA,University of Bonn,NA,https://clinicalzeros.gov/ct2/show/NCT04360733,0,0,0,0,1,0,Germany,0,blood sample,NA
NCT04876560,2020-03-11,2020-10-10,Interventional,Implementation of a CDSS in Oncology Patients During COVID-19,Completed,N/A,"Iaso Maternity Hospital, Athens, Greece",NA,https://clinicalzeros.gov/ct2/show/NCT04876560,0,0,0,0,0,0,Greece,0,application of cdss to provide nutritional care in breast cancer patients from home|general lifestyle advice to breast cancer patients by phone,NA
NCT04876417,2021-02-01,2023-02-01,Interventional,tDCS for Post COVID-19 Fatigue,Recruiting,N/A,University of Iowa,NA,https://clinicalzeros.gov/ct2/show/NCT04876417,0,0,0,0,0,1,United States,0,transcranial direct current stimulation,NA
NCT04876443,2020-10-08,2022-07-31,Observational,Impact of COVID-19 Outbreak on the Alcohol Consumption in Patients With Alcohol-related Liver Disease (ICoLD),Recruiting,NA,King's College Hospital NHS Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04876443,0,0,0,0,0,0,United Kingdom,0,study questionnaire,NA
NCT04874792,2020-07-01,2020-11-30,Observational,Clinical Characteristics of Deceased With COVID-19,Completed,NA,Dhaka Medical College,NA,https://clinicalzeros.gov/ct2/show/NCT04874792,0,0,0,0,0,0,Bangladesh,0,"NA",NA
NCT04874779,2020-06-08,2020-11-18,Observational,Acute Kidney Injury Risk in COVID-19,Completed,NA,Zagazig University,NA,https://clinicalzeros.gov/ct2/show/NCT04874779,0,0,0,0,0,0,Egypt,0,non,NA
NCT04874753,2020-11-03,2020-12-01,Observational,The Effect of COVID-19 Pandemia on Follow up of Patients With Chronic Kidney Disease,Completed,NA,UÅŸak University,NA,https://clinicalzeros.gov/ct2/show/NCT04874753,0,0,0,0,0,0,Turkey,0,change in kidney function/proteinuria|change in kidney function|proteinuria,NA
NCT04874740,2021-04-30,2022-10-30,Observational,Seroprevalence of the Anti-SARS-CoV-2 Antibodies in Kidney Transplant Recipients in Severely Affected Region,Recruiting,NA,University Hospital Ostrava,NA,https://clinicalzeros.gov/ct2/show/NCT04874740,0,0,0,0,0,0,Czechia,0,no intervention,NA
NCT04872673,2020-02-15,2020-07-13,Observational,The Professional Values and Ethical Sensitivities During the COVID-19 Pandemic,Completed,NA,Ankara Yildirim BeyazÄ±t University,NA,https://clinicalzeros.gov/ct2/show/NCT04872673,0,0,0,0,1,0,Turkey,0,"NA",NA
NCT04870606,2021-04-24,2021-08-24,Interventional,Proxalutamide (GT0918) Treatment for Outpatients With Mild or Moderate COVID-19 Illness,Recruiting,Phase 3,"Suzhou Kintor Pharmaceutical Inc,",NA,https://clinicalzeros.gov/ct2/show/NCT04870606,0,0,0,0,1,1,United States,0,proxalutamide (gt0918)|placebo,NA
NCT04870164,2020-11-18,2021-07-31,Interventional,"Safety, Tolerability and PK of Ensovibep (MP0420 - a New Candidate With Potential for Treatment of COVID-19)",Recruiting,Phase 1,Molecular Partners AG,NA,https://clinicalzeros.gov/ct2/show/NCT04870164,0,0,0,0,1,0,United Kingdom,0,ensovibep|placebo,NA
NCT04866069,2021-04-25,2021-10-31,Interventional,Study of a Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) Adjuvanted Inactivated Vaccine in Healthy Adults,Recruiting,Phase 1,The Scientific and Technological Research Council of Turkey,NA,https://clinicalzeros.gov/ct2/show/NCT04866069,0,0,0,1,1,0,Turkey,0,sars-cov-2 vaccine|placebo,NA
NCT04864561,2021-04-26,2021-07-15,Interventional,"Study To Compare The Immunogenicity Against COVID-19, Of VLA2001 Vaccine To AZD1222 Vaccine",Recruiting,Phase 3,Valneva Austria GmbH,NA,https://clinicalzeros.gov/ct2/show/NCT04864561,0,0,0,1,2,0,United Kingdom,0,vla2001|azd1222,NA
NCT04860895,2021-02-11,2021-05-01,Interventional,Detection of SARS-CoV-2 in Nasopharyngeal Swabs by Using Multi-Spectral Screening System,Recruiting,N/A,Fable Biyoteknoloji San ve Tic A.S,NA,https://clinicalzeros.gov/ct2/show/NCT04860895,0,0,0,0,1,0,Turkey,0,ap-23,NA
NCT04853940,2021-01-01,2021-11-30,Observational,"Respiratory Muscle Function, Dyspnea, Exercise Capacity and Quality of Life in Severe COVID19 Patients",Recruiting,NA,Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal,NA,https://clinicalzeros.gov/ct2/show/NCT04853940,0,0,0,0,1,0,Spain,0,data collection/clinical testing of subjects|data collection|clinical testing of subjects,NA
NCT04852861,2021-05-10,2021-07-30,Interventional,Safety and Immunogenicity of a Reduced Dose of the BioNTech/Pfizer BNT162b2 Vaccine (REDU-VAC),Enrolling by invitation,Phase 4,Sciensano,NA,https://clinicalzeros.gov/ct2/show/NCT04852861,0,0,0,1,1,0,Belgium,0,immunogenicity after first/second dose|immunogenicity after first|second dose,NA
NCT04852289,2021-05-11,2022-03-31,Observational,A Clinical Observational Study of SARS-CoV-2 Specific CD8 T-Cell Responses to COVID-19 Vaccines in Humans,Recruiting,NA,National Institutes of Health Clinical Center (CC),NA,https://clinicalzeros.gov/ct2/show/NCT04852289,0,0,0,0,12,1,United States,0,"NA",NA
NCT04859517,2021-04-23,2022-07-31,Interventional,Evaluation of ADG20 for the Prevention of COVID-19,Recruiting,Phase 2/Phase 3,"Adagio Therapeutics, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04859517,0,0,0,0,3,1,United States,0,adg20|placebo,NA
NCT04859023,2021-02-22,2021-02-28,Interventional,Comparison of Strategies Based on RT-PCR or Antigenic Test for the Screening of SARS-CoV-2 Infection (COVID-19).,Completed,N/A,Centre Hospitalier Universitaire de Saint Etienne,NA,https://clinicalzeros.gov/ct2/show/NCT04859023,0,0,0,0,1,0,France,0,saliva sample/to an anterior nare self-swabbing (self-samples)|saliva sample (self-sample)|survey of sars-cov-19 knowledge|survey of acceptability of the different self-samples.|saliva|to an anterior nare self-swabbing (self-samples),NA
NCT04826588,2021-06-30,2022-04-30,Interventional,Randomised Evaluation of COVID-19 Therapy (RECOVERY) in Children With PIMS-TS in Switzerland (SWISSPED-RECOVERY),Recruiting,Phase 3,University Children's Hospital Basel,NA,https://clinicalzeros.gov/ct2/show/NCT04826588,0,0,0,0,3,0,Switzerland,0,methylprednisolone|human normal immunoglobulin (ivig),NA
NCT04839107,2020-04-14,2021-12-31,Observational [Patient Registry],Institutional Registry on Outpatient and Hospitalized COVID-19 Infected Patients,Recruiting,NA,Hospital Italiano de Buenos Aires,NA,https://clinicalzeros.gov/ct2/show/NCT04839107,0,0,0,0,1,0,Argentina,0,"NA",NA
NCT04836767,2021-02-16,2022-01-01,Observational [Patient Registry],Evaluation of Physical and Functional Status in Patients With COVID-19 in Long Term,"Active, not recruiting",NA,Hacettepe University,NA,https://clinicalzeros.gov/ct2/show/NCT04836767,0,0,0,0,2,0,Turkey,0,"NA",NA
NCT04834726,2021-04-29,2021-06-02,Interventional,COVID-19 Vaccine Text Outreach,Enrolling by invitation,N/A,University of Pennsylvania,NA,https://clinicalzeros.gov/ct2/show/NCT04834726,0,0,0,1,2,1,United States,0,opt-in (call-back)|opt-in (in-bound)|standard message|clinician endorsement|scarcity|opt-out framing|phone call,NA
NCT04834583,2020-11-02,2021-12-31,Observational,Corona And Manual Professions,"Active, not recruiting",NA,Karolinska Institutet,NA,https://clinicalzeros.gov/ct2/show/NCT04834583,0,0,0,0,1,0,Sweden,0,"NA",NA
NCT04798027,2021-03-12,2022-07-31,Interventional,Study of mRNA Vaccine Formulation Against COVID-19 in Healthy Adults 18 Years of Age and Older,Recruiting,Phase 1/Phase 2,Sanofi,NA,https://clinicalzeros.gov/ct2/show/NCT04798027,0,0,0,1,3,1,United States,0,sars-cov-2 mrna vaccine formulation 1|sars-cov-2 mrna vaccine formulation 2|sars-cov-2 mrna vaccine formulation 3|placebo,NA
NCT04794829,2021-05-11,2026-12-31,Observational,Natural History of Systemic and Nasal Mucosal Immunity to Influenza and SARS-CoV-2 in Adults After Vaccination,Recruiting,NA,National Institutes of Health Clinical Center (CC),NA,https://clinicalzeros.gov/ct2/show/NCT04794829,0,0,0,0,39,1,United States,0,"NA",NA
NCT04794400,2021-02-04,2021-03-31,Interventional,The Application of an Oxygen Mask in Patients With Severe Covid-19 Already Treated With High-flow Nasal Cannula.,Completed,N/A,Region Skane,NA,https://clinicalzeros.gov/ct2/show/NCT04794400,0,0,0,0,3,0,Sweden,0,oxygen mask,NA
NCT04762056,2021-02-22,2021-05-30,Observational,CPAx for Assessing Functional Status of COVID-19 Patients After Intensive Care Unit Discharge,Recruiting,NA,Gaziosmanpasa Research and Education Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04762056,0,0,0,0,2,0,Turkey,0,chelsea critical care physical assessment tool,NA
NCT04718519,2020-06-22,2020-10-11,Observational,Migrant Workers' Responses to the COVID-19 Pandemic,Completed,NA,Yale-NUS College,NA,https://clinicalzeros.gov/ct2/show/NCT04718519,0,0,0,0,2,0,Singapore,0,"NA",NA
NCT04684615,2021-05-11,2022-07-31,Observational,Mental Health Impact of the COVID-19 Pandemic on Amish and Mennonite Participants in AMBiGen,Enrolling by invitation,NA,National Institutes of Health Clinical Center (CC),NA,https://clinicalzeros.gov/ct2/show/NCT04684615,0,0,0,0,91,1,United States,0,"NA",NA
NCT04780113,2021-02-25,2021-10-25,Observational,Evolution of Perceived Stress in General Practice Residents During COVID-19 Sanitary Crisis,Recruiting,NA,Centre Hospitalier Eure-Seine,NA,https://clinicalzeros.gov/ct2/show/NCT04780113,0,0,0,0,1,0,France,0,"NA",NA
NCT04707664,2021-04-27,2021-06-30,Interventional,Sargramostim Use in COVID-19 to Recover Patient Health,Recruiting,Phase 2,"Partner Therapeutics, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04707664,0,0,0,0,10,1,United States,0,sargramostim|placebo,NA
NCT04652674,2020-09-28,2021-06-30,Interventional,Impact of Postoperative Telemedicine Visit vs In-person Visit on Patient Satisfaction During the COVID-19 Pandemic: A Prospective Randomized Trial,Recruiting,N/A,Cedars-Sinai Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04652674,0,0,0,0,2,1,United States,0,telemedicine visit|in-person postoperative visit,NA
NCT04619628,2020-12-11,2021-06-30,Interventional,"Safety and Immunogenicity of COVI-VAC, a Live Attenuated Vaccine Against COVID-19","Active, not recruiting",Phase 1,"Codagenix, Inc",NA,https://clinicalzeros.gov/ct2/show/NCT04619628,0,0,0,1,2,0,United Kingdom,0,covi-vac|placebo,NA
NCT04582903,2021-05-11,2025-08-31,Observational,Send-In Sample Collection for Comprehensive Analyses of Innate and Adaptive Immune Responses During Acute COVID-19 and Convalescence,Recruiting,NA,National Institutes of Health Clinical Center (CC),NA,https://clinicalzeros.gov/ct2/show/NCT04582903,0,0,0,0,140,1,United States,0,"NA",NA
NCT04602312,2020-10-28,2021-06-30,Interventional,How Does Mindfulness Meditation Buffer the Negative Effects of Pain and Suffering in the COVID-19 World? (Healthy Sample),Recruiting,N/A,The University of Queensland,NA,https://clinicalzeros.gov/ct2/show/NCT04602312,0,0,0,0,3,0,Australia,0,meditation (1 x 20-minute guided audio training),NA
NCT04602286,2020-10-28,2021-06-30,Interventional,How Does Mindfulness Meditation Buffer the Negative Effects of Pain and Suffering in the COVID-19 World? (Pain Sample),Recruiting,N/A,The University of Queensland,NA,https://clinicalzeros.gov/ct2/show/NCT04602286,0,0,0,0,3,0,Australia,0,meditation (1 x 20-minute guided audio training),NA
NCT04611802,2020-12-27,2023-06-30,Interventional,"A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults â‰¥ 18 Years With a Pediatric Expansion in Adolescents (12-17 Years) at Risk for SARS-CoV-2",Recruiting,Phase 3,Novavax,NA,https://clinicalzeros.gov/ct2/show/NCT04611802,0,0,0,1,15,1,United States|Mexico|Puerto Rico,0,sars-cov-2 rs/matrix-m1 adjuvant (initial vaccination period)|placebo (initial vaccination period)|sars-cov-2 rs/matrix-m1 adjuvant (crossover vaccination period)|placebo (crossover vaccination period)|sars-cov-2 rs|matrix-m1 adjuvant (initial vaccination period)|matrix-m1 adjuvant (crossover vaccination period),NA
NCT04609085,2021-05-11,2023-04-30,Observational,SARS-COV2 Pandemic Serosurvey in a Rare Disease Population,Enrolling by invitation,NA,National Institutes of Health Clinical Center (CC),NA,https://clinicalzeros.gov/ct2/show/NCT04609085,0,0,0,0,127,1,United States,0,"NA",NA
NCT04532372,2020-10-23,2022-09-18,Interventional,Leflunomide for the Treatment of Severe COVID-19 in Patients With a Concurrent Malignancy,Recruiting,Phase 1/Phase 2,City of Hope Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04532372,0,0,0,0,3,1,United States,0,best available therapy|leflunomide|placebo,NA
NCT04573062,2021-05-11,2024-12-31,Observational,Natural History of Post-Coronavirus Disease 19 Convalescence at the National Institutes of Health,Recruiting,NA,National Institutes of Health Clinical Center (CC),NA,https://clinicalzeros.gov/ct2/show/NCT04573062,0,0,0,0,146,1,United States,0,"NA",NA
NCT04565080,2021-05-11,2021-12-31,Observational,Clinical Correlates of COVID-19 Pandemic in Patients With Functional Movement Disorder (FMD) and Parkinson's Disease (PD),Recruiting,NA,National Institutes of Health Clinical Center (CC),NA,https://clinicalzeros.gov/ct2/show/NCT04565080,0,0,0,0,151,1,United States,0,"NA",NA
NCT04565067,2021-05-11,2021-12-31,Observational,Identification and Characterization of SARS-CoV-2 Specific CD8 T Cells in Humans,Recruiting,NA,National Institutes of Health Clinical Center (CC),NA,https://clinicalzeros.gov/ct2/show/NCT04565067,0,0,0,0,151,1,United States,0,"NA",NA
NCT04564274,2021-05-11,2021-09-01,Observational,COV2Base-A Rare Disease by COVID Study,Recruiting,NA,National Institutes of Health Clinical Center (CC),NA,https://clinicalzeros.gov/ct2/show/NCT04564274,0,0,0,0,151,1,United States,0,"NA",NA
NCT04445493,2021-03-01,2021-07-31,Observational,EPISODE-PS-COVID: hEad Pulse for Ischemic StrOke DEtection Prehospital Study During the COVID-19 Pandemic ( EPISODEPSCOVID ),Recruiting,NA,"MindRhythm, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04445493,0,0,0,0,3,1,United States,0,mindrhythm harmony,NA
NCT04529421,2020-09-04,2020-12-31,Observational,Assocation Between In-person Instruction and COVID-19 Risk,"Active, not recruiting",NA,Oslo Metropolitan University,NA,https://clinicalzeros.gov/ct2/show/NCT04529421,0,0,0,0,3,0,Norway,0,online instruction|in-person instruction,NA
NCT04528888,2020-11-25,2021-06-30,Interventional,Steroids and Unfractionated Heparin in Critically Ill Patients With Pneumonia From COVID-19 Infection,Recruiting,Phase 3,University of Modena and Reggio Emilia,NA,https://clinicalzeros.gov/ct2/show/NCT04528888,0,0,0,0,1,0,Italy,0,enoxaparin|methylprednisolone|heparin,NA
NCT04527432,2020-12-16,2022-03-31,Interventional,COVID-19 Health Professional Impact Study,"Active, not recruiting",N/A,The Royal Wolverhampton Hospitals NHS Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04527432,0,0,0,0,4,0,United Kingdom,0,questionnaire|sars-cov-2 antibody test,NA
NCT04432272,2020-07-16,2020-11-13,Interventional,ANTIBODY-LEVEL BASED ANALYSIS OF COVID-19 CONVALESCENT SERUM (ABACCuS),Completed,Phase 2,William Beaumont Hospitals,NA,https://clinicalzeros.gov/ct2/show/NCT04432272,0,0,0,0,4,1,United States,0,convalescent plasma,NA
NCT04518410,2020-08-19,2023-05-31,Interventional,ACTIV-2: A Study for Outpatients With COVID-19,Recruiting,Phase 2/Phase 3,National Institute of Allergy and Infectious Diseases (NIAID),NA,https://clinicalzeros.gov/ct2/show/NCT04518410,0,0,0,0,67,1,United States|Argentina|Puerto Rico|South Africa,0,"bamlanivimab|placebo (iv)|brii-196/brii-198|azd7442 (iv)|azd7442 (im)|sng001|camostat|placebo (im)|placebo (inhaled solution)|placebo (oral tablet)|c135-ls / c144-ls|placebo (sc injections)|sab-185 (3,840 units/kg)|sab-185 (10,240 units/kg)|brii-196|brii-198|c135-ls|c144-ls|sab-185 (3,840 units|kg)|sab-185 (10,240 units",NA
NCT04510194,2021-01-01,2021-06-30,Interventional,Outpatient Treatment of COVID-19 With Metformin,Recruiting,Phase 2/Phase 3,University of Minnesota,NA,https://clinicalzeros.gov/ct2/show/NCT04510194,0,0,0,0,7,1,United States,0,metformin|placebo|fluvoxamine|ivermectin,NA
NCT04453852,2020-06-30,2021-02-01,Interventional,Monovalent Recombinant COVID19 Vaccine,Completed,Phase 1,Vaxine Pty Ltd,NA,https://clinicalzeros.gov/ct2/show/NCT04453852,0,0,0,1,2,0,Australia,0,covid19 vaccine|saline,NA
NCT04412785,2020-06-30,2021-10-31,Interventional,Cyclosporine in Patients With Moderate COVID-19,"Active, not recruiting",Phase 1,University of Pennsylvania,NA,https://clinicalzeros.gov/ct2/show/NCT04412785,0,0,0,0,3,1,United States,0,cyclosporine,NA
NCT04409873,2021-03-31,2021-09-30,Interventional,Antiseptic Mouthwash / Pre-Procedural Rinse on SARS-CoV-2 Load (COVID-19),Recruiting,Phase 2,"University of California, San Francisco",NA,https://clinicalzeros.gov/ct2/show/NCT04409873,0,0,0,0,7,1,United States,0,oral-b mouth sore mouthwash|crest pro-health multi-protection mouthwash|closys ultra sensitive rinse mouthwash|distilled water|listerine zero mouthwash product,NA
NCT04402957,2020-10-14,2021-05-31,Interventional,LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19),"Active, not recruiting",Phase 2,Arch Biopartners Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04402957,0,0,0,0,7,1,United States|Canada|Turkey,0,lsalt peptide|placebo,NA
NCT04401449,2020-01-08,2024-05-01,Observational,Cardiopulmonary Inflammation and Multi-System Imaging During the Clinical Course of COVID-19 Infection in Asymptomatic and Symptomatic Persons,Recruiting,NA,National Institutes of Health Clinical Center (CC),NA,https://clinicalzeros.gov/ct2/show/NCT04401449,0,0,0,0,19,1,United States,0,"NA",NA
NCT04365530,2020-04-01,2022-04-01,Observational,Become of Patients Infected or Suspected of Being Infected by Covid-19 and Supported by the GHPSJ and the Establishments of the Paris Plaisance Hospital City,Recruiting,NA,Groupe Hospitalier Paris Saint Joseph,NA,https://clinicalzeros.gov/ct2/show/NCT04365530,0,0,0,0,2,0,France,0,"NA",NA
NCT04421612,2020-04-02,2021-01-01,Interventional,COVID-19 - No Health Without Mental Health,Completed,N/A,Haukeland University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04421612,0,0,0,0,4,0,Norway,0,co-mestring (co-coping),NA
NCT04419870,2021-05-11,2025-05-01,Observational,"Acute Infection in Mitochondrial Disease: Metabolism, Infection and Immunity During the COVID19 Pandemic",Recruiting,NA,National Institutes of Health Clinical Center (CC),NA,https://clinicalzeros.gov/ct2/show/NCT04419870,0,0,0,0,217,1,United States,0,"NA",NA
NCT04387656,2020-05-21,2023-05-31,Observational,"NCI COVID-19 in Cancer Patients, NCCAPS Study",Recruiting,NA,National Cancer Institute (NCI),NA,https://clinicalzeros.gov/ct2/show/NCT04387656,0,0,0,0,141,1,United States|Canada|Puerto Rico,0,biospecimen collection|biospeciman collection|data collection|quality-of-life assessment|questionnaire,NA
NCT04379518,2020-09-04,2021-09-04,Interventional,Rintatolimod and IFN Alpha-2b for the Treatment of Mild or Moderate COVID-19 Infection in Cancer Patients,Recruiting,Phase 1/Phase 2,Roswell Park Cancer Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04379518,0,0,0,0,8,1,United States,0,best available therapy|interferon|rintatolimod,NA
NCT04377100,2021-05-11,2022-02-28,Interventional,Impact on Anxiety and Motivation of COVID-19 and Predictors of Individual Responses,Recruiting,N/A,National Institutes of Health Clinical Center (CC),NA,https://clinicalzeros.gov/ct2/show/NCT04377100,0,0,0,0,236,1,United States,0,questionnaire,NA
NCT04332094,2020-04-02,2021-06-30,Interventional,Clinical Trial of the Use of Tocilizumab for Treatment of SARS-CoV-2 Infection (COVID-19),Recruiting,Phase 2,FundaciÃ³ Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau,NA,https://clinicalzeros.gov/ct2/show/NCT04332094,0,0,0,0,4,0,Spain,0,tocilizumab|hydroxychloroquine|azithromycin,NA
NCT04319445,2020-03-22,2020-08-31,Interventional,Mindfulness During COVID-19,Completed,N/A,Wake Forest University Health Sciences,NA,https://clinicalzeros.gov/ct2/show/NCT04319445,0,0,0,0,5,1,United States,0,mindfulness session(s),NA
